



**Sponsor:**

3M  
St. Paul, Minnesota

**FINAL REPORT**

**Study Title:**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

**Author:**

Peter J. Thomford, PhD

**Study Completion Date:**

January 11, 2002

**Testing Facility:**

Covance Laboratories Inc.  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704-2595

**Laboratory Study Identification:**

Covance 6329-223


**Sponsor Study Identification:**

3M Study No. T-6295.7

Volume I of II

Page 1 of 1086

1818.0001




3M\_MN03278834


---

**COMPLIANCE STATEMENT**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

All aspects of this study were in accordance with the Environmental Protection Agency Good Laboratory Practice Regulations, 40 CFR 792, with the exception that the analysis of fecal samples for urobilinogen at the Mayo Clinic were not done in compliance with Good Laboratory Practice Regulations.

  
\_\_\_\_\_  
Peter J. Thornford, PhD  
Study Director  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date


\_\_\_\_\_  
Andrew M. Seacat, PhD  
Study Monitor  
3M

\_\_\_\_\_  
Date

**QUALITY ASSURANCE STATEMENT**

This report has been reviewed by the Quality Assurance Unit of Covance Laboratories Inc., in accordance with the Environmental Protection Agency (EPA) Good Laboratory Practice Standards, 40 CFR 792. The following inspections were conducted and findings reported to the study director and study director management.

Inspection Dates		Phase	Date Reported to Study Director and Study Director Management
From	To		
08/06/98	08/06/98	Test Article Preparation	08/06/98
08/24/98	08/24/98	Protocol Review	08/24/98
11/25/98	11/25/98	Body Weight	11/25/98
03/03/99	03/03/99	Analytical Laboratory Inspection	03/03/99
04/09/99	04/12/99	Protocol Amendment Review	04/12/99
05/23/99	05/23/99	Protocol Amendment Review	05/23/99
09/27/99	09/27/99	Protocol Amendment Review	09/27/99
10/22/99	10/25/99	Data Review	10/27/99
10/20/99	10/27/99	Data Review	10/27/99
02/11/00	02/13/00	Protocol Amendment Review	02/13/00
03/16/00	03/16/00	Protocol Amendment Review	03/16/00
03/13/00	03/23/00	Data Review	03/23/00
04/04/00	04/04/00	Protocol Amendment Review	04/04/00
04/18/00	05/05/00	Report Review	05/09/00
05/31/00	05/31/00	Protocol Amendment Review	05/31/00
10/23/01	10/23/01	Protocol Amendment Review	10/23/01
12/18/01	12/18/01	Report Review	12/18/01

  
 Representative  
 Quality Assurance Unit

11 Jan 2002  
 Date

### STUDY IDENTIFICATION

#### 26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Test Material	Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)
Sponsor	3M Toxicology Services Building 220-2E-02, 3M Center St. Paul, Minnesota 55144-1000
Study Monitor	Andrew M. Seacat, PhD 3M 651.575.3161
Alternate Study Monitor	Marvin T. Case, DVM, PhD 3M Toxicology Services 651.733.5180
Study Location	Covance Laboratories Inc. 3301 Kinsman Boulevard Madison, Wisconsin 53704-2595
Study Director	Peter J. Thomford, PhD Covance Laboratories Inc. PO Box 7545 Madison, Wisconsin 53707-7545 608.241.7207
Study Timetable	
Study Initiation Date	August 20, 1998
In-Life (Experimental) Start Date	August 26, 1998
In-Life Termination Date	March 8, 2000
Experimental Termination Date	December 21, 2001



**KEY PERSONNEL**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Study Director	Peter J. Thomford, PhD
Study Toxicologist	Dale Aldridge, BS
Study Coordinator	Elizabeth A. Disch, BA
Manager, Large Animal Toxicology	Sharon Dunn, LATG, AT
Supervisor, Dose Formulation	Dixie Bushee, BS, LATG
Associate Director, Laboratory Animal Medicine	Donna J. Clemons, DVM, MS Diplomate, ACLAM
Clinical Pathologist	Robert L. Hall, DVM, PhD Diplomate, ACVP (Clinical Pathology)
Supervisor, Clinical Pathology	Ronald Markevitch, BS, MT (ASCP)
Anatomic Pathologist	Robert A. Leedle, DVM, PhD Diplomate, ACVP
Supervisor, Anatomic Pathology	Laurie J. Schuller, BA, LAT
Supervisor, Anatomic Pathology	Kimberly W. Durland, BS, HT
Consultant	Stephen I. Bistner, DVM Diplomate, ACVO Veterinary Ophthalmologist
Consultant	Dr. Saroj Das AniLytics Inc.
Consultant	Sandra R. Eldridge, PhD Pathology Associates North Carolina Division, A Charles River Company
Consultant	Sharon Ambrose Pathology Associates North Carolina Division, A Charles River Company
Consultant	Dr. Joe McConnell Mayo Clinic

**CONTENTS**

<b>VOLUME I OF II</b>	<b>Page</b>
ABSTRACT.....	11
PURPOSE.....	14
REGULATORY COMPLIANCE.....	14
TEST MATERIAL, VEHICLE, AND SOLVENT.....	14
Test Material .....	14
Vehicle.....	14
Solvent.....	15
Gelatin Capsules.....	15
Reserve (Archive) Samples.....	15
Disposition.....	15
TEST ANIMALS AND HUSBANDRY.....	15
Animals.....	15
Identification.....	16
Justification.....	16
Husbandry.....	16
Acclimation.....	17
PROCEDURES.....	17
Group Designations and Dosage Levels.....	17
Dosing Procedures.....	18
Dose Analyses.....	19
Observation of Animals.....	19
Clinical Pathology.....	20
Blood Hormone Determination.....	21
Serum PFOS Level Determination.....	21
Additional Serum Collection.....	22
Urine and Feces PFOS Level Determination.....	22
Additional Fecal Samples.....	23
Interim Liver Biopsy Samples.....	23
Terminal Liver Biopsy Samples.....	23
Anatomic Pathology - Terminal Sacrifice.....	24
Anatomic Pathology - Recovery Sacrifice.....	26
Statistical Analyses.....	27
Record Retention.....	28

**CONTENTS (Continued)**

<b>VOLUME I OF II</b>	<b>Page</b>
RESULTS AND DISCUSSION .....	28
Observation of Animals .....	28
Clinical Pathology .....	30
Palmitoyl CoA Oxidase Determination .....	31
Blood Hormone Determination .....	31
Anatomic Pathology .....	31
CONCLUSION .....	33
SIGNATURES .....	34
REFERENCES .....	35
OPHTHALMOLOGY REPORT .....	36
PATHOLOGY REPORT .....	37
COMMENTS ON THE DATA .....	45
CODES, ABBREVIATIONS, AND UNITS .....	47
General Codes and Abbreviations .....	48
Codes for Clinical Pathology .....	49
Abbreviations and Units for Clinical Hematology .....	52
Abbreviations and Units for Clinical Chemistry .....	54
Abbreviations and Units for Clinical Urinalysis .....	56
Codes for Anatomic Pathology .....	57
FIGURES	
1 Mean Body Weight Data (kg) - Males .....	59
2 Mean Body Weight Data (kg) - Females .....	60
TABLES	
1 Summary of Clinical Observations - Treatment .....	61
2 Summary of Clinical Observations - Recovery (Days 186 through 365) .....	65
3 Summary of Clinical Observations - Recovery (Days 366 through 561) .....	66
4 Summary of Ophthalmic Observations - Treatment .....	68
5 Summary of Ophthalmic Observations - Recovery .....	70
6 Summary of Body Weight Data (kg) - Treatment .....	71
7 Summary of Body Weight Data (kg) - Recovery .....	76
8 Summary of Clinical Hematology Data - Day -27 .....	84
9 Summary of Clinical Hematology Data - Day 37 .....	88
10 Summary of Clinical Hematology Data - Day 62 .....	92
11 Summary of Clinical Hematology Data - Day 91 .....	96

**CONTENTS (Continued)**

**VOLUME I OF II**

**Page**

**TABLES**

12 Summary of Clinical Hematology Data - Day 153 .....	100
13 Summary of Clinical Hematology Data - Day 182 .....	104
14 Summary of Clinical Hematology Data - Day 217 .....	108
15 Summary of Clinical Hematology Data - Day 245 .....	112
16 Summary of Clinical Hematology Data - Day 274 .....	116
17 Summary of Clinical Hematology Data - Day 322 .....	120
18 Summary of Clinical Hematology Data - Day 364 .....	124
19 Summary of Clinical Hematology Data - Day 456 .....	128
20 Summary of Clinical Hematology Data - Day 546 .....	132
21 Summary of Clinical Chemistry Data - Day -27 .....	136
22 Summary of Clinical Chemistry Data - Day 37 .....	142
23 Summary of Clinical Chemistry Data - Day 62 .....	148
24 Summary of Clinical Chemistry Data - Day 91 .....	154
25 Summary of Clinical Chemistry Data - Day 153 .....	160
26 Summary of Clinical Chemistry Data - Day 182 .....	166
27 Summary of Clinical Chemistry Data - Day 217 .....	172
28 Summary of Clinical Chemistry Data - Day 245 .....	178
29 Summary of Clinical Chemistry Data - Day 274 .....	184
30 Summary of Clinical Chemistry Data - Day 322 .....	190
31 Summary of Clinical Chemistry Data - Day 364 .....	196
32 Summary of Clinical Chemistry Data - Day 456 .....	202
33 Summary of Clinical Chemistry Data - Day 546 .....	208
34 Summary of Clinical Urinalysis Data - Day -27 .....	214
35 Summary of Clinical Urinalysis Data - Day 37 .....	216
36 Summary of Clinical Urinalysis Data - Day 62 .....	218
37 Summary of Clinical Urinalysis Data - Day 91 .....	220
38 Summary of Clinical Urinalysis Data - Day 153 .....	222
39 Summary of Clinical Urinalysis Data - Day 182 .....	224
40 Summary of Clinical Urinalysis Data - Day 217 .....	226
41 Summary of Clinical Urinalysis Data - Day 245 .....	228
42 Summary of Clinical Urinalysis Data - Day 274 .....	230
43 Summary of Clinical Urinalysis Data - Day 322 .....	232
44 Summary of Clinical Urinalysis Data - Day 364 .....	234
45 Summary of Clinical Urinalysis Data - Day 456 .....	236
46 Summary of Clinical Urinalysis Data - Day 546 .....	238
47 Summary of Palmitoyl CoA Oxidase Determinations - Terminal Sacrifice.....	240
48 Summary of Organ Weight Data - Terminal Sacrifice .....	242
49 Incidence of Macroscopic Observations - Terminal Sacrifice .....	272
50 Incidence of Macroscopic Observations - Recovery Sacrifice .....	275

**CONTENTS (Continued)**

<b>VOLUME I OF II</b>	<b>Page</b>
<b>TABLES</b>	
51 Incidence of Microscopic Observations - Terminal Sacrifice.....	276
52 Incidence of Microscopic Observations - Recovery Sacrifice.....	286
<b>APPENDIX 1</b> .....	<b>287</b>
Protocol Deviations.....	288
Protocol.....	293
Protocol Amendment No. 1.....	311
Protocol Amendment No. 2.....	320
Protocol Amendment No. 3.....	328
Protocol Amendment No. 4.....	334
<b>APPENDIX 2</b> .....	<b>336</b>
Individual Animal Fate Data.....	337
Individual Clinical Observations.....	339
Individual Ophthalmic Observations.....	481
<b>APPENDIX 3</b> .....	<b>496</b>
Individual Body Weight Data (kg).....	497
 <b>VOLUME II OF II</b>	
<b>APPENDIX 4</b> .....	<b>511</b>
Individual Clinical Hematology Data.....	512
Individual Clinical Chemistry Data.....	614
Individual Clinical Urinalysis Data.....	728
<b>APPENDIX 5</b> .....	<b>818</b>
Individual Palmitoyl CoA Oxidase Determinations.....	819
Individual Anatomic Pathology Data.....	823
<b>APPENDIX 6</b> .....	<b>907</b>
AniLytics Inc. Quality Assurance Statements.....	908
Summary and Individual Blood Hormone Determination.....	917
<b>APPENDIX 7</b> .....	<b>963</b>
Cell Proliferation Report.....	964
<b>APPENDIX 8</b> .....	<b>977</b>
Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys.....	978

**CONTENTS (Continued)**

<b>VOLUME II OF II</b>	<b>Page</b>
APPENDIX 9.....	1069
Urobilinogen Analysis Report .....	1070
APPENDIX 10.....	1072
Dose Confirmation Analysis Report .....	1073
Compound Stability Report .....	1078
Analytical Laboratory Report .....	1080
Certificate of Analysis .....	1083
Quality Assurance Statement.....	1086

## ABSTRACT

The purpose of this study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt [PFOS; T-6295 (hereafter referred to as PFOS)] on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by oral capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

Male and female cynomolgus monkeys were assigned to four groups (six animals/sex in Groups 1, 3, and 4; four animals/sex in Group 2). Each group received dose preparations containing the vehicle, lactose, or 0.03, 0.15, or 0.75 mg of PFOS/kg of body weight/day (mg/kg/day). Two animals/group in Groups 1, 3, and 4 were in a recovery period and were not treated for at least 52 weeks following the 26 week treatment period.

Food was provided *ad libitum*, except when animals were fasted. Water was provided *ad libitum*. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. At least once daily, animals were examined for abnormalities and signs of toxicity, and food consumption was assessed qualitatively. Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. Body weight data were recorded weekly before initiation of treatment, on Days -1 and 1, and weekly thereafter. Blood and urine samples were collected for clinical hematology, clinical chemistry, and urinalysis tests before initiation of treatment and at specified intervals during treatment and recovery. Blood was also collected for blood hormone and PFOS level determinations before, during, and after treatment at specified intervals. Feces and liver samples were also collected at specified intervals. On Day 155 (Week 23), one male given 0.75 mg/kg/day died, and on Day 179 (Week 26), one male given 0.75 mg/kg/day was sacrificed due to poor health. On Days 184 and 185 (Week 27), four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were anesthetized, weighed, exsanguinated, and necropsied. At necropsy at the scheduled and unscheduled sacrifices, a serum sample was collected, macroscopic observations were recorded, selected organs were weighed, and selected tissues were collected and preserved. Microscopic examinations were done on tissues from each animal in the control and high-dose groups and selected tissues from animals in the low- and mid-dose groups. Tissues were also collected for palmitoyl CoA oxidase determination, cell proliferation evaluation, PFOS determination, and electron microscopy. Additionally, the bile was collected from the gallbladder, and the gallbladder was preserved. At the recovery sacrifice on Day 549, the remaining Group 4

animals were anesthetized, weighed, exsanguinated, and necropsied. Macroscopic observations were recorded and specified tissues and serum were collected. Remaining animals in Groups 1 and 3 were transferred to Covance stock or transferred to a follow-up study, Covance 6329-268.

At all dose levels, clinical observations, ophthalmic observations, and palmitoyl CoA oxidase determinations do not appear to be affected by treatment with PFOS.

Two males given 0.75 mg/kg/day did not survive to scheduled termination. These deaths were preceded by some adverse clinical observations (constricted pupil, pale gums, abnormal feces, excessive salivation, labored respiration, dehydrated appearance, hypoactive, ataxic, recumbent, low food consumption) and appeared to be related to the administration of PFOS. When compared with animals given the control material, covariate adjusted mean body weights (CAM) for males given 0.75 mg/kg/day were slightly lower beginning at Week 21, and for females given 0.75 mg/kg/day CAM body weights were, in general, significantly lower beginning at Week 11. Similar decreases were not seen in the other treated groups; therefore, this finding is likely test material-related. Test material-related effects on body weights were not apparent during recovery. Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day throughout treatment. The incidence of low food consumption was generally higher in the groups given 0.15 or 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, effects on food consumption were reversed.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182. Triiodothyronine values were notably lower in both males and females given 0.15 and 0.75 mg/kg/day on Days 91 and 182. With the single exception of males given 0.15 mg/kg/day on Day 91, all values were significantly lower. During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material. Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.



The only clinical pathology parameters considered related to the test material were lower total cholesterol for animals given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for animals given 0.15 or 0.75 mg/kg/day. These effects were reversed within the first 5 and 9 weeks of recovery, respectively.

At the terminal sacrifice, increased liver weights, macroscopic observations of mottled liver, hepatocellular hypertrophy, and hepatocellular vacuolation in animals given 0.75 mg/kg/day were considered related to PFOS treatment. However, the microscopic examination liver biopsies taken during recovery did not indicate any test material-related findings and none of the macroscopic observations made at the recovery sacrifice were considered test material-related. There were no microscopic findings in the liver from the animals in the high-dose recovery group. This indicates that the hepatic test material-related effects were reversible.

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-adverse-effect level is 0.15 mg/kg/day. Dose analyses (provided by the Sponsor), fecal analysis results (provided by the Mayo Clinic) and electron microscopy results (provided by Pathology Associates North Carolina Division, A Charles River Company), were provided for inclusion in the final report.

## **PURPOSE**

The purpose of this study was to assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

## **REGULATORY COMPLIANCE**

All aspects of this study were done in accordance with the Environmental Protection Agency Good Laboratory Practice Regulations, 40 CFR 792, with the exception that the analysis of fecal samples for urobilinogen at the Mayo Clinic were not done in compliance with Good Laboratory Practice Regulations.

## **TEST MATERIAL, VEHICLE, AND SOLVENT**

### **Test Material**

The test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295), Lot No. 217 (expiration date: August 31, 2001), is a white to off-white powder and is 86.9% pure. It was received at Covance on September 4, 1997. The test material was stored at room temperature.

Information on synthesis methods, composition, or other characteristics that define the test material is on file with the Sponsor.

### **Vehicle**

The vehicle was lactose (Spectrum, New Brunswick, New Jersey), Lot No. NN0192 (expiration date February 13, 1999). It was received at Covance on March 30, 1998.

The vehicle was stored at room temperature.

Information on synthesis methods, purity, stability, composition, or other characteristics that define the vehicle is on file with the manufacturer.

### **Solvent**

The solvent was acetone (Spectrum, Gardena, California), Lot No. LH0253, (expiration date June 2000). It was received at Covance on June 23, 1997. The solvent was stored at room temperature.

Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

### **Gelatin Capsules**

Gelatin capsules, Size Nos. 2 (Lot No. 122932, expiration date June 12, 2003) and 4 (Lot No. 544043, expiration date August 1, 2002) were manufactured by Torpac Inc., (Fairfield, New Jersey). Lot No. 122932 was received at Covance on June 12, 1998, and Lot No. 544043 was received on September 1 and November 10, 1998. The capsules were stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer is maintained in the data.

### **Reserve (Archive) Samples**

A reserve sample (1 g) of each lot of the test material, vehicle, and each test material/lactose dilution was taken and stored at room temperature. These samples were transferred to the Sponsor after completion of the treatment phase (see Protocol Deviations).

### **Disposition**

Remaining test material will be retained at Covance for use in possible future studies.

## **TEST ANIMALS AND HUSBANDRY**

### **Animals**

Young adult to adult cynomolgus monkeys were obtained from Covance Research Products Inc. (Denver, Pennsylvania) on June 30, 1998. The animals weighed 2.4 to 4.4 kg at initiation of treatment.

### **Identification**

Each animal was assigned a permanent number upon arrival and identified with a collar tag before initiation of treatment. All data for an animal are recorded under this number.

### **Justification**

PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to a PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

### **Husbandry**

Animal Rooms 251, 258, 259, and 527 were used for this study. Environmental controls for the animal rooms were set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. Variations from these conditions are documented in the data and are considered to have had no effect on the outcome of the study.

The animals were housed individually in suspended, stainless-steel cages.

Certified primate diet (#8726C, Harlan Teklad) was provided once or twice daily, unless otherwise specified. The lot numbers are recorded in the data. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file with Covance-Madison. Fruits or additional supplements were provided, but did not require analysis.

Water was provided *ad libitum*. Samples of the water are analyzed for specified microorganisms and environmental contaminants. The results are on file with Covance-Madison.

There were no known contaminants in the diet or water at levels that would have interfered with this study.

**Acclimation**

Twenty-four males and 24 females were received on June 30, 1998, and acclimated in Animal Room 251 for 57 days before initiation of treatment. In general, animals in this shipment appeared healthy. During acclimation, the animals were examined for abnormalities indicative of health problems. In addition, three tuberculosis tests, a physical examination, and a fecal flotation for parasites were performed on each animal.

**PROCEDURES**

This study was conducted in accordance with the Protocol dated August 20, 1998, and Protocol Amendment Nos. 1, 2, 3, and 4. The protocol, protocol amendments, and protocol deviations are in Appendix 1.

**Group Designations and Dosage Levels**

Selection of animals for the study was based on data collected during acclimation. Animals were assigned to treatment groups using a computerized blocking procedure designed to achieve body weight balance with respect to treatment group.

Group	Dose Level (mg/kg/day) <sup>a</sup>	Total Material Dose Level (mg/kg/day) <sup>b</sup>	Number of Animals	
			Males	Females
1	0 <sup>a</sup>	30 <sup>a</sup>	6 <sup>d</sup>	6 <sup>d</sup>
2	0.03	15 <sup>b</sup>	4	4
3	0.15	6 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>
4	0.75	30 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>

- a The control group (Group 1) received the equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.
- b The low-dose (Group 2) received the test material diluted with lactose (1:499, w:w).
- c The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).
- d Two animals in Groups 1, 3, and 4 designated as recovery animals were treated for at least 26 weeks, then treatment was discontinued, and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

### **Dosing Procedures**

**Vehicle.** Dose levels were based on the vehicle as supplied for Group 1. For Group 1 dose preparations, the specified amount of lactose was weighed, transferred into gelatin capsules, and the top and bottom halves of each capsule were joined. Capsules were prepared at least once weekly.

**Test Material.** The test material/lactose preparations for Groups 2 through 4 were diluted once before initiation of treatment; capsules were prepared at least once weekly.

A specified amount of test material was weighed, placed into a labeled mixing container, and the appropriate volume of acetone was added. After stirring manually until the test material was dissolved, the required amount of lactose was weighed and transferred to the container. The components were mixed thoroughly using a spatula. The prepared test material dilution was stirred periodically while allowed to stand exposed to the air until the acetone had evaporated. Preparations were diluted to facilitate capsule preparation.

Samples of the finished mixture for dose analyses were taken directly from the container.

The dose preparations were stored at room temperature between capsule preparations. The appropriate amount of prepared test material was weighed and transferred into Size 2 (Days 1 through 8) or 4 (Days 9 through 184) gelatin capsules and the top and bottom halves of each capsule were joined. Size 4 capsules were used instead of Size 2 to better facilitate dose administration. Individual daily doses were based on the most recently recorded body weight, with the exception of doses given on days when body weight measurements were performed; on those days, the previous body weight was used.

All capsule preparations were stored at room temperature until used for dosing.

**Method of Administration.** Gelatin capsules were used to facilitate comparison with data from previous toxicology studies that used the oral route. Also, oral is the most likely route of exposure in humans. Partial or intact capsules were noted in the vomitus of several animals on occasion; however, this is not considered to have adversely affected the results of the study.

The dose preparations were administered orally in gelatin capsules once daily 7 days/week for at least 26 weeks (see Protocol Deviations for exceptions).

### **Dose Analyses**

Homogeneity and stability analyses were the responsibility of the Sponsor.

Samples (approximately 1 g each) were taken from the top, middle, and bottom of the test material/lactose preparations on Day -15 for homogeneity analysis. Samples collected from the middle of the preparations were also designated for prestudy stability analysis. A set of samples (approximately 1 g each) were taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase for test material content analysis.

All samples were stored at room temperature until sent under ambient conditions to the Sponsor for analysis. Results of dose analyses were provided for inclusion in the final report.

### **Observation of Animals**

**Clinical Observations.** The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. Animals were also observed at least once daily (a.m.) for signs of poor health or abnormal behavior, and food consumption was assessed qualitatively; only abnormal findings were recorded. Once weekly and on the day of scheduled sacrifice, each animal was observed; abnormal findings or an indication of normal was recorded (see Protocol Deviations for exceptions). Additionally, postdose observations were recorded during treatment approximately 30 to 90 minutes after the last dose administration; only abnormal findings were recorded.

**Ophthalmology.** Ophthalmic examinations were done on each animal before initiation of treatment, before the scheduled terminal sacrifice during Week 26, and during Week 52 (see Protocol Deviations). The pupils were dilated with 1% Mydracil® and the anterior portion of the eye, optic media, and ocular fundus were examined with an indirect ophthalmoscope by a board-certified ophthalmologist.

**Body Weights.** Individual body weight data were recorded weekly before initiation of treatment, on Day -1, on the first day of treatment, and weekly thereafter.

### Clinical Pathology

Blood and urine samples were collected from each animal once before initiation of treatment (Day -27); on Days 37, 62, 91, 153, and 182 of treatment; and on Days 217, 245, 274, 322, 364, 456, and 546 during recovery (see Protocol Deviations). Animals were fasted overnight, and urine was collected overnight on wet ice before blood sampling; water was provided *ad libitum*. Blood was collected from the femoral vein. Potassium EDTA was the anticoagulant used for hematology tests; no anticoagulant was used for the chemistry tests. Blood samples were collected from the animal that was sacrificed at an unscheduled interval. Animals were bled in sequential order on Days 37, 62, and 91 and in random order at all other scheduled collections; this is not expected to have an impact on the clinical pathology results. The following were evaluated (see Protocol Deviations for exceptions).

#### Hematology

red blood cell (erythrocyte) count	differential blood cell count
hemoglobin	segmented neutrophil count
hematocrit	lymphocyte count
mean corpuscular volume	monocyte count
mean corpuscular hemoglobin	eosinophil count
mean corpuscular hemoglobin concentration	basophil count
platelet count	blood cell morphology
white blood cell (leukocyte) count	reticulocyte count

#### Clinical Chemistry

glucose	sorbitol dehydrogenase
urea nitrogen	creatine kinase
creatinine	calcium
total protein	inorganic phosphorus
albumin	sodium
globulin	potassium
total bilirubin	chloride
cholesterol	bile acids
triglycerides	amylase
alanine aminotransferase	lipase
alkaline phosphatase	pancreatic-specific amylase
aspartate aminotransferase	high density lipoprotein (HDL)
gamma glutamyltransferase	(effective with collection on Day 153)



### Urinalysis

volume (approximately 16 hours)	bilirubin
specific gravity	blood
pH	urobilinogen
protein	microscopic examination of sediment
glucose	appearance
ketones	

### Blood Hormone Determination

Blood samples (approximately 5 mL) were collected from each animal three times before initiation of treatment (Days -50, -40, and -27); on Days 37, 62, 91, and 182 of treatment; and on Days 217, 245, 274, 322, 364, 456, and 546 during recovery (see Protocol Deviations). Animals were fasted overnight. Blood was collected from a femoral vein without using an anticoagulant. Samples were allowed to clot and centrifuged within 1 hour after collection; serum was harvested. The serum was divided into two approximately equal aliquots and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to AniLytics Inc. for analysis of cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total triiodothyronine, and total thyroxin. Beginning with the collection on Day 322 the samples were also analyzed for free triiodothyronine and free thyroxin.

### Serum PFOS Level Determination

Blood samples (approximately 2 mL) were collected from each animal once before initiation of treatment (Day -27); during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, and 26, and 27 (Day 183) of treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 198), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79 (see Protocol Deviations). Animals were fasted overnight and water was provided *ad libitum*. Blood was collected from a femoral vein without using an anticoagulant. Samples were centrifuged within 1 hour after collection and serum was harvested. Serum samples were stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for analysis. Results will be reported separately.

### **Additional Serum Collection**

At the scheduled terminal necropsy and the necropsy of Animal No. I05506 (Group 4 male), blood samples (approximately 20 mL) were collected from the vena cava at the time of exsanguination. Samples were collected without using an anticoagulant and centrifuged within 1 hour of collection. Serum was harvested and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for possible future analysis.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3, and 4 sacrificed at the terminal necropsy were sent on dry ice by the Sponsor to AniLytics for total triiodothyronine, total thyroxin, free triiodothyronine, and free thyroxin determinations.

Additional serum samples collected at the terminal and recovery sacrifices were transferred by the Sponsor to Anilytics for analysis of estradiol, follicle stimulating hormone (FSH), and lutenizing hormone (LH) for females, and estradiol in males. Results were provided for inclusion in the final report.

Additionally, samples were transferred by the Sponsor to the Mayo Clinic for analysis of triiodothyronine (T3), total thyroxin (T4), free thyroxin (free T4), and thyroid stimulating hormone (TSH). Additional reserve samples of serum were transferred for possible future anlysis for estradiol. Any unused serum will be returned to the Sponsor. Results were provided for inclusion in the final report.

### **Urine and Feces PFOS Level Determination**

Urine [at least 2 mL (see Protocol Deviations)] and feces (at least 5 g) were collected overnight on the first day of recovery (Day 184) and on Days 189, 216, 275, 321, and 366 during recovery. In addition, a 24-hour sample of urine and feces was collected before the completion of 52 weeks of recovery. Except for the first day of recovery, animals were not fasted. Samples were stored in a freezer set to maintain -10 to -30°C, until they were packed on dry ice and shipped to the Sponsor. The samples will be analyzed for PFOS. Results will be reported separately.

### **Additional Fecal Samples**

During Week 23, a fresh fecal sample (up to 5 g) was collected from all animals in the control and high-dose groups. Samples were collected in white polypropylene containers after pans were cleaned in the morning to ensure that the fecal samples were not more than 6 hours old (see Protocol Deviations). Samples were packed on dry ice and shipped to the Mayo Clinic for analysis of urobilinogen using a routine, standardized, colorimetric assay. Results were provided for inclusion in the final report.

### **Interim Liver Biopsy Samples**

A sample of liver (approximately 1 to 2 g) was collected by biopsy from animals in Group 4 only during recovery [Week 57 (Day 393), on the same day as the serum PFOS blood collection]. This sample was divided into four portions as follows.

One subsample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis (see Protocol Deviations). Results will be reported separately.

The third subsample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to Pathology Associates. Tissues were processed and evaluated by electron microscopy by Pathology Associates. A report was provided by Pathology Associates for inclusion in the final report.

The fourth subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until transferred to the Sponsor for possible future analysis.

### **Terminal Liver Biopsy Samples**

A sample of liver (approximately 1 g) was collected by biopsy from all animals in Group 3 during recovery [Week 80 (Day 554), one week after the serum PFOS blood collection (see Protocol Deviations)]. This sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

### **Anatomic Pathology - Terminal Sacrifice**

**Necropsy.** A necropsy was done on Animal No. I05509 (Group 4 male) that died on Day 155 (Week 23) and Animal No. I05506 (Group 4 male) that was sacrificed in a moribund condition on Day 179 (Week 26). During Week 27 (Days 184 and 185) four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were fasted overnight, anesthetized with ketamine and xylazine, weighed, bled for required tests, exsanguinated, and necropsied. Animals were necropsied in random order.

The necropsy included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

**Organ Weights.** At scheduled and unscheduled sacrifices, the following organs (when present) were weighed; paired organs were weighed separately.

adrenal (2)	ovary (2)
brain	pancreas
epididymis (2)	testis (2)
kidney (2)	thyroid (2) with parathyroid
liver	

Organ-to-body weight percentages and organ-to-brain weight ratios were calculated.

**Palmitoyl CoA Oxidase Determinations.** Representative samples of the right lateral lobe of liver were collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until analyzed for palmitoyl CoA oxidase activity.

**Cell Proliferation Evaluation.** Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas were collected and preserved in zinc formalin. A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc were also prepared. After fixation, samples were embedded in paraffin and shipped to Pathology Associates North Carolina Division, A Charles River Company (Pathology Associates) for proliferation cell nuclear antigen (PCNA) evaluation, including the examination of slides stained with

hematoxylin and eosin (see Protocol Deviations). Results were provided by Pathology Associates for inclusion in the final report (Appendix 7).

**Liver PFOS Determination.** A section of liver (approximately 20 g) was collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped with plasma samples to the Sponsor. Results will be reported separately.

**Gallbladder and Bile Collection.** At the scheduled terminal sacrifice for each animal, bile was collected from the gallbladder, measured, transferred into a cryovial, and flash-frozen in liquid nitrogen. The gallbladder, once emptied, was weighed, and a section (approximately 4 to 5 mm) from the mid-portion was collected. The remaining gallbladder was placed in a cryovial and flash-frozen in liquid nitrogen. The bile and gallbladder samples were stored on dry ice until transferred to a freezer set to maintain -60 to -80°C. Samples were packed on dry ice and shipped to the Sponsor for possible future analysis.

**Tissue Preservation.** The following tissues (when present) or representative samples were collected and preserved in 10% neutral-buffered formalin, unless otherwise specified (see Protocol Deviations).

adrenal (2)	lesions
aorta	liver
brain	lung
cecum	mammary gland
cervix	mesenteric lymph node
colon	ovary (2)
duodenum	pancreas
epididymis (2)	pituitary
esophagus	prostate
eyes [(2) preserved in Davidson's fixative for all sacrificed animals]	rectum
femur with bone marrow (articular surface of the distal end)	salivary gland [mandibular (2)]
gallbladder	sciatic nerve
heart	seminal vesicle (2)
ileum	skeletal muscle (thigh)
jejunum	skin
kidney (2)	spinal cord (cervical, thoracic, and lumbar)
	spleen

sternum with bone marrow	thyroid (2) with parathyroid
stomach	trachea
testis [(2) preserved in Bouin's solution for all sacrificed animals]	urinary bladder
thymus	uterus
	vagina

**Histopathology.** Tissues (as appropriate) were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically from each animal in the control and high-dose groups (see Protocol Deviations for exceptions). In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

Bone marrow smears from the sternum of each animal at scheduled and unscheduled sacrifices were prepared, stained with Wright's stain, and retained for possible examination.

**Electron Microscopy.** A sample of the liver was collected from each animal at the scheduled terminal sacrifice. Tissues were processed into blocks and, along with a hematoxylin and eosin-stained slide, were shipped to Pathology Associates for analysis. Results were provided for inclusion in the final report.

#### **Anatomic Pathology - Recovery Sacrifice**

**Termination.** Remaining animals in Group 1 were transferred to Covance stock on Day 549 and remaining animals in Group 3 were transferred to Covance 6329-268 on Day 561. On Day 549, remaining animals in Group 4 were fasted overnight, anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

The necropsy of the animals in Group 4 included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

**Liver Samples.** Samples of liver were collected from animals in Group 4 as follows.

One sample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

The third sample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to Pathology Associates. Tissues were processed and evaluated by electron microscopy by Pathology Associates. A report was provided by Pathology Associates for inclusion in the final report.

**Additional Tissue and Serum Samples.** Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each, if possible), and bile and serum (each as much as possible) were collected. These samples were flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for possible future analysis.

#### **Statistical Analyses**

Levene's test (Levene, 1960) was done to test for variance homogeneity. In the case of heterogeneity of variance at  $p \leq 0.05$ , transformations were used to stabilize the variance. Comparison tests took variance heterogeneity into consideration.

One-way analysis of variance [ANOVA (Winer, 1971a)] was used (if applicable) to analyze initial body weights, organ weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, and blood hormone determinations. If the ANOVA was significant, Dunnett's t-test (Dunnett, 1964) was used for control versus treated group comparisons.

One-way analysis of covariance [ANCOVA (Winer, 1971b)] was used to analyze body weights, with initial body weights as the covariate. If the ANCOVA was significant, covariate-adjusted means were used for control versus treated group comparisons.

Group comparisons (Groups 2 through 4 versus Group 1) were evaluated at the 5.0%, two-tailed probability level. Only data collected on or after the first day of treatment were analyzed statistically. Statistical analyses were not performed on data collected during recovery.

### **Record Retention**

All raw data, documentation, records, protocol, and specimens generated as a result of this study will be archived in the storage facilities of Covance-Madison for a period of at least 1 year. At least one year after the submission of the final report, the Sponsor will determine the final disposition of the materials. All raw data stored on magnetic media and the protocol, study correspondence, and an original copy of the final report will be retained by Covance-Madison.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (AniLytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

## **RESULTS AND DISCUSSION**

### **Observation of Animals**

**Clinical Observations.** Clinical observations are summarized in Tables 1, 2, and 3; individual data are presented in Appendix 2. Individual animal fate data are also presented in Appendix 2.

Animal Nos. I05506 and I05509 given 0.75 mg/kg/day (Group 4 males) did not survive to the scheduled terminal sacrifice. All other animals survived to the scheduled study termination. No clinical observations noted in the animals that survived to the terminal sacrifice or recovery were attributable to the administration of PFOS.

Animal No. I05509 (Group 4 male) died after dosing on Day 155 (Week 23). On Day 154 (Week 22) observations of constricted pupil in both eyes and pale gums were noted. Observations noted on Day 155 prior to dosing included few, mucoid, liquid, and black-colored feces and low food consumption. Approximately 15 minutes after dosing, the animal was observed as hypoactive with labored respiration and pale gums. This



animal also appeared dehydrated and was cold to the touch. These observations persisted until approximately 30 minutes postdose when the animal was also noted as recumbent. Shortly thereafter, the animal died during an examination by a laboratory animal veterinarian. An enlarged liver was detected by palpation. The cause of death was determined to be pulmonary necrosis with severe acute inflammation.

On Day 179 (Week 26), Animal No. I05506 (Group 4 male) was sacrificed in a moribund condition. Low food consumption was noted on Day 178 (Week 26) and at the a.m. observation interval on Day 179. Approximately 5 to 10 minutes postdose on Day 179, the animal had excessive salivation, labored respiration, and hypoactive and ataxic behavior. With the exception of excessive salivation, these findings continued to be observed approximately 3 hours postdose. The cause of the moribund condition was not determined.

Two additional animals had noteworthy observations during treatment. One female in the group given the control material, Animal No. I05529, was examined by a laboratory animal veterinarian on Day 5 (Week 1) due to observations of dehydration, thin appearance, clear oral and nasal discharge, excessive salivation, and audible respiration. This animal was diagnosed with pneumonia and treated with Lactated Ringer's solution and antibiotics. This animal had recovered by Day 14 (Week 2). Animal No. I05534 (Group 4 female) was diagnosed with a tapeworm infection during Week 23 and was treated with praziquantel. Neither infection was test material-related.

Clinical observations during recovery were typical of laboratory primates.

**Ophthalmology.** Ophthalmic observations are summarized in Tables 4 and 5; individual data are presented in Appendix 2.

There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS.

**Body Weights.** Body weight data are illustrated in Figures 1 and 2 and summarized in Tables 6 and 7; individual data are presented in Appendix 3.

Covariate-adjusted mean (CAM) body weights were slightly lower in males given 0.75 mg/kg/day when compared with males given the control material beginning at Week 21; the difference was significant at Weeks 23 and 27. In females given 0.75 mg/kg/day, CAM body weights were significantly lower at Weeks 11 through 16, 19 through 23, and 25 through 27 when compared with females given the control material. These decreases were likely test material-related.

Differences in body weights were not apparent during the recovery period.

**Food Consumption.** Food consumption data are summarized in Tables 1, 2, and 3 (Summary of Clinical Observations); individual data are included in the individual clinical observations in Appendix 2.

Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day. The incidence of low food consumption was generally higher in the groups given 0.15 and 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, instances of low food consumption were sporadic and were similar for animals in the control and treated groups.

### **Clinical Pathology**

Hematology, clinical chemistry, and urinalysis data are summarized in Tables 8 through 46; individual data are presented in Appendix 4.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

### **Palmitoyl CoA Oxidase Determination**

Palmitoyl CoA oxidase determinations are summarized in Table 47; individual data are presented in Appendix 5.

Results of palmitoyl CoA oxidase determinations were not considered to be related to the test material.

### **Blood Hormone Determination**

Summary and Individual Blood Hormone Data are presented in Appendix 6.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182.

Triiodothyronine values were notably lower on Days 91 and 182 in both males and females given 0.15 or 0.75 mg/kg/day. With the single exception on Day 91 of males given 0.15 mg/kg/day, all values were significantly lower. There were several other instances in which the hormone values in treated groups differed from those of controls, but these differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be related to the administration of the test material.

During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material.

Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.

### **Anatomic Pathology**

Terminal body weights, absolute organ weights, organ-to-body weight percentages, and organ-to-brain weight ratios are summarized in Table 48; incidences of macroscopic and microscopic observations are summarized in Tables 49 through 52. Individual data are presented in Appendix 5.

Two of four males receiving 0.75 mg/kg/day (high dose) did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to the control group. Absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only “mottled” liver was considered test material-related. “Mottled” livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had “mottled” and “large” liver.

Microscopic examination of animals sacrificed at Week 27 and of the two males sacrificed at an unscheduled interval yielded test material-related observations in the liver. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobularly or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in all high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.


At the recovery sacrifice, one of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically, and no test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.


## CONCLUSION

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-adverse-effect level is 0.15 mg/kg/day. Dose analysis results (provided by the Sponsor), fecal analysis results (provided by the Mayo Clinic), and electron microscopy results (provided by Pathology Associates), were provided for inclusion in the final report.

**SIGNATURES**

  
\_\_\_\_\_  
Elizabeth A. Disch, BA  
Study Coordinator  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Peter J. Thomford, PhD  
Study Director  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date

## REFERENCES

Dunnett, C. W., "New Tables for Multiple Comparisons with a Control," Biometrics, 20:482-491 (1964).

Levene, H., "Robust Tests for Equality of Variances," Contributions to Probability and Statistics, (eds.) I. Olkin et al., Ch. 25, pp. 278-292, Stanford University Press: Stanford, California (1960).

Winer, B. J., "Design and Analysis of Single-Factor Experiments," Statistical Principles in Experimental Design, Second Ed., Ch. 3, pp. 149-260, McGraw-Hill: New York, New York (1971a).

Winer, B. J., "Analysis of Covariance," Statistical Principles in Experimental Design, Second Ed., Ch. 10, pp. 752-812, McGraw-Hill: New York, New York (1971b).

### OPHTHALMOLOGY REPORT

Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS. There were no test material-related observations at any of the examinations.

Stephen I. Bistner DVM, DACVO  
Stephen I. Bistner, DVM  
Diplomate, ACVO  
Veterinary Ophthalmologist

December 18, 2001  
Date



## PATHOLOGY REPORT

### SUMMARY

The purpose of the study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The test material was administered at dose levels of 0.03, 0.15, and 0.75 mg/kg/day. One male given 0.75 mg/kg/day died on Day 155 after dose administration and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health. The treatment period was followed by an approximate 52-week recovery period.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

Two of four males receiving 0.75 mg/kg/day did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. These absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had "mottled" and "large" liver.

Microscopic examination of animals sacrificed at Week 27 and the two unscheduled sacrifice males yielded test material-related observations in the liver. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobularly or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was also observed in four of four high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.

For the recovery sacrifice at Week 79, only high-dose animals were necropsied. One of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

## METHODS

Four groups of male and female cynomolgus monkeys were administered the test material daily by capsule at a dose level of 0 (control group; received capsules containing lactose), 0.03, 0.15, or 0.75 mg/kg of body weight/day (mg/kg/day). There were six animals/sex in the control group and the groups given 0.15 or 0.75 mg/kg/day; two animals/sex in these groups were designated as recovery animals to be observed for approximately 26 weeks posttreatment. The recovery period was later extended an additional 26 weeks. There were four animals/sex in the group given 0.03 mg/kg/day.

One male given 0.75 mg/kg/day died on Day 155 following dose administration, and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health.

Blood and urine were collected for hematology, clinical chemistry, and urinalysis tests once before initiation of treatment (Week -4), on Days 37, 62, 91, 153, and 182 and on Days 217, 245, 274, 322, 364, 456, and 546 (recovery animals). High density lipoprotein cholesterol was not measured at the clinical pathology intervals before Day 153.

The terminal sacrifice and necropsy occurred on Days 184/185; macroscopic observations were recorded, organ weights were obtained, and tissues were placed in fixative as specified by the protocol. Samples of the right lateral lobe of the liver from each animal were frozen for analysis of palmitoyl CoA oxidase activity. Sections of liver from each animal were processed to block for electron microscopy and shipped to the Sponsor's designee for ultrastructural evaluation. Samples of liver from each animal were frozen and shipped to the Sponsor for PFOS determination. The gallbladders and bile from each animal were collected, frozen, and shipped to the Sponsor. Samples of pancreas, left and right testes, and the left lateral lobe of the liver were preserved for cell proliferation evaluation by the Sponsor's designee using proliferation cell nuclear antigen. Light microscopic examinations were done on collected tissues from control animals and animals given 0.75 mg/kg/day. In addition, liver and thymus from all animals given 0.03 or 0.15 mg/kg/day and spinal cord gray matter from females given 0.03 or 0.15 mg/kg/day were examined by light microscopy.

During Week 57, liver biopsies were performed on the recovery animals that had been given 0.75 mg/kg/day. The tissue was divided into four samples. Three of the samples were used for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively. The fourth sample was frozen and shipped to the Sponsor for possible analysis. At the end of the recovery period (Week 79), the control animals were returned to the Covance stock colony, the animals that had been given 0.15 mg/kg/day were transferred to a subsequent study for the Sponsor (Covance 6329-268) following liver biopsy for PFOS analysis by the Sponsor, and the animals that had been given 0.75 mg/kg/day were sacrificed and necropsied. At this recovery necropsy, macroscopic observations were recorded, and three samples of liver were collected for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively.

Statistically significant differences cited in the Results and Discussion are based on comparisons between the control and treated groups.

## RESULTS AND DISCUSSION

### **Mortality**

Two of four males receiving 0.75 mg/kg/day (high dose) of the test material did not survive to the scheduled terminal sacrifice at Week 27. One was found dead on Day 155. The other was sacrificed on Day 179 due to poor health. The cause of death in the animal found dead was judged to be pulmonary necrosis with severe acute inflammation. Microscopically, the pulmonary lesion appeared to be an acute exacerbation of a chronic lesion. The cause of death in the moribund animal was not determined. All other animals survived to their scheduled sacrifices.

### **Clinical Pathology**

**Week -4.** Results of clinical pathology tests indicated no obvious group or individual health abnormalities. Several animals, however, had mildly elevated alanine aminotransferase activities at Week -4. These animals were primarily females and were dispersed among all of the groups. By Day 37, their alanine aminotransferase activities were no longer elevated. The transient increase in this liver enzyme was considered likely due to subclinical infection with Hepatitis A virus, a common infection in cynomolgus monkeys, and did not negatively impact evaluation of the test material.

**Days 37, 62, 91, 153, and 182.** Although there were several statistically significant or otherwise notable differences for clinical pathology test results between the control and treated animals, most of the differences were inconsistent over time or similar to differences present before initiation of treatment (i.e., Week -4). The only differences considered to represent effects of the test material were lower total cholesterol for males and females given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. The effect on total cholesterol became progressively worse over time. At Day 182, the mean total cholesterol concentrations for the males and females given 0.75 mg/kg/day were approximately 68% and 49% lower, respectively, than those for the control males and females. The effect on high density lipoprotein cholesterol, measured only at Days 153 and 182, was proportionately greater than that for total cholesterol. At Day 182, the mean high density lipoprotein cholesterol

concentrations for the males and females given 0.75 mg/kg/day were approximately 79% and 62% lower, respectively, than those for the control males and females.

Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day (statistically lower on Days 91, 153, and 182) and higher serum bile acid concentration for males given 0.75 mg/kg/day (statistically higher on Day 182 only). These potential effects of the test material were very mild, and neither was considered adverse.

Statistically significant differences for other test results were considered incidental and unrelated to administration of the test material. These differences were inconsistent over time or were similar to differences that existed before the initiation of treatment.

Unscheduled sacrifice Animal No. I05506, a male given 0.75 mg/kg/day, was sacrificed on Day 179. The most notable findings for this animal were a moderate neutrophilic leukocytosis, mildly increased serum bile acid and globulin concentrations, and moderately to markedly decreased total cholesterol and high density lipoprotein cholesterol.

**Days 217, 245, 274, 322, 364, 456, and 546 (Recovery animals).** The effect on cholesterol was reversed by Day 217, and the effect on high density lipoprotein cholesterol was reversed by Day 245. There were no other findings considered to represent persistent or delayed occurrence of toxic effects.

### **Anatomic Pathology**

**Organ Weights.** At the terminal sacrifice (Week 27) females in the group receiving 0.75 mg/kg/day (high-dose) had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. This increase was regarded as test material-related. In females the absolute pancreas weights were higher in animals receiving 0.03 mg/kg/day (low-dose) than in those receiving 0 mg/kg/day (control). Increased pancreatic weights were not regarded as test material-related.

In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. The increase was regarded as test material-related. Left adrenal-to-body weight percentages were also increased in high dose males compared to controls. The significance of the increase left adrenal weight percentage was not known.

Organ weights were not taken at the recovery sacrifice at Week 79.

**Macroscopic Observations.** Twenty one of 30 animals at the terminal sacrifice had at least one macroscopic observation. One of the observations was obesity; it was not regarded as pathologic. Thus, 20 animals had macroscopic observations. Of all the macroscopic observations, only “mottled” liver was considered test material-related. “Mottled” liver was observed in the two high-dose males and in one high-dose female.

The other observations included adhesions and dark or red foci in any of several organs. Among high-dose females, each had at least one observation of a dark or red focus. In addition, adrenal cortices of the two high-dose males and two of four high dose females were recorded as dark. In one high-dose female (Animal No. I05540), the red focus in the lung correlated microscopically with hemorrhage. There were no microscopic correlates for the other observations. Hence, dark or red foci were considered too non-specific to be considered test material-related. Additionally, dark and red foci were observed in animals in other dose groups. Dark adrenal cortices did not have a microscopic correlate; they, too, were not considered test material-related.

Of the two males not surviving until the scheduled terminal sacrifice, one did not have any macroscopic observations. The other (Animal No. I05509) had several observations. Of these observations, those in the liver were considered test material-related. The liver observations were “mottled” and “large”.

For the recovery sacrifice at Week 79, only high dose animals were necropsied. One of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related.

**Microscopic Observations.** At the terminal sacrifice, all tissues from the control and high dose groups were examined. All tissues were examined on the two high-dose males not surviving until the terminal sacrifice; the microscopic data were grouped with that of the terminal sacrifice animals. Liver, thymus, and spinal cord (females only) were examined from animals in the low and intermediate dose groups. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobularly or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in four of four high-dose females. The microscopic observations of

hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent. Multifocal hepatic vacuoles were found in one of four low dose males, and in a control and a low-dose female.

Two other observations were suggestive of possible test material effects upon examination of only control and high-dose animals. When tissues were examined from the low and intermediate dose groups as well, test material-dependency was not supported. In females, thymic atrophy was more pronounced in dosed animals than in controls. However, there is no clear dose-dependent pattern and thus, thymic atrophy cannot be considered test material-dependent. Intra-neuronal pigment was observed in the spinal cord gray matter of two of four high dose, four of four mid-dose, three of four low-dose and one of four control females. And thus, spinal cord pigment was considered unrelated to the test material.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material related findings.

At the recovery sacrifice, livers were examined from high-dose animals. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

In those animals from which all tissues were examined, the width of the femoral growth plates were assessed as a general indication of the maturity of the animals. Based on this indicator, males were less mature than females.

*Robert L. Hall*

Robert L. Hall, DVM, PhD  
Diplomate, ACVP  
(Clinical Pathology)

*21 December 2001*

Date

*Robert A. Leedle*

Robert A. Leedle, DVM, PhD  
Diplomate, ACVP

*21 December 2001*

Date



## COMMENTS ON THE DATA

Various models of calculators, computers, and computer programs were used to analyze data in this study. Because different models round off or truncate numbers differently, values in some tables (e.g., means, standard deviations, or individual values) may differ slightly from those in other tables, from individually calculated data, or from statistical analysis data. Neither the integrity nor the interpretation of the data was affected by these differences.

Some tabular data were compiled using Excel® Version 7.0 software.

The units for the dose levels on the data collection system (PTS) summary tables are mg/kg/day.

The number of animals listed in the heading of the summary table for clinical observations reflects the number of animals assigned to each group at the start of the study.

The summary table for clinical observations indicates the number of animals for which a condition was observed without regard to the specific nature, severity, reversibility, number of incidences/animal, or the length of time the condition persisted.

Only observations other than normal are indicated on the summary of clinical observations table.

The specific details for comments in the individual clinical observations tables that are indicated with a “C” can be found at the end of each group for each sex.

The day of initiation of treatment is “Day 1, Week 1.” Body weight data are entered at the start of a study week (e.g., a body weight recorded on Day 1 is considered a Week 1 body weight, a body weight recorded on Day 8 is considered a Week 2 body weight).

Differences in the population size (N) on the summary tables for clinical and anatomic pathology are explained on the individual data tables.

Results of clinical pathology samples collected for animals sacrificed at an unscheduled interval appear on the individual clinical pathology tables for the next scheduled interval. These results are not on the summary tables and are not included in the statistical analyses.

Statistical analyses were not done when there were two or fewer values for a parameter.

**COMMENTS ON THE DATA (continued)**

Bile volume is located on the individual anatomic pathology table under the heading of “absolute organ weight (grams)”. The value listed for bile is not a weight and is designated with a unit of mL.

Some clinical observations discussed in the report were documented on the Request for Veterinary Services form and will be archived with the raw data, but they do not appear on the individual clinical observations tables.

## **CODES, ABBREVIATIONS, AND UNITS**

General Codes and Abbreviations  
Codes for Clinical Pathology  
Abbreviations and Units for Clinical Hematology  
Abbreviations and Units for Clinical Chemistry  
Abbreviations and Units for Clinical Urinalysis  
Codes for Anatomic Pathology

Note: The following lists of codes, abbreviations, and units are used by Covance. Some, but not necessarily all, of this information may be needed for this report.

---

### General Codes and Abbreviations

WK	Week
N	Number of measurements in a group
Mean; MEAN	Arithmetic mean
CAM	Covariate-adjusted mean
SD; S.D.; STAND DEV; STANDARD DEV; sd	Standard deviation
*	Group mean is significantly different from the mean of the control group (Group 1) at $p \leq 0.05$
-, NA	No value; not applicable; not present
P	Present
C	Comment found at the end of each group for each sex
UNSCHEDED DISPATCH	Unscheduled Observations transferred from the in-life module of the data collection system to the necropsy module for reference during necropsy. Observations are duplicates of the last in-life observations.
TBW	Terminal body weight
#	Number
VET EXAM	Veterinary examination
AM OBS	Observations recorded during the daily, morning observation interval.
30-90 OB	Observations recorded during the 30 to 90 minute postdose observation interval.
E2	Estradiol
FSH	Follicle stimulating hormone
LH	Lutenizing hormone
T3	Triiodothyronine
T4	Total thyroxin
FREE T4	Free thyroxin
TSH	Thyroid stimulating hormone

## Codes for Clinical Pathology

### GENERAL CODES

NS	No sample
QS/QNS	Quantity not sufficient
NR	No repeat (sample volume not sufficient for repeat analysis)
FS	Fibrin strands
SC	Sample clotted
SH	Slightly hemolyzed
H	Hemolyzed
SL	Slightly lipemic
L	Lipemic
SI	Slightly icteric
I	Icteric
NF	Animal not fasted
U	Unscheduled/moribund bleed
DT/DOT	Animal died on test
DB	Died during bleeding
TJ	Technician judgment to repeat test
TE	Technical error (instrument or technician error that results in unacceptable data, e.g., unacceptable instrument output, sample spilled, entry of invalid data)
RE	Recording error (recorded incorrect data, e.g., wrong number, spelling error, incorrect date)
EE	Entry error (incorrect keyboard entry)
SE	Sampling error
PC	Platelets clumped
PD	Platelets decreased
PI	Platelets increased
PL	Platelets large
PA	Platelets appear adequate
CO	Color interferes with test
HB	Heinz bodies observed
PLASMO	Plasmodium
NO AGG	No aggregation
FR	Fractionous
UTD	Unable to determine
NO COAG	No coagulation

**Codes for Clinical Pathology (Continued)**

**RESULTS NOT INCLUDED IN STATISTICAL ANALYSES**

Hemolyzed clinical chemistry or coagulation samples  
 Samples from animals at unscheduled intervals  
 Prothrombin times (PT) greater than 50 seconds  
 Activated partial thromboplastin times (PTT) greater than 110 seconds  
 Bleed times (BLETIME) greater than 30 minutes

**CODES FOR BLOOD CELL MORPHOLOGY**

The following scale was used to measure the degree of anisocytosis (ANISO), poikilocytosis (POIK), polychromasia (POLY), hypochromasia (HYPO), and toxic neutrophils (TOXNEUT):

Scale	Degree	Presence
-	Normal for the species	Not present
1	Slight	Rare
2	Moderate	Few
3	Marked	Moderate
4	Not applicable	Many

**URINE APPEARANCE**

Color			Clarity	Miscellaneous
A Pale	E Amber	I Black	J Clear	M Debris
B Straw	F Brown	P Blue/green	K Hazy	O Feces
C Yellow	G Red	Q Blue	L Cloudy	
D Dark yellow	H Green	R Orange		

**Codes for Clinical Pathology (Continued)**

**URINE CHEMISTRY MULTISTIX® STRIP**

Urine Glucose	Urine Ketone	Urine Blood
- Negative	- Negative	- Negative
+ 100 mg/dL	+ 5 mg/dL	+ Small
++ 250 mg/dL	++ 15 mg/dL	++ Moderate
+++ 500 mg/dL	+++ 40 mg/dL	+++ Large
++++ 1,000 mg/dL	++++ 80 mg/dL	
+++++ ≥2,000 mg/dL	+++++ 160 mg/dL	

Urine Urobilinogen	Urine Bilirubin
- 0.2 mg/dL	- Negative
+ 1 mg/dL	+ Small
++ 2 mg/dL	++ Moderate
+++ 4 mg/dL	+++ Large
++++ 8 mg/dL	

(1 mg = approximately 1 Ehrlich unit)

**URINE SEDIMENT**

Cells, Crystals, Casts, and Comments	Bacteria
A Amorphous urates	Q Sperm
B Amorphous phosphates	R Fecal contamination
C Uric acid	S Pinworm ova found
D Triple phosphates	T Pinworm larvae found
E Calcium oxalate	U Parasite ova found
F Calcium carbonate	
G Granular casts	0 Not present
H Hyaline casts	1 1-5 per field
I Cellular casts	2 6-10 per field
J Waxy casts	3 11-20 per field
K Unknown crystal	4 >20 per field
P Mucous threads	

### Abbreviations and Units for Clinical Hematology

<b>Test</b>	<b>Abbreviation (Units)</b>
Red blood cell count	RBC (E6/UL or X10 <sup>6</sup> /mcL)
Hemoglobin	HGB (G/DL)
Hematocrit	HCT (%)
Mean corpuscular volume	MCV (FL)
Mean corpuscular hemoglobin	MCH (PG)
Mean corpuscular hemoglobin concentration	MCHC (%)
Platelet count	PLT (E3/UL or X10 <sup>3</sup> /mcL)
Mean platelet volume	MPV (FL)
Reticulocyte count	RETIC (%)
Absolute reticulocyte count	RETIC (E3/UL or X10 <sup>3</sup> /mcL)
Heinz body count	HEINZ (%)
Erythrocyte sedimentation rate	ESR (MM/HR)
Prothrombin time	PT (SEC)
Activated partial thromboplastin time	PTT (SEC)
Thrombin time	TT (SEC)
Activated coagulation time	ACT (SEC)
Fibrinogen	FBR (MG/DL)
Fibrin/fibrinogen degradation products	FDP (UG/ML)
Platelet aggregation	
Collagen	PAGG/COL (%)
Adenosine diphosphate	PAGG/ADP (%)
Alpha 2-antiplasmin	ANTIPLAS (%)
Bleeding time	BLE TIME (SEC)
Methemoglobin	METHGB (%)
Plasma hemoglobin	PLA HGB (MG/DL)
Myeloid/erythroid ratio	M/E RATIO
Estimated myeloid/erythroid ratio	EST M/E RATIO
White blood cell count	WBC (E3/UL or X10 <sup>3</sup> /mcL)
Differential blood cell count	
Nucleated red blood cell count	NRBC (/100 WBC)
Corrected white blood cell count	COR WBC (E3/UL or X10 <sup>3</sup> /mcL)
Segmented neutrophil count	N-SEG (E3/UL or X10 <sup>3</sup> /mcL) and %
Band neutrophil count	N-BAND (E3/UL or X10 <sup>3</sup> /mcL) and %
Lymphocyte count	LYMPH (E3/UL or X10 <sup>3</sup> /mcL) and %
Monocyte count	MONO (E3/UL or X10 <sup>3</sup> /mcL) and %
Eosinophil count	EOSIN (E3/UL or X10 <sup>3</sup> /mcL) and %
Basophil count	BASO (E3/UL or X10 <sup>3</sup> /mcL) and %
Anisocytosis	ANISO (-,1,2,3)
Polychromasia	POLY (-,1,2,3)
Poikilocytosis	POIK (-,1,2,3)



**Abbreviations and Units for Clinical Hematology (Continued)**

<b>Test</b>	<b>Abbreviation (Units)</b>
Hypochromasia	HYPO (-,1,2,3)
Howell-Jolly bodies	HJBODY (-,1,2,3,4)
Basophilic stippling	BASTIP (-,1,2,3)
Toxic neutrophils	TOXNEUT (-,1,2,3,4)
Atypical lymphocytes	ATYPLYM (-,1,2,3,4)
Aqueous white blood cell count (right eye)	R EYE (WBC/UL)
Aqueous white blood cell count (left eye)	L EYE (WBC/UL)

### Abbreviations and Units for Clinical Chemistry

<b>Test</b>	<b>Abbreviation (Units)</b>
Glucose	GLU (MG/DL)
Urea nitrogen	UN (MG/DL)
Urea	UREA (MG/DL)
Creatinine	CREAT (MG/DL)
Total protein	T PRO (G/DL)
Albumin	ALB (G/DL)
Globulin	GLOB (G/DL)
Albumin/globulin ratio	A/G RATIO
Total bilirubin	T BILI (MG/DL)
Direct bilirubin	D BILI (MG/DL)
Indirect bilirubin	I BILI (MG/DL)
Cholesterol	CHOL (MG/DL)
Triglyceride	TRIG (MG/DL)
Urea nitrogen/creatinine ratio	UN/CREAT (RATIO)
Total lipids	T LIPIDS (MG/DL)
Phospholipids	P LIPIDS (MG/DL)
High-density lipoprotein cholesterol	HDL (MG/DL)
Low-density lipoprotein cholesterol	LDL (MG/DL)
Uric acid	UA (MG/DL)
Aspartate aminotransferase	AST/SGOT (IU/L)
Alanine aminotransferase	ALT/SGPT (IU/L)
Alkaline phosphatase	ALK PHOS (IU/L)
Gamma glutamyl transferase	GGT (IU/L)
Sorbitol dehydrogenase	SDH (IU/L)
Lactate dehydrogenase	LDH (IU/L)
Creatine kinase	CK (IU/L)
Amylase	AMYLASE (IU/L)
Lipase	LIPASE (IU/L)
Palmitoyl CoA oxidase	PCOAO (IU/G)
Calcium	CA (MG/DL)
Ionized calcium	ION CA (MG/DL)
Inorganic phosphorus	I PHOS (MG/DL)
Sodium	NA (MMOL/L)
Potassium	K (MMOL/L)
Chloride	CL (MMOL/L)
Magnesium	MG (MEQ/L or MG/DL)
Zinc	ZN (MG/L or PPM)
Strontium	SR (MG/L or PPM)
Iron	FE (UG/DL)

**Abbreviations and Units for Clinical Chemistry (Continued)**

<b>Test</b>	<b>Abbreviation (Units)</b>
Excess iron	EX FE (UG/DL)
Total iron binding capacity	TIBC (UG/DL)
Unbound iron binding capacity	UIBC (UG/DL)
Percent iron saturation	FE %SAT (%)
Plasma cholinesterase	CHEP (MU/ML)
Red blood cell cholinesterase	CHER (MU/ML)
Brain cholinesterase	CHEB (MU/ML)
Caudate putamen	CAUD PUT (UMOL/G)
Hippocampus	HIPPOCAM (UMOL/G)
Frontal cortex	F CORTEX (UMOL/G)
Cerebellum	CEREBELL (UMOL/G)
Bicarbonate	BICARB (MMOL/L)
Serum hemoglobin	SER HGB (MG/DL)
Serum bile acids	SBA (UMOL/L or MG/DL)
Fecal bile acids	FBA (UG/ML)
Average fecal weight	FCC WGT (G)
Fecal bile acids (calculation)	FBA (MG/Day)
Osmolality	OSMO (MOSM/KG)
Electrophoresis	
Albumin	E ALB (G/DL)
Alpha-1-globulin	E A-1 (G/DL)
Alpha-2-globulin	E A-2 (G/DL)
Beta globulin	E BETA (G/DL)
Gamma globulin	E GAMMA (G/DL)
High-density lipoprotein	E-HDL (%)
Low-density lipoprotein	E-LDL (%)
Very-low-density lipoprotein	E-VLDL (%)
Insulin	INSULIN (UU/ML)
Adrenocorticotrophic hormone	ACTH (PG/ML)
Cortisol	CORTISOL (UG/ML)
Glucagon	GLUCAGON (PG/ML)
Triiodothyronine	T3 (NG/DL)
Thyroxine	T4 (UG/DL)
Creatine kinase isoenzymes	
BB	CK-BB (U/L)
MB	CK-MB (U/L)
MM	CK-MM (U/L)

**Abbreviations and Units for Clinical Urinalysis**

<b>Test</b>	<b>Abbreviation (Units)</b>
Urine volume	U VOL (ML)
8 hour urine volume	8 HR VOL (ML)
Specific gravity	SP GR
Urine osmolality	U OSMO (MOSM/KG)
Quantitative urinary/cerebrospinal fluid protein	QUAN PRO (MG/DL)
Urine protein excretion	PRO EXC (MG)
Urine chemistry Multistix® strip	
Urine pH	U PH
Urine protein	U PRO (MG/DL)
Urine glucose	U GLU
Urine ketones	U KET
Urine bilirubin	U BILI
Urine blood	U BLOOD
Urine urobilinogen	UROBILI
Urine reducing substances	U RE SUB
Microscopic examination of urine sediment	
Red blood cells per high-power field	RBC (PER HPF)
White blood cells per high-power field	WBC (PER HPF)
Epithelial cells per high-power field	EPITH (PER HPF)
Bacteria per high-power field	BACT (PER HPF)
Casts per low-power field	CASTS (PER LPF)
Crystals per low-power field	CRYSTALS (PER LPF1 or PER LPF2)
Urine appearance	URINE APP1 or URINE APP2
Comments	COMMENTS

**Miscellaneous Codes and Abbreviations for Clinical Pathology**

Fecal occult blood	Not applicable
Fecal parasite detection	Not applicable
Hemolytic potential	Not applicable

---

**Codes for Anatomic Pathology**

<b>Code</b>	<b>Definition</b>
<b>ANIMAL DEATH CODES</b>	
T	Terminal sacrifice
U	Recovery sacrifice
D	Found dead
M	Moribund
P/O	Transferred to Covance stock
6	Transferred to Covance 6329-268

**MACROSCOPIC CODES**

EX	Indicates that organ weight is excluded from calculations
NOT TAKEN	Organ weight not taken; explanation given in necropsy notes
MISSING	Organ missing or lost
UNSUITABLE	Organ technically unsuitable for weighing
AUTOLYTIC	Organ autolyzed and could not be weighed
EXCLUDE	Weight was taken, but was excluded from all calculations

**MICROSCOPIC CODES**

**Codes Prefacing Neoplastic Findings**

B-	Primary, benign neoplasm
M-	Primary, malignant neoplasm
N-	Metastatic neoplasm
I-	Locally invasive neoplasm
X-	Other neoplasm

**Distribution of Findings**

Focal  
Diffuse  
Multifocal

**Codes for Anatomic Pathology (Continued)**

<b>Code</b>	<b>Definition</b>
<b>Grades for Severity or Amount</b>	
1	Minimal - the least amount of change that can be observed with the light microscope
2	Slight - less than average amount of change, but readily discernible as abnormal
3	Moderate - the average amount of change that is expected for a lesion
4	Moderately severe (marked) - a marked amount of change with possible loss of function of the affected cells or organs
5	Severe - a great amount of change with probable loss of function of the affected cell or organs and frequently involves large areas of the organ

**Other Microscopic Codes**

TL	Total
P	Finding present
-	Finding not present

**TISSUE ABBREVIATIONS**

<b>Abbreviation</b>	<b>Definition</b>
LF	Left
RT	Right
LN	Lymph node
GL	Gland
STOMACH, GL	Glandular stomach
STOMACH, NONGL	Nonglandular
SALIV GL, MANDIB	Mandibular salivary gland
LN, ANT MES/PANC	Anterior mesenteric/pancreatic lymph node
AUDITORY SEB GL	Auditory sebaceous gland
LACRIMAL GLAND, EX	Exorbital lacrimal gland
HEMATO NEOPLASIA	Hematopoietic neoplasia
LACRIMAL GL, INT	Internal lacrimal gland
CAVITY, ABDOM	Abdominal cavity
SALIV GL, PAROTID	Parotid salivary gland
LN, TRACHEOBRON	Tracheobronchial lymph node
THYROID/PARA	Thyroid with parathyroid

Figure 1  
Mean Body Weight Data (kg) - Males

Covance 6329-223  
3M T-6295.7




Figure 2  
Mean Body Weight Data (kg) - Females

Covance 6329-223  
3M T-6295.7






Table 1  
Summary of Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185	SEX:	NUMBER OF ANIMALS AFFECTED							
		-----MALE-----				-----FEMALE-----			
		GROUP:	1	2	3	4	1	2	3
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD	NUMBER:	6	4	6	6	6	4	6	6
QUALIFIER									
*** TOP OF LIST ***									
APPEARANCE									
APPEARS DEHYDRATED		0	0	0	1	1	0	0	0
RECUMBENT		0	0	0	1	0	0	0	0
BEHAVIOR									
ATAXIC		0	0	0	1	0	0	0	0
HYPOACTIVE		0	0	0	2	1	0	0	0
DISCHARGE									
NASAL									
CLEAR		0	0	0	0	1	0	0	0
ORAL									
CLOUDY		0	0	0	0	1	0	0	0
VOMITUS									
WHITE IN COLOR		0	0	0	0	0	1	0	0
CONTAINING FOOD		1	1	3	1	2	0	2	1
INTACT CAPSULE		0	0	0	0	1	0	0	2
PARTIAL CAPSULE		0	1	0	3	3	0	0	3
EXCESSIVE SALIVATION		0	0	0	1	1	0	0	0
APPEARS TO BE MENSTRUATING		0	0	0	0	4	4	2	4
DISCHARGE UNKNOWN SOURCE									
FOUND IN PAN		1	0	0	0	1	0	0	0
RED IN COLOR									

Table 1  
Summary of Clinical Observations  
Treatment  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185	SEX:	NUMBER OF ANIMALS AFFECTED							
		-----MALE-----				-----FEMALE-----			
		GROUP:	1	2	3	4	1	2	3
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD	NUMBER:	6	4	6	6	6	4	6	6
QUALIFIER									
EXCRETION									
DISCOLORED FECES									
BLACK IN COLOR		0	0	0	1	0	0	0	0
RED IN COLOR		0	0	0	0	1	0	0	3
YELLOW IN COLOR		0	0	0	0	0	0	0	1
DISCOLORED URINE									
GREEN IN COLOR		0	0	0	0	0	0	0	1
RED IN COLOR		0	0	1	0	0	0	0	0
FEW FECES									
LIQUID FECES		1	1	0	1	2	0	0	2
MUCOID FECES		0	0	0	2	1	0	0	2
NO FECES		0	0	0	2	0	1	1	1
NON-FORMED FECES		3	2	1	1	2	1	0	2
SMALL FECES		0	0	0	0	0	0	0	1
EYES									
CONSTRICTED PUPIL									
EYES		0	0	0	1	0	0	0	0
RESPIRATION									
LABORED									
		0	0	0	2	0	0	0	0
SKIN & PELAGE									
ALOPECIA									
DORSAL		0	0	0	0	0	0	0	1
DORSAL-THORACIC		0	0	0	0	0	0	0	1

Table 1  
Summary of Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185	SEX:	NUMBER OF ANIMALS AFFECTED							
		-----MALE-----				-----FEMALE-----			
		GROUP:	1	2	3	4	1	2	3
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD	NUMBER:	6	4	6	6	6	4	6	6
QUALIFIER									
-----									
SKIN & PELAGE									
ALOPECIA									
DORSAL-THORACIC-LEFT		0	0	0	0	0	0	0	1
FEET		0	0	0	0	1	0	0	0
HEAD-ENTIRE		0	0	0	0	0	0	0	1
HEAD-CRANIAL		0	0	0	0	0	0	0	1
HEAD-MAXILLARY-LEFT		0	0	0	0	0	0	0	1
HEAD-MAXILLARY-RIGHT		0	0	0	0	0	0	0	1
LIMB-HIND-LEFT		0	0	0	0	0	0	0	1
LIMBS-ALL		0	0	0	0	0	0	0	2
LIMBS-FRONT		0	0	0	0	0	0	0	1
LIMBS-HIND		0	0	0	0	1	0	0	0
TAIL		0	0	0	0	1	0	0	1
BROKEN SKIN									
HAND-LEFT		1	0	0	0	0	0	0	0
DIGIT(S)-FRONT-LEFT		0	0	0	1	0	0	0	0
HEAD-CRANIAL		0	0	0	0	1	0	1	0
HEAD-MAXILLARY-LEFT		0	0	0	0	0	1	0	0
HEAD-MAXILLARY-RIGHT		0	0	0	0	0	1	0	0
MOUTH		0	0	0	0	1	0	0	0
PERI-ORBITAL-LEFT		0	0	0	0	1	1	0	1
PERI-ORBITAL-RIGHT		0	1	0	0	0	2	1	0
TAIL		1	0	1	0	0	0	0	0
TAIL-DISTAL		1	0	0	0	0	0	0	0
COLD TO TOUCH									
BODY-ENTIRE		0	0	0	1	0	0	0	0

Table 1  
Summary of Clinical Observations  
Treatment  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185 CATEGORY KEYWORD QUALIFIER	NUMBER OF ANIMALS AFFECTED								
	SEX:	-----MALE-----				-----FEMALE-----			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
	NUMBER:	6	4	6	6	6	4	6	6
SKIN & PELAGE									
PALE SKIN									
HEAD-ENTIRE		0	0	0	0	0	0	0	1
GUMS		0	0	0	1	0	0	0	0
RED SKIN									
LIMB-FRONT-RIGHT		0	0	0	0	1	0	0	0
SCAB(S)									
HEAD-MAXILLARY-LEFT		0	0	0	0	0	1	0	0
LIMB-FRONT-LEFT		0	0	0	0	1	0	0	0
LIMB-FRONT-RIGHT		0	0	0	0	1	0	0	0
BRUISED SKIN									
PERI-ORBITAL-LEFT		0	0	0	0	0	0	0	1
QUALITATIVE FOOD CONSUMPTION									
LOW		3	3	6	6	5	3	6	6
*** END OF LIST ***									

Table 2

Summary of Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

DAYS 186-365	SEX:	NUMBER OF ANIMALS AFFECTED							
		-----MALE-----				-----FEMALE-----			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
-----									
*** TOP OF LIST ***									
DISCHARGE									
APPEARS TO BE MENSTRUATING		0	0	0	0	1	0	1	1
EXCRETION									
FEW FECES		0	0	0	0	0	0	1	0
LIQUID FECES		0	0	0	0	1	0	0	0
NON-FORMED FECES		0	0	1	0	0	0	0	1
SKIN & PELAGE									
ALOPECIA									
FEET		0	0	0	0	1	0	0	0
TAIL		0	0	0	0	1	0	0	0
BROKEN SKIN									
DIGIT(S)-FRONT-LEFT		1	0	0	0	0	0	0	0
QUALITATIVE FOOD CONSUMPTION									
LOW		1	0	2	1	2	0	2	2
*** END OF LIST ***									

Table 3

Summary of Clinical Observations  
Recovery (Days 366 through 561)

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 368-558	SEX:	NUMBER OF ANIMALS AFFECTED							
		MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***									
APPEARANCE									
SWOLLEN									
HEAD-MAXILLARY-RIGHT		0	0	1	0	0	0	0	0
DISCHARGE									
VOMITUS									
CONTAINING FOOD		1	0	2	0	1	0	1	0
APPEARS TO BE MENSTRUATING		0	0	0	0	1	0	0	1
DISCHARGE UNKNOWN SOURCE									
FOUND IN PAN									
RED IN COLOR		0	0	0	0	0	0	1	1
EXCRETION									
FEW FECES		0	0	1	0	0	0	2	0
LIQUID FECES		0	0	0	0	1	0	0	1
NO FECES		0	0	1	0	0	0	2	0
NON-FORMED FECES		1	0	1	1	1	0	0	1
SKIN & PELAGE									
ALOPECIA									
LIMB-HIND-RIGHT		0	0	0	0	1	0	0	0

Table 3

Summary of Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DAYS 368-558	SEX:	NUMBER OF ANIMALS AFFECTED							
		-----MALE-----				-----FEMALE-----			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
QUALITATIVE FOOD CONSUMPTION									
LOW		1	0	2	1	2	0	2	2
NONE		0	0	0	0	0	0	2	0

\*\*\* END OF LIST \*\*\*

Table 4  
Summary of Ophthalmic Observations  
Treatment  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

WEEK -4	CATEGORY	KEYWORD	QUALIFIER	NUMBER OF ANIMALS AFFECTED								
				SEX: -----MALE-----				-----FEMALE-----				
				GROUP:	1	2	3	4	1	2	3	4
				DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
				NUMBER:	6	4	6	6	6	4	6	6
*** TOP OF LIST ***												
NO VISIBLE LESIONS												
NO VISIBLE LESIONS												
EYE-LEFT												
					0	0	0	0	1	0	0	0
				EYES	6	4	6	6	5	4	6	6
MISCELLANEOUS OPHTHALMICS												
INCREASED MYELINATION OF OPTIC NERVE												
				EYE-RIGHT	0	0	0	0	1	0	0	0
*** END OF LIST ***												



Table 4

Summary of Ophthalmic Observations  
Treatment

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK 26	SEX:	NUMBER OF ANIMALS AFFECTED							
		MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
QUALIFIER	NUMBER:	6	4	6	5	6	4	6	6
*** TOP OF LIST ***									
NO VISIBLE LESIONS									
NO VISIBLE LESIONS									
EYES		6	4	6	5	6	4	6	6
*** END OF LIST ***									

Table 5  
Summary of Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

WEEK 52	SEX:	NUMBER OF ANIMALS AFFECTED							
		MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***									
NO VISIBLE LESIONS									
EYES									
EYE-LEFT									
EYE-RIGHT									
*** END OF LIST ***									
MISCELLANEOUS OPHTHALMICS									
INCREASED MYELINATION OF OPTIC NERVE									
EYE-RIGHT									

Table 6  
Summary of Body Weight Data (kg)  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

WEEK	SEX: GROUP:	-----MALE-----				-----FEMALE-----			
		1 DOSE: UNITS:	2 0.03 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	2 0.03 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
-1 <sup>c</sup>	N	6	4	6	6	6	4	6	6
	MEAN	3.2	3.4	3.0	3.3	2.8	3.0	3.0	2.9
	S.D.	0.43	0.73	0.33	0.59	0.33	0.55	0.38	0.54
-1 <sup>b</sup>	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.0	3.0	2.9
	S.D.	0.45	0.65	0.34	0.55	0.29	0.55	0.41	0.52
1	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.45	0.70	0.35	0.55	0.29	0.60	0.41	0.52
2	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.2	3.3	3.2	2.9	3.0	3.0	2.9
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.44	0.64	0.34	0.62	0.26	0.59	0.43	0.49
3	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.3	3.3	3.3	2.9	3.0	2.9	2.9
	MEAN	3.3	3.4	3.2	3.4	2.8	3.1	3.0	2.9
	S.D.	0.41	0.68	0.32	0.59	0.38	0.59	0.43	0.49
4	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.38	0.64	0.34	0.58	0.34	0.65	0.43	0.52
5	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	2.9	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.39	0.64	0.34	0.60	0.35	0.60	0.44	0.55

a Day -7.  
b Day -1.

Table 6

Summary of Body Weight Data (kg)  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

SEX:		-MALE-				-FEMALE-			
GROUP:		1	2	3	4	1	2	3	4
DOSE:		0	0.03	0.15	0.75	0	0.03	0.15	0.75
UNITS:		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
6	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	3.0	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.41	0.63	0.34	0.60	0.36	0.57	0.48	0.55
7	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.42	0.64	0.33	0.63	0.38	0.61	0.47	0.48
8	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.3	3.4	2.9	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.39	0.64	0.30	0.65	0.39	0.61	0.47	0.50
9	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.4	3.5	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.2	3.0	2.9
	S.D.	0.43	0.60	0.29	0.65	0.40	0.66	0.46	0.55
10	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.3	3.4	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.43	0.60	0.33	0.65	0.36	0.62	0.44	0.55
11	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.5	3.0	3.0	3.0	2.8*
	MEAN	3.4	3.7	3.2	3.6	2.9	3.1	3.0	2.8
	S.D.	0.46	0.68	0.33	0.66	0.35	0.60	0.46	0.51
12	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.4	3.1	3.0	3.0	2.9*
	MEAN	3.4	3.7	3.2	3.5	3.0	3.2	3.0	2.9
	S.D.	0.47	0.68	0.29	0.65	0.37	0.59	0.48	0.50

Table 6

Summary of Body Weight Data (kg)  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

WEEK	SEX: GROUP:	-MALE-				-FEMALE-			
		1 DOSE: UNITS:	2 0.03 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	2 0.03 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
13	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.5	3.1	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.3	3.6	3.0	3.2	3.1	2.8
	S.D.	0.46	0.65	0.27	0.66	0.36	0.62	0.47	0.46
14	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.5	3.4	3.4	3.0	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.2	3.5	2.9	3.2	3.1	2.8
	S.D.	0.44	0.57	0.31	0.67	0.37	0.62	0.48	0.44
15	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.0	3.1	3.1	2.8*
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.8
	S.D.	0.46	0.61	0.30	0.68	0.38	0.63	0.49	0.38
16	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.6	3.4	3.3	3.0	3.1	3.0	2.8*
	MEAN	3.4	3.8	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.48	0.60	0.27	0.71	0.34	0.63	0.45	0.38
17	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.4	3.4	3.1	3.1	3.1	2.9
	MEAN	3.5	3.8	3.3	3.5	3.0	3.2	3.1	2.9
	S.D.	0.49	0.56	0.26	0.75	0.37	0.70	0.45	0.44
18	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.1	3.1	3.0	2.9
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.9
	S.D.	0.50	0.56	0.23	0.69	0.38	0.68	0.48	0.45
19	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.4	3.1	3.1	3.1	2.9*
	MEAN	3.6	3.8	3.3	3.5	3.0	3.3	3.1	2.9
	S.D.	0.50	0.59	0.19	0.73	0.34	0.66	0.50	0.39

Table 6

Summary of Body Weight Data (kg)  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

WEEK	SEX: GROUP: DOSE: UNITS:	-----MALE-----				-----FEMALE-----			
		1	2	3	4	1	2	3	4
		0	0.03	0.15	0.75	0	0.03	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
20	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.5	3.8	3.3	3.4	3.0	3.2	3.2	2.8
	S.D.	0.53	0.59	0.22	0.73	0.34	0.67	0.48	0.38
21	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.6	3.4	3.2	3.0	3.1	3.0	2.8*
	MEAN	3.6	3.8	3.2	3.3	2.9	3.2	3.0	2.8
	S.D.	0.55	0.64	0.26	0.72	0.34	0.70	0.46	0.33
22	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.56	0.56	0.25	0.62	0.37	0.68	0.44	0.31
23	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.2*	3.0	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.3	2.9	3.2	3.1	2.8
	S.D.	0.58	0.55	0.25	0.67	0.31	0.68	0.46	0.35
24	N	6	4	6	5	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.0	3.1	3.1	2.8
	MEAN	3.6	3.9	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.63	0.60	0.26	0.69	0.32	0.76	0.46	0.32
25	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.6	3.3	3.1	3.2	3.1	2.8*
	MEAN	3.7	3.9	3.4	3.5	3.0	3.3	3.2	2.8
	S.D.	0.61	0.55	0.20	0.72	0.37	0.76	0.46	0.31
26	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.7	3.9	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.67	0.55	0.20	0.73	0.37	0.79	0.46	0.35

Table 6  
Summary of Body Weight Data (kg)  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

SEX:		-----MALE-----				-----FEMALE-----			
GROUP:		1	2	3	4	1	2	3	4
DOSE:		0	0.03	0.15	0.75	0	0.03	0.15	0.75
UNITS:		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
27	N	5	4	6	4	5	4	6	5
	CAM	3.7	3.8	3.5	3.0*	3.1	3.1	3.0	2.8*
	MRAN	3.7	3.9	3.3	3.2	3.0	3.2	3.1	2.8
	S.D.	0.68	0.56	0.26	0.63	0.35	0.72	0.51	0.37

Table 7  
Summary of Body Weight Data (kg)  
Recovery

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP:	MALE			FEMALE		
		1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
28	N	2	2	2	2	2	2
	MEAN	3.5	3.1	3.1	2.7	3.3	2.6
	S.D.	0.42	0.21	0.57	0.35	0.71	0.14
29	N	2	2	2	2	2	2
	MEAN	3.6	3.1	3.3	2.7	3.4	2.7
	S.D.	0.42	0.28	0.64	0.42	0.71	0.14
30	N	2	2	2	2	2	2
	MEAN	3.6	3.0	3.3	2.7	3.3	2.7
	S.D.	0.42	0.28	0.57	0.35	0.71	0.14
31	N	2	2	2	2	2	2
	MEAN	3.7	3.1	3.5	2.7	3.4	2.8
	S.D.	0.42	0.35	0.71	0.42	0.78	0.21
32	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.6	2.8	3.5	2.9
	S.D.	0.42	0.35	0.85	0.35	0.78	0.35
33	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.7	2.8	3.5	3.0
	S.D.	0.42	0.28	0.78	0.42	0.78	0.28
34	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.8	2.8	3.4	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.28



Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
35	N	2	2	2	2	2	2
	MEAN	3.8	3.1	3.7	2.8	3.5	3.0
	S.D.	0.35	0.28	0.99	0.35	0.92	0.21
36	N	2	2	2	2	2	2
	MEAN	3.8	3.3	3.9	2.8	3.6	3.1
	S.D.	0.42	0.21	1.06	0.35	0.92	0.35
37	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.9	2.8	3.6	3.1
	S.D.	0.42	0.28	1.06	0.42	0.78	0.35
38	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.8	2.8	3.5	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.42
39	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.7	3.5	2.9
	S.D.	0.35	0.28	0.99	0.42	0.85	0.35
40	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.6	3.4	3.0
	S.D.	0.35	0.28	1.06	0.42	0.85	0.21
41	N	2	2	2	2	2	2
	MEAN	4.0	3.3	3.8	2.8	3.6	3.1
	S.D.	0.42	0.21	0.99	0.42	0.85	0.35

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
42	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	2.9
	S.D.	0.28	0.21	1.06	0.42	0.78	0.35
43	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	3.0
	S.D.	0.28	0.21	0.99	0.42	0.78	0.42
44	N	2	2	2	2	2	2
	MEAN	4.2	3.3	3.8	2.6	3.7	3.1
	S.D.	0.28	0.21	0.92	0.35	0.92	0.35
45	N	2	2	2	2	2	2
	MEAN	4.3	3.3	3.8	2.8	3.7	3.1
	S.D.	0.21	0.28	0.92	0.42	0.78	0.35
46	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.8	3.6	3.1
	S.D.	0.21	0.28	0.92	0.42	0.85	0.42
47	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.8	2.7	3.6	3.1
	S.D.	0.14	0.28	0.85	0.42	0.92	0.49
48	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.9	2.6	3.6	3.1
	S.D.	0.18	0.25	0.78	0.35	0.94	0.49

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
49	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.8	3.7	3.2
	S.D.	0.21	0.21	0.78	0.35	0.92	0.35
50	N	2	2	2	2	2	2
	MEAN	4.3	3.2	4.0	2.7	3.6	3.1
	S.D.	0.21	0.28	0.71	0.35	0.92	0.35
51	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.64	0.42	0.92	0.35
52	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.57	0.28	0.92	0.42
53	N	2	2	2	2	2	2
	MEAN	4.4	3.2	4.1	2.6	3.6	3.1
	S.D.	0.21	0.28	0.49	0.28	0.99	0.49
54	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.2	2.6	3.6	3.1
	S.D.	0.28	0.21	0.49	0.28	0.92	0.49
55	N	2	2	2	2	2	2
	MEAN	4.5	3.3	4.1	2.7	3.5	3.1
	S.D.	0.28	0.21	0.42	0.35	0.99	0.64

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP:	MALE			FEMALE		
		1 DOSE: UNITS:	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
56	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.1
	S.D.	0.35	0.14	0.35	0.35	0.92	0.57
57	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.6	3.6	3.0
	S.D.	0.35	0.21	0.28	0.35	0.92	0.57
58	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.0
	S.D.	0.35	0.14	0.35	0.28	0.78	0.57
59	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.5	3.0
	S.D.	0.42	0.14	0.42	0.35	0.71	0.57
60	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.8	3.6	3.2
	S.D.	0.49	0.14	0.42	0.35	0.85	0.49
61	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.7	3.6	3.2
	S.D.	0.49	0.14	0.42	0.28	0.78	0.49
62	N	2	2	2	2	2	2
	MEAN	4.5	3.5	4.4	2.7	3.6	3.2
	S.D.	0.49	0.21	0.49	0.42	0.78	0.57

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
63	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.8	3.6	3.2
	S.D.	0.57	0.14	0.42	0.35	0.71	0.57
64	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.5	2.7	3.6	3.2
	S.D.	0.64	0.14	0.21	0.35	0.78	0.64
65	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.4	2.7	3.5	3.1
	S.D.	0.57	0.07	0.21	0.35	0.78	0.57
66	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.3	2.6	3.5	3.1
	S.D.	0.64	0.14	0.28	0.28	0.78	0.57
67	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.7	3.6	3.2
	S.D.	0.57	0.14	0.21	0.35	0.71	0.57
68	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.21	0.21	0.35	0.78	0.64
69	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.14	0.28	0.28	0.85	0.71

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP:	MALE			FEMALE		
		1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
70	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.07	0.21	0.35	0.78	0.71
71	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.64	0.07	0.28	0.35	0.85	0.71
72	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.71	0.07	0.21	0.35	0.78	0.78
73	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.71	0.07	0.21	0.35	0.85	0.78
74	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.85	0.07	0.21	0.42	0.78	0.78
75	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.78	0.07	0.21	0.28	0.78	0.78
76	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.4
	S.D.	0.85	0.07	0.21	0.28	0.71	0.78

Table 7  
Summary of Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
77	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.7	3.3
	S.D.	0.85	0.07	0.14	0.35	0.78	0.78
78	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.6	3.5	3.2
	S.D.	0.92	0.07	0.14	0.28	0.85	0.85
79	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.3
	S.D.	0.92	0.00	0.07	0.35	0.85	0.85
80	N	0	2	0	0	2	0
	MEAN		3.3			3.4	
	S.D.		0.21			0.85	

Table 8  
Summary of Clinical Hematology Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>12</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL	
0	MEAN S.D. N	6.45 .275 6	12.2 .36 6	41.2 1.30 6	63.9 2.32 6	19.0 .87 6	29.8 .56 6	530 125.0 6	.3 .19 6	20 12.6 6
0.03	MEAN S.D. N	6.99 .688 4	12.4 .46 4	42.9 2.95 4	61.5 2.51 4	17.8 1.13 4	29.0 1.34 4	574 210.3 4	.4 .24 4	24 14.9 4
0.15	MEAN S.D. N	6.76 .315 6	12.6 .41 6	42.9 1.88 6	63.5 2.38 6	18.7 .76 6	29.5 .41 6	493 109.0 6	.5 .53 6	32 34.5 6
0.75	MEAN S.D. N	6.88 .575 6	12.5 .82 6	43.1 2.06 6	62.8 3.44 6	18.2 1.01 6	29.0 .61 6	415 202.6 6	.5 .47 6	33 27.8 6



Table 8  
Summary of Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 8.6	3.9	4.0	.6	.1	.0	44	47	7	1	0
	S.D. 1.76	1.28	.90	.24	.08	.05	8.9	9.2	2.4	.8	.5
	N 6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN 11.0	5.2	4.6	.8	.2	.0	47	43	8	2	0
	S.D. 1.00	1.88	1.05	.48	.17	.00	15.2	9.4	4.4	1.3	.0
	N 4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN 11.9	6.6	4.1	.9	.2	.0	54	36	8	2	0
	S.D. 1.95	2.42	1.14	.25	.31	.04	13.4	10.9	3.3	2.1	.4
	N 6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN 9.4	3.7	4.3	1.1	.2	.1	39	46	12	2	1
	S.D. 2.53	1.40	1.25	.53	.25	.08	10.9	9.5	3.3	3.3	.8
	N 6	6	6	6	6	6	6	6	6	6	6

Table 8  
Summary of Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>12</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL	
0	MEAN S.D. N	6.09 .681 6	12.0 .97 6	39.3 3.93 6	64.7 4.51 6	19.7 1.81 6	30.4 .87 6	539 79.5 6	.6 .46 6	35 24.2 6
0.03	MEAN S.D. N	6.31 .522 4	11.5 1.06 4	39.5 3.26 4	62.7 4.49 4	18.3 1.73 4	29.2 .71 4	482 72.4 4	.4 .31 4	27 17.1 4
0.15	MEAN S.D. N	6.54 .320 6	12.0 .49 6	40.1 1.97 6	61.4 2.79 6	18.3 .50 6	29.8 .68 6	481 100.9 6	.4 .26 6	29 16.2 6
0.75	MEAN S.D. N	6.50 .195 6	12.1 .50 6	41.5 1.68 6	63.9 1.14 6	18.7 .50 6	29.2 .52 6	435 108.9 6	.2 .18 6	16 11.4 6

Table 8  
Summary of Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	10.2 2.52 6	4.6 1.14 6	4.5 1.36 6	.8 .24 6	.3 .28 6	.0 .05 6	45 8.3 6	44 7.6 6	7 1.2 6	3 2.1 6	0 .5 6
0.03	MEAN S.D. N	8.7 2.41 4	5.0 2.52 4	2.9 .79 4	.6 .17 4	.1 .05 4	.0 .05 4	55 14.3 4	35 11.6 4	8 2.8 4	2 .6 4	0 .5 4
0.15	MEAN S.D. N	10.1 2.94 6	5.1 2.81 6	3.8 .40 6	.8 .20 6	.3 .27 6	.0 .04 6	48 13.0 6	40 8.4 6	9 3.8 6	3 3.0 6	0 .4 6
0.75	MEAN S.D. N	9.0 3.08 6	4.8 1.70 6	3.2 1.66 6	.8 .32 6	.1 .18 6	.0 .04 6	54 10.7 6	35 9.7 6	9 4.2 6	1 1.4 6	0 .4 6

Table 9  
Summary of Clinical Hematology Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>12</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL	
0	MEAN S.D. N	6.45 .221 6	12.4 .55 6	40.6 1.44 6	63.0 2.74 6	19.1 .97 6	30.4 .58 6	486 117.8 6	.2 .16 6	14 10.4 6
0.03	MEAN S.D. N	6.86 .501 4	12.5 .38 4	42.4 3.93 4	61.9 4.61 4	18.2 1.17 4	29.5 1.69 4	532 146.1 4	.4 .35 4	29 23.8 4
0.15	MEAN S.D. N	6.66 .385 6	12.5 .27 6	41.2 .76 6	62.0 2.96 6	18.8 1.06 6	30.3 .53 6	476 58.6 6	.4 .14 6	25 10.5 6
0.75	MEAN S.D. N	6.53 .431 6	11.8 .57 6	40.2 1.74 6	61.7 2.63 6	18.1 .85 6	29.4 .57 6	383 164.3 6	.4 .10 6	25 5.9 6

Table 9  
Summary of Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 7.6	3.9	3.1	.5	.0	.0	50	43	7	1	0
	S.D. 1.98	2.01	.67	.31	.08	.08	14.4	12.8	3.4	1.2	.8
	N 6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN 10.8	6.3	3.7	.5	.2	.0	58	36	5	2	0
	S.D. 1.89	2.40	1.26	.17	.05	.00	15.9	14.2	1.7	.5	.0
	N 4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN 10.0	6.0	3.2	.6	.2	.0	58	33	6	2	0
	S.D. 2.06	2.23	.91	.24	.32	.05	12.5	10.4	3.6	2.3	.4
	N 6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN 10.3	6.6	2.9	.6	.1	.0	62	30	7	1	1
	S.D. 4.16	3.69	.52	.18	.11	.05	9.8	7.5	2.7	1.2	.4
	N 6	6	6	6	6	6	6	6	6	6	6

Table 9  
Summary of Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.41 .351 6	12.2 .69 6	40.5 2.42 6	63.1 2.31 6	19.0 .83 6	30.2 .29 6	538 84.2 6	.3 .16 6	22 10.8 6
0.03	MEAN S.D. N	6.60 .664 4	11.8 .97 4	40.6 2.92 4	61.8 6.28 4	18.1 1.80 4	29.2 .48 4	417 23.6 4	.3 .28 4	18 15.6 4
0.15	MEAN S.D. N	6.55 .343 6	11.8 .41 6	39.7 1.06 6	60.7 2.68 6	18.1 .75 6	29.7 .29 6	431 85.3 6	.3 .12 6	19 8.0 6
0.75	MEAN S.D. N	6.21 .280 6	11.6 .38 6	39.1 1.96 6	63.0 1.48 6	18.6 .44 6	29.6 .89 6	469 95.4 6	.3 .23 6	20 13.1 6

Table 9  
Summary of Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	12.7 4.75 6	7.8 3.77 6	3.6 1.59 6	1.1 .67 6	.3 .26 6	.0 .08 6	59 18.2 6	30 16.2 6	8 2.3 6	2 1.7 6	0 .5 6
0.03	MEAN S.D. N	9.6 2.37 4	5.7 1.90 4	2.8 .82 4	.8 .24 4	.2 .17 4	.0 .05 4	60 10.6 4	29 6.0 4	8 2.1 4	3 2.2 4	0 1.0 4
0.15	MEAN S.D. N	9.1 2.66 6	5.5 2.48 6	2.9 .72 6	.5 .13 6	.2 .18 6	.0 .00 6	56 17.0 6	35 15.7 6	6 1.6 6	3 1.2 6	0 .0 6
0.75	MEAN S.D. N	8.9 2.85 6	5.3 3.19 6	2.9 1.06 6	.6 .20 6	.1 .08 6	.0 .00 6	56 15.1 6	35 13.7 6	7 2.7 6	1 1.2 6	0 .4 6

Table 10  
Summary of Clinical Hematology Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.49 .292 6	12.5 .53 6	41.1 1.78 6	63.3 3.03 6	19.2 .95 6	30.4 .84 6	522 126.9 6	.3 .27 6	18 17.3 6
0.03	MEAN S.D. N	6.84 .437 4	12.4 .33 4	41.4 1.36 4	60.7 2.92 4	18.2 .91 4	29.9 .62 4	536 152.1 4	.4 .45 4	25 29.6 4
0.15	MEAN S.D. N	6.60 .315 6	12.5 .52 6	40.7 1.42 6	61.7 2.56 6	18.9 .87 6	30.6 .50 6	504 97.3 6	.3 .25 6	21 17.3 6
0.75	MEAN S.D. N	6.73 .516 6	12.3 .75 6	41.2 2.31 6	61.3 3.02 6	18.3 .72 6	29.8 .52 6	437 217.8 6	.3 .19 6	19 12.6 6



Table 10  
Summary of Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 7.3	3.0	3.5	.6	.1	.0	42	48	8	2	0
	S.D. .81	.68	.87	.26	.08	.05	10.5	8.2	3.2	.8	.8
	N 6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN 10.5	6.1 *	3.4	.8	.2	.0	58	32	8	2	0
	S.D. 1.79	1.51	.82	.38	.05	.00	9.5	6.5	3.5	.5	.0
	N 4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN 11.8 *	7.0 *	3.9	.7	.2	.0	56	35	7	2	0
	S.D. 3.02	3.16	1.18	.40	.13	.05	16.3	14.6	4.0	.8	.4
	N 6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN 9.6	5.3	3.4	.6	.2	.0	52	38	6	2	0
	S.D. 2.97	2.52	.52	.23	.21	.08	10.0	11.2	1.0	2.1	.5
	N 6	6	6	6	6	6	6	6	6	6	6

Table 10  
Summary of Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.23 .766 6	12.3 .66 6	40.2 3.27 6	64.9 4.33 6	19.9 1.87 6	30.6 1.01 6	572 74.6 6	.4 .22 6	27 11.2 6
0.03	MEAN S.D. N	6.48 .593 4	12.0 .83 4	40.2 2.39 4	62.4 6.25 4	18.5 2.02 4	29.7 .67 4	462 83.8 4	.4 .37 4	28 24.1 4
0.15	MEAN S.D. N	7.00 1.068 6	12.8 2.17 6	42.3 6.70 6	60.5 2.31 6	18.3 .76 6	30.3 .57 6	436 133.5 6	.4 .28 6	24 18.2 6
0.75	MEAN S.D. N	6.28 .397 6	11.8 .29 6	40.2 1.96 6	64.0 1.27 6	18.9 .72 6	29.5 .70 6	504 148.3 6	.3 .25 6	17 14.9 6

Table 10  
Summary of Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 11.1	5.8	4.3	.6	.3	.0	50	40	6	2	0
	S.D. 2.93	3.08	1.73	.48	.18	.08	17.6	15.9	4.6	2.0	.5
	N 6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN 8.7	4.4	3.4	.6	.2	.0	50	40	8	2	0
	S.D. 1.42	1.59	1.16	.13	.17	.06	14.5	14.9	.5	1.7	.6
	N 4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN 8.8	4.3	3.6	.5	.3	.0	48	42	6	3	0
	S.D. 1.78	1.75	.93	.16	.15	.05	13.1	11.2	2.9	1.6	.5
	N 6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN 9.3	5.6	3.0	.6	.1	.0	56	36	7	1	0
	S.D. 4.59	3.89	1.07	.40	.08	.05	13.2	14.2	2.7	1.0	.4
	N 6	6	6	6	6	6	6	6	6	6	6

Table 11  
Summary of Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.43 .314 6	12.4 .53 6	40.3 2.17 6	62.8 3.11 6	19.3 1.06 6	30.7 1.00 6	490 124.3 6	.3 .26 6	21 16.4 6
0.03	MEAN S.D. N	7.00 .628 4	12.7 .55 4	42.5 1.78 4	61.0 3.13 4	18.2 1.02 4	29.8 .43 4	512 208.8 4	.7 .54 4	47 33.7 4
0.15	MEAN S.D. N	6.50 .295 6	12.3 .16 6	40.4 .93 6	62.1 2.53 6	19.0 .76 6	30.6 .49 6	496 82.6 6	.5 .54 6	33 32.0 6
0.75	MEAN S.D. N	6.66 .488 6	12.2 .81 6	41.0 2.23 6	61.6 2.47 6	18.2 .77 6	29.6 * .65 6	431 198.6 6	.4 .19 6	26 11.8 6

Table 11  
Summary of Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 6.7	2.4	3.7	.4	.1	.0	37	55	6	2	0
	S.D. 1.99	.64	1.24	.16	.08	.04	4.1	2.8	2.1	1.3	.5
	N 6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN 8.5	4.4	3.3	.6	.2	.0	50	40 *	7	2	0
	S.D. 1.60	1.79	.88	.00	.10	.00	13.9	12.6	1.0	1.4	.0
	N 4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN 10.3	5.7 *	3.7	.6	.2	.0	56 *	36 *	7	2	0
	S.D. 3.21	1.85	1.61	.27	.18	.05	9.3	8.4	2.6	1.8	.5
	N 6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN 9.4	5.1 *	3.5	.6	.2	.0	52 *	38 *	6	2	0
	S.D. 2.56	2.06	.71	.28	.16	.05	9.8	7.8	3.2	1.6	.5
	N 6	6	6	6	6	6	6	6	6	6	6

Table 11  
Summary of Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.31 .565 6	12.3 .77 6	40.3 2.79 6	64.1 3.90 6	19.5 1.21 6	30.4 .33 6	562 83.6 6	.3 .08 6	20 5.7 6
0.03	MEAN S.D. N	6.20 .472 4	11.7 .97 4	39.2 2.18 4	63.6 7.19 4	19.0 2.78 4	29.9 1.21 4	467 33.4 4	.5 .13 4	30 7.9 4
0.15	MEAN S.D. N	6.50 .298 6	12.0 .42 6	39.4 1.44 6	60.7 2.35 6	18.6 .78 6	30.6 .57 6	442 78.9 6	.2 .10 6	14 6.6 6
0.75	MEAN S.D. N	6.32 .210 6	11.9 .36 6	40.3 1.54 6	63.8 1.37 6	18.8 .51 6	29.4 .54 6	504 124.1 6	.2 .15 6	12 9.4 6

Table 11  
Summary of Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	9.4 1.89 6	4.0 1.31 6	4.3 1.59 6	.6 .10 6	.4 .27 6	.0 .04 6	44 12.5 6	46 10.3 6	7 1.0 6	4 2.4 6	0 .5 6
0.03	MEAN S.D. N	8.7 3.42 4	4.4 2.74 4	3.2 1.22 4	.8 .41 4	.2 .10 4	.0 .10 4	48 13.2 4	39 11.2 4	9 3.9 4	2 1.0 4	0 1.0 4
0.15	MEAN S.D. N	8.7 1.25 6	4.4 .82 6	3.4 .69 6	.6 .18 6	.2 .12 6	.0 .00 6	51 6.4 6	39 6.6 6	7 1.5 6	2 1.0 6	0 .4 6
0.75	MEAN S.D. N	8.1 1.91 6	4.6 1.75 6	2.9 1.02 6	.6 .26 6	.1 .08 6	.0 .05 6	56 13.1 6	36 10.4 6	7 3.5 6	2 1.2 6	0 .5 6

Table 12  
Summary of Clinical Hematology Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.68 .421 6	12.5 .54 6	40.9 2.28 6	61.4 2.74 6	18.7 .88 6	30.6 .62 6	464 131.6 6	.2 .26 6	17 18.7 6
0.03	MEAN S.D. N	7.08 .513 4	12.6 .46 4	41.7 1.91 4	59.0 2.70 4	17.8 .90 4	30.2 .82 4	483 167.0 4	.2 .16 4	14 10.7 4
0.15	MEAN S.D. N	6.78 .479 6	12.6 .38 6	41.3 1.47 6	61.1 2.82 6	18.7 .95 6	30.6 .40 6	519 146.4 6	.4 .15 6	30 9.6 6
0.75	MEAN S.D. N	6.65 .641 6	11.8 1.04 6	40.0 3.32 6	60.3 2.43 6	17.7 .87 6	29.4 * .50 6	396 199.1 6	.6 .48 6	39 30.3 6



Table 12  
Summary of Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	7.3 2.62 6	2.7 1.64 6	3.9 .91 6	.5 .29 6	.2 .15 6	.0 .08 6	35 8.6 6	54 8.3 6	7 2.9 6	2 2.7 6	0 .8 6
0.03	MEAN S.D. N	9.9 1.04 4	5.6 1.70 4	3.5 1.08 4	.6 .22 4	.2 .08 4	.0 .00 4	56 15.0 4	36 13.5 4	6 1.8 4	2 1.0 4	0 .0 4
0.15	MEAN S.D. N	10.1 2.44 6	5.2 2.81 6	4.0 1.17 6	.7 .12 6	.3 .21 6	.0 .05 6	49 18.2 6	42 16.4 6	7 2.5 6	2 2.0 6	0 .5 6
0.75	MEAN S.D. N	9.0 2.87 6	4.3 3.02 6	3.6 1.08 6	.8 .44 6	.2 .18 6	.0 .04 6	45 15.3 6	44 16.1 6	9 3.7 6	2 1.5 6	0 .4 6

Table 12  
Summary of Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.60 .559 6	12.4 .85 6	40.6 2.96 6	61.7 2.45 6	18.8 .77 6	30.6 .46 6	520 73.1 6	.4 .31 6	24 20.5 6
0.03	MEAN S.D. N	6.66 .641 4	12.0 .92 4	40.4 2.44 4	61.1 6.52 4	18.1 2.23 4	29.6 * .82 4	387 52.3 4	.6 .61 4	39 33.6 4
0.15	MEAN S.D. N	6.66 .257 6	12.1 .45 6	39.9 1.31 6	59.8 2.12 6	18.2 .64 6	30.4 .18 6	460 83.7 6	.3 .24 6	20 16.1 6
0.75	MEAN S.D. N	6.33 .288 6	11.7 .44 6	39.5 1.98 6	62.4 2.21 6	18.5 .70 6	29.7 * .65 6	492 144.0 6	.2 .12 6	11 7.9 6

Table 12  
Summary of Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	9.7 2.44 6	4.6 2.98 6	4.1 1.08 6	.8 .30 6	.2 .18 6	.0 .05 6	44 18.7 6	44 15.9 6	9 3.9 6	3 2.3 6	0 .5 6
0.03	MEAN S.D. N	9.3 4.49 4	5.0 3.55 4	2.9 .62 4	1.1 1.00 4	.2 .14 4	.1 .08 4	50 12.6 4	36 15.6 4	11 3.6 4	2 1.4 4	1 1.0 4
0.15	MEAN S.D. N	8.1 2.23 6	3.7 1.98 6	3.4 .96 6	.6 .14 6	.3 .15 6	.0 .00 6	44 14.5 6	44 14.4 6	8 2.2 6	3 1.9 6	0 .5 6
0.75	MEAN S.D. N	9.5 2.99 6	4.4 2.33 6	4.0 2.19 6	.8 .35 6	.2 .13 6	.0 .05 6	46 17.4 6	43 16.5 6	9 4.3 6	2 .9 6	1 .5 6

Table 13  
Summary of Clinical Hematology Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.60 .354 6	12.5 .50 6	41.1 2.07 6	62.3 2.53 6	18.9 .78 6	30.3 .79 6	467 90.4 6	.2 .08 6	11 5.8 6
0.03	MEAN S.D. N	6.96 .627 4	12.5 .45 4	42.1 1.79 4	60.7 2.81 4	18.0 1.05 4	29.6 .88 4	466 183.0 4	.2 .17 4	12 11.8 4
0.15	MEAN S.D. N	6.65 .372 6	12.5 .31 6	41.0 1.15 6	61.8 2.76 6	18.8 .80 6	30.4 .30 6	470 63.1 6	.3 .04 6	19 3.2 6
0.75	MEAN S.D. N	6.32 .387 4	11.4 * .83 4	38.8 2.45 4	61.5 2.72 4	17.9 1.08 4	29.2 * .48 4	401 228.0 4	.2 .24 4	12 14.6 4

Table 13  
Summary of Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	9.7 1.76 6	4.2 1.66 6	4.4 1.46 6	.7 .46 6	.2 .18 6	.0 .05 6	45 16.1 6	46 12.4 6	7 4.1 6	2 2.0 6	0 .5 6
0.03	MEAN S.D. N	8.4 .74 4	4.8 1.46 4	2.8 .74 4	.6 .26 4	.2 .06 4	.0 .00 4	57 15.1 4	34 10.6 4	6 3.8 4	2 1.0 4	0 .5 4
0.15	MEAN S.D. N	10.0 2.44 6	5.2 2.10 6	4.1 1.39 6	.5 .14 6	.2 .20 6	.0 .00 6	50 15.2 6	42 13.6 6	5 2.4 6	2 2.1 6	0 .0 6
0.75	MEAN S.D. N	7.6 2.09 4	2.9 1.13 4	4.0 1.16 4	.5 .12 4	.1 .10 4	.0 .06 4	38 6.9 4	53 9.1 4	7 2.9 4	2 1.7 4	0 .6 4

Table 13  
Summary of Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.40 .461 6	12.1 .64 6	40.8 2.67 6	63.8 2.49 6	19.0 .70 6	29.7 .65 6	484 100.1 6	.4 .24 6	27 15.1 6
0.03	MEAN S.D. N	6.15 .798 4	11.2 1.66 4	38.3 5.67 4	62.3 6.23 4	18.2 2.09 4	29.3 .94 4	429 54.7 4	.2 .13 4	13 5.8 4
0.15	MEAN S.D. N	6.57 .256 6	11.9 .62 6	39.9 1.78 6	60.8 2.50 6	18.2 .73 6	29.9 .35 6	412 74.4 6	.2 .12 6	12 7.5 6
0.75	MEAN S.D. N	6.09 .360 6	11.3 .37 6	39.2 2.17 6	64.3 1.46 6	18.6 .71 6	29.0 1.09 6	490 166.0 6	.2 .21 6	12 12.7 6

Table 13  
Summary of Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	10.4 3.59 6	5.0 3.41 6	4.3 1.96 6	.7 .15 6	.2 .19 6	.0 .05 6	46 17.5 6	44 15.1 6	8 3.4 6	3 1.8 6	0 .5 6
0.03	MEAN S.D. N	8.5 2.05 4	4.3 1.45 4	3.2 .57 4	.7 .32 4	.3 .15 4	.0 .10 4	50 9.3 4	38 10.1 4	8 2.2 4	3 1.4 4	0 1.0 4
0.15	MEAN S.D. N	9.2 1.61 6	4.5 1.73 6	3.8 .61 6	.6 .18 6	.3 .24 6	.0 .04 6	48 13.0 6	43 11.7 6	6 2.1 6	3 2.0 6	0 .8 6
0.75	MEAN S.D. N	9.7 2.73 6	4.2 1.10 6	4.6 2.70 6	.7 .32 6	.2 .08 6	.1 .05 6	46 14.6 6	45 14.8 6	8 3.4 6	2 .8 6	0 .5 6

Table 14  
Summary of Clinical Hematology Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.26	12.0	38.1	60.8	19.1	31.5	483	.4	22
S.D.	.007	.21	.28	.35	.28	.35	193.7	.07	4.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.49	12.7	40.7	62.8	19.6	31.2	488	.3	20
S.D.	.057	.42	1.27	1.34	.42	.07	118.8	.14	9.2
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	5.90	11.6	37.8	64.0	19.5	30.6	469	.4	26
S.D.	.042	.07	.64	.71	.07	.42	22.6	.21	12.0
N	2	2	2	2	2	2	2	2	2



Table 14  
Summary of Clinical Hematology Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	7.3	2.4	4.0	.6	.2	.0	34	54	9	3	1
S.D.	1.70	.14	1.63	.14	.07	.00	4.9	9.9	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	11.5	6.2	4.5	.6	.3	.0	53	38	6	3	0
S.D.	3.82	2.05	2.12	.21	.14	.00	.0	5.7	3.5	2.8	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	11.8	6.0	4.4	.9	.4	.0	50	39	7	4	0
S.D.	4.10	2.69	.78	.57	.07	.00	5.7	7.1	2.8	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

Table 14  
Summary of Clinical Hematology Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	5.94	11.8	36.9	62.0	19.8	32.0	468	.3	18
S.D.	.714	1.20	4.81	.64	.35	.99	111.0	.28	19.1
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.14	11.9	37.6	61.4	19.5	31.7	408	.4	22
S.D.	.092	.14	.57	.07	.07	.14	37.5	.21	13.4
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.42	12.0	40.2	62.6	18.7	29.8	444	.5	32
S.D.	.417	.28	2.90	.57	.71	1.34	160.5	.28	20.5
N	2	2	2	2	2	2	2	2	2

Table 14  
Summary of Clinical Hematology Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	8.2	4.6	2.8	.6	.1	.0	55	36	8	2	0
	S.D.	2.76	2.12	.35	.28	.00	.00	7.1	7.8	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	7.6	2.6	4.0	.6	.4	.0	34	53	8	4	1
	S.D.	1.06	1.20	.35	.14	.21	.07	10.6	11.3	2.8	2.1	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	9.3	2.6	5.8	.6	.2	.0	28	64	6	3	0
	S.D.	2.26	.64	1.20	.35	.07	.07	.7	2.1	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2

Table 15  
Summary of Clinical Hematology Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL	
0	MEAN S.D. N	6.52 .332 2	12.6 .57 2	39.2 1.91 2	60.2 .07 2	19.4 .07 2	32.1 .00 2	556 181.7 2	.2 .14 2	13 8.5 2
0.15	MEAN S.D. N	6.78 .049 2	13.3 .00 2	42.2 .49 2	62.1 1.13 2	19.6 .28 2	31.6 .21 2	493 36.8 2	.2 .07 2	10 4.9 2
0.75	MEAN S.D. N	6.20 .191 2	11.9 .71 2	39.5 .64 2	63.7 .99 2	19.2 .49 2	30.1 1.27 2	532 43.1 2	.6 .28 2	36 16.3 2

Table 15  
Summary of Clinical Hematology Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	10.0	3.2	6.1	.4	.3	.0	32	60	4	3	0
S.D.	2.90	.78	2.12	.07	.00	.00	1.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	11.4	5.5	4.8	.6	.4	.0	48	42	6	3	0
S.D.	1.13	.42	1.06	.28	.07	.00	.7	4.9	3.5	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	13.4	5.6	6.2	1.0	.5	.1	41	47	8	4	1
S.D.	5.52	2.63	1.77	.64	.14	.00	4.2	5.7	2.1	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

Table 15  
Summary of Clinical Hematology Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.22	12.3	38.4	61.6	19.8	32.1	519	.2	16
S.D.	.735	1.41	4.95	.71	.07	.49	82.0	.07	6.4
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.74	12.7	40.7	60.3	18.8	31.2	425	.2	10
S.D.	.191	.28	.35	1.27	.14	.28	48.1	.07	4.2
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.70	12.5	42.0	62.7	18.7	29.8	440	.2	17
S.D.	.453	.42	2.97	.21	.71	1.20	149.2	.21	15.6
N	2	2	2	2	2	2	2	2	2

Table 15  
Summary of Clinical Hematology Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	11.4	7.1	3.4	.7	.2	.0	62	30	6	2	0
	S.D.	1.56	2.83	.85	.28	.14	.00	16.3	12.0	2.8	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	9.4	3.0	5.0	1.0	.4	.0	28	56	11	4	0
	S.D.	2.76	2.97	.49	.00	.28	.07	23.3	21.9	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	11.0	3.6	6.2	.9	.2	.1	32	56	8	2	1
	S.D.	.21	1.34	1.77	.28	.07	.00	12.7	14.8	2.8	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 16  
Summary of Clinical Hematology Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.72	12.6	40.1	59.6	18.8	31.6	504	.2	17
S.D.	.198	.49	2.12	1.34	.21	.42	228.4	.07	4.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.78	13.1	41.8	61.5	19.3	31.4	496	.4	27
S.D.	.106	.42	2.05	1.98	.28	.49	105.4	.28	19.8
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.45	12.3	41.0	63.6	19.1	29.9	519	.3	19
S.D.	.495	1.13	2.40	1.13	.21	.92	60.8	.14	7.1
N	2	2	2	2	2	2	2	2	2



Table 16  
Summary of Clinical Hematology Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	7.3	2.6	3.7	.8	.1	.0	36	51	10	2	1
	S.D.	.42	.28	.42	.35	.00	.07	6.4	2.8	4.2	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	11.5	6.6	4.1	.4	.2	.0	58	36	4	2	0
	S.D.	2.26	2.05	.14	.21	.14	.00	6.4	8.5	1.4	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	11.6	5.0	5.4	.8	.4	.0	40	49	7	2	1
	S.D.	6.22	3.54	1.91	.49	.21	.07	9.2	9.9	.0	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 16  
Summary of Clinical Hematology Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.32	12.3	39.0	61.7	19.5	31.6	510	.4	25
S.D.	1.062	1.70	7.57	1.41	.71	1.91	135.8	.00	4.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.64	12.6	40.1	60.3	18.8	31.2	423	.4	23
S.D.	.071	.07	.57	.21	.35	.64	5.7	.21	14.1
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.78	12.5	40.8	60.2	18.4	30.5	440	.4	30
S.D.	.410	.35	1.56	1.34	.64	.35	137.9	.35	21.9
N	2	2	2	2	2	2	2	2	2

Table 16  
Summary of Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	8.8	5.4	2.8	.5	.0	.0	60	33	6	1	0
S.D.	1.13	2.40	.99	.14	.07	.00	19.1	15.6	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	7.8	2.9	3.8	.6	.4	.0	34	53	8	5	1
S.D.	2.26	2.55	.64	.07	.28	.07	22.6	22.6	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	9.2	4.4	4.1	.6	.1	.0	48	44	6	0	0
S.D.	2.26	.92	.85	.49	.00	.07	2.1	2.1	3.5	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2

Table 17  
Summary of Clinical Hematology Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.72	12.6	40.2	59.8	18.8	31.5	544	.3	20
S.D.	.078	.35	.57	.07	.28	.42	209.3	.28	19.1
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.80	13.2	41.9	61.5	19.4	31.5	491	.2	10
S.D.	.127	.57	1.84	1.48	.49	.07	80.6	.07	4.9
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.22	11.8	38.1	61.1	19.0	31.0	572	.6	34
S.D.	.198	.42	.35	1.34	.07	.71	43.1	.35	21.2
N	2	2	2	2	2	2	2	2	2

Table 17  
Summary of Clinical Hematology Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	8.6	4.2	3.8	.6	.1	.0	48	42	8	1	0
S.D.	1.20	.21	1.06	.07	.00	.00	4.9	6.4	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	12.8	8.2	3.7	.8	.2	.0	64	30	6	1	0
S.D.	1.34	2.05	.99	.21	.07	.00	9.2	10.6	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	9.0	4.0	3.9	.8	.2	.0	43	44	10	2	0
S.D.	3.75	2.55	1.13	.07	.07	.07	9.9	6.4	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

Table 17  
Summary of Clinical Hematology Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.32	12.3	38.4	60.8	19.6	32.1	546	.2	13
S.D.	.403	.64	2.12	.49	.21	.07	140.0	.14	9.9
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.76	12.5	40.1	59.4	18.4	31.0	472	.4	24
S.D.	.071	.00	.78	1.77	.21	.64	103.9	.07	4.9
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.50	11.9	39.5	60.8	18.4	30.2	424	.3	20
S.D.	.431	.42	2.19	.64	.64	.71	155.6	.28	19.8
N	2	2	2	2	2	2	2	2	2

Table 17  
Summary of Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	11.8	7.2	3.2	1.0	.2	.0	59	30	8	2	0
	S.D.	4.38	3.96	.07	.57	.07	.00	11.3	11.3	2.1	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	9.4	4.2	4.2	.6	.4	.0	42	48	7	4	0
	S.D.	2.83	3.18	.42	.21	.28	.00	21.2	19.1	4.2	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	8.9	2.7	5.6	.6	.2	.0	30	62	6	2	0
	S.D.	1.56	.57	.78	.07	.07	.00	1.4	1.4	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 18  
Summary of Clinical Hematology Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.53	12.4	39.5	60.5	19.2	31.6	514	.1	6
S.D.	.042	.07	.07	.49	.21	.07	179.6	.14	9.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.72	13.0	41.2	61.3	19.4	31.7	448	.1	7
S.D.	.283	.64	2.97	1.91	.28	.57	68.6	.14	9.9
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.23	12.2	38.9	62.5	19.5	31.2	508	.8	46
S.D.	.198	.21	.28	2.40	.28	.85	17.7	1.06	64.3
N	2	2	2	2	2	2	2	2	2



Table 18  
Summary of Clinical Hematology Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	10.8	6.6	3.4	.7	.0	.0	61	32	6	0	0
	S.D.	.14	.99	.92	.14	.07	.07	8.5	9.2	.7	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	12.5	8.2	3.5	.8	.1	.0	64	28	6	0	0
	S.D.	1.84	1.98	.71	.49	.14	.00	6.4	10.6	2.8	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	12.2	6.4	4.2	1.1	.4	.0	52	36	9	3	0
	S.D.	3.96	2.69	.78	.42	.07	.07	4.9	5.7	.0	.0	.7
	N	2	2	2	2	2	2	2	2	2	2	2

Table 18  
Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.28	12.4	38.1	60.8	19.8	32.6	534	.2	10
S.D.	.453	.78	2.90	.35	.14	.42	142.8	.07	4.9
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.77	12.6	40.8	60.2	18.6	31.0	456	.2	10
S.D.	.113	.14	1.34	.92	.07	.64	67.9	.07	4.2
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.54	12.2	40.1	61.3	18.6	30.4	448	.2	10
S.D.	.028	.07	.57	1.13	.14	.78	181.7	.07	4.2
N	2	2	2	2	2	2	2	2	2

Table 18  
Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	7.4	3.4	2.8	1.0	.2	.0	45	37	14	3	0
	S.D.	1.48	1.13	.42	.28	.14	.00	6.4	1.4	6.4	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	8.1	3.0	3.7	.9	.4	.0	38	46	11	5	0
	S.D.	.57	.71	.99	.42	.14	.07	10.6	9.2	4.2	2.8	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	10.8	4.7	5.2	.8	.1	.0	43	48	8	1	0
	S.D.	.78	.57	.21	.42	.14	.00	1.4	4.9	3.5	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 19  
Summary of Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.63	12.9	40.2	60.7	19.4	32.0	460	.3	20
S.D.	.269	.57	1.34	.42	.00	.28	174.7	.14	9.9
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	7.16	14.0	45.6	63.7	19.5	30.6	490	.3	22
S.D.	.049	.21	.99	.92	.14	.21	106.8	.28	20.5
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.30	12.6	40.6	64.5	19.9	31.0	510	.7	42
S.D.	.530	.92	2.69	1.13	.21	.14	92.6	.99	58.7
N	2	2	2	2	2	2	2	2	2

Table 19  
Summary of Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	11.6	6.4	4.4	.6	.1	.0	55	38	6	1	0
S.D.	.57	1.48	.78	.07	.00	.07	9.9	8.5	.7	.0	.7
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	11.6	4.9	5.9	.6	.2	.0	42	50	6	2	0
S.D.	1.27	1.13	.42	.21	.00	.00	4.9	2.1	2.1	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	16.6	10.3	4.8	1.2	.4	.1	62	28	6	2	0
S.D.	6.51	3.96	1.77	.64	.21	.00	.7	.7	.7	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

Table 19  
Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.26	12.4	38.5	61.6	19.8	32.2	494	.5	31
S.D.	.884	1.56	5.23	.35	.35	.49	122.3	.14	4.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.66	12.7	40.8	61.4	19.2	31.2	451	.3	20
S.D.	.064	.00	.85	.71	.21	.78	14.1	.14	9.2
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	7.06	13.1	42.9	60.8	18.5	30.6	446	.2	12
S.D.	.629	.57	3.18	.92	.78	.92	215.7	.21	16.3
N	2	2	2	2	2	2	2	2	2

Table 19  
Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	8.8	4.4	3.4	.7	.3	.0	50	38	8	3	0
S.D.	.78	.14	.64	.14	.14	.00	6.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	9.9	3.8	4.6	.9	.6	.0	37	48	9	6	0
S.D.	1.70	1.70	.07	.14	.28	.00	11.3	6.4	.0	4.2	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	10.6	3.0	6.2	1.0	.3	.2	29	58	9	3	2
S.D.	.92	.71	1.56	.07	.14	.07	9.9	9.9	1.4	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

Table 20  
Summary of Clinical Hematology Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.56	12.6	40.7	61.9	19.2	31.0	434	.5	33
S.D.	.035	.00	1.06	1.27	.07	.71	96.9	.28	18.4
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.90	13.6	43.9	63.6	19.8	31.1	373	.7	48
S.D.	.141	.21	.42	.71	.00	.28	5.7	.00	.7
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.42	12.6	42.4	65.0	19.6	29.8	520	.6	38
S.D.	.000	.14	1.56	2.33	.14	.78	59.4	.42	27.6
N	2	2	2	2	2	2	2	2	2



Table 20  
Summary of Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN	8.4	3.1	4.2	.8	.1	.2	36	52	9	1	2
	S.D.	1.77	1.56	.14	.42	.00	.21	11.3	12.0	2.8	.0	2.1
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	10.9	5.0	4.7	.8	.4	.1	46	42	8	2	1
	S.D.	3.96	1.70	2.12	.14	.21	.00	1.4	4.2	4.2	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	16.0	9.8	4.4	1.2	.2	.2	62	28	8	2	2
	S.D.	.35	1.48	1.41	.07	.21	.14	11.3	7.8	.7	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2

Table 20  
Summary of Clinical Hematology Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
0									
MEAN	6.02	11.8	37.5	62.5	19.8	31.6	508	.4	26
S.D.	.700	1.06	4.17	.21	.49	.71	35.4	.21	9.2
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	6.46	12.3	40.2	62.2	19.0	30.6	406	.4	29
S.D.	.191	.42	1.34	.21	.14	.14	2.1	.21	12.7
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	6.72	12.4	40.8	60.8	18.5	30.4	396	.3	20
S.D.	.134	.14	.28	1.56	.57	.14	146.4	.14	9.9
N	2	2	2	2	2	2	2	2	2

Table 20  
Summary of Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 11.2	7.0	2.8	1.0	.3	.2	58	28	10	2	1
	S.D. 6.15	4.95	.49	.42	.14	.07	12.0	11.3	.7	.7	.0
	N 2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN 11.5	5.4	4.2	1.0	.6	.2	46	37	10	5	2
	S.D. 3.25	2.33	1.20	.07	.21	.00	7.1	.0	2.8	2.8	.0
	N 2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN 10.4	3.1	6.4	.5	.2	.2	30	61	5	2	2
	S.D. .85	.14	.92	.00	.14	.07	3.5	4.2	.0	.7	.7
	N 2	2	2	2	2	2	2	2	2	2	2

Table 21  
Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	76	20	1.2	9.0	4.9	4.1	.6	9	138	70
	S.D.	12.5	3.8	.10	.32	.21	.26	.45	2.0	33.7	13.3
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	70	20	1.2	9.6	5.2	4.4	.4	9	110	61
	S.D.	8.3	6.2	.17	.58	.46	.48	.18	1.4	20.1	35.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	82	21	1.2	9.5	5.1	4.4	.6	10	151	56
	S.D.	30.4	3.3	.22	.44	.34	.26	.37	2.2	26.1	4.9
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	20	1.3	9.4	5.2	4.3	.5	9	138	67
	S.D.	15.4	2.0	.11	.38	.28	.37	.29	1.3	29.3	11.0
	N	6	6	6	6	6	6	6	6	6	6

Table 21  
Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	56	32	711	134	7	1133	395	55	247
	S.D.	16.5	9.7	252.6	42.8	1.9	535.3	93.4	84.4	54.0
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	44	36	700	141	3	936	476	35	302
	S.D.	6.3	11.2	265.6	34.5	1.0	709.0	164.6	20.6	107.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	72	69	770	160	8	1087	386	51	242
	S.D.	23.5	35.7	210.3	68.4	5.4	322.3	94.5	42.4	62.4
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	68	80	840	171	6	1094	529	41	324
	S.D.	11.7	54.2	360.9	53.3	1.5	497.4	135.6	31.8	72.2
	N	6	6	6	6	6	6	6	6	6

Table 21  
Summary of Clinical Chemistry Data  
Males Day -27  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.8	6.2	159	5.4	109
	S.D.	.60	.84	4.6	.58	2.9
	N	6	6	6	6	6
0.03	MEAN	11.6	6.6	164	5.9	111
	S.D.	.53	.44	6.0	.32	2.2
	N	4	4	4	4	4
0.15	MEAN	11.5	7.1	163	6.4	112
	S.D.	.62	.99	5.3	.60	2.7
	N	6	6	6	6	6
0.75	MEAN	11.3	6.9	161	5.8	108
	S.D.	.54	1.06	4.8	.62	2.9
	N	6	6	6	6	6

Table 21  
Summary of Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	76	22	1.2	9.6	4.9	4.7	.5	7	149	73
	S.D.	22.2	1.6	.08	.78	.35	.83	.34	1.9	37.2	32.4
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	73	22	1.2	9.3	4.7	4.6	.5	6	130	62
	S.D.	10.7	1.3	.08	.50	.18	.41	.17	1.7	12.4	7.5
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	76	23	1.1	9.6	4.7	4.9	.6	12	144	58
	S.D.	12.0	3.9	.10	.62	.57	.38	.21	12.1	14.0	11.7
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	78	24	1.2	9.4	4.8	4.6	.6	9	154	61
	S.D.	16.3	3.9	.18	.78	.40	.65	.37	1.4	10.1	16.6
	N	6	6	6	6	6	6	6	6	6	6

Table 21  
Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	64	140	291	123	4	979	374	28	220
	S.D.	6.7	76.9	130.1	54.0	1.6	384.3	121.9	12.5	73.1
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	54	103	201	94	3	484	378	26	237
	S.D.	10.2	29.4	12.5	48.5	.8	156.7	153.7	15.9	79.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	74	110	257	87	4	844	416	35	244
	S.D.	35.5	41.0	118.5	32.9	2.4	306.4	121.0	21.2	81.3
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	72	123	310	75	4	1624	384	19	247
	S.D.	15.4	54.2	141.4	24.3	2.0	1251.5	88.6	15.4	54.1
	N	6	6	6	6	6	6	6	6	6



Table 21  
Summary of Clinical Chemistry Data  
Females Day -27  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	11.4	6.2	163	6.2	114
	S.D.	1.10	.63	7.1	.96	5.0
	N	6	6	6	6	6
0.03	MEAN	10.9	4.7	163	5.9	115
	S.D.	.58	.99	3.4	.70	3.3
	N	4	4	4	4	4
0.15	MEAN	11.0	5.9	162	6.1	115
	S.D.	.59	.78	6.1	.63	3.1
	N	6	6	6	6	6
0.75	MEAN	11.3	5.5	163	6.1	114
	S.D.	.59	.50	4.9	.80	1.5
	N	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	60	20	1.1	8.9	4.7	4.2	.8	9	140	69
	S.D.	5.9	2.3	.12	.56	.13	.49	.43	1.5	22.1	18.7
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	62	18	1.2	9.3	5.0	4.3	.4	8	118	47
	S.D.	8.3	3.9	.18	1.02	.46	.85	.16	1.3	28.4	4.6
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	61	21	1.2	9.2	4.8	4.4	.6	8	146	58
	S.D.	9.8	4.9	.23	.33	.25	.32	.27	.8	21.5	5.3
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	65	21	1.3	9.3	5.1	4.2	.4	7	130	91
	S.D.	7.8	2.3	.12	.37	.36	.40	.17	1.5	18.0	27.3
	N	6	6	6	6	6	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	45	39	888	134	7	354	374	22	222
	S.D.	15.9	19.5	339.5	42.9	2.6	461.0	106.3	12.5	58.4
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	37	40	876	120	3	191	459	24	282
	S.D.	6.3	13.0	384.3	35.4	1.5	58.2	149.3	13.6	93.3
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	48	50	896	136	5	184	369	40	221
	S.D.	15.9	23.8	267.3	57.3	3.2	59.7	78.9	21.7	55.5
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	43	46	996	142	2 *	283	522	26	307
	S.D.	10.0	23.0	417.0	39.9	.4	149.7	124.7	10.9	55.9
	N	6	6	6	6	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data  
Males Day 37  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.6	6.7	160	5.4	115
	S.D.	.25	.80	2.6	.28	2.4
	N	6	6	6	6	6
0.03	MEAN	11.2	6.9	165	5.8	116
	S.D.	1.12	1.58	10.1	.74	4.2
	N	4	4	4	4	4
0.15	MEAN	11.0	6.8	160	5.6	115
	S.D.	.39	1.00	3.1	.38	.9
	N	6	6	6	6	6
0.75	MEAN	10.9	6.6	162	5.4	114
	S.D.	.43	1.29	2.4	.29	2.7
	N	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	58	22	1.1	9.3	4.4	4.9	.6	8	147	71
	S.D.	14.7	4.4	.16	.71	.26	.80	.34	.5	26.9	25.7
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	67	21	1.1	9.0	4.5	4.5	.5	9	124	64
	S.D.	15.2	3.0	.05	.41	.15	.39	.25	2.5	11.1	12.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	60	20	1.0	9.2	4.3	4.9	.6	8	133	57
	S.D.	8.4	3.6	.04	.26	.37	.40	.14	3.2	22.4	11.3
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	70	22	1.1	9.1	4.4	4.7	.4	7	123	66
	S.D.	11.5	5.4	.14	.31	.10	.38	.15	1.2	14.1	23.0
	N	6	6	6	6	6	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	44	59	362	102	5	240	339	18	194
	S.D.	12.1	30.2	125.6	42.9	2.4	146.6	89.9	13.2	58.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	49	70	240	88	3	378	384	28	237
	S.D.	15.9	13.3	48.7	54.7	1.3	262.2	110.9	15.2	55.5
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	36	68	319	76	3	198	414	34	230
	S.D.	6.6	30.9	129.0	20.3	1.5	101.3	115.1	17.4	70.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	36	46	415	58	2 *	331	373	23	230
	S.D.	8.0	7.5	188.9	20.0	.9	242.1	83.3	5.9	66.0
	N	6	6	6	6	6	6	6	6	6

Table 22  
Summary of Clinical Chemistry Data  
Females Day 37  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.4	5.7	161	5.7	115
	S.D.	.39	.73	4.9	.38	4.4
	N	6	6	6	6	6
0.03	MEAN	10.2	4.2 *	161	5.2	116
	S.D.	.42	.37	5.4	.92	4.3
	N	4	4	4	4	4
0.15	MEAN	9.7	5.1	157	5.2	114
	S.D.	.73	.65	2.5	.39	1.1
	N	6	6	6	6	6
0.75	MEAN	10.4	5.0	160	5.9	116
	S.D.	.25	.48	5.3	.42	3.0
	N	6	6	6	6	6

Table 23  
Summary of Clinical Chemistry Data  
Males Day 62  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	59	20	1.1	8.6	4.6	4.0	.7	9	153	62
	S.D.	9.1	3.9	.08	.50	.17	.42	.42	1.5	23.0	19.0
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	59	20	1.2	9.0	4.7	4.3	.4	10	114 *	60
	S.D.	2.9	3.7	.14	.69	.36	.58	.10	2.2	25.1	14.8
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	67	18	1.2	8.8	4.6	4.1	.5	10	144	57
	S.D.	13.3	3.9	.13	.42	.48	.44	.23	1.7	19.7	13.4
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	74	19	1.3	8.8	4.8	4.0	.3	10	125	76
	S.D.	10.6	2.6	.12	.41	.53	.59	.06	2.7	20.6	16.6
	N	6	6	6	6	6	6	6	6	6	6



Table 23  
Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	36	34	839	130	7	132	371	22	224
	S.D.	7.9	15.2	321.9	46.2	2.3	27.8	115.8	13.9	64.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	35	35	750	116	4	149	428	21	270
	S.D.	7.2	17.5	369.9	25.0	1.5	47.7	143.3	13.8	92.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	40	37	806	128	5	153	344	20	213
	S.D.	9.4	11.7	237.8	39.4	3.8	19.9	88.3	11.3	61.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	43	823	125	3	203 *	499	22	301
	S.D.	6.3	16.2	367.0	29.9	.8	57.2	119.4	13.4	53.4
	N	6	6	6	6	6	6	6	6	6

Table 23  
Summary of Clinical Chemistry Data  
Males Day 62  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.4	7.1	160	5.4	120
	S.D.	.39	.66	2.9	.44	2.5
	N	6	6	6	6	6
0.03	MEAN	10.5	6.8	166	5.6	122
	S.D.	.44	.88	12.5	.92	9.3
	N	4	4	4	4	4
0.15	MEAN	10.4	6.6	160	5.4	120
	S.D.	.26	1.08	3.5	.50	3.5
	N	6	6	6	6	6
0.75	MEAN	10.5	6.8	159	5.6	120
	S.D.	.60	1.31	6.4	.63	2.8
	N	6	6	6	6	6

Table 23  
Summary of Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	57	21	1.1	9.0	4.4	4.7	.5	9	155	86
	S.D.	10.2	3.5	.13	.57	.21	.75	.24	.8	45.4	49.4
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	66	22	1.1	8.8	4.3	4.5	.6	10	127	76
	S.D.	17.3	3.4	.05	.44	.10	.46	.26	3.7	11.2	21.5
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	62	20	1.0	9.0	4.3	4.7	.6	10	137	64
	S.D.	12.6	2.7	.10	.15	.33	.24	.18	3.2	19.5	18.0
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	74	20	1.2	9.0	4.4	4.6	.4	9	127	61
	S.D.	7.2	5.0	.13	.44	.17	.39	.10	1.9	18.9	10.5
	N	6	6	6	6	6	6	6	6	6	6

Table 23  
Summary of Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	38	53	360	106	4	262	342	14	198
	S.D.	3.4	16.7	152.5	47.7	1.8	123.6	86.9	14.7	55.5
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	45	77	241	84	4	276	358	19	228
	S.D.	9.9	15.8	45.3	44.5	2.2	67.9	108.3	16.7	55.8
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	60	305	75	4	194	410	28	234
	S.D.	7.8	29.3	134.0	20.8	1.0	76.1	129.7	19.6	82.3
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	31	42	398	58	2 *	243	385	27	246
	S.D.	7.8	6.2	200.5	20.0	.4	130.1	89.4	9.9	56.7
	N	6	6	6	6	6	6	6	6	6

Table 23  
Summary of Clinical Chemistry Data  
Females Day 62  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.0	6.0	162	5.8	120
	S.D.	.24	.36	6.5	.59	5.1
	N	6	6	6	6	6
0.03	MEAN	9.9	4.6 *	160	5.2	120
	S.D.	.22	.30	2.9	.43	2.2
	N	4	4	4	4	4
0.15	MEAN	9.6	5.1 *	160	5.5	123
	S.D.	.48	.51	3.6	.60	3.0
	N	6	6	6	6	6
0.75	MEAN	10.2	5.0 *	161	5.8	120
	S.D.	.60	.30	3.5	.87	1.8
	N	6	6	6	6	6

Table 24  
Summary of Clinical Chemistry Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	60	20	1.1	8.7	4.8	3.9	.7	8	154	68
	S.D.	8.0	4.3	.14	.40	.12	.33	.38	1.2	24.6	20.4
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	20	1.3	9.6	5.3 *	4.2	.4	8	126	54
	S.D.	7.6	4.9	.22	.98	.39	.75	.13	.6	14.9	9.8
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	75	19	1.2	9.0	5.0	4.0	.4	9	150	50
	S.D.	18.5	4.6	.16	.19	.14	.21	.22	2.7	18.8	10.4
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	19	1.4	9.4	5.2 *	4.2	.3 *	10	112 *	73
	S.D.	19.1	1.3	.19	.36	.31	.35	.05	3.6	27.0	21.0
	N	6	6	6	6	6	6	6	6	6	6

Table 24  
Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	39	35	866	136	7	168	392	33	265
	S.D.	7.7	15.8	296.2	50.1	2.6	32.4	111.8	30.3	71.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	35	60	789	131	4	175	465	48	318
	S.D.	7.0	55.8	401.7	34.5	1.4	42.5	185.6	57.9	125.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	42	45	851	140	6	164	377	27	258
	S.D.	12.2	22.4	265.3	58.6	4.3	36.2	94.9	18.3	70.1
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	36	44	807	127	2 *	214	468	32	350
	S.D.	6.3	21.0	428.6	27.4	.6	75.7	149.1	17.5	70.4
	N	6	6	6	6	6	6	6	6	6

Table 24  
Summary of Clinical Chemistry Data  
Males Day 91  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.3	6.8	160	5.1	117
	S.D.	.77	.37	7.1	.56	5.3
	N	6	6	6	6	6
0.03	MEAN	10.5	6.7	167	5.7	120
	S.D.	.79	.70	4.9	1.04	4.1
	N	4	4	4	4	4
0.15	MEAN	10.6	6.8	161	5.4	118
	S.D.	.51	1.05	4.6	.35	7.0
	N	6	6	6	6	6
0.75	MEAN	10.8	6.4	163	5.4	117
	S.D.	.41	.94	5.0	.45	4.2
	N	6	6	6	6	6



Table 24  
Summary of Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHCL MG/DL	TRIG MG/DL
0	MEAN	66	20	1.2	9.2	4.7	4.6	.4	8	166	67
	S.D.	20.5	2.7	.10	.51	.38	.51	.16	1.5	42.0	10.9
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	68	22	1.1	9.0	4.6	4.4	.5	8	134	61
	S.D.	14.7	3.3	.08	.69	.19	.54	.27	1.4	15.6	14.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	60	20	1.0	9.1	4.4	4.6	.4	10	140	56
	S.D.	12.4	4.2	.05	.24	.41	.32	.10	5.8	13.1	18.0
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	79	22	1.2	9.5	4.8	4.7	.3	11	111 *	60
	S.D.	15.5	6.3	.19	.45	.29	.33	.08	7.0	26.6	14.4
	N	6	6	6	6	6	6	6	6	6	6

Table 24  
Summary of Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	44	54	329	110	6	786	370	15	236
	S.D.	9.1	17.9	128.7	46.5	2.2	947.2	87.4	17.5	62.7
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	43	79	233	103	4	220	390	18	269
	S.D.	14.6	26.6	57.5	78.3	4.4	39.4	99.8	10.9	62.5
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	67	324	74	4	209	442	40	282
	S.D.	11.1	42.8	140.3	19.2	2.5	81.8	127.6	46.1	87.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	45	388	63	2 *	416	379	19	263
	S.D.	9.8	13.0	150.1	22.3	.5	377.0	96.5	13.6	59.4
	N	6	6	6	6	6	6	6	6	6

Table 24  
Summary of Clinical Chemistry Data  
Females Day 91  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.2	5.7	161	5.6	118
	S.D.	1.11	.66	5.9	.74	6.1
	N	6	6	6	6	6
0.03	MEAN	10.2	4.2 *	161	5.2	117
	S.D.	1.21	.44	7.5	.93	6.8
	N	4	4	4	4	4
0.15	MEAN	10.0	5.2	160	5.7	120
	S.D.	.53	.63	3.4	.45	4.2
	N	6	6	6	6	6
0.75	MEAN	10.6	5.1	162	5.8	118
	S.D.	.58	.53	4.7	.54	3.9
	N	6	6	6	6	6

Table 25  
Summary of Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	60 8.0 6	20 3.0 6	1.1 .12 6	8.2 .45 6	4.8 .19 6	3.4 .34 6	.7 .41 6	10 1.5 6	154 29.9 6	60 18.3 6	69 10.6 6
0.03	MEAN S.D. N	61 4.3 4	19 2.2 4	1.2 .19 4	8.8 .83 4	5.2 .24 4	3.6 .66 4	.4 .08 4	7 1.0 4	120 16.3 4	60 24.9 4	46 * 4.5 4
0.15	MEAN S.D. N	63 9.4 6	22 4.5 6	1.2 .18 6	8.8 .55 6	5.0 .31 6	3.8 .61 6	.5 .20 6	10 2.3 6	149 22.8 6	65 9.5 6	55 * 12.5 6
0.75	MEAN S.D. N	76 17.0 6	20 2.2 6	1.3 .20 6	9.0 .23 6	4.9 .48 6	4.1 .43 6	.2 * .05 6	14 5.5 6	65 * 20.3 6	60 26.3 6	19 * 6.5 6

Table 25  
Summary of Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN S.D. N	31 4.9 6	43 27.3 6	792 305.3 6	142 53.1 6	3 2.6 6	165 28.5 6	392 112.8 6	23 10.5 6	276 74.9 6
0.03	MEAN S.D. N	30 6.3 4	36 19.8 4	684 348.2 4	123 32.2 4	2 1.5 4	133 42.6 4	470 165.2 4	41 40.0 4	339 123.2 4
0.15	MEAN S.D. N	40 15.7 6	55 17.2 6	853 207.5 6	148 63.8 6	4 3.1 6	193 38.4 6	429 68.9 6	166 339.9 6	312 67.7 6
0.75	MEAN S.D. N	39 8.8 6	52 26.6 6	646 384.1 6	112 36.1 6	2 1.2 6	352 * 297.5 6	517 124.5 6	32 17.2 6	364 59.9 6

Table 25  
Summary of Clinical Chemistry Data  
Males Day 153  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.1	6.6	157	5.4	116
	S.D.	.73	.31	6.1	.48	4.1
	N	6	6	6	6	6
0.03	MEAN	10.8	6.3	159	5.5	117
	S.D.	.56	1.09	3.9	.67	4.1
	N	4	4	4	4	4
0.15	MEAN	10.4	6.8	158	5.5	115
	S.D.	.64	1.01	3.2	.43	4.2
	N	6	6	6	6	6
0.75	MEAN	10.8	6.8	158	5.8	113
	S.D.	.76	1.66	7.9	.73	7.8
	N	6	6	6	6	6

Table 25  
Summary of Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	58	20	1.1	8.9	4.7	4.2	.5	9	163	80	59
	S.D.	9.9	4.0	.14	.80	.47	.63	.27	1.3	48.5	47.1	16.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	20	1.1	8.6	4.4	4.2	.5	8	110 *	82	47
	S.D.	12.1	6.0	.17	.25	.40	.29	.34	1.7	22.1	28.5	9.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	57	22	1.1	8.8	4.5	4.2	.5	10	130	69	41 *
	S.D.	4.9	3.1	.08	.33	.37	.48	.12	3.1	23.2	13.7	9.2
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	70	18	1.2	8.9	4.5	4.4	.3	15	91 *	64	23 *
	S.D.	14.6	5.3	.14	.43	.41	.40	.08	13.8	23.1	13.5	4.3
	N	6	6	6	6	6	6	6	6	6	6	6

Table 25  
Summary of Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN S.D. N	36 8.2 6	77 43.3 6	315 143.3 6	112 51.2 6	2 .8 6	235 105.0 6	373 74.3 6	18 17.7 5	256 55.7 6
0.03	MEAN S.D. N	38 16.2 4	80 52.8 4	262 42.2 4	108 97.8 4	2 .8 4	255 131.7 4	378 108.8 4	18 13.5 4	275 67.7 4
0.15	MEAN S.D. N	36 13.4 6	66 34.1 6	308 120.9 6	72 20.3 6	3 2.5 6	242 116.5 6	432 165.5 6	25 15.2 6	293 129.4 6
0.75	MEAN S.D. N	40 18.1 6	48 10.0 6	336 146.9 6	61 24.2 6	2 2.3 6	695 1217.1 6	380 104.1 6	26 10.9 6	281 76.1 6



Table 25  
Summary of Clinical Chemistry Data  
Females Day 153  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.2	5.6	158	6.0	119
	S.D.	.67	.34	8.5	.81	7.2
	N	6	6	6	6	6
0.03	MEAN	9.8	4.1 *	155	5.6	116
	S.D.	1.04	.84	6.9	.46	6.8
	N	4	4	4	4	4
0.15	MEAN	9.8	5.0	154	5.4	116
	S.D.	.42	.96	2.2	.52	3.6
	N	6	6	6	6	6
0.75	MEAN	10.5	4.9	158	6.3	116
	S.D.	.67	.71	5.0	.75	4.4
	N	6	6	6	6	6

Table 26  
Summary of Clinical Chemistry Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	60 6.1 6	18 3.9 6	1.1 .16 6	8.2 .54 6	4.8 .23 6	3.5 .40 6	.6 .23 6	6 .8 6	152 27.5 6	45 8.7 6	63 11.1 6
0.03	MEAN S.D. N	64 9.1 4	18 6.3 4	1.2 .16 4	8.8 .65 4	5.0 .34 4	3.8 .47 4	.3 * .08 4	5 * .5 4	110 * 17.0 4	33 6.6 4	42 * 3.7 4
0.15	MEAN S.D. N	70 8.3 6	17 2.6 6	1.1 .17 6	8.5 .30 6	4.9 .31 6	3.6 .17 6	.4 .10 6	6 1.3 6	147 24.0 6	36 10.4 6	48 14.3 6
0.75	MEAN S.D. N	76 12.6 4	22 4.5 4	1.2 .24 4	9.0 .77 4	4.9 .53 4	4.1 .44 4	.2 * .05 4	18 * 8.6 4	48 * 18.8 4	30 11.8 4	13 * 5.4 4

Table 26  
Summary of Clinical Chemistry Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	32	39	735	150	6	210	393	29	280
	S.D.	6.2	17.9	316.7	65.6	3.7	158.7	102.8	13.4	68.5
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	27	29	604	126	4	138	442	24	314
	S.D.	6.2	8.8	353.5	42.6	1.9	58.8	136.5	10.6	96.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	36	47	688	148	6	174	381	30	270
	S.D.	13.3	16.9	178.3	55.8	3.8	101.5	82.3	11.8	59.0
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	47	389	104	3	182	446	36	320
	S.D.	5.3	19.7	155.7	25.3	1.0	64.5	65.3	22.2	25.2
	N	4	4	4	4	4	4	4	4	4

Table 26  
Summary of Clinical Chemistry Data  
Males Day 182  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.2	6.4	154	5.1	111
	S.D.	.43	.82	4.8	.23	1.5
	N	6	6	6	6	6
0.03	MEAN	10.0	5.8	156	5.0	109
	S.D.	.20	.96	1.5	.32	2.2
	N	4	4	4	4	4
0.15	MEAN	10.1	6.2	154	5.0	110
	S.D.	.41	.82	4.7	.25	2.9
	N	6	6	6	6	6
0.75	MEAN	10.3	6.1	153	5.4	106
	S.D.	.62	1.22	6.4	.17	5.3
	N	4	4	4	4	4

Table 26  
Summary of Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	58	20	1.1	8.9	4.7	4.2	.4	6	160	56	56
	S.D.	15.2	3.7	.18	.66	.42	.55	.25	.6	46.5	13.3	16.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	54	20	1.0	8.6	4.4	4.2	.5	5	122	49	42
	S.D.	7.8	3.4	.17	.76	.47	.38	.24	1.5	21.6	14.7	9.1
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	64	19	1.0	8.9	4.5	4.4	.4	8	129	49	36 *
	S.D.	9.0	3.1	.09	.47	.35	.67	.08	2.0	22.3	15.8	12.1
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	20	1.2	9.2	4.6	4.7	.2	7	82 *	53	21 *
	S.D.	11.0	4.7	.16	.37	.31	.63	.08	3.4	14.7	15.8	7.2
	N	6	6	6	6	6	6	6	6	6	6	6

Table 26  
Summary of Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0	MEAN	41	87	283	114	5	212	378	32	258
	S.D.	25.0	85.9	137.1	53.3	3.1	123.4	84.6	37.1	64.1
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	42	72	239	111	6	823	358	19	260
	S.D.	14.6	26.3	39.7	99.5	6.0	1281.8	100.7	15.0	64.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	53	254	71	7	182	439	33	294
	S.D.	13.0	36.1	85.3	19.7	5.2	84.7	140.9	21.6	111.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	33	44	316	64	3	284	375	31	273
	S.D.	6.2	9.9	172.4	22.7	1.5	119.3	64.9	21.2	43.1
	N	6	6	6	6	6	6	6	6	6

Table 26  
Summary of Clinical Chemistry Data  
Females Day 182  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.2	5.3	156	5.3	111
	S.D.	.68	.84	6.8	.56	5.0
	N	6	6	6	6	6
0.03	MEAN	9.6	4.4	152	4.8	109
	S.D.	.84	.39	7.2	.94	3.6
	N	4	4	4	4	4
0.15	MEAN	9.8	4.8	154	5.0	110
	S.D.	.16	1.10	3.3	.37	1.8
	N	6	6	6	6	6
0.75	MEAN	10.3	5.2	156	5.4	110
	S.D.	.69	.76	4.9	.82	3.1
	N	6	6	6	6	6

Table 27  
Summary of Clinical Chemistry Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	57	16	1.0	8.0	4.6	3.4	.5	12	132	44	58
	S.D.	2.8	4.9	.07	.21	.07	.14	.14	1.4	28.3	.7	12.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	70	17	.9	9.0	5.1	3.9	.6	16	158	39	61
	S.D.	12.0	.0	.14	.42	.00	.42	.21	.0	37.5	2.8	19.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	73	14	1.0	8.7	4.6	4.2	.6	14	137	69	28
	S.D.	4.2	2.1	.07	.00	.35	.35	.00	3.5	4.2	32.5	7.8
	N	2	2	2	2	2	2	2	2	2	2	2



Table 27  
Summary of Clinical Chemistry Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	22	26	932	150	4	139	338	36	250
	S.D.	3.5	3.5	316.1	123.7	.7	77.8	87.7	7.8	58.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	37	44	793	138	12	162	454	46	288
	S.D.	8.5	2.1	175.4	68.6	1.4	21.9	42.4	2.1	62.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	32	48	518	143	2	200	505	38	346
	S.D.	4.9	28.3	27.6	22.6	.7	32.5	53.7	21.2	23.3
	N	2	2	2	2	2	2	2	2	2

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.0	6.3	152	5.0	111
S.D.	.57	1.13	2.8	.49	1.4
N	2	2	2	2	2
0.15					
MEAN	11.0	6.6	155	5.3	108
S.D.	.78	.00	1.4	.28	2.8
N	2	2	2	2	2
0.75					
MEAN	10.8	6.2	159	5.4	111
S.D.	.21	1.13	2.8	.07	1.4
N	2	2	2	2	2

Table 27  
Summary of Clinical Chemistry Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	59	16	.8	8.6	4.6	4.0	.4	14	119	72	54
	S.D.	11.3	4.9	.14	.42	.21	.21	.42	1.4	46.7	50.2	29.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	76	18	1.0	8.7	4.0	4.6	.6	14	145	56	44
	S.D.	.7	2.1	.00	.14	.07	.21	.00	.7	4.2	4.9	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	75	23	1.0	9.3	4.6	4.7	.6	19	133	78	34
	S.D.	9.9	2.8	.21	.42	.57	.14	.07	7.1	2.8	21.9	12.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 27  
Summary of Clinical Chemistry Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	34	103	184	61	4	137	343	13	244
	S.D.	.7	24.0	33.2	28.3	.7	28.3	48.1	18.4	17.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	26	48	182	70	4	657	486	32	350
	S.D.	9.9	7.8	97.6	2.1	4.2	763.7	244.0	21.9	163.3
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	23	50	220	94	4	165	345	38	256
	S.D.	.0	16.3	29.0	37.5	2.1	29.7	68.3	4.2	47.4
	N	2	2	2	2	2	2	2	2	2

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	9.8	4.8	148	5.4	108
	S.D.	.14	1.56	4.9	.64	6.4
	N	2	2	2	2	2
0.15	MEAN	9.8	5.5	152	5.5	110
	S.D.	.14	.28	3.5	.00	2.1
	N	2	2	2	2	2
0.75	MEAN	10.3	5.8	152	5.0	110
	S.D.	.14	.64	.0	.21	2.1
	N	2	2	2	2	2

Table 28  
Summary of Clinical Chemistry Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	101	16	1.1	8.7	4.8	3.8	.4	8	134	33	77
	S.D.	21.2	1.4	.14	.14	.07	.07	.07	.7	29.0	7.1	5.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	81	17	1.1	9.0	5.2	3.8	.6	8	160	48	84
	S.D.	2.8	.0	.14	.14	.07	.07	.28	4.2	46.0	5.7	26.9
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	72	17	1.0	8.8	4.6	4.2	.4	11	136	64	52
	S.D.	16.3	1.4	.00	.35	.35	.00	.00	5.7	4.9	10.6	2.1
	N	2	2	2	2	2	2	2	2	2	2	2

Table 28  
Summary of Clinical Chemistry Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	27	28	900	144	4	177	358	42	270
	S.D.	4.2	.7	334.5	107.5	2.8	45.3	72.1	13.4	50.9
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	34	40	838	142	4	156	462	37	297
	S.D.	21.2	.0	62.9	62.2	3.5	46.0	57.3	21.2	79.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	46	53	680	166	4	257	544	32	372
	S.D.	4.9	28.3	78.5	14.1	3.5	111.7	118.8	21.9	54.4
	N	2	2	2	2	2	2	2	2	2

Table 28  
Summary of Clinical Chemistry Data  
Males Day 245  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.2	6.6	154	5.0	117
	S.D.	.35	.64	3.5	.00	.0
	N	2	2	2	2	2
0.15	MEAN	10.9	6.6	160	5.2	117
	S.D.	.57	.21	.7	.07	1.4
	N	2	2	2	2	2
0.75	MEAN	10.8	7.0	162	5.2	116
	S.D.	.64	1.13	3.5	.28	2.8
	N	2	2	2	2	2



Table 28  
Summary of Clinical Chemistry Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	58	18	1.0	9.0	4.6	4.4	.6	9	131	57	70
	S.D.	14.1	3.5	.35	.64	.14	.49	.35	1.4	52.3	5.7	25.5
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	87	20	1.0	9.0	4.1	4.9	.4	11	150	71	72
	S.D.	5.7	1.4	.14	.28	.14	.14	.14	1.4	17.7	1.4	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	92	22	1.2	9.4	4.7	4.7	.2	15	149	95	64
	S.D.	.7	.0	.07	.57	.42	.14	.07	5.7	2.8	48.1	13.4
	N	2	2	2	2	2	2	2	2	2	2	2

Table 28  
Summary of Clinical Chemistry Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	36	116	182	58	2	168	329	10	242
	S.D.	9.2	59.4	30.4	20.5	.7	50.9	48.1	14.8	27.6
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	30	66	188	80	3	392	482	34	346
	S.D.	9.2	7.1	105.4	4.2	2.8	384.0	242.5	17.7	157.7
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	25	40	236	98	2	148	331	66	250
	S.D.	4.2	1.4	17.7	33.2	.7	27.6	76.4	66.5	54.4
	N	2	2	2	2	2	2	2	2	2

Table 28

Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	9.7	4.6	150	4.6	114
	S.D.	.14	.28	4.2	.21	4.9
	N	2	2	2	2	2
0.15	MEAN	9.8	5.4	152	5.4	118
	S.D.	.49	.28	4.9	.71	2.1
	N	2	2	2	2	2
0.75	MEAN	10.6	5.4	160	5.5	120
	S.D.	.57	.71	7.8	.99	6.4
	N	2	2	2	2	2

Table 29  
Summary of Clinical Chemistry Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	67	16	1.2	8.5	4.7	3.8	.4	2	130	36	64
	S.D.	18.4	3.5	.14	.42	.14	.28	.42	.7	26.2	15.6	14.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	74	19	1.0	8.8	5.0	3.8	.4	9	168	48	76
	S.D.	2.8	1.4	.14	.21	.21	.00	.14	2.8	50.2	13.4	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	70	18	1.2	8.8	4.8	4.0	.3	8	139	74	40
	S.D.	9.2	3.5	.21	.07	.42	.35	.14	3.5	5.7	23.3	7.1
	N	2	2	2	2	2	2	2	2	2	2	2

Table 29  
Summary of Clinical Chemistry Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	28	35	842	124	7	176	318	36	239
	S.D.	12.7	5.7	409.4	90.5	4.2	35.4	71.4	7.1	53.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	26	39	850	146	4	141	444	39	285
	S.D.	6.4	4.2	105.4	70.0	2.8	22.6	43.1	2.8	75.0
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	38	54	689	164	4	230	512	35	354
	S.D.	3.5	21.2	186.7	7.8	.7	89.8	84.1	24.0	32.5
	N	2	2	2	2	2	2	2	2	2

Table 29

Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.2	6.0	154	5.8	116
S.D.	.21	1.13	4.9	.21	.7
N	2	2	2	2	2
0.15					
MEAN	11.2	6.4	159	5.6	118
S.D.	1.20	.21	7.1	.35	6.4
N	2	2	2	2	2
0.75					
MEAN	11.2	6.4	160	5.6	114
S.D.	.57	.92	3.5	.35	2.1
N	2	2	2	2	2

Table 29  
Summary of Clinical Chemistry Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	56	20	.8	8.7	4.4	4.3	.6	8	129	48	62
	S.D.	15.6	4.9	.00	.85	.28	.57	.57	2.1	58.0	7.8	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	74	21	.9	8.9	4.0	4.9	.4	5	144	59	52
	S.D.	4.9	2.8	.14	.28	.00	.28	.21	.0	6.4	11.3	22.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	92	23	1.0	9.0	4.4	4.6	.1	6	144	70	56
	S.D.	3.5	4.2	.14	.35	.42	.07	.00	2.1	.7	31.8	4.2
	N	2	2	2	2	2	2	2	2	2	2	2

Table 29  
Summary of Clinical Chemistry Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN S.D. N	40 9.9 2	104 34.6 2	163 35.4 2	58 17.7 2	3 1.4 2	301 189.5 2	309 26.9 2	9 12.7 2	225 9.9 2
0.15	MEAN S.D. N	37 14.1 2	58 2.1 2	172 94.0 2	76 .7 2	9 7.1 2	1214 1557.8 2	468 256.0 2	74 33.9 2	340 177.5 2
0.75	MEAN S.D. N	29 18.4 2	44 10.6 2	226 25.5 2	87 29.7 2	5 1.4 2	142 31.8 2	316 113.8 2	32 2.1 2	236 83.4 2



Table 29

Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	9.8	4.4	150	5.0	110
	S.D.	.78	.28	7.8	.92	4.9
	N	2	2	2	2	2
0.15	MEAN	9.5	5.2	150	4.8	111
	S.D.	.60	.07	2.8	.92	5.7
	N	2	2	2	2	2
0.75	MEAN	10.4	5.2	156	6.0	119
	S.D.	.60	.85	2.1	.07	2.8
	N	2	2	2	2	2

Table 30  
Summary of Clinical Chemistry Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	71	18	1.2	8.6	4.8	3.8	4	6	134	52	69
	S.D.	4.2	2.1	.07	.07	.14	.07	.57	.7	34.6	21.9	17.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	62	28	1.4	8.7	5.1	3.6	.7	7	163	61	72
	S.D.	23.3	2.8	.21	.42	.14	.28	.71	1.4	65.1	18.4	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	66	18	1.4	8.6	4.7	3.8	.4	8	136	90	39
	S.D.	14.8	.7	.35	.49	.42	.07	.28	2.1	.7	51.6	7.1
	N	2	2	2	2	2	2	2	2	2	2	2

Table 30  
Summary of Clinical Chemistry Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	38	38	772	124	4	966	487	94	366
	S.D.	5.7	6.4	386.6	105.4	1.4	149.2	35.4	5.7	19.8
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	53	68	882	140	6	570	1297	710	962
	S.D.	9.9	7.1	159.1	68.6	.0	77.1	454.0	227.7	326.7
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	61	76	708	157	2	1048	625	30	442
	S.D.	21.2	23.3	191.6	1.4	1.4	369.4	144.2	7.8	85.6
	N	2	2	2	2	2	2	2	2	2

Table 30

Summary of Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.4	5.4	150	5.0	106
S.D.	.49	.57	3.5	.14	.7
N	2	2	2	2	2
0.15					
MEAN	11.0	5.8	154	5.0	106
S.D.	.92	.64	.0	.07	2.8
N	2	2	2	2	2
0.75					
MEAN	10.6	5.8	154	5.4	108
S.D.	.92	1.13	4.9	.35	.0
N	2	2	2	2	2

Table 30  
Summary of Clinical Chemistry Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	54	15	1.2	8.4	4.4	4.1	.5	10	118	42	58
	S.D.	14.1	1.4	.21	.37	.07	.14	.57	4.9	41.7	8.5	23.3
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	64	28	1.3	8.8	3.9	4.8	.5	8	148	86	60
	S.D.	7.8	.7	.14	.78	.14	.64	.00	3.5	9.2	23.3	19.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	85	18	1.5	8.7	4.3	4.4	.0	6	129	74	60
	S.D.	1.4	9.2	.14	.64	.42	.21	.07	2.1	14.1	9.2	.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 30  
Summary of Clinical Chemistry Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	56	87	156	60	4	1118	366	0	268
	S.D.	14.1	14.1	18.4	30.4	2.1	132.9	33.9	.0	12.0
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	48	78	160	73	6	1058	554	73	406
	S.D.	17.0	9.9	64.3	8.5	3.5	644.2	237.6	14.1	166.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	44	112	235	80	2	1065	449	64	338
	S.D.	2.1	60.1	21.2	35.4	.7	574.2	1.4	43.1	1.4
	N	2	2	2	2	2	2	2	2	2

Table 30

Summary of Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHCS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	9.7	4.7	147	5.0	104
	S.D.	.14	.42	1.4	.21	4.9
	N	2	2	2	2	2
0.15	MEAN	9.8	5.2	151	5.2	108
	S.D.	.57	.49	4.2	.07	1.4
	N	2	2	2	2	2
0.75	MEAN	10.3	4.2	156	5.5	110
	S.D.	.00	.21	2.8	.42	1.4
	N	2	2	2	2	2

Table 31  
Summary of Clinical Chemistry Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	72	20	1.3	8.9	5.2	3.8	.5	6	126	40	61
S.D.	2.1	4.9	.00	.00	.21	.21	.28	.7	30.4	7.8	14.1
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	74	26	1.2	8.6	5.2	3.4	.8	6	166	48	74
S.D.	2.1	3.5	.07	.64	.35	.28	.42	.7	55.9	21.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	70	18	1.2	8.4	4.8	3.6	.4	4	119	51	38
S.D.	9.2	1.4	.14	.14	.35	.21	.21	2.1	4.2	21.2	4.9
N	2	2	2	2	2	2	2	2	2	2	2



Table 31  
Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L
0									
MEAN	50	42	714	138	6	2137	376	38	272
S.D.	4.9	4.9	461.7	119.5	3.5	19.8	17.7	.7	36.8
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	60	66	820	143	8	1495	1294	579	958
S.D.	6.4	4.9	134.4	63.6	.7	356.4	489.3	302.6	351.4
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	60	66	622	155	4	1310	516	33	358
S.D.	2.8	25.5	202.2	1.4	2.8	980.8	142.1	2.8	79.2
N	2	2	2	2	2	2	2	2	2

Table 31

Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.6	4.7	156	5.4	111
S.D.	.49	.71	2.1	.14	.0
N	2	2	2	2	2
0.15					
MEAN	10.9	5.6	155	5.4	111
S.D.	1.41	.14	7.1	.49	2.8
N	2	2	2	2	2
0.75					
MEAN	10.6	4.9	154	5.4	110
S.D.	.49	.42	2.1	.64	3.5
N	2	2	2	2	2

Table 31  
Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SEA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	55	20	1.0	9.0	4.7	4.2	.8	6	137	49	60
	S.D.	1.4	2.1	.14	.07	.00	.07	.49	.7	35.4	9.9	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	73	24	1.0	8.7	3.9	4.8	.8	6	137	54	54
	S.D.	9.9	2.8	.07	.57	.14	.42	.07	.0	1.4	16.3	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	88	23	1.2	8.7	4.4	4.2	.4	9	142	75	60
	S.D.	4.2	2.8	.07	.78	.64	.14	.07	5.7	14.8	28.3	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

Table 31  
Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	86	202	162	77	6	2408	398	16	300
	S.D.	34.6	135.1	7.1	45.3	1.4	806.1	85.6	23.3	50.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	50	78	148	79	12	871	467	47	345
	S.D.	17.7	24.0	55.9	1.4	4.9	195.2	230.5	7.1	161.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	56	80	228	86	4	1797	479	47	370
	S.D.	15.6	3.5	21.2	43.1	1.4	786.3	67.9	.0	58.7
	N	2	2	2	2	2	2	2	2	2

Table 31

Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	9.9	4.9	148	5.0	106
S.D.	.28	.99	4.9	.92	4.2
N	2	2	2	2	2
0.15					
MEAN	9.4	4.8	148	5.4	110
S.D.	.64	.07	3.5	.71	2.1
N	2	2	2	2	2
0.75					
MEAN	10.2	4.4	155	5.4	112
S.D.	.35	.21	2.8	.21	1.4
N	2	2	2	2	2

Table 32  
Summary of Clinical Chemistry Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	74	14	1.2	8.7	5.0	3.6	.6	3	132	32	58
	S.D.	8.5	2.8	.00	.28	.21	.07	.35	.0	14.1	.7	3.5
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	91	16	1.2	9.1	5.4	3.6	.4	6	178	41	80
	S.D.	4.2	1.4	.07	.28	.07	.35	.21	.7	54.4	2.8	36.1
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	70	14	1.2	8.9	5.0	4.0	.6	4	118	59	35
	S.D.	7.8	.7	.21	.57	.64	.07	.35	.7	5.7	31.1	12.7
	N	2	2	2	2	2	2	2	2	2	2	2

Table 32  
Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN	24	24	620	124	6	102	298	16	233
	S.D.	7.1	3.5	320.3	91.9	5.7	34.6	30.4	7.1	18.4
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	25	46	871	150	2	141	450	16	294
	S.D.	5.7	.7	141.4	68.6	.7	31.1	52.3	2.1	83.4
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	34	41	418	138	0	202	422	16	294
	S.D.	4.9	12.7	55.9	13.4	.7	32.5	82.0	4.9	44.5
	N	2	2	2	2	2	2	2	2	2

Table 32

Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.2	6.0	153	5.4	111
S.D.	.21	.49	4.2	.42	2.8
N	2	2	2	2	2
0.15					
MEAN	11.8	6.9	164	6.0	116
S.D.	1.20	.42	4.2	.49	3.5
N	2	2	2	2	2
0.75					
MEAN	10.6	5.3	155	5.0	111
S.D.	.78	1.98	4.2	.57	2.8
N	2	2	2	2	2



Table 32  
Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SEA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	64	17	1.0	8.5	4.6	3.9	.6	6	120	56	50
	S.D.	21.9	.0	.07	.28	.00	.28	.49	2.1	30.4	5.7	23.3
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	78	17	1.0	8.7	4.1	4.6	.6	5	144	71	47
	S.D.	.7	1.4	.07	.42	.00	.42	.07	1.4	.0	17.0	15.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	100	19	1.0	8.7	4.5	4.2	.2	4	138	78	64
	S.D.	2.1	2.8	.07	.64	.57	.07	.07	1.4	1.4	50.9	12.0
	N	2	2	2	2	2	2	2	2	2	2	2

Table 32  
Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN S.D. N	43 18.4 2	134 69.3 2	156 24.7 2	72 33.2 2	4 2.1 2	222 31.1 2	268 34.6 2	10 2.1 2	204 17.0 2
0.15	MEAN S.D. N	32 10.6 2	50 22.6 2	140 65.1 2	78 3.5 2	7 4.2 2	183 100.4 2	339 137.2 2	13 2.8 2	250 87.0 2
0.75	MEAN S.D. N	25 .0 2	54 14.8 2	232 22.6 2	94 43.1 2	2 2.1 2	124 14.1 2	296 89.8 2	18 7.1 2	230 66.5 2

Table 32

Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	9.9	5.2	148	5.0	108
S.D.	.42	.35	5.7	.14	3.5
N	2	2	2	2	2
0.15					
MEAN	9.8	5.2	152	5.6	112
S.D.	.42	.21	1.4	.35	.7
N	2	2	2	2	2
0.75					
MEAN	10.4	5.4	154	6.2	116
S.D.	.14	.35	.7	.85	2.8
N	2	2	2	2	2

Table 33  
Summary of Clinical Chemistry Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	82	16	1.2	8.8	4.7	4.1	.4	6	134	31	70
S.D.	4.9	2.8	.07	.14	.14	.00	.21	.7	21.9	1.4	9.9
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	79	19	1.2	8.8	5.1	3.7	.4	4	166	36	92
S.D.	2.8	.0	.07	.28	.28	.00	.21	1.4	48.1	6.4	31.8
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	79	16	1.4	9.4	5.1	4.3	.6	7	138	44	57
S.D.	5.7	.0	.00	.14	.14	.28	.35	4.2	9.2	10.6	14.1
N	2	2	2	2	2	2	2	2	2	2	2

Table 33  
Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L	
0	MEAN S.D. N	24 6.4 2	25 7.1 2	505 277.2 2	116 94.8 2	10 12.7 2	111 46.7 2	262 4.2 2	14 4.9 2	202 1.4 2
0.15	MEAN S.D. N	30 .7 2	34 2.1 2	754 130.1 2	136 60.1 2	3 2.8 2	171 58.0 2	402 62.9 2	12 .7 2	264 81.3 2
0.75	MEAN S.D. N	36 12.7 2	40 3.5 2	404 88.4 2	148 1.4 2	0 .0 2	165 .0 2	440 111.0 2	16 7.8 2	297 52.3 2

Table 33

Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.6	6.6	160	6.0	116
S.D.	.21	.07	3.5	.57	6.4
N	2	2	2	2	2
0.15					
MEAN	11.2	7.0	166	6.4	120
S.D.	.28	.92	3.5	.78	3.5
N	2	2	2	2	2
0.75					
MEAN	11.9	5.8	172	6.1	118
S.D.	.14	.57	3.5	.14	3.5
N	2	2	2	2	2

Table 33  
Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SEA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	60	16	1.0	8.5	4.4	4.1	.6	6	124	53	64
S.D.	9.9	.7	.07	.42	.00	.42	.35	.7	39.6	2.8	27.6
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	72	18	1.0	8.4	3.8	4.6	.6	5	138	60	62
S.D.	2.1	1.4	.21	.21	.21	.00	.07	.0	12.7	19.1	34.6
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	96	19	1.2	8.4	4.3	4.2	.3	5	146	76	74
S.D.	4.9	.0	.00	.78	.42	.35	.00	1.4	1.4	50.9	7.8
N	2	2	2	2	2	2	2	2	2	2	2

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	F AMYL U/L	
0	MEAN S.D. N	42 16.3 2	120 100.4 2	151 28.3 2	69 33.9 2	0 .0 2	154 87.0 2	280 50.2 2	12 .7 2	212 28.3 2
0.15	MEAN S.D. N	26 .7 2	34 4.2 2	146 70.0 2	79 4.2 2	2 .7 2	94 20.5 2	353 142.8 2	11 4.2 2	261 93.3 2
0.75	MEAN S.D. N	28 12.0 2	59 28.3 2	213 38.2 2	89 39.6 2	2 2.1 2	130 47.4 2	311 86.3 2	15 4.2 2	240 64.3 2



Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.1	5.4	151	5.2	110
S.D.	.00	.28	1.4	.14	2.1
N	2	2	2	2	2
0.15					
MEAN	10.0	5.2	156	5.8	114
S.D.	.28	.35	1.4	.49	3.5
N	2	2	2	2	2
0.75					
MEAN	10.5	5.6	162	6.2	120
S.D.	.28	.35	4.2	.78	6.4
N	2	2	2	2	2

Table 34  
Summary of Clinical Urinalysis Data  
Males Day -27  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	41.5	1.026	7.3
	S.D.	17.76	.0050	.75
	N	6	6	6
0.03	MEAN	52.5	1.021	7.4
	S.D.	10.15	.0021	.48
	N	4	4	4
0.15	MEAN	97.8	1.019	7.1
	S.D.	71.41	.0078	.20
	N	6	6	6
0.75	MEAN	83.5	1.018	7.2
	S.D.	46.63	.0066	.26
	N	6	6	6

Table 34

Summary of Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	90.7	1.018	7.3
	S.D.	75.84	.0060	.41
	N	6	6	6
0.03	MEAN	92.5	1.019	7.1
	S.D.	88.38	.0082	.25
	N	4	4	4
0.15	MEAN	71.8	1.021	7.8
	S.D.	33.80	.0052	.42
	N	6	6	6
0.75	MEAN	88.0	1.020	7.3
	S.D.	78.91	.0088	.41
	N	6	6	6

Table 35  
Summary of Clinical Urinalysis Data  
Males Day 37  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	50.2	1.018	7.5
	S.D.	13.75	.0071	.45
	N	6	5	6
0.03	MEAN	72.5	1.021	7.5
	S.D.	29.73	.0048	.41
	N	4	4	4
0.15	MEAN	94.3	1.019	7.2
	S.D.	105.16	.0092	.27
	N	6	5	6
0.75	MEAN	79.0	1.018	7.3
	S.D.	42.12	.0082	.75
	N	6	5	6

Table 35

Summary of Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	118.5	1.014	8.0
	S.D.	218.53	.0103	.32
	N	6	6	6
0.03	MEAN	86.8	1.018	7.8
	S.D.	56.91	.0056	.29
	N	4	4	4
0.15	MEAN	83.7	1.017	7.5
	S.D.	53.05	.0076	.32
	N	6	5	6
0.75	MEAN	100.2	1.022	7.8
	S.D.	155.27	.0094	.61
	N	6	5	6

Table 36  
Summary of Clinical Urinalysis Data  
Males Day 62  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	77.5	1.018	8.0
	S.D.	50.66	.0054	.32
	N	6	6	6
0.03	MEAN	62.2	1.018	8.0
	S.D.	34.86	.0076	.41
	N	4	4	4
0.15	MEAN	94.5	1.015	7.8
	S.D.	59.43	.0095	.42
	N	6	6	6
0.75	MEAN	68.0	1.017	7.9
	S.D.	26.39	.0051	.38
	N	6	6	6

Table 36

Summary of Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	74.3	1.019	8.2
	S.D.	61.32	.0076	.26
	N	6	6	6
0.03	MEAN	53.5	1.020	7.6
	S.D.	32.58	.0056	.48
	N	4	4	4
0.15	MEAN	62.3	1.020	7.8
	S.D.	28.86	.0061	.26
	N	6	6	6
0.75	MEAN	81.0	1.017	7.6 *
	S.D.	51.27	.0091	.38
	N	6	6	6

Table 37

Summary of Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	47.5	1.024	7.5
	S.D.	7.31	.0046	.77
	N	6	6	6
0.03	MEAN	65.8	1.018	7.8
	S.D.	40.43	.0062	.29
	N	4	4	4
0.15	MEAN	101.2	1.014 *	7.4
	S.D.	73.16	.0061	.49
	N	6	6	6
0.75	MEAN	54.0	1.020	7.2
	S.D.	19.47	.0066	.88
	N	6	6	6



Table 37

Summary of Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
-----				
0	MEAN	93.3	1.015	8.0
	S.D.	68.15	.0053	.00
	N	6	6	6
0.03	MEAN	64.8	1.018	7.4
	S.D.	30.02	.0034	.48
	N	4	4	4
0.15	MEAN	63.2	1.018	7.5
	S.D.	22.56	.0073	.63
	N	6	6	6
0.75	MEAN	120.5	1.017	7.8
	S.D.	125.14	.0096	.42
	N	6	6	6

Table 38  
Summary of Clinical Urinalysis Data  
Males Day 153  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	131.3	1.013	7.1
	S.D.	110.42	.0072	.49
	N	6	6	6
0.03	MEAN	55.0	1.020	7.4
	S.D.	21.32	.0052	.48
	N	4	4	4
0.15	MEAN	137.8	1.011	7.1
	S.D.	114.54	.0062	.20
	N	6	6	6
0.75	MEAN	180.0	1.011	7.1
	S.D.	136.48	.0082	.58
	N	6	6	6

Table 38

Summary of Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	85.2	1.016	7.5
	S.D.	53.91	.0084	.32
	N	6	6	6
0.03	MEAN	60.5	1.016	7.0
	S.D.	36.93	.0029	.41
	N	4	4	4
0.15	MEAN	40.7	1.022	7.1
	S.D.	11.15	.0040	.20
	N	6	6	6
0.75	MEAN	89.0	1.017	7.1
	S.D.	93.46	.0085	.66
	N	6	6	6

Table 39

Summary of Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	116.2	1.014	7.9
	S.D.	79.33	.0072	.20
	N	6	5	6
0.03	MEAN	75.5	1.017	7.9
	S.D.	26.20	.0022	.25
	N	4	4	4
0.15	MEAN	122.3	1.013	7.5
	S.D.	125.43	.0053	1.00
	N	6	5	6
0.75	MEAN	121.0	1.013	7.2
	S.D.	108.83	.0059	.65
	N	4	4	4

Table 39

Summary of Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	85.7	1.016	8.1
	S.D.	40.59	.0050	.20
	N	6	5	6
0.03	MEAN	76.2	1.016	7.6
	S.D.	31.48	.0054	.48
	N	4	4	4
0.15	MEAN	73.3	1.017	7.9
	S.D.	25.33	.0055	.20
	N	6	5	6
0.75	MEAN	131.8	1.014	7.8
	S.D.	156.54	.0058	.26
	N	6	5	6

Table 40

Summary of Clinical Urinalysis Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	179.5	1.010	7.2
	S.D.	24.75	.0000	.35
	N	2	2	2
0.15	MEAN	239.5	1.007	7.5
	S.D.	79.90	.0028	.00
	N	2	2	2
0.75	MEAN	87.5	1.013	7.0
	S.D.	36.06	.0028	.71
	N	2	2	2

Table 40

Summary of Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	143.0	1.014	7.8
	S.D.	77.78	.0078	.35
	N	2	2	2
0.15	MEAN	121.0	1.015	7.2
	S.D.	80.61	.0000	.35
	N	2	2	2
0.75	MEAN	89.0	1.015	7.5
	S.D.	36.77	.0000	.71
	N	2	2	2

Table 41

Summary of Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	195.5	1.009	7.8
	S.D.	9.19	.0014	.35
	N	2	2	2
0.15	MEAN	196.0	1.010	7.5
	S.D.	132.94	.0064	.00
	N	2	2	2
0.75	MEAN	83.0	1.017	7.8
	S.D.	29.70	.0042	.35
	N	2	2	2



Table 41

Summary of Clinical Urinalysis Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	117.0	1.018	8.0
	S.D.	100.41	.0113	.00
	N	2	2	2
0.15	MEAN	131.5	1.016	7.2
	S.D.	62.93	.0021	.35
	N	2	2	2
0.75	MEAN	91.5	1.016	7.8
	S.D.	48.79	.0035	.35
	N	2	2	2

Table 42

Summary of Clinical Urinalysis Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	284.0	1.004	6.8
	S.D.	50.91	.0007	.35
	N	2	2	2
0.15	MEAN	234.0	1.007	7.2
	S.D.	169.71	.0042	.35
	N	2	2	2
0.75	MEAN	67.5	1.018	7.0
	S.D.	50.20	.0106	.71
	N	2	2	2

Table 42

Summary of Clinical Urinalysis Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	141.5	1.006	7.8
	S.D.	33.23	.0014	.35
	N	2	2	2
0.15	MEAN	63.5	1.020	7.5
	S.D.	37.48	.0050	.00
	N	2	2	2
0.75	MEAN	64.5	1.010	7.2
	S.D.	58.69	.0007	1.06
	N	2	2	2

Table 43

Summary of Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	296.0	1.008	6.8
	S.D.	254.55	.0092	.35
	N	2	2	2
0.15	MEAN	99.5	1.016	6.5
	S.D.	94.05	.0099	.71
	N	2	2	2
0.75	MEAN	47.5	1.020	6.0
	S.D.	4.95	.0092	.00
	N	2	2	2

Table 43

Summary of Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	220.5	1.006	8.0
	S.D.	188.80	.0050	.00
	N	2	2	2
0.15	MEAN	59.0	1.018	6.5
	S.D.	24.04	.0042	.71
	N	2	2	2
0.75	MEAN	92.0	1.014	6.8
	S.D.	29.70	.0035	.35
	N	2	2	2

Table 44

Summary of Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	206.5	1.017	7.8
	S.D.	81.32	.0028	.35
	N	2	2	2
0.15	MEAN	74.5	1.018	7.5
	S.D.	10.61	.0000	.71
	N	2	2	2
0.75	MEAN	90.0	1.018	6.8
	S.D.	14.14	.0050	1.06
	N	2	2	2

Table 44

Summary of Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	158.0	1.011	8.0
	S.D.	11.31	.0000	.00
	N	2	2	2
0.15	MEAN	68.5	1.021	7.0
	S.D.	13.44	.0014	.00
	N	2	2	2
0.75	MEAN	76.0	1.018	7.0
	S.D.	46.67	.0007	.71
	N	2	2	2

Table 45

Summary of Clinical Urinalysis Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	185.0	1.010	8.0
	S.D.	120.21	.0028	.00
	N	2	2	2
0.15	MEAN	182.0	1.008	8.0
	S.D.	147.08	.0050	.00
	N	2	2	2
0.75	MEAN	84.0	1.012	8.0
	S.D.	8.49	.0050	.00
	N	2	2	2



Table 45  
Summary of Clinical Urinalysis Data  
Females Day 456  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	214.0	1.009	8.0
	S.D.	164.05	.0057	.00
	N	2	2	2
0.15	MEAN	145.0	1.011	7.8
	S.D.	74.85	.0042	.35
	N	2	2	2
0.75	MEAN	118.0	1.005	8.0
	S.D.	82.02	.0042	.00
	N	2	2	2

Table 46

Summary of Clinical Urinalysis Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	430.0	1.005	8.0
	S.D.	70.71	.0000	.00
	N	2	2	2
0.15	MEAN	300.0	1.006	7.8
	S.D.	148.49	.0028	.35
	N	2	2	2
0.75	MEAN	222.5	1.010	8.0
	S.D.	173.24	.0071	.00
	N	2	2	2

Table 46

Summary of Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0	MEAN	132.5	1.011	8.0
	S.D.	38.89	.0057	.00
	N	2	2	2
0.15	MEAN	67.5	1.018	8.0
	S.D.	24.75	.0014	.00
	N	2	2	2
0.75	MEAN	99.0	1.014	8.0
	S.D.	80.61	.0050	.00
	N	2	2	2

Table 47

Summary of Palmitoyl CoA Oxidase Determinations  
Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
-----		-----
0	MEAN	5
	S.D.	1.5
	N	4
0.03	MEAN	5
	S.D.	1.0
	N	4
0.15	MEAN	6
	S.D.	.6
	N	4
0.75	MEAN	7
	S.D.	1.4
	N	2

Table 47

Summary of Palmitoyl CoA Oxidase Determinations  
Terminal Sacrifice  
Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
-----		-----
0	MEAN	4
	S.D.	.8
	N	4
0.03	MEAN	4
	S.D.	1.3
	N	4
0.15	MEAN	6
	S.D.	1.0
	N	4
0.75	MEAN	6 *
	S.D.	.8
	N	4

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.2858	0.0083	0.0045	MEAN:		2821.3	0.2933	0.0103	0.0052
STANDARD DEV:		765.9	0.0195	0.0012	0.0002	STANDARD DEV:		304.9	0.0650	0.0016	0.0014
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.3105	0.0087	0.0051	MEAN:		2988.8	0.3815	0.0132	0.0063
STANDARD DEV:		524.0	0.0367	0.0015	0.0008	STANDARD DEV:		723.4	0.0508	0.0033	0.0010
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2692	0.0084	0.0043	MEAN:		2768.8	0.3400	0.0122	0.0058
STANDARD DEV:		199.8	0.0298	0.0006	0.0003	STANDARD DEV:		335.9	0.0589	0.0012	0.0010

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.3665	0.0120*	0.0055	MEAN:		2653.8	0.3468	0.0134	0.0061
STANDARD DEV:		1120.8	0.1237	0.0003	0.0012	STANDARD DEV:		403.1	0.0265	0.0029	0.0004

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.2093	0.0059	0.0033	MEAN:		2821.3	0.2178	0.0076	0.0039
STANDARD DEV:		765.9	0.0503	0.0011	0.0008	STANDARD DEV:		304.9	0.0772	0.0021	0.0016
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2240	0.0063	0.0036	MEAN:		2988.8	0.2768	0.0095	0.0046
STANDARD DEV:		524.0	0.0243	0.0012	0.0005	STANDARD DEV:		723.4	0.0356	0.0020	0.0005
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2135	0.0067	0.0033	MEAN:		2768.8	0.2425	0.0088	0.0042
STANDARD DEV:		199.8	0.0484	0.0014	0.0006	STANDARD DEV:		335.9	0.0377	0.0008	0.0006



TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2725	0.0090	0.0041	MEAN:		2653.8	0.2535	0.0098	0.0044
STANDARD DEV:		1120.8	0.0686	0.0011	0.0006	STANDARD DEV:		403.1	0.0306	0.0025	0.0004

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

BRAIN

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	63.1425	1.8330	1.0000	MEAN:		2821.3	56.6408	2.0307	1.0000
STANDARD DEV:		765.9	1.1363	0.3051	0.0000	STANDARD DEV:		304.9	4.1710	0.3056	0.0000
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	61.7943	1.7415	1.0000	MEAN:		2988.8	60.6083	2.1053	1.0000
STANDARD DEV:		524.0	5.5692	0.3701	0.0000	STANDARD DEV:		723.4	2.6726	0.4471	0.0000
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	63.3520	1.9873	1.0000	MEAN:		2768.8	58.3910	2.1321	1.0000
STANDARD DEV:		199.8	5.3720	0.1406	0.0000	STANDARD DEV:		335.9	3.2163	0.2735	0.0000

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

BRAIN

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	66.2635	2.2566	1.0000	MEAN:		2653.8	57.0957	2.1883	1.0000
STANDARD DEV:		1120.8	7.8154	0.5678	0.0000	STANDARD DEV:		403.1	2.2179	0.3459	0.0000

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LF EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3540.0	1.1407	0.0314	0.0180	MEAN:		2821.3			
STANDARD DEV:		765.9	0.5031	0.0076	0.0076	STANDARD DEV:		304.9			
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3631.3	1.4208	0.0371	0.0243	MEAN:		2988.8			
STANDARD DEV:		524.0	0.9897	0.0196	0.0197	STANDARD DEV:		723.4			
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3190.0	0.9760	0.0306	0.0155	MEAN:		2768.8			
STANDARD DEV:		199.8	0.0910	0.0027	0.0025	STANDARD DEV:		335.9			

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LF EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	1.3095	0.0387	0.0189	MEAN:		2653.8			
STANDARD DEV:		1120.8	1.0812	0.0210	0.0141	STANDARD DEV:		403.1			

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 9

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3540.0	1.2160	0.0340	0.0192	MEAN:		2821.3			
STANDARD DEV:		765.9	0.4066	0.0063	0.0061	STANDARD DEV:		304.9			
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3631.3	1.3563	0.0353	0.0232	MEAN:		2988.8			
STANDARD DEV:		524.0	0.9663	0.0191	0.0192	STANDARD DEV:		723.4			
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3190.0	1.0213	0.0322	0.0163	MEAN:		2768.8			
STANDARD DEV:		199.8	0.0786	0.0039	0.0025	STANDARD DEV:		335.9			

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 10

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	1.3805	0.0396	0.0198	MEAN:		2653.8			
STANDARD DEV:		1120.8	1.3371	0.0290	0.0178	STANDARD DEV:		403.1			

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 11

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.2305	0.1780	0.0985	MEAN:		2821.3	5.5023	0.1943	0.0978
STANDARD DEV:		765.9	0.8729	0.0147	0.0120	STANDARD DEV:		304.9	0.9665	0.0191	0.0214
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	6.6015	0.1838	0.1078	MEAN:		2988.8	5.8693	0.1993	0.0972
STANDARD DEV:		524.0	0.4812	0.0231	0.0163	STANDARD DEV:		723.4	0.9019	0.0191	0.0166
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.8875	0.1844	0.0936	MEAN:		2768.8	5.5955	0.2033	0.0960
STANDARD DEV:		199.8	0.6683	0.0157	0.0150	STANDARD DEV:		335.9	0.4375	0.0174	0.0090



TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 12

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	5.5310	0.1837	0.0828	MEAN:		2653.8	5.7638	0.2190	0.1007
STANDARD DEV:		1120.8	1.3916	0.0217	0.0112	STANDARD DEV:		403.1	0.9586	0.0364	0.0138

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 13

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.0052	0.1712	0.0949	MEAN:		2821.3	5.2995	0.1876	0.0941
STANDARD DEV:		765.9	0.9353	0.0127	0.0130	STANDARD DEV:		304.9	0.7814	0.0168	0.0173
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	6.7495	0.1875	0.1104	MEAN:		2988.8	5.7718	0.1966	0.0956
STANDARD DEV:		524.0	0.6929	0.0228	0.0206	STANDARD DEV:		723.4	0.8467	0.0260	0.0163
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.7358	0.1795	0.0910	MEAN:		2768.8	5.4028	0.1965	0.0926
STANDARD DEV:		199.8	0.6730	0.0140	0.0131	STANDARD DEV:		335.9	0.4663	0.0210	0.0067

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 14

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	5.4045	0.1801	0.0810	MEAN:		2653.8	5.7878	0.2191	0.1011
STANDARD DEV:		1120.8	1.2594	0.0247	0.0095	STANDARD DEV:		403.1	1.1793	0.0375	0.0181

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 15

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	54.9200	1.5733	0.8689	MEAN:		2821.3	51.0925	1.8015	0.9104
STANDARD DEV:		765.9	8.1496	0.2144	0.1203	STANDARD DEV:		304.9	9.4330	0.1518	0.2199
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	62.0868	1.7413	1.0090	MEAN:		2988.8	56.8278	1.9074	0.9392
STANDARD DEV:		524.0	5.2757	0.3311	0.0994	STANDARD DEV:		723.4	12.5811	0.0398	0.2089
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	57.3325	1.7955	0.9059	MEAN:		2768.8	57.0393	2.0747	0.9783
STANDARD DEV:		199.8	5.5102	0.0901	0.0581	STANDARD DEV:		335.9	3.1240	0.1801	0.0629

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 16

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	85.2815	2.7247*	1.2616	MEAN:		2653.8	75.2997*	2.8465*	1.3189*
STANDARD DEV:		1120.8	38.3782	0.2548	0.4304	STANDARD DEV:		403.1	13.3835	0.3447	0.2262

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 17

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0				MEAN:		2821.3	0.1688	0.0059	0.0030
STANDARD DEV:		765.9				STANDARD DEV:		304.9	0.0679	0.0022	0.0013
M	2					F	2				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3				MEAN:		2988.8	0.1723	0.0056	0.0028
STANDARD DEV:		524.0				STANDARD DEV:		723.4	0.0729	0.0011	0.0012
M	3					F	3				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0				MEAN:		2768.8	0.1873	0.0067	0.0032
STANDARD DEV:		199.8				STANDARD DEV:		335.9	0.0847	0.0028	0.0015

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 18

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2				NUMBER IN GROUP:		4			
MEAN:		3077.5				MEAN:		2653.8			
STANDARD DEV:		1120.8				STANDARD DEV:		403.1			
								0.1590			
								0.0063			
								0.0031			
								0.0028			
								0.0009			

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 19

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0				MEAN:		2821.3	0.1423	0.0050	0.0025
STANDARD DEV:		765.9				STANDARD DEV:		304.9	0.0491	0.0012	0.0010
M	2					F	2				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3				MEAN:		2988.8	0.1788	0.0061	0.0029
STANDARD DEV:		524.0				STANDARD DEV:		723.4	0.0453	0.0014	0.0007
M	3					F	3				
NUMBER IN GROUP:		4				NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0				MEAN:		2768.8	0.1367	0.0049	0.0024
STANDARD DEV:		199.8				STANDARD DEV:		335.9	0.0353	0.0010	0.0007



TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 20

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP: 2						NUMBER IN GROUP: 4					
MEAN: 3077.5						MEAN: 2653.8					
STANDARD DEV: 1120.8						STANDARD DEV: 403.1					

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 21

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3540.0	6.9795	0.1918	0.1100	MEAN:		2821.3			
STANDARD DEV:		765.9	3.7391	0.0803	0.0572	STANDARD DEV:		304.9			
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3631.3	7.8848	0.2009	0.1369	MEAN:		2988.8			
STANDARD DEV:		524.0	7.4545	0.1587	0.1434	STANDARD DEV:		723.4			
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3190.0	5.0977	0.1600	0.0814	MEAN:		2768.8			
STANDARD DEV:		199.8	0.6925	0.0215	0.0173	STANDARD DEV:		335.9			

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 22

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LP TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	7.0340	0.1946	0.0998	MEAN:		2653.8			
STANDARD DEV:		1120.8	7.9238	0.1866	0.1078	STANDARD DEV:		403.1			

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 23

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO- BODY WT (%)	ORGAN TO- BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3540.0	6.7453	0.1868	0.1064	MEAN:		2821.3			
STANDARD DEV:		765.9	3.3813	0.0764	0.0518	STANDARD DEV:		304.9			
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3631.3	8.1230	0.2089	0.1403	MEAN:		2988.8			
STANDARD DEV:		524.0	7.2175	0.1504	0.1403	STANDARD DEV:		723.4			
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4			
MEAN:		3190.0	5.0045	0.1568	0.0798	MEAN:		2768.8			
STANDARD DEV:		199.8	0.7091	0.0194	0.0163	STANDARD DEV:		335.9			

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 24

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	6.9155	0.1906	0.0980	MEAN:		2653.8			
STANDARD DEV:		1120.8	7.8977	0.1872	0.1076	STANDARD DEV:		403.1			

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 25

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

PANCREAS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	5.4570	0.1576	0.0863	MEAN:		2821.3	4.4270	0.1571	0.0787
STANDARD DEV:		765.9	0.8021	0.0319	0.0119	STANDARD DEV:		304.9	0.4797	0.0097	0.0125
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	4.8133	0.1309	0.0799	MEAN:		2988.8	5.9108*	0.2030	0.0982
STANDARD DEV:		524.0	1.3674	0.0234	0.0298	STANDARD DEV:		723.4	1.0351	0.0437	0.0216
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	4.3790	0.1365	0.0687	MEAN:		2768.8	4.6248	0.1678	0.0792
STANDARD DEV:		199.8	1.1403	0.0294	0.0138	STANDARD DEV:		335.9	0.4099	0.0126	0.0059

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 26

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

PANCREAS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	4.1355	0.1341	0.0615	MEAN:		2653.8	4.3725	0.1659	0.0768
STANDARD DEV:		1120.8	1.5450	0.0014	0.0161	STANDARD DEV:		403.1	0.4273	0.0119	0.0089

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 27

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LF THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.1675	0.0047	0.0026	MEAN:		2821.3	0.2567	0.0088	0.0047
STANDARD DEV:		765.9	0.0479	0.0004	0.0007	STANDARD DEV:		304.9	0.1415	0.0037	0.0029
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2750	0.0074	0.0046	MEAN:		2988.8	0.2138	0.0071	0.0035
STANDARD DEV:		524.0	0.1374	0.0028	0.0027	STANDARD DEV:		723.4	0.0751	0.0013	0.0012
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2075	0.0064	0.0032	MEAN:		2768.8	0.1542	0.0057	0.0027
STANDARD DEV:		199.8	0.0792	0.0022	0.0011	STANDARD DEV:		335.9	0.0382	0.0018	0.0007



TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 28

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

LF THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2020	0.0063	0.0030	MEAN:		2653.8	0.1872	0.0071	0.0033
STANDARD DEV:		1120.8	0.1174	0.0015	0.0014	STANDARD DEV:		403.1	0.0463	0.0017	0.0008

-----

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 29

TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO-BODY WT (%)	ORGAN TO-BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.1690	0.0046	0.0027	MEAN:		2821.3	0.2455	0.0084	0.0044
STANDARD DEV:		765.9	0.0711	0.0009	0.0011	STANDARD DEV:		304.9	0.1300	0.0034	0.0027
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2632	0.0070	0.0045	MEAN:		2988.8	0.2350	0.0078	0.0039
STANDARD DEV:		524.0	0.1614	0.0035	0.0031	STANDARD DEV:		723.4	0.0815	0.0016	0.0013
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2575	0.0080	0.0040	MEAN:		2768.8	0.1332	0.0048	0.0023
STANDARD DEV:		199.8	0.1150	0.0032	0.0016	STANDARD DEV:		335.9	0.0279	0.0007	0.0005

TABLE 48  
 Summary of Organ Weight Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 30

-----  
 TABLE INCLUDES:  
 SEX=ALL;GROUP=ALL;WEEKS=ALL  
 DEATH=T;SUBSET=ALL

RT THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN TO BODY WT (%)	ORGAN TO BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2360	0.0072	0.0034	MEAN:		2653.8	0.1945	0.0073	0.0034
STANDARD DEV:		1120.8	0.1556	0.0024	0.0019	STANDARD DEV:		403.1	0.0633	0.0019	0.0011

-----

TABLE 49  
Incidence of Macroscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

TABLE INCLUDES: --- N U M B E R - O F - A N I M A L S - A F F E C T E D ---  
SEX=ALL;GROUP=ALL;WEEKS=ALL  
DEATH=T;SUBSET=ALL

ORGAN AND KEYWORD(S) OR PHRASE	SEX: -----MALE----- FEMALE-----								
	GROUP: -1- -2- -3- -4- -1- -2- -3- -4-								
	NUMBER:	4	4	4	2	4	4	4	4
** TOP OF LIST **	---	---	---	---	---	---	---	---	---
GENERAL COMMENT (GC) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
BONE MARROW SMEAR TAKEN		4	4	4	2	4	4	4	4
EYES - DAVIDSONS		4	4	4	2	4	4	4	4
NO MACROSCOPIC LESIONS		2	2	3	0	1	0	1	0
ANIMAL OBESE		0	0	0	0	0	1	0	0
LUNG (LU) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	3	2	2	1	1	0
ADHESION(S)		0	1	1	0	2	3	1	0
RED FOCUS(I)/AREA(S)		1	0	0	0	0	0	1	2
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	2	1	2
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1
LIVER (LI) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	0	3	3	4	3
MOTTLED		0	0	0	2	0	0	0	1
ADHESION(S)		0	0	0	0	0	1	0	0
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	1	0	0	0
SPLEEN (SP) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	4	2	4	4	3	4
LARGE		1	1	0	0	0	0	0	0

\*\* CONTINUED ON NEXT PAGE \*\*

TABLE 49  
Incidence of Macroscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

-----

TABLE INCLUDES:  
SEX=ALL;GROUP=ALL;WEEKS=ALL  
DEATH=T;SUBSET=ALL

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND KEYWORD(S) OR PHRASE	SEX: -----MALE----- FEMALE-----								
	GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-				
	NUMBER:	4	4	4	2	4	4	4	4
** FROM PREVIOUS PAGE **									
SPLLEN (SP) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	4	2	4	4	3	4
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	0	0	1	0
LN, MESENTERIC (MS) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	1	4	4	4	4
DIFFUSELY RED		0	0	0	1	0	0	0	0
ADRENAL, CORTEX (AC) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	0	4	4	4	2
DIFFUSELY DARK		0	0	0	2	0	0	0	2
STOMACH, GL (ST) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	3	4	4	4
RED FOCUS(I)/AREA(S)		0	0	0	0	1	0	0	0
CECUM (CE) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	2	3
RED FOCUS(I)/AREA(S)		0	0	0	0	0	0	2	0
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1

TABLE 49  
Incidence of Macroscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND KEYWORD(S) OR PHRASE	NUMBER	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1- -2- -3- -4- -1- -2- -3- -4-							
		4	4	4	2	4	4	4	4
COLON (CO) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	4	3
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1
SKIN (SK) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	4	4	2	4	4	4	2
ABRASION(S) /ULCERATION(S)		1	0	0	0	0	0	0	0
ALOPECIA-DIFFUSE		0	0	0	0	0	0	0	1
ALOPECIA-FOCAL		0	0	0	0	0	0	0	1
TESTIS (TE) .....	NUMBER EXAMINED:	4	4	4	2	0	0	0	0
	NOT REMARKABLE:	4	3	4	2	0	0	0	0
LARGE		0	1	0	0	0	0	0	0
ADIPOSE TISSUE (AT) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	3	2	4	4	4	3
RAISED FOCUS(I)/AREA(S)		0	0	1	0	0	0	0	1

\*\* END OF LIST \*\*

TABLE 50  
Incidence of Macroscopic Observations  
Recovery Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

-----

TABLE INCLUDES:  
SEX=ALL;GROUP=4;WEEKS=ALL  
DEATH=U;SUBSET=ALL

SEX: MALE FEMALE  
GROUP: -4- -4-

ORGAN AND KEYWORD(S) OR PHRASE  
-----

NUMBER: 2 2  
-----

\*\* TOP OF LIST \*\*

ORGAN AND KEYWORD(S) OR PHRASE	NUMBER EXAMINED:	
	MALE	FEMALE
GENERAL COMMENT (GC) .....	2	2
	NOT REMARKABLE:	1 1
NO MACROSCOPIC LESIONS	1	1
LUNG (LU) .....	2	2
	NOT REMARKABLE:	1 2
ADHESION(S)	1	0
LIVER (LI) .....	2	2
	NOT REMARKABLE:	2 1
ADHESION(S)	0	1
CAVITY, THORACIC (TA) .....	2	2
	NOT REMARKABLE:	1 2
NODULE(S)	1	0

\*\* END OF LIST \*\*

-----

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

----- N U M B E R - O F - A N I M A L S - A F F E C T E D -----

ORGAN AND FINDING DESCRIPTION	SEX: -----MALE----- FEMALE-----								
	GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-				
	NUMBER:	4	4	4	2	4	4	4	4
** TOP OF LIST **	-----								
BONE, FEMUR (FE) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	3
--GROWTH PLATE OPEN		4	0	0	2	1	0	0	1
MARROW, FEMUR (FM) .....	NUMBER EXAMINED:	1	0	0	0	2	0	0	1
	NOT REMARKABLE:	1	0	0	0	2	0	0	1
MARROW, STERNUM (SE) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
--HYPOCELLULAR, MARROW		0	0	0	0	1	0	0	0
BONE, STERNUM (SB) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
EYE (EY) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
BRAIN (BR) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR		0	0	0	1	0	0	0	0
--INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR		2	0	0	2	3	0	0	2
--INPLAMMATION, LYMPHOHISTIOCYTIC		0	0	0	0	0	0	0	1



TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		-----	-----	-----	-----	-----	-----	-----	-----
KIDNEY (KD) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		2	0	0	1	1	0	0	0
--GLOMERULOSCLEROSIS		1	0	0	0	1	0	0	0
--MINERALIZATION, CORTEX		0	0	0	1	0	0	0	0
--MINERALIZATION, MEDULLA		0	0	0	0	0	0	0	2
LUNG (LU) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	2	2	0	0	2
--HYPERPLASIA, LYMPHOHISTIOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR		4	0	0	0	1	0	0	1
--FIBROSIS, PLEURAL/SUBPLEURAL		0	0	0	0	2	0	0	0
--FIBROSIS, INTERSTITIAL		0	0	0	0	1	0	0	0
--INFILTRATE, MACROPHAGE, ALVEOLAR		0	0	0	0	0	0	0	1
--HEMORRHAGE		0	0	0	0	0	0	0	1
HEART (HT) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
LIVER (LI) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	1	3	0	0	0	1	0
--INFILTRATE, LYMPHOHISTIOCYTIC		4	3	1	0	4	4	3	3
--GRANULOMA		1	0	0	0	0	0	0	0
--HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR		0	0	0	1	0	0	0	3
--HYPERTROPHY, HEPATOCELLULAR		0	0	1	1	0	0	0	1

\*\* CONTINUED ON NEXT PAGE \*\*

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1- -2- -3- -4- -1- -2- -3- -4-							
		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
TABLE INCLUDES: SEX=ALL;GROUP=ALL;WEEKS=ALL DEATH=T;FIND=ALL;SUBSET=ALL									
-----									
** FROM PREVIOUS PAGE **									
LIVER (LI) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	1	3	0	0	0	1	0
--VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR		0	0	0	1	0	0	0	1
--VACUOLATION, HEPATOCELLULAR		0	1	0	0	1	1	0	1
--STASIS, BILE		0	1	0	0	0	0	0	0
--DEGENERATION/NECROSIS, HEPATOCELLULAR		0	0	0	0	0	0	1	0
GALLBLADDER (GB) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	1	3	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	1	1	0	0	2
SPLEEN (SP) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
THYMUS (TH) .....	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	1	1	0	4	0	0	1
--CYST		0	1	0	1	0	1	1	2
--ATROPHY		1	2	3	2	0	4	4	3
LN, MESENTERIC (MS) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	3	0	0	4
--HEMORRHAGE		1	0	0	1	0	0	0	0
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	1	0	0	0

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	SEX:	MALE				FEMALE			
		GROUP: -1- -2- -3- -4- -1- -2- -3- -4-							
		NUMBER:	4	4	4	2	4	4	4
TRACHEA (TR)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	1	0	0	0	2	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		3	0	0	2	2	0	0	4
--INFLAMMATION, ACUTE		0	0	0	1	0	0	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
THYROID (TY)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	1
--CYST, ULTIMOBRANCHIAL		0	0	0	0	0	0	0	2
PARATHYROID (PT)	NUMBER EXAMINED:	4	0	0	2	3	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	4
--CYST		1	0	0	0	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	3	0	0	3
--HYPERTROPHY, CORTICAL CELL		1	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	0
--PIGMENT		0	0	0	0	0	0	0	1

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		-----	-----	-----	-----	-----	-----	-----	-----
ADRENAL, MEDULLA (MA) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
AORTA (AO) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	3
--PROLIFERATION, INTIMAL		0	0	0	0	0	0	0	1
PITUITARY (PI) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
SALIV GL, MANDIB (SG) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	1	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		4	0	0	1	2	0	0	2
MUSCLE, SKELETAL (SM) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	1
--DEGENERATION		0	0	0	0	1	0	0	0
--INFLAMMATION, GRANULOMATOUS		0	0	0	0	1	0	0	0
--REGENERATION, MYOFIBER		0	0	0	0	1	0	0	0
--PARASITES, CYST		0	0	0	0	1	0	0	1

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		---	---	---	---	---	---	---	---
SPINAL CORD (SC) .....	NUMBER EXAMINED:	4	0	0	2	4	4	4	4
	NOT REMARKABLE:	4	0	0	2	3	1	0	2
--PIGMENT, NEURONAL		0	0	0	0	1	3	4	2
NERVE, SCIATIC (SN) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
STOMACH, GL (ST) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
DUODENUM (DU) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	1
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	2	0	0	3
PANCREAS (PA) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	4
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	0
JEJUNUM (JE) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	0	1	0	0	1
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	2	3	0	0	3

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

-----

TABLE INCLUDES:  
SEX=ALL;GROUP=ALL;WEEKS=ALL  
DEATH=T;FIND=ALL;SUBSET=ALL

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-			
		4	4	4	2	4	4	4	4
ILEUM (IL) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	1	0	0	2
--INFILTRATE, MACROPHAGE, PIGMENTED		2	0	0	1	3	0	0	2
CECUM (CE) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	2
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	1	0	0	1
--PARASITISM		0	0	0	0	0	0	0	1
COLON (CO) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	4	0	0	3
--INFILTRATE, EOSINOPHILIC		1	0	0	0	0	0	0	0
--PARASITISM, INTRAMUSCULAR		1	0	0	0	0	0	0	1
RECTUM (RE) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
SKIN (SK) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	2
--HYPERPLASIA, EPIDERMAL (ACANTHOSIS)		1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC-ACTIVE		1	0	0	0	0	0	0	0
--ULCERATION		1	0	0	0	0	0	0	0
--HAIR FOLLICLES, DECREASED		0	0	0	0	0	0	0	2

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	NUMBER:	SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		---	---	---	---	---	---	---	---
MAMMARY, FEMALE (MF) .....	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	4
--INFLAMMATION, ACUTE		0	0	0	0	1	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
MAMMARY, MALE (MM) .....	NUMBER EXAMINED:	2	0	0	1	0	0	0	0
	NOT REMARKABLE:	2	0	0	1	0	0	0	0
URINARY BLADDER (UB) .....	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	1	0	0	3
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	3	0	0	1
UTERUS (UT) .....	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	3
--AMYLOID		0	0	0	0	2	0	0	1
OVARY (OV) .....	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	2
--MINERALIZATION		0	0	0	0	1	0	0	1
--AMYLOID		0	0	0	0	0	0	0	1
--ONE EXAMINED		0	0	0	0	0	0	0	1

TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 9

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---								
		SEX: -----MALE-----				-----FEMALE-----				
		GROUP: -1- -2- -3- -4- -1- -2- -3- -4-								
ORGAN AND FINDING DESCRIPTION		NUMBER:	4	4	4	2	4	4	4	4
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4	4
CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4	4
PROSTATE (PR)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0	0
	NOT REMARKABLE:	2	0	0	0	0	0	0	0	0
	--INFLAMMATION, LYMPHOHISTIOCYTIC	2	0	0	2	0	0	0	0	0
SEMINAL VESICLES (SV)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0	0
	NOT REMARKABLE:	4	0	0	2	0	0	0	0	0
EPIDIDYMIDES (EP)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0	0
	--HYOSPERMIA	1	0	0	1	0	0	0	0	0
TESTIS (TE)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0	0
	--IMMATURE	1	0	0	1	0	0	0	0	0



TABLE 51  
Incidence of Microscopic Observations  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 10

-----

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---

ORGAN AND FINDING DESCRIPTION	SEX: -----MALE----- FEMALE-----								
	GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-				
	NUMBER:	4	4	4	2	4	4	4	4
ADIPOSE TISSUE (AT) .....	NUMBER EXAMINED:	0	0	0	0	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--LYMPHOID TISSUE		0	0	0	0	0	0	0	1
CAUSE OF DEATH (CD) .....	NUMBER EXAMINED:	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
LN, TRACHEOBRON (TB) .....	NUMBER EXAMINED:	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0

\*\* END OF LIST \*\*

TABLE 52  
 Incidence of Microscopic Observations  
 Recovery Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

-----

TABLE INCLUDES: SEX=ALL;GROUP=4;WEEKS=ALL  
 DEATH=U;FIND=ALL;SUBSET=ALL

SEX: MALE FEMALE  
 GROUP: -4- -4-

ORGAN AND FINDING DESCRIPTION	NUMBER:	2	2
** TOP OF LIST **			
LIVER, BIOPSY <sup>a</sup> (LI0) .....	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
--PIGMENT, HEPATOCELLULAR		1	0
LIVER (LI) .....	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		2	1
--PIGMENT, HEPATOCELLULAR		1	0
--HYPERPLASIA, BILE DUCT		1	0
--INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT		1	0
--FIBROSIS, CAPSULAR		0	1
** END OF LIST **			

a The liver biopsy was taken during Week 57 of recovery.

**APPENDIX 1**

Protocol Deviations

Protocol

Protocol Amendment No. 1

Protocol Amendment No. 2

Protocol Amendment No. 3

Protocol Amendment No. 4

### **Protocol Deviations**

**Protocol.** Reserve (Archive) Samples. “These samples will be transferred to the Sponsor after completion of the in-life phase.”

**Actual Procedure.** These samples were shipped to the Sponsor after the dosing phase was completed, which was prior to the end of the in-life phase.

**Protocol.** Dosing Procedures. Method of Administration. “Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks.”

**Actual Procedure.** On Day 3, Animal Nos. I05520 (Group 1 male) and I05529 (Group 1 female) did not receive a dose administration due to bleeding and irritation in the throat. Dosing was discontinued for Animal No. I05530 (Group 1 female) from Days 10 through 14 due to a sore inside its mouth.

**Protocol.** Observation of Animals. Clinical Observations. “Once weekly, each animal will be observed; abnormal findings or an indication that the animal was normal will be recorded.”

**Actual Procedure.** During the course of the study, several animals did not have a weekly observation of normal or abnormal recorded on various scheduled days.

**Protocol.** Observation of Animals. Ophthalmic Examinations. Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

**Actual Procedure.** An ophthalmic examination was completed during Week 52 instead of prior to the recovery sacrifice during Week 79.

**Protocol Deviations (Continued)**

**Protocol.** Clinical Pathology. Frequency. Scheduled Collections. “Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery”

**Actual Procedure.** On Day 184, urine samples were collected for several animals; however, these samples were not required by the protocol and were discarded.

Samples were collected on Days 273 and 363 of recovery.

**Protocol.** Clinical Pathology. Tests. Hematology. Eleven hematological parameters were to be tested at all intervals.

**Actual Procedure.** In addition to the required hematology tests at the pretreatment interval, mean platelet volume, red blood cell distribution width, platelet distribution width, and plateletcrit were also inadvertently tested for.

**Protocol.** Blood Hormone Determination. Frequency. “Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery.”

**Actual Procedure.** Samples were collected on Days 273 and 363 of recovery.

**Protocol.** Serum PFOS Level Determination. Method of Collection. “Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant.”

**Actual Procedure.** Animals were not fasted overnight for the scheduled collection on Day 197; however, animals were fasted the following night and collection was done on Day 198.

**Protocol Deviations (Continued)**

**Protocol.** Urine and Feces PFOS Level Determination. Method of Collection. “Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight.”

**Actual Procedure.** The amount of urine collected was not documented at the time of each collection and therefore cannot be verified.

**Protocol.** Additional Fecal Samples. “The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old.”

**Actual Procedure.** On Day 160, some fecal samples were collected in the late morning rather than the early afternoon.

**Protocol.** Interim Liver Biopsy Samples. “Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.”

**Actual Procedure.** The phone call made to notify Kris J. Hansen prior to shipment of these samples was not documented and therefore cannot be verified.

**Protocol.** Terminal Liver Biopsy Samples. “A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection).”

**Actual Procedure.** These samples were collected during Week 80, and were not collected within one day of the serum PFOS blood collection.

**Protocol.** Postmortem Procedures. Cell Proliferation Evaluation. “After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:”

**Protocol Deviations (Continued)**

**Actual Procedure.** PCNA analysis was not done for Animal No. I05509 (Group 4 male).

**Protocol.** Termination. Postmortem Procedures. Additional Lung Tissue Samples. “At the terminal necropsy, a sample of lung (approximately 5 g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen sample, and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.”

**Actual Procedure.** This procedure was inadvertently not done at the terminal sacrifice; thus no samples were available for shipment to Kris J. Hansen, PhD.

**Protocol.** Termination. Postmortem Procedures. Tissue Preservation. “The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination.”

**Protocol Deviations (Continued)**

**Actual Procedure.** Femoral bone marrow from Animal Nos. I05517, I05519, I05527 (Group 1 males), I05507, I05509, I05512 (Group 4 males), I05531, I05535 (Group 1 females), I05536, I05540, and I05551 (Group 4 females); mammary gland from Animal Nos. I05508, I05519 (Group 1 males), and I05512 (Group 4 male); and parathyroid from Animal No. I05544 (Group 1 female) were insufficient. These tissues, therefore, were not examined microscopically. Additionally, one ovary of a possible two was examined from Animal No. I05536 (Group 4 female). Missing tissues are listed with appropriate comments in the pathology data sheets for individual animals. Summary tables do not include them as having been examined.

These deviations are not expected to have affected the results of the study.





**Sponsor:**

3M  
St. Paul, Minnesota

**PROTOCOL**

**Study Title:**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

**Date:**

August 20, 1998

**Performing Laboratory:**

Covance Laboratories Inc.  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704-2595

**Laboratory Study Identification:**

Proposal No. 90545B

Covance 6329-223

**Sponsor Project Identification:**

3M Study No. T-6295.7

**Study**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

**Purpose**

To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks

**Sponsor**

3M  
Toxicology Services  
Building 220-2E-02, 3M Center  
St. Paul, Minnesota 55144-1000

**Study Monitor**

Andrew M. Seacat, PhD  
3M  
Telephone No.: 651.575.3161  
Facsimile No.: 651.733.1773

**Alternate Study Monitor**

Marvin T. Case, DVM, PhD  
3M Toxicology Services  
Telephone No.: 651.733.5180  
Facsimile No.: 651.733.1773

**Study Location**

Covance Laboratories Inc.  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704-2595

Mailing Address: PO Box 7545  
Madison, Wisconsin 53707-7545

**Study Director**

Peter J. Thomford, PhD  
Covance Laboratories Inc.  
Telephone No.: 608.241.7207  
Facsimile No.: 608.242.2736

**Study Toxicologist**

Dale Aldridge, BS  
Covance Laboratories Inc.

**Proposed Study Timetable**

Experimental Start Date: August 26, 1998  
In-life Start Date: August 26, 1998  
In-life Termination Date: To be determined  
Audited Draft Report Date: To be determined  
Experimental Termination Date: To be determined

**Regulatory Compliance**

This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments.

**Animal Care and Use Statement**

All procedures in this protocol are in compliance with the Animal Welfare Act Regulations, 9 CFR 1-4. In the opinion of the Sponsor and study director, the study does not unnecessarily duplicate any previous work.

**Quality Assurance**

The protocol, study conduct, and final report will be audited by the Covance Quality Assurance Unit (QAU). The proliferation cell nuclear antigen evaluation data and report will be audited by the QAU of Pathology Associates International. The dose analysis and serum and liver PFOS analysis and report will be audited by the QAU of 3M Environmental Laboratories. The blood hormone determinations and report will be audited by the QAU of Ani Lytics Inc.

**Test Material**

**Identification**

Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)

**Lot Number**

The lot number will be maintained in the raw data.

**Purity**

Responsibility of the Sponsor

**Stability**

Responsibility of the Sponsor

**Storage Conditions**

At room temperature

**Characteristics**

Information on synthesis methods, composition, or other characteristics that define the test material is on file with the Sponsor.

**Vehicle**

**Identification**

Lactose

**Lot Number**

The lot number will be maintained in the raw data.

**Purity**

On file with the manufacturer

**Stability**

On file with the manufacturer

**Storage Conditions**

At room temperature

**Gelatin Capsules**

Capsules (Size No. 2) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer. Gelatin capsules will be stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer will be maintained in the data.

**Reserve (Archive) Samples**

A reserve sample of each lot of test material, vehicle, and each test material/lactose dilution (1 g each) will be taken and stored at room temperature. These samples will be transferred to the Sponsor after completion of the in-life phase.

**Disposition of Test Material**

Any remaining test material will be retained at Covance for use in possible future studies.

**Animals**

**Species**

Cynomolgus monkey

**Source**

Covance Research Products Inc.

**Age at Initiation of Treatment**

Young adult/adult

**Weight at Initiation of Treatment**

Approximately 2 to 5 kg

**Number and Sex**

22 males and 22 females

**Identification**

Collar tag

**Husbandry**

**Housing**

Individual; animals will be housed in suspended, stainless steel cages.

**Diet**

Certified primate diet (#8726C, Harlan Teklad) once or twice daily. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file at Covance-Madison. Fruit, vegetables, or other supplements may be provided but will not require analysis.

**Water**

*Ad libitum*. Samples of the water are routinely analyzed for specified microorganisms and environmental contaminants. The results are on file at Covance-Madison.

**Contaminants**

There are no known contaminants in the diet or water at levels that might interfere with this study.

**Environment**

Environmental controls for the animal room will be set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. The dark cycle may be interrupted to accommodate in-life procedures.

**Acclimation**

Minimum of 4 weeks

**Randomization**

Animals will be weighed, stratified by body weight, and allocated to the number of blocks equal to the number of animals to be selected for each group. Animals in each block will then be assigned to groups using computer-generated random numbers.

**Justification**

PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

### Group Designations and Dosage Levels

Group	Dose Level (mg/kg/day) <sup>a</sup>	Total Material Dose Level (mg/kg/day) <sup>b</sup>	Number of Animals	
			Males	Females
1	0 <sup>a</sup>	30 <sup>a</sup>	6 <sup>d</sup>	6 <sup>d</sup>
2	0.03	15 <sup>b</sup>	4	4
3	0.15	6 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>
4	0.75	30 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>

- a Dose levels will be provided. The control group (Group 1) will receive an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.
- b The low-dose (Group 2) will receive the test material diluted with lactose (1:499, w:w).
- c The mid-dose (Group 3) and high-dose (Group 4) groups will receive the test material diluted with lactose (1:39, w:w).
- d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 13 weeks posttreatment. Based on plasma test material levels and clinical pathology findings, the recovery may be reduced or extended, at the discretion of the study director and after consultation with the Sponsor.

### Dosing Procedures

#### Method of Administration

Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks

#### Reason for Dosing Route

To compare with data from previous toxicology studies using the oral route, which is the most likely route of exposure

#### Dose Preparation

Capsules will be prepared at least weekly. The size and number of capsules will depend on the physical characteristics of the test material, the dose level, and the weight of the monkey. Individual daily doses will be based on the most recent individual body weights, with the exception of body weight collection days when the previous body weight will be used. Dose levels will be based on the vehicle as supplied for Group 1.

For the Groups 2 through 4 dose preparations, the test material will be dissolved in acetone and diluted with lactose (1:499, 1:39, and 1:39, w:w, respectively) once before initiation of treatment. Dilution with lactose is necessary to facilitate capsule preparation. All dose preparations will be stored at room temperature until dosed.

#### **Dose Analyses**

Dose analyses will be done by the Sponsor.

#### **Homogeneity**

Samples (approximately 1 g each) will be collected from the top, middle, and bottom of the test material/lactose preparations for the low- and high-dose groups and analyzed for test material content. All samples will be stored at room temperature until analyzed.

#### **Stability**

Homogeneity samples collected from the middle of the preparations will be used for the prestudy stability analysis. One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the in-life phase and analyzed for test material content.

#### **Sample Shipping**

Samples will be shipped under ambient conditions to:

Kris J. Hansen, PhD  
3M E. T. & S  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of for test material content will be done on the samples. Results will be provided for inclusion in the final report.

#### **Observation of Animals**

##### **Clinical Observations**

Each animal will be observed twice daily (a.m. and p.m.) for mortality and moribundity; findings will be recorded as they are observed.



Each animal will be observed daily and food consumption will be assessed qualitatively; abnormal findings will be recorded. Once weekly, each animal will be observed; abnormal findings, or an indication that the animal is normal will be recorded. During treatment, each animal will be observed for signs of poor health or abnormal behavior approximately 30 to 90 minutes after the last animal on test has been dosed; abnormal findings will be recorded.

Additional findings will be recorded as they are observed.

#### **Body Weights**

Weekly before initiation of treatment, on the first day of treatment, and weekly thereafter. An additional body weight will be recorded on Day -1 for the Day 1 dose calculations.

#### **Ophthalmic Examinations**

Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

### **Clinical Pathology**

#### **Frequency**

##### **Unscheduled Collections**

When possible, blood will be collected for clinical pathology tests from animals sacrificed at unscheduled intervals

##### **Scheduled Collections**

Once before initiation of treatment; and (before the daily dose) after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

##### **Method of Collection**

Animals will be fasted overnight; blood will be collected from a femoral vein. Anticoagulant will be potassium EDTA for hematology tests. No anticoagulant is required for clinical chemistry tests. Urine will be collected overnight on wet ice:

## Tests

### Hematology

red blood cell (erythrocyte) count	platelet count
hemoglobin	white blood cell (leukocyte) count
hematocrit	differential blood cell count
mean corpuscular volume	blood cell morphology
mean corpuscular hemoglobin	reticulocyte count
mean corpuscular hemoglobin concentration	

### Clinical Chemistry

glucose	aspartate aminotransferase gamma
urea nitrogen	glutamyltransferase
creatinine	sorbitol dehydrogenase
total protein	creatine kinase
albumin	calcium
globulin	inorganic phosphorus
total bilirubin	sodium
direct bilirubin (if total bilirubin is greater than 2.0 mg/dL)	potassium
cholesterol	chloride
triglycerides	bile acids
alanine aminotransferase	amylase
alkaline phosphatase	lipase
	pancreatic-specific amylase

### Urinalysis

appearance	glucose
volume (approximately 16 hours)	ketones
specific gravity	bilirubin
pH	blood
protein	microscopic examination of sediment
urobilinogen	

## Blood Hormone Determination

### Frequency

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

**Number of Animals**

All

**Method of Collection**

Animals will be fasted overnight; blood will be collected from a femoral vein. Approximately 5 mL of blood will be collected without anticoagulant and allowed to clot for serum samples.

**Sample Handling**

Samples for serum will be centrifuged within 1 hour after collection, and serum will be harvested. Serum will be divided into two approximately equal aliquots and stored in a freezer set to maintain -60 to -80°C until packed on dry ice and shipped to:

Dr. Saroj Das  
Ani Lytics Inc.  
200 Girard Street, Suite 200  
Gaithersburg, Maryland 20877  
Telephone No.: 301.921.0168  
Facsimile No.: 301.977.0433

Ani Lytics Inc. will be notified regarding shipment of samples.

**Tests**

Samples will be analyzed by Ani Lytics Inc., for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, triiodothyronine (T3), and thyroxin (T4).

**Serum PFOS Level Determination****Frequency**

Before initiation of treatment, and during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, 28, 30, 32, 34, and 39.

**Number of Animals**

All

**Method of Collection**

Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant.

**Sample Handling**

Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum samples will be stored in a freezer set to maintain -60 to -80°C.

**Sample Shipping**

Serum samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD  
3M E. T. & S  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of serum for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

**Additional Serum Collection**

At scheduled and unscheduled necropsies, blood (as much as possible, up to 20 mL) will be collected from the vena cava without an anticoagulant from animals at the time of exsanguination. Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum from each animal will be transferred into an appropriate container and stored in a freezer set to maintain -60 to -80°C until shipped to the Sponsor (Kris J. Hansen) for possible future analysis.

**Urine and Feces PFOS Level Determination**

**Frequency**

On the first day of recovery and after at least 6, 30, and 90 days of recovery

**Number of Animals**

All

**Method of Collection**

Animals will not be fasted; urine (approximately 2 mL) and feces (approximately 5 grams) will be collected overnight.

### **Sample Handling**

Samples will be stored in a freezer set to maintain -10 to -30°C.

### **Sample Shipping**

Samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD  
3M E. T. & S  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of urine and feces for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

### **Termination**

#### **Unscheduled Sacrifices and Deaths**

Necropsies will be done. Animals to be sacrificed will be anesthetized with ketamine and xylazine, weighed, bled for required tests, and exsanguinated.

#### **Scheduled Sacrifices**

After at least 26 weeks of treatment, four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 13 weeks without treatment, the remaining animals will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

### **Postmortem Procedures**

#### **Necropsy**

The necropsy will include examination of:

all orifices  
cranial cavity  
external surface of the brain; the external surface of the spinal cord and cut surfaces of the brain and spinal cord will be examined when tissue trimming is performed.  
cervical tissues and organs

thoracic, abdominal, and pelvic cavities and viscera  
external surface of the body  
nasal cavity and paranasal sinuses

**Organ Weights**

From each animal at scheduled and unscheduled sacrifices, the following organs (when present) will be weighed; paired organs will be weighed separately:

adrenal (2)	ovary (2)
brain	pancreas
epididymis (2)	testis (2)
kidney (2)	thyroid (2) with parathyroid
liver	

Organ-to-body weight percentages and organ-to-brain weight ratios will be calculated.

**Palmitoyl CoA Oxidase Determinations**

Representative samples of the right lateral lobe of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until analyzed for palmitoyl CoA oxidase activity.

**Cell Proliferation Evaluation**

Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas will be collected and preserved in zinc formalin.

After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:

Sandra R. Eldridge, PhD  
Pathology Associates International  
15 Worman's Mill Court  
Suite I  
Frederick, Maryland 21701  
Telephone: 301.663.1644 ext. 2036  
Facsimile: 301.663.8994

Pathology Associates International will be notified regarding shipment of samples. PCNA evaluation will be done on the samples. Results will be provided for inclusion in the final report.

### **Liver PFOS Determination**

A section (approximately 20 g) of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until shipped with plasma samples to 3M (Kris Hansen) for analysis. Results will be provided for inclusion in the final report.

### **Tissue Preservation**

The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination:

adrenal (2)	mesenteric lymph node
aorta	pancreas
brain	pituitary
cecum	prostate
cervix	rectum
colon	salivary gland [mandibular (2)]
duodenum	sciatic nerve
epididymis (2)	seminal vesicle (2)
esophagus	skeletal muscle (thigh)
eye [(2) to be preserved in Davidson's fixative for sacrificed animals only]	skin
femur with bone marrow (articular surface of the distal end)	spinal cord (cervical, thoracic, and lumbar)
gallbladder	spleen
heart	sternum with bone marrow
ileum	stomach
jejunum	testis [(2) to be preserved in Bouin's solution for sacrificed animals only]
kidney (2)	thymus
lesions	thyroid (2) with parathyroid
liver	trachea
lung	urinary bladder
mammary gland	uterus
ovary (2)	vagina

### **Bone Marrow Smear**

From the sternum of each animal at unscheduled and scheduled sacrifices (made and held for possible future examination).

### **Histopathology**

Tissues from each animal in the control and high-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Tissues from all other animals will be retained for possible future examination.

### **Reports**

#### **Letter Report**

A letter report will be prepared following the terminal sacrifice.

#### **Final Report**

A draft report that includes the following information will be prepared and submitted:

#### **Experimental Design and Methods**

##### **Results**

- mortality
- clinical observations
- body weights
- food consumption
- ophthalmic examinations
- clinical pathology results
- palmitoyl CoA oxidase activities
- hormone analyses (provided by Ani Lytics)
- serum, urine, feces, and liver PFOS levels (provided by 3M)
- cell proliferation evaluations (provided by Pathology Associates International)
- dose analyses (provided by 3M)
- organ weights
- organ-to-body weight percentages
- organ-to-brain weight ratios
- macroscopic observations
- microscopic observations

##### **Statistical Evaluation**

Levene's test will be done to test for variance homogeneity. In the case of heterogeneity of variance at  $p \leq 0.05$ , transformations will be used to stabilize the variance. Comparison tests will take variance heterogeneity into consideration.



One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, and continuous clinical pathology values. If the ANOVA is significant, Dunnett's t-test will be used for control versus treated group comparisons.

One-way analysis of covariance (ANCOVA) will be used to analyze body weights, with initial body weights as the covariate. If the ANCOVA is significant, covariate-adjusted means will be used for control versus treated group comparisons.

Group comparisons (Groups 2 through 4 versus Group 1) will be evaluated at the 5.0% two-tailed probability level. Only data collected on or after the first day of treatment will be analyzed statistically.

At the end of 1 year after issuance of the audited draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, then the audited draft report will be considered 'final' and issued as the final report, signed by the study director, and submitted to the Sponsor.


Any modifications or changes to the audited draft report requested 1 year after issuance will be performed at additional cost to the Sponsor.


#### **Record Retention**


All raw data, documentation, records, protocol, specimens, and final report generated as a result of this study generated by Covance will be archived in the storage facilities of Covance for a period of 1 year following submission of the final report to the Sponsor. One year after submission of the final report, all of the aforementioned materials will be sent to the Sponsor, and a return fee will be charged. The Sponsor may elect to have the materials retained in the Covance archives for an additional period of time, and Covance will charge a storage fee. If the Sponsor chooses to have Covance dispose of the materials, a disposal fee will be charged. All raw data stored on magnetic media will be retained by Covance.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

**PROTOCOL APPROVAL**

  
\_\_\_\_\_  
Andrew M. Seacat, PhD  
Study Monitor  
3M

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Peter J. Thomford, PhD  
Study Director  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date



**PROTOCOL AMENDMENT NO. 1**

Covance 6329-223  
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

---

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

---

This amendment modifies the following portions of the protocol.

**Effective August 20, 1998**

1. **Page 4, Vehicle, Storage Conditions.** To include the solvent used to dissolve the test material before mixing with the lactose, add the following after this section.

**Solvent**

**Identification**

Acetone

**Lot Numbers**

The lot numbers will be maintained in the raw data.

**Purity**

On file with the manufacturer

**Stability**

On file with the manufacturer

**Storage Conditions**

At room temperature

**Characteristics**

Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

2. **Page 7, Group Designations and Dosage Levels, Footnote a, Sentence 1.** To correct an error, delete this sentence.

**Effective September 2, 1998**

3. **Page 5, Gelatin Capsules, Sentence 1.** To change the size of the gelatin capsules, delete this sentence and replace with the following.

Capsules (Size Nos. 2 or 4) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer.

**Effective December 15, 1998**

4. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 3, Sentence 2.** To include evaluation of slides stained with hematoxylin and eosin in the PCNA evaluation, delete this sentence and replace with the following.

PCNA evaluation (including examination of slides stained with hematoxylin and eosin) will be done on the samples.

**Effective January 21, 1999**

5. **Page 10, Clinical Pathology, Tests, Clinical Chemistry.** To include an additional clinical chemistry test, add the following.

High density lipoprotein (HDL)

**Effective January 21 and 28 and February 2, 1999**

6. **Page 12, Urine and Feces PFOS Level Determination, Sample Shipping.** At the request of the Sponsor to collect additional fecal samples (effective January 21, 1999) and to clarify the sample collection requirements (effective January 28 and February 2, 1999), add the following after this section.

**Additional Fecal Samples**

During Week 23, a fresh fecal sample of at least 5 g, if possible, will be collected from 6 males and 6 females each in the control and high-dose groups, survival permitting. The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old. The samples will be collected in white polypropylene containers and sent on dry ice to:

Joe McConnell  
Porphyrins and Nutritional Chemistry Group  
Mayo Clinic  
200 First Street SW  
Rochester, Minnesota 55905  
Telephone: 507.284.2150  
Lab Telephone: 507.284.3232

Dr. McConnell will be contacted before shipping the samples.

**Effective January 21 and February 12 and 16, 1999**

7. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to add a collection interval after 150 days of treatment (effective January 21, 1999), to extend the length of recovery (effective February 12, 1999), and to clarify the collection requirement (effective February 12, 1999), delete the text in this section and replace with the following.

Once before initiation of treatment; and after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, and 180 days of recovery

**Effective February 10 and 16, 1999**

8. **Page 12, Urine and Feces PFOS Level Determination, Method of Collection.** To modify the amount of sample to be collected (effective February 10, 1999) and to permit collection of samples from fasted animals on the first day of recovery (effective February 16, 1999), delete the text in this section and replace with the following.

Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight.

**Effective February 12, 1999**

9. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.
- d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 26 weeks posttreatment.

**Effective February 12 and 15, 1999**

10. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to revise the requirements for these collections during recovery (effective February 15, 1999), delete the text in this section and replace with the following.
- Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, and 53.
11. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to prioritize the number of animals designated for recovery (effective February 15, 1999), delete the text in this section and replace with the following.
- After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.
- After at least 26 weeks of treatment and at least 26 weeks without treatment, two animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

**Effective February 12 and 16, 1999**

12. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, and 180 days of recovery

13. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery

**Effective February 15, 17, and 18, 1999**

14. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to transfer samples of lung tissue (effective February 15 and 18, 1999) and gallbladder and bile (effective February 17, 1999), add the following.

**Additional Lung Tissue Samples**

At the terminal necropsy, a sample of lung (approximately 5g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen sample and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

**Additional Gallbladder and Bile Samples**

At the scheduled necropsies, the gallbladder and bile will be collected and stored according to a special collection and fixation procedure. Frozen gallbladder and bile samples will be packed on dry ice and transferred to:

Kris J. Hansen, PhD  
3M E. T. & S  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone: 651.778.6018  
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

**Effective February 24 and March 9, 1999**

15. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to prepare (effective February 24, 1999) and transfer (effective March 9, 1999) samples of liver for electron microscopy and to prepare and transfer hematoxylin and eosin-stained slides for light microscopy (effective March 9, 1999), add the following.

**Electron Microscopy**

At the terminal necropsy, samples of liver will be collected and processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose  
Division Director  
Pathology Associates International  
4915 D. Prospectus Drive  
Durham, North Carolina 27713  
Telephone: 919.544.5257  
Facsimile: 919.544.3218



Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. PAI is responsible for the quality assurance auditing and maintenance of any raw data or specimens produced by PAI.

Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

**Effective April 22, 1999**

16. **Page 16, Reports, Statistical Evaluation, Paragraph 2, Sentence 1.** To add statistical analysis of organ weight and hormone values, delete this sentence and replace with the following.

One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, hormone values, and organ weight data.

**Effective April 26, 1999**

17. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 1.** To add a second set of tissues for cell proliferation evaluation, add the following to this paragraph.

A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc will also be prepared.

**Effective April 28, 1999**

18. **Page 8, Dose Analyses, Stability, Sentence 2.** To change the schedule for the return of the samples, delete this sentence and replace with the following.

One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase and will be analyzed for test material content.

**Effective May 6, 1999**

19. **Page 16, Reports, Letter Report.** To change the letter report to an interim report, delete the text in this section and replace with the following.

**Interim Report**

An interim report, including all items from the final report as appropriate, will be prepared following the terminal sacrifice.

**Effective May 17, 1999**

20. **Page 16, Postmortem Procedures, Histopathology, Sentence 2.** To include target organs for animals in the low- and mid-dose groups, delete this sentence and replace with the following.

In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

**Effective May 18, 1999**

21. **Page 3, Proposed Study Timetable.** To include proposed dates for in-life termination, the unaudited draft interim report, and the audited draft report, delete the text in this section and replace with the following.

Experimental Start Date: August 26, 1998

In-life Start Date: August 26, 1998

In-life Termination Date: August 27, 1999

Unaudited Draft Interim Report Date: May 11, 1999

Audited Draft Report Date: December 28, 1999

Experimental Termination Date: To be determined

**AMENDMENT APPROVAL**

Andrew M. Seacat  
Andrew M. Seacat, PhD  
Study Monitor  
3M

6/10/99  
Date

Peter J. Thomford  
Peter J. Thomford, PhD  
Study Director  
Covance Laboratories Inc.

03 June 1999  
Date



**PROTOCOL AMENDMENT NO. 2**

Covance 6329-223  
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

---

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

---

This amendment modifies the following portions of the protocol.

**Effective February 19, 1999**

1. **Page 9, Observation of Animals, Clinical Observations, Paragraph 2, Sentence 2.** To add an observation on the day of scheduled sacrifice, delete this sentence and replace with the following.

Once weekly and on the day of scheduled sacrifice, each animal will be observed; abnormal findings or an indication that the animal is normal will be recorded.

**Effective June 11, 1999**

2. **Page 11, Blood Hormone Determination, Tests.** To add free triiodothyronine (T3) and free thyroxin (T4) tests, delete the text in this section and replace with the following.

Samples will be analyzed by Ani Lytics Inc. for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total and free triiodothyronine (T3), and total and free thyroxin (T4).

3. **Page 16, Reports, Final Report, Statistical Evaluation.** To add repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3), add the following to the end of the section.

Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at  $p = 0.05$  level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one  $t$  procedure.

Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

**Effective August 24, 1999**

4. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.

d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

5. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

6. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

7. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79

**Effective August 24, 1999, and January 12 and 21, 2000**

8. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective August 24, 1999), to reflect the decision of the Sponsor to cancel the recovery necropsy (effective January 12, 2000), and to subsequently clarify the requirement (effective January 21, 2000), delete the text in this section and replace with the following.

After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 52 weeks without treatment, the remaining animals will be removed from the study as follows.

Two animals/sex in Group 1 will be returned to the Covance stock.

Two animals/sex in Group 3 will be transferred to a subsequent study (Covance 6329-268).

Two animals/sex in Group 4 will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

**Effective August 24 and September 22, 1999**

9. **Page 12, Additional Fecal Samples.** At the request of the Sponsor to collect liver samples by biopsy (effective August 24, 1999) and to modify the procedures (effective September 22, 1999), add the following after this section.

### **Interim Liver Biopsy Samples**

A sample of liver (approximately 1 to 2 g) will be collected by biopsy from animals in Group 4 only during recovery (Week 57, within 1 day of the serum PFOS blood collection). This sample will be divided into four portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose  
Division Director  
Pathology Associates International  
4915 D. Prospectus Drive  
Durham, North Carolina 27713  
Telephone No.: 919.544.5257  
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

The fourth subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, and transferred to the Sponsor for possible future analysis.

**Effective January 12 and 21, 2000**

10. **Page 12, Interim Liver Biopsy Samples.** At the request of the Sponsor to collect liver samples by biopsy, then terminate the study and transfer the animals to a subsequent study (effective January 12, 2000) and to modify the requirement (effective January 21, 2000), add the following after this section.

**Terminal Liver Biopsy Samples**

A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection). This sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

**Effective January 21, 2000**

11. **Page 12, Additional Serum Collection.** To reflect the decision of the Sponsor to analyze additional serum samples for specified thyroid hormones, add following to the end of this section.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3 and 4 sacrificed at the terminal necropsy will be sent on dry ice by the Sponsor to Dr. Saroj Das, Ani Lytics, for free T3, free T4, total T3, and total T4 determinations.



12. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor to collect a 24-hour urine and fecal sample after one year of recovery, delete the text in this section and replace with the following.

On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery. In addition, a 24-hour sample of urine and feces will be collected before the completion of 52 weeks of recovery.

13. **Page 16, Postmortem Procedures, Histopathology.** To define the postmortem procedures for recovery animals in the high-dose group, add the following after this section.

**Postmortem Procedures for Recovery Animals in the High-Dose Group**

At necropsy of the recovery animals in the high-dose group, procedures (including organ weights and collection of tissues for histopathological examination) described previously are not required. The following procedures will be done.

**Necropsy**

The necropsy will include examination of:

all orifices  
cranial cavity  
external surface of the brain; the external surface of the spinal cord and cut surfaces of the brain and spinal cord will be examined when tissue trimming is performed  
cervical tissues and organs  
thoracic, abdominal, and pelvic cavities and viscera  
external surface of the body  
nasal cavity and paranasal sinuses

**Liver Samples**

A sample of liver (approximately 1 to 2 g) will be collected. This sample will be divided into three portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose  
Division Director  
Pathology Associates International  
4915 D. Prospectus Drive  
Durham, North Carolina 27713  
Telephone No.: 919.544.5257  
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

**Additional Tissue and Serum Samples**

Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, bile, (approximately 3 g each), and serum (as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176


Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.


**Effective February 11 and 15, 2000**


14. **Page 3, Proposed Study Timetable.** To change proposed dates for in-life termination (effective February 11, 2000) and the audited draft report (effective February 15, 2000), delete the text in this section and replace with the following.


Experimental Start Date: August 26, 1998  
In-life Start Date: August 26, 1998  
In-life Termination Date: March 7, 2000  
Unaudited Draft Interim Report Date: May 11, 1999  
Audited Draft Report Date: May 29, 2000  
Experimental Termination Date: To be determined

**AMENDMENT APPROVAL**

  
\_\_\_\_\_  
Andrew M. Seacat, PhD  
Study Monitor  
3M

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Peter J. Thomford, PhD  
Study Director  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date



**PROTOCOL AMENDMENT NO. 3**

Covance 6329-223  
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

---

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

---

This amendment modifies the following portions of the protocol.

**Effective August 20, 1998**

1. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To correct an omission, add the following to the end of the section.

Data collected during recovery will not be analyzed statistically due to the small sample size.

**Effective January 21, 2000**

2. **Protocol Amendment No. 2, Item 13.** To correct a typographical error, change the font to bold on the following heading.

**Postmortem Procedures for Recovery Animals in the High-Dose Group**

**Effective February 18, 2000**

3. **Page 12, Serum PFOS Level Determinations, Sample Shipping, Paragraph 3, Sentence 3.** To indicate that the results of the Sponsor's analysis of serum samples for PFOS will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

4. **Page 12, Interim Liver Biopsy Samples, Paragraph 3, Sentence 2.** To indicate that the results of the Sponsor's analysis of the interim liver biopsy samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

5. **Page 12, Terminal Liver Biopsy Samples, Paragraph 2, Sentence 2.** To indicate that the results of the Sponsor's analysis of the terminal liver biopsy samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

6. **Page 15, Postmortem Procedures, Liver PFOS Determinations, Sentence 2.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

7. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To remove repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3) at the request of the Sponsor, delete the following.

Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at  $p = 0.05$  level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one  $t$  procedure.

Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

**Effective February 18 and 22, 2000**

8. **Page 16, Reports, Final Report, Results.** To indicate that the results of the Sponsor's analysis of the serum and liver samples (effective February 18, 2000) and urine and feces samples (effective February 22, 2000) will be reported separately, delete the following.

serum, urine, feces, and liver PFOS levels (provided by 3M)

9. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Liver Samples.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately (effective February 18, 2000) and to modify the amount of liver collected at necropsy (effective February 22, 2000), delete the text in this section and replace with the following.

Samples of liver will be collected as follows.

One sample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be reported separately.

The third sample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose  
Division Director  
Pathology Associates International  
4915 D. Prospectus Drive  
Durham, North Carolina 27713  
Telephone No.: 919.544.5257  
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

**Effective February 22, 2000**

10. **Page 13, Urine and Feces PFOS Determination, Sample Shipping, Paragraph 2, Sentence 3.** To indicate that the results of the Sponsor's analysis of the urine and feces samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

11. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Additional Tissue and Serum Samples, Paragraph 1.** To modify the amount of tissue collected at necropsy, delete this paragraph and replace with the following.

Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each, if possible), and bile and serum (each as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

Kris J. Hansen, PhD  
3M E. T. & S.  
Bldg. 2-3E-09  
935 Bush Avenue  
St. Paul, Minnesota 55106  
Telephone No.: 651.778.6018  
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

**Effective April 6, 2000**

12. **Page 3, Regulatory Compliance.** To include a compliance exception for the fecal analysis done at the Mayo Clinic, delete the text in this section and replace with the following.

This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments with the following exception. Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs.

13. **Page 3, Quality Assurance.** To include an exception for the fecal analysis done at the Mayo Clinic, add the following to the end of the section.

Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs and will not be audited by a Quality Assurance Unit.

14. **Page 12, Additional Fecal Samples.** To clarify analysis and reporting requirements for fecal analysis, add the following to the end of this section.

The samples will be analyzed for urobilinogen using a routine standardized colorimetric assay. The results of these analyses will be provided for inclusion in the final report.

15. **Page 17, Record Retention, Paragraph 2.** To include the record retention requirements for fecal analysis, delete this paragraph and replace with the following.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

**Effective April 7, 2000**

16. **Page 2, Purpose.** To modify the purpose of the study, delete the text in this section and replace with the following.

To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period will be followed by an approximate 52-week recovery period.





**Effective April 17, 2000**


17. **Page 12, Additional Serum Collection.** To reflect the decision of the Sponsor to analyze additional serum samples for specified thyroid hormones and lipoproteins, add following to the end of this section.


An additional aliquot (1.0 ml) of the additional serum collection samples collected from specified animals sacrificed at the terminal and recovery necropsies will be sent on dry ice by the Sponsor to Dr. Saroj Das, Ani Lytics, for thyroid stimulating hormone (TSH), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total lipoprotein, and calculated very low-density lipoprotein determinations. Results of these analyses will be provided for inclusion in the final report.

**AMENDMENT APPROVAL**

  
\_\_\_\_\_  
Andrew M. Seacat, PhD  
Study Monitor  
3M

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Peter J. Thomford, PhD  
Study Director  
Covance Laboratories Inc.

  
\_\_\_\_\_  
Date



**PROTOCOL AMENDMENT NO. 4**

Covance 6329-223  
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

---

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

---

This amendment modifies the following portions of the protocol.

**Effective 24 May 2001**

1. **Page 13, Postmortem Procedures, Electron Microscopy, and all other occurrences of “Pathology Associates International.”** To reflect a change in the name of the subcontractor, delete all occurrences of “Pathology Associates International” in the protocol and replace with the following.

Pathology Associates North Carolina Division, A Charles River Company

**Effective 27 August 2001**

2. **Page 12, Additional Serum Collection** To reflect the Sponsor’s decision to do additional hormone analyses at Ani Lytics, Inc. on serum samples, add the following to the end of the section.


At the request of the sponsor, serum samples collected at the terminal and recovery sacrifices will be transferred by the sponsor to Ani Lytics, Inc. for analysis of estradiol, follicle stimulating hormone (FSH), and lutenizing hormone (LH) for females, and estradiol in males. Results of these analyses will be provided for inclusion in the final report.

**Effective 17 September 2001**


3. **Page 12, Additional Serum Collection** To reflect the Sponsor's decision to do additional analyses at Mayo Clinic on serum samples, add the following to the end of the section.

At the request of the sponsor, specified serum samples will be transferred by the sponsor to R. Singh, PhD, Hilton 730, Mayo Clinic, Rochester, MN for analysis of triiodothyronine (T3), total thyroxin (T4), free thyroxin (free T4), and thyroid stimulating hormone (TSH). Additional reserve samples of serum will be transferred for possible future analysis for estradiol. Any unused serum will be returned to the sponsor. Results of these analyses will be provided for inclusion in the final report.

**AMENDMENT APPROVAL**

  
\_\_\_\_\_  
Andrew M. Seacat, PhD  
Study Monitor  
3M

10/17/2001  
Date

  
\_\_\_\_\_  
Peter J. Thornford, PhD  
Study Director  
Covance Laboratories Inc.

15 Oct 2001  
Date

**APPENDIX 2**

Individual Animal Fate Data  
Individual Clinical Observations  
Individual Ophthalmic Observations

APPENDIX 2  
Individual Animal Fate Data

Covance 6329-223  
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
105508	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105517	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105519	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105520	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
105526	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
105527	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105514	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105515	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105516	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105521	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105505	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
105510	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105518	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105523	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
105524	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105528	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105506	4	MALE	M	UNSCHEDULED	UNSCHEDULED DEATH	02/20/99	179	26
105507	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105509	4	MALE	D	UNSCHEDULED	UNSCHEDULED DEATH	01/27/99	155	23
105511	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
105512	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105522	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
105529	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
105530	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105531	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105535	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105544	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105549	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
105537	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105541	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105547	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105550	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
105532	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105538	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27

APPENDIX 2  
Individual Animal Fate Data

Covance 6329-223  
3M T-6295.7

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
105539	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
105545	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105548	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105552	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
105533	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
105534	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	185	27
105536	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
105540	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	185	27
105542	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
105551	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	185	27

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
I05508	T	27	NORMAL NO REMARKABLE OBSERVATIONS							
					1	P	-	-	-	
					8	P	-	-	-	
					15	P	-	-	-	
					22	P	-	-	-	
					29	P	-	-	-	
					36	P	-	-	-	
					43	P	-	-	-	
					50	P	-	-	-	
					57	P	-	-	-	
					64	P	-	-	-	
					71	P	-	-	-	
					78	P	-	-	-	
					85	P	-	-	-	
					92	P	-	-	-	
					99	P	-	-	-	
					106	P	-	-	-	
					113	P	-	-	-	
					120	P	-	-	-	
					127	P	-	-	-	
					134	P	-	-	-	
					141	P	-	-	-	
					148	P	-	-	-	
					155	P	-	-	-	
					162	P	-	-	-	
					169	P	-	-	-	
					176	P	-	-	-	
					183	P	-	-	-	
					184	P	-	-	-	P

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
I05517	T	27	NORMAL NO REMARKABLE OBSERVATIONS							
					1	P	-	-	-	
					8	P	-	-	-	
					15	P	-	-	-	
					22	P	-	-	-	
					29	P	-	-	-	
					36	P	-	-	-	
					43	P	-	-	-	
					50	P	-	-	-	
					57	P	-	-	-	
					64	P	-	-	-	
					71	P	-	-	-	
					78	P	-	-	-	
					85	P	-	-	-	
					92	P	-	-	-	
					99	P	-	-	-	
					106	P	-	-	-	
					113	P	-	-	-	
					120	P	-	-	-	
					127	P	-	-	-	
					134	P	-	-	-	
					141	P	-	-	-	
					148	P	-	-	-	
					155	P	-	-	-	
					162	P	-	-	-	
					169	P	-	-	-	
					176	P	-	-	-	
					183	P	-	-	-	
					184	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW		102	P	-	-	-	



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05517	T	27	QUALITATIVE FOOD CONSUMPTION LOW						
				141	P	-	-	-	
				176	P	-	-	-	
				177	P	-	-	-	
				179	P	-	-	-	
I05519	T	27	NORMAL NO REMARKABLE OBSERVATIONS						
				1	P	-	-	-	
				8	P	-	-	-	
				15	P	-	-	-	
				22	P	-	-	-	
				29	P	-	-	-	
				36	P	-	-	-	
				43	P	-	-	-	
				50	P	-	-	-	
				57	P	-	-	-	
				64	P	-	-	-	
				71	P	-	-	-	
				78	P	-	-	-	
				85	P	-	-	-	
				92	P	-	-	-	
				99	P	-	-	-	
				106	P	-	-	-	
				113	P	-	-	-	
				120	P	-	-	-	
				127	P	-	-	-	
				134	P	-	-	-	
				141	P	-	-	-	
				148	P	-	-	-	
				155	P	-	-	-	
				162	P	-	-	-	
				169	P	-	-	-	

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05519	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
I05520	O	79	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		141	P	-	-	-
			EXCRETION						
			LIQUID FECES		29	-	-	P	-
			NON-FORMED FECES		29	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05520	O	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION LOW		122	P	-	-	-
I05526	O	79	EXCRETION NON-FORMED FECES		179	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05526	O	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
I05527	T	27	DISCHARGE UNKNOWN SOURCE						
			FOUND IN PAN						
			RED IN COLOR		144	P	-	-	-
			EXCRETION						
			NON-FORMED FECES		2	P	-	-	-
			SKIN & PELAGE						
			BROKEN SKIN						
			HAND-LEFT		37	P	-	-	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					43	P	-	-	-
			TAIL		158	-	-	P	-
					169	P	-	-	-
					170	-	-	P	-
					176	P	-	-	-
					177	-	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105527	T	27	SKIN & PELAGE						
			BROKEN SKIN						
			TAIL		178	P	-	P	-
					179	P	-	-	-
					180	P	-	-	-
					181	-	-	P	-
					183	P	-	-	-
					184	P	-	-	P
			TAIL-DISTAL		145	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105527	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		155	P	-	-	-
					162	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION LOW		43	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05514	T	27	EXCRETION						
			LIQUID FECES		91	P	-	-	-
			NON-FORMED FECES		105	-	-	P	-
					132	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 10

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05514	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW		102	P	-	-	-
					179	P	-	-	-
I05515	T	27	EXCRETION NON-FORMED FECES		69	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05515	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					162	P	-	-	-
I05516	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		179	P	-	-	-
			PARTIAL CAPSULE		85	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05516	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		179	P	-	-	-
I05521	T	27	SKIN & PELAGE						
			BROKEN SKIN						
			PERI-ORBITAL-RIGHT		20	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 13

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105521	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS						
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05505	6	81	DISCHARGE VOMITUS CONTAINING FOOD		141	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05505	6	81	QUALITATIVE FOOD CONSUMPTION LOW						
					80	P	-	-	-
					141	P	-	-	-
					180	P	-	-	-
I05510	T	27	EXCRETION DISCOLORED URINE RED IN COLOR		97	-	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 16

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05510	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		67	P	-	-	-
					73	P	-	-	-
					109	P	-	-	-
					127	P	-	-	-
					141	P	-	-	-
					142	P	-	-	-
					148	P	-	-	-
					154	P	-	-	-
					180	P	-	-	-
					183	P	-	-	-
I05518	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		179	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)										
105518	T	27	NORMAL							
			NO REMARKABLE OBSERVATIONS		50	P	-	-	-	
					57	P	-	-	-	
					64	P	-	-	-	
					71	P	-	-	-	
					78	P	-	-	-	
					85	P	-	-	-	
					92	P	-	-	-	
					99	P	-	-	-	
					106	P	-	-	-	
					113	P	-	-	-	
					120	P	-	-	-	
					127	P	-	-	-	
					134	P	-	-	-	
					141	P	-	-	-	
					148	P	-	-	-	
					155	P	-	-	-	
					162	P	-	-	-	
					169	P	-	-	-	
					176	P	-	-	-	
					183	P	-	-	-	
					185	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION							
			LOW		141	P	-	-	-	
					179	P	-	-	-	

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05523	6	81	SKIN & PELAGE BROKEN SKIN TAIL		149	-	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	D	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)										
I05523	6	81	QUALITATIVE FOOD CONSUMPTION LOW			6 141 179	P P P	- - -	- - -	- - -
I05524	T	27	DISCHARGE VOMITUS CONTAINING FOOD			141	P	-	-	-
			EXCRETION NON-FORMED FECES			179 180	P P	- -	- -	- -
			NORMAL NO REMARKABLE OBSERVATIONS			1 8 15 22 29 36 50 57 64 71 78 85 92 99 106 113	P P P P P P P P P P P P P P P P	- - - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - -

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05524	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		43	P	-	-	-
					65	P	-	-	-
					141	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-
I05528	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					85	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHE	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105528	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					120	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		78	P	-	-	-
					113	P	-	-	-
					116	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					162	P	-	-	-
					176	P	-	-	-
					179	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05506	M	26	BEHAVIOR ATAXIC <UNSPECIFIED>		179	-	P	-	P
			HYPOACTIVE <UNSPECIFIED>		179	-	P	-	P
			DISCHARGE EXCESSIVE SALIVATION		179	-	P	-	-
			RESPIRATION LABORED		179	-	P	-	P
			NORMAL NO REMARKABLE OBSERVATIONS		1		P	-	-
					8		P	-	-
					15		P	-	-
					22		P	-	-
					29		P	-	-
					36		P	-	-
					43		P	-	-
					50		P	-	-
					57		P	-	-
					64		P	-	-
					71		P	-	-
					78		P	-	-
					85		P	-	-
					92		P	-	-
					99		P	-	-
					106		P	-	-
					113		P	-	-
					120		P	-	-
					127		P	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105506	M	26	NORMAL						
			NO REMARKABLE OBSERVATIONS		134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION LOW		3	P	-	-	-
					141	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
105507	T	27	DISCHARGE						
			VOMITUS						
			PARTIAL CAPSULE		11	-	-	P	-
					111	-	-	P	-
					178	-	-	P	-
			SKIN & PELAGE						
			BROKEN SKIN						
			DIGIT(S)-FRONT-LEFT		97	-	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	P	-
					101	-	-	P	-
					102	P	-	-	-
					104	P	-	P	-
					106	P	-	P	-
					107	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 24

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)										
105507	T	27	SKIN & PELAGE BROKEN SKIN DIGIT(S)-FRONT-LEFT			108	P	-	-	-
						111	-	-	P	-
						112	P	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS			1	P	-	-	-
						8	P	-	-	-
						15	P	-	-	-
						22	P	-	-	-
						29	P	-	-	-
						36	P	-	-	-
						43	P	-	-	-
						50	P	-	-	-
						57	P	-	-	-
						64	P	-	-	-
						71	P	-	-	-
						78	P	-	-	-
						85	P	-	-	-
						92	P	-	-	-
						113	P	-	-	-
						120	P	-	-	-
						127	P	-	-	-
						134	P	-	-	-
						141	P	-	-	-
						148	P	-	-	-
						155	P	-	-	-
						162	P	-	-	-
						169	P	-	-	-
						176	P	-	-	-
						183	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05507	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW		141	P	-	-	-
I05509	D	23	APPEARANCE						
			APPEARS DEHYDRATED		155	-	P	-	P
			OTHER		155	-	-	-	PC
			BEHAVIOR						
			HYPOACTIVE						
			<UNSPECIFIED>		155	-	P	-	P
			EXCRETION						
			DISCOLORED FECES		155	P	-	-	-
			BLACK IN COLOR		152	P	-	-	-
			FEW FECES		155	P	-	-	-
			LIQUID FECES		155	P	-	-	-
			MUCOID FECES		155	P	-	-	-
			NO FECES		154	P	-	-	-
			EYES						
			CONSTRICTED PUPIL						
			EYES		154	-	-	P	-
			RESPIRATION						
			LABORED		155	-	P	-	P

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105509	D	23	SKIN & PELAGE COLD TO TOUCH BODY-ENTIRE PALE SKIN GUMS		155	-	P	-	P
					154	-	-	P	-
					155	-	P	-	P
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)										
I05509	D	23	QUALITATIVE FOOD CONSUMPTION LOW			141	P	-	-	-
						152	P	-	-	-
						154	P	-	-	-
						155	P	-	-	-
I05511	U	79	DISCHARGE VOMITUS CONTAINING FOOD PARTIAL CAPSULE			100	P	-	-	-
						155	-	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS			1	P	-	-	-
						8	P	-	-	-
						15	P	-	-	-
						22	P	-	-	-
						29	P	-	-	-
						36	P	-	-	-
						43	P	-	-	-
						50	P	-	-	-
						57	P	-	-	-
						64	P	-	-	-
						71	P	-	-	-
						78	P	-	-	-
						85	P	-	-	-
						92	P	-	-	-
						99	P	-	-	-
						106	P	-	-	-
						113	P	-	-	-
						120	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105511	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		57	P	-	-	-
					60	P	-	-	-
					100	P	-	-	-
					102	P	-	-	-
					141	P	-	-	-
					145	P	-	-	-
					148	P	-	-	-
					154	P	-	-	-
					155	P	-	-	-
					170	P	-	-	-
					171	P	-	-	-
					172	P	-	-	-
					173	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					177	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05512	T	27	DISCHARGE						
			VOMITUS						
			PARTIAL CAPSULE		32	-	-	P	-
					37	-	-	P	-
			EXCRETION						
			FEW FECES		100	P	-	-	-
					102	P	-	-	-
					105	P	-	-	-
					106	P	-	-	-
					110	P	-	-	-
					125	P	-	-	-
					126	P	-	-	-
					127	P	-	-	-
					128	P	-	-	-
					129	P	-	-	-
					130	P	-	-	-
					133	P	-	-	-
					134	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	-	-
					158	P	-	-	-
					159	P	-	-	-
					161	P	-	-	-
					161	P	-	-	-
					163	P	-	-	-
					164	P	-	-	-
			NO FECES		99	P	-	-	-
					131	P	-	-	-
					132	P	-	-	-
			NON-FORMED FECES		130	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105512	T	27	EXCRETION						
			NON-FORMED FECES		133	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					184	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		17	P	-	-	-
					98	P	-	-	-
					99	P	-	-	-
					100	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 31

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105512	T	27	QUALITATIVE FOOD CONSUMPTION LOW						
					102	P	-	-	-
					105	P	-	-	-
					110	P	-	-	-
					116	P	-	-	-
					125	P	-	-	-
					126	P	-	-	-
					127	P	-	-	-
					128	P	-	-	-
					129	P	-	-	-
					130	P	-	-	-
					131	P	-	-	-
					132	P	-	-	-
					133	P	-	-	-
					134	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	-	-
					158	P	-	-	-
					159	P	-	-	-
					160	P	-	-	-
					161	P	-	-	-
					162	P	-	-	-
					164	P	-	-	-
					168	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-
					181	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05512	T	27	QUALITATIVE FOOD CONSUMPTION LOW		183	P	-	-	-
I05522	U	79	EXCRETION MUCOID FECES		179	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105522	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		102	P	-	-	-
					180	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

---

ANIMAL	GROUP	STUDY DAY WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05509	M4	155 23	APPEARANCE OTHER	AFTER DOSING ANIMAL BECAME RECUMBENT. VET WAS CALLED. ANIMAL DIED PRIOR TO VET EXAM.

---



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05529	P	79	APPEARANCE APPEARS DEHYDRATED		5 6 7	- P P	- - -	P - -	- - -
			BEHAVIOR HYPOACTIVE <UNSPECIFIED>		6 7 8	- P P	- - -	P - P	- - -
			DISCHARGE NASAL CLEAR		5 6 7 8 9	- P P P P	- - - - -	P P - P -	- - - - -
			ORAL CLOUDY		6 7 8	- P P	- - -	P - -	- - -
			EXCESSIVE SALIVATION		5 6 7 8	- P P P	- - - -	P P - -	- - - -
			EXCRETION LIQUID FECES		29 30 38 39	P P P P	- - - -	- - P -	- - - -

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105529	P	79	EXCRETION LIQUID FECES					P	-
					40	-	-	P	-
					41	P	-	-	-
					42	P	-	P	-
					43	P	-	-	-
					44	P	-	-	-
					65	-	-	P	-
					66	P	-	-	-
					67	P	-	-	-
					68	P	-	-	-
					69	P	-	-	-
					70	P	-	-	-
					99	-	-	P	-
					100	P	-	P	-
					101	P	-	-	-
					102	P	-	-	-
					115	-	-	P	-
			NON-FORMED FECES		71	P	-	-	-
					73	P	-	-	-
					77	P	-	-	-
					103	P	-	-	-
					115	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			FEET		105	P	-	P	-
					106	P	-	P	-
					107	P	-	P	-
					108	P	-	P	-
					109	P	-	P	-
					110	P	-	P	-
					111	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105529	F	79	SKIN & PELAGE ALOPECIA FBET				112	P	-	P	-
							113	P	-	P	-
							114	P	-	P	-
							115	P	-	P	-
							117	P	-	P	-
							118	P	-	P	-
							119	P	-	P	-
							120	P	-	P	-
							121	P	-	P	-
							122	-	-	P	-
							124	-	-	P	-
							125	P	-	P	-
							126	P	-	P	-
							127	P	-	P	-
							128	P	-	P	-
							129	-	-	P	-
							130	P	-	P	-
							131	P	-	P	-
							132	P	-	P	-
							133	P	-	P	-
							134	P	-	P	-
							135	P	-	P	-
							136	P	-	P	-
							137	P	-	P	-
							138	P	-	P	-
							139	P	-	P	-
							140	P	-	P	-
							142	P	-	P	-
							143	P	-	P	-
							146	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105529	P	79	SKIN & PELAGE ALOPECIA FBET						
					147	P	-	P	-
					148	P	-	-	-
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	P	-
					158	-	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105529	F	79	SKIN & PELAGE ALOPECIA								
			FBET				180	P	-	P	
							181	-	-	P	
							182	P	-	P	
							183	P	-	P	
							184	P	-	-	
							185	P	-	-	
			LIMBS-HIND				92	-	-	P	
							93	-	-	P	
							94	P	-	P	
							95	P	-	P	
							96	P	-	P	
							98	P	-	P	
							99	P	-	P	
							100	P	-	P	
							101	P	-	-	
							102	P	-	P	
							142	-	-	P	
							144	-	-	P	
			TAIL				134	P	-	P	
							135	P	-	P	
							136	P	-	P	
							137	P	-	P	
							138	P	-	-	
							139	P	-	-	
							140	P	-	P	
							142	P	-	P	
							143	P	-	P	
							146	P	-	P	
							147	P	-	P	
							148	P	-	-	

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105529	F	79	SKIN & PELAGE ALOPECIA TAIL						
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	P	-
					158	-	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	-	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 41

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH NUMBER	WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105529	P	79	SKIN & PELAGE ALOPECIA TAIL		182 183 184 185	P P P P	- - - -	P P - -	- - - -
			NORMAL NO REMARKABLE OBSERVATIONS		1 15 22 36 50 57 64 78 85 92 141	P P P P P P P P P P P	- - - - - - - - - - -	- - - - - - - - - - -	- - - - - - - - - - -
			QUALITATIVE FOOD CONSUMPTION LOW		5 8 41 42 69 72 73 75 102 174 179	P P P P P P P P P P P	- - - - - - - - - - -	- - - - - - - - - - -	- - - - - - - - - - -

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05530	T	27	DISCHARGE						
			VOMITUS						
			PARTIAL CAPSULE		97	-	-	P	-
			APPEARS TO BE MENSTRUATING		39	-	-	P	-
					40	P	-	-	-
					92	P	-	-	-
					176	P	-	-	-
					180	P	-	-	-
			EXCRETION						
			DISCOLORED FECES						
			RED IN COLOR		28	P	-	-	-
			LIQUID FECES		27	P	-	-	-
					28	P	-	P	-
					29	P	-	-	-
					31	-	-	P	-
					32	P	-	-	-
					33	P	-	-	-
					34	P	-	P	-
					35	P	-	-	-
					36	P	-	-	-
					37	P	-	-	-
					38	P	-	P	-
					39	-	-	P	-
					40	P	-	-	-
					49	P	-	-	-
					50	P	-	-	-
					51	P	-	P	-
					55	P	-	-	-
			MUCOID FECES		28	P	-	-	-
			NON-FORMED FECES		12	P	-	-	-
					31	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105530	T	27	EXCRETION						
			NON-FORMED FECES		41	P	-	-	-
					54	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
			SKIN & PELAGE						
			BROKEN SKIN						
			MOUTH		10	-	-	P	-
					12	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					23	P	-	-	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-
					28	P	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					43	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					75	P	-	-	-
					85	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHE	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05530	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		26	P	-	-	-
					27	P	-	-	-
					29	P	-	-	-
					141	P	-	-	-
I05531	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		179	P	-	-	-
			APPEARS TO BE MENSTRUATING		176	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105531	T	27	NORMAL								
			NO REMARKABLE OBSERVATIONS				57	P	-	-	-
							64	P	-	-	-
							71	P	-	-	-
							78	P	-	-	-
							85	P	-	-	-
							92	P	-	-	-
							99	P	-	-	-
							106	P	-	-	-
							113	P	-	-	-
							120	P	-	-	-
							127	P	-	-	-
							134	P	-	-	-
							141	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							183	P	-	-	-
							185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION								
			LOW				141	P	-	-	-
							179	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 46

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
I05535	T	27	DISCHARGE APPEARS TO BE MENSTRUATING					P	-	
					37	-	-	P	-	
					38	P	-	-	-	
					108	P	-	P	-	
					137	P	-	P	-	
					138	P	-	-	-	
					166	P	-	P	-	
					167	P	-	P	-	
			SKIN & PELAGE							
			RED SKIN							
			LIMB-FRONT-RIGHT		22	-	-	P	-	
					23	-	-	P	-	
					24	P	-	P	-	
			SCAB(S)							
			LIMB-FRONT-LEFT		183	P	-	-	-	
			LIMB-FRONT-RIGHT		22	-	-	P	-	
					23	-	-	P	-	
					24	P	-	P	-	
			NORMAL							
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-	
					8	P	-	-	-	
					15	P	-	-	-	
					22	P	-	-	-	
					29	P	-	-	-	
					36	P	-	-	-	
					43	P	-	-	-	
					50	P	-	-	-	
					57	P	-	-	-	
					64	P	-	-	-	
					71	P	-	-	-	

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 47

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05535	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					185	P	-	-	P
I05544	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		141	P	-	-	-
			PARTIAL CAPSULE		29	-	-	P	-
					33	-	-	P	-
					34	-	-	P	-
					66	-	-	P	-
					117	-	-	P	-
					141	-	-	P	-
			DISCHARGE UNKNOWN SOURCE						
			FOUND IN PAN						
			RED IN COLOR		112	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 48

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105544	T	27							
			NORMAL						
			NO REMARKABLE OBSERVATIONS						
					1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW						
					6	P	-	-	-
					36	P	-	-	-
					38	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05544	T	27	QUALITATIVE FOOD CONSUMPTION LOW						
					42	P	-	-	-
					43	P	-	-	-
					127	P	-	-	-
					171	P	-	-	-
					174	P	-	-	-
					176	P	-	-	-
I05549	P	79	DISCHARGE						
			VOMITUS						
			INTACT CAPSULE		111	-	-	P	-
			PARTIAL CAPSULE		97	-	-	P	-
			APPEARS TO BE MENSTRUATING		175	P	-	-	-
			SKIN & PELAGE						
			BROKEN SKIN						
			HEAD-CRANIAL		3	-	-	P	-
			PERI-ORBITAL-LEFT		7	-	-	P	-
					8	P	-	P	-
					15	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105549	P	79	NORMAL								
			NO REMARKABLE OBSERVATIONS				85	P	-	-	-
							92	P	-	-	-
							99	P	-	-	-
							106	P	-	-	-
							113	P	-	-	-
							120	P	-	-	-
							127	P	-	-	-
							134	P	-	-	-
							141	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION								
			LOW				141	P	-	-	-
							175	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 51

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05537	T	27	DISCHARGE VOMITUS WHITE IN COLOR APPEARS TO BE MENSTRUATING					P	-
					1	-	-	P	-
					45	-	-	P	-
					46	-	-	P	-
					47	P	-	-	-
					48	P	-	-	-
					49	-	-	P	-
					72	P	-	P	-
					73	P	-	-	-
					74	P	-	P	-
					75	P	-	-	-
					104	P	-	-	-
					105	P	-	P	-
					106	P	-	P	-
					107	P	-	-	-
					168	P	-	P	-
					169	P	-	P	-
			SKIN & PELAGE						
			BROKEN SKIN						
			HEAD-MAXILLARY-RIGHT		50	-	-	P	-
					52	-	-	P	-
			PERI-ORBITAL-LEFT		8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
			PERI-ORBITAL-RIGHT		3	P	-	P	-
					4	-	-	-	-
					6	P	-	P	-
					7	-	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL DEATH WK OF CATEGORY GROUP: P2 DOSE: 0.03 MG/KG/DAY 'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP  
NUMBER CODE DEATH KEYWORD QUALIFIER DAYS 1-185 DAY AM OBS UNSCHED 30-90 OB DISPATCH  
-----

(CONTINUED FROM PREVIOUS PAGE)  
105537 T 27

NORMAL  
NO REMARKABLE OBSERVATIONS

1	P	-	-	-
15	P	-	-	-
22	P	-	-	-
29	P	-	-	-
36	P	-	-	-
43	P	-	-	-
50	P	-	-	-
57	P	-	-	-
64	P	-	-	-
71	P	-	-	-
78	P	-	-	-
85	P	-	-	-
92	P	-	-	-
99	P	-	-	-
113	P	-	-	-
120	P	-	-	-
127	P	-	-	-
134	P	-	-	-
141	P	-	-	-
148	P	-	-	-
155	P	-	-	-
162	P	-	-	-
176	P	-	-	-
183	P	-	-	-
184	P	-	-	P

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05541	T	27	DISCHARGE APPEARS TO BE MENSTRUATING		99 102 152 154	- P - -	- - - -	P - P P	- - - -
			EXCRETION FEW FECES		141	P	-	-	-
			SKIN & PELAGE BROKEN SKIN PERI-ORBITAL-RIGHT		98 99 102	- P P	- - -	P P -	- - -
			NORMAL NO REMARKABLE OBSERVATIONS		1 8 15 36 50 57 64 71 78 85 92 106 120 127 134 148	P P P P P P P P P P P P P P P P	- - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - -	

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 54

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105541	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW		3	P	-	-	-
					22	P	-	-	-
					28	P	-	-	-
					29	P	-	-	-
					43	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
					76	P	-	-	-
					87	P	-	-	-
					113	P	-	-	-
					140	P	-	-	-
					169	P	-	-	-
					174	P	-	-	-
					179	P	-	-	-
105547	T	27	DISCHARGE APPEARS TO BE MENSTRUATING		129	P	-	-	-
					164	-	-	P	-
					165	P	-	-	-
					167	P	-	-	-
			EXCRETION FEW FECES		150	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 55

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
							AM OBS	UNSCHED	30-90 OB	DISPATCH
			DAYS 1-185	DAY						
(CONTINUED FROM PREVIOUS PAGE)										
105547	T	27	EXCRETION							
			FEW FECES		151	P	-	-	-	-
					152	P	-	-	-	-
					156	P	-	-	-	-
					168	P	-	-	-	-
			NO FECES		154	P	-	-	-	-
					155	P	-	-	-	-
			NON-FORMED FECES		178	P	-	-	-	-
					161	-	-	P	-	-
			SKIN & PELAGE							
			BROKEN SKIN							
			HEAD-MAXILLARY-LEFT		170	P	-	-	P	-
					171	P	-	-	P	-
					172	P	-	-	P	-
					173	-	-	-	P	-
					174	P	-	-	P	-
					175	P	-	-	-	-
			SCAB(S)							
			HEAD-MAXILLARY-LEFT		176	P	-	-	-	-
					178	P	-	-	P	-
			NORMAL							
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-	-
					8	P	-	-	-	-
					15	P	-	-	-	-
					22	P	-	-	-	-
					29	P	-	-	-	-
					36	P	-	-	-	-
					50	P	-	-	-	-
					57	P	-	-	-	-
					64	P	-	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2 DAYS 1-185	DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105547	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		71	P	-	-	-
					76	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		17	P	-	-	-
					41	P	-	-	-
					43	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
					66	P	-	-	-
					99	P	-	-	-
					120	P	-	-	-
					121	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					150	P	-	-	-
					151	P	-	-	-
					152	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 57

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2	DOSE: 0.03 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
I05547	T	27	QUALITATIVE FOOD CONSUMPTION LOW				154	P	-	-	-
							155	P	-	-	-
							156	P	-	-	-
							160	P	-	-	-
							161	P	-	-	-
							162	P	-	-	-
							165	P	-	-	-
							167	P	-	-	-
							168	P	-	-	-
							169	P	-	-	-
							170	P	-	-	-
							171	P	-	-	-
							174	P	-	-	-
							175	P	-	-	-
							179	P	-	-	-
							184	P	-	-	-
I05550	T	27	DISCHARGE APPEARS TO BE MENSTRUATING				91	-	-	P	-
							92	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS				1	P	-	-	-
							8	P	-	-	-
							15	P	-	-	-
							22	P	-	-	-
							29	P	-	-	-
							36	P	-	-	-
							43	P	-	-	-
							50	P	-	-	-
							57	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 58

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P2	DOSE: 0.03 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105550	T	27	NORMAL								
			NO REMARKABLE OBSERVATIONS				64	P	-	-	-
							71	P	-	-	-
							78	P	-	-	-
							85	P	-	-	-
							99	P	-	-	-
							106	P	-	-	-
							113	P	-	-	-
							120	P	-	-	-
							127	P	-	-	-
							134	P	-	-	-
							141	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
							185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION								
			LOW				3	P	-	-	-
							141	P	-	-	-
							179	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05532	T	27	SKIN & PELAGE						
			BROKEN SKIN		2	P	-	P	-
			HEAD-CRANIAL		3	P	-	P	-
			PERI-ORBITAL-RIGHT		31	-	-	P	-
					32	P	-	P	-
					33	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 60

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105532	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		26	P	-	-	-
					29	P	-	-	-
					32	P	-	-	-
					41	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
					58	P	-	-	-
					65	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					115	P	-	-	-
					116	P	-	-	-
					120	P	-	-	-
					126	P	-	-	-
					141	P	-	-	-
					143	P	-	-	-
					147	P	-	-	-
					150	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					164	P	-	-	-
					169	P	-	-	-
					170	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					179	P	-	-	-
					183	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05538	T	27	DISCHARGE VOMITUS CONTAINING FOOD		141 179	P P	- -	- -	- -
			EXCRETION FEW FECES		43	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		1 8 15 22 29 36 50 57 64 71 78 85 92 99 106 113 120 127 134 148 155 162 169	P P	- -	- -	- -

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05538	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW		27	P	-	-	-
					41	P	-	-	-
					42	P	-	-	-
					43	P	-	-	-
					141	P	-	-	-
					160	P	-	-	-
					167	P	-	-	-
					174	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
I05539	6	81	DISCHARGE APPEARS TO BE MENSTRUATING		71	P	-	P	-
			EXCRETION FEW FECES		141	P	-	-	-
			NORMAL		1	P	-	-	-
			NO REMARKABLE OBSERVATIONS		8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 63

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105539	6	81	NORMAL								
			NO REMARKABLE OBSERVATIONS				57	P	-	-	-
							64	P	-	-	-
							78	P	-	-	-
							92	P	-	-	-
							99	P	-	-	-
							106	P	-	-	-
							120	P	-	-	-
							134	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION								
			LOW				17	P	-	-	-
							18	P	-	-	-
							24	P	-	-	-
							57	P	-	-	-
							60	P	-	-	-
							70	P	-	-	-
							85	P	-	-	-
							109	P	-	-	-
							113	P	-	-	-
							116	P	-	-	-
							127	P	-	-	-
							132	P	-	-	-
							133	P	-	-	-
							138	P	-	-	-
							139	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 64

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK OF CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
					AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05539	6	81	QUALITATIVE FOOD CONSUMPTION LOW	150	P	-	-	-
				155	P	-	-	-
				158	P	-	-	-
				159	P	-	-	-
				162	P	-	-	-
				171	P	-	-	-
				174	P	-	-	-
				179	P	-	-	-
I05545	T	27	DISCHARGE APPEARS TO BE MENSTRUATING	136	P	-	P	-
			EXCRETION NO FECEES	51	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				127	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105545	T	27	NORMAL								
			NO REMARKABLE OBSERVATIONS				134	P	-	-	-
							141	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
							184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION								
			LOW				25	P	-	-	-
							30	P	-	-	-
							35	P	-	-	-
							43	P	-	-	-
							74	P	-	-	-
							78	P	-	-	-
							86	P	-	-	-
							113	P	-	-	-
							116	P	-	-	-
							120	P	-	-	-
							141	P	-	-	-
							149	P	-	-	-
							150	P	-	-	-
							155	P	-	-	-
							161	P	-	-	-
							169	P	-	-	-
							171	P	-	-	-
							174	P	-	-	-
							175	P	-	-	-
							176	P	-	-	-
							179	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05545	T	27	QUALITATIVE FOOD CONSUMPTION LOW						
					180	P	-	-	-
					183	P	-	-	-
I05548	T	27	DISCHARGE VOMITUS CONTAINING FOOD						
			EXCRETION FEW FECES		141	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		178	P	-	-	-
					1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 67

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
I05548	T	27	NORMAL								
			NO REMARKABLE OBSERVATIONS				148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
							184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION								
			LOW				18	P	-	-	-
							28	P	-	-	-
							58	P	-	-	-
							141	P	-	-	-
							142	P	-	-	-
							174	P	-	-	-
I05552	6	81	NORMAL								
			NO REMARKABLE OBSERVATIONS				1	P	-	-	-
							8	P	-	-	-
							15	P	-	-	-
							22	P	-	-	-
							29	P	-	-	-
							36	P	-	-	-
							43	P	-	-	-
							50	P	-	-	-
							57	P	-	-	-
							64	P	-	-	-
							71	P	-	-	-
							78	P	-	-	-
							85	P	-	-	-
							92	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105552	6	81	NORMAL								
			NO REMARKABLE OBSERVATIONS				99	P	-	-	-
							106	P	-	-	-
							113	P	-	-	-
							120	P	-	-	-
							127	P	-	-	-
							134	P	-	-	-
							141	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION								
			LOW				20	P	-	-	-
							141	P	-	-	-
							156	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 69

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05533	U	79	DISCHARGE APPEARS TO BE MENSTRUATING		39	P	-	P	-
					40	P	-	-	-
			SKIN & PELAGE ALOPECIA HEAD-CRANIAL		22	-	-	P	-
					24	-	-	P	-
					27	P	-	P	-
					28	-	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	-	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	-	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
					42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					48	-	-	P	-
					49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105533	U	79	SKIN & PELAGE								
			ALOPECIA				53	P	-	P	-
			HEAD-CRANIAL				54	P	-	P	-
							55	P	-	P	-
							56	P	-	P	-
							57	P	-	P	-
							58	P	-	P	-
							59	P	-	P	-
							60	P	-	P	-
							61	P	-	P	-
							62	P	-	P	-
			HEAD-MAXILLARY-LEFT				27	-	-	P	-
							28	-	-	P	-
							29	P	-	P	-
							30	P	-	P	-
							31	P	-	P	-
							32	P	-	P	-
							33	-	-	P	-
							34	P	-	P	-
							35	P	-	P	-
							36	P	-	P	-
							37	-	-	P	-
							38	P	-	P	-
							39	P	-	P	-
							40	P	-	P	-
							41	P	-	P	-
							42	P	-	P	-
							43	P	-	P	-
							44	-	-	P	-
							45	-	-	P	-
							48	-	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105533	U	79	SKIN & PELAGE ALOPECIA						
			HEAD-MAXILLARY-LEFT		49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-
					53	P	-	P	-
					54	P	-	P	-
					55	P	-	P	-
					56	P	-	P	-
					57	P	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	-	-	P	-
					61	-	-	P	-
					62	P	-	P	-
					63	P	-	P	-
			HEAD-MAXILLARY-RIGHT		27	-	-	P	-
					28	-	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	-	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	-	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	P	-
					41	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 72

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105533	U	79	SKIN & PELAGE ALOPECIA						
			HEAD-MAXILLARY-RIGHT		42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					48	-	-	P	-
					49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-
					53	P	-	P	-
					54	P	-	P	-
					55	P	-	P	-
					56	P	-	P	-
					57	P	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	-	-	P	-
					61	-	-	P	-
					62	P	-	P	-
					63	P	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05533	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
I05534	T	27	DISCHARGE						
			VOMITUS		6	-	-	P	-
			PARTIAL CAPSULE		10	-	-	P	-
					72	-	-	P	-
			APPEARS TO BE MENSTRUATING		59	P	-	-	-
					98	P	-	-	-
					133	P	-	-	-
					134	P	-	-	-
			EXCRETION						
			DISCOLORED FECES						
			RED IN COLOR		149	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 74

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH NUMBER	WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105534	T	27	EXCRETION						
			DISCOLORED FECES						
			RED IN COLOR		150	P	-	-	-
			YELLOW IN COLOR		156	P	-	-	-
			FEW FECES		102	P	-	-	-
					105	P	-	-	-
					107	P	-	-	-
					109	P	-	-	-
					113	P	-	-	-
					127	P	-	-	-
					163	P	-	-	-
			LIQUID FECES		92	P	-	-	-
					93	P	-	-	-
					136	P	-	-	-
					137	P	-	P	-
					138	P	-	-	-
					139	P	-	-	-
					141	P	-	P	-
					142	P	-	-	-
					143	P	-	-	-
					144	P	-	-	-
					156	P	-	-	-
					185	P	-	-	-
			MUCOID FECES		150	P	-	-	-
			NO FECES		49	P	-	-	-
			NON-FORMED FECES		110	P	-	-	-
					113	P	-	-	-
					127	P	-	-	-
					137	P	-	-	-
					140	P	-	-	-
					144	P	-	-	-
					145	P	-	-	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 75

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105534	T	27	EXCRETION						
			NON-FORMED FECES		146	P	-	-	-
					147	P	-	-	-
					148	P	-	-	-
					149	P	-	-	-
					150	P	-	-	-
			SKIN & PELAGE						
			BROKEN SKIN						
			PERI-ORBITAL-LEFT		70	-	-	P	-
					71	P	-	P	-
			OTHER		9	PC	-	PC	-
					10	PC	-	PC	-
					12	PC	-	-	-
					15	PC	-	PC	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					85	P	-	-	-
					93	P	-	-	-
					106	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	-	-	-	P

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 76

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL DEATH WK OF CATEGORY GROUP: P4 DOSE: 0.75 MG/KG/DAY 'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP  
NUMBER CODE DEATH KEYWORD QUALIFIER DAYS 1-185 DAY AM OBS UNSCHED 30-90 OB DISPATCH  
-----

(CONTINUED FROM PREVIOUS PAGE)  
105534 T 27

QUALITATIVE FOOD CONSUMPTION  
LOW

2	P	-	-	-
3	P	-	-	-
8	P	-	-	-
10	P	-	-	-
22	P	-	-	-
24	P	-	-	-
38	P	-	-	-
43	P	-	-	-
49	P	-	-	-
60	P	-	-	-
63	P	-	-	-
66	P	-	-	-
78	P	-	-	-
80	P	-	-	-
81	P	-	-	-
92	P	-	-	-
93	P	-	-	-
98	P	-	-	-
100	P	-	-	-
102	P	-	-	-
105	P	-	-	-
109	P	-	-	-
113	P	-	-	-
116	P	-	-	-
120	P	-	-	-
122	P	-	-	-
125	P	-	-	-
127	P	-	-	-
128	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 77

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105534	T	27	QUALITATIVE FOOD CONSUMPTION LOW						
					129	P	-	-	-
					133	P	-	-	-
					134	P	-	-	-
					137	P	-	-	-
					138	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					149	P	-	-	-
					150	P	-	-	-
					154	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	-	-
					162	P	-	-	-
					164	P	-	-	-
					167	P	-	-	-
					170	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					180	P	-	-	-
					184	P	-	-	-
105536	T	27	DISCHARGE VOMITUS CONTAINING FOOD PARTIAL CAPSULE		141	P	-	-	-
					30	-	-	P	-
			EXCRETION DISCOLORED FECES RED IN COLOR		69	-	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 78

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105536	T	27	EXCRETION								
			FEW FECES				88	P	-	-	-
			LIQUID FECES				88	P	-	-	-
			NON-FORMED FECES				179	P	-	-	-
							183	P	-	-	-
			NORMAL								
			NO REMARKABLE OBSERVATIONS				1	P	-	-	-
							8	P	-	-	-
							15	P	-	-	-
							22	P	-	-	-
							29	P	-	-	-
							36	P	-	-	-
							43	P	-	-	-
							50	P	-	-	-
							57	P	-	-	-
							64	P	-	-	-
							71	P	-	-	-
							78	P	-	-	-
							85	P	-	-	-
							92	P	-	-	-
							99	P	-	-	-
							106	P	-	-	-
							113	P	-	-	-
							120	P	-	-	-
							134	P	-	-	-
							148	P	-	-	-
							155	P	-	-	-
							162	P	-	-	-
							169	P	-	-	-
							176	P	-	-	-
							184	P	-	-	P

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 79

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
I05536	T	27	QUALITATIVE FOOD CONSUMPTION LOW								
							3	P	-	-	-
							65	P	-	-	-
							72	P	-	-	-
							81	P	-	-	-
							88	P	-	-	-
							114	P	-	-	-
							117	P	-	-	-
							126	P	-	-	-
							127	P	-	-	-
							129	P	-	-	-
							130	P	-	-	-
							141	P	-	-	-
							149	P	-	-	-
							156	P	-	-	-
							157	P	-	-	-
							160	P	-	-	-
							160	P	-	-	-
							181	P	-	-	-
I05540	T	27	DISCHARGE VOMITUS INTACT CAPSULE				99	-	-	P	-
			EXCRETION DISCOLORED FECES RED IN COLOR				27	P	-	P	-
							28	P	-	P	-
			DISCOLORED URINE GREEN IN COLOR				71	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105540	T	27	EXCRETION						
			DISCOLORED URINE		72	P	-	-	-
			GREEN IN COLOR		28	P	-	-	-
			FEW FECES		29	P	-	-	-
			MUCOID FECES		28	-	-	P	-
					29	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			DORSAL		1	P	-	-	-
					141	-	-	P	-
			DORSAL-THORACIC		1	-	-	P	-
					2	P	-	P	-
					3	-	-	P	-
					5	-	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-
					15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 81

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA DORSAL-THORACIC				22	P	-	P	-
							23	P	-	P	-
							24	P	-	P	-
							25	P	-	P	-
							26	P	-	P	-
							27	P	-	P	-
							28	P	-	P	-
							29	P	-	P	-
							30	P	-	P	-
							31	P	-	P	-
							32	P	-	P	-
							33	P	-	P	-
							34	P	-	P	-
							35	P	-	P	-
							36	P	-	P	-
							37	P	-	P	-
							38	P	-	P	-
							39	P	-	P	-
							40	P	-	P	-
							41	P	-	P	-
							42	P	-	P	-
							43	P	-	P	-
							44	P	-	P	-
							45	P	-	P	-
							46	P	-	P	-
							47	P	-	P	-
							48	P	-	P	-
							49	P	-	P	-
							50	P	-	P	-
							51	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA DORSAL-THORACIC								
							142	P	-	P	-
							143	P	-	P	-
							146	P	-	P	-
							147	P	-	P	-
							148	P	-	P	-
							149	P	-	P	-
							150	P	-	P	-
							151	P	-	P	-
							152	P	-	P	-
							153	P	-	P	-
							154	P	-	P	-
							155	P	-	P	-
							156	P	-	P	-
							157	P	-	P	-
							158	P	-	P	-
							159	P	-	P	-
							160	P	-	P	-
							161	P	-	P	-
							162	P	-	P	-
							163	P	-	P	-
							164	P	-	P	-
							165	P	-	P	-
							166	P	-	P	-
							167	P	-	P	-
							168	P	-	P	-
							169	P	-	P	-
							170	P	-	P	-
							171	P	-	P	-
							172	P	-	P	-
							173	P	-	P	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 83

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105540	T	27	SKIN & PELAGE ALOPECIA						
			DORSAL-THORACIC		174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	P	-	P	-
					182	P	-	P	-
					183	P	-	P	-
					184	P	-	P	-
					185	P	-	-	P
			DORSAL-THORACIC-LEFT		57	-	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	P	-	P	-
					61	P	-	P	-
					62	P	-	P	-
					63	P	-	P	-
					64	P	-	P	-
					65	P	-	P	-
					66	P	-	P	-
					67	P	-	P	-
					68	P	-	P	-
					69	P	-	P	-
					70	P	-	P	-
					71	P	-	P	-
					72	P	-	P	-
					73	P	-	P	-
					74	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 84

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA DORSAL-THORACIC-LEFT								
						76	P	-	P	-	
						77	P	-	P	-	
						78	P	-	P	-	
						79	P	-	P	-	
						80	P	-	P	-	
						81	P	-	P	-	
						82	P	-	P	-	
						83	P	-	P	-	
						84	P	-	P	-	
						85	P	-	P	-	
						86	P	-	P	-	
						87	P	-	P	-	
						88	P	-	P	-	
						89	P	-	P	-	
						90	P	-	P	-	
						91	P	-	P	-	
						92	P	-	P	-	
						93	P	-	P	-	
						94	P	-	P	-	
						95	P	-	P	-	
						96	P	-	P	-	
						97	P	-	P	-	
						98	P	-	P	-	
						99	P	-	P	-	
						100	P	-	P	-	
						101	P	-	P	-	
						102	P	-	P	-	
						103	P	-	P	-	
						104	P	-	P	-	
						105	P	-	P	-	

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105540	T	27	SKIN & PELAGE ALOPECIA DORSAL-THORACIC-LEFT						
					106	P	-	P	-
					107	P	-	P	-
					108	P	-	P	-
					109	P	-	P	-
					110	P	-	P	-
					111	P	-	P	-
					112	P	-	P	-
					113	P	-	P	-
					114	P	-	P	-
					115	P	-	P	-
					117	P	-	P	-
					118	P	-	P	-
					119	P	-	P	-
					120	P	-	P	-
					121	P	-	P	-
					122	P	-	P	-
					123	P	-	P	-
					124	P	-	P	-
					125	P	-	P	-
					126	P	-	P	-
					127	P	-	P	-
					128	P	-	P	-
					129	-	-	P	-
					130	-	-	P	-
					131	-	-	P	-
					132	P	-	P	-
					133	P	-	P	-
					134	P	-	P	-
					135	P	-	P	-
					136	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 86

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105540	T	27	SKIN & PELAGE ALOPECIA						
			DORSAL-THORACIC-LEFT		137	P	-	P	-
					138	P	-	P	-
					139	P	-	P	-
					140	P	-	P	-
			HEAD-ENTIRE		1	P	-	P	-
					2	P	-	P	-
					3	P	-	P	-
					5	P	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-
					15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-
					22	P	-	P	-
					23	P	-	P	-
					24	P	-	P	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 87

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE								
			ALOPECIA				28	P	-	P	-
			HEAD-ENTIRE				29	P	-	P	-
							30	P	-	P	-
							31	P	-	P	-
							32	P	-	P	-
							33	P	-	P	-
							34	P	-	P	-
							35	P	-	P	-
							36	P	-	P	-
							37	P	-	P	-
							38	P	-	P	-
							39	P	-	P	-
							40	P	-	P	-
							41	P	-	P	-
			LIMB-HIND-LEFT				57	P	-	P	-
							58	P	-	P	-
							59	P	-	P	-
							60	P	-	P	-
							61	P	-	P	-
							62	P	-	P	-
							63	P	-	P	-
							64	P	-	P	-
							65	P	-	P	-
							66	P	-	P	-
							67	P	-	P	-
							68	P	-	P	-
							69	P	-	P	-
							70	P	-	P	-
							71	P	-	P	-
							72	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 88

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA								
			LIMB-HIND-LEFT				73	P	-	P	-
							74	P	-	P	-
							76	P	-	P	-
							77	P	-	P	-
							78	P	-	P	-
							79	P	-	P	-
							80	P	-	P	-
							81	P	-	P	-
							82	P	-	P	-
							83	P	-	P	-
							84	P	-	P	-
							85	P	-	P	-
							86	P	-	P	-
							87	P	-	P	-
							88	P	-	P	-
							89	P	-	P	-
							90	P	-	P	-
							91	P	-	P	-
							92	P	-	P	-
							93	P	-	P	-
							94	P	-	P	-
							95	P	-	P	-
							96	P	-	P	-
							97	P	-	P	-
							98	P	-	P	-
							99	P	-	P	-
							100	P	-	P	-
							101	-	-	P	-
							102	P	-	P	-
							103	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 89

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE								
			ALOPECIA				104	P	-	-	-
			LIMB-HIND-LEFT				42	P	-	P	-
			LIMBS-ALL				43	P	-	P	-
							44	-	-	P	-
							45	-	-	P	-
							46	P	-	P	-
							47	P	-	P	-
							48	-	-	P	-
							49	-	-	P	-
							50	P	-	P	-
							51	P	-	P	-
							52	P	-	P	-
							53	P	-	P	-
							54	P	-	P	-
							55	P	-	P	-
							56	P	-	-	-
							57	P	-	-	-
			LIMBS-FRONT				1	P	-	P	-
							2	P	-	P	-
							3	-	-	P	-
							5	-	-	P	-
							6	P	-	P	-
							7	P	-	P	-
							8	P	-	P	-
							9	P	-	P	-
							10	P	-	P	-
							11	P	-	P	-
							12	P	-	P	-
							13	P	-	P	-
							14	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 90

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA				15	P	-	P	-
			LIMBS-FRONT				16	P	-	P	-
							17	P	-	P	-
							18	P	-	P	-
							19	P	-	P	-
							20	P	-	P	-
							21	P	-	P	-
							22	P	-	P	-
							23	P	-	P	-
							24	P	-	P	-
							25	P	-	P	-
							26	P	-	P	-
							27	P	-	P	-
							28	P	-	P	-
							29	P	-	P	-
							30	P	-	P	-
							31	P	-	P	-
							32	P	-	P	-
							33	P	-	P	-
							34	P	-	P	-
							35	P	-	P	-
							36	P	-	P	-
							37	P	-	P	-
							38	P	-	P	-
							39	P	-	P	-
							40	P	-	P	-
							41	P	-	P	-
			TAIL				145	-	-	P	-
							146	P	-	P	-
							147	P	-	P	-



Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA TAIL								
							148	P	-	P	-
							149	P	-	P	-
							150	P	-	P	-
							151	P	-	P	-
							152	P	-	P	-
							153	P	-	P	-
							154	P	-	P	-
							155	P	-	P	-
							156	P	-	P	-
							157	P	-	P	-
							158	P	-	P	-
							159	P	-	P	-
							160	P	-	P	-
							161	P	-	P	-
							162	P	-	P	-
							163	P	-	P	-
							164	P	-	P	-
							165	P	-	P	-
							166	P	-	P	-
							167	P	-	P	-
							168	P	-	P	-
							169	P	-	P	-
							170	P	-	P	-
							171	P	-	P	-
							172	P	-	P	-
							173	P	-	P	-
							174	P	-	P	-
							175	P	-	P	-
							176	P	-	P	-
							177	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 92

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105540	T	27	SKIN & PELAGE ALOPECIA TAIL				178	P	-	P	-
							179	P	-	P	-
							180	P	-	P	-
							181	P	-	P	-
							182	P	-	P	-
							183	P	-	P	-
							184	P	-	P	-
							185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW				17	P	-	-	-
							20	P	-	-	-
							25	P	-	-	-
							27	P	-	-	-
							69	P	-	-	-
							71	P	-	-	-
							73	P	-	-	-
							74	P	-	-	-
							78	P	-	-	-
							80	P	-	-	-
							85	P	-	-	-
							87	P	-	-	-
							120	P	-	-	-
							132	P	-	-	-
							137	P	-	-	-
							141	P	-	-	-
							155	P	-	-	-
							179	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05542	U	79	DISCHARGE						
			VOMITUS						
			INTACT CAPSULE		136	P	-	P	-
			PARTIAL CAPSULE		65	-	-	P	-
					78	-	-	P	-
					126	-	-	P	-
					131	-	-	P	-
			APPEARS TO BE MENSTRUATING		71	P	-	P	-
					115	P	-	-	-
					161	P	-	-	-
			EXCRETION						
			FEW FECES		155	P	-	-	-
					161	P	-	-	-
					162	P	-	-	-
			SKIN & PELAGE						
			FALE SKIN						
			HEAD-ENTIRE		182	-	-	P	-
					183	P	-	-	-
					184	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					85	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 94

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105542	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		14	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					49	P	-	-	-
					57	P	-	-	-
					59	P	-	-	-
					60	P	-	-	-
					65	P	-	-	-
					78	P	-	-	-
					92	P	-	-	-
					98	P	-	-	-
					125	P	-	-	-
					134	P	-	-	-
					139	P	-	-	-
					141	P	-	-	-
					142	P	-	-	-
					143	P	-	-	-
					154	P	-	-	-
					155	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05542	U	79	QUALITATIVE FOOD CONSUMPTION LOW						
					161	P	-	-	-
					162	P	-	-	-
					175	P	-	-	-
I05551	T	27	DISCHARGE APPEARS TO BE MENSTRUATING						
					43	-	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					73	P	-	-	-
					74	P	-	P	-
					75	P	-	P	-
					76	P	-	P	-
					80	P	-	-	-
					112	P	-	P	-
					113	P	-	P	-
					137	-	-	P	-
					138	P	-	P	-
					139	P	-	P	-
					140	P	-	P	-
					141	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	-	-
			EXCRETION						
			FEW FECES		161	P	-	-	-
			SMALL FECES		49	P	-	P	-
			SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL		1	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL								
							2	P	-	P	-
							3	-	-	P	-
							4	-	-	P	-
							5	-	-	P	-
							6	P	-	P	-
							7	P	-	P	-
							8	P	-	P	-
							9	P	-	P	-
							10	P	-	P	-
							11	P	-	P	-
							12	P	-	P	-
							13	P	-	P	-
							14	P	-	P	-
							15	P	-	P	-
							16	P	-	P	-
							17	P	-	P	-
							18	P	-	P	-
							19	P	-	P	-
							20	P	-	P	-
							21	P	-	P	-
							22	P	-	P	-
							23	P	-	P	-
							24	P	-	P	-
							25	P	-	P	-
							26	P	-	P	-
							27	P	-	P	-
							28	P	-	P	-
							29	P	-	P	-
							30	P	-	P	-
							31	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL				32	P	-	P	-
							33	P	-	P	-
							34	P	-	P	-
							35	P	-	P	-
							36	P	-	P	-
							37	P	-	P	-
							38	P	-	P	-
							39	P	-	P	-
							40	P	-	P	-
							41	P	-	P	-
							42	P	-	P	-
							43	P	-	P	-
							44	-	-	P	-
							45	-	-	P	-
							46	P	-	P	-
							47	P	-	P	-
							48	-	-	P	-
							49	P	-	P	-
							50	P	-	P	-
							51	P	-	P	-
							52	P	-	P	-
							53	P	-	P	-
							54	P	-	P	-
							55	P	-	P	-
							56	P	-	P	-
							57	P	-	P	-
							58	P	-	P	-
							59	P	-	P	-
							60	P	-	P	-
							61	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL				62	P	-	P	-
							63	P	-	P	-
							64	P	-	P	-
							65	P	-	P	-
							66	P	-	P	-
							67	P	-	P	-
							68	P	-	P	-
							69	P	-	P	-
							70	P	-	P	-
							71	P	-	P	-
							72	P	-	P	-
							73	P	-	P	-
							74	P	-	P	-
							75	P	-	P	-
							76	P	-	P	-
							77	P	-	P	-
							78	P	-	P	-
							79	P	-	P	-
							80	P	-	P	-
							81	P	-	P	-
							82	P	-	P	-
							83	P	-	P	-
							84	P	-	P	-
							85	P	-	P	-
							86	P	-	P	-
							87	P	-	P	-
							88	P	-	P	-
							89	P	-	P	-
							90	P	-	P	-
							91	P	-	P	-



Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL				92	P	-	P	-
							93	P	-	P	-
							94	P	-	P	-
							95	P	-	P	-
							96	P	-	P	-
							97	P	-	P	-
							98	P	-	P	-
							99	P	-	P	-
							100	P	-	P	-
							101	-	-	P	-
							102	P	-	P	-
							103	P	-	P	-
							104	P	-	P	-
							105	P	-	P	-
							106	P	-	P	-
							107	P	-	P	-
							108	P	-	P	-
							109	P	-	P	-
							110	P	-	P	-
							111	P	-	P	-
							112	P	-	P	-
							113	P	-	P	-
							114	P	-	P	-
							115	P	-	P	-
							116	-	-	P	-
							117	P	-	P	-
							118	P	-	P	-
							119	P	-	P	-
							120	P	-	P	-
							121	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 100

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL								
							122	P	-	P	-
							123	P	-	P	-
							124	P	-	P	-
							125	P	-	P	-
							126	P	-	P	-
							127	P	-	P	-
							128	P	-	P	-
							129	P	-	P	-
							130	-	-	P	-
							131	-	-	P	-
							132	P	-	P	-
							133	P	-	P	-
							134	P	-	P	-
							135	P	-	P	-
							136	P	-	P	-
							137	P	-	P	-
							138	P	-	P	-
							139	P	-	P	-
							140	P	-	P	-
							141	-	-	P	-
							142	P	-	P	-
							143	P	-	P	-
							144	-	-	P	-
							145	-	-	P	-
							146	P	-	P	-
							147	P	-	P	-
							148	P	-	P	-
							149	P	-	P	-
							150	P	-	P	-
							151	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

PAGE: 101

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL						
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	P	-
					155	P	-	P	-
					156	P	-	P	-
					157	P	-	P	-
					158	P	-	P	-
					159	P	-	P	-
					160	P	-	P	-
					161	P	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	P	-	P	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)										
105551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL			182	P	-	P	-
						183	P	-	P	-
						184	P	-	P	-
						185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION LOW			72	P	-	-	-
						85	P	-	-	-
						102	P	-	-	-
						146	P	-	-	-
						162	P	-	-	-

Appendix 2

Individual Clinical Observations  
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 103

---

ANIMAL	GROUP	STUDY DAY WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05534	F4	9 2 TO 15 3	SKIN & PELAGE OTHER	BRUISED SKIN PERI-ORBITAL LEFT EYE.

---



Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 186-365	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05520	O	79	QUALITATIVE FOOD CONSUMPTION LOW		273	P	-	-	-
I05526	O	79	NORMAL NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 186-365	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05505	6	81	EXCRETION NON-FORMED FECES		191	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-



Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 186-365	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05505	6	81	QUALITATIVE FOOD CONSUMPTION LOW		240	P	-	-	-
I05523	6	81	NORMAL NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL DEATH WK OF CATEGORY GROUP: M3 DOSE: 0.15 MG/KG/DAY 'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP  
NUMBER CODE DEATH KEYWORD QUALIFIER DAYS 186-365 DAY AM OBS UNSCHED 30-90 OB DISPATCH  
-----  
(CONTINUED FROM PREVIOUS PAGE)

105523 6 81

QUALITATIVE FOOD CONSUMPTION  
LOW

247 P - - -

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP							
						AM OBS	UNSCHED	30-90 OB	DISPATCH				
I05511	U	79	NORMAL NO REMARKABLE OBSERVATIONS										
					190	P	-	-	-				
					197	P	-	-	-				
					204	P	-	-	-				
					211	P	-	-	-				
					218	P	-	-	-				
					225	P	-	-	-				
					232	P	-	-	-				
					239	P	-	-	-				
					246	P	-	-	-				
					253	P	-	-	-				
					260	P	-	-	-				
					267	P	-	-	-				
					274	P	-	-	-				
					281	P	-	-	-				
					288	P	-	-	-				
					295	P	-	-	-				
					302	P	-	-	-				
					309	P	-	-	-				
					316	P	-	-	-				
					323	P	-	-	-				
					330	P	-	-	-				
					337	P	-	-	-				
					344	P	-	-	-				
					351	P	-	-	-				
					358	P	-	-	-				
					365	P	-	-	-				
			QUALITATIVE FOOD CONSUMPTION LOW		255	P	-	-	-				

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
I05522	U	79	NORMAL NO REMARKABLE OBSERVATIONS							
					190	P	-	-	-	
					197	P	-	-	-	
					204	P	-	-	-	
					211	P	-	-	-	
					218	P	-	-	-	
					225	P	-	-	-	
					232	P	-	-	-	
					239	P	-	-	-	
					246	P	-	-	-	
					253	P	-	-	-	
					260	P	-	-	-	
					267	P	-	-	-	
					274	P	-	-	-	
					281	P	-	-	-	
					288	P	-	-	-	
					295	P	-	-	-	
					302	P	-	-	-	
					309	P	-	-	-	
					316	P	-	-	-	
					323	P	-	-	-	
					330	P	-	-	-	
					337	P	-	-	-	
					344	P	-	-	-	
					351	P	-	-	-	
					358	P	-	-	-	
					365	P	-	-	-	

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 186-365	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCHED	30-90 OB	DISPATCH	
I05529	P	79	EXCRETION LIQUID FECES							
					277	P	-	-	-	
					278	P	-	-	-	
					306	P	-	-	-	
					308	P	-	-	-	
			SKIN & PELAGE ALOPECIA FEET							
					186	P	-	-	-	
					187	P	-	-	-	
					188	P	-	-	-	
					189	P	-	-	-	
					190	P	-	-	-	
					191	P	-	-	-	
					192	P	-	-	-	
					193	P	-	-	-	
					194	P	-	-	-	
					195	P	-	-	-	
					197	P	-	-	-	
					200	P	-	-	-	
					201	P	-	-	-	
					203	P	-	-	-	
					204	P	-	-	-	
					206	P	-	-	-	
					210	P	-	-	-	
					211	P	-	-	-	
					213	P	-	-	-	
					216	P	-	-	-	
					217	P	-	-	-	
					218	P	-	-	-	
					219	P	-	-	-	
					220	P	-	-	-	

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105529	P	79	SKIN & PELAGE ALOPECIA FBET				221	P	-	-	-
							222	P	-	-	-
							223	P	-	-	-
							225	P	-	-	-
							226	P	-	-	-
							229	P	-	-	-
							230	P	-	-	-
							231	P	-	-	-
							232	P	-	-	-
							233	P	-	-	-
							234	P	-	-	-
							235	P	-	-	-
							236	P	-	-	-
							237	P	-	-	-
							238	P	-	-	-
							239	P	-	-	-
							240	P	-	-	-
							241	P	-	-	-
							244	P	-	-	-
							245	P	-	-	-
							246	P	-	-	-
							247	P	-	-	-
							248	P	-	-	-
							251	P	-	-	-
							252	P	-	-	-
							253	P	-	-	-
							254	P	-	-	-
							255	P	-	-	-
							257	P	-	-	-
							258	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105529	F	79	SKIN & PELAGE ALOPECIA FBET				259	P	-	-	-
							260	P	-	-	-
							261	P	-	-	-
							263	P	-	-	-
							264	P	-	-	-
							265	P	-	-	-
							266	P	-	-	-
							267	P	-	-	-
							268	P	-	-	-
							269	P	-	-	-
							272	P	-	-	-
							273	P	-	-	-
							274	P	-	-	-
							275	P	-	-	-
							276	P	-	-	-
							277	P	-	-	-
							278	P	-	-	-
							279	P	-	-	-
							280	P	-	-	-
							281	P	-	-	-
							288	P	-	-	-
							289	P	-	-	-
							294	P	-	-	-
							295	P	-	-	-
							298	P	-	-	-
							301	P	-	-	-
							302	P	-	-	-
							305	P	-	-	-
							306	P	-	-	-
							308	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH NUMBER	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
							AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)										
105529	F	79 SKIN & PELAGE ALOPECIA								
		FBET				309	P	-	-	-
						310	P	-	-	-
						311	P	-	-	-
						314	P	-	-	-
		TAIL				186	P	-	-	-
						187	P	-	-	-
						188	P	-	-	-
						189	P	-	-	-
						190	P	-	-	-
						191	P	-	-	-
						192	P	-	-	-
						193	P	-	-	-
						194	P	-	-	-
						195	P	-	-	-
						197	P	-	-	-
						200	P	-	-	-
						201	P	-	-	-
						203	P	-	-	-
						204	P	-	-	-
						206	P	-	-	-
						210	P	-	-	-
						211	P	-	-	-
						213	P	-	-	-
						216	P	-	-	-
						217	P	-	-	-
						218	P	-	-	-
						219	P	-	-	-
						220	P	-	-	-
						221	P	-	-	-
						222	P	-	-	-



Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105529	P	79	SKIN & PELAGE ALOPECIA TAIL				223	P	-	-	-
							225	P	-	-	-
							226	P	-	-	-
							229	P	-	-	-
							230	P	-	-	-
							231	P	-	-	-
							232	P	-	-	-
							233	P	-	-	-
							234	P	-	-	-
							235	P	-	-	-
							236	P	-	-	-
							237	P	-	-	-
							238	P	-	-	-
							239	P	-	-	-
							240	P	-	-	-
							241	P	-	-	-
							244	P	-	-	-
							245	P	-	-	-
							246	P	-	-	-
							247	P	-	-	-
			NORMAL				316	P	-	-	-
			NO REMARKABLE OBSERVATIONS				323	P	-	-	-
							330	P	-	-	-
							337	P	-	-	-
							344	P	-	-	-
							351	P	-	-	-
							358	P	-	-	-
							365	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 186-365	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	QUALITATIVE FOOD CONSUMPTION LOW						
					195	P	-	-	-
					210	P	-	-	-
					247	P	-	-	-
					248	P	-	-	-
					260	P	-	-	-
					272	P	-	-	-
					273	P	-	-	-
					294	P	-	-	-
I05549	P	79	DISCHARGE APPEARS TO BE MENSTRUATING		261	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 186-365	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105549	P	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		195	P	-	-	-
					231	P	-	-	-
					248	P	-	-	-
					272	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DAYS 186-365	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05539	6	81	DISCHARGE APPEARS TO BE MENSTRUATING		216 217 246 275	P P P P	- - - -	- - - -	- - - -
			EXCRETION FEW FECES		191 195	P P	- -	- -	- -
			NORMAL NO REMARKABLE OBSERVATIONS		190 197 204 211 218 225 232 239 253 260 267 274 281 288 295 302 309 316 323 330 337	P P	- -	- -	

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK	OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 186-365	DAY					
(CONTINUED FROM PREVIOUS PAGE)										
I05539	6	81	NORMAL							
			NO REMARKABLE OBSERVATIONS		344	P	-	-	-	-
					351	P	-	-	-	-
					358	P	-	-	-	-
					365	P	-	-	-	-
			QUALITATIVE FOOD CONSUMPTION							
			LOW		191	P	-	-	-	-
					195	P	-	-	-	-
					213	P	-	-	-	-
					218	P	-	-	-	-
					251	P	-	-	-	-
					254	P	-	-	-	-
					259	P	-	-	-	-
					269	P	-	-	-	-
					316	P	-	-	-	-
					346	P	-	-	-	-
I05552	6	81	NORMAL							
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-	-
					197	P	-	-	-	-
					204	P	-	-	-	-
					211	P	-	-	-	-
					218	P	-	-	-	-
					225	P	-	-	-	-
					232	P	-	-	-	-
					239	P	-	-	-	-
					246	P	-	-	-	-
					253	P	-	-	-	-
					260	P	-	-	-	-
					267	P	-	-	-	-
					274	P	-	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK	OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
							AM OBS	UNCHED	30-90 OB	DISPATCH
NUMBER	CODE	DEATH	QUALIFIER	DAYS 186-365	DAY					
(CONTINUED FROM PREVIOUS PAGE)										
105552	6	81	NORMAL							
			NO REMARKABLE OBSERVATIONS		281	P	-	-	-	-
					288	P	-	-	-	-
					295	P	-	-	-	-
					302	P	-	-	-	-
					309	P	-	-	-	-
					316	P	-	-	-	-
					323	P	-	-	-	-
					330	P	-	-	-	-
					337	P	-	-	-	-
					344	P	-	-	-	-
					351	P	-	-	-	-
					358	P	-	-	-	-
					365	P	-	-	-	-
			QUALITATIVE FOOD CONSUMPTION							
			LOW		220	P	-	-	-	-
					343	P	-	-	-	-
					344	P	-	-	-	-
					346	P	-	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05533	U	79	EXCRETION NON-FORMED FECES		245	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05533	U	79							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		241	P	-	-	-
					244	P	-	-	-
					343	P	-	-	-
I05542	U	79	DISCHARGE						
			APPEARS TO BE MENSTRUATING		260	P	-	-	-
					299	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-



Appendix 2

Individual Clinical Observations  
Recovery (Days 186 through 365)

PAGE: 20

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105542	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		269	P	-	-	-
					273	P	-	-	-
					275	P	-	-	-
					281	P	-	-	-
					302	P	-	-	-
					343	P	-	-	-
					344	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCH	EXTRA	DISPATCH	
I05520	0	79	EXCRETION							
			NON-FORMED FECES		533	P	-	-	-	
					534	P	-	-	-	
			NORMAL		372	P	-	-	-	
			NO REMARKABLE OBSERVATIONS		379	P	-	-	-	
					386	P	-	-	-	
					393	P	-	-	-	
					400	P	-	-	-	
					407	P	-	-	-	
					414	P	-	-	-	
					421	P	-	-	-	
					428	P	-	-	-	
					435	P	-	-	-	
					442	P	-	-	-	
					449	P	-	-	-	
					456	P	-	-	-	
					463	P	-	-	-	
					470	P	-	-	-	
					477	P	-	-	-	
					484	P	-	-	-	
		491	P	-	-	-				
		498	P	-	-	-				
		505	P	-	-	-				
		512	P	-	-	-				
		519	P	-	-	-				
		526	P	-	-	-				
		540	P	-	-	-				
		547	P	-	-	-				

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05520	O	79	QUALITATIVE FOOD CONSUMPTION LOW		541	P	-	-	-
I05526	O	79	DISCHARGE VOMITUS CONTAINING FOOD		535	P	-	-	-
					541	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105526	0	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCH	EXTRA	DISPATCH	
I05505	6	81	APPEARANCE SWOLLEN HEAD-MAXILLARY-RIGHT			390	P	-	-	-
						391	P	-	-	-
						393	P	-	-	-
						394	P	-	-	-
						395	P	-	-	-
						397	P	-	-	-
						400	P	-	-	-
			DISCHARGE VOMITUS CONTAINING FOOD			535	P	-	-	-
			EXCRETION FEW FECES			555	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS			372	P	-	-	-
						379	P	-	-	-
						386	P	-	-	-
						407	P	-	-	-
						414	P	-	-	-
						421	P	-	-	-
						428	P	-	-	-
						435	P	-	-	-
						442	P	-	-	-
						449	P	-	-	-
						456	P	-	-	-
						463	P	-	-	-
						470	P	-	-	-
						477	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK OF CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05505	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		375	P	-	-	-
					376	P	-	-	-
					555	P	-	-	-
I05523	6	81	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		535	P	-	-	-
			EKCRETION						
			NO FECEs		555	P	-	-	-
					556	P	-	-	-
			NON-FORMED FECEs		557	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105523	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		375	P	-	-	-
					379	P	-	-	-
					553	P	P	-	-
					555	P	-	-	-
					558	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
						AM OBS	UNSCH	EXTRA	DISPATCH	
I05511	U	79	NORMAL NO REMARKABLE OBSERVATIONS							
					372	P	-	-	-	
					379	P	-	-	-	
					386	P	-	-	-	
					393	P	-	-	-	
					400	P	-	-	-	
					407	P	-	-	-	
					414	P	-	-	-	
					421	P	-	-	-	
					428	P	-	-	-	
					435	P	-	-	-	
					442	P	-	-	-	
					449	P	-	-	-	
					456	P	-	-	-	
					463	P	-	-	-	
					470	P	-	-	-	
					477	P	-	-	-	
					484	P	-	-	-	
					491	P	-	-	-	
					498	P	-	-	-	
					505	P	-	-	-	
					512	P	-	-	-	
					519	P	-	-	-	
					526	P	-	-	-	
					533	P	-	-	-	
					540	P	-	-	-	
					547	P	-	-	-	
					549	P	-	-	-	P



Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05522	U	79	EXCRETION NON-FORMED FECES		402	P	-	-	-
					403	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					549	P	-	-	P

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - AM OBS	COMMENTS LISTED AT END OF OBSERVATIONS	UNSCH	EXTRA	DISPATCH	FOR SEX/GROUP
(CONTINUED FROM PREVIOUS PAGE)											
I05522	U	79					QUALITATIVE FOOD CONSUMPTION LOW				
					394	P		-	-	-	

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05529	P	79	EXCRETION LIQUID FECES		489	P	-	-	-
					491	P	-	-	-
					492	P	-	-	-
					493	P	-	-	-
					494	P	-	-	-
			NON-FORMED FECES		496	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			LIMB-HIND-RIGHT		368	P	-	-	-
					369	P	-	-	-
					372	P	-	-	-
					376	P	-	-	-
					377	P	-	-	-
					378	P	-	-	-
					549	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION LOW		372	P	-	-	-
					376	P	-	-	-
					452	P	-	-	-
I05549	P	79	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		535	P	-	-	-
			APPEARS TO BE MENSTRUATING		372	P	-	-	-
					400	P	-	-	-
					456	P	-	-	-
					484	P	-	-	-
					541	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					407	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P1	DOSE: 0 MG/KG/DAY	DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
								AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
105549	P	79	NORMAL								
			NO REMARKABLE OBSERVATIONS				414	P	-	-	-
							421	P	-	-	-
							428	P	-	-	-
							435	P	-	-	-
							442	P	-	-	-
							449	P	-	-	-
							463	P	-	-	-
							470	P	-	-	-
							477	P	-	-	-
							491	P	-	-	-
							498	P	-	-	-
							505	P	-	-	-
							512	P	-	-	-
							519	P	-	-	-
							526	P	-	-	-
							533	P	-	-	-
							540	P	-	-	-
							547	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION								
			LOW				372	P	-	-	-
							452	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05539	6	81	DISCHARGE UNKNOWN SOURCE FOUND IN PAN RED IN COLOR		555 556	P P	- -	- -	- -
			EXCRETION FEW FECES		404	P	-	-	-
			NO FECES		558 555 556 557	P P P P	- - - -	- - - -	- - - -
			NORMAL NO REMARKABLE OBSERVATIONS		372 379 386 393 400 407 414 421 428 435 442 449 456 463 470 477 484 491 498	P P P P P P P P P P P P P P P P P P	- - - - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - - - -

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH WK	OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' AM OBS	COMMENTS UNSCH	LISTED AT END OF OBSERVATIONS EXTRA	FOR SEX/GROUP DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05539	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		375	P	-	-	-
					376	P	-	-	-
					399	P	-	-	-
					404	P	-	-	-
					407	P	-	-	-
					553	P	P	-	-
					556	P	-	-	-
					557	P	-	-	-
					558	P	-	-	-
			NONE		555	P	-	-	-
I05552	6	81	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		535	P	-	-	-
			EXCRETION						
			FEW FECES		555	P	-	-	-
					557	P	-	-	-
					558	P	-	-	-
			NO FECES		556	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105552	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS			372	P	-	-
						379	P	-	-
						386	P	-	-
						393	P	-	-
						400	P	-	-
						407	P	-	-
						414	P	-	-
						421	P	-	-
						428	P	-	-
						435	P	-	-
						442	P	-	-
						449	P	-	-
						456	P	-	-
						463	P	-	-
						470	P	-	-
						477	P	-	-
						484	P	-	-
						491	P	-	-
						498	P	-	-
						505	P	-	-
						512	P	-	-
						519	P	-	-
						526	P	-	-
						533	P	-	-
						540	P	-	-
						547	P	-	-
						554	P	-	-



Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY	'C' - AM OBS	COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP		
							UNSCHEMATED	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
105552	6	81							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		372	P	-	-	-
					557	P	-	-	-
					558	P	-	-	-
			NONE		555	P	-	-	-
					556	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05533	U	79	EXCRETION						
			LIQUID FECES		399	P	-	-	-
					400	P	-	-	-
			NON-FORMED FECES		402	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					366	P	-	-	-
					393	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					549	P	-	-	P

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05533	U	79	QUALITATIVE FOOD CONSUMPTION LOW		394	P	-	-	-
I05542	U	79	DISCHARGE APPEARS TO BE MENSTRUATING		496	P	-	-	-
			DISCHARGE UNKNOWN SOURCE FOUND IN PAN RED IN COLOR		375	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-

Appendix 2

Individual Clinical Observations  
Recovery (Days 366 through 561)

PAGE: 19

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - AM OBS	COMMENTS UNSCH	LISTED AT END OF OBSERVATIONS EXTRA	DISPATCH	FOR SEX/GROUP
(CONTINUED FROM PREVIOUS PAGE)										
105542	U	79	NORMAL							
			NO REMARKABLE OBSERVATIONS			505	P	-	-	-
						512	P	-	-	-
						519	P	-	-	-
						526	P	-	-	-
						533	P	-	-	-
						540	P	-	-	-
						547	P	-	-	-
						549	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION							
			LOW			375	P	-	-	-
						394	P	-	-	-
						395	P	-	-	-

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05508	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05517	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05519	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05520	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05526	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05527	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05514	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05515	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05516	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05521	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3	DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05510	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05518	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05523	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05524	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05528	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05506	M	26	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05507	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05509	D	23	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4
I05511	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05512	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05522	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26



Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYE-LEFT EYES			-4 26
			MISCELLANEOUS OPHTHALMICS INCREASED MYELINATION OF OPTIC NERVE EYE-RIGHT			-4
I05530	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05531	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05535	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05544	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05549	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2	DOSE: 0.03 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05537	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05541	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05547	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05550	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Treatment

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: P3	DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05532	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05538	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05539	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05545	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05548	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05552	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2  
Individual Ophthalmic Observations  
Treatment

PAGE: 8

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05534	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05536	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05540	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05542	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05551	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations  
Recovery

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05520	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05526	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

Appendix 2

Individual Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

---

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3	DOSE: 0.15 MG/KG/DAY	WEEK 52	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	
I05523	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	

---

Appendix 2

Individual Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

---

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	WEEK 52	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05511	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	
I05522	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	

---

Appendix 2

Individual Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYE-LEFT			52
			MISCELLANEOUS OPHTHALMICS OTHER EYE-RIGHT			52C
I05549	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52



Appendix 2

Individual Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

---

ANIMAL	GROUP	STUDY DAY WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05529	F1	363 52	MISCELLANEOUS OPHTHALMICS OTHER EYE-RIGHT	INCREASED MYELINATION OF OPTIC NERVE HEAD THAT MAY BE ASSOCIATED WITH OPTIC NEURITIS. MACULA NORMAL.

---

Appendix 2

Individual Ophthalmic Observations  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3	DOSE: 0.15 MG/KG/DAY	WEEK 52	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05539	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	
I05552	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	

Appendix 2

Individual Ophthalmic Observations  
Recovery

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

---

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	WEEK 52	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	
I05542	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52	

---

**APPENDIX 3**

Individual Body Weight Data (kg)

Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	WEEK <sup>a</sup> -1	WEEK <sup>b</sup> -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.0	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2
I05517	3.4	3.4	3.4	3.3	3.2	3.2	3.3	3.3	3.3	3.3
I05519	2.9	3.0	3.0	3.0	3.0	3.1	3.1	3.0	3.0	3.1
I05520	2.9	2.9	2.9	2.9	3.0	3.1	3.0	3.0	2.9	3.0
I05526	3.0	3.0	3.0	3.1	3.2	3.3	3.3	3.3	3.3	3.3
I05527	4.0	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.1	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3
I05515	3.3	3.3	3.3	3.2	3.3	3.4	3.4	3.5	3.4	3.4
I05516	2.7	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9
I05521	4.4	4.3	4.4	4.3	4.4	4.4	4.4	4.4	4.4	4.4
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.1	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.2
I05510	2.9	3.0	2.9	2.9	2.9	3.0	3.0	3.0	3.1	3.1
I05518	3.0	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2
I05523	2.6	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
I05524	2.9	2.9	2.9	3.0	3.1	3.1	3.1	3.1	3.1	3.0
I05528	3.6	3.7	3.7	3.7	3.7	3.8	3.8	3.8	3.8	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.3	3.4	3.4	3.4	3.5	3.5	3.6	3.7	3.7	3.7
I05507	4.4	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.6
I05509	3.1	3.2	3.2	3.1	3.2	3.2	3.3	3.3	3.2	3.2
I05511	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.8
I05512	2.8	2.9	2.9	2.8	2.9	3.0	3.0	3.0	3.1	3.0
I05522	3.4	3.4	3.4	3.4	3.5	3.6	3.6	3.6	3.6	3.6

a Day -7.  
b Day -1.

Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	WEEK <sup>a</sup> -1	WEEK <sup>b</sup> -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.5	2.5	2.7	2.3	2.4	2.4	2.4	2.4	2.4
I05530	2.9	2.9	2.9	2.8	2.9	2.9	2.7	2.7	2.8	2.8
I05531	2.6	2.6	2.6	2.6	2.6	2.7	2.6	2.6	2.7	2.6
I05535	3.4	3.3	3.3	3.3	3.4	3.4	3.4	3.4	3.5	3.5
I05544	2.6	2.7	2.7	2.6	2.6	2.7	2.7	2.6	2.6	2.6
I05549	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY										
I05537	3.8	3.8	3.9	3.9	3.9	4.0	3.9	3.9	4.0	4.0
I05541	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6
I05547	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
I05550	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05532	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05538	3.2	3.2	3.2	3.1	3.1	3.0	3.0	3.0	3.0	3.0
I05539	3.6	3.7	3.7	3.8	3.8	3.8	3.8	3.9	3.9	3.9
I05545	2.6	2.6	2.6	2.7	2.7	2.7	2.6	2.6	2.6	2.6
I05548	2.8	2.9	2.9	3.0	2.9	3.0	3.0	3.0	3.0	3.0
I05552	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.7
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.6	2.6	2.6	2.6	2.6	2.6	2.5	2.6	2.6	2.5
I05534	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05536	3.9	3.9	3.9	3.8	3.8	3.9	3.9	3.9	3.8	3.8
I05540	2.9	3.0	3.0	3.1	3.1	2.8	2.6	2.6	2.8	2.9
I05542	2.8	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05551	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.3	2.4	2.4

a Day -7.  
b Day -1.

Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4	3.4
I05517	3.4	3.3	3.3	3.3	3.3	3.3	3.3	3.1	3.3	3.3
I05519	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.3	3.2
I05520	3.0	3.0	3.1	3.0	3.0	3.1	3.0	3.0	3.0	3.0
I05526	3.4	3.4	3.5	3.5	3.6	3.5	3.6	3.6	3.7	3.7
I05527	4.2	4.2	4.3	4.3	4.3	4.3	4.3	4.3	4.4	4.4
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.3	3.3	3.4	3.4	3.4	3.4	3.5	3.5	3.6	3.5
I05515	3.5	3.5	3.6	3.7	3.7	3.6	3.6	3.7	3.8	3.7
I05516	3.0	3.0	3.0	3.0	3.1	3.2	3.2	3.2	3.3	3.2
I05521	4.4	4.4	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.2	3.3	3.3	3.3	3.2	3.3	3.3	3.3	3.3
I05510	3.1	3.1	3.2	3.2	3.3	3.1	3.2	3.2	3.3	3.3
I05518	3.3	3.2	3.2	3.3	3.3	3.2	3.2	3.3	3.3	3.3
I05523	2.8	2.7	2.8	2.8	2.9	2.9	2.9	2.9	3.0	2.9
I05524	3.2	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.0	3.2
I05528	3.7	3.7	3.8	3.7	3.7	3.8	3.8	3.7	3.7	3.6
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.8	3.7	3.9	3.8	3.9	3.8	3.9	3.9	4.0	3.9
I05507	4.7	4.6	4.7	4.7	4.7	4.6	4.6	4.5	4.6	4.5
I05509	3.2	3.2	3.2	3.2	3.2	3.1	3.1	3.0	3.1	3.0
I05511	2.9	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.7	2.8
I05512	3.1	3.0	3.1	3.1	3.1	2.9	2.9	2.7	2.8	2.8
I05522	3.6	3.6	3.7	3.6	3.7	3.7	3.7	3.6	3.7	3.7

Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.5	2.5	2.6	2.6	2.6	2.4	2.5	2.5	2.5
I05530	2.9	2.9	3.0	3.1	3.0	3.0	3.0	3.0	3.0	3.0
I05531	2.7	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05535	3.6	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6	3.6
I05544	2.6	2.7	2.7	2.7	2.8	2.7	2.7	2.8	2.8	2.7
I05549	3.0	3.0	2.9	3.0	3.0	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY										
I05537	4.1	4.0	4.0	4.0	4.1	4.1	4.1	4.1	4.2	4.2
I05541	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.6	2.7
I05547	3.0	3.0	3.0	3.1	3.1	3.1	3.0	3.0	3.0	3.0
I05550	2.9	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05532	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.8
I05538	3.0	3.0	3.2	3.2	3.3	3.2	3.3	3.3	3.4	3.4
I05539	3.9	3.9	3.9	3.9	3.9	4.0	4.0	3.9	3.9	3.9
I05545	2.6	2.7	2.7	2.6	2.6	2.7	2.7	2.7	2.7	2.6
I05548	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.0	3.1	3.0
I05552	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.6	2.6	2.6	2.7	2.7	2.6	2.6	2.6	2.7	2.6
I05534	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
I05536	3.9	3.9	3.8	3.8	3.7	3.6	3.5	3.4	3.7	3.6
I05540	3.1	3.0	2.8	2.8	2.8	2.7	2.9	3.0	3.1	3.1
I05542	2.8	2.7	2.7	2.7	2.7	2.7	2.6	2.6	2.8	2.7
I05551	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.3	2.4	2.3



Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: MALE 1 - 0 MG/KG/DAY									
I05508	3.4	3.4	3.4	3.4	3.4	3.4	3.6	3.6	3.6
I05517	3.4	3.4	3.3	3.3	3.3	3.4	3.4	3.3	3.3
I05519	3.3	3.2	3.2	3.2	3.3	3.3	3.4	3.4	3.4
I05520	3.1	3.0	3.1	3.1	3.1	3.0	3.2	3.2	3.1
I05526	3.7	3.7	3.7	3.8	3.7	3.7	3.8	3.9	3.8
I05527	4.5	4.5	4.6	4.6	4.7	4.8	4.9	5.0	5.0
GROUP: MALE 2 - 0.03 MG/KG/DAY									
I05514	3.6	3.6	3.6	3.6	3.7	3.7	3.8	3.8	3.8
I05515	3.8	3.8	3.6	3.7	3.7	3.7	3.8	3.8	3.7
I05516	3.2	3.2	3.2	3.3	3.3	3.3	3.4	3.4	3.4
I05521	4.6	4.6	4.7	4.6	4.6	4.7	4.7	4.7	4.7
GROUP: MALE 3 - 0.15 MG/KG/DAY									
I05505	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.3	3.2
I05510	3.3	3.3	3.2	3.3	3.3	3.4	3.5	3.4	3.4
I05518	3.3	3.3	3.2	3.3	3.3	3.3	3.3	3.4	3.3
I05523	3.0	3.0	2.9	2.9	2.9	2.9	3.1	3.0	2.9
I05524	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.4	3.3
I05528	3.6	3.7	3.7	3.7	3.7	3.7	3.7	3.6	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY									
I05506	4.0	4.0	3.9	3.9	3.9	4.0	4.0	3.9	
I05507	4.5	4.4	4.3	4.2	4.2	4.1	4.2	4.2	4.2
I05509	3.0	3.1	2.9	3.0	2.8				
I05511	2.9	2.8	2.6	2.7	2.7	2.8	2.7	2.6	2.5
I05512	2.6	2.5	2.6	2.7	2.8	2.7	2.6	2.7	2.5
I05522	3.7	3.6	3.6	3.6	3.6	3.6	3.7	3.7	3.5

Appendix 3

Individual Body Weight Data (kg)  
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: FEMALE 1 - 0 MG/KG/DAY									
I05529	2.5	2.5	2.5	2.5	2.5	2.6	2.5	2.5	2.4
I05530	3.0	3.0	2.9	3.0	3.0	3.0	3.1	3.0	3.0
I05531	2.8	2.8	2.7	2.8	2.7	2.7	2.8	2.8	2.9
I05535	3.5	3.5	3.5	3.6	3.4	3.5	3.6	3.6	3.5
I05544	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9
I05549	3.1	3.1	3.0	3.1	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY									
I05537	4.2	4.2	4.2	4.2	4.2	4.3	4.4	4.4	4.3
I05541	2.7	2.7	2.6	2.7	2.8	2.7	2.8	2.8	2.8
I05547	3.1	3.0	3.0	2.9	2.8	2.7	2.8	2.7	2.8
I05550	3.0	3.0	2.9	3.0	2.9	3.0	3.1	3.0	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY									
I05532	2.8	2.8	2.7	2.8	2.8	2.8	2.8	2.8	2.7
I05538	3.4	3.4	3.3	3.5	3.5	3.4	3.5	3.4	3.5
I05539	4.0	4.0	3.8	3.8	3.8	3.9	3.9	3.9	3.9
I05545	2.7	2.8	2.6	2.7	2.6	2.7	2.7	2.7	2.7
I05548	3.1	3.1	3.0	3.1	3.1	3.1	3.1	3.1	3.1
I05552	2.8	2.8	2.7	2.8	2.8	2.8	2.9	2.8	2.7
GROUP: FEMALE 4 - 0.75 MG/KG/DAY									
I05533	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.5
I05534	2.9	2.8	2.7	2.9	2.8	2.9	2.8	2.7	2.8
I05536	3.5	3.5	3.3	3.3	3.4	3.3	3.3	3.4	3.4
I05540	3.1	3.0	3.0	2.9	2.9	3.0	3.0	3.0	3.0
I05542	2.7	2.7	2.6	2.7	2.6	2.6	2.7	2.6	2.6
I05551	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4

Appendix 3

Individual Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	WEEK 28	WEEK 29	WEEK 30	WEEK 31	WEEK 32	WEEK 33	WEEK 34	WEEK 35	WEEK 36	WEEK 37
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.2	3.3	3.3	3.4	3.5	3.5	3.5	3.5	3.5	3.6
I05526	3.8	3.9	3.9	4.0	4.1	4.1	4.1	4.0	4.1	4.2
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.2	3.3	3.2	3.3	3.4	3.4	3.3	3.3	3.4	3.4
I05523	2.9	2.9	2.8	2.8	2.9	3.0	3.0	2.9	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	2.7	2.8	2.9	3.0	3.0	3.1	3.1	3.0	3.1	3.1
I05522	3.5	3.7	3.7	4.0	4.2	4.2	4.5	4.4	4.6	4.6
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
I05549	2.9	3.0	2.9	3.0	3.0	3.1	3.0	3.0	3.0	3.1
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	3.8	3.9	3.8	3.9	4.0	4.0	4.0	4.1	4.2	4.1
I05552	2.8	2.9	2.8	2.8	2.9	2.9	2.8	2.8	2.9	3.0
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.5	2.6	2.6	2.6	2.7	2.8	2.8	2.8	2.8	2.8
I05542	2.7	2.8	2.8	2.9	3.2	3.2	3.2	3.1	3.3	3.3

Appendix 3

Individual Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	WEEK 38	WEEK 39	WEEK 40	WEEK 41	WEEK 42	WEEK 43	WEEK 44	WEEK 45	WEEK 46	WEEK 47
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.6	3.6	3.6	3.7	3.8	3.8	4.0	4.1	4.2	4.1
I05526	4.2	4.1	4.1	4.3	4.2	4.2	4.4	4.4	4.5	4.3
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.3	3.3	3.4	3.3	3.3	3.4	3.5	3.5	3.4
I05523	3.0	2.9	2.9	3.1	3.0	3.0	3.1	3.1	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	3.1	3.0	2.9	3.1	3.0	3.1	3.2	3.2	3.3	3.2
I05522	4.5	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.4
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.4	2.3	2.5	2.4	2.4	2.5	2.5	2.5	2.4
I05549	3.0	3.0	2.9	3.1	3.0	3.0	3.0	3.1	3.1	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	4.1	4.1	4.0	4.2	4.1	4.1	4.3	4.2	4.2	4.2
I05552	2.9	2.9	2.8	3.0	3.0	3.0	3.0	3.1	3.0	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.7	2.7	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.7
I05542	3.3	3.2	3.1	3.3	3.2	3.3	3.3	3.3	3.4	3.4

Appendix 3

Individual Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	WEEK 48	WEEK 49	WEEK 50	WEEK 51	WEEK 52	WEEK 53	WEEK 54	WEEK 55	WEEK 56	WEEK 57
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.1	4.1	4.1	4.1	4.2	4.2	4.2	4.3	4.2	4.1
I05526	4.3	4.4	4.4	4.4	4.5	4.5	4.6	4.7	4.7	4.6
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4
I05523	3.0	3.1	3.0	3.1	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.3	3.5	3.5	3.6	3.7	3.7	3.8	3.8	3.9	3.8
I05522	4.4	4.6	4.5	4.5	4.5	4.4	4.5	4.4	4.4	4.2
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.3	2.5	2.4	2.4	2.5	2.4	2.4	2.4	2.4	2.3
I05549	2.8	3.0	2.9	3.0	2.9	2.8	2.8	2.9	2.9	2.8
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.3	4.3	4.2	4.3	4.3	4.3	4.2	4.2	4.2	4.2
I05552	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.9	2.8	2.8	2.8	2.7	2.7	2.6	2.7	2.6
I05542	3.4	3.4	3.3	3.3	3.4	3.4	3.4	3.5	3.5	3.4

Appendix 3

Individual Body Weight Data (kg)  
Recovery

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 58	WEEK 59	WEEK 60	WEEK 61	WEEK 62	WEEK 63	WEEK 64	WEEK 65	WEEK 66	WEEK 67
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.1	4.2	4.2	4.1	4.1	4.0	4.0	4.0	4.1
I05526	4.7	4.7	4.9	4.9	4.8	4.9	4.9	4.8	4.9	4.9
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.5	3.5	3.6	3.5	3.5	3.4	3.4	3.5
I05523	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.2	3.3
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.9	3.8	4.0	4.0	4.0	4.1	4.3	4.2	4.1	4.2
I05522	4.4	4.4	4.6	4.6	4.7	4.7	4.6	4.5	4.5	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.5	2.4	2.5	2.5	2.4	2.5	2.4	2.4	2.4	2.4
I05549	2.9	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.0	4.2	4.1	4.1	4.1	4.1	4.0	4.0	4.1
I05552	3.0	3.0	3.0	3.0	3.0	3.1	3.0	2.9	2.9	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.6	2.6	2.8	2.8	2.8	2.8	2.7	2.7	2.7	2.8
I05542	3.4	3.4	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6

Appendix 3

Individual Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL NUMBER	WEEK 68	WEEK 69	WEEK 70	WEEK 71	WEEK 72	WEEK 73	WEEK 74	WEEK 75	WEEK 76	WEEK 77
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.3	4.2	4.2	4.3	4.2	4.2	4.2	4.2	4.1
I05526	5.0	5.1	5.0	5.1	5.3	5.2	5.4	5.3	5.4	5.3
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.6	3.6	3.5	3.5	3.6	3.5	3.6	3.6	3.6	3.5
I05523	3.3	3.4	3.4	3.4	3.5	3.4	3.5	3.5	3.5	3.4
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	4.3	4.3	4.3	4.2	4.3	4.2	4.3	4.3	4.3	4.3
I05522	4.6	4.7	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.4	2.5	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.4
I05549	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.2	4.1	4.2	4.2	4.2	4.2	4.2	4.2	4.2
I05552	3.0	3.0	3.0	3.0	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.7	2.7	2.7	2.7	2.6	2.7	2.7	2.8	2.7
I05542	3.6	3.7	3.7	3.7	3.8	3.7	3.8	3.8	3.9	3.8

Appendix 3

Individual Body Weight Data (kg)  
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPCS; T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	WEEK 78	WEEK 79	WEEK 80
GROUP: MALE 1 - 0 MG/KG/DAY			
I05520	4.0	4.0	
I05526	5.3	5.3	
GROUP: MALE 3 - 0.15 MG/KG/DAY			
I05505	3.5	3.5	3.5
I05523	3.4	3.5	3.2
GROUP: MALE 4 - 0.75 MG/KG/DAY			
I05511	4.3	4.4	
I05522	4.5	4.5	
GROUP: FEMALE 1 - 0 MG/KG/DAY			
I05529	2.4	2.4	
I05549	2.8	2.9	
GROUP: FEMALE 3 - 0.15 MG/KG/DAY			
I05539	4.1	4.2	4.0
I05552	2.9	3.0	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY			
I05533	2.6	2.7	
I05542	3.8	3.9	





**Sponsor:**

3M  
St. Paul, Minnesota

**FINAL REPORT**

**Study Title:**

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

**Author:**

Peter J. Thomford, PhD

**Study Completion Date:**

January 11, 2002

**Testing Facility:**

Covance Laboratories Inc.  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704-2595

**Laboratory Study Identification:**

Covance 6329-223

**Sponsor Study Identification:**

3M Study No. T-6295.7

Volume II of II

Page 509 of 1086

3M\_MN03279342

1818.0509

---

**CONTENTS**

<b>VOLUME II OF II</b>	<b>Page</b>
APPENDIX 4.....	511
Individual Clinical Hematology Data.....	512
Individual Clinical Chemistry Data.....	614
Individual Clinical Urinalysis Data.....	728
APPENDIX 5.....	818
Individual Palmitoyl CoA Oxidase Determinations.....	819
Individual Anatomic Pathology Data.....	823
APPENDIX 6.....	907
AniLytics Inc. Quality Assurance Statements.....	908
Summary and Individual Blood Hormone Determination.....	917
APPENDIX 7.....	963
Cell Proliferation Report.....	964
APPENDIX 8.....	977
Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys.....	978
APPENDIX 9.....	1069
Urobilinogen Analysis Report.....	1070
APPENDIX 10.....	1072
Dose Confirmation Analysis Report.....	1073
Compound Stability Report.....	1078
Analytical Laboratory Report.....	1080
Certificate of Analysis.....	1083
Quality Assurance Statement.....	1086

**APPENDIX 4**

Individual Clinical Hematology Data  
Individual Clinical Chemistry Data  
Individual Clinical Urinalysis Data

Appendix 4  
Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	6.48	12.3	40.3	62.2	19.0	30.5	419	.3	19
I05517	6.25	12.8	42.4	67.8	20.5	30.2	380	.5	31
I05519	6.97	12.5	42.9	61.5	17.9	29.0	577	.5	35
I05520	6.27	11.8	39.4	62.9	18.8	29.9	601	.0	0
I05526	6.48	12.0	41.1	63.5	18.6	29.3	472	.2	13
I05527	6.27	12.1	40.9	65.3	19.3	29.6	652	.3	19
MEAN	6.45	12.2	41.2	63.9	19.0	29.8	530	.3	20
S.D.	.275	.36	1.30	2.32	.87	.56	125.0	.19	12.6
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	7.28	12.5	45.5	62.5	17.2	27.5	469	.5	36
I05515	6.22	11.8	39.8	64.0	18.9	29.6	675	.6	37
I05516	6.67	12.5	40.9	61.3	18.7	30.6	341	.1	7
I05521	7.79	12.9	45.3	58.1	16.6	28.5	813	.2	16
MEAN	6.99	12.4	42.9	61.5	17.8	29.0	574	.4	24
S.D.	.688	.46	2.95	2.51	1.13	1.34	210.3	.24	14.9
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.45	12.6	42.0	65.2	19.6	30.0	469	1.4	90
I05510	6.58	11.9	39.7	60.3	18.1	29.9	546	.5	33
I05518	7.36	13.0	44.8	60.9	17.6	29.0	375	.7	52
I05523	6.73	12.8	43.1	64.1	19.0	29.7	569	.0	0
I05524	6.76	13.0	44.6	65.1	19.3	29.2	635	.0	0
I05528	6.67	12.6	43.1	64.6	18.9	29.3	366	.3	20
MEAN	6.76	12.6	42.9	63.5	18.7	29.5	493	.5	32
S.D.	.315	.41	1.88	2.38	.76	.41	109.0	.53	34.5
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.63	13.4	45.6	60.0	17.6	29.3	519	.6	46
I05507	6.94	12.0	41.5	59.7	17.3	28.9	58	.3	21
I05509	6.89	11.9	42.3	61.4	17.3	28.1	409	.4	28
I05511	5.90	11.4	40.3	69.4	19.4	28.4	528	1.4	83
I05512	7.20	13.1	44.5	61.8	18.1	29.3	342	.2	14
I05522	6.73	13.1	44.1	65.5	19.5	29.7	636	.1	7
MEAN	6.88	12.5	43.1	62.8	18.2	29.0	415	.5	33
S.D.	.575	.82	2.06	3.44	1.01	.61	202.6	.47	27.8
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	6.6	2.1	4.0	.4	.0	.0	32	61	6	0	0
I05517	9.2	3.3	4.7	1.0	.1	.1	36	52	11	1	1
I05519	6.7	3.1	3.1	.4	.2	.0	46	46	5	2	0
I05520	9.0	5.1	3.0	.8	.0	.1	56	34	9	0	1
I05526	11.3	5.4	5.3	.5	.1	.0	48	47	5	1	0
I05527	8.9	4.4	3.7	.7	.1	.0	49	41	8	1	0
MEAN	8.6	3.9	4.0	.6	.1	.0	44	47	7	1	0
S.D.	1.76	1.28	.90	.24	.08	.05	8.9	9.2	2.4	.8	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	11.7	7.2	4.0	.4	.2	.0	62	34	3	2	0
I05515	11.5	3.2	6.2	1.5	.5	.0	28	54	13	4	0
I05516	9.5	4.0	4.4	.9	.1	.0	42	47	10	1	0
I05521	11.1	6.3	4.0	.6	.2	.0	56	36	6	2	0
MEAN	11.0	5.2	4.6	.8	.2	.0	47	43	8	2	0
S.D.	1.00	1.88	1.05	.48	.17	.00	15.2	9.4	4.4	1.3	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	12.5	9.4	2.4	.6	.1	.0	75	19	5	1	0
I05510	11.1	5.8	4.2	1.0	.1	.0	52	38	9	1	0
I05518	10.7	4.8	4.6	1.3	.0	.0	45	43	12	0	0
I05523	15.0	9.8	3.7	.8	.6	.0	66	25	5	4	0
I05524	9.4	4.2	4.0	1.1	.0	.1	45	42	12	0	1
I05528	12.7	5.3	5.9	.8	.7	.0	42	46	6	5	0
MEAN	11.9	6.6	4.1	.9	.2	.0	54	36	8	2	0
S.D.	1.95	2.42	1.14	.25	.31	.04	13.4	10.9	3.3	2.1	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	9.3	3.0	5.0	1.1	.2	.1	32	54	12	2	1
I05507	13.7	4.9	6.3	2.1	.1	.2	36	46	15	1	2
I05509	7.5	3.3	2.8	.7	.7	.0	44	37	9	9	0
I05511	8.0	3.9	3.3	.6	.1	.0	49	41	9	1	0
I05512	7.1	1.6	4.3	1.2	.0	.0	22	60	16	0	1
I05522	11.0	5.5	4.1	1.1	.2	.1	50	37	10	2	1
MEAN	9.4	3.7	4.3	1.1	.2	.1	39	46	12	2	1
S.D.	2.53	1.40	1.25	.53	.25	.08	10.9	9.5	3.3	3.3	.8
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-



Appendix 4  
Individual Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.96	11.5	37.1	62.2	19.3	31.0	631	.4	24
I05530	6.78	13.3	45.0	66.4	19.6	29.5	552	.3	20
I05531	5.72	10.5	34.7	60.6	18.3	30.2	584	.1	6
I05535	6.66	12.2	40.8	61.3	18.3	29.9	577	.5	33
I05544	4.98	11.6	36.2	72.7	23.2	31.9	471	1.3	65
I05549	6.45	12.6	41.9	65.0	19.5	30.1	417	1.0	64
MEAN	6.09	12.0	39.3	64.7	19.7	30.4	539	.6	35
S.D.	.681	.97	2.93	4.51	1.81	.87	79.5	.46	24.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.13	10.6	36.7	59.9	17.3	28.8	529	.3	18
I05541	5.78	12.0	40.0	69.1	20.8	30.2	426	.9	52
I05547	6.30	10.7	37.4	59.3	17.0	28.6	558	.4	25
I05550	7.02	12.8	43.9	62.5	18.2	29.1	414	.2	14
MEAN	6.31	11.5	39.5	62.7	18.3	29.2	482	.4	27
S.D.	.522	1.06	3.26	4.49	1.73	.71	72.4	.31	17.1
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.95	12.7	43.2	62.2	18.2	29.3	433	.4	28
I05538	6.16	11.3	38.3	62.1	18.4	29.6	475	.3	18
I05539	6.23	11.7	39.2	62.9	18.8	29.9	477	.8	50
I05545	6.72	12.3	40.7	60.6	18.3	30.1	325	.1	7
I05548	6.76	11.8	38.0	56.2	17.4	31.0	615	.4	27
I05552	6.39	12.0	41.1	64.2	18.7	29.1	560	.7	45
MEAN	6.54	12.0	40.1	61.4	18.3	29.8	481	.4	29
S.D.	.320	.49	1.97	2.79	.50	.68	100.9	.26	16.2
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>2</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.46	12.1	41.2	63.8	18.7	29.3	337	.2	13
I05534	6.72	13.1	44.2	65.8	19.5	29.6	438	.4	27
I05536	6.67	12.1	41.7	62.6	18.2	29.1	606	.1	7
I05540	6.21	11.8	39.6	63.8	19.0	29.8	433	.0	0
I05542	6.57	12.0	42.4	64.5	18.2	28.3	492	.4	26
I05551	6.35	11.7	40.0	63.0	18.5	29.4	304	.4	25
MEAN	6.50	12.1	41.5	63.9	18.7	29.2	435	.2	16
S.D.	.195	.50	1.68	1.14	.50	.52	108.9	.18	11.4
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	7.4	3.4	3.3	.6	.2	.0	45	45	8	2	0
I05530	11.7	6.0	4.9	.7	.1	.0	51	42	6	1	0
I05531	8.4	5.0	2.6	.7	.1	.1	59	31	8	1	1
I05535	12.6	5.0	6.0	.8	.6	.1	39	48	7	5	1
I05544	13.0	5.3	5.8	1.2	.7	.0	40	44	9	6	0
I05549	8.0	3.1	4.3	.5	.1	.0	38	54	6	2	0
MEAN	10.2	4.6	4.5	.8	.3	.0	45	44	7	3	0
S.D.	2.52	1.14	1.36	.24	.28	.05	8.3	7.6	1.2	2.1	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	12.2	8.6	2.7	.6	.2	.0	70	22	5	2	0
I05541	8.1	3.0	4.1	.9	.1	.1	36	50	11	1	1
I05547	6.8	3.6	2.5	.6	.1	.0	53	36	9	2	0
I05550	7.6	4.6	2.4	.5	.1	.0	60	32	6	1	0
MEAN	8.7	5.0	2.9	.6	.1	.0	55	35	8	2	0
S.D.	2.41	2.52	.79	.17	.05	.05	14.3	11.6	2.8	.6	.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	7.6	2.6	3.6	1.2	.2	.0	35	48	15	2	0
I05538	12.0	7.4	3.7	.7	.2	.0	62	31	6	2	0
I05539	7.1	2.6	3.5	.9	.2	.0	36	49	12	2	0
I05545	14.4	9.4	4.2	.7	.0	.0	65	29	5	0	0
I05548	11.3	5.4	4.4	.8	.7	.0	48	39	7	6	0
I05552	8.0	3.3	3.4	.7	.6	.1	41	42	9	8	1
MEAN	10.1	5.1	3.8	.8	.3	.0	48	40	9	3	0
S.D.	2.94	2.81	.40	.20	.27	.04	13.0	8.4	3.8	3.0	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	10.0	4.1	5.1	.7	.0	.0	41	51	7	0	0
I05534	13.3	6.9	5.2	.7	.4	.0	52	39	6	3	0
I05536	9.6	4.4	3.5	1.3	.3	.1	46	36	14	3	1
I05540	8.9	5.4	2.4	.9	.1	.0	61	27	10	1	0
I05542	8.3	5.9	2.0	.4	.0	.0	71	24	4	0	0
I05551	3.8	2.0	1.2	.5	.0	.0	53	32	14	1	0
MEAN	9.0	4.8	3.2	.8	.1	.0	54	35	9	1	0
S.D.	3.08	1.70	1.66	.32	.18	.04	10.7	9.7	4.2	1.4	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.53	13.0	41.4	63.4	19.9	31.4	369	.1	7
I05517	6.32	13.0	42.7	67.5	20.5	30.4	443	.2	13
I05519	6.83	12.2	40.9	59.8	17.8	29.8	474	.3	20
I05520	6.50	12.1	39.5	60.7	18.6	30.7	644	.1	6
I05526	6.20	11.6	38.6	62.3	18.7	30.0	375	.1	6
I05527	6.34	12.2	40.6	64.0	19.3	30.1	614	.5	32
MEAN	6.45	12.4	40.6	63.0	19.1	30.4	486	.2	14
S.D.	.221	.55	1.44	2.74	.97	.58	117.8	.16	10.4
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	7.32	13.0	47.9	65.5	17.8	27.2	492	.6	44
I05515	6.51	12.5	42.5	65.2	19.2	29.4	629	.8	52
I05516	6.35	12.2	39.0	61.4	19.2	31.2	344	.3	19
I05521	7.26	12.2	40.3	55.6	16.8	30.1	665	.0	0
MEAN	6.86	12.5	42.4	61.9	18.2	29.5	532	.4	29
S.D.	.501	.38	3.93	4.61	1.17	1.69	146.1	.35	23.8
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.34	12.8	41.3	65.1	20.3	31.1	421	.3	19
I05510	6.99	12.3	41.5	59.3	17.6	29.7	483	.4	28
I05518	7.20	12.7	42.1	58.5	17.7	30.2	498	.6	43
I05523	6.78	12.6	41.3	60.9	18.5	30.5	544	.4	27
I05524	6.31	12.3	41.4	65.6	19.5	29.7	519	.2	13
I05528	6.34	12.1	39.8	62.7	19.1	30.4	388	.3	19
MEAN	6.66	12.5	41.2	62.0	18.8	30.3	476	.4	25
S.D.	.385	.27	.76	2.96	1.06	.53	59.6	.14	10.5
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.03	12.3	41.0	58.3	17.4	29.9	459	.3	21
I05507	6.57	11.4	39.6	60.2	17.3	28.7	58 PA	.3	20
I05509	6.84	12.1	41.9	61.3	17.6	28.8	399	.3	21
I05511	5.80	10.9	37.1	63.9	18.8	29.5	490	.4	23
I05512	6.60	12.1	40.3	61.0	18.3	30.1	362	.5	33
I05522	6.32	12.3	41.5	65.6	19.4	29.6	519	.5	32
MEAN	6.53	11.8	40.2	61.7	18.1	29.4	383	.4	25
S.D.	.431	.57	1.74	2.63	.85	.57	164.3	.10	5.9
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	5.2	1.8	2.9	.4	.0	.0	34	57	9	1	0
I05517	7.8	2.5	4.2	.9	.0	.2	32	53	12	0	2
I05519	7.1	3.5	3.4	.2	.1	.0	49	48	3	1	0
I05520	6.8	3.5	2.9	.4	.0	.0	52	43	5	0	0
I05526	7.5	4.7	2.2	.3	.2	.0	63	30	4	3	0
I05527	11.2	7.5	2.8	.9	.0	.0	67	25	8	0	0
MEAN	7.6	3.9	3.1	.5	.0	.0	50	43	7	1	0
S.D.	1.98	2.01	.67	.31	.08	.08	14.4	12.8	3.4	1.2	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	11.9	5.9	5.3	.5	.2	.0	50	44	4	2	0
I05515	8.0	3.1	4.1	.6	.2	.0	39	51	7	2	0
I05516	12.1	8.2	3.1	.7	.2	.0	67	25	5	2	0
I05521	11.0	8.1	2.4	.3	.1	.0	74	22	3	1	0
MEAN	10.8	6.3	3.7	.5	.2	.0	58	36	5	2	0
S.D.	1.89	2.40	1.26	.17	.05	.00	15.9	14.2	1.7	.5	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	11.7	9.3	2.0	.2	.3	.0	79	17	2	2	0
I05510	8.8	5.1	2.9	.7	.0	.0	58	32	8	1	0
I05518	9.4	3.9	4.6	.8	.0	.0	42	49	8	0	0
I05523	11.1	7.0	3.6	.4	.1	.0	63	32	4	1	0
I05524	6.9	3.5	2.6	.8	.0	.1	50	37	12	0	1
I05528	12.4	7.2	3.6	.7	.8	.1	58	30	5	6	0
MEAN	10.0	6.0	3.2	.6	.2	.0	58	33	6	2	0
S.D.	2.06	2.23	.91	.24	.32	.05	12.5	10.4	3.6	2.3	.4
N	6	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Hematology Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	7.1	3.4	2.9	.7	.1	.0	48	41	9	1	1
I05507	17.9	13.3	3.8	.7	.1	.1	74	21	4	0	1
I05509	11.6	8.0	2.8	.4	.3	.0	69	24	4	3	0
I05511	9.5	5.5	2.4	.5	.1	.1	65	28	6	1	1
I05512	6.6	3.5	2.4	.7	.0	.0	53	36	10	0	1
I05522	10.2	6.2	3.0	.9	.0	.1	61	30	9	0	1
MEAN	10.3	6.6	2.9	.6	.1	.0	62	30	7	1	1
S.D.	4.16	3.69	.52	.18	.11	.05	9.8	7.5	2.7	1.2	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	6.43	12.3	40.4	62.8	19.1	30.5	647	.3	19
I05530	6.51	12.7	42.1	64.7	19.6	30.2	629	.5	33
I05531	6.37	11.6	38.8	60.8	18.1	29.8	439	.2	13
I05535	6.52	11.8	39.1	60.0	18.0	30.0	538	.1	7
I05544	5.78	11.6	37.9	65.6	20.0	30.5	499	.4	23
I05549	6.85	13.3	44.4	64.8	19.5	30.0	475	.5	34
MEAN	6.41	12.2	40.5	63.1	19.0	30.2	538	.3	22
S.D.	.351	.69	2.42	2.31	.83	.29	84.2	.16	10.8
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.60	10.9	38.1	57.8	16.6	28.7	448	.3	20
I05541	5.70	11.7	40.5	70.9	20.6	29.0	391	.7	40
I05547	6.79	11.6	39.0	57.4	17.0	29.7	417	.1	7
I05550	7.29	13.2	44.7	61.3	18.1	29.6	411	.1	7
MEAN	6.60	11.8	40.6	61.8	18.1	29.2	417	.3	18
S.D.	.664	.97	2.92	6.28	1.80	.48	23.6	.28	15.6
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.43	11.9	39.5	61.3	18.5	30.1	451	.4	26
I05538	6.40	11.3	38.4	60.1	17.7	29.5	398	.4	26
I05539	6.35	12.0	40.6	63.8	18.9	29.5	406	.1	6
I05545	6.85	12.4	41.2	60.1	18.1	30.1	300	.3	21
I05548	7.09	11.9	39.8	56.1	16.8	29.8	553	.3	21
I05552	6.19	11.4	38.8	62.7	18.5	29.5	478	.2	12
MEAN	6.55	11.8	39.7	60.7	18.1	29.7	431	.3	19
S.D.	.343	.41	1.06	2.68	.75	.29	85.3	.12	8.0
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.04	11.6	38.0	62.8	19.1	30.5	345	.3	18
I05534	5.91	11.3	38.4	65.0	19.2	29.5	532	.7	41
I05536	6.43	11.7	41.3	64.2	18.3	28.4	531	.2	13
I05540	6.09	11.4	37.1	60.9	18.7	30.8	501	.1	6
I05542	6.66	12.2	41.8	62.8	18.3	29.2	555	.2	13
I05551	6.12	11.1	37.9	62.0	18.2	29.3	351	.5	31
MEAN	6.21	11.6	39.1	63.0	18.6	29.6	469	.3	20
S.D.	.280	.38	1.96	1.48	.44	.89	95.4	.23	13.1
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	9.6	6.2	2.8	.5	.1	.0	65	30	5	1	0
I05530	12.1	8.3	2.8	1.0	.0	.0	69	23	8	0	0
I05531	14.6	11.7	1.9	.9	.1	.1	80	13	6	1	0
I05535	21.4	12.2	5.9	2.4	.7	.2	57	28	11	3	1
I05544	8.6	2.3	5.2	.7	.3	.0	26	61	8	4	1
I05549	10.1	5.9	2.8	1.0	.4	.0	58	28	10	4	0
MEAN	12.7	7.8	3.6	1.1	.3	.0	59	30	8	2	0
S.D.	4.75	3.77	1.59	.67	.26	.08	18.2	16.2	2.3	1.7	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	7.7	3.5	2.8	.8	.5	.1	46	36	10	6	2
I05541	11.5	6.5	3.7	1.1	.2	.0	56	32	10	2	0
I05547	7.3	5.0	1.7	.5	.1	.0	68	24	7	1	0
I05550	11.7	7.9	2.8	.8	.2	.0	68	24	6	2	0
MEAN	9.6	5.7	2.8	.8	.2	.0	60	29	8	3	0
S.D.	2.37	1.90	.82	.24	.17	.05	10.6	6.0	2.1	2.2	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	8.0	5.4	2.0	.4	.1	.0	68	25	5	2	0
I05538	9.4	5.1	3.4	.6	.3	.0	54	36	6	3	0
I05539	4.4	1.2	2.8	.4	.1	.0	26	62	8	2	0
I05545	10.0	5.2	3.9	.7	.1	.0	52	39	7	1	0
I05548	11.7	7.7	3.0	.5	.4	.0	66	26	4	4	0
I05552	11.2	8.2	2.2	.4	.5	.0	73	19	4	4	0
MEAN	9.1	5.5	2.9	.5	.2	.0	56	35	6	3	0
S.D.	2.66	2.48	.72	.13	.18	.00	17.0	15.7	1.6	1.2	.0
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.8	3.9	4.4	.4	.0	.0	45	50	5	0	0
I05534	8.8	4.6	3.0	.9	.2	.0	52	34	11	3	1
I05536	7.6	4.8	2.0	.6	.1	.0	63	27	8	2	0
I05540	9.7	5.0	3.9	.6	.1	.0	51	40	7	1	0
I05542	13.7	11.5	1.8	.4	.0	.0	84	13	3	0	0
I05551	5.0	2.2	2.3	.4	.1	.0	44	47	7	2	0
MEAN	8.9	5.3	2.9	.6	.1	.0	56	35	7	1	0
S.D.	2.85	3.19	1.06	.20	.08	.00	15.1	13.7	2.7	1.2	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	6.68	13.2	42.0	62.8	19.8	31.5	463	.1	7
I05517	6.29	12.9	42.8	69.0	20.4	30.1	423	.5	31
I05519	6.93	12.2	41.6	59.9	17.6	29.4	524	.3	21
I05520	6.53	12.4	39.9	61.1	18.9	31.0	699	.0	0
I05526	6.10	11.7	38.1	62.4	19.1	30.7	377	.1	6
I05527	6.43	12.5	42.3	65.8	19.4	29.5	644	.7	45
MEAN	6.49	12.5	41.1	63.3	19.2	30.4	522	.3	18
S.D.	.292	.53	1.78	3.03	.95	.84	126.9	.27	17.3
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	6.86	12.2	41.7	60.9	17.7	29.1	438	.1	7
I05515	6.61	12.6	42.3	63.9	19.1	29.9	647	1.0	66
I05516	6.44	12.0	39.4	61.1	18.7	30.6	376	.4	26
I05521	7.44	12.7	42.2	56.8	17.1	30.0	684	.0	0
MEAN	6.84	12.4	41.4	60.7	18.2	29.9	536	.4	25
S.D.	.437	.33	1.36	2.92	.91	.62	152.1	.45	29.6
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.47	13.0	41.6	64.2	20.1	31.3	450	.5	32
I05510	6.82	12.4	40.1	58.8	18.2	30.9	499	.5	34
I05518	7.10	12.7	41.5	58.5	17.8	30.5	578	.6	43
I05523	6.51	12.7	40.9	62.8	19.5	31.0	625	.1	7
I05524	6.54	12.6	42.1	64.3	19.3	30.0	520	.0	0
I05528	6.19	11.5	38.2	61.8	18.6	30.2	349	.2	12
MEAN	6.60	12.5	40.7	61.7	18.9	30.6	504	.3	21
S.D.	.315	.52	1.42	2.56	.87	.50	97.3	.25	17.3
N	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Hematology Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.46	13.1	42.4	58.2	17.6	30.2	534	.3	22
I05507	6.81	12.1	40.5	59.4	17.7	29.8	36	.1	7
I05509	6.69	11.9	40.0	59.8	17.7	29.6	480	.5	33
I05511	5.86	11.1	37.6	64.1	18.9	29.5	629	.4	23
I05512	6.90	12.8	41.6	60.3	18.5	30.7	359	.0	0
I05522	6.65	12.8	43.8	65.9	19.3	29.3	586	.4	27
MEAN	6.73	12.3	41.2	61.3	18.3	29.8	437	.3	19
S.D.	.516	.75	2.31	3.02	.72	.52	217.8	.19	12.6
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	7.4	3.7	3.3	.4	.0	.0	49	45	5	1	0
I05517	8.0	2.1	4.7	1.0	.1	.1	27	59	12	1	2
I05519	6.7	3.1	3.2	.4	.0	.0	46	48	5	1	0
I05520	8.0	3.8	3.4	.6	.1	.1	48	43	7	1	1
I05526	6.0	3.2	2.2	.5	.1	.0	52	36	9	2	0
I05527	7.8	2.4	4.2	.9	.2	.0	31	54	12	3	0
MEAN	7.3	3.0	3.5	.6	.1	.0	42	48	8	2	0
S.D.	.81	.68	.87	.26	.08	.05	10.5	8.2	3.2	.8	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	8.1	5.0	2.3	.5	.2	.0	62	29	6	2	0
I05515	10.3	4.6	4.3	1.2	.2	.0	44	42	12	2	0
I05516	12.1	7.3	3.5	1.1	.1	.0	61	29	9	1	0
I05521	11.6	7.5	3.4	.5	.2	.0	65	29	4	2	0
MEAN	10.5	6.1	3.4	.8	.2	.0	58	32	8	2	0
S.D.	1.79	1.51	.82	.38	.05	.00	9.5	6.5	3.5	.5	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	10.8	8.0	2.3	.2	.3	.0	73	21	2	3	0
I05510	13.3	8.7	3.7	.7	.1	.0	65	28	6	1	0
I05518	9.9	3.2	5.8	.8	.1	.0	32	59	8	1	0
I05523	12.7	7.7	4.5	.4	.1	.0	60	36	3	1	0
I05524	7.7	3.2	3.4	1.0	.1	.1	41	44	13	1	1
I05528	16.4	11.1	3.6	1.3	.4	.1	68	22	8	2	0
MEAN	11.8	7.0	3.9	.7	.2	.0	56	35	7	2	0
S.D.	3.02	3.16	1.18	.40	.13	.05	16.3	14.6	4.0	.8	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	6.5	2.5	3.5	.4	.1	.0	38	54	6	1	0
I05507	14.6	9.6	3.6	1.0	.2	.2	66	24	7	2	1
I05509	10.6	6.4	2.8	.7	.6	.1	60	27	7	6	1
I05511	7.7	4.2	3.0	.4	.1	.0	54	39	5	1	0
I05512	7.7	3.6	3.5	.6	.0	.0	46	45	8	0	0
I05522	10.7	5.5	4.3	.7	.2	.0	51	40	6	2	0
MEAN	9.6	5.3	3.4	.6	.2	.0	52	38	6	2	0
S.D.	2.97	2.52	.52	.23	.21	.08	10.0	11.2	1.0	2.1	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	6.15	12.0	38.4	62.4	19.5	31.3	668	.5	31
I05530	5.93	12.1	39.7	65.8	20.3	30.4	515	.6	36
I05531	6.56	12.1	40.5	61.6	18.5	30.0	644	.1	7
I05535	7.02	12.7	42.4	60.4	18.2	30.0	600	.3	21
I05544	4.91	11.5	35.4	72.1	23.4	32.4	506	.7	34
I05549	6.83	13.4	44.9	65.8	19.6	29.8	501	.5	34
MEAN	6.23	12.3	40.2	64.9	19.9	30.6	572	.4	27
S.D.	.766	.66	2.27	4.33	1.87	1.01	74.6	.22	11.2
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	6.44	10.9	37.8	58.8	16.9	28.8	357	.3	19
I05541	5.67	12.2	40.5	71.3	21.4	30.1	507	.7	40
I05547	6.82	11.9	39.2	57.4	17.4	30.3	548	.8	55
I05550	7.01	12.9	43.4	62.0	18.4	29.7	437	.0	0
MEAN	6.48	12.0	40.2	62.4	18.5	29.7	462	.4	28
S.D.	.593	.83	2.39	6.25	2.02	.67	83.8	.37	24.1
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	9.13	17.2	55.9	61.2	18.8	30.8	306	.1	9
I05538	6.64	11.8	40.0	60.3	17.8	29.5	456	.6	40
I05539	6.45	12.5	40.4	62.6	19.3	30.9	374	.0	0
I05545	6.74	12.2	40.3	59.8	18.0	30.2	326	.7	47
I05548	6.80	11.7	38.4	56.4	17.2	30.4	667	.3	20
I05552	6.21	11.6	38.9	62.6	18.6	29.7	486	.5	31
MEAN	7.00	12.8	42.3	60.5	18.3	30.3	436	.4	24
S.D.	1.068	2.17	6.70	2.31	.76	.57	133.5	.28	18.2
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.04	11.7	39.0	64.6	19.3	29.9	355	.4	24
I05534	5.74	11.4	37.9	65.0	19.8	30.0	620	.5	29
I05536	6.72	12.2	42.6	63.5	18.2	28.7	622	.1	7
I05540	6.13	11.9	39.5	64.5	19.4	30.1	432	.6	37
I05542	6.75	12.1	42.6	63.0	18.0	28.5	665	.0	0
I05551	6.32	11.7	39.5	62.5	18.6	29.7	333	.1	6
MEAN	6.28	11.8	40.2	64.0	18.9	29.5	504	.3	17
S.D.	.397	.29	1.96	1.27	.72	.70	148.3	.25	14.9
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	5.8	2.9	2.2	.5	.1	.0	50	38	9	1	1
I05530	13.0	7.8	4.5	.5	.1	.0	60	35	4	1	0
I05531	14.1	9.9	3.0	.9	.2	.1	70	22	6	1	1
I05535	10.9	3.5	5.4	1.4	.5	.2	32	49	13	5	1
I05544	10.5	2.9	7.0	.0	.5	.0	27	67	0	5	0
I05549	12.4	7.9	3.7	.4	.3	.0	64	30	3	2	0
MEAN	11.1	5.8	4.3	.6	.3	.0	50	40	6	2.0	0
S.D.	2.93	3.08	1.73	.48	.18	.08	17.6	15.9	4.6	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	10.6	5.7	3.4	.8	.5	.1	54	33	8	5	1
I05541	8.3	2.4	5.0	.6	.2	.1	29	61	8	2	1
I05547	7.2	3.7	2.7	.5	.2	.0	52	38	7	2	0
I05550	8.8	5.6	2.4	.7	.1	.0	63	27	8	1	0
MEAN	8.7	4.4	3.4	.6	.2	.0	50	40	8	2	0
S.D.	1.42	1.59	1.16	.13	.17	.06	14.5	14.9	4.5	1.7	.6
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	8.9	5.7	2.3	.7	.1	.0	64	26	8	1	0
I05538	10.6	5.7	4.1	.4	.4	.0	54	39	4	4	0
I05539	6.1	2.2	3.1	.5	.2	.1	37	51	9	3	1
I05545	9.7	4.0	5.0	.5	.2	.0	41	51	5	2	0
I05548	7.1	2.3	3.7	.7	.3	.1	32	52	10	5	1
I05552	10.1	6.0	3.2	.3	.5	.0	60	32	3	5	0
MEAN	8.8	4.3	3.6	.5	.3	.0	48	42	6	3	0
S.D.	1.78	1.75	.93	.16	.15	.05	13.1	11.2	2.9	1.6	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.4	3.2	4.8	.4	.0	.0	38	57	4	0	0
I05534	18.0	12.8	3.6	1.4	.2	.1	71	20	8	1	0
I05536	6.7	3.9	1.8	.7	.2	.1	58	27	11	3	1
I05540	9.1	4.5	2.9	.6	.1	.0	55	36	7	1	0
I05542	10.0	6.9	2.6	.4	.1	.0	69	27	4	1	0
I05551	4.8	2.1	2.3	.3	.1	.0	44	48	6	1	0
MEAN	9.3	5.6	3.0	.6	.1	.0	56	36	7	1	0
S.D.	4.59	3.89	1.07	.40	.08	.05	13.2	14.2	2.7	1.0	.4
N	6	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Hematology Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.39	12.8	39.6	62.0	20.0	32.2	387	.3	19
I05517	6.21	12.8	41.3	66.6	20.7	31.1	406	.7	43
I05519	6.92	12.2	40.7	58.8	17.6	29.9	475	.1	7
I05520	6.45	12.1	39.2	60.8	18.8	30.8	671	.1	6
I05526	6.01	11.5	37.4	62.3	19.2	30.8	384	.2	12
I05527	6.59	12.8	43.8	66.4	19.4	29.3	614	.6	40
MEAN	6.43	12.4	40.3	62.8	19.3	30.7	490	.3	21
S.D.	.314	.53	2.17	3.11	1.06	1.00	124.3	.26	16.4
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	6.96	12.3	42.2	60.6	17.7	29.2	389	.3	21
I05515	6.71	12.8	42.9	63.9	19.1	29.8	630	1.0	67
I05516	6.43	12.2	40.4	62.8	19.0	30.2	290	1.3	84
I05521	7.88	13.4	44.7	56.8	17.0	30.0	741	.2	16
MEAN	7.00	12.7	42.5	61.0	18.2	29.8	512	.7	47
S.D.	.628	.55	1.78	3.13	1.02	.43	208.8	.54	33.7
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.07	12.1	39.4	64.8	19.9	30.7	505	1.6	97
I05510	6.64	12.2	39.6	59.6	18.3	30.7	487	.4	27
I05518	6.95	12.5	40.9	58.8	18.0	30.5	501	.2	14
I05523	6.33	12.5	40.0	63.2	19.7	31.2	585	.4	25
I05524	6.48	12.4	41.9	64.6	19.2	29.7	555	.2	13
I05528	6.51	12.3	40.3	61.8	18.8	30.5	346	.3	20
MEAN	6.50	12.3	40.4	62.1	19.0	30.6	496	.5	33
S.D.	.295	.16	.93	2.53	.76	.49	82.6	.54	32.0
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.22	13.0	42.6	59.0	18.0	30.5	522	.3	22
I05507	6.81	11.9	41.5	61.0	17.4	28.6	50	.4	27
I05509	6.37	11.3	38.3	60.2	17.7	29.4	475	.6	38
I05511	5.94	11.2	38.0	64.0	18.8	29.4	552	.4	24
I05512	7.13	12.9	43.0	60.2	18.1	30.0	396	.1	7
I05522	6.48	12.7	42.3	65.3	19.5	29.9	592	.6	39
MEAN	6.66	12.2	41.0	61.6	18.2	29.6	431	.4	26
S.D.	.488	.81	2.23	2.47	.77	.65	198.6	.19	11.8
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	6.1	2.3	3.2	.3	.2	.0	38	52	5	4	1
I05517	7.8	2.9	4.2	.6	.1	.1	37	54	8	1	1
I05519	5.8	2.5	3.0	.2	.0	.0	44	52	3	1	0
I05520	5.1	1.7	2.9	.4	.1	.0	34	57	9	1	1
I05526	5.1	1.7	2.8	.4	.1	.0	34	56	8	3	0
I05527	10.2	3.3	6.0	.6	.2	.0	33	59	6	2	0
MEAN	6.7	2.4	3.7	.4	.1	.0	37	55	6	2	0
S.D.	1.99	.64	1.24	.16	.08	.04	4.1	2.8	2.1	1.3	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	6.9	3.5	2.6	.6	.3	.0	50	38	8	4	0
I05515	7.7	2.4	4.5	.6	.2	.0	31	58	8	2	0
I05516	10.6	6.4	3.4	.6	.1	.0	60	32	6	1	0
I05521	8.7	5.3	2.7	.6	.1	.0	61	31	7	1	0
MEAN	8.5	4.4	3.3	.6	.2	.0	50	40	7	2	0
S.D.	1.60	1.79	.88	.00	.10	.00	13.9	12.6	1.0	1.4	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	8.9	6.2	2.2	.3	.1	.0	70	25	4	1	0
I05510	10.7	6.4	3.2	.9	.1	.1	60	30	9	1	1
I05518	15.8	7.9	6.8	1.0	.1	.1	50	43	6	1	1
I05523	8.6	4.3	3.7	.4	.1	.0	50	43	5	1	0
I05524	6.4	2.8	2.8	.7	.0	.1	44	44	11	0	1
I05528	11.4	6.8	3.4	.6	.5	.0	59	30	6	5	0
MEAN	10.3	5.7	3.7	.6	.2	.0	56	36	7	2	0
S.D.	3.21	1.85	1.61	.27	.18	.05	9.3	8.4	2.6	1.8	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	7.9	3.6	3.5	.6	.1	.0	46	45	7	1	1
I05507	10.3	5.0	3.9	1.1	.2	.1	48	38	10	2	1
I05509	9.1	5.3	2.8	.5	.4	.0	58	31	6	5	0
I05511	11.5	7.5	3.4	.4	.2	.0	65	30	4	1	0
I05512	5.3	2.0	2.7	.5	.0	.1	38	50	10	1	1
I05522	12.3	7.0	4.6	.3	.4	.0	57	37	2	3	0
MEAN	9.4	5.1	3.5	.6	.2	.0	52	38	6	2	0
S.D.	2.56	2.06	.71	.28	.16	.05	9.8	7.8	3.2	1.6	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	6.13	11.9	38.3	62.5	19.4	31.0	682	.2	12
I05530	6.50	13.0	43.2	66.5	20.0	30.1	556	.3	20
I05531	6.44	12.0	39.2	60.9	18.6	30.5	628	.4	26
I05535	6.71	12.1	40.1	59.9	18.0	30.1	515	.4	27
I05544	5.26	11.3	37.0	70.4	21.5	30.5	446	.3	16
I05549	6.81	13.4	44.1	64.7	19.7	30.4	544	.3	20
MEAN	6.31	12.3	40.3	64.1	19.5	30.4	562	.3	20
S.D.	.565	.77	2.79	3.90	1.21	.33	83.6	.08	5.7
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	6.22	10.6	37.1	59.7	17.0	28.4	492	.5	31
I05541	5.52	12.8	40.8	73.9	23.1	31.3	462	.5	28
I05547	6.49	11.3	37.5	57.8	17.5	30.2	493	.6	39
I05550	6.55	12.2	41.3	63.0	18.6	29.6	422	.3	20
MEAN	6.20	11.7	39.2	63.6	19.0	29.9	467	.5	30
S.D.	.472	.97	2.18	7.19	2.78	1.21	33.4	.13	7.9
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	6.49	12.2	40.0	61.6	18.8	30.6	423	.2	13
I05538	6.70	12.0	40.8	61.0	18.0	29.5	432	.1	7
I05539	6.16	12.1	39.3	63.8	19.7	30.8	394	.3	18
I05545	6.89	12.7	40.9	59.3	18.4	31.1	355	.3	21
I05548	6.59	11.5	37.6	56.9	17.5	30.7	585	.3	20
I05552	6.14	11.7	37.8	61.6	19.0	30.9	461	.1	6
MEAN	6.50	12.0	39.4	60.7	18.6	30.6	442	.2	14
S.D.	.298	.42	1.44	2.35	.78	.57	78.9	.10	6.6
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.39	11.9	40.1	62.7	18.7	29.8	328	.1	6
I05534	6.06	11.8	39.8	65.7	19.5	29.7	520	.4	24
I05536	6.35	11.7	40.4	63.6	18.4	28.9	568	.1	6
I05540	6.47	12.5	42.2	65.2	19.3	29.5	597	.3	19
I05542	6.57	11.9	41.6	63.3	18.2	28.7	635	.0	0
I05551	6.07	11.4	37.8	62.3	18.7	30.1	378	.3	18
MEAN	6.32	11.9	40.3	63.8	18.8	29.4	504	.2	12
S.D.	.210	.36	1.54	1.37	.51	.54	124.1	.15	9.4
N	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	6.4	3.2	2.6	.5	.1	.0	50	41	8	1	1
I05530	11.1	6.2	4.1	.6	.2	.0	56	37	5	2	0
I05531	9.1	4.7	3.5	.6	.3	.0	51	38	7	3	0
I05535	11.7	3.0	7.1	.8	.7	.1	26	61	7	6	1
I05544	9.1	2.8	5.1	.6	.7	.0	30	56	6	7	0
I05549	8.7	4.4	3.5	.6	.2	.0	50	40	7	2	0
MEAN	9.4	4.0	4.3	.6	.4	.0	44	46	7	4	0
S.D.	1.89	1.31	1.59	.10	.27	.04	12.5	10.3	1.0	2.4	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	8.3	3.5	3.0	1.3	.3	.2	42	37	15	3	2
I05541	10.4	4.4	4.9	.8	.2	.0	42	47	8	2	0
I05547	4.1	1.7	2.0	.3	.1	.0	41	48	8	3	0
I05550	12.0	8.2	2.9	.8	.1	.0	68	24	6	1	0
MEAN	8.7	4.4	3.2	.8	.2	.0	48	39	9	2	0
S.D.	3.42	2.74	1.22	.41	.10	.10	13.2	11.2	3.9	1.0	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	6.5	3.6	2.4	.3	.1	.0	56	37	5	2	0
I05538	9.5	5.2	3.2	.8	.2	.0	55	34	9	2	0
I05539	8.5	3.3	4.4	.5	.2	.0	39	52	6	2	1
I05545	8.8	4.4	3.5	.7	.1	.0	50	40	8	1	0
I05548	10.2	5.2	3.9	.7	.3	.0	51	38	7	3	0
I05552	8.9	4.9	3.1	.5	.4	.0	55	35	6	4	0
MEAN	8.7	4.4	3.4	.6	.2	.0	51	39	7	2	0
S.D.	1.25	.82	.69	.18	.12	.00	6.4	6.6	1.5	1.0	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.2	3.1	4.3	.7	.1	.1	38	53	8	1	1
I05534	8.5	4.1	3.1	1.0	.2	.1	48	37	12	3	1
I05536	5.7	2.8	2.2	.6	.2	.0	50	38	10	3	0
I05540	10.7	6.5	3.8	.4	.1	.0	60	35	4	1	0
I05542	9.5	7.0	2.2	.3	.0	.0	74	23	3	0	0
I05551	6.2	4.1	1.7	.4	.1	.0	66	27	6	1	0
MEAN	8.1	4.6	2.9	.6	.1	.0	56	36	7	2	0
S.D.	1.91	1.75	1.02	.26	.08	.05	13.1	10.4	3.5	1.2	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	6.44	12.3	39.3	61.0	19.1	31.4	351	.1	6
I05517	6.54	13.1	43.3	65.3	20.0	30.2	379	.2	13
I05519	7.40	12.8	42.9	58.0	17.3	29.9	447	.4	30
I05520	6.44	12.1	38.7	60.1	18.8	31.2	643	.0	0
I05526	6.28	11.7	38.6	61.3	18.7	30.5	354	.1	6
I05527	6.95	12.9	42.8	61.6	18.5	30.1	613	.7	49
MEAN	6.68	12.5	40.9	61.4	18.7	30.6	464	.2	17
S.D.	.421	.54	2.28	2.74	.88	.62	131.6	.26	18.7
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	6.80	12.0	40.8	59.9	17.7	29.5	389	.2	14
I05515	7.26	13.0	44.0	60.7	17.9	29.5	618	.2	15
I05516	6.55	12.4	39.6	60.5	18.9	31.2	296	.4	26
I05521	7.71	12.9	42.4	55.0	16.7	30.4	630	.0	0
MEAN	7.08	12.6	41.7	59.0	17.8	30.2	483	.2	14
S.D.	.513	.46	1.91	2.70	.90	.82	167.0	.16	10.7
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.35	12.6	40.5	63.7	19.9	31.2	406	.5	32
I05510	7.19	12.6	41.3	57.5	17.5	30.5	496	.2	14
I05518	7.53	13.2	43.4	57.6	17.6	30.5	546	.4	30
I05523	6.39	12.2	39.8	62.3	19.2	30.8	783	.4	26
I05524	6.74	12.8	42.8	63.5	19.1	30.0	515	.6	40
I05528	6.50	12.2	40.2	61.9	18.8	30.4	366	.6	39
MEAN	6.78	12.6	41.3	61.1	18.7	30.6	519	.4	30
S.D.	.479	.38	1.47	2.82	.95	.40	146.4	.15	9.6
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.78	13.4	45.6	59.0	17.3	29.3	486	.4	31
I05507	6.93	11.7	39.3	56.7	16.8	29.7	21	.1	7
I05509	6.08	10.3	36.1	59.4	16.9	28.5	373	.7	43
I05511	6.10	11.1	37.7	61.8	18.2	29.5	553	1.1	67
I05512	6.61	12.0	40.4	61.2	18.2	29.7	405	1.2	79
I05522	6.38	12.1	40.5	63.6	19.0	29.9	552	.1	6
MEAN	6.65	11.8	40.0	60.3	17.7	29.4	398	.6	39
S.D.	.641	1.04	2.32	2.43	.87	.50	199.1	.48	30.3
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	5.3	1.8	2.9	.3	.4	.0	34	54	5	7	0
I05517	6.7	1.7	4.5	.4	.0	.0	25	68	6	0	0
I05519	6.7	2.9	3.5	.2	.1	.0	43	52	3	1	0
I05520	7.8	2.3	4.3	.7	.3	.2	30	55	9	4	2
I05526	5.2	1.6	2.9	.6	.1	.0	32	56	11	1	0
I05527	12.3	5.9	5.1	1.0	.1	.0	48	42	8	1	0
MEAN	7.3	2.7	3.9	.5	.2	.0	35	54	7	2.7	0
S.D.	2.62	1.64	.91	.29	.15	.08	8.6	8.3	2.9	2.7	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	10.0	6.2	3.0	.4	.3	.0	62	30	4	3	0
I05515	8.8	3.1	4.8	.6	.2	.0	35	55	7	3	0
I05516	11.3	6.4	3.8	.9	.2	.0	56	34	8	2	0
I05521	9.6	6.8	2.3	.5	.1	.0	70	24	5	1	0
MEAN	9.9	5.6	3.5	.6	.2	.0	56	36	6	2	0
S.D.	1.04	1.70	1.08	.22	.08	.00	15.0	13.5	1.8	1.0	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	11.8	8.6	2.5	.5	.3	.0	73	21	4	2	0
I05510	9.3	5.5	3.1	.6	.1	.0	59	33	7	1	0
I05518	9.7	2.9	5.9	.8	.1	.1	30	61	9	1	1
I05523	13.8	8.3	4.4	.6	.4	.0	60	32	4	3	0
I05524	6.7	1.9	4.1	.7	.1	.1	28	61	10	1	1
I05528	9.2	3.8	3.9	.8	.6	.1	42	43	8	6	1
MEAN	10.1	5.2	4.0	.7	.3	.0	49	42	7	2	0
S.D.	2.44	2.81	1.17	.12	.21	.05	18.2	16.4	2.5	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	6.7	2.5	3.6	.5	.1	.0	38	54	7	1	0
I05507	8.9	3.9	4.4	.5	.1	.0	44	50	5	1	0
I05509	13.2	10.0	1.8	1.4	.0	.0	76	13	11	0	0
I05511	5.9	2.2	3.2	.3	.2	.0	37	55	6	3	0
I05512	7.6	2.2	4.0	1.2	.1	.0	29	53	15	2	0
I05522	11.6	5.2	4.9	.9	.5	.1	45	42	8	4	1
MEAN	9.0	4.3	3.6	.8	.2	.0	45	44	9	2	0
S.D.	2.87	3.02	1.08	.44	.18	.04	16.3	16.1	3.7	1.5	.4
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-



Appendix 4  
Individual Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.82	11.3	36.1	61.9	19.3	31.2	609	.2	12
I05530	6.31	12.5	41.0	65.1	19.8	30.4	544	.5	32
I05531	6.88	12.6	40.7	59.1	18.3	31.0	586	.1	7
I05535	7.30	12.9	42.9	59.7	17.7	30.2	469	.0	0
I05544	6.25	11.6	38.7	62.0	18.6	30.0	498	.7	44
I05549	7.02	13.6	44.4	63.3	19.3	30.5	416	.7	49
MEAN	6.60	12.4	40.6	61.7	18.8	30.6	520	.4	24
S.D.	.559	.85	2.96	2.45	.77	.46	73.1	.31	20.5
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.74	10.9	38.5	57.0	16.2	28.4	322	.4	27
I05541	5.74	12.2	40.3	70.3	21.2	30.2	385	1.5	86
I05547	6.96	11.7	39.0	56.0	16.8	30.0	450	.1	7
I05550	7.20	13.1	43.9	61.0	18.2	29.8	391	.5	36
MEAN	6.66	12.0	40.4	61.1	18.1	29.6	387	.6	39
S.D.	.641	.92	2.44	6.52	2.23	.82	52.3	.61	33.6
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.80	12.5	40.8	60.0	18.4	30.7	424	.7	48
I05538	6.37	11.7	38.5	60.5	18.4	30.4	425	.4	25
I05539	6.59	12.3	40.6	61.6	18.7	30.3	506	.3	20
I05545	7.00	12.7	41.5	59.3	18.1	30.6	326	.0	0
I05548	6.84	11.6	38.3	55.9	17.0	30.3	545	.2	14
I05552	6.39	11.9	39.4	61.6	18.7	30.3	532	.2	13
MEAN	6.66	12.1	39.9	59.8	18.2	30.4	460	.3	20
S.D.	.257	.45	1.31	2.12	.64	.18	83.7	.24	16.1
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.67	12.2	41.2	61.7	18.4	29.8	320	.3	20
I05534	6.20	12.1	41.4	66.7	19.5	29.3	582	.3	19
I05536	6.07	11.0	36.8	60.7	18.2	30.0	563	.1	6
I05540	5.97	11.5	37.3	62.4	19.2	30.8	491	.0	0
I05542	6.56	11.6	40.0	60.9	17.6	28.9	671	.1	7
I05551	6.51	11.9	40.3	61.9	18.3	29.6	322	.2	13
MEAN	6.33	11.7	39.5	62.4	18.5	29.7	492	.2	11
S.D.	.288	.44	1.98	2.21	.70	.65	144.0	.12	7.9
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	8.4	5.1	2.6	.6	.1	.0	60	31	7	1	0
I05530	8.3	1.8	5.9	.5	.1	.0	22	70	6	2	0
I05531	14.5	9.9	3.8	.7	.1	.0	68	26	5	1	0
I05535	8.3	2.4	4.4	1.0	.5	.1	28	52	12	6	1
I05544	8.7	2.9	3.9	1.3	.4	.1	34	45	15	5	1
I05549	10.0	5.3	3.8	.7	.1	.1	53	38	7	1	1
MEAN	9.7	4.6	4.1	.8	.2	.0	44	44	9	3	0
S.D.	2.44	2.98	1.08	.30	.18	.05	18.7	15.9	3.9	2.3	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	8.5	4.2	3.0	.9	.4	.2	49	35	10	4	2
I05541	6.5	2.2	3.6	.5	.1	.1	34	56	8	1	1
I05547	15.9	10.2	2.8	2.6	.1	.1	64	18	16	1	0
I05550	6.4	3.5	2.1	.5	.2	.0	55	34	9	2	0
MEAN	9.3	5.0	2.9	1.1	.2	.1	50	36	11	2	1
S.D.	4.49	3.55	.62	1.00	.14	.08	12.6	15.6	3.6	1.4	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	5.6	2.5	2.4	.6	.1	.0	45	43	10	1	1
I05538	10.6	6.6	2.9	.8	.3	.0	63	27	7	3	0
I05539	6.3	1.1	4.5	.5	.2	.0	18	71	8	3	0
I05545	11.0	5.3	4.8	.6	.2	.0	48	44	5	2	0
I05548	7.6	3.2	3.1	.8	.4	.0	42	41	11	5	0
I05552	7.5	3.4	3.0	.5	.5	.0	45	40	7	6	1
MEAN	8.1	3.7	3.4	.6	.3	.0	44	44	8	3	0
S.D.	2.23	1.98	.96	.14	.15	.00	14.5	14.4	2.2	1.9	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.2	2.1	4.9	.9	.2	.1	26	60	11	3	1
I05534	13.2	3.8	7.9	1.0	.4	.1	29	60	7	3	1
I05536	10.1	6.6	1.9	1.3	.2	.1	65	19	13	2	1
I05540	11.7	7.4	3.5	.6	.1	.0	64	30	5	1	0
I05542	9.0	5.0	3.6	.3	.2	.0	55	39	3	2	0
I05551	4.6	1.7	2.2	.6	.0	.0	38	48	13	1	1
MEAN	9.5	4.4	4.0	.8	.2	.0	46	43	9	2	1
S.D.	2.99	2.33	2.19	.35	.13	.05	17.4	16.5	4.3	.9	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

Appendix 4  
Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	6.43	12.8	40.3	62.7	19.9	31.7	404	.1	6
I05517	6.72	13.1	44.2	65.8	19.5	29.6	399	.2	13
I05519	7.22	12.7	42.0	58.1	17.6	30.2	445	.2	14
I05520	6.17	11.7	38.0	61.6	18.9	30.7	591	.1	6
I05526	6.48	12.2	40.4	62.3	18.8	30.2	392	.1	6
I05527	6.57	12.3	41.7	63.5	18.8	29.6	571	.3	20
MEAN	6.60	12.5	41.1	62.3	18.9	30.3	467	.2	11
S.D.	.354	.50	2.07	2.53	.78	.79	90.4	.08	5.8
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	6.88	12.1	42.5	61.7	17.6	28.5	398	.4	28
I05515	6.47	12.2	40.7	62.9	18.8	29.9	559	.2	13
I05516	6.61	12.5	40.8	61.7	18.9	30.6	246	.0	0
I05521	7.86	13.1	44.5	56.6	16.7	29.5	663	.1	8
MEAN	6.96	12.5	42.1	60.7	18.0	29.6	466	.2	12
S.D.	.627	.45	1.79	2.81	1.05	.88	183.0	.17	11.8
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.43	12.5	41.8	65.0	19.5	30.0	411	.3	19
I05510	6.98	12.4	40.8	58.4	17.8	30.4	464	.3	21
I05518	7.21	12.8	42.1	58.4	17.7	30.4	514	.3	22
I05523	6.50	12.6	40.7	62.6	19.3	30.9	526	.3	20
I05524	6.57	12.6	41.8	63.5	19.2	30.2	527	.2	13
I05528	6.21	11.9	39.0	62.9	19.1	30.4	380	.3	19
MEAN	6.65	12.5	41.0	61.8	18.8	30.4	470	.3	19
S.D.	.372	.31	1.15	2.76	.80	.30	63.1	.04	3.2
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506 a	7.69	13.3	44.3	57.7	17.2	29.9	560	.2	15
I05507	6.64	11.0	38.4	57.9	16.5	28.5	78 PA	.3	20
I05511	5.76	10.4	35.7	62.0	18.1	29.2	486	.5	29
I05512	6.46	11.7	39.8	61.6	18.1	29.4	429	.0	0
I05522	6.44	12.3	41.5	64.5	19.1	29.6	610	.0	0
MEAN	6.32	11.4	38.8	61.5	17.9	29.2	401	.2	12
S.D.	.387	.83	2.45	2.72	1.08	.48	228.0	.24	14.6
N	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

Appendix 4  
Individual Clinical Hematology Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	9.5	3.6	4.8	.6	.5	.0	38	50	6	6	0
I05517	9.0	2.6	5.6	.6	.1	.1	30	62	7	1	1
I05519	6.8	4.0	2.5	.3	.1	.0	58	37	4	1	0
I05520	12.0	5.8	5.0	.7	.4	.1	49	42	6	3	1
I05526	10.0	6.7	2.8	.4	.1	.0	67	28	4	1	0
I05527	10.8	2.8	6.0	1.6	.3	.1	26	55	15	3	1
MEAN	9.7	4.2	4.4	.7	.2	.0	45	46	7	2	0
S.D.	1.76	1.66	1.46	.46	.18	.05	16.1	12.4	4.1	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	8.9	5.7	2.6	.4	.2	.0	64	30	4	2	0
I05515	7.5	2.7	3.6	.9	.2	.0	36	48	12	3	1
I05516	8.1	5.8	1.9	.3	.1	.0	71	23	4	1	0
I05521	9.1	5.2	3.2	.6	.1	.0	58	35	6	1	0
MEAN	8.4	4.8	2.8	.6	.2	.0	57	34	6	2	0
S.D.	.74	1.46	.74	.26	.06	.00	15.1	10.6	3.8	1.0	.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	10.3	7.5	2.3	.4	.2	.0	72	22	4	2	0
I05510	9.1	4.6	3.9	.4	.1	.0	51	43	5	1	0
I05518	13.6	6.6	6.6	.3	.1	.0	48	48	2	0	0
I05523	10.8	6.3	3.8	.5	.1	.0	59	35	5	1	0
I05524	6.1	1.6	3.8	.5	.1	.0	26	63	9	1	0
I05528	10.0	4.6	4.1	.7	.6	.0	46	41	7	6	0
MEAN	10.0	5.2	4.1	.5	.2	.0	50	42	5	2	0
S.D.	2.44	2.10	1.39	.14	.20	.00	15.2	13.6	2.4	2.1	.0
N	6	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Hematology Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4      Dose Level: 0.75      Dosage Unit: mg/kg/day											
I05506 a	19.7	14.7	4.0	1.0	.0	.0	74	20	5	0	0
I05507	9.4	3.9	4.9	.4	.1	.0	42	52	5	1	0
I05511	5.1	2.0	2.3	.6	.2	.1	39	45	11	4	1
I05512	6.6	1.9	4.3	.4	.0	.0	28	66	5	0	0
I05522	9.2	3.9	4.5	.6	.2	.1	43	49	6	2	1
MEAN	7.6	2.9	4.0	.5	.1	.0	38	53	7	2	0
S.D.	2.09	1.13	1.16	.12	.10	.06	6.9	9.1	2.9	1.7	.6
N	4	4	4	4	4	4	4	4	4	4	4

a    Unscheduled sacrifice on Day 179.

Appendix 4  
Individual Clinical Hematology Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516 b	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506 a	-	-	-	-	-
I05507	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

a Unscheduled sacrifice on Day 179.  
b Plasmodium was observed.

Appendix 4  
Individual Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	5.66	11.0	35.7	63.0	19.5	31.0	595	.2	11
I05530	6.38	12.6	42.6	66.8	19.7	29.6	583	.4	26
I05531	6.63	12.0	40.5	61.2	18.1	29.5	534	.3	20
I05535	7.04	12.7	42.8	60.8	18.1	29.7	369	.2	14
I05544	6.20	11.9	40.9	65.9	19.2	29.1	439	.8	50
I05549	6.52	12.5	42.3	64.9	19.2	29.6	383	.6	39
MEAN	6.40	12.1	40.8	63.8	19.0	29.7	484	.4	27
S.D.	.461	.64	2.67	2.49	.70	.65	100.1	.24	15.1
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	6.69	10.8	38.9	58.2	16.2	27.9	442	.2	13
I05541	5.80	12.2	41.4	71.3	21.1	29.5	380	.2	12
I05547	5.20	9.0	30.1	58.0	17.4	30.0	501	.4	21
I05550	6.92	12.7	42.7	61.8	18.3	29.7	394	.1	7
MEAN	6.15	11.2	38.3	62.3	18.2	29.3	429	.2	13
S.D.	.798	1.66	5.67	6.23	2.09	.94	54.7	.13	5.8
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	6.65	12.3	40.8	61.3	18.4	30.1	373	.3	20
I05538	6.14	11.0	37.6	61.2	17.9	29.3	381	.3	18
I05539	6.67	12.5	41.9	62.7	18.8	29.9	400	.2	13
I05545	6.81	12.4	41.0	60.3	18.3	30.3	318	.0	0
I05548	6.75	11.3	37.8	56.1	16.8	30.0	484	.2	14
I05552	6.38	11.9	40.2	63.0	18.7	29.7	517	.1	6
MEAN	6.57	11.9	39.9	60.8	18.2	29.9	412	.2	12
S.D.	.256	.62	1.78	2.50	.73	.35	74.4	.12	7.5
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.00	11.3	37.6	62.6	18.9	30.1	288	.2	12
I05534	5.65	11.0	37.7	65.8	18.4	29.1	587	.5	28
I05536	6.08	10.9	39.3	64.6	17.9	27.8	559	.0	0
I05540	5.99	11.6	38.6	64.5	19.3	29.9	454	.0	0
I05542	6.75	11.9	43.4	64.3	17.7	27.5	725	.4	27
I05551	6.09	11.3	38.4	63.1	18.6	29.5	328	.1	6
MEAN	6.09	11.3	39.2	64.3	18.6	29.0	490	.2	12
S.D.	.360	.37	2.17	1.46	.71	1.09	166.0	.21	12.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	14.6	11.4	2.5	.6	.1	.1	78	17	4	1	1
I05530	7.3	2.6	3.9	.6	.2	.0	35	54	8	3	0
I05531	10.5	5.2	4.3	.7	.2	.1	50	41	7	2	1
I05535	13.9	5.5	7.0	1.0	.3	.1	39	50	7	2	1
I05544	10.4	2.9	6.2	.6	.6	.0	28	60	6	6	0
I05549	5.4	2.4	2.1	.7	.1	.0	44	40	14	2	0
MEAN	10.4	5.0	4.3	.7	.2	.0	46	44	8	3	0
S.D.	3.59	3.41	1.96	.15	.19	.05	17.5	15.1	3.4	1.8	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	10.1	5.4	3.1	1.1	.4	.2	54	30	11	4	2
I05541	6.6	2.4	3.5	.5	.2	.0	37	53	7	3	0
I05547	6.8	4.0	2.4	.4	.1	.0	58	35	6	1	0
I05550	10.4	5.5	3.7	.8	.4	.0	53	35	7	4	0
MEAN	8.5	4.3	3.2	.7	.3	.0	50	38	8	3	0
S.D.	2.05	1.45	.57	.22	.15	.10	9.3	10.1	2.2	1.4	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	8.2	3.9	3.8	.4	.1	.0	48	46	5	1	0
I05538	9.2	4.5	3.8	.6	.3	.0	49	41	6	4	0
I05539	7.5	1.6	4.9	.8	.1	.1	22	65	10	2	2
I05545	11.0	6.3	3.9	.6	.1	.0	57	36	6	1	0
I05548	11.3	6.2	3.7	.6	.7	.0	55	33	5	6	0
I05552	8.0	4.3	3.0	.3	.4	.0	54	37	4	4	0
MEAN	9.2	4.5	3.8	.6	.3	.0	48	43	6	3	0
S.D.	1.61	1.73	.61	.18	.24	.04	13.0	11.7	2.1	2.0	.8
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	7.5	3.2	3.8	.4	.1	.1	42	51	5	1	1
I05534	12.1	5.0	6.0	1.0	.2	.1	41	49	8	1	1
I05536	8.4	4.1	2.8	1.2	.2	.1	49	34	14	2	1
I05540	10.3	5.9	3.8	.5	.1	.0	58	37	5	1	0
I05542	13.4	3.0	9.3	.8	.3	.1	22	69	6	3	0
I05551	6.4	4.0	1.8	.5	.1	.0	63	28	8	1	0
MEAN	9.7	4.2	4.6	.7	.2	.1	46	45	8	2	0
S.D.	2.73	1.10	2.70	.32	.08	.05	14.6	14.8	3.4	.8	.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Hematology Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mCL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mCL	RETIC %	RETIC X10 <sup>3</sup> /mCL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	6.27	12.1	38.3	61.0	19.3	31.7	620	.3	19
I05526	6.26	11.8	37.9	60.5	18.9	31.2	346	.4	25
MEAN	6.26	12.0	38.1	60.8	19.1	31.5	483	.4	22
S.D.	.007	.21	.28	.35	.28	.35	193.7	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.53	13.0	41.6	63.7	19.9	31.3	404	.4	26
I05523	6.45	12.4	39.8	61.8	19.3	31.2	572	.2	13
MEAN	6.49	12.7	40.7	62.8	19.6	31.2	488	.3	20
S.D.	.057	.42	1.27	1.34	.42	.07	118.8	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	5.93	11.6	38.2	64.5	19.5	30.3	485	.3	18
I05522	5.87	11.5	37.3	63.5	19.6	30.9	453	.6	35
MEAN	5.90	11.6	37.8	64.0	19.5	30.6	469	.4	26
S.D.	.042	.07	.64	.71	.07	.42	22.6	.21	12.0
N	2	2	2	2	2	2	2	2	2



APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	8.5	2.5	5.2	.5	.3	.0	30	61	6	3	1
I05526	6.1	2.3	2.9	.7	.2	.0	37	47	12	3	1
MEAN	7.3	2.4	4.0	.6	.2	.0	34	54	9	3	1
S.D.	1.70	.14	1.63	.14	.07	.00	4.9	9.9	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	8.8	4.7	3.0	.7	.4	.0	53	34	8	5	0
I05523	14.2	7.6	6.0	.4	.2	.0	53	42	3	1	0
MEAN	11.5	6.2	4.5	.6	.3	.0	53	38	6	3	0
S.D.	3.82	2.05	2.12	.21	.14	.00	.0	5.7	3.5	2.8	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	8.9	4.1	3.9	.5	.4	.0	46	44	5	4	0
I05522	14.7	7.9	5.0	1.3	.5	.0	54	34	9	4	0
MEAN	11.8	6.0	4.4	.9	.4	.0	50	39	7	4	0
S.D.	4.10	2.69	.78	.57	.07	.00	5.7	7.1	2.8	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1		Dose Level: 0		Dosage Unit: mg/kg/day					
I05529	5.44	10.9	32.5	61.5	20.1	32.7	547	.1	5
I05549	6.45	12.6	40.3	62.4	19.6	31.3	390	.5	32
MEAN	5.94	11.8	36.9	62.0	19.8	32.0	468	.3	18
S.D.	.714	1.20	4.81	.64	.35	.99	111.0	.28	19.1
N	2	2	2	2	2	2	2	2	2
Group: 3		Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05539	6.07	11.8	37.2	61.4	19.5	31.8	382	.2	12
I05552	6.20	12.0	38.0	61.3	19.4	31.6	435	.5	31
MEAN	6.14	11.9	37.6	61.4	19.5	31.7	408	.4	22
S.D.	.092	.14	.57	.07	.07	.14	37.5	.21	13.4
N	2	2	2	2	2	2	2	2	2
Group: 4		Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05533	6.13	11.8	38.2	62.2	19.2	30.8	330	.3	18
I05542	6.72	12.2	42.3	63.0	18.2	28.9	557	.7	47
MEAN	6.42	12.0	40.2	62.6	18.7	29.8	444	.5	32
S.D.	.417	.28	2.90	.57	.71	1.34	160.5	.28	20.5
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mCL	N-SEG X10 <sup>3</sup> /mCL	LYMPH X10 <sup>3</sup> /mCL	MONO X10 <sup>3</sup> /mCL	EOSIN X10 <sup>3</sup> /mCL	BASO X10 <sup>3</sup> /mCL	N-SEG% X10 <sup>3</sup> /mCL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	10.1	6.1	3.0	.8	.1	.0	60	30	8	1	0
I05549	6.2	3.1	2.5	.4	.1	.0	50	41	7	2	0
MEAN	8.2	4.6	2.8	.6	.1	.0	55	36	8	2	0
S.D.	2.76	2.12	.35	.28	.00	.00	7.1	7.8	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	6.9	1.8	4.3	.7	.2	.1	26	61	10	3	1
I05552	8.4	3.5	3.8	.5	.5	.0	41	45	6	6	1
MEAN	7.6	2.6	4.0	.6	.4	.0	34	53	8	4	1
S.D.	1.06	1.20	.35	.14	.21	.07	10.6	11.3	2.8	2.1	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	7.7	2.1	5.0	.3	.3	.0	27	65	4	4	0
I05542	10.9	3.0	6.7	.8	.2	.1	28	62	8	2	1
MEAN	9.3	2.6	5.8	.6	.2	.0	28	64	6	3	0
S.D.	2.26	.64	1.20	.35	.07	.07	.7	2.1	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----	-----	-----	-----	-----	-----
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.75	13.0	40.6	60.2	19.3	32.1	685	.1	7
I05526	6.28	12.2	37.9	60.3	19.4	32.1	428	.3	19
MEAN	6.52	12.6	39.2	60.2	19.4	32.1	556	.2	13
S.D.	.332	.57	1.91	.07	.07	.00	181.7	.14	8.5
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.75	13.3	42.5	62.9	19.8	31.4	467	.1	7
I05523	6.82	13.3	41.8	61.3	19.4	31.7	519	.2	14
MEAN	6.78	13.3	42.2	62.1	19.6	31.6	493	.2	10
S.D.	.049	.00	.49	1.13	.28	.21	36.8	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.06	11.4	39.0	64.4	18.8	29.2	501	.8	48
I05522	6.33	12.4	39.9	63.0	19.5	31.0	562	.4	25
MEAN	6.20	11.9	39.5	63.7	19.2	30.1	532	.6	36
S.D.	.191	.71	.64	.99	.49	1.27	43.1	.28	16.3
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	12.1	3.8	7.6	.5	.3	.0	31	63	4	2	0
I05526	8.0	2.7	4.6	.4	.3	.0	33	58	5	4	0
MEAN	10.0	3.2	6.1	.4	.3	.0	32	60	4	3	0
S.D.	2.90	.78	2.12	.07	.00	.00	1.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	10.6	5.2	4.1	.8	.4	.0	49	39	8	4	0
I05523	12.2	5.8	5.6	.4	.3	.0	48	46	3	2	0
MEAN	11.4	5.5	4.8	.6	.4	.0	48	42	6	3	0
S.D.	1.13	.42	1.06	.28	.07	.00	.7	4.9	3.5	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	9.5	3.6	4.9	.6	.4	.1	38	51	6	4	1
I05522	17.3	7.6	7.4	1.5	.6	.1	44	43	9	4	1
MEAN	13.4	5.6	6.2	1.0	.5	.1	41	47	8	4	1
S.D.	5.52	2.83	1.77	.64	.14	.00	4.2	5.7	2.1	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----	-----	-----	-----	-----	-----
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-



APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	5.70	11.3	34.9	61.1	19.8	32.4	577	.2	11
I05549	6.74	13.3	41.9	62.1	19.7	31.7	461	.3	20
MEAN	6.22	12.3	38.4	61.6	19.8	32.1	519	.2	16
S.D.	.735	1.41	4.95	.71	.07	.49	82.0	.07	6.4
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	6.88	12.9	40.9	59.4	18.7	31.4	391	.1	7
I05552	6.61	12.5	40.4	61.2	18.9	31.0	459	.2	13
MEAN	6.74	12.7	40.7	60.3	18.8	31.2	425	.2	10
S.D.	.191	.28	.35	1.27	.14	.28	48.1	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	6.38	12.2	39.9	62.5	19.2	30.7	335	.1	6
I05542	7.02	12.8	44.1	62.8	18.2	29.0	546	.4	28
MEAN	6.70	12.5	42.0	62.7	18.7	29.8	440	.2	17
S.D.	.453	.42	2.97	.21	.71	1.20	149.2	.21	15.6
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	12.5	9.1	2.8	.5	.1	.0	73	22	4	1	0
I05549	10.3	5.1	4.0	.9	.3	.0	50	39	8	3	0
MEAN	11.4	7.1	3.4	.7	.2	.0	62	30	6	2	0
S.D.	1.56	2.83	.85	.28	.14	.00	16.3	12.0	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	7.5	.9	5.3	1.0	.2	.1	12	71	13	3	1
I05552	11.4	5.1	4.6	1.0	.6	.0	45	40	9	5	0
MEAN	9.4	3.0	5.0	1.0	.4	.0	28	56	11	4	0
S.D.	2.76	2.97	.49	.00	.28	.07	23.3	21.9	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	10.8	4.5	5.0	1.1	.2	.1	41	46	10	1	1
I05542	11.1	2.6	7.5	.7	.3	.1	23	67	6	3	1
MEAN	11.0	3.6	6.2	.9	.2	.1	32	56	8	2	1
S.D.	.21	1.34	1.77	.28	.07	.00	12.7	14.8	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----	-----	-----	-----	-----	-----
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05549 a	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05542	-	-	-	-	-

a Plasmodium was observed.

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	6.86	13.0	41.6	60.6	19.0	31.3	666	.2	14
I05526	6.58	12.3	38.6	58.7	18.7	31.9	343	.3	20
MEAN	6.72	12.6	40.1	59.6	18.8	31.6	504	.2	17
S.D.	.198	.49	2.12	1.34	.21	.42	228.4	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.86	13.4	43.2	62.9	19.5	31.0	421	.6	41
I05523	6.71	12.8	40.3	60.1	19.1	31.7	570	.2	13
MEAN	6.78	13.1	41.8	61.5	19.3	31.4	496	.4	27
S.D.	.106	.42	2.05	1.98	.28	.49	105.4	.28	19.8
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	6.10	11.5	39.3	64.4	18.9	29.3	476	.4	24
I05522	6.80	13.1	42.7	62.8	19.2	30.6	562	.2	14
MEAN	6.45	12.3	41.0	63.6	19.1	29.9	519	.3	19
S.D.	.495	1.13	2.40	1.13	.21	.92	60.8	.14	7.1
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	7.6	2.4	4.0	1.0	.1	.0	32	53	13	2	1
I05526	7.0	2.8	3.4	.5	.1	.1	41	49	7	2	1
MEAN	7.3	2.6	3.7	.8	.1	.0	36	51	10	2	1
S.D.	.42	.28	.42	.35	.00	.07	6.4	2.8	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	13.1	8.1	4.0	.6	.3	.0	62	30	5	3	0
I05523	9.9	5.2	4.2	.3	.1	.0	53	42	3	1	0
MEAN	11.5	6.6	4.1	.4	.2	.0	58	36	4	2	0
S.D.	2.26	2.05	.14	.21	.14	.00	6.4	8.5	1.4	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	7.2	2.5	4.0	.5	.2	.0	34	56	7	2	1
I05522	16.0	7.5	6.7	1.2	.5	.1	47	42	7	3	1
MEAN	11.6	5.0	5.4	.8	.4	.0	40	49	7	2	1
S.D.	6.22	3.54	1.91	.49	.21	.07	9.2	9.9	.0	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	5.55	11.1	32.7	60.7	20.0	33.0	606	.4	22
I05549	7.08	13.5	44.4	62.7	19.0	30.3	414	.4	28
MEAN	6.32	12.3	39.0	61.7	19.5	31.6	510	.4	25
S.D.	1.082	1.70	7.57	1.41	.71	1.91	135.8	.00	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	6.59	12.6	39.7	60.2	19.1	31.7	419	.5	33
I05552	6.69	12.5	40.5	60.5	18.6	30.8	427	.2	13
MEAN	6.64	12.6	40.1	60.3	18.8	31.2	423	.4	23
S.D.	.071	.07	.57	.21	.35	.64	5.7	.21	14.1
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	6.49	12.2	39.7	61.2	18.8	30.7	343	.7	45
I05542	7.07	12.7	41.9	59.3	17.9	30.2	538	.2	14
MEAN	6.78	12.5	40.8	60.2	18.4	30.5	440	.4	30
S.D.	.410	.35	1.56	1.34	.64	.35	137.9	.35	21.9
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	9.6	7.1	2.1	.4	.0	.0	73	22	4	0	0
I05549	8.0	3.7	3.5	.6	.1	.0	46	44	8	2	1
MEAN	8.8	5.4	2.8	.5	.0	.0	60	33	6	1	0
S.D.	1.13	2.40	.99	.14	.07	.00	19.1	15.6	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	6.2	1.1	4.3	.5	.2	.0	18	69	8	4	1
I05552	9.4	4.7	3.4	.6	.6	.1	50	37	7	6	1
MEAN	7.8	2.9	3.8	.6	.4	.0	34	53	8	5	1
S.D.	2.26	2.55	.64	.07	.28	.07	22.6	22.6	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	10.8	5.0	4.7	1.0	.1	.1	46	43	9	0	1
I05542	7.6	3.7	3.5	.3	.1	.0	49	46	4	1	0
MEAN	9.2	4.4	4.1	.6	.1	.0	48	44	6	0	0
S.D.	2.26	.92	.85	.49	.00	.07	2.1	2.1	3.5	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2



APPENDIX 4

Individual Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	6.78	12.9	40.6	59.8	19.0	31.8	692	.5	34
I05526	6.67	12.4	39.8	59.7	18.6	31.2	396	.1	7
MEAN	6.72	12.6	40.2	59.8	18.8	31.5	544	.3	20
S.D.	.078	.35	.57	.07	.28	.42	209.3	.28	19.1
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	6.89	13.6	43.2	62.6	19.8	31.6	434	.2	14
I05523	6.71	12.8	40.6	60.5	19.1	31.5	548	.1	7
MEAN	6.80	13.2	41.9	61.5	19.4	31.5	491	.2	10
S.D.	.127	.57	1.84	1.48	.49	.07	80.6	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	6.08	11.5	37.8	62.1	18.9	30.5	542	.8	49
I05522	6.36	12.1	38.3	60.2	19.0	31.5	603	.3	19
MEAN	6.22	11.8	38.1	61.1	19.0	31.0	572	.6	34
S.D.	.198	.42	.35	1.34	.07	.71	43.1	.35	21.2
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	9.5	4.3	4.5	.6	.1	.0	45	47	7	1	0
I05526	7.8	4.0	3.0	.7	.1	.0	52	38	9	1	0
MEAN	8.6	4.2	3.8	.6	.1	.0	48	42	8	1	0
S.D.	1.20	.21	1.06	.07	.00	.00	4.9	6.4	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	13.7	9.6	3.0	.9	.2	.0	70	22	7	1	0
I05523	11.8	6.7	4.4	.6	.1	.0	57	37	5	1	0
MEAN	12.8	8.2	3.7	.8	.2	.0	64	30	6	1	0
S.D.	1.34	2.05	.99	.21	.07	.00	9.2	10.6	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	6.3	2.2	3.1	.8	.2	.1	36	49	12	3	1
I05522	11.6	5.8	4.7	.9	.1	.0	50	40	8	1	0
MEAN	9.0	4.0	3.9	.8	.2	.0	43	44	10	2	0
S.D.	3.75	2.55	1.13	.07	.07	.07	9.9	6.4	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----	-----	-----	-----	-----	-----
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>5</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	6.04	11.9	36.9	61.1	19.7	32.2	645	.1	6
I05549	6.61	12.8	39.9	60.4	19.4	32.1	447	.3	20
MEAN	6.32	12.3	38.4	60.8	19.6	32.1	546	.2	13
S.D.	.403	.64	2.12	.49	.21	.07	140.0	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	6.81	12.5	39.6	59.2	18.3	31.5	399	.4	27
I05552	6.71	12.5	40.7	60.7	18.6	30.6	546	.3	20
MEAN	6.76	12.5	40.1	59.4	18.4	31.0	472	.4	24
S.D.	.071	.00	.78	1.77	.21	.64	103.9	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	6.20	11.6	37.9	61.2	18.8	30.7	314	.1	6
I05542	6.81	12.2	41.0	60.3	17.9	29.7	534	.5	34
MEAN	6.50	11.9	39.5	60.8	18.4	30.2	424	.3	20
S.D.	.431	.42	2.19	.64	.64	.71	155.6	.28	19.8
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG% X10 <sup>3</sup> /mcL	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	14.9	10.0	3.2	1.4	.2	.0	67	22	10	1	0
I05549	8.7	4.4	3.3	.6	.3	.0	51	38	7	3	0
MEAN	11.8	7.2	3.2	1.0	.2	.0	59	30	8	2	0
S.D.	4.38	3.96	.07	.57	.07	.00	11.3	11.3	2.1	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	7.4	2.0	4.5	.7	.2	.0	27	61	10	3	0
I05552	11.4	6.5	3.9	.4	.6	.0	57	34	4	5	0
MEAN	9.4	4.2	4.2	.6	.4	.0	42	48	7	4	0
S.D.	2.83	3.18	.42	.21	.28	.00	21.2	19.1	4.2	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	7.8	2.3	5.0	.5	.1	.0	29	63	7	1	0
I05542	10.0	3.1	6.1	.6	.2	.0	31	61	6	2	0
MEAN	8.9	2.7	5.6	.6	.2	.0	30	62	6	2	0
S.D.	1.56	.57	.78	.07	.07	.00	1.4	1.4	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
-----	-----	-----	-----	-----	-----
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05542	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.50	12.5	39.5	60.8	19.3	31.7	641	.2	13
I05526	6.56	12.4	39.4	60.1	19.0	31.6	387	.0	0
MEAN	6.53	12.4	39.5	60.5	19.2	31.6	514	.1	6
S.D.	.042	.07	.07	.49	.21	.07	179.6	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.92	13.5	43.3	62.7	19.6	31.3	399	.2	14
I05523	6.52	12.6	39.1	60.0	19.2	32.1	496	.0	0
MEAN	6.72	13.0	41.2	61.3	19.4	31.7	448	.1	7
S.D.	.283	.64	2.97	1.91	.28	.57	68.6	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.09	12.0	39.1	64.2	19.7	30.6	520	1.5	91
I05522	6.37	12.3	38.7	60.8	19.3	31.8	495	.0	0
MEAN	6.23	12.2	38.9	62.5	19.5	31.2	508	.8	46
S.D.	.198	.21	.28	2.40	.28	.85	17.7	1.06	64.3
N	2	2	2	2	2	2	2	2	2



APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	10.7	5.9	4.1	.6	.0	.1	55	38	6	0	1
I05526	10.9	7.3	2.8	.8	.1	.0	67	25	7	1	0
MEAN	10.8	6.6	3.4	.7	.0	.0	61	32	6	0	0
S.D.	.14	.99	.92	.14	.07	.07	8.5	9.2	2.7	2.7	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	13.8	9.6	3.0	1.1	.2	.0	69	21	8	1	0
I05523	11.2	6.8	4.0	.4	.0	.0	60	36	4	0	0
MEAN	12.5	8.2	3.5	.8	.1	.0	64	28	6	0	0
S.D.	1.84	1.98	.71	.49	.14	.00	6.4	10.6	2.8	2.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	9.4	4.5	3.7	.8	.3	.0	48	40	9	3	0
I05522	15.0	8.3	4.8	1.4	.4	.1	55	32	9	3	1
MEAN	12.2	6.4	4.2	1.1	.4	.0	52	36	9	3	0
S.D.	3.96	2.69	.78	.42	.07	.07	4.9	5.7	2.0	2.0	.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 364  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.96	11.9	36.1	60.5	19.9	32.9	635	.1	6
I05549	6.60	13.0	40.2	61.0	19.7	32.3	433	.2	13
MEAN	6.28	12.4	38.1	60.8	19.8	32.6	534	.2	10
S.D.	.453	.78	2.90	.35	.14	.42	142.8	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.69	12.5	39.8	59.5	18.7	31.4	408	.2	13
I05552	6.85	12.7	41.7	60.8	18.6	30.5	504	.1	7
MEAN	6.77	12.6	40.8	60.2	18.6	31.0	456	.2	10
S.D.	.113	.14	1.34	.92	.07	.64	67.9	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.56	12.2	39.7	60.5	18.7	30.9	320	.1	7
I05542	6.52	12.1	40.5	62.1	18.5	29.8	577	.2	13
MEAN	6.54	12.2	40.1	61.3	18.6	30.4	448	.2	10
S.D.	.028	.07	.57	1.13	.14	.78	181.7	.07	4.2
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	8.5	4.2	3.1	.8	.3	.0	50	36	10	4	0
I05549	6.4	2.6	2.5	1.2	.1	.0	41	38	19	2	0
MEAN	7.4	3.4	2.8	1.0	.2	.0	46	37	14	3	0
S.D.	1.48	1.13	.42	.28	.14	.00	6.4	1.4	6.4	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	8.5	2.5	4.4	1.2	.3	.1	30	52	14	3	1
I05552	7.7	3.5	3.0	.6	.5	.0	45	39	8	7	0
MEAN	8.1	3.0	3.7	.9	.4	.0	38	46	11	5	0
S.D.	.57	.71	.99	.42	.14	.07	10.6	9.2	4.2	2.8	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	11.4	5.1	5.1	1.1	.0	.0	44	45	10	0	0
I05542	10.3	4.3	5.4	.5	.2	.0	42	52	5	2	0
MEAN	10.8	4.7	5.2	.8	.1	.0	43	48	8	1	0
S.D.	.78	.57	.21	.42	.14	.00	1.4	4.9	3.5	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mL	RETIC %	RETIC X10 <sup>3</sup> /mL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.82	13.3	41.2	60.4	19.4	32.2	584	.4	27
I05526	6.44	12.5	39.3	61.0	19.4	31.8	337	.2	13
MEAN	6.63	12.9	40.2	60.7	19.4	32.0	460	.3	20
S.D.	.269	.57	1.34	.42	.00	.28	174.7	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	7.19	14.1	46.3	64.3	19.6	30.5	415	.5	36
I05523	7.12	13.8	44.9	63.0	19.4	30.8	566	.1	7
MEAN	7.16	14.0	45.6	63.7	19.5	30.6	490	.3	22
S.D.	.049	.21	.99	.92	.14	.21	106.8	.28	20.5
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	5.93	11.9	38.7	65.3	20.1	30.9	445	1.4	83
I05522	6.68	13.2	42.5	63.7	19.8	31.1	576	.0	0
MEAN	6.30	12.6	40.6	64.5	19.9	31.0	510	.7	42
S.D.	.530	.92	2.69	1.13	.21	.14	92.6	.99	58.7
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	11.2	5.4	4.9	.7	.1	.1	48	44	6	1	1
I05526	12.0	7.5	3.8	.6	.1	.0	62	32	5	1	0
MEAN	11.6	6.4	4.4	.6	.1	.0	55	38	6	1	0
S.D.	.57	1.48	.78	.07	.00	.07	9.9	8.5	2.7	2.0	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	10.7	4.1	5.6	.8	.2	.0	38	52	7	2	0
I05523	12.5	5.7	6.2	.5	.2	.0	45	49	4	1	0
MEAN	11.6	4.9	5.9	.6	.2	.0	42	50	6	2	0
S.D.	1.27	1.13	.42	.21	.00	.00	4.9	2.1	2.1	2.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	12.0	7.5	3.5	.7	.2	.1	63	29	6	1	1
I05522	21.2	13.1	6.0	1.6	.5	.1	62	28	7	3	0
MEAN	16.6	10.3	4.8	1.2	.4	.1	62	28	6	2	0
S.D.	6.51	3.96	1.77	.64	.21	.00	.7	2.7	2.7	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 456  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-



APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	5.63	11.3	34.8	61.8	20.1	32.6	580	.6	34
I05549	6.88	13.5	42.2	61.3	19.6	31.9	407	.4	28
MEAN	6.26	12.4	38.5	61.6	19.8	32.2	494	.5	31
S.D.	.884	1.56	5.23	.35	.35	.49	122.3	.14	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	6.61	12.7	40.2	60.9	19.3	31.7	441	.4	26
I05552	6.70	12.7	41.4	61.9	19.0	30.6	461	.2	13
MEAN	6.66	12.7	40.8	61.4	19.2	31.2	451	.3	20
S.D.	.064	.00	.85	.71	.21	.78	14.1	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	6.62	12.7	40.7	61.4	19.1	31.2	293	.0	0
I05542	7.51	13.5	45.2	60.1	18.0	29.9	598	.3	23
MEAN	7.06	13.1	42.9	60.8	18.5	30.6	446	.2	12
S.D.	.629	.57	3.18	.92	.78	.92	215.7	.21	16.3
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	8.2	4.5	2.9	.6	.2	.0	55	36	7	2	0
I05549	9.3	4.3	3.8	.8	.4	.0	46	41	8	4	0
MEAN	8.8	4.4	3.4	.7	.3	.0	50	38	8	3	0
S.D.	.78	.14	.64	.14	.14	.00	6.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	11.1	5.0	4.7	1.0	.4	.0	45	43	9	3	0
I05552	8.7	2.6	4.6	.8	.8	.0	29	52	9	9	0
MEAN	9.9	3.8	4.6	.9	.6	.0	37	48	9	6	0
S.D.	1.70	1.70	.07	.14	.28	.00	11.3	6.4	.0	4.2	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	9.9	3.5	5.1	1.0	.2	.1	36	51	10	2	1
I05542	11.2	2.5	7.3	.9	.4	.2	22	65	8	4	2
MEAN	10.6	3.0	6.2	1.0	.3	.2	29	58	9	3	2
S.D.	.92	.71	1.56	.07	.14	.07	9.9	9.9	1.4	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>3</sup> /mcL	RETIC %	RETIC X10 <sup>3</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.54	12.6	39.9	61.0	19.2	31.5	503	.7	46
I05526	6.59	12.6	41.4	62.8	19.1	30.5	366	.3	20
MEAN	6.56	12.6	40.7	61.9	19.2	31.0	434	.5	33
S.D.	.035	.00	1.06	1.27	.07	.71	96.9	.28	18.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.80	13.5	43.6	64.1	19.8	30.9	377	.7	48
I05523	7.00	13.8	44.2	63.1	19.8	31.3	369	.7	49
MEAN	6.90	13.6	43.9	63.6	19.8	31.1	373	.7	48
S.D.	.141	.21	.42	.71	.00	.28	5.7	.00	.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.42	12.7	43.5	67.6	19.7	29.2	478	.9	58
I05522	6.42	12.5	41.3	64.3	19.5	30.3	562	.3	19
MEAN	6.42	12.6	42.4	66.0	19.6	29.8	520	.6	38
S.D.	.000	.14	1.56	2.33	.14	.78	59.4	.42	27.6
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	7.1	2.0	4.3	.5	.1	.3	28	60	7	1	4
I05526	9.6	4.2	4.1	1.1	.1	.0	44	43	11	1	1
MEAN	8.4	3.1	4.2	.8	.1	.2	36	52	9	1	2
S.D.	1.77	1.56	.14	.42	.00	.21	11.3	12.0	2.8	.0	2.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	8.1	3.8	3.2	.9	.2	.1	47	39	11	2	1
I05523	13.7	6.2	6.2	.7	.5	.1	45	45	5	3	1
MEAN	10.9	5.0	4.7	.8	.4	.1	46	42	8	2	1
S.D.	3.96	1.70	2.12	.14	.21	.00	1.4	4.2	4.2	2.7	1.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	15.7	10.9	3.4	1.2	.1	.1	70	22	7	1	1
I05522	16.2	8.8	5.4	1.3	.4	.3	54	33	8	2	2
MEAN	16.0	9.8	4.4	1.2	.2	.2	62	28	8	2	2
S.D.	.35	1.48	1.41	.07	.21	.14	11.3	7.8	2.7	2.7	2.7
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Males Day 546  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

APPENDIX 4  
Individual Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10 <sup>6</sup> /mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 <sup>9</sup> /mcL	RETIC %	RETIC X10 <sup>9</sup> /mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.52	11.1	34.6	62.6	20.1	32.1	533	.6	33
I05549	6.51	12.6	40.5	62.3	19.4	31.1	483	.3	20
MEAN	6.02	11.8	37.5	62.5	19.8	31.6	508	.4	26
S.D.	.700	1.06	4.17	.21	.49	.71	35.4	.21	9.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.60	12.6	41.2	62.4	19.1	30.7	405	.3	20
I05552	6.33	12.0	39.3	62.1	18.9	30.5	408	.6	38
MEAN	6.46	12.3	40.2	62.2	19.0	30.6	406	.4	29
S.D.	.191	.42	1.34	.21	.14	.14	2.1	.21	12.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.62	12.5	41.0	61.9	18.9	30.5	293	.2	13
I05542	6.81	12.3	40.6	59.7	18.1	30.3	500	.4	27
MEAN	6.72	12.4	40.8	60.8	18.5	30.4	396	.3	20
S.D.	.134	.14	.28	1.56	.57	.14	146.4	.14	9.9
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Hematology Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC X10 <sup>3</sup> /mcL	N-SEG X10 <sup>3</sup> /mcL	LYMPH X10 <sup>3</sup> /mcL	MONO X10 <sup>3</sup> /mcL	EOSIN X10 <sup>3</sup> /mcL	BASO X10 <sup>3</sup> /mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	6.9	3.5	2.5	.7	.2	.1	50	36	10	2	1
I05549	15.6	10.5	3.2	1.3	.4	.2	67	20	9	3	1
MEAN	11.2	7.0	2.8	1.0	.3	.2	58	28	10	2	1
S.D.	6.15	4.95	.49	.42	.14	.07	12.0	11.3	2.7	2.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	13.8	7.1	5.1	1.0	.4	.2	51	37	8	3	2
I05552	9.2	3.8	3.4	1.1	.7	.2	41	37	12	7	2
MEAN	11.5	5.4	4.2	1.0	.6	.2	46	37	10	5	2
S.D.	3.25	2.33	1.20	.07	.21	.00	7.1	2.0	2.8	2.8	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	9.8	3.2	5.7	.5	.1	.2	33	58	5	1	2
I05542	11.0	3.0	7.0	.5	.3	.1	28	64	5	2	1
MEAN	10.4	3.1	6.4	.5	.2	.2	30	61	5	2	2
S.D.	.85	.14	.92	.00	.14	.07	3.5	4.2	2.0	2.7	.7
N	2	2	2	2	2	2	2	2	2	2	2



APPENDIX 4

Individual Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

Appendix 4  
Individual Clinical Chemistry Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05508	62	22	1.0	8.7	4.6	4.1	1.3	5	88	71
I05517	76	21	1.3	9.2	4.7	4.5	1.0	11	137	92
I05519	74	27	1.2	9.3	5.0	4.3	.3	10	174	58
I05520	69	17	1.1	8.7	4.9	3.8	.7	9	111	78
I05526	75	19	1.1	9.4	5.2	4.2	.3	9	150	63
I05527	99	17	1.2	8.8	4.9	3.9	.2	9	170	58
MEAN	76	20	1.2	9.0	4.9	4.1	.6	9	138	70
S.D.	12.5	3.8	.10	.22	.21	.26	.45	2.0	33.7	13.3
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05514	76	17	1.2	9.7	5.5	4.2	.5	9	138	41
I05515	69	17	1.0	9.5	4.6	4.9	.2	8	111	48
I05516	58	29	1.1	8.8	5.0	3.8	.6	11	98	113
I05521	75	16	1.4	10.2	5.6	4.6	.3	8	93	41
MEAN	70	20	1.2	9.6	5.2	4.4	.4	9	110	61
S.D.	8.3	6.2	.17	.58	.46	.48	.18	1.4	20.1	35.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05505	59	20	1.2	9.3	5.2	4.1	1.3	14	186	48
I05510	138	16	.9	8.8	4.4	4.4	.3	10	157	59
I05518	95	22	1.5	10.1	5.3	4.8	.5	9	124	55
I05523	76	20	1.1	9.3	5.2	4.1	.3	8	124	53
I05524	69	25	1.4	9.6	5.2	4.4	.7	10	141	62
I05528	58	24	1.3	9.7	5.2	4.5	.7	8	175	57
MEAN	82	21	1.2	9.5	5.1	4.4	.6	10	151	56
S.D.	30.4	3.3	.22	.44	.34	.26	.37	2.2	26.1	4.9
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Doseage Unit: mg/kg/day							
I05506	67	18	1.3	9.6	5.1	4.5	.4	10	129	68
I05507	102	22	1.4	9.9	5.0	4.9	.4	7	121	58
I05509	71	22	1.4	9.5	5.3	4.2	.8	10	117	62
I05511	59	21	1.1	8.8	4.7	4.1	1.0	8	115	55
I05512	75	22	1.3	9.2	5.3	3.9	.3	10	188	77
I05522	64	18	1.3	9.5	5.5	4.0	.3	9	159	83
MEAN	73	20	1.3	9.4	5.2	4.3	.5	9	138	67
S.D.	15.4	2.0	.11	.38	.28	.37	.29	1.3	29.3	11.0
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGPT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	58	24	546	152	8	1086	451	12	284
I05517	84	51	628	125	9	1908	508	226	325
I05519	58	33	514	117	9	783	448	12	249
I05520	36	26	866	89	4	660	336	17	220
I05526	58	31	1156	211	7	1671	250	25	168
I05527	43	29	556	113	6	692	376	37	235
MEAN	56	32	711	134	7	1133	395	55	247
S.D.	16.5	9.7	252.6	42.8	1.9	535.3	93.4	84.4	54.0
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	53	27	642	155	4	1955	413	19	243
I05515	38	43	787	125	4	348	715	43	441
I05516	43	48	1002	182	2	848	435	60	326
I05521	43	26	369	103	3	595	340	17	196
MEAN	44	36	700	141	3	936	476	35	302
S.D.	6.3	11.2	265.6	34.5	1.0	709.0	164.6	20.6	107.4
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	66	99	720	194	12	670	367	133	190
I05510	39	29	814	130	4	1109	450	15	301
I05518	54	34	579	124	2	1047	326	33	218
I05523	99	78	716	82	16	1549	471	29	291
I05524	84	118	1165	154	10	820	469	56	296
I05528	93	56	624	278	5	1329	236	39	156
MEAN	72	69	770	160	8	1087	386	51	242
S.D.	23.5	35.7	210.3	68.4	5.4	322.3	94.5	42.4	62.4
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	54	49	1443	167	6	1602	653	52	359
I05507	54	94	447	138	9	575	515	19	326
I05509	80	181	585	156	6	1265	704	39	435
I05511	71	32	927	199	6	540	543	99	325
I05512	69	48	646	105	5	907	396	15	274
I05522	80	78	992	259	5	1676	362	21	224
MEAN	68	80	840	171	6	1094	529	41	324
S.D.	11.7	54.2	360.9	53.3	1.5	497.4	135.6	31.8	72.2
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	10.2	6.5	154	4.9	106
I05517	10.3	5.8	154	4.8	106
I05519	11.1	6.6	161	5.9	113
I05520	10.5	6.1	158	5.7	111
I05526	11.8	7.5	166	6.1	111
I05527	10.7	5.0	160	4.9	109
MEAN	10.8	6.2	159	5.4	109
S.D.	.60	.84	4.6	.58	2.9
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	12.2	6.5	171	6.2	114
I05515	11.3	6.9	159	5.8	110
I05516	11.1	7.1	159	5.5	109
I05521	12.0	6.1	167	6.1	112
MEAN	11.6	6.6	164	5.9	111
S.D.	.53	.44	6.0	.32	2.2
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.9	5.9	161	5.8	112
I05510	10.7	7.5	156	5.8	111
I05518	12.2	6.9	169	7.2	113
I05523	11.2	6.6	164	6.1	116
I05524	11.9	8.8	168	7.0	110
I05528	10.9	6.7	158	6.3	108
MEAN	11.5	7.1	163	6.4	112
S.D.	.62	.99	5.3	.60	2.7
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	11.6	8.0	165	6.1	112
I05507	11.3	6.0	157	6.5	108
I05509	10.9	5.9	158	5.5	104
I05511	10.5	6.1	156	4.8	106
I05512	11.8	7.0	162	5.8	109
I05522	11.7	8.3	168	6.3	110
MEAN	11.3	6.9	161	5.8	108
S.D.	.54	1.06	4.8	.62	2.9
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05529	54	23	1.2	9.4	5.1	4.3	1.2	7	93	56
I05530	108	23	1.3	9.9	5.5	4.4	.3	10	168	91
I05531	70	23	1.3	8.6	4.6	4.0	.5	7	137	54
I05535	51	19	1.3	9.9	4.6	5.3	.5	4	203	131
I05544	82	22	1.2	10.8	4.7	6.1	.4	7	133	56
I05549	92	21	1.1	9.0	4.9	4.1	.3	7	159	48
MEAN	76	22	1.2	9.6	4.9	4.7	.5	7	149	73
S.D.	22.2	1.6	.08	.78	.35	.83	.34	1.9	37.2	32.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05537	71	21	1.3	10.0	4.9	5.1	.5	5	120	68
I05541	66	23	1.2	9.2	4.5	4.7	.7	6	133	69
I05547	89	22	1.2	8.9	4.6	4.3	.3	9	146	55
I05550	67	24	1.1	9.0	4.8	4.2	.6	6	120	56
MEAN	73	22	1.2	9.3	4.7	4.6	.5	6	130	62
S.D.	10.7	1.3	.08	.50	.18	.41	.17	1.7	12.4	7.5
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05532	86	20	1.2	10.7	5.5	5.2	.8	7	162	50
I05538	87	21	1.1	9.8	5.2	4.6	.3	7	142	42
I05539	82	29	1.3	9.2	3.9	5.3	.6	7	141	66
I05545	72	20	1.1	9.1	4.7	4.4	.9	37	156	74
I05548	55	21	1.0	9.1	4.4	4.7	.5	11	122	63
I05552	74	27	1.1	9.8	4.6	5.2	.6	6	140	53
MEAN	76	23	1.1	9.6	4.7	4.9	.6	12	144	58
S.D.	12.0	3.9	.10	.62	.57	.38	.21	12.1	14.0	11.7
N	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Doseage Unit: mg/kg/day							
I05533	106	27	1.3	9.4	4.9	4.5	.4	11	163	69
I05534	71	21	1.4	10.1	5.5	4.6	.4	8	149	65
I05536	89	17	1.2	10.5	4.6	5.9	.3	9	137	53
I05540	74	26	1.1	8.6	4.4	4.2	.4	8	164	37
I05542	71	25	1.3	8.8	4.6	4.2	.5	9	152	86
I05551	60	26	.9	8.8	4.5	4.3	1.3	7	158	56
MEAN	78	24	1.2	9.4	4.8	4.6	.6	9	154	61
S.D.	16.3	3.9	.18	.78	.40	.65	.37	1.4	10.1	16.6
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	66	202	195	101	3	484	425	27	255
I05530	65	211	274	121	5	1588	281	39	135
I05531	75	215	217	98	7	732	360	46	211
I05535	61	48	550	163	5	872	314	12	184
I05544	61	82	256	204	3	896	595	27	342
I05549	55	83	254	50	3	1242	272	19	185
MEAN	64	140	291	123	4	979	374	28	220
S.D.	6.7	76.9	130.1	54.0	1.6	384.3	121.9	12.5	73.1
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	68	89	200	166	2	706	219	25	152
I05541	54	146	184	72	3	395	293	12	189
I05547	44	80	210	62	3	477	433	17	286
I05550	50	98	211	75	4	356	566	48	322
MEAN	54	103	201	94	3	484	378	26	237
S.D.	10.2	29.4	12.5	48.5	.8	156.7	153.7	15.9	79.9
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	77	76	201	127	2	1192	366	35	177
I05538	68	135	454	120	4	1003	411	46	230
I05539	39	65	122	64	2	362	269	44	179
I05545	140	160	198	41	8	663	484	25	272
I05548	74	143	334	80	6	1073	352	0	210
I05552	48	78	232	91	3	769	617	62	393
MEAN	74	110	257	87	4	844	416	35	244
S.D.	35.5	41.0	118.5	32.9	2.4	306.4	121.0	21.2	81.3
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	101	216	301	121	5	3858	411	25	269
I05534	63	88	329	64	3	902	545	0	343
I05536	68	148	575	63	7	2229	336	15	205
I05540	57	126	182	52	4	417	380	39	223
I05542	74	99	204	79	3	1377	294	31	196
I05551	67	63	269	70	1	964	337	4	246
MEAN	72	123	310	75	4	1624	384	19	247
S.D.	15.4	54.2	141.4	24.3	2.0	1251.5	88.6	15.4	54.1
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	10.9	5.8	155	5.6	106
I05530	13.0	6.5	173	8.0	119
I05531	10.4	5.6	159	5.4	110
I05535	12.4	7.1	166	6.4	116
I05544	11.5	6.8	167	6.0	118
I05549	10.3	5.7	156	5.7	112
MEAN	11.4	6.2	163	6.2	114
S.D.	1.10	.63	7.1	.96	5.0
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	10.9	4.4	165	5.2	113
I05541	11.7	3.8	164	6.5	117
I05547	10.3	4.4	158	5.4	112
I05550	10.8	6.1	165	6.5	119
MEAN	10.9	4.7	163	5.9	115
S.D.	.58	.99	3.4	.70	3.3
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	11.5	6.2	167	6.4	113
I05538	11.5	5.6	164	6.3	116
I05539	10.5	6.1	164	6.3	118
I05545	10.3	4.9	156	5.3	111
I05548	10.6	5.3	152	5.5	112
I05552	11.6	7.1	166	7.0	118
MEAN	11.0	5.9	162	6.1	115
S.D.	.59	.78	6.1	.63	3.1
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.9	5.1	163	5.1	114
I05534	11.6	5.7	164	6.3	112
I05536	12.1	5.7	166	6.0	115
I05540	10.7	6.1	159	6.8	116
I05542	11.7	4.7	167	7.1	115
I05551	10.7	5.6	155	5.3	113
MEAN	11.3	5.5	163	6.1	114
S.D.	.59	.50	4.9	.80	1.5
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05508	54	20	1.1	9.2	4.8	4.4	1.4	8	118	70
I05517	68	19	1.2	9.9	4.8	5.1	1.1	11	171	85
I05519	57	26	1.1	8.5	4.5	4.0	.4	9	161	45
I05520	62	19	1.0	8.7	4.8	3.9	.9	7	117	90
I05526	54	19	.9	8.4	4.6	3.8	.4	10	134	48
I05527	65	16	1.2	8.8	4.8	4.0	.4	8	139	74
MEAN	60	20	1.1	8.9	4.7	4.2	.8	9	140	69
S.D.	5.9	3.3	.12	.56	.13	.49	.43	1.5	22.1	18.7
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05514	65	22	1.4	10.0	5.7	4.3	.6	9	148	51
I05515	72	14	1.1	9.9	4.8	5.1	.2	7	132	45
I05516	58	21	1.0	7.8	4.7	3.1	.4	8	108	50
I05521	53	16	1.3	9.5	4.9	4.6	.4	6	83	41
MEAN	62	18	1.2	9.3	5.0	4.3	.4	8	118	47
S.D.	8.3	3.9	.18	1.02	.46	.85	.16	1.3	28.4	4.6
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05505	52	17	1.1	9.0	5.0	4.0	1.0	7	176	50
I05510	62	17	.8	9.0	4.7	4.3	.3	7	159	54
I05518	71	19	1.4	9.7	4.9	4.8	.4	8	135	61
I05523	68	18	1.1	9.3	5.2	4.1	.3	8	116	65
I05524	69	26	1.4	8.8	4.5	4.3	.6	7	134	59
I05528	47	28	1.1	9.4	4.7	4.7	.7	9	155	56
MEAN	61	21	1.2	9.2	4.8	4.4	.6	8	146	58
S.D.	9.8	4.9	.23	.33	.25	.32	.27	.8	21.5	5.3
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Doseage Unit: mg/kg/day							
I05506	58	20	1.4	9.1	4.9	4.2	.5	8	112	109
I05507	75	24	1.4	9.4	5.0	4.4	.3	6	109	72
I05509	66	19	1.3	9.9	5.4	4.5	.4	6	127	68
I05511	54	21	1.1	9.3	4.5	4.8	.7	5	130	62
I05512	64	23	1.2	8.8	5.1	3.7	.2	8	156	108
I05522	71	18	1.3	9.4	5.5	3.9	.4	9	143	128
MEAN	65	21	1.3	9.3	5.1	4.2	.4	7	130	91
S.D.	7.8	2.3	.12	.27	.26	.40	.17	1.5	18.0	27.3
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	37	30	776	159	4	173	482	21	288
I05517	53	59	605	130	7	170	268	23	155
I05519	46	28	690	112	11	231	451	12	235
I05520	26	23	876	77	5	99	349	11	223
I05526	35	27	1552	203	9	160	235	17	152
I05527	71	69	830	126	7	1291	462	45	278
MEAN	45	39	888	134	7	354	374	22.5	222
S.D.	15.9	19.5	339.5	42.9	2.6	461.0	106.3	12.5	58.4
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	30	23	855	144	2	169	440	14	252
I05515	38	53	999	104	4	137	666	44	391
I05516	35	36	1284	153	2	186	421	18	314
I05521	45	46	365	77	5	273	310	20	171
MEAN	37	40	876	120	3	181	459	24	282
S.D.	6.3	13.0	384.3	35.4	1.5	58.2	149.3	13.6	93.3
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	55	58	721	154	10	176	339	29	163
I05510	25	20	1042	127	1	138	451	6	295
I05518	46	38	733	117	3	140	339	61	212
I05523	35	45	878	73	6	143	436	39	264
I05524	54	91	1359	103	6	222	407	42	238
I05528	70	45	643	239	3	287	240	65	155
MEAN	48	50	896	136	5	184	369	40	221
S.D.	15.9	23.8	267.3	57.3	3.2	59.7	78.9	21.7	55.5
N	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	29	20	1772	149	3	154	675	38	341
I05507	33	35	564	112	2	164	536	9	329
I05509	54	87	967	169	2	436	626	21	350
I05511	46	36	798	138	2	143	539	35	311
I05512	50	43	808	85	2	329	348	20	236
I05522	48	54	1069	197	2	473	409	30	247
MEAN	43	46	996	142	2	283	522	26	307
S.D.	10.0	23.0	417.0	39.9	.4	149.7	124.7	10.9	55.9
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	10.3	7.0	161	5.4	114
I05517	11.0	6.7	163	5.8	115
I05519	10.6	7.0	155	5.3	112
I05520	10.5	6.8	158	5.2	115
I05526	10.4	7.4	159	5.2	114
I05527	10.7	5.1	165	5.8	122
MEAN	10.6	6.7	160	5.4	115
S.D.	.25	.80	3.6	.28	3.4
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	12.9	9.0	180	6.6	121
I05515	10.8	6.8	162	6.2	114
I05516	10.5	6.5	160	5.1	116
I05521	10.7	5.2	158	5.2	111
MEAN	11.2	6.9	165	5.8	116
S.D.	1.12	1.58	10.1	.74	4.2
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.2	5.4	159	5.1	114
I05510	11.2	7.4	161	5.3	116
I05518	11.4	6.4	162	5.6	114
I05523	10.9	6.9	163	6.1	116
I05524	10.4	8.3	163	5.8	115
I05528	10.6	6.3	155	5.9	115
MEAN	11.0	6.8	160	5.6	115
S.D.	.39	1.00	3.1	.38	.9
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.6	7.8	164	5.1	119
I05507	10.6	5.1	158	5.1	111
I05509	10.9	6.1	162	5.4	115
I05511	10.6	5.2	157	5.8	114
I05512	11.3	7.8	162	5.5	114
I05522	11.6	7.6	166	5.7	113
MEAN	10.9	6.6	162	5.4	114
S.D.	.43	1.29	3.4	.29	2.7
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05529	50	21	.9	9.2	4.5	4.7	1.1	8	106	64
I05530	86	25	1.3	9.0	4.8	4.2	.4	8	154	56
I05531	57	25	1.2	8.5	4.4	4.1	.8	7	160	65
I05535	43	16	1.1	9.6	4.0	5.6	.3	7	183	123
I05544	59	27	1.1	10.6	4.5	6.1	.6	8	127	63
I05549	55	18	.9	9.1	4.5	4.6	.2	8	151	56
MEAN	58	22	1.1	9.3	4.4	4.9	.6	8	147	71
S.D.	14.7	4.4	.16	.71	.26	.80	.34	.5	26.9	25.7
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05537	87	20	1.1	9.1	4.4	4.7	.4	5	114	60
I05541	65	22	1.1	9.3	4.4	4.9	.8	10	130	78
I05547	65	18	1.0	8.4	4.4	4.0	.2	10	137	50
I05550	50	25	1.1	9.2	4.7	4.5	.5	10	116	69
MEAN	67	21	1.1	9.0	4.5	4.5	.5	9	124	64
S.D.	15.2	3.0	.05	.41	.15	.39	.25	2.5	11.1	12.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05532	53	22	1.0	9.4	4.4	5.0	.7	8	146	60
I05538	60	21	1.0	9.0	4.7	4.3	.4	7	105	36
I05539	72	15	1.1	9.0	3.9	5.1	.7	7	149	65
I05545	64	17	1.0	9.4	4.7	4.7	.6	15	162	66
I05548	48	20	1.0	8.9	4.0	4.9	.4	7	114	54
I05552	60	25	1.0	9.5	4.0	5.5	.5	7	123	63
MEAN	60	20	1.0	9.2	4.3	4.9	.6	8	133	57
S.D.	8.4	3.6	.04	.26	.37	.40	.14	3.2	22.4	11.3
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dose Unit: mg/kg/day							
I05533	86	27	1.1	9.2	4.3	4.9	.3	9	136	68
I05534	70	19	1.3	9.1	4.3	4.8	.3	6	130	59
I05536	77	15	1.1	9.6	4.3	5.3	.3	7	102	51
I05540	58	21	1.0	9.0	4.5	4.5	.4	6	121	61
I05542	74	30	1.2	8.7	4.5	4.2	.4	7	138	110
I05551	56	22	.9	8.9	4.4	4.5	.7	6	113	46
MEAN	70	22	1.1	9.1	4.4	4.7	.4	7	123	66
S.D.	11.5	5.4	.14	.31	.10	.38	.15	1.2	14.1	23.0
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	28	36	209	88	3	109	376	14	232
I05530	54	108	400	98	9	205	244	27	107
I05531	33	51	330	80	4	156	326	38	168
I05535	44	38	593	138	7	180	332	11	166
I05544	44	38	351	164	3	274	494	18	279
I05549	60	85	298	44	5	518	263	0	169
MEAN	44	59	362	102	5	240	339	18	194
S.D.	12.1	30.2	125.6	42.9	2.4	146.6	89.9	13.2	58.2
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	49	73	210	170	3	287	254	24	168
I05541	68	81	257	65	2	761	344	15	218
I05547	29	51	193	54	3	165	423	23	273
I05550	49	76	301	64	5	301	514	50	290
MEAN	49	70	240	88	3	378	384	28	237
S.D.	15.9	13.3	48.7	54.7	1.3	262.2	110.9	15.2	55.5
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	33	35	286	103	1	206	364	41	172
I05538	41	69	459	90	4	121	387	50	200
I05539	26	49	130	73	2	110	305	36	198
I05545	45	125	219	43	2	267	533	41	282
I05548	35	70	423	70	5	123	317	0	179
I05552	38	60	396	76	4	363	580	36	350
MEAN	36	68	319	76	3	198	414	34	230
S.D.	6.6	30.9	129.0	20.3	1.5	101.3	115.1	17.4	70.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	34	56	305	95	1	153	404	32	251
I05534	37	35	543	37	2	766	485	15	298
I05536	42	49	743	52	2	352	341	20	203
I05540	37	50	269	46	3	413	394	27	215
I05542	22	40	296	61	3	130	233	24	119
I05551	45	46	332	60	1	174	383	21	284
MEAN	36	46	415	58	2	331	373	23	230
S.D.	8.0	7.5	188.9	20.0	.9	242.1	83.3	5.9	66.0
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	10.5	6.8	151	5.3	108
I05530	10.8	5.6	163	6.0	111
I05531	9.7	5.0	165	6.2	120
I05535	10.6	5.6	161	5.9	117
I05544	10.6	6.4	162	5.4	115
I05549	10.2	5.0	162	5.4	117
MEAN	10.4	5.7	161	5.7	115
S.D.	.39	.73	4.9	.38	4.4
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	9.9	4.7	154	4.0	110
I05541	10.7	4.3	166	6.2	118
I05547	9.8	3.8	159	5.1	117
I05550	10.4	4.2	164	5.5	120
MEAN	10.2	4.2	161	5.2	116
S.D.	.42	.37	5.4	.92	4.3
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	9.2	5.5	159	5.0	113
I05538	10.0	4.9	154	5.3	114
I05539	8.5	5.2	156	5.3	114
I05545	10.5	4.0	160	5.0	116
I05548	9.7	4.9	155	4.8	113
I05552	10.2	5.9	159	5.9	114
MEAN	9.7	5.1	157	5.2	114
S.D.	.73	.65	2.5	.39	1.1
N	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.0	5.4	152	5.6	114
I05534	10.5	4.1	162	5.9	117
I05536	10.6	4.9	161	5.9	117
I05540	10.5	5.1	158	6.3	115
I05542	10.7	5.4	168	6.3	122
I05551	10.3	4.9	158	5.2	114
MEAN	10.4	5.0	160	5.9	116
S.D.	.25	.48	5.3	.42	3.0
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05508	51	21	1.1	9.1	4.7	4.4	1.3	8	132	67
I05517	71	17	1.2	9.3	4.8	4.5	1.0	11	179	97
I05519	54	26	1.1	8.4	4.7	3.7	.4	11	178	44
I05520	56	16	1.0	8.3	4.4	3.9	.8	8	124	63
I05526	52	22	1.0	8.1	4.7	3.4	.3	8	147	48
I05527	70	17	1.1	8.2	4.4	3.8	.3	10	158	56
MEAN	59	20	1.1	8.6	4.6	4.0	.7	9	153	62
S.D.	9.1	3.9	.08	.50	.17	.42	.42	1.5	23.0	19.0
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05514	56	18	1.2	8.6	4.9	3.7	.5	13	142	57
I05515	62	17	1.3	9.9	4.8	5.1	.4	8	129	73
I05516	61	25	1.0	8.4	4.2	4.2	.3	10	98	71
I05521	57	18	1.3	9.3	5.0	4.3	.3	9	89	41
MEAN	59	20	1.2	9.0	4.7	4.3	.4	10	114	60
S.D.	2.9	3.7	.14	.69	.36	.58	.10	2.2	25.1	14.8
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05505	58	16	1.1	8.8	4.9	3.9	.9	9	183	53
I05510	59	14	.8	8.1	4.1	4.0	.3	8	145	57
I05518	83	16	1.3	9.0	4.8	4.2	.3	10	142	48
I05523	84	19	1.2	9.0	5.4	3.6	.3	13	130	55
I05524	62	22	1.3	8.4	4.4	4.0	.5	10	135	46
I05528	54	24	1.2	9.2	4.3	4.9	.5	9	132	83
MEAN	67	18	1.2	8.8	4.6	4.1	.5	10	144	57
S.D.	13.3	3.9	.19	.42	.48	.44	.23	1.7	19.7	13.4
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Doseage Unit: mg/kg/day							
I05506	68	18	1.3	8.2	4.4	3.8	.3	10	106	70
I05507	95	23	1.4	9.1	4.5	4.6	.3	8	104	81
I05509	71	18	1.2	9.3	5.1	4.2	.3	14	117	62
I05511	67	17	1.1	8.8	4.3	4.5	.4	6	125	56
I05512	71	22	1.4	8.4	4.9	3.5	.2	11	144	96
I05522	70	17	1.2	8.8	5.7	3.1	.3	9	155	94
MEAN	74	19	1.3	8.8	4.8	4.0	.3	10	125	76
S.D.	10.6	2.6	.12	.41	.53	.59	.06	2.7	20.6	16.6
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	34	24	709	154	4	116	510	18	312
I05517	44	47	512	102	8	144	280	47	168
I05519	45	27	742	125	9	148	448	9	235
I05520	24	21	848	77	5	82	365	11	241
I05526	33	27	1455	209	9	143	197	20	133
I05527	33	59	767	114	5	156	428	27	256
MEAN	36	34	839	130	7	132	371	22	224
S.D.	7.9	15.2	321.9	46.2	2.3	27.8	115.8	13.9	64.2
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	26	16	634	121	5	93	359	11	214
I05515	43	57	955	109	5	173	641	38	390
I05516	38	40	1125	147	2	201	383	9	295
I05521	34	28	287	87	5	129	331	27	182
MEAN	35	35	750	116	4	149	428	21	270
S.D.	7.2	17.5	369.9	25.0	1.5	47.7	143.3	13.8	92.9
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	44	41	643	143	10	127	305	14	155
I05510	23	20	980	134	1	157	442	0	294
I05518	38	31	698	109	3	133	327	32	216
I05523	41	40	798	80	6	175	436	24	268
I05524	49	55	1181	106	9	152	354	23	212
I05528	47	33	535	194	2	173	203	26	135
MEAN	40	37	806	128	5	153	344	20	213
S.D.	9.4	11.7	237.8	39.4	3.8	19.9	89.3	11.3	61.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	26	28	1502	139	4	155	657	38	349
I05507	27	31	462	96	2	163	496	14	312
I05509	36	64	626	127	2	300	593	15	367
I05511	43	38	683	127	2	169	516	20	299
I05512	34	34	725	89	3	189	340	8	237
I05522	35	63	941	171	3	244	390	40	243
MEAN	34	43	823	125	3	203	499	22	301
S.D.	6.3	16.2	267.0	29.9	.8	57.2	119.4	13.4	53.4
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	10.0	6.8	159	4.7	116
I05517	10.8	6.9	161	5.7	118
I05519	10.6	7.6	157	5.7	121
I05520	10.0	6.4	158	5.4	120
I05526	10.9	8.2	159	5.0	121
I05527	10.3	6.8	165	5.8	123
MEAN	10.4	7.1	160	5.4	120
S.D.	.39	.66	2.9	.44	2.5
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	10.0	6.8	160	5.1	117
I05515	11.0	7.2	185	7.0	136
I05516	10.3	7.5	159	5.2	116
I05521	10.7	5.5	161	5.2	120
MEAN	10.5	6.8	166	5.6	122
S.D.	.44	.88	12.5	.92	9.3
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	10.6	5.3	158	4.9	121
I05510	10.1	7.4	154	4.9	115
I05518	10.7	6.6	161	6.1	120
I05523	10.4	7.2	162	5.1	121
I05524	10.2	7.8	161	5.8	120
I05528	10.1	5.3	164	5.3	126
MEAN	10.4	6.6	160	5.4	120
S.D.	.26	1.08	3.5	.50	3.5
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.0	7.6	159	5.3	121
I05507	10.3	6.2	153	5.6	118
I05509	10.1	5.9	158	5.3	121
I05511	10.1	5.1	152	4.7	115
I05512	11.1	8.7	163	6.5	123
I05522	11.4	7.3	169	6.0	120
MEAN	10.5	6.8	159	5.6	120
S.D.	.60	1.31	6.4	.63	2.8
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05529	51	18	.9	8.5	4.4	4.1	.9	8	93	59
I05530	69	22	1.2	8.6	4.5	4.1	.3	9	152	59
I05531	61	25	1.2	8.5	4.5	4.0	.7	8	176	61
I05535	47	16	1.2	9.5	4.2	5.3	.4	9	227	185
I05544	67	24	1.2	9.8	4.0	5.8	.6	9	126	79
I05549	46	22	1.0	9.3	4.5	4.8	.3	10	156	70
MEAN	57	21	1.1	9.0	4.4	4.7	.5	9	155	86
S.D.	10.2	3.5	.13	.57	.21	.75	.24	.8	45.4	49.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05537	92	19	1.1	9.2	4.4	4.8	.4	7	126	87
I05541	62	23	1.1	9.2	4.2	5.0	.8	8	130	99
I05547	58	19	1.0	8.3	4.3	4.0	.3	15	140	50
I05550	54	26	1.1	8.7	4.4	4.3	.8	12	113	68
MEAN	66	22	1.1	8.8	4.3	4.5	.6	10	127	76
S.D.	17.3	3.4	.05	.44	.10	.46	.26	3.7	11.2	21.5
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05532	53	20	1.2	9.2	4.7	4.5	.8	10	148	58
I05538	60	20	1.0	9.1	4.6	4.5	.4	9	113	33
I05539	76	18	1.1	8.9	4.0	4.9	.8	6	153	86
I05545	79	16	.9	9.0	4.4	4.6	.4	15	153	62
I05548	48	20	1.0	8.8	4.0	4.8	.5	13	112	75
I05552	57	24	1.0	9.1	4.0	5.1	.6	9	145	68
MEAN	62	20	1.0	9.0	4.3	4.7	.6	10	137	64
S.D.	12.6	2.7	.10	.15	.33	.24	.18	3.2	19.5	18.0
N	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dose Unit: mg/kg/day							
I05533	88	19	1.2	8.8	4.4	4.4	.3	9	139	53
I05534	73	20	1.4	9.5	4.7	4.8	.5	9	142	63
I05536	75	14	1.2	9.6	4.3	5.3	.2	9	101	56
I05540	69	18	1.1	9.0	4.5	4.5	.4	12	148	79
I05542	74	19	1.2	8.5	4.2	4.3	.3	6	120	68
I05551	69	29	1.0	8.7	4.4	4.3	.4	8	111	50
MEAN	74	20	1.2	9.0	4.4	4.6	.4	9	127	61
S.D.	7.2	5.0	.13	.44	.17	.39	.10	1.9	18.9	10.5
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	35	49	245	86	2	182	352	11	219
I05530	38	49	331	92	6	226	272	5	118
I05531	32	45	321	83	5	450	346	38	201
I05535	39	39	665	170	6	294	330	5	191
I05544	41	49	290	159	2	245	498	26	286
I05549	40	86	308	48	4	138	251	0	170
MEAN	38	53	360	106	4	262	342	14	198
S.D.	3.4	16.7	152.5	47.7	1.8	123.6	86.9	14.7	55.5
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	55	77	241	150	3	316	244	27	166
I05541	41	98	239	67	2	334	296	0	196
I05547	33	60	186	53	4	182	410	12	270
I05550	51	73	297	66	7	270	483	38	280
MEAN	45	77	241	84	4	276	358	19	228
S.D.	9.9	15.8	45.3	44.5	2.2	67.9	108.3	16.7	55.8
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	35	31	233	99	2	302	365	41	172
I05538	46	87	451	89	5	124	381	35	208
I05539	29	43	129	72	3	121	271	30	180
I05545	48	105	202	39	4	253	528	11	283
I05548	33	41	428	68	4	142	310	0	162
I05552	33	54	386	81	4	224	605	53	380
MEAN	37	60	305	75	4	194	410	28	234
S.D.	7.8	29.3	134.0	20.8	1.0	76.1	129.7	19.6	82.3
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
-----									
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	29	39	285	96	2	172	414	30	271
I05534	35	41	506	39	2	285	503	41	317
I05536	31	44	755	52	1	204	340	23	204
I05540	31	52	240	49	2	483	434	34	240
I05542	19	33	250	52	2	113	241	18	161
I05551	43	42	351	62	2	200	377	15	283
MEAN	31	42	398	58	2	243	385	27	246
S.D.	7.8	6.2	200.5	20.0	.4	130.1	89.4	9.9	56.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.7	5.9	151	4.7	114
I05530	9.6	6.2	159	6.3	114
I05531	10.4	5.9	166	6.0	123
I05535	10.3	6.5	167	6.1	125
I05544	9.9	5.7	160	5.5	119
I05549	10.3	5.5	168	6.0	125
MEAN	10.0	6.0	162	5.8	120
S.D.	.34	.36	6.5	.59	5.1
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	9.7	4.8	159	4.9	120
I05541	10.2	4.2	163	5.6	119
I05547	10.0	4.4	156	4.8	118
I05550	9.8	4.8	160	5.6	123
MEAN	9.9	4.6	160	5.2	120
S.D.	.22	.30	2.9	.43	2.2
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	9.7	5.2	166	6.5	127
I05538	10.0	4.8	156	5.4	121
I05539	8.8	5.3	160	5.6	127
I05545	10.1	4.3	158	5.5	121
I05548	9.9	5.2	158	4.7	122
I05552	9.4	5.8	162	5.1	121
MEAN	9.6	5.1	160	5.5	123
S.D.	.48	.51	3.6	.60	3.0
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	9.9	5.0	157	5.4	118
I05534	10.8	4.6	163	6.9	121
I05536	11.0	5.1	160	6.2	119
I05540	9.4	5.2	157	5.8	121
I05542	10.4	4.7	164	5.1	119
I05551	10.0	5.4	165	5.3	123
MEAN	10.2	5.0	161	5.8	120
S.D.	.60	.30	3.5	.67	1.8
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05508	53	19	1.0	8.7	4.7	4.0	1.2	6	119	61
I05517	64	19	1.3	9.1	4.8	4.3	1.1	8	177	101
I05519	57	28	1.1	8.3	4.7	3.6	.5	9	170	56
I05520	54	19	1.0	8.4	4.7	3.7	.6	8	132	81
I05526	56	17	1.1	8.3	4.8	3.5	.3	7	151	43
I05527	74	20	1.3	9.2	5.0	4.2	.4	9	177	66
MEAN	60	20	1.1	8.7	4.8	3.9	.7	8	154	68
S.D.	8.0	4.3	.14	.40	.12	.33	.38	1.2	24.6	20.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05514	57	19	1.2	9.0	5.1	3.9	.6	7	143	51
I05515	74	14	1.2	10.3	5.2	5.1	.3	8	132	60
I05516	64	26	1.1	8.5	5.1	3.4	.4	7	109	64
I05521	59	19	1.6	10.5	5.9	4.6	.4	8	119	42
MEAN	64	20	1.3	9.6	5.3	4.2	.4	8	126	54
S.D.	7.6	4.9	.22	.98	.39	.75	.13	.6	14.9	9.8
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05505	65	15	1.2	8.7	5.1	3.6	.8	8	173	49
I05510	70	14	1.0	9.0	4.9	4.1	.3	6	163	56
I05518	108	19	1.3	9.0	5.0	4.0	.2	8	125	38
I05523	78	16	1.0	9.1	5.2	3.9	.3	9	139	48
I05524	75	26	1.4	8.8	4.8	4.0	.5	14	136	68
I05528	53	22	1.2	9.2	5.0	4.2	.5	8	161	44
MEAN	75	19	1.2	9.0	5.0	4.0	.4	9	150	50
S.D.	18.5	4.6	.16	.19	.14	.21	.22	2.7	18.8	10.4
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Doseage Unit: mg/kg/day							
I05506	63	20	1.6	9.5	5.5	4.0	.3	9	107	88
I05507	111	21	1.6	9.8	5.1	4.7	.2	8	80	57
I05509	75	18	1.3	9.8	5.4	4.4	.3	17	90	59
I05511	62	18	1.1	9.0	4.7	4.3	.3	9	105	56
I05512	63	20	1.4	9.0	5.3	3.7	.2	10	147	68
I05522	65	18	1.3	9.5	5.5	4.0	.3	7	141	108
MEAN	73	19	1.4	9.4	5.2	4.2	.3	10	112	73
S.D.	19.1	1.3	.19	.36	.31	.35	.05	3.6	27.0	21.0
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	41	25	706	152	4	222	525	18	359
I05517	48	45	533	102	6	164	275	23	184
I05519	46	31	782	130	11	166	437	0	261
I05520	27	24	901	82	7	120	377	20	275
I05526	36	24	1408	226	9	167	251	53	186
I05527	36	63	863	126	5	168	487	84	325
MEAN	39	35	866	136	7	168	392	33	265
S.D.	7.7	15.8	296.2	50.1	2.6	32.4	111.8	30.3	71.2
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	26	16	692	127	5	130	386	10	254
I05515	35	38	824	113	4	153	741	134	492
I05516	37	46	1306	181	2	189	396	30	322
I05521	43	142	335	104	5	227	338	18	205
MEAN	35	60	789	131	4	175	465	48	318
S.D.	7.0	55.8	401.7	34.5	1.4	42.5	185.6	57.9	125.4
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	46	39	710	143	11	164	356	38	200
I05510	25	21	1097	160	1	137	501	5	365
I05518	41	37	645	111	4	140	324	25	240
I05523	34	38	724	76	11	129	454	25	306
I05524	45	87	1271	108	4	184	394	12	266
I05528	61	49	660	244	3	220	235	56	174
MEAN	42	45	851	140	6	164	377	27	258
S.D.	12.2	22.4	265.3	58.6	4.3	36.2	94.9	18.3	70.1
N	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	29	21	1624	154	3	133	730	63	433
I05507	30	34	463	108	2	174	556	18	381
I05509	40	75	563	122	2	305	409	26	417
I05511	43	35	566	118	1	204	345	35	320
I05512	31	34	726	95	2	157	353	15	263
I05522	41	65	900	166	2	308	414	38	287
MEAN	36	44	807	127	2	214	468	32	350
S.D.	6.3	21.0	428.6	27.4	.6	75.7	149.1	17.5	70.4
N	6	6	6	6	6	6	6	6	6

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	9.7	6.9	158	4.7	115
I05517	11.0	6.3	160	5.1	117
I05519	9.8	6.6	154	4.7	112
I05520	10.2	6.7	156	5.2	114
I05526	9.5	6.9	159	4.9	119
I05527	11.4	7.4	174	6.2	127
MEAN	10.3	6.8	160	5.1	117
S.D.	.77	.37	7.1	.56	5.3
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	9.8	6.9	163	4.6	117
I05515	10.1	6.7	173	6.8	125
I05516	10.6	7.5	163	5.1	117
I05521	11.6	5.8	169	6.4	123
MEAN	10.5	6.7	167	5.7	120
S.D.	.79	.70	4.9	1.04	4.1
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.0	5.8	160	4.8	117
I05510	11.4	8.2	169	5.6	129
I05518	10.0	6.6	159	5.3	115
I05523	10.7	6.5	160	5.7	122
I05524	10.4	8.0	162	5.7	110
I05528	10.3	5.8	155	5.3	112
MEAN	10.6	6.8	161	5.4	118
S.D.	.51	1.05	4.6	.35	7.0
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.7	7.1	170	5.1	125
I05507	11.2	6.7	160	5.9	114
I05509	10.4	5.6	158	5.1	117
I05511	10.3	5.0	158	5.0	116
I05512	11.2	6.6	163	5.2	115
I05522	11.1	7.5	167	6.1	114
MEAN	10.8	6.4	163	5.4	117
S.D.	.41	.94	5.0	.45	4.2
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05529	48	20	1.0	8.8	4.7	4.1	.7	8	99	65
I05530	78	22	1.3	9.8	5.4	4.4	.3	6	189	65
I05531	95	21	1.2	8.5	4.5	4.0	.4	10	162	61
I05535	59	15	1.2	9.4	4.4	5.0	.3	7	217	88
I05544	78	22	1.1	9.7	4.4	5.3	.5	9	136	57
I05549	42	18	1.1	9.3	4.7	4.6	.3	9	171	65
MEAN	66	20	1.2	9.2	4.7	4.6	.4	8	166	67
S.D.	20.5	2.7	.10	.51	.38	.51	.16	1.5	42.0	10.9
N	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day										
I05537	81	18	1.1	9.0	4.7	4.3	.3	7	114	53
I05541	51	22	1.2	9.8	4.7	5.1	.9	7	143	81
I05547	61	22	1.0	8.1	4.3	3.8	.4	8	149	50
I05550	80	26	1.1	9.0	4.6	4.4	.4	10	129	60
MEAN	68	22	1.1	9.0	4.6	4.4	.5	8	134	61
S.D.	14.7	3.3	.08	.69	.19	.54	.27	1.4	15.6	14.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05532	62	15	1.1	9.2	4.8	4.4	.6	7	153	42
I05538	55	20	1.1	9.3	4.9	4.4	.3	7	122	35
I05539	74	18	1.0	8.7	3.8	4.9	.4	8	143	77
I05545	49	24	1.0	8.9	4.6	4.3	.5	22	151	67
I05548	45	17	1.0	9.0	4.3	4.7	.4	10	125	43
I05552	74	26	1.0	9.3	4.2	5.1	.4	8	143	72
MEAN	60	20	1.0	9.1	4.4	4.6	.4	10	140	56
S.D.	12.4	4.2	.05	.24	.41	.32	.10	5.8	13.1	18.0
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dose Unit: mg/kg/day							
I05533	84	22	1.2	9.8	4.8	5.0	.3	9	142	62
I05534	89	18	1.4	9.5	5.0	4.5	.3	6	131	76
I05535	89	14	1.2	9.6	4.5	5.1	.3	6	65	51
I05540	63	20	1.4	10.0	5.2	4.8	.3	13	105	53
I05542	93	32	1.3	9.1	4.5	4.6	.3	7	115	78
I05551	56	26	.9	8.8	4.6	4.2	.5	24	109	42
MEAN	79	22	1.2	9.5	4.8	4.7	.3	11	111	60
S.D.	15.5	6.3	.19	.45	.29	.33	.08	7.0	26.6	14.4
N	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	36	55	220	81	3	188	387	8	264
I05530	57	78	322	123	9	1481	292	0	144
I05531	35	43	292	84	6	128	410	45	259
I05535	53	38	583	161	7	2407	350	10	224
I05544	40	38	274	164	5	146	510	25	327
I05549	44	74	284	50	4	368	269	0	198
MEAN	44	54	329	110	6	786	370	15	236
S.D.	9.1	17.9	128.7	46.5	2.2	947.2	87.4	17.5	62.7
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	39	72	219	220	2	247	269	23	190
I05541	39	80	238	73	2	250	348	2	249
I05547	30	50	168	53	3	165	454	23	330
I05550	64	114	307	67	11	217	487	25	306
MEAN	43	79	233	103	4	220	390	18	269
S.D.	14.6	26.6	57.5	78.3	4.4	39.4	99.8	10.9	62.5
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	30	34	235	98	1	196	447	130	245
I05538	37	57	531	85	4	149	426	41	261
I05539	23	52	157	69	3	107	290	26	213
I05545	56	153	229	42	2	345	520	25	319
I05548	38	54	404	68	7	230	329	0	214
I05552	40	54	390	82	7	227	640	18	443
MEAN	37	67	324	74	4	209	442	40	282
S.D.	11.1	42.8	140.3	19.2	2.5	81.8	127.6	46.1	87.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	35	43	296	106	1	1132	389	35	281
I05534	38	34	447	43	1	476	482	0	338
I05536	33	42	668	54	2	367	343	18	221
I05540	31	41	294	52	2	141	490	35	292
I05542	20	40	280	58	2	105	225	16	169
I05551	50	71	346	63	2	276	353	12	279
MEAN	34	45	388	63	2	416	379	19	263
S.D.	9.8	13.0	150.1	22.3	.5	377.0	96.5	13.6	59.4
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	10.2	5.5	151	5.0	109
I05530	11.1	6.0	168	6.7	125
I05531	10.3	4.8	160	5.1	116
I05535	11.0	6.8	166	5.7	125
I05544	8.1	5.6	160	4.8	118
I05549	10.7	5.5	162	6.1	117
MEAN	10.2	5.7	161	5.6	118
S.D.	1.11	.66	5.9	.74	6.1
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	9.7	4.5	156	4.6	110
I05541	11.5	3.6	170	6.5	122
I05547	8.8	4.5	154	4.5	113
I05550	10.9	4.0	165	5.4	124
MEAN	10.2	4.2	161	5.2	117
S.D.	1.21	.44	7.5	.93	6.8
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	9.7	5.4	160	5.2	116
I05538	10.7	5.0	161	6.2	121
I05539	9.2	5.4	156	5.3	116
I05545	10.1	4.1	156	5.6	118
I05548	10.4	5.2	160	5.7	125
I05552	9.9	6.0	165	6.3	125
MEAN	10.0	5.2	160	5.7	120
S.D.	.53	.63	3.4	.45	4.2
N	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.4	4.9	159	5.4	122
I05534	10.5	4.2	165	6.2	124
I05536	10.7	5.0	160	5.9	114
I05540	11.5	5.8	170	6.6	117
I05542	10.6	5.3	163	5.8	118
I05551	9.7	5.2	157	5.1	115
MEAN	10.6	5.1	162	5.8	118
S.D.	.58	.53	4.7	.54	3.9
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	57	22	1.0	7.7	4.6	3.1	1.2	8	115	68	58
I05517	74	16	1.2	8.9	5.0	3.9	1.2	11	178	82	77
I05519	52	25	1.1	7.9	4.7	3.2	.4	12	183	39	84
I05520	55	19	1.0	8.2	4.6	3.6	.6	11	124	78	57
I05526	60	20	1.2	8.1	5.0	3.1	.4	9	147	42	70
I05527	65	20	1.3	8.6	4.9	3.7	.3	10	178	54	67
MEAN	60	20	1.1	8.2	4.8	3.4	.7	10	154	60	69
S.D.	8.0	3.0	.12	.45	.19	.34	.41	1.5	29.9	18.3	10.6
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	56	18	1.1	8.3	5.0	3.3	.5	7	136	49	52
I05515	63	19	1.3	9.6	5.2	4.4	.3	8	127	97	45
I05516	60	22	1.1	7.9	5.0	2.9	.4	8	117	49	42
I05521	66	17	1.5	9.4	5.5	3.9	.4	6	98	44	43
MEAN	61	19	1.2	8.8	5.2	3.6	.4	7	120	60	46
S.D.	4.3	2.2	.19	.83	.24	.66	.08	1.0	16.3	24.9	4.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	58	21	1.1	8.4	5.3	3.1	.7	11	191	49	74
I05510	62	16	.9	8.2	4.7	3.5	.3	7	135	69	60
I05518	71	24	1.3	9.3	5.4	3.9	.4	10	145	73	56
I05523	74	17	1.1	9.6	4.7	4.9	.2	9	129	74	49
I05524	65	27	1.4	8.5	5.0	3.5	.6	11	136	64	53
I05528	48	25	1.1	8.6	4.8	3.8	.6	14	157	59	36
MEAN	63	22	1.2	8.8	5.0	3.8	.5	10	149	65	55
S.D.	9.4	4.5	.18	.55	.31	.61	.20	2.3	22.8	9.5	12.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	80	22	1.6	9.4	5.4	4.0	.2	11	57	51	16
I05507	98	23	1.4	9.0	4.8	4.2	.2	14	29	29	9
I05509	60	21	1.2	9.0	4.2	4.8	.3	17	65	89	18
I05511	55	17	1.0	9.0	4.6	4.4	.3	8	75	41	25
I05512	91	19	1.2	8.7	5.1	3.6	.2	24	76	58	27
I05522	72	19	1.3	9.2	5.4	3.8	.2	13	87	95	20
MEAN	76	20	1.3	9.0	4.9	4.1	.2	14	65	60	19
S.D.	17.0	2.2	.20	.23	.48	.43	.05	5.5	20.3	26.3	6.5
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	29	31	723	156	2	157	527	28	377
I05517	34	51	490	125	2	130	290	27	203
I05519	37	29	666	128	8	194	457	12	285
I05520	23	22	842	79	3	135	408	20	307
I05526	30	30	1370	238	1	184	226	12	174
I05527	33	95	659	126	1	191	446	39	309
MEAN	31	43	792	142	3	165	392	23	276
S.D.	4.9	27.3	305.3	53.1	2.6	28.5	112.8	10.5	74.9
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	22	13	606	132	4	92	403	14	273
I05515	35	59	778	109	3	144	713	100	502
I05516	35	43	1093	163	1	188	420	19	360
I05521	28	28	258	88	1	108	344	31	220
MEAN	30	36	684	123	2	133	470	41	339
S.D.	6.3	19.8	348.2	32.2	1.5	42.6	165.2	40.0	123.2
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	43	72	740	160	4	218	348	30	211
I05510	28	43	848	143	1	178	514	9	392
I05518	33	40	720	129	2	201	356	36	274
I05523	20	36	897	70	1	122	479	28	346
I05524	50	75	1241	121	7	213	402	36	282
I05528	63	63	673	262	8	225	475	860	365
MEAN	40	55	853	148	4	193	429	166	312
S.D.	15.7	17.2	207.5	63.8	3.1	38.4	69.9	339.9	67.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	28	24	1262	168	2	180	758	61	475
I05507	31	39	239	109	2	219	499	9	359
I05509	52	85	902	88	5	954	504	25	371
I05511	44	33	415	98	2	207	494	33	340
I05512	40	46	377	70	2	267	439	25	346
I05522	37	85	683	141	2	285	406	36	296
MEAN	39	52	646	112	2	352	517	32	364
S.D.	8.8	26.6	384.1	36.1	1.2	297.5	124.5	17.2	59.9
N	6	6	6	6	6	6	6	6	6

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	9.0	6.6	154	4.7	116
I05517	11.0	6.2	160	5.4	116
I05519	10.3	6.8	150	5.3	110
I05520	9.8	6.9	151	5.3	112
I05526	9.9	6.9	163	5.8	121
I05527	10.8	6.3	164	6.1	119
MEAN	10.1	6.6	157	5.4	116
S.D.	.73	.31	6.1	.48	4.1
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	10.2	6.6	154	5.0	113
I05515	11.3	6.6	163	6.1	114
I05516	10.4	7.2	159	4.9	118
I05521	11.2	4.7	161	6.1	122
MEAN	10.8	6.3	159	5.5	117
S.D.	.56	1.09	3.9	.67	4.1
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	9.6	5.7	161	5.7	120
I05510	10.1	7.2	154	4.8	119
I05518	11.3	6.9	159	6.0	114
I05523	10.9	6.2	158	5.3	116
I05524	9.9	8.6	161	5.6	109
I05528	10.3	6.5	154	5.8	112
MEAN	10.4	6.8	158	5.5	115
S.D.	.64	1.01	3.2	.43	4.2
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	11.4	7.9	171	6.6	128
I05507	10.4	6.7	150	6.4	111
I05509	9.5	4.3	153	4.8	107
I05511	10.5	5.9	153	5.8	108
I05512	11.4	9.1	160	5.1	109
I05522	11.3	7.2	163	6.2	114
MEAN	10.8	6.8	158	5.8	113
S.D.	.76	1.66	7.9	.73	7.8
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	48	21	.9	7.6	4.3	3.3	1.0	7	80	53	39
I05530	74	22	1.3	9.6	5.6	4.0	.3	9	175	65	73
I05531	62	25	1.2	8.2	4.6	3.6	.6	9	177	70	64
I05535	57	16	1.2	9.2	4.4	4.8	.4	9	226	175	56
I05544	57	23	1.1	9.4	4.6	4.8	.6	9	143	59	42
I05549	47	15	1.1	9.3	4.8	4.5	.3	11	175	56	81
MEAN	58	20	1.1	8.9	4.7	4.2	.5	9	163	80	59
S.D.	9.9	4.0	.14	.80	.47	.63	.27	1.3	48.5	47.1	16.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	46	18	1.0	8.6	4.4	4.2	.4	6	102	61	43
I05541	70	25	1.3	8.9	4.6	4.3	1.0	9	128	123	61
I05547	72	12	.9	8.3	3.8	4.5	.2	10	82	65	41
I05550	68	24	1.1	8.5	4.7	3.8	.5	9	127	77	42
MEAN	64	20	1.1	8.6	4.4	4.2	.5	8	110	82	47
S.D.	12.1	6.0	.17	.25	.40	.29	.34	1.7	22.1	28.5	9.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	49	20	1.1	9.2	5.1	4.1	.6	8	133	54	33
I05538	53	23	1.0	8.5	4.6	3.9	.3	7	100	57	37
I05539	62	18	1.2	8.8	4.2	4.6	.4	9	144	72	56
I05545	59	24	1.0	8.3	4.7	3.6	.5	12	136	83	37
I05548	58	23	1.1	8.7	4.3	4.4	.4	15	107	66	48
I05552	60	27	1.0	9.0	4.1	4.9	.6	8	162	60	34
MEAN	57	22	1.1	8.8	4.5	4.2	.5	10	130	69	41
S.D.	4.9	3.1	.08	.33	.37	.48	.12	3.1	23.2	13.7	9.2
N	6	6	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	81	21	1.2	9.6	5.1	4.5	.3	15	100	62	25
I05534	74	12	1.4	9.1	4.6	4.5	.3	9	128	69	23
I05536	70	13	1.1	9.0	3.9	5.1	.2	8	62	44	20
I05540	62	15	1.1	8.7	4.6	4.1	.3	8	80	67	16
I05542	87	18	1.1	8.4	4.2	4.2	.4	9	77	84	25
I05551	46	26	1.0	8.6	4.6	4.0	.4	43	99	55	28
MEAN	70	18	1.2	8.9	4.5	4.4	.3	15	91	64	23
S.D.	14.6	5.3	.14	.43	.41	.40	.08	13.8	23.1	13.5	4.3
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	52	159	175	78	3	192	395	11	285
I05530	33	82	305	115	1	377	296	-	175
I05531	30	51	277	82	2	156	383	45	255
I05535	31	48	593	171	2	362	361	8	244
I05544	37	44	266	176	1	155	499	25	342
I05549	33	79	272	53	2	169	302	0	232
MEAN	36	77	315	112	2	235	373	18	256
S.D.	8.2	43.3	143.3	51.2	.8	105.0	74.3	17.7	55.7
N	6	6	6	6	6	6	6	5	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	54	88	221	254	3	395	249	25	182
I05541	33	70	233	70	2	293	358	3	276
I05547	17	18	280	42	2	79	394	11	302
I05550	46	146	312	68	1	253	513	33	341
MEAN	38	80	262	108	2	255	378	18	275
S.D.	16.2	52.8	42.2	97.8	.8	131.7	108.8	13.5	67.7
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	36	47	259	100	2	268	371	23	212
I05538	31	53	498	78	3	118	405	45	264
I05539	24	38	169	68	3	201	280	34	211
I05545	61	131	228	38	2	330	494	28	322
I05548	26	75	401	67	1	126	310	0	208
I05552	38	52	292	78	8	412	733	19	541
MEAN	36	66	308	72	3	242	432	25	293
S.D.	13.4	34.1	120.9	20.3	2.5	116.5	165.5	15.2	129.4
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	33	45	285	107	1	297	374	33	284
I05534	73	42	359	44	2	3173	554	6	406
I05536	34	41	616	47	7	89	344	23	238
I05540	30	40	230	44	2	139	404	36	270
I05542	22	62	216	57	1	154	232	31	178
I05551	46	60	310	66	1	306	373	30	308
MEAN	40	48	336	61	2	695	380	26	281
S.D.	18.1	10.0	146.9	24.2	2.3	1217.1	104.1	10.9	76.1
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.4	5.2	144	4.7	107
I05530	11.7	6.0	169	6.6	124
I05531	10.1	5.8	155	5.8	116
I05535	10.7	5.8	163	6.3	125
I05544	10.1	5.2	159	5.6	125
I05549	9.4	5.8	161	6.5	116
MEAN	10.2	5.6	158	6.0	119
S.D.	.87	.34	8.5	.81	7.2
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	8.4	4.0	148	5.1	108
I05541	10.9	4.9	163	6.1	118
I05547	10.0	3.0	151	5.3	113
I05550	10.0	4.6	159	5.8	124
MEAN	9.8	4.1	155	5.6	116
S.D.	1.04	.84	6.9	.46	6.8
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	9.5	5.0	153	4.7	110
I05538	9.3	3.8	152	5.3	118
I05539	9.7	5.7	154	5.8	115
I05545	9.9	4.0	152	5.7	114
I05548	10.4	5.1	158	4.8	120
I05552	10.2	6.3	154	5.9	118
MEAN	9.8	5.0	154	5.4	116
S.D.	.42	.96	2.2	.52	3.6
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.6	5.0	158	5.3	116
I05534	11.7	6.0	166	7.1	114
I05536	10.5	5.0	153	7.1	116
I05540	10.1	4.0	153	5.9	111
I05542	10.6	4.3	161	6.5	124
I05551	9.7	5.3	156	5.7	114
MEAN	10.5	4.9	158	6.3	116
S.D.	.67	.71	5.0	.75	4.4
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05508	64	18	1.1	8.5	4.9	3.6	.9	5	127	45	56
I05517	68	14	1.2	9.1	4.9	4.2	.8	7	166	55	66
I05519	51	25	1.0	7.7	4.6	3.1	.5	5	186	37	82
I05520	59	16	.8	7.7	4.5	3.2	.5	6	112	35	53
I05526	57	21	1.2	8.4	5.1	3.3	.3	6	165	41	67
I05527	64	17	1.2	8.1	4.6	3.5	.4	6	158	55	54
MEAN	60	18	1.1	8.2	4.8	3.5	.6	6	152	45	63
S.D.	6.1	3.9	.16	.54	.23	.40	.23	.8	27.5	8.7	11.1
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05514	62	18	1.2	8.6	4.9	3.7	.3	5	135	28	47
I05515	77	12	1.2	9.1	4.8	4.3	.2	4	104	35	42
I05516	59	27	1.0	8.0	4.8	3.2	.4	5	98	41	38
I05521	57	16	1.4	9.5	5.5	4.0	.3	5	102	27	41
MEAN	64	18	1.2	8.8	5.0	3.8	.3	5	110	33	42
S.D.	9.1	6.3	.16	.65	.34	.47	.08	.5	17.0	6.6	3.7
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	70	15	1.1	8.6	5.2	3.4	.5	8	190	22	73
I05510	71	13	.8	8.2	4.4	3.8	.2	5	136	51	53
I05518	83	18	1.2	8.5	5.0	3.5	.3	7	119	31	48
I05523	68	16	1.1	9.0	5.2	3.8	.3	5	137	45	39
I05524	72	19	1.3	8.4	4.8	3.6	.4	5	151	32	42
I05528	57	20	1.1	8.2	4.7	3.5	.4	5	149	35	32
MEAN	70	17	1.1	8.5	4.9	3.6	.4	6	147	36	48
S.D.	8.3	2.6	.17	.30	.31	.17	.10	1.3	24.0	10.4	14.3
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4    Dose Level: 0.75    Dosage Unit: mg/kg/day											
I05506 a	107	28	1.8	9.2	4.4	4.8	.2	58	67	75	11
I05507	93	22	1.4	9.3	4.8	4.5	.2	28	28	22	8
I05511	66	23	.9	8.0	4.2	3.8	.2	18	59	36	20
I05512	78	27	1.3	8.8	5.2	3.6	.2	7	39	19	10
I05522	67	16	1.4	9.8	5.4	4.4	.3	19	69	44	15
MEAN	76	22	1.2	9.0	4.9	4.1	.2	18	48	30	13
S.D.	12.6	4.5	.24	.77	.53	.44	.05	8.6	18.8	11.8	5.4
N	4	4	4	4	4	4	4	4	4	4	4

a    Unscheduled sacrifice on Day 179.

Appendix 4  
Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	28	32	756	169	2	122	524	15	373
I05517	35	52	420	126	5	106	308	37	210
I05519	41	27	628	149	10	526	440	19	281
I05520	23	26	776	72	3	207	398	30	298
I05526	30	26	1322	266	7	159	243	22	194
I05527	33	69	510	118	11	140	454	51	327
MEAN	32	39	735	150	6	210	393	29	280
S.D.	6.2	17.9	318.7	65.6	3.7	158.7	102.8	13.4	68.5
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	19	16	548	136	2	93	379	15	260
I05515	34	35	552	100	6	219	646	37	443
I05516	29	34	1085	182	2	143	391	15	329
I05521	27	31	233	87	4	96	354	27	224
MEAN	27	29	604	126	4	138	442	24	314
S.D.	6.2	8.8	353.5	42.6	1.9	58.8	136.5	10.6	96.4
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	30	39	650	171	4	118	412	36	234
I05510	21	20	634	133	3	102	431	7	333
I05518	39	51	558	115	7	116	336	36	256
I05523	22	58	697	95	3	101	472	36	337
I05524	50	69	1035	125	13	286	397	37	277
I05528	51	43	557	250	5	314	240	27	164
MEAN	36	47	688	148	6	174	381	30	270
S.D.	13.3	16.9	178.3	55.8	3.8	101.5	82.3	11.8	59.0
N	6	6	6	6	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506 a	73	29	876	134	10	4040	738	67	432
I05507	30	46	208	110	2	182	474	17	344
I05511	41	25	344	101	4	101	524	27	339
I05512	36	44	422	71	3	175	379	32	297
I05522	30	73	581	132	2	258	408	68	299
MEAN	34	47	389	104	3	182	446	36	320
S.D.	5.3	19.7	155.7	25.3	1.0	64.5	65.3	22.2	25.2
N	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	10.1	6.8	156	4.7	111
I05517	10.9	5.5	160	5.3	113
I05519	10.2	6.5	149	5.2	112
I05520	9.7	6.2	151	5.2	109
I05526	10.5	7.7	159	5.2	112
I05527	9.9	5.6	150	4.9	110
MEAN	10.2	6.4	154	5.1	111
S.D.	.43	.82	4.8	.23	1.5
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	9.9	5.7	157	5.1	112
I05515	9.9	5.3	155	4.8	107
I05516	9.9	7.1	154	4.7	109
I05521	10.3	4.9	157	5.4	108
MEAN	10.0	5.8	156	5.0	109
S.D.	.20	.96	1.5	.32	2.2
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	10.8	5.0	157	4.8	112
I05510	9.7	6.5	152	4.9	113
I05518	10.2	6.1	147	5.4	107
I05523	10.2	6.3	158	5.2	112
I05524	10.1	7.5	158	5.2	110
I05528	9.7	5.8	150	4.8	106
MEAN	10.1	6.2	154	5.0	110
S.D.	.41	.82	4.7	.25	2.9
N	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506 a	10.6	6.9	157	7.5	111
I05507	10.1	7.2	144	5.5	99
I05511	9.6	4.4	152	5.2	111
I05512	10.3	6.1	157	5.6	109
I05522	11.1	6.7	158	5.4	106
MEAN	10.3	6.1	153	5.4	106
S.D.	.62	1.22	6.4	.17	5.3
N	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	35	23	.8	8.0	4.4	3.6	.9	5	87	46	32
I05530	58	21	1.3	9.6	5.5	4.1	.3	6	181	48	71
I05531	68	22	1.2	8.4	4.5	3.9	.4	6	176	74	59
I05535	44	16	1.2	9.4	4.7	4.7	.3	6	226	72	60
I05544	75	22	1.2	9.5	4.4	5.1	.4	7	143	55	43
I05549	65	14	1.0	8.7	4.6	4.1	.2	6	149	44	73
MEAN	58	20	1.1	8.9	4.7	4.2	.4	6	160	56	56
S.D.	15.2	3.7	.18	.66	.42	.55	.25	.6	46.5	13.3	16.0
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day											
I05537	62	18	1.1	9.1	4.6	4.5	.5	4	99	53	33
I05541	58	18	1.2	9.3	4.7	4.6	.8	6	143	66	54
I05547	53	19	.8	7.6	3.7	3.9	.2	4	109	31	42
I05550	44	25	1.0	8.5	4.6	3.9	.5	7	138	45	37
MEAN	54	20	1.0	8.6	4.4	4.2	.5	5	122	49	42
S.D.	7.8	3.4	.17	.76	.47	.38	.24	1.5	21.6	14.7	9.1
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05532	80	17	1.1	9.2	5.0	4.2	.4	10	130	44	25
I05538	63	17	.9	8.6	4.6	4.0	.3	7	98	26	34
I05539	66	18	1.1	9.0	4.3	4.7	.4	6	154	68	58
I05545	56	21	1.0	8.4	4.7	3.7	.5	11	137	56	38
I05548	55	16	.9	8.5	4.3	4.2	.3	7	108	37	38
I05552	66	24	1.0	9.6	4.0	5.6	.3	7	149	61	25
MEAN	64	19	1.0	8.9	4.5	4.4	.4	8	129	49	36
S.D.	9.0	3.1	.09	.47	.35	.67	.08	2.0	22.3	15.8	12.1
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILLI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	78	23	1.2	9.1	4.8	4.3	.2	5	88	46	22
I05534	74	22	1.4	9.4	4.8	4.6	.2	6	93	77	15
I05536	86	12	1.2	9.9	4.0	5.9	.2	5	67	34	21
I05540	67	18	1.1	9.1	4.7	4.4	.3	12	76	45	11
I05542	80	22	1.1	9.2	4.4	4.8	.2	4	66	67	26
I05551	55	25	.9	8.8	4.6	4.2	.4	11	102	50	31
MEAN	73	20	1.2	9.2	4.6	4.7	.2	7	82	53	21
S.D.	11.0	4.7	.16	.37	.31	.63	.08	3.4	14.7	15.8	7.2
N	6	6	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	91	262	169	86	10	151	350	19	252
I05530	30	55	274	113	2	197	282	16	158
I05531	25	42	243	81	4	84	407	103	274
I05535	37	56	554	172	5	287	351	14	234
I05544	39	61	237	182	7	134	530	41	355
I05549	26	47	222	48	2	422	345	0	275
MEAN	41	87	283	114	5	212	378	32	258
S.D.	25.0	85.9	137.1	53.3	3.1	123.4	84.6	37.1	64.1
N	6	6	6	6	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	58	61	207	260	3	2745	254	14	184
I05541	34	60	218	70	2	209	337	12	252
I05547	26	55	296	50	5	147	347	8	265
I05550	50	111	236	65	15	190	496	41	341
MEAN	42	72	239	111	6	823	358	19	260
S.D.	14.6	26.3	39.7	99.5	6.0	1281.8	100.7	15.0	64.4
N	4	4	4	4	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	34	38	228	102	5	167	372	56	204
I05538	29	32	363	69	5	95	430	52	272
I05539	21	43	118	74	2	238	302	42	232
I05545	59	126	219	41	3	321	514	29	323
I05548	42	35	303	65	14	109	335	0	226
I05552	35	43	295	76	13	164	683	17	505
MEAN	37	53	254	71	7	182	439	33	294
S.D.	13.0	36.1	85.3	19.7	5.2	84.7	140.9	21.6	111.7
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	33	43	243	107	4	253	337	29	256
I05534	33	34	245	43	1	203	467	9	338
I05536	31	38	659	58	4	189	408	19	277
I05540	25	37	217	48	2	236	399	68	252
I05542	32	59	212	63	5	515	279	42	213
I05551	44	53	320	65	4	251	358	20	300
MEAN	33	44	316	64	3	284	375	31	273
S.D.	6.2	9.9	172.4	22.7	1.5	119.3	64.9	21.2	43.1
N	6	6	6	6	6	6	6	6	6

Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.1	4.5	142	4.5	102
I05530	11.1	6.1	159	6.1	112
I05531	9.8	5.2	155	5.1	108
I05535	10.6	6.1	159	5.0	112
I05544	10.2	5.7	160	5.4	115
I05549	10.1	4.1	158	5.7	115
MEAN	10.2	5.3	156	5.3	111
S.D.	.68	.84	6.8	.56	5.0
N	6	6	6	6	6
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05537	9.2	4.2	148	3.9	106
I05541	10.9	4.2	163	6.1	114
I05547	9.1	5.0	149	4.5	110
I05550	9.4	4.3	149	4.5	107
MEAN	9.6	4.4	152	4.8	109
S.D.	.84	.39	7.2	.94	3.6
N	4	4	4	4	4
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	9.7	5.4	155	4.8	110
I05538	9.6	3.3	149	4.4	108
I05539	9.8	5.8	155	5.1	110
I05545	9.9	3.7	156	5.1	112
I05548	9.6	4.6	151	5.0	113
I05552	10.0	5.9	158	5.5	110
MEAN	9.8	4.8	154	5.0	110
S.D.	.16	1.10	3.3	.37	1.8
N	6	6	6	6	6



Appendix 4  
Individual Clinical Chemistry Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	9.3	4.7	148	4.3	109
I05534	10.8	5.3	160	6.6	113
I05536	10.9	5.3	162	5.9	112
I05540	9.9	4.4	155	5.0	106
I05542	11.0	6.6	158	5.7	107
I05551	10.0	5.0	155	4.9	113
MEAN	10.3	5.2	156	5.4	110
S.D.	.69	.76	4.9	.82	3.1
N	6	6	6	6	6

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	59	12	1.1	7.9	4.6	3.3	.6	11	112	43	49
I05526	55	19	1.0	8.2	4.7	3.5	.4	13	152	44	67
MEAN	57	16	1.0	8.0	4.6	3.4	.5	12	132	44	58
S.D.	2.8	4.9	.07	.21	.07	.14	.14	1.4	28.3	.7	12.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	61	17	.8	8.7	5.1	3.6	.8	16	184	37	75
I05523	78	17	1.0	9.3	5.1	4.2	.5	16	131	41	47
MEAN	70	17	.9	9.0	5.1	3.9	.6	16	158	39	61
S.D.	12.0	.0	.14	.42	.00	.42	.21	.0	37.5	2.8	19.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	70	13	1.0	8.7	4.3	4.4	.6	12	140	46	33
I05522	76	16	1.1	8.7	4.8	3.9	.6	17	134	92	22
MEAN	73	14	1.0	8.7	4.6	4.2	.6	14	137	69	28
S.D.	4.2	2.1	.07	.00	.35	.35	.00	3.5	4.2	32.5	7.8
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	19	23	709	62	3	84	400	30	292
I05526	24	28	1156	237	4	194	276	41	209
MEAN	22	26	932	150	4	139	338	36	250
S.D.	3.5	3.5	316.1	123.7	.7	77.8	87.7	7.8	58.7
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	43	45	917	186	11	177	424	48	244
I05523	31	42	669	89	13	146	484	45	332
MEAN	37	44	793	138	12	162	454	46	288
S.D.	6.5	2.1	175.4	68.6	1.4	21.9	42.4	2.1	62.2
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	36	28	538	127	1	177	543	23	362
I05522	29	68	499	159	2	223	467	53	329
MEAN	32	48	518	143	2	200	505	38	346
S.D.	4.9	28.3	27.6	22.6	.7	32.5	53.7	21.2	23.3
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	9.6	5.5	150	4.6	112
I05526	10.4	7.1	154	5.3	110
MEAN	10.0	6.3	152	5.0	111
S.D.	.57	1.13	2.8	.49	1.4
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.5	6.6	156	5.5	110
I05523	10.4	6.6	154	5.1	106
MEAN	11.0	6.6	155	5.3	108
S.D.	.78	.00	1.4	.28	2.8
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	10.6	5.4	157	5.4	112
I05522	10.9	7.0	161	5.5	110
MEAN	10.8	6.2	159	5.4	111
S.D.	.21	1.13	2.8	.07	1.4
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	51	19	.7	8.3	4.4	3.9	.7	13	86	108	33
I05549	67	12	.9	8.9	4.7	4.2	.1	15	152	37	74
MEAN	59	16	.8	8.6	4.6	4.0	.4	14	119	72	54
S.D.	11.3	4.9	.14	.42	.21	.21	.42	1.4	46.7	50.2	29.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	76	19	1.0	8.6	4.1	4.5	.6	14	142	59	61
I05552	77	16	1.0	8.8	4.0	4.8	.6	13	148	52	26
MEAN	76	18	1.0	8.7	4.0	4.6	.6	14	145	56	44
S.D.	.7	2.1	.00	.14	.07	.21	.00	.7	4.2	4.9	24.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	82	21	1.1	9.6	5.0	4.6	.6	14	135	62	25
I05542	68	25	.8	9.0	4.2	4.8	.5	24	131	93	42
MEAN	75	23	1.0	9.3	4.6	4.7	.6	19	133	78	34
S.D.	9.9	2.8	.21	.42	.57	.14	.07	7.1	2.8	21.9	12.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	35	120	161	81	4	157	377	26	257
I05549	34	86	208	41	5	117	309	0	232
MEAN	34	103	184	61	4	137	343	13	244
S.D.	.7	24.0	33.2	28.3	.7	28.3	48.1	18.4	17.7
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	19	43	113	69	1	117	313	48	235
I05552	33	54	251	72	7	1197	658	17	466
MEAN	26	48	182	70	4	657	486	32	350
S.D.	9.9	7.8	97.6	2.1	4.2	763.7	244.0	21.9	163.3
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	23	38	241	121	2	144	394	35	289
I05542	23	61	200	68	5	186	296	41	222
MEAN	23	50	220	94	4	165	345	38	256
S.D.	.0	16.3	29.0	37.5	2.1	29.7	69.3	4.2	47.4
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.7	5.9	145	5.0	103
I05549	9.9	3.7	152	5.9	112
MEAN	9.8	4.8	148	5.4	108
S.D.	.14	1.56	4.9	.64	6.4
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.9	5.7	155	5.5	112
I05552	9.7	5.3	150	5.5	109
MEAN	9.8	5.5	152	5.5	110
S.D.	.14	.28	3.5	.00	2.1
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.4	5.4	152	5.2	111
I05542	10.2	6.3	152	4.9	108
MEAN	10.3	5.8	152	5.0	110
S.D.	.14	.64	.0	.21	2.1
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	116	15	1.2	8.6	4.9	3.9	.5	8	114	28	73
I05526	86	17	1.0	8.6	4.8	3.8	.4	9	155	38	81
MEAN	101	16	1.1	8.7	4.8	3.8	.4	8	134	33	77
S.D.	21.2	1.4	.14	.14	.07	.07	.07	.7	29.0	7.1	5.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	79	17	1.2	9.1	5.3	3.8	.8	5	193	44	103
I05523	83	17	1.0	8.9	5.2	3.7	.4	11	128	52	65
MEAN	81	17	1.1	9.0	5.2	3.8	.6	8	160	48	84
S.D.	2.8	.0	.14	.14	.07	.07	.28	4.2	46.0	5.7	26.9
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	61	16	1.0	8.6	4.4	4.2	.4	7	132	56	54
I05522	84	18	1.0	9.1	4.9	4.2	.4	15	139	71	51
MEAN	72	17	1.0	8.8	4.6	4.2	.4	11	136	64	52
S.D.	16.3	1.4	.00	.35	.35	.00	.00	5.7	4.9	10.6	2.1
N	2	2	2	2	2	2	2	2	2	2	2



APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	24	27	664	68	2	145	409	33	306
I05526	30	28	1137	220	6	209	307	52	234
MEAN	27	28	900	144	4	177	358	42	270
S.D.	4.2	.7	334.5	107.5	2.8	45.3	72.1	13.4	50.9
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	49	40	882	186	6	189	422	22	241
I05523	19	40	793	98	1	124	503	52	353
MEAN	34	40	838	142	4	156	462	37	297
S.D.	21.2	.0	62.9	62.2	3.5	46.0	57.3	21.2	79.2
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	42	33	736	156	1	178	628	17	410
I05522	49	73	625	176	6	336	460	48	333
MEAN	46	53	680	166	4	257	544	32	372
S.D.	4.9	28.3	78.5	14.1	3.5	111.7	118.8	21.9	54.4
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	9.9	6.2	152	5.0	117
I05526	10.4	7.1	157	5.0	117
MEAN	10.2	6.6	154	5.0	117
S.D.	.35	.64	3.5	.00	.0
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.3	6.5	160	5.2	118
I05523	10.5	6.8	159	5.1	116
MEAN	10.9	6.6	160	5.2	117
S.D.	.57	.21	.7	.07	1.4
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	10.4	6.2	159	5.0	118
I05522	11.3	7.8	164	5.4	114
MEAN	10.8	7.0	162	5.2	116
S.D.	.64	1.13	3.5	.28	2.8
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	48	20	.7	8.5	4.5	4.0	.8	8	94	61	52
I05549	68	15	1.2	9.4	4.7	4.7	.3	10	168	53	88
MEAN	58	18	1.0	9.0	4.6	4.4	.6	9	131	57	70
S.D.	14.1	3.5	.35	.64	.14	.49	.35	1.4	52.3	5.7	25.5
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	83	19	1.1	8.8	4.0	4.8	.5	12	163	72	91
I05552	91	21	.9	9.2	4.2	5.0	.3	10	138	70	52
MEAN	87	20	1.0	9.0	4.1	4.9	.4	11	150	71	72
S.D.	5.7	1.4	.14	.28	.14	.14	.14	1.4	17.7	1.4	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	92	22	1.3	9.8	5.0	4.8	.2	19	151	61	54
I05542	91	22	1.2	9.0	4.4	4.6	.3	11	147	129	73
MEAN	92	22	1.2	9.4	4.7	4.7	.2	15	149	95	64
S.D.	.7	.0	.07	.57	.42	.14	.07	5.7	2.8	48.1	13.4
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	42	158	160	73	2	204	363	21	251
I05549	29	74	203	44	3	132	295	0	222
MEAN	36	116	182	58	2	168	329	10	242
S.D.	9.2	59.4	30.4	20.5	.7	50.9	48.1	14.8	27.6
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	24	61	113	77	1	120	311	46	235
I05552	37	71	262	83	5	663	654	21	458
MEAN	30	66	188	80	3	392	482	34	346
S.D.	9.2	7.1	105.4	4.2	2.8	384.0	242.5	17.7	157.7
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	28	41	249	121	2	168	385	113	289
I05542	22	39	224	74	1	129	277	19	212
MEAN	25	40	236	98	2	148	331	66	250
S.D.	4.2	1.4	17.7	33.2	.7	27.6	76.4	66.5	54.4
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.6	4.8	147	4.5	111
I05549	9.8	4.4	153	4.8	118
MEAN	9.7	4.6	150	4.6	114
S.D.	.14	.28	4.2	.21	4.9
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.5	5.6	148	4.9	117
I05552	10.2	5.2	155	5.9	120
MEAN	9.8	5.4	152	5.4	118
S.D.	.49	.28	4.9	.71	2.1
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.2	4.9	155	4.8	116
I05542	11.0	5.9	166	6.2	125
MEAN	10.6	5.4	160	5.5	120
S.D.	.57	.71	7.8	.99	6.4
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	80	13	1.3	8.8	4.8	4.0	.7	3	112	25	54
I05526	54	18	1.1	8.2	4.6	3.6	.1	2	149	47	75
MEAN	67	16	1.2	8.5	4.7	3.8	.4	2	130	36	64
S.D.	18.4	3.5	.14	.42	.14	.28	.42	.7	26.2	15.6	14.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	76	18	.9	9.0	5.2	3.8	.5	11	203	38	94
I05523	72	20	1.1	8.7	4.9	3.8	.3	7	132	57	57
MEAN	74	19	1.0	8.8	5.0	3.8	.4	9	168	48	76
S.D.	2.8	1.4	.14	.21	.21	.00	.14	2.8	50.2	13.4	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	63	20	1.0	8.8	4.5	4.3	.4	5	135	58	45
I05522	76	15	1.3	8.9	5.1	3.8	.2	10	143	91	35
MEAN	70	18	1.2	8.8	4.8	4.0	.3	8	139	74	40
S.D.	9.2	3.5	.21	.07	.42	.35	.14	3.5	5.7	23.3	7.1
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	19	31	552	60	4	151	368	31	277
I05526	37	39	1131	188	10	201	267	41	201
MEAN	28	35	842	124	7	176	318	36	239
S.D.	12.7	5.7	409.4	90.5	4.2	35.4	71.4	7.1	53.7
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	31	42	925	195	2	157	414	41	232
I05523	22	36	776	96	6	125	475	37	338
MEAN	26	39	850	146	4	141	444	39	285
S.D.	6.4	4.2	105.4	70.0	2.8	22.6	43.1	2.8	75.0
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	41	39	821	158	3	167	572	18	377
I05522	36	69	557	169	4	294	453	52	331
MEAN	38	54	689	164	4	230	512	35	354
S.D.	3.5	21.2	186.7	7.8	.7	89.8	84.1	24.0	32.5
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	10.3	5.2	157	5.9	116
I05526	10.0	6.8	150	5.6	115
MEAN	10.2	6.0	154	5.8	116
S.D.	.21	1.13	4.9	.21	.7
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	12.0	6.2	164	5.9	123
I05523	10.3	6.5	154	5.4	114
MEAN	11.2	6.4	159	5.6	118
S.D.	1.20	.21	7.1	.35	6.4
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	10.8	5.7	158	5.4	115
I05522	11.6	7.0	163	5.9	112
MEAN	11.2	6.4	160	5.6	114
S.D.	.57	.92	3.5	.35	2.1
N	2	2	2	2	2



APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	45	23	.8	8.1	4.2	3.9	1.0	7	88	42	43
I05549	67	16	.8	9.3	4.6	4.7	.2	10	170	53	80
MEAN	56	20	.8	8.7	4.4	4.3	.6	8	129	48	62
S.D.	15.6	4.9	.00	.85	.28	.57	.57	2.1	58.0	7.8	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	78	19	.8	8.7	4.0	4.7	.5	5	148	67	68
I05552	71	23	1.0	9.1	4.0	5.1	.2	5	139	51	36
MEAN	74	21	.9	8.9	4.0	4.9	.4	5	144	59	52
S.D.	4.9	2.8	.14	.28	.00	.28	.21	.0	6.4	11.3	22.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	95	20	.9	9.2	4.7	4.5	.1	4	145	47	53
I05542	90	26	1.1	8.7	4.1	4.6	.1	7	144	92	59
MEAN	92	23	1.0	9.0	4.4	4.6	.1	6	144	70	56
S.D.	3.5	4.2	.14	.35	.42	.07	.00	2.1	.7	31.8	4.2
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	47	128	136	70	2	167	328	18	232
I05549	33	79	188	45	4	435	290	0	218
MEAN	40	104	163	58	3	301	309	9	225
S.D.	9.9	34.6	35.4	17.7	1.4	189.5	26.9	12.7	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	27	60	105	77	4	113	287	50	214
I05552	47	57	238	76	14	2316	649	98	465
MEAN	37	58	172	76	9	1214	468	74	340
S.D.	14.1	2.1	94.0	.7	7.1	1557.8	256.0	33.9	177.5
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	42	51	244	108	6	165	396	34	295
I05542	16	36	208	66	4	120	235	31	177
MEAN	29	44	226	87	5	142	316	32	236
S.D.	18.4	10.6	25.5	29.7	1.4	31.8	113.8	2.1	83.4
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.3	4.6	144	4.3	107
I05549	10.4	4.2	155	5.6	114
MEAN	9.8	4.4	150	5.0	110
S.D.	.78	.28	7.8	.92	4.9
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.5	5.3	152	5.4	115
I05552	9.5	5.2	148	4.1	107
MEAN	9.5	5.2	150	4.8	111
S.D.	.00	.07	2.8	.92	5.7
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.4	5.8	154	6.1	121
I05542	10.4	4.6	157	6.0	117
MEAN	10.4	5.2	156	6.0	119
S.D.	.00	.85	2.1	.07	2.8
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05520	74	19	1.3	8.5	4.7	3.8	.8	5	109	67	57
I05526	68	16	1.2	8.6	4.9	3.7	.0	6	158	36	81
MEAN	71	18	1.2	8.6	4.8	3.8	.4	6	134	52	69
S.D.	4.2	2.1	.07	.07	.14	.07	.57	.7	34.6	21.9	17.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05505	45	26	1.3	9.0	5.2	3.8	1.2	8	209	48	91
I05523	78	30	1.6	8.4	5.0	3.4	.2	6	117	74	54
MEAN	62	28	1.4	8.7	5.1	3.6	.7	7	163	61	72
S.D.	23.3	2.8	.21	.42	.14	.28	.71	1.4	65.1	18.4	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05511	55	18	1.2	8.2	4.4	3.8	.6	6	137	54	44
I05522	76	19	1.7	8.9	5.0	3.9	.2	9	136	127	34
MEAN	66	18	1.4	8.6	4.7	3.8	.4	8	136	90	39
S.D.	14.8	.7	.35	.49	.42	.07	.28	2.1	.7	51.6	7.1
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	34	34	499	50	3	860	512	90	380
I05526	42	43	1046	199	5	1071	462	98	352
MEAN	38	38	772	124	4	966	487	94	366
S.D.	5.7	6.4	386.8	105.4	1.4	149.2	35.4	5.7	19.8
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	60	63	995	189	6	515	1618	871	1193
I05523	46	73	770	92	6	624	976	549	731
MEAN	53	68	882	140	6	570	1297	710	962
S.D.	9.9	7.1	159.1	68.6	.0	77.1	454.0	227.7	326.7
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	76	59	844	156	3	787	727	36	503
I05522	46	92	573	158	1	1308	523	25	382
MEAN	61	76	708	157	2	1048	625	30	442
S.D.	21.2	23.3	191.6	1.4	1.4	368.4	144.2	7.8	85.6
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	10.1	5.0	148	4.9	107
I05526	10.8	5.8	153	5.1	106
MEAN	10.4	5.4	150	5.0	106
S.D.	.49	.57	3.5	.14	.7
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.6	6.3	154	5.1	104
I05523	10.3	5.4	154	5.0	108
MEAN	11.0	5.8	154	5.0	106
S.D.	.92	.64	.0	.07	2.8
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	9.9	5.0	151	5.1	108
I05522	11.2	6.6	158	5.6	108
MEAN	10.6	5.8	154	5.4	108
S.D.	.92	1.13	4.9	.35	.0
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day											
I05529	44	16	1.4	8.4	4.4	4.0	.9	6	89	48	41
I05549	64	14	1.1	8.5	4.3	4.2	.1	13	148	36	74
MEAN	54	15	1.2	8.4	4.4	4.1	.5	10	118	42	58
S.D.	14.1	1.4	.21	.07	.07	.14	.57	4.9	41.7	8.5	23.3
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day											
I05539	69	27	1.4	8.2	3.8	4.4	.5	11	141	102	74
I05552	58	28	1.2	9.3	4.0	5.3	.5	6	154	69	46
MEAN	64	28	1.3	8.8	3.9	4.8	.5	8	148	86	60
S.D.	7.8	.7	.14	.78	.14	.64	.00	3.5	9.2	23.3	19.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day											
I05533	86	25	1.6	9.1	4.6	4.5	.1	8	139	68	60
I05542	84	12	1.4	8.2	4.0	4.2	.0	5	119	81	60
MEAN	85	18	1.5	8.7	4.3	4.4	.0	6	129	74	60
S.D.	1.4	9.2	.14	.64	.42	.21	.07	2.1	14.1	9.2	.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	66	97	143	82	2	1212	390	0	277
I05549	46	77	169	39	5	1024	342	0	260
MEAN	56	87	156	60	4	1118	366	0	268
S.D.	14.1	14.1	18.4	30.4	2.1	132.9	33.9	.0	12.0
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	36	71	114	67	4	602	386	63	288
I05552	60	85	205	79	9	1513	722	83	524
MEAN	48	78	160	73	6	1058	554	73	406
S.D.	17.0	9.9	64.3	8.5	3.5	644.2	237.6	14.1	166.9
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	43	70	250	105	2	1471	448	33	337
I05542	46	155	220	55	1	659	450	94	339
MEAN	44	112	235	80	2	1065	449	64	338
S.D.	2.1	60.1	21.2	35.4	.7	574.2	1.4	43.1	1.4
N	2	2	2	2	2	2	2	2	2



APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PFOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.8	5.0	146	5.1	100
I05549	9.6	4.4	148	4.8	107
MEAN	9.7	4.7	147	5.0	104
S.D.	.14	.42	1.4	.21	4.9
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.4	4.8	148	5.2	107
I05552	10.2	5.5	154	5.1	109
MEAN	9.8	5.2	151	5.2	108
S.D.	.57	.49	4.2	.07	1.4
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.3	4.4	154	5.2	109
I05542	10.3	4.1	158	5.8	111
MEAN	10.3	4.2	156	5.5	110
S.D.	.00	.21	2.8	.42	1.4
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	74	17	1.3	8.9	5.0	3.9	.7	5	105	35	51
I05526	71	24	1.3	8.9	5.3	3.6	.3	6	148	46	71
MEAN	72	20	1.3	8.9	5.2	3.8	.5	6	126	40	61
S.D.	2.1	4.9	.00	.00	.21	.21	.28	.7	30.4	7.8	14.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	73	23	1.2	9.0	5.4	3.6	1.1	7	206	33	93
I05523	76	28	1.1	8.1	4.9	3.2	.5	6	127	64	54
MEAN	74	26	1.2	8.6	5.2	3.4	.8	6	166	48	74
S.D.	2.1	3.5	.07	.64	.35	.28	.42	.7	55.9	21.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	63	19	1.1	8.3	4.5	3.8	.6	6	116	36	41
I05522	76	17	1.3	8.5	5.0	3.5	.3	3	122	66	34
MEAN	70	18	1.2	8.4	4.8	3.6	.4	4	119	51	38
S.D.	9.2	1.4	.14	.14	.35	.21	.21	2.1	4.2	21.2	4.9
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	46	45	387	53	3	2123	388	38	298
I05526	53	38	1040	222	8	2151	363	37	246
MEAN	50	42	714	138	6	2137	376	38	272
S.D.	4.9	4.9	461.7	119.5	3.5	19.8	17.7	.7	36.8
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	64	63	915	188	9	1243	1640	793	1207
I05523	55	70	725	98	8	1747	948	365	710
MEAN	60	66	820	143	8	1495	1294	579	958
S.D.	6.4	4.9	134.4	63.6	.7	356.4	489.3	302.6	351.4
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	62	48	765	154	6	617	616	35	414
I05522	58	84	479	156	2	2004	415	31	302
MEAN	60	66	622	155	4	1310	516	33	358
S.D.	2.8	25.5	202.2	1.4	2.8	980.8	142.1	2.8	79.2
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	10.3	4.2	154	5.3	111
I05526	11.0	5.2	157	5.5	111
MEAN	10.6	4.7	156	5.4	111
S.D.	.49	.71	2.1	.14	.0
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	11.9	5.7	160	5.8	113
I05523	9.9	5.5	150	5.1	109
MEAN	10.9	5.6	155	5.4	111
S.D.	1.41	.14	7.1	.49	2.8
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	10.2	5.2	153	5.9	113
I05522	10.9	4.6	156	5.0	108
MEAN	10.6	4.9	154	5.4	110
S.D.	.49	.42	2.1	.64	3.5
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	54	21	.9	8.9	4.7	4.2	1.1	5	112	56	40
I05549	56	18	1.1	9.0	4.7	4.3	.4	6	162	42	79
MEAN	55	20	1.0	9.0	4.7	4.2	.8	6	137	49	60
S.D.	1.4	2.1	.14	.07	.00	.07	.49	.7	35.4	9.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	66	22	1.1	8.3	3.8	4.5	.8	6	136	66	71
I05552	80	26	1.0	9.1	4.0	5.1	.7	6	138	43	36
MEAN	73	24	1.0	8.7	3.9	4.8	.8	6	137	54	54
S.D.	9.9	2.8	.07	.57	.14	.42	.07	.0	1.4	16.3	24.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	91	21	1.2	9.2	4.9	4.3	.3	13	152	55	55
I05542	85	25	1.1	8.1	4.0	4.1	.4	5	131	95	66
MEAN	88	23	1.2	8.7	4.4	4.2	.4	9	142	75	60
S.D.	4.2	2.8	.07	.78	.64	.14	.07	5.7	14.8	28.3	7.8
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	110	297	157	109	7	2978	459	33	336
I05549	61	106	167	45	5	1838	338	0	265
MEAN	86	202	162	77	6	2408	398	16	300
S.D.	34.6	135.1	7.1	45.3	1.4	806.1	85.6	23.3	50.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	37	61	109	78	8	733	304	42	231
I05552	62	95	188	80	15	1009	630	52	459
MEAN	50	78	148	79	12	871	467	47	345
S.D.	17.7	24.0	55.9	1.4	4.9	195.2	230.5	7.1	161.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	67	78	243	117	5	2353	527	47	412
I05542	45	83	213	56	3	1241	431	47	329
MEAN	56	80	228	86	4	1797	479	47	370
S.D.	15.6	3.5	21.2	43.1	1.4	786.3	67.9	0	58.7
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 364  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.7	5.6	144	4.3	103
I05549	10.1	4.2	151	5.6	109
MEAN	9.9	4.9	148	5.0	106
S.D.	.28	.89	4.9	.92	4.2
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.0	4.8	146	4.9	108
I05552	9.9	4.7	151	5.9	111
MEAN	9.4	4.8	148	5.4	110
S.D.	.64	.07	3.5	.71	2.1
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.5	4.6	153	5.3	111
I05542	10.0	4.3	157	5.6	113
MEAN	10.2	4.4	155	5.4	112
S.D.	.35	.21	2.8	.21	1.4
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	80	12	1.2	8.9	5.2	3.7	.8	3	122	31	56
I05526	68	16	1.2	8.5	4.9	3.6	.3	3	142	32	61
MEAN	74	14	1.2	8.7	5.0	3.6	.6	3	132	32	58
S.D.	8.5	2.8	.00	.28	.21	.07	.35	.0	14.1	.7	3.5
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	88	15	1.2	9.3	5.4	3.9	.6	5	216	39	106
I05523	94	17	1.1	8.9	5.5	3.4	.3	6	139	43	55
MEAN	91	16	1.2	9.1	5.4	3.6	.4	6	179	41	80
S.D.	4.2	1.4	.07	.28	.07	.35	.21	.7	54.4	2.8	36.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	64	13	1.0	8.5	4.5	4.0	.8	4	122	37	44
I05522	75	14	1.3	9.3	5.4	3.9	.3	3	114	81	26
MEAN	70	14	1.2	8.9	5.0	4.0	.6	4	118	59	35
S.D.	7.8	.7	.21	.57	.64	.07	.35	.7	5.7	31.1	12.7
N	2	2	2	2	2	2	2	2	2	2	2



APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	19	21	394	59	2	77	319	11	246
I05526	29	26	847	189	10	126	276	21	220
MEAN	24	24	620	124	6	102	298	16	233
S.D.	7.1	3.5	320.3	91.9	5.7	34.6	30.4	7.1	18.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	29	46	971	198	2	163	413	14	235
I05523	21	45	771	101	1	119	487	17	353
MEAN	25	46	871	150	2	141	450	16	294
S.D.	5.7	.7	141.4	68.6	2.7	31.1	52.3	2.1	83.4
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	37	32	458	129	1	179	480	20	326
I05522	30	50	379	148	0	225	364	13	263
MEAN	34	41	418	138	0	202	422	16	294
S.D.	4.9	12.7	55.9	13.4	0.7	32.5	82.0	4.9	44.5
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05520	10.4	5.7	156	5.7	113
I05526	10.1	6.4	150	5.1	109
MEAN	10.2	6.0	153	5.4	111
S.D.	.21	.49	4.2	.42	2.8
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05505	12.6	6.6	167	6.3	118
I05523	10.9	7.2	161	5.6	113
MEAN	11.8	6.9	164	6.0	116
S.D.	1.20	.42	4.2	.49	3.5
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05511	10.0	3.9	152	4.6	113
I05522	11.1	6.7	158	5.4	109
MEAN	10.6	5.3	155	5.0	111
S.D.	.78	1.98	4.2	.57	2.8
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	48	17	.9	8.3	4.6	3.7	1.0	7	99	60	34
I05549	79	17	1.0	8.7	4.6	4.1	.3	4	142	52	67
MEAN	64	17	1.0	8.5	4.6	3.9	.6	6	120	56	50
S.D.	21.9	2.0	.07	.28	.00	.28	.49	2.1	30.4	5.7	23.3
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	79	16	1.0	8.4	4.1	4.3	.6	4	144	83	58
I05552	78	18	.9	9.0	4.1	4.9	.5	6	144	59	36
MEAN	78	17	1.0	8.7	4.1	4.6	.6	5	144	71	47
S.D.	2.7	1.4	.07	.42	.00	.42	.07	1.4	2.0	17.0	15.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	98	17	1.1	9.1	4.9	4.2	.2	5	137	42	55
I05542	101	21	1.0	8.2	4.1	4.1	.3	3	139	114	72
MEAN	100	19	1.0	8.7	4.5	4.2	.2	4	138	78	64
S.D.	2.1	2.8	.07	.64	.57	.07	.07	1.4	1.4	50.9	12.0
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	56	183	139	96	6	200	293	9	216
I05549	30	85	174	49	3	244	244	12	192
MEAN	43	134	156	72	4	222	268	10	204
S.D.	18.4	69.3	24.7	33.2	2.1	31.1	34.6	2.1	17.0
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	25	34	94	76	4	112	242	15	189
I05552	40	66	186	81	10	254	436	11	312
MEAN	32	50	140	78	7	183	339	13	250
S.D.	10.6	22.6	65.1	3.5	4.2	100.4	137.2	2.8	87.0
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	25	64	248	124	0	134	360	13	277
I05542	25	43	216	63	3	114	233	23	183
MEAN	25	54	232	94	2	124	296	18	230
S.D.	0	14.8	22.6	43.1	2.1	14.1	89.8	7.1	66.5
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 456  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	9.6	4.9	144	4.9	105
I05549	10.2	5.4	152	5.1	110
MEAN	9.9	5.2	148	5.0	108
S.D.	.42	.35	5.7	.14	3.5
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.5	5.3	151	5.4	111
I05552	10.1	5.0	153	5.9	112
MEAN	9.8	5.2	152	5.6	112
S.D.	.42	.21	1.4	.35	.7
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.3	5.1	155	5.6	114
I05542	10.5	5.6	154	6.8	118
MEAN	10.4	5.4	154	6.2	116
S.D.	.14	.35	.7	.85	2.8
N	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	79	14	1.2	8.7	4.6	4.1	.5	6	119	30	63
I05526	86	18	1.3	8.9	4.8	4.1	.2	5	150	32	77
MEAN	82	16	1.2	8.8	4.7	4.1	.4	6	134	31	70
S.D.	4.9	2.8	.07	.14	.14	.00	.21	.7	21.9	1.4	9.9
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	77	19	1.2	8.6	4.9	3.7	.6	5	200	31	114
I05523	81	19	1.1	9.0	5.3	3.7	.3	3	132	40	69
MEAN	79	19	1.2	8.8	5.1	3.7	.4	4	166	36	92
S.D.	2.8	.0	.07	.28	.28	.00	.21	1.4	48.1	6.4	31.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	75	16	1.4	9.5	5.0	4.5	.8	4	145	37	67
I05522	83	16	1.4	9.3	5.2	4.1	.3	10	132	52	47
MEAN	79	16	1.4	9.4	5.1	4.3	.6	7	138	44	57
S.D.	5.7	.0	.00	.14	.14	.28	.35	4.2	9.2	10.6	14.1
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	19	20	309	49	1	78	265	10	203
I05526	28	30	701	183	19	144	259	17	201
MEAN	24	25	505	116	10	111	262	14	202
S.D.	6.4	7.1	277.2	94.8	12.7	46.7	4.2	4.9	1.4
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	31	36	846	178	1	130	357	12	206
I05523	30	33	662	93	5	212	446	13	321
MEAN	30	34	754	136	3	171	402	12	264
S.D.	2.7	2.1	130.1	60.1	2.8	58.0	62.9	2.7	81.3
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	45	37	467	149	0	165	519	22	334
I05522	27	42	342	147	0	165	362	11	260
MEAN	36	40	404	148	0	165	440	16	297
S.D.	12.7	3.5	88.4	1.4	0	0	111.0	7.8	52.3
N	2	2	2	2	2	2	2	2	2

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----					
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.8	6.5	162	6.4	120
I05526	10.5	6.6	157	5.6	111
MEAN	10.6	6.6	160	6.0	116
S.D.	.21	.07	3.5	.57	6.4
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.4	6.3	164	5.8	117
I05523	11.0	7.6	169	6.9	122
MEAN	11.2	7.0	166	6.4	120
S.D.	.28	.92	3.5	.78	3.5
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	12.0	5.4	174	6.0	121
I05522	11.8	6.2	169	6.2	116
MEAN	11.9	5.8	172	6.1	118
S.D.	.14	.57	3.5	.14	3.5
N	2	2	2	2	2



APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	67	17	.9	8.2	4.4	3.8	.8	6	96	55	44
I05549	53	16	1.0	8.8	4.4	4.4	.3	5	152	51	83
MEAN	60	16.7	1.0	8.5	4.4	4.1	.6	6	124	53	64
S.D.	9.9		.07	.42	.00	.42	.35	.7	39.6	2.8	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	71	19	1.1	8.5	3.9	4.6	.5	5	147	73	86
I05552	74	17	.8	8.2	3.6	4.6	.6	5	129	46	37
MEAN	72	18	1.0	8.4	3.8	4.6	.6	5	139	60	62
S.D.	2.1	1.4	.21	.21	.21	.00	.07	.0	12.7	19.1	34.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	100	19	1.2	9.0	4.6	4.4	.3	6	145	40	68
I05542	93	19	1.2	7.9	4.0	3.9	.3	4	147	112	79
MEAN	96	19	1.2	8.4	4.3	4.2	.3	5	146	76	74
S.D.	4.9	.0	.00	.78	.42	.35	.00	1.4	1.4	50.9	7.8
N	2	2	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	53	191	131	93	0	216	316	11	232
I05549	30	49	171	45	0	93	245	12	192
MEAN	42	120	151	69	0	154	280	12	212
S.D.	16.3	100.4	28.3	33.9	0	87.0	50.2	2.7	28.3
N	2	2	2	2	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	27	31	96	76	2	80	252	14	195
I05552	26	37	195	82	1	109	454	8	327
MEAN	26	34	146	79	2	94	353	11	261
S.D.	2.7	4.2	70.0	4.2	2.7	20.5	142.8	4.2	93.3
N	2	2	2	2	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	36	79	240	117	3	164	372	12	286
I05542	19	39	186	61	0	97	250	18	195
MEAN	28	59	213	89	2	130	311	15	240
S.D.	12.0	28.3	38.2	39.6	2.1	47.4	86.3	4.2	64.3
N	2	2	2	2	2	2	2	2	2

APPENDIX 4  
Individual Clinical Chemistry Data  
Females Day 546  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05529	10.1	5.2	150	5.1	108
I05549	10.1	5.6	152	5.3	111
MEAN	10.1	5.4	151	5.2	110
S.D.	.00	.28	1.4	.14	2.1
N	2	2	2	2	2
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05539	9.8	5.4	155	5.4	112
I05552	10.2	4.9	157	6.1	117
MEAN	10.0	5.2	156	5.8	114
S.D.	.28	.35	1.4	.49	3.5
N	2	2	2	2	2
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05533	10.3	5.9	159	5.6	115
I05542	10.7	5.4	165	6.7	124
MEAN	10.5	5.6	162	6.2	120
S.D.	.28	.35	4.2	.78	6.4
N	2	2	2	2	2

Appendix 4  
Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	37.0	1.025	8.0
I05517	28.0	1.032	7.0
I05519	47.0	1.025	8.0
I05520	75.0	1.018	7.5
I05526	32.0	1.030	7.5
I05527	30.0	1.023	6.0
MEAN	41.5	1.026	7.3
S.D.	17.76	.0050	.75
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	67.0	1.019	7.0
I05515	46.0	1.023	7.5
I05516	52.0	1.020	7.0
I05521	45.0	1.023	8.0
MEAN	52.5	1.021	7.4
S.D.	10.15	.0021	.48
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	228.0	1.007	7.0
I05510	52.0	1.025	7.0
I05518	93.0	1.020	7.0
I05523	43.0	1.026	7.0
I05524	46.0	1.025	7.5
I05528	125.0	1.013	7.0
MEAN	97.8	1.019	7.1
S.D.	71.41	.0078	.20
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	43.0	1.025	7.0
I05507	59.0	1.022	7.5
I05509	68.0	1.018	7.0
I05511	173.0	1.008	7.0
I05512	92.0	1.013	7.5
I05522	66.0	1.022	7.0
MEAN	83.5	1.018	7.2
S.D.	46.63	.0066	.25
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	+++	-	+++	-
I05517	10	-	+++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	+	+++	-	-	-
I05526	10	+	+	-	-	-
I05527	0	-	++	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	0	-	-	-	-	-
I05516	10	-	++	-	+	-
I05521	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	10	-	-	-	-	-
I05518	30	+	-	-	+++	-
I05523	10	-	-	-	-	-
I05524	10	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	++	-	+	-
I05507	0	-	-	-	++	-
I05509	10	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	+	-	+	-
I05522	10	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	0	3	0	2B4D	0	DK	-
I05517	0	0	2	3	0	2B4D	0	DK	PQ
I05519	0	0	0	3	0	4B4E	0	CL	-
I05520	0	0	1	2	0	4B4D	0	BK	-
I05526	0	0	1	2	0	4B3D	0	CK	-
I05527	0	0	0	1	0	4B3E	0	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	0	0	1	3	0	4B2E	0	CK	-
I05515	0	0	0	3	0	4B4D	4E	CL	-
I05516	0	0	0	3	0	4B2D	0	CK	-
I05521	0	0	0	3	0	4B4D	0	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	1	2	0	3B	0	BK	-
I05510	0	0	0	3	0	4B4D	4E	BL	-
I05518	0	0	4	3	0	4B	0	DL	-
I05523	0	0	0	3	0	4B2D	0	BL	-
I05524	0	0	0	3	0	3B4D	0	CK	-
I05528	0	0	1	3	0	4B	0	BK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05506	2	0	1	3	0	2B2D	0	CK	-
I05507	0	1	0	3	0	4B4D	0	CL	Q
I05509	0	1	4	3	0	4B1E	0	BK	Q
I05511	0	0	1	3	0	4B	0	BK	Q
I05512	0	0	1	3	0	2B	0	BK	-
I05522	0	1	1	2	0	2B	0	BJ	-

Appendix 4  
Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0	Dosage Unit: mg/kg/day	
I05529	52.0	1.017	7.0
I05530	100.0	1.020	7.0
I05531	57.0	1.020	7.5
I05535	45.0	1.023	7.0
I05544	240.0	1.007	7.5
I05549	50.0	1.023	8.0
MEAN	90.7	1.018	7.3
S.D.	75.84	.0060	.41
N	6	6	6
Group: 2	Dose Level: 0.03	Dosage Unit: mg/kg/day	
I05537	225.0	1.007	7.5
I05541	48.0	1.023	7.0
I05547	45.0	1.024	7.0
I05550	52.0	1.023	7.0
MEAN	92.5	1.019	7.1
S.D.	88.38	.0082	.25
N	4	4	4
Group: 3	Dose Level: 0.15	Dosage Unit: mg/kg/day	
I05532	140.0	1.012	8.0
I05538	61.0	1.023	7.5
I05539	53.0	1.026	8.0
I05545	62.0	1.018	7.0
I05548	64.0	1.020	8.0
I05552	51.0	1.025	8.0
MEAN	71.8	1.021	7.8
S.D.	33.80	.0052	.42
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	35.0	1.026	7.5
I05534	59.0	1.024	8.0
I05536	64.0	1.023	7.5
I05540	247.0	1.007	7.0
I05542	72.0	1.019	7.0
I05551	51.0	1.021	7.0
MEAN	88.0	1.020	7.3
S.D.	78.91	.0068	.41
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	++	-	-	-
I05530	10	-	-	-	+	-
I05531	0	-	-	-	-	-
I05535	0	-	++	-	-	-
I05544	0	-	-	-	+	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	-	-	+++	-
I05541	0	-	+	-	-	-
I05547	10	-	-	-	++	-
I05550	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	-	-	-	-
I05538	0	-	+	-	-	-
I05539	10	-	-	-	++	-
I05545	0	-	++	-	-	-
I05548	0	-	+	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+++	-	-	-
I05534	0	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	-	-	-	-
I05551	0	-	+	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	1	1	3	1H	3B4D	0	BK	P
I05530	0	0	0	3	0	4B	0	DL	-
I05531	0	0	1	3	0	4B4D	0	CK	-
I05535	0	0	0	3	0	2B2D	0	CL	-
I05544	0	0	2	3	0	4B	0	AK	-
I05549	0	0	0	1	0	4B1D	1E	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	0	1	3	0	4B4D	0	BK	-
I05541	0	1	1	3	0	4B2D	0	DL	-
I05547	0	0	0	3	0	2B	0	DL	-
I05550	0	0	1	2	0	4B1E	0	CK	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	0	2	2	0	1D4F	0	BJ	-
I05538	0	0	1	2	0	1B1E	1F	CK	-
I05539	0	0	1	3	0	4B	0	CK	-
I05545	0	0	1	2	0	4B	0	CK	P
I05548	0	0	0	3	0	2B	0	CL	-
I05552	0	0	2	3	0	4B	0	CL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	1	2	3	0	2B4D	0	DK	-
I05534	0	0	1	2	0	4B4D	0	CL	-
I05536	0	0	1	3	0	3B3D	0	CL	-
I05540	0	0	4	3	0	0	0	AK	-
I05542	0	1	1	3	0	4B1E	0	CK	-
I05551	0	0	1	3	0	4B1D	0	CK	-

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	56.0	1.023	8.0
I05517	47.0	1.025	7.0
I05519	48.0	1.021	8.0
I05520	66.0	1.013	7.0
I05526	26.0	1.008	7.5
I05527	58.0	1.017	7.5
MEAN	50.2	1.018	7.5
S.D.	13.75	.0071	.45
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	62.0	1.020	7.0
I05515	108.0	1.017	7.5
I05516	38.0	1.028	8.0
I05521	82.0	1.019	7.5
MEAN	72.5	1.021	7.5
S.D.	29.73	.0048	.41
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	307.0	1.002	7.0
I05510	34.0	1.023	7.5
I05518	70.0	1.017	7.5
I05523	54.0	1.019	7.5
I05524	37.0	1.028	7.0
I05528	64.0	1.025	7.0
MEAN	94.3	1.019	7.2
S.D.	105.16	.0092	.27
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	50.0	1.023	8.0
I05507	52.0	1.025	8.0
I05509	36.0	1.023	8.0
I05511	110.0	1.008	6.5
I05512	146.0	1.007	7.0
I05522	80.0	1.018	6.5
MEAN	79.0	1.018	7.3
S.D.	42.12	.0082	.75
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	+	-	-	-
I05517	0	-	++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	+++	-	-	-
I05526	0	-	+	-	-	-
I05527	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	0	-	-	-	-	-
I05516	0	-	-	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	+	-	-	-
I05523	0	-	-	-	-	-
I05524	0	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	0	-	++	-	-	-
I05507	0	-	-	-	-	-
I05509	0	-	-	-	-	-
I05511	0	-	+	-	-	-
I05512	0	-	+	-	-	-
I05522	0	-	+++	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	1	2	0	4D	0	BK	-
I05517	0	0	1	2	0	1D	0	CK	-
I05519	0	0	0	2	0	3E3F	0	BK	-
I05520	0	0	1	1	0	0	0	BU	P
I05526	0	0	0	1	0	1B1D	0	BU	-
I05527	0	0	0	1	0	4D	0	BU	P
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	1	0	1	2	0	2E	0	BK	PQ
I05515	0	0	0	3	0	4B4D	0	BK	P
I05516	0	0	1	2	0	4B1D	0	CK	-
I05521	0	0	0	2	0	4B2D	1E	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	0	0	0	1B	0	AJ	Q
I05510	0	0	0	3	0	4D	0	BK	-
I05518	0	0	0	1	0	3D	0	BK	PQ
I05523	0	0	1	2	0	2D3E	0	BK	Q
I05524	0	1	1	1	0	0	0	CK	-
I05528	0	0	0	2	0	4B1E	0	BK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05506	0	0	1	2	0	0	0	BK	P
I05507	0	0	0	1	0	3B4D	0	BK	Q
I05509	0	0	1	1	0	0	0	BK	Q
I05511	0	0	0	3	0	1B	0	BU	Q
I05512	0	0	0	3	0	2B	0	BU	-
I05522	0	0	0	2	0	0	0	BK	PQ

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	14.0	1.010	8.5
I05530	20.0	1.003	8.0
I05531	31.0	1.025	8.0
I05535	564.0	1.001	7.5
I05544	38.0	1.020	8.0
I05549	44.0	1.021	8.0
MEAN	118.5	1.014	8.0
S.D.	218.53	.0103	.32
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	170.0	1.011	7.5
I05541	46.0	1.020	8.0
I05547	76.0	1.016	8.0
I05550	55.0	1.024	7.5
MEAN	86.8	1.018	7.8
S.D.	56.91	.0056	.29
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	78.0	1.014	7.5
I05538	186.0	1.005	7.5
I05539	66.0	1.019	7.0
I05545	85.0	1.012	7.5
I05548	47.0	1.024	8.0
I05552	40.0	1.026	7.5
MEAN	83.7	1.017	7.5
S.D.	53.05	.0076	.32
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	38.0	1.024	8.0
I05534	32.0	1.025	8.5
I05536	44.0	1.028	8.0
I05540	417.0	1.003	8.0
I05542	34.0	1.025	7.0
I05551	36.0	1.025	7.0
MEAN	100.2	1.022	7.8
S.D.	155.27	.0094	.61
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05530	10	-	-	-	++	-
I05531	0	-	-	-	-	-
I05535	0	-	-	-	+++	-
I05544	0	-	+	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	-	-	-	-
I05541	0	-	+	-	-	-
I05547	0	-	-	-	-	-
I05550	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	-	-	-	-
I05538	0	-	-	-	-	-
I05539	0	-	-	-	-	-
I05545	0	-	-	-	-	-
I05548	0	-	+	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	+	-	+	-
I05534	10	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	+++	-	-	-
I05551	0	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS FER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	2	1	0	1E2F	0	BU	P
I05530	0	0	0	3	0	4B	0	BLM	-
I05531	0	1	0	2	0	3B4D	0	CL	-
I05535	0	0	1	1	0	0	0	AK	-
I05544	0	0	0	2	0	3B3D	0	BK	-
I05549	0	1	0	3	0	1E1F	0	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	0	1	2	0	4B	0	BK	-
I05541	0	0	1	2	0	4B4D	0	BK	-
I05547	0	0	0	1	0	2D	0	BK	P
I05550	0	0	0	1	0	1B	0	BK	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	1	1	2	0	4B2E	0	BK	-
I05538	0	0	2	1	0	3B	0	BK	-
I05539	0	0	0	3	0	4B3E	0	BK	-
I05545	0	0	1	3	0	4B4D	0	BL	-
I05548	0	0	0	3	0	3B1D	0	BK	-
I05552	0	0	1	1	0	3B1D	1E	BL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	1	1	3	0	3B3D	1E	BK	-
I05534	0	0	1	1	0	2B4D	0	BK	P
I05536	0	0	0	1	0	4B1D	3E	BL	-
I05540	0	0	1	2	0	0	0	AK	-
I05542	0	1	1	1	0	3D	0	BK	P
I05551	0	1	1	2	0	4B1D	0	BK	-

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	40.0	1.025	8.0
I05517	67.0	1.017	8.0
I05519	54.0	1.017	8.0
I05520	65.0	1.014	7.5
I05526	179.0	1.010	8.0
I05527	60.0	1.022	8.5
MEAN	77.5	1.018	8.0
S.D.	50.66	.0054	.32
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	44.0	1.010	8.5
I05515	69.0	1.020	8.0
I05516	28.0	1.028	7.5
I05521	108.0	1.016	8.0
MEAN	62.2	1.018	8.0
S.D.	34.86	.0076	.41
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	192.0	1.006	8.0
I05510	53.0	1.021	8.0
I05518	82.0	1.014	8.0
I05523	131.0	1.006	7.5
I05524	25.0	1.031	8.0
I05528	84.0	1.014	7.0
MEAN	94.5	1.015	7.8
S.D.	59.43	.0095	.42
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	50.0	1.020	7.5
I05507	66.0	1.018	8.0
I05509	34.0	1.023	8.0
I05511	107.0	1.009	8.0
I05512	89.0	1.013	7.5
I05522	62.0	1.019	8.5
MEAN	68.0	1.017	7.9
S.D.	26.39	.0051	.38
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	++	-	-	-
I05517	10	-	+	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	+++	-	-	-
I05526	0	-	+	-	-	-
I05527	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	10	-	++	-	-	-
I05516	10	-	++	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	-	-	-	-
I05523	0	-	+	-	+++	-
I05524	10	-	+++	-	-	-
I05528	0	-	+	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	+++	-	-	-
I05507	10	-	-	-	-	-
I05509	10	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	+++	-	-	-
I05522	10	-	-	-	+++	-

Appendix 4

Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	0	3	0	2B3D	0	CK	Q
I05517	0	1	1	2	0	2B2D	0	CK	-
I05519	0	0	1	1	0	2E	0	CK	-
I05520	0	0	1	2	0	2B3D	0	BK	-
I05526	0	0	1	2	0	2B	0	BU	-
I05527	0	0	1	3	0	2B4D	0	CK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	0	0	1	2	0	2B1E	0	AJ	Q
I05515	0	0	1	3	0	2B4D	0	CK	-
I05516	0	0	1	2	0	4D	0	CK	P
I05521	0	0	0	3	0	3B1D	0	BK	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	1	0	3	0	4B1D	0	AK	Q
I05510	0	0	0	1	0	3B4D	1E	CK	-
I05518	0	0	1	3	0	4B3D	0	BK	-
I05523	0	1	1	2	0	2B	0	AK	-
I05524	0	0	1	2	0	2B4D	0	CK	P
I05528	0	0	1	2	0	3B1E	0	BK	P
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05506	0	0	1	1	0	4D	0	CK	Q
I05507	0	0	1	2	0	4D	0	CK	PQ
I05509	0	1	1	1	0	0	0	CK	P
I05511	0	0	1	1	0	2B1D	0	CK	Q
I05512	0	0	1	2	0	1D	0	BU	-
I05522	0	1	0	3	0	1B3D	0	BK	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	62.0	1.020	8.0
I05530	68.0	1.022	8.5
I05531	31.0	1.024	8.0
I05535	195.0	1.005	8.0
I05544	60.0	1.016	8.0
I05549	30.0	1.026	8.5
MEAN	74.3	1.019	8.2
S.D.	61.32	.0076	.26
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	97.0	1.015	8.0
I05541	18.0	1.028	8.0
I05547	50.0	1.018	7.5
I05550	49.0	1.021	7.0
MEAN	53.5	1.020	7.6
S.D.	32.58	.0056	.48
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	98.0	1.010	7.5
I05538	56.0	1.022	8.0
I05539	47.0	1.022	8.0
I05545	98.0	1.016	8.0
I05548	30.0	1.028	7.5
I05552	45.0	1.020	8.0
MEAN	62.3	1.020	7.8
S.D.	28.86	.0061	.26
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	45.0	1.020	7.5
I05534	115.0	1.011	8.0
I05536	42.0	1.024	7.5
I05540	158.0	1.010	8.0
I05542	99.0	1.007	7.5
I05551	27.0	1.030	7.0
MEAN	81.0	1.017	7.6
S.D.	51.27	.0091	.38
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	++++	-	-	-
I05530	10	-	-	-	+++	-
I05531	0	-	+	-	-	-
I05535	0	-	-	-	-	-
I05544	0	-	++	-	-	-
I05549	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	10	-	-	-	-	-
I05541	10	-	++++	-	-	-
I05547	10	-	-	-	-	-
I05550	10	-	++++	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	10	-	+	-	-	-
I05538	10	-	-	-	-	-
I05539	10	-	+++	-	-	-
I05545	0	-	-	-	-	-
I05548	10	-	++++	-	-	-
I05552	10	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+	-	-	-
I05534	0	-	-	-	-	-
I05536	10	-	+	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	-	-	-	-
I05551	10	-	+++	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295); IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS FER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	1	2	0	4D	0	CK	P
I05530	1	0	1	3	0	4B	0	CK	-
I05531	0	1	1	2	0	2B3D	0	CK	-
I05535	0	0	1	2	0	0	0	BU	P
I05544	0	0	1	1	0	4D1E	0	BK	-
I05549	0	0	1	3	0	2B1D	0	CK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	0	1	2	0	2B4D	0	BK	P
I05541	0	1	1	3	0	4B4D	0	CK	P
I05547	0	1	1	1	0	4B2D	0	CK	P
I05550	0	1	2	1	0	2D	0	CK	P
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	4	2	1	0	0	0	BU	P
I05538	0	0	1	2	0	3B3D	0	CK	-
I05539	0	1	2	1	0	4D	0	CK	P
I05545	0	0	1	1	0	4B1D	0	BK	-
I05548	0	1	1	3	0	4D	0	CK	P
I05552	0	1	0	2	0	2B2D	0	CK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	1	1	1	2	0	4B2D	0	CK	-
I05534	0	0	2	3	0	4D	0	BK	P
I05536	0	1	1	1	0	3D1E	0	CK	P
I05540	0	1	1	3	0	1E	0	BK	-
I05542	0	1	1	3	0	2B3D	0	AJ	P
I05551	0	1	1	3	0	2B4D	0	CK	P

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	46.0	1.023	8.0
I05517	40.0	1.026	6.0
I05519	60.0	1.017	8.0
I05520	43.0	1.023	7.5
I05526	52.0	1.026	7.5
I05527	44.0	1.031	8.0
MEAN	47.5	1.024	7.5
S.D.	7.31	.0046	.77
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	29.0	1.010	8.0
I05515	66.0	1.017	8.0
I05516	46.0	1.025	7.5
I05521 a	122.0	1.019	7.5
MEAN	65.8	1.018	7.8
S.D.	40.43	.0062	.29
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	241.0	1.005	7.0
I05510	48.0	1.010	7.0
I05518	106.0	1.017	8.0
I05523	72.0	1.010	7.0
I05524	42.0	1.021	7.5
I05528	98.0	1.018	8.0
MEAN	101.2	1.014	7.4
S.D.	73.16	.0061	.49
N	6	6	6

a Sample collected on Day 92.

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	42.0	1.021	6.5
I05507	28.0	1.030	8.0
I05509	48.0	1.021	8.0
I05511	70.0	1.017	8.0
I05512	82.0	1.010	6.0
I05522	54.0	1.023	7.0
MEAN	54.0	1.020	7.2
S.D.	19.47	.0066	.88
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	-	-	-	-
I05517	10	-	++++	-	-	-
I05519	10	-	+	-	-	-
I05520	10	-	++++	-	-	-
I05526	10	-	+	-	-	-
I05527	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	10	-	-	-	-	-
I05516	10	-	-	-	-	-
I05521 a	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	-	-	-	-
I05523	0	-	-	-	-	-
I05524	10	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	++++	-	-	-
I05507	10	-	-	-	-	-
I05509	0	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	++	-	-	-
I05522	10	-	-	-	-	-

a Sample collected on Day 92.

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	0	3	0	3D2F	0	CK	-
I05517	0	0	2	3	0	4B	0	CK	P
I05519	0	0	0	3	0	3B1D	1F	BK	-
I05520	0	0	0	3	0	4B4D	1E	BK	-
I05526	0	0	0	2	0	1B4D	0	CK	-
I05527	0	0	0	2	0	4B4D	3E	CL	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	0	0	0	3	0	4B2E	0	BK	Q
I05515	0	0	0	3	0	4B1D	0	BK	-
I05516	0	0	1	3	0	1D	0	CK	-
I05521 a	0	0	0	1	0	4B2E	0	CK	Q
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	1	2	0	0	0	AJ	PQ
I05510	0	1	0	3	0	3B	0	BK	PQ
I05518	0	0	0	3	0	2B1E	0	BL	-
I05523	0	1	0	3	0	4B	0	AK	PQ
I05524	0	0	1	2	0	0	0	CK	P
I05528	0	0	0	2	0	3B2E	1F	BK	Q
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05506	0	1	1	2	0	0	0	CK	PQ
I05507	0	0	0	1	0	4B4D	1E	CL	-
I05509	0	0	0	3	0	1B	0	BJ	-
I05511	0	0	0	2	0	3B1E	0	BL	Q
I05512	0	0	1	2	0	0	0	BJ	Q
I05522	0	0	1	1	0	4D	0	BJ	Q

a Sample collected on Day 92.

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	45.0	1.016	8.0
I05530	67.0	1.020	8.0
I05531	62.0	1.019	8.0
I05535	229.0	1.005	8.0
I05544	65.0	1.018	8.0
I05549	92.0	1.012	8.0
MEAN	93.3	1.015	8.0
S.D.	68.15	.0053	.00
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	104.0	1.017	7.0
I05541	31.0	1.021	7.5
I05547	60.0	1.014	7.0
I05550	64.0	1.021	8.0
MEAN	64.8	1.018	7.4
S.D.	30.02	.0034	.48
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	102.0	1.011	8.0
I05538	74.0	1.012	7.0
I05539	56.0	1.025	7.5
I05545	48.0	1.014	6.5
I05548	61.0	1.020	8.0
I05552	38.0	1.028	8.0
MEAN	63.2	1.018	7.5
S.D.	22.56	.0073	.63
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	30.0	1.025	8.0
I05534	46.0	1.023	8.0
I05536	268.0	1.005	8.0
I05540	295.0	1.005	8.0
I05542	38.0	1.022	7.0
I05551	46.0	1.024	7.5
MEAN	120.5	1.017	7.8
S.D.	125.14	.0096	.42
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	10	-	-	-	-	-
I05530	10	-	-	-	+++	-
I05531	10	-	-	-	-	-
I05535	10	-	-	-	-	-
I05544	10	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03			Dosage Unit: mg/kg/day		
I05537	0	-	-	-	-	-
I05541	10	-	+	-	-	-
I05547	0	-	-	-	-	-
I05550	30	-	-	-	+++	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05532	10	-	-	-	-	-
I05538	0	-	+	-	+	-
I05539	10	-	-	-	-	-
I05545	0	-	+	-	-	-
I05548	10	-	+	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	10	-	+	-	-	-
I05534	10	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	10	-	++	-	-	-
I05551	10	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	0	3	0	3B4D	0	BK	-
I05530	4	0	0	3	0	3B4D	0	BL	-
I05531	0	0	0	3	0	4B2E	0	BL	-
I05535	0	0	1	3	0	2B1P	0	BU	-
I05544	0	0	0	3	0	2B	0	BL	-
I05549	0	0	1	3	0	2B1D	1E	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	0	1	2	0	3B1D	1E	BK	-
I05541	0	0	1	3	0	4B4D	1E1F	BL	-
I05547	0	0	0	3	0	3B1D	0	BL	P
I05550	4	0	1	3	0	3B	0	CL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	1	4	3	0	1B4D	0	BK	P
I05538	0	0	2	3	0	3D	0	BK	-
I05539	0	0	0	2	0	4B2E	0	BL	-
I05545	0	0	1	1	0	0	0	BK	-
I05548	0	0	1	1	0	4B4D	0	BL	-
I05552	0	0	1	1	0	4B1D	1E	CL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	3	1	3	0	4D	0	CK	P
I05534	0	0	0	2	0	4B4D	0	BL	-
I05536	0	0	1	2	0	3D	0	AJ	-
I05540	0	0	2	3	0	0	0	AK	-
I05542	0	2	1	3	0	2B2D	0	BK	P
I05551	0	0	1	3	0	3B1D	0	BL	-

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	68.0	1.017	7.5
I05517	76.0	1.013	7.0
I05519	210.0	1.004	7.5
I05520	34.0	1.019	6.5
I05526	320.0	1.005	6.5
I05527	60.0	1.021	7.5
MEAN	131.3	1.013	7.1
S.D.	110.42	.0072	.49
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	56.0	1.017	7.5
I05515	46.0	1.020	7.0
I05516	34.0	1.028	7.0
I05521	64.0	1.017	8.0
MEAN	55.0	1.020	7.4
S.D.	21.32	.0052	.48
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	360.0	1.004	7.5
I05510	92.0	1.009	7.0
I05518	66.0	1.014	7.0
I05523	140.0	1.008	7.0
I05524	44.0	1.022	7.0
I05528	125.0	1.011	7.0
MEAN	137.8	1.011	7.1
S.D.	114.54	.0062	.20
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	80.0	1.012	7.0
I05507	200.0	1.008	7.5
I05509	32.0	1.025	6.0
I05511	390.0	1.003	7.0
I05512	280.0	1.005	7.5
I05522	98.0	1.013	7.5
MEAN	180.0	1.011	7.1
S.D.	136.48	.0082	.58
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	-	-	-	-
I05517	0	-	++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	++++	-	-	-
I05526	0	-	+	-	-	-
I05527	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	++	-	+	-
I05515	0	-	++	-	-	-
I05516	0	-	-	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	+	-	-	-
I05523	0	-	-	-	-	-
I05524	0	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	0	-	+++	-	-	-
I05507	0	-	-	-	-	-
I05509	10	-	++	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	-	-	-	-
I05522	0	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295); IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS FER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	1	3	0	4B	0	BK	Q
I05517	0	0	1	2	0	0	0	BK	P
I05519	0	0	0	2	0	0	0	AJ	-
I05520	0	0	1	3	0	0	0	BK	-
I05526	0	0	1	3	0	0	0	AK	-
I05527	0	0	0	3	0	4B4D	0	BL	Q
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	0	0	0	3	0	3B1D	1E	BK	PQ
I05515	0	0	1	3	0	1B1D	1E	BK	PQ
I05516	0	0	1	3	0	4B1D	0	BK	PQ
I05521	0	0	1	3	0	4B4D	0	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	1	3	0	0	0	AK	-
I05510	0	0	1	3	0	0	0	BK	-
I05518	0	0	0	3	0	4B	0	BK	-
I05523	0	1	1	3	0	0	0	BK	Q
I05524	0	0	1	2	0	0	0	BK	-
I05528	0	1	1	3	0	0	0	BK	Q
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05506	0	0	1	3	0	2B	0	BK	Q
I05507	0	0	0	2	0	0	0	AK	-
I05509	0	1	1	3	0	0	0	BK	P
I05511	0	0	0	2	0	0	0	AK	-
I05512	0	0	1	2	0	0	0	AK	-
I05522	0	0	1	3	0	0	0	BK	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	44.0	1.022	7.5
I05530	36.0	1.024	8.0
I05531	36.0	1.023	7.5
I05535	145.0	1.006	7.0
I05544	100.0	1.011	7.5
I05549	150.0	1.007	7.5
MEAN	85.2	1.016	7.5
S.D.	53.91	.0084	.32
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	110.0	1.013	7.0
I05541	40.0	1.020	7.0
I05547	26.0	1.017	6.5
I05550	66.0	1.016	7.5
MEAN	60.5	1.016	7.0
S.D.	36.93	.0029	.41
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	44.0	1.023	7.0
I05538	46.0	1.027	7.0
I05539	54.0	1.018	7.0
I05545	46.0	1.018	7.0
I05548	28.0	1.022	7.5
I05552	26.0	1.027	7.0
MEAN	40.7	1.022	7.1
S.D.	11.15	.0040	.20
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	30.0	1.025	7.0
I05534	52.0	1.011	8.0
I05536	110.0	1.012	7.5
I05540	270.0	1.005	6.0
I05542	36.0	1.021	7.0
I05551	36.0	1.026	7.0
MEAN	89.0	1.017	7.1
S.D.	93.46	.0085	.66
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	+	-	+++	-
I05530	10	-	-	-	-	-
I05531	0	-	+	-	-	-
I05535	0	-	+	-	-	-
I05544	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	+	-	-	-
I05541	30	-	++	-	+++	-
I05547	10	-	++++	-	-	-
I05550	0	-	+	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	+	-	-	-
I05538	0	-	+++	-	-	-
I05539	0	-	+	-	-	-
I05545	0	-	++	-	-	-
I05548	10	-	+++	-	-	-
I05552	0	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	+++	-	-	-
I05534	0	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	+	-	-	-
I05542	0	-	++	-	-	-
I05551	0	-	++	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS FER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	2	1	0	3	0	3B1D	0	BL	-
I05530	0	1	0	3	0	4B4D	0	BL	-
I05531	0	0	0	2	0	4B4D	2E4F	BL	P
I05535	0	0	1	2	0	0	0	BK	-
I05544	0	0	1	3	0	4B	0	BL	-
I05549	0	0	2	3	0	0	0	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	0	1	3	0	2B4D	0	BK	-
I05541	4	1	1	3	0	0	0	CK	P
I05547	0	1	1	3	0	3B2B	0	BL	P
I05550	0	0	2	3	0	0	0	BK	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	4	2	2	0	0	0	BK	P
I05538	0	0	1	1	0	1D	0	CK	-
I05539	0	1	3	3	0	1D	0	BK	P
I05545	0	0	2	3	0	4D	0	BK	P
I05548	0	1	1	3	0	4B4D	0	BL	-
I05552	0	0	1	3	0	4D	0	CK	P
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	1	1	3	0	2B2D	0	BK	-
I05534	0	0	1	3	0	2B4D	0	BK	-
I05536	0	1	1	2	0	4B3D	1E	BL	-
I05540	0	1	2	1	0	0	0	AK	-
I05542	0	2	1	3	0	2B4D	0	BK	-
I05551	0	1	1	3	0	3B4D	0	CK	-

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	184.0	1.006	8.0
I05517	49.0	1.021	7.5
I05519	62.0	1.012	8.0
I05520	102.0	1.013	8.0
I05526	242.0	1.006	8.0
I05527	58.0	1.023	8.0
MEAN	116.2	1.014	7.9
S.D.	79.33	.0072	.20
N	6	6	6
-----			
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	94.0	1.014	8.0
I05515	52.0	1.019	7.5
I05516	54.0	1.018	8.0
I05521	102.0	1.016	8.0
MEAN	75.5	1.017	7.9
S.D.	26.20	.0022	.25
N	4	4	4
-----			
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	368.0	1.003	8.0
I05510	122.0	1.012	8.0
I05518	78.0	1.016	8.5
I05523	21.0	1.017	6.0
I05524	49.0	1.015	6.5
I05528	96.0	1.016	8.0
MEAN	122.3	1.013	7.5
S.D.	125.43	.0053	1.00
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 4	Dose Level: 0.75	Dosage Unit: mg/kg/day	
I05507	280.0	1.005	7.5
I05511	96.0	1.017	8.0
I05512	36.0	1.018	6.5
I05522	72.0	1.012	7.0
MEAN	121.0	1.013	7.2
S.D.	108.83	.0059	.65
N	4	4	4

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	-	-	-	-
I05517	10	-	-	-	-	-
I05519	10	-	-	-	-	-
I05520	10	-	-	-	-	-
I05526	10	-	-	-	-	-
I05527	10	-	+	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	10	-	-	-	-	-
I05515	10	-	-	-	-	-
I05516	10	-	-	-	-	-
I05521	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	10	-	-	-	-	-
I05510	10	-	-	-	-	-
I05518	10	-	-	-	-	-
I05523	10	-	++	-	-	-
I05524	10	-	-	-	-	-
I05528	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05507	10	-	-	-	-	-
I05511	10	-	-	-	-	-
I05512	10	-	-	-	-	-
I05522	10	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS FER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05508	0	0	0	3	0	2B1E	0	BK	-
I05517	0	0	0	2	0	3B3D	0	BL	-
I05519	0	0	0	3	0	4B	0	BK	-
I05520	0	0	0	3	0	3B1D	0	BL	-
I05526	0	1	0	3	0	2B	0	AK	-
I05527	0	0	0	3	0	4B4D	0	BL	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05514	0	0	0	2	0	2B2E	0	BK	Q
I05515	0	0	0	3	0	4B1E	0	BK	-
I05516	0	0	1	3	0	2B	0	BK	-
I05521	0	0	0	3	0	4B	0	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	0	3	0	2B	0	AK	-
I05510	0	0	1	3	0	2B1E	0	BK	-
I05518	0	0	0	3	0	4B4D	0	BK	-
I05523	0	0	0	1	0	1B	0	BJ	P
I05524	0	0	0	3	0	0	0	BK	-
I05528	0	0	0	1	0	4B1E	0	BL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05507	0	0	0	1	0	0	0	AJ	Q
I05511	0	0	1	2	0	4B	0	BK	Q
I05512	0	0	0	2	0	0	0	BJ	P
I05522	0	0	1	2	0	2D	0	BK	PQ

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	50.0	1.020	8.0
I05530	62.0	1.015	8.0
I05531	57.0	1.023	8.5
I05535	159.0	1.009	8.0
I05544	86.0	1.017	8.0
I05549	100.0	1.013	8.0
MEAN	85.7	1.016	8.1
S.D.	40.59	.0050	.20
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	108.0	1.013	7.0
I05541	38.0	1.020	7.5
I05547	95.0	1.009	8.0
I05550	64.0	1.020	8.0
MEAN	76.2	1.016	7.6
S.D.	31.48	.0054	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	118.0	1.010	8.0
I05538	61.0	1.021	8.0
I05539	70.0	1.022	8.0
I05545	66.0	1.013	7.5
I05548	82.0	1.014	8.0
I05552	43.0	1.023	8.0
MEAN	73.3	1.017	7.9
S.D.	25.33	.0055	.20
N	6	6	6



Appendix 4  
Individual Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----	-----	-----	-----
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	47.0	1.016	7.5
I05534	82.0	1.015	8.0
I05536	72.0	1.017	8.0
I05540	450.0	1.003	7.5
I05542	84.0	1.018	8.0
I05551	56.0	1.018	8.0
MEAN	131.8	1.014	7.8
S.D.	156.54	.0058	.26
N	6	6	6

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	-	-	-	-
I05530	10	-	-	-	-	-
I05531	10	-	-	-	-	-
I05535	10	-	-	-	-	-
I05544	10	-	-	-	-	-
I05549	10	-	-	-	+	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	10	-	++	-	-	-
I05541	10	-	++	-	-	-
I05547	10	-	-	-	-	-
I05550	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	10	-	-	-	-	-
I05538	10	-	-	-	-	-
I05539	10	-	-	-	-	-
I05545	10	-	-	-	-	-
I05548	10	-	-	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	30	-	+++	-	+++	-
I05534	10	-	-	-	+	-
I05536	10	-	-	-	-	-
I05540	10	-	-	-	-	-
I05542	10	-	-	-	-	-
I05551	10	-	-	-	-	-

Appendix 4  
Individual Clinical Urinalysis Data  
Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	1	3	0	4B1D	0	BL	-
I05530	0	0	0	3	0	4B2D	0	BL	-
I05531	0	0	1	3	1G	4B1E	0	BK	-
I05535	0	0	1	3	0	4D	0	BK	-
I05544	0	0	1	3	0	4B	0	BL	-
I05549	0	1	1	3	0	2B1D	0	BK	-
Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day									
I05537	0	1	1	3	0	3B2E	0	BK	-
I05541	0	1	1	3	0	3B1E	0	BL	-
I05547	0	0	1	3	0	4B	0	BK	P
I05550	0	0	1	3	0	4B1E	0	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05532	0	3	0	3	0	2B2E	0	BK	-
I05538	0	0	1	2	0	4B2E	1F	BL	-
I05539	0	0	0	1	0	3B1E	0	BL	-
I05545	0	0	1	2	0	2B2D	0	BK	-
I05548	0	0	1	3	0	3B	0	BK	-
I05552	0	1	1	3	0	3B3D	0	BL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	2	0	1	3	0	0	0	BK	-
I05534	0	1	1	3	0	3B	0	BL	-
I05536	0	0	2	2	0	4B3D	0	BL	-
I05540	0	0	1	2	0	1B	0	AK	-
I05542	0	0	0	3	0	4B	0	BK	-
I05551	0	1	1	3	0	3B3D	0	BL	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	162.0	1.010	7.5
I05526	197.0	1.010	7.0
MEAN	179.5	1.010	7.2
S.D.	24.75	.0000	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	296.0	1.005	7.5
I05523	183.0	1.009	7.5
MEAN	239.5	1.007	7.5
S.D.	79.90	.0028	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	62.0	1.011	6.5
I05522	113.0	1.015	7.5
MEAN	87.5	1.013	7.0
S.D.	36.06	.0028	.71
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	-	-	+	-
I05522	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05520	0	1	0	1	0	4B	BK	-
I05526	0	0	1	2	0	4B	BJ	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	0	0	0	2	0	2B	AJ	-
I05523	0	0	0	2	0	2B	AK	Q
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05511	0	0	1	3	0	3B	BK	-
I05522	0	0	0	3	0	3B	BK	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	88.0	1.020	8.0
I05549	198.0	1.009	7.5
MEAN	143.0	1.014	7.8
S.D.	77.78	.0078	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	178.0	1.015	7.5
I05552	64.0	1.015	7.0
MEAN	121.0	1.015	7.2
S.D.	80.61	.0000	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	63.0	1.015	7.0
I05542	115.0	1.015	8.0
MEAN	89.0	1.015	7.5
S.D.	36.77	.0000	.71
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	0	-	-	-	+	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	10	-	-	-	+++	-
I05552	10	-	+	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	+	-	-	-
I05542	0	-	-	-	-	-



APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05529	0	0	1	3	0	4B	CK	-
I05549	0	0	0	3	0	3B	AK	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05539	4	0	1	3	0	4B3E	BK	-
I05552	0	0	1	3	0	4B	BK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05533	0	0	1	3	0	4B	BK	P
I05542	0	0	0	3	0	3B	BK	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	202.0	1.008	7.5
I05526	189.0	1.010	8.0
MEAN	195.5	1.009	7.8
S.D.	9.19	.0014	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	290.0	1.005	7.5
I05523	102.0	1.014	7.5
MEAN	196.0	1.010	7.5
S.D.	132.94	.0064	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	62.0	1.014	7.5
I05522	104.0	1.020	8.0
MEAN	83.0	1.017	7.8
S.D.	29.70	.0042	.35
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	-	-	-	-
I05522	10	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	0	0	1	3	0	0	0	AJ	Q
I05526	0	0	0	3	0	1D	0	AJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	0	3	0	0	0	AJ	-
I05523	0	1	1	2	1H	2B2F	0	AJ	PQ
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	0	0	1	2	0	3D	0	BJ	-
I05522	0	0	0	3	0	4B	0	BL	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	46.0	1.025	8.0
I05549	188.0	1.010	8.0
MEAN	117.0	1.018	8.0
S.D.	100.41	.0113	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	176.0	1.015	7.0
I05552	87.0	1.018	7.5
MEAN	131.5	1.016	7.2
S.D.	62.93	.0021	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	57.0	1.014	7.5
I05542	126.0	1.019	8.0
MEAN	91.5	1.016	7.8
S.D.	48.79	.0035	.35
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	0	-	-	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+	-	-	-
I05542	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
-----									
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	0	3	0	3B1D	1E	BK	-
I05549	0	0	1	3	0	2B	0	BJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	0	0	1	3	0	1B	0	BJ	-
I05552	0	0	1	1	0	4B1E	0	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	1	1	3	0	2B1D	0	BK	-
I05542	0	0	1	2	0	3B2E	2F	BL	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	248.0	1.004	6.5
I05526	320.0	1.003	7.0
MEAN	284.0	1.004	6.8
S.D.	50.91	.0007	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	354.0	1.004	7.5
I05523	114.0	1.010	7.0
MEAN	234.0	1.007	7.2
S.D.	169.71	.0042	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	32.0	1.026	6.5
I05522	103.0	1.011	7.5
MEAN	67.5	1.018	7.0
S.D.	50.20	.0106	.71
N	2	2	2



APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	10	-	-	-	+++	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	10	-	+	-	-	-
I05522	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05520	0	0	0	3	0	0	AJ	-
I05526	0	0	1	2	0	0	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	0	0	0	3	0	0	AJ	-
I05523	0	0	0	3	0	0	BJ	PQ
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05511	0	0	0	2	0	1B4E	BJ	-
I05522	0	0	0	3	0	1B	BJ	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	118.0	1.007	7.5
I05549	165.0	1.005	8.0
MEAN	141.5	1.006	7.8
S.D.	33.23	.0014	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	90.0	1.016	7.5
I05552	37.0	1.023	7.5
MEAN	63.5	1.020	7.5
S.D.	37.48	.0050	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	23.0	1.011	8.0
I05542	106.0	1.010	6.5
MEAN	64.5	1.010	7.2
S.D.	58.69	.0007	1.06
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	10	-	-	-	-	-
I05552	10	-	++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	-	-	-	-
I05542	0	-	++	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05529	0	0	1	3	0	0	AJ	P
I05549	0	0	1	3	0	1D	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05539	0	1	1	3	0	1B2E	BJ	-
I05552	0	0	1	3	0	4B	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05533	0	0	0	3	0	4B	BL	-
I05542	0	0	1	3	0	1B	BJ	P

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	116.0	1.015	6.5
I05526	476.0	1.002	7.0
MEAN	296.0	1.008	6.8
S.D.	254.56	.0092	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	166.0	1.009	7.0
I05523	33.0	1.023	6.0
MEAN	99.5	1.016	6.5
S.D.	94.05	.0099	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	51.0	1.013	6.0
I05522	44.0	1.026	6.0
MEAN	47.5	1.020	6.0
S.D.	4.95	.0092	.00
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	+++	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	0	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	++++	-	-	-
I05522	0	-	++++	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05520	0	0	1	1	0	1B	BU	-
I05526	0	0	1	1	0	0	AJ	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	0	1	1	3	0	3B	BU	-
I05523	0	0	1	3	0	2B	BU	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05511	0	1	1	2	0	2B	BU	Q
I05522	0	0	0	2	0	0	BU	Q



APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	87.0	1.010	8.0
I05549	354.0	1.003	8.0
MEAN	220.5	1.006	8.0
S.D.	188.80	.0050	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	76.0	1.015	7.0
I05552	42.0	1.021	6.0
MEAN	59.0	1.018	6.5
S.D.	24.04	.0042	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	71.0	1.017	6.5
I05542	113.0	1.012	7.0
MEAN	92.0	1.014	6.8
S.D.	29.70	.0035	.35
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	URCBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	10	-	-	-	++	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	0	-	++	-	-	-
I05552	0	-	+++++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+++	-	++	-
I05542	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LFP	CRYSTALS PER LPF1	URINE APP1	COMMENTS
-----								
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05529	0	1	1	2	0	2B	BU	-
I05549	0	0	1	3	0	0	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05539	0	1	1	3	0	1D	BK	-
I05552	0	0	1	3	0	1B	CU	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05533	0	1	1	2	0	0	BU	-
I05542	0	1	1	1	0	0	BU	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 364  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	149.0	1.019	8.0
I05526	264.0	1.015	7.5
MEAN	206.5	1.017	7.8
S.D.	81.32	.0028	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	82.0	1.018	8.0
I05523	67.0	1.018	7.0
MEAN	74.5	1.018	7.5
S.D.	10.61	.0000	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	100.0	1.015	7.5
I05522	80.0	1.022	6.0
MEAN	90.0	1.018	6.8
S.D.	14.14	.0050	1.06
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	10	++++	-	-	+	-
I05526	10	+	-	-	+	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	+	-	-	+	-
I05523	10	-	++	-	+++	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	10	-	-	-	++	-
I05522	10	+	-	-	+++	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HFP	EPITH PER HPF	BACT PER HFP	CASTS PER LFP	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	0	1	1	3	0	3B1E	1K	BL	-
I05526	0	0	1	3	0	3B1K	0	BL	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	1	2	0	3B3D	0	BL	-
I05523	0	1	1	3	0	3B3D	0	CK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	0	0	0	3	0	4B3D	0	BK	-
I05522	0	0	1	3	0	3B	0	BL	-

APPENDIX 4  
Individual Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	166.0	1.011	8.0
I05549	150.0	1.011	8.0
MEAN	158.0	1.011	8.0
S.D.	11.31	.0000	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	78.0	1.020	7.0
I05552	59.0	1.022	7.0
MEAN	68.5	1.021	7.0
S.D.	13.44	.0014	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	43.0	1.018	6.5
I05542	109.0	1.019	7.5
MEAN	76.0	1.018	7.0
S.D.	46.67	.0007	.71
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	+	-	-	+	-
I05549	0	+	-	-	+	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	10	-	+	-	+++	-
I05552	10	+	++	-	++	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	++	-	++	-
I05542	10	+	+	-	+	-



APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPP	EPITH PER HPF	BACT PER HPP	CASTS PER LPF	CRYSTALS PER LPP1	CRYSTALS PER LPP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	0	3	0	4B2D	3K	BL	-
I05549	0	0	1	3	0	4B1D	0	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	0	0	1	3	0	4K	0	BK	-
I05552	0	0	1	3	0	3B1D	0	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	1	1	3	0	2B	0	BK	-
I05542	0	0	0	3	0	3B3K	0	BL	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	100.0	1.012	8.0
I05526	270.0	1.008	8.0
MEAN	185.0	1.010	8.0
S.D.	120.21	.0028	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	266.0	1.004	8.0
I05523	78.0	1.011	8.0
MEAN	182.0	1.008	8.0
S.D.	147.08	.0050	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	90.0	1.008	8.0
I05522	78.0	1.015	8.0
MEAN	84.0	1.012	8.0
S.D.	8.49	.0050	.00
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	-	-	-	-
I05522	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPP	EPITH PER HPF	BACT PER HPP	CASTS PER LFP	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	0	0	0	3	0	1B1D	0	BK	-
I05526	0	0	1	3	0	0	0	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	0	2	0	0	0	AJ	Q
I05523	0	0	0	3	0	4B1D	0	BK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	0	0	1	3	0	0	0	BJ	Q
I05522	0	0	0	3	0	2B4D	0	BJ	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 456  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	98.0	1.013	8.0
I05549	330.0	1.005	8.0
MEAN	214.0	1.009	8.0
S.D.	164.05	.0057	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	198.0	1.008	7.5
I05552	92.0	1.014	8.0
MEAN	145.0	1.011	7.8
S.D.	74.95	.0042	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	60.0	1.002	8.0
I05542	176.0	1.008	8.0
MEAN	118.0	1.005	8.0
S.D.	82.02	.0042	.00
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
-----						
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	10	-	-	-	+++	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	0	-	-	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	-	-	-	-
I05542	0	-	-	-	+	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HFP	EPITH PER HPF	BACT PER HFP	CASTS PER LFP	CRYSTALS PER LFP1	CRYSTALS PER LFP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	1	3	0	2B4D	0	BK	-
I05549	0	1	1	3	0	0	0	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	0	1	1	3	0	0	0	AJ	-
I05552	0	0	1	3	0	3B	0	BK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	0	1	3	0	2B	0	AK	-
I05542	0	0	0	3	0	4B	0	AL	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 546  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	480.0	1.005	8.0
I05526	380.0	1.005	8.0
MEAN	430.0	1.005	8.0
S.D.	70.71	.0000	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	405.0	1.004	7.5
I05523	195.0	1.008	8.0
MEAN	300.0	1.005	7.8
S.D.	148.49	.0028	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	345.0	1.005	8.0
I05522	100.0	1.015	8.0
MEAN	222.5	1.010	8.0
S.D.	173.24	.0071	.00
N	2	2	2



APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	-	-	-	-
I05522	0	-	-	-	-	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPP	EPITH PER HPF	BACT PER HPP	CASTS PER LPF	CRYSTALS PER LPP1	CRYSTALS PER LPP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	0	0	1	1	0	1B	0	AJ	-
I05526	0	0	0	3	0	1B	0	AJ	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	0	2	0	0	0	AJ	-
I05523	0	0	0	1	0	2B	0	AJ	Q
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	0	0	0	1	0	1B	0	AJ	Q
I05522	0	0	0	1	0	2B1D	2E	BK	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 546  
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
-----			
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	105.0	1.015	8.0
I05549	160.0	1.007	8.0
MEAN	132.5	1.011	8.0
S.D.	38.89	.0057	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	85.0	1.017	8.0
I05552	50.0	1.019	8.0
MEAN	67.5	1.018	8.0
S.D.	24.75	.0014	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	42.0	1.017	8.0
I05542	156.0	1.010	8.0
MEAN	99.0	1.014	8.0
S.D.	80.61	.0050	.00
N	2	2	2

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	10	-	-	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	-	-	-	-
I05542	0	-	-	-	+++	-

APPENDIX 4  
Individual Clinical Urinalysis Data  
Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPP	EPITH PER HPF	BACT PER HPP	CASTS PER LPF	CRYSTALS PER LPP1	CRYSTALS PER LPP2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	1	0	2	0	2B2D	1F	BU	-
I05549	0	0	0	2	0	2B	0	BU	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	0	0	0	2	0	3B1E	0	BK	-
I05552	0	0	0	2	0	2B2E	0	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	0	0	2	0	3B3D	0	BL	-
I05542	0	1	1	1	0	3B	0	AL	-

**APPENDIX 5**

Individual Palmitoyl CoA Oxidase Determinations  
Individual Anatomic Pathology Data

Appendix 5

Covance 6329-223  
3M T-6295.7

Individual Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PPOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	PCOAO IU/G	
-----	-----	
Group: 1	Dose Level: 0	Dosage Unit: mg/kg/day
I05508	4	
I05517	4	
I05519	6	
I05527	7	
MEAN	5	
S.D.	1.5	
N	4	
Group: 2	Dose Level: 0.03	Dosage Unit: mg/kg/day
I05514	4	
I05515	5	
I05516	4	
I05521	6	
MEAN	5	
S.D.	1.0	
N	4	
Group: 3	Dose Level: 0.15	Dosage Unit: mg/kg/day
I05510	6	
I05518	6	
I05524	5	
I05528	5	
MEAN	6	
S.D.	.6	
N	4	

Appendix 5

Individual Palmitoyl CoA Oxidase Determinations  
Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER -----	PCOAO IU/G -----	
Group: 4	Dose Level: 0.75	Dosage Unit: mg/kg/day
I05507	8	
I05512	6	
MEAN	7	
S.D.	1.4	
N	2	



Appendix 5

Individual Palmitoyl CoA Oxidase Determinations  
Terminal Sacrifice

Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER -----	PCOAO IU/G -----	
Group: 1	Dose Level: 0	Dosage Unit: mg/kg/day
I05530	3	
I05531	4	
I05535	4	
I05544	5	
MEAN	4	
S.D.	.8	
N	4	
Group: 2	Dose Level: 0.03	Dosage Unit: mg/kg/day
I05537	4	
I05541	4	
I05547	2	
I05550	5	
MEAN	4	
S.D.	1.3	
N	4	
Group: 3	Dose Level: 0.15	Dosage Unit: mg/kg/day
I05532	5	
I05538	5	
I05545	6	
I05548	7	
MEAN	6	
S.D.	1.0	
N	4	

Appendix 5  
Individual Palmitoyl CoA Oxidase Determinations  
Terminal Sacrifice

Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER -----	PCOAO IU/G -----	
Group: 4	Dose Level: 0.75	Dosage Unit: mg/kg/day
I05534	6	
I05536	7	
I05540	6	
I05551	5	
MEAN	6	
S.D.	.8	
N	4	

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Unscheduled Deaths

Covance 6329-223  
 3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M)  
 DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.4730	.0130 %	.0072	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3840	.0106 %	.0058	WEIGHT TAKEN
BRAIN (BR)	65.9350	1.8189 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	1.2760	.0352 %	.0194	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.2520	.0345 %	.0190	WEIGHT TAKEN
LP KIDNEY (KD0)	6.1230	.1689 %	.0929	WEIGHT TAKEN
RT KIDNEY (KD1)	5.9240	.1634 %	.0898	WEIGHT TAKEN
LIVER (LI)	89.6340	2.4451 %	1.3443	WEIGHT TAKEN
LP TESTIS (TE0)	7.0730	.1951 %	.1073	WEIGHT TAKEN
RT TESTIS (TE1)	7.0020	.1932 %	.1062	WEIGHT TAKEN
PANCREAS (PA)	6.7010	.1849 %	.1016	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1980	.0055 %	.0030	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2070	.0057 %	.0031	WEIGHT TAKEN
GALLEBLADDER (GB)				NOT SCHEDULED
BILE (VOLUME) (BI)				NOT SCHEDULED

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MODERATELY SEVERE	
	BRAIN (BR) : -INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR, -MINIMAL -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MINIMAL -INFILTRATE, LYMPHOHISTIOCYTIC, MENINGEAL, -SLIGHT	
	KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL -CAST, PROTEINACEOUS, -SLIGHT	

## Individual Anatomic Pathology Data

## Unscheduled Deaths

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05506      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: UNSCHEDULED (M)  
DATE OF DEATH: 02/20/99      STUDY DAY OF DEATH: 179      STUDY WEEK OF DEATH: 26      TERMINAL BODY WEIGHT: 3625.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/20/99 12:40      PROSECTOR: DAVID SCHUETTE      RECORDER: NANCY DIEDRICH  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: NANCY DIEDRICH  
-----

## NECROPSY

## O B S E R V A T I O N S (CONTINUED)

## HISTOPATHOLOGY

-----  
LIVER (LI) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL  
- HYPERTROPHY, HEPATOCELLULAR, -MODERATE, DIFFUSE  
- STASIS, BILE, -SLIGHT, MULTI-FOCAL  
THYMUS (TH) :  
- CYST, -PRESENT  
- ATROPHY, -MODERATELY SEVERE  
TRACHEA (TR) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
ESOPHAGUS (ES) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
THYROID (TY) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
- CYST, ULTIMOBRANCHIAL, -PRESENT  
ADRENAL, CORTEX (AC) :  
- MINERALIZATION, VASCULAR, -MINIMAL  
SALIV GL, MANDIB (SG) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
SPINAL CORD (SC) :  
- INFILTRATION, LYMPHOHISTIOCYTIC MENINGEAL/PERIVASCULAR, -  
SLIGHT  
DUODENUM (DU) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
JEJUNUM (JE) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
ILEUM (IL) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
URINARY BLADDER (UB) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
-----

## Individual Anatomic Pathology Data

## Unscheduled Deaths

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: I05506	SEX: MALE	DOSE GROUP: 4	SACRIFICE STATUS: UNSCHEDULED (M)
DATE OF DEATH: 02/20/99	STUDY DAY OF DEATH: 179	STUDY WEEK OF DEATH: 26	TERMINAL BODY WEIGHT: 3625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/20/99 12:40	PROSECTOR: DAVID SCHUETTE	RECORDER: NANCY DIEDRICH	WEIGHER: NANCY DIEDRICH
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE		

-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

CAUSE OF DEATH (CD) :  
-UNDETERMINED,-PRESENT

GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
-NO MACROSCOPIC LESIONS

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Unscheduled Deaths

Covance 6329-223  
 3M T-6295.7

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
 ANIMAL NUMBER: 105509      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: UNSCHEDULED (D)  
 DATE OF DEATH: 01/27/99      STUDY DAY OF DEATH: 155      STUDY WEEK OF DEATH: 23      TERMINAL BODY WEIGHT: NOT ENTERED  
 DATE AND TIME OF NECROPSY: 01/27/99 10:21      PROSECTOR: NANCY DIEDRICH      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: NOT AVAILABLE  
 -----

\*\*\* ORGAN WEIGHTS WERE NOT RECORDED \*\*\*

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
	BONE, FEMUR (FE) :	
	-GROWTH PLATE OPEN,-MODERATELY SEVERE	
	MARROW, FEMUR (FM) :	
	>SECTION EXAMINED; TISSUE NOT PRESENT	
	KIDNEY (KD) :	
	-MINERALIZATION, PAPILLARY,-MODERATE	
LUNG (LU) :	LUNG (LU) :	
-ADHESION(S); ALL LOBES TO EACH OTHER AND PLEURA: MULTIPLE	-FIBROSIS, PLEURAL/SUBPLEURAL,-MODERATE	
INDISTINCT ADHESIONS; CANNOT DISTINGUISH LOBES FROM ONE	-INFILTRATE, MACROPHAGE, ALVEOLAR,-MODERATE	
ANOTHER; COLLECTED	-NECROSIS,-SEVERE	
-MOTTLED; ALL RIGHT LOBES: RED, DARK RED, AND TAN; LOBES	-INFLAMMATION, ACUTE,-SEVERE	
APPEAR FIRM	-FIBRIN, PLEURAL,-MODERATELY SEVERE	
-EROSION(S)/ULCERATION(S); APPEARS TO BE RIGHT CAUDAL LOBE:		
SINGLE ULCERATED AREA, 2.5 X 1.5 CM; ULCERATED AREA EXTENDS	LIVER (LI) :	
DEEP INTO LUNG TISSUE; WALLS OF ULCERATION APPEAR GREEN,	-HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE	
TAN, GRAY AND MOIST; COLLECTED INTACT	-VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATE	
LIVER (LI) :	THYMUS (TH) :	
-MOTTLED; ALL LOBES: DARK BROWN AND TAN	-ATROPHY,-MODERATE	
-LARGE; ALL LOBES: THICKENED	TRACHEA (TR) :	
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL	
	SALIV GL, MANDIB (SG) :	
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL	

Individual Anatomic Pathology Data  
Unscheduled Deaths

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPGS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: 105509      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: UNSCHEDULED (D)  
DATE OF DEATH: 01/27/99      STUDY DAY OF DEATH: 155      STUDY WEEK OF DEATH: 23      TERMINAL BODY WEIGHT: NOT ENTERED  
DATE AND TIME OF NECROPSY: 01/27/99 10:21      PROSECTOR: NANCY DIEDRICH      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDELE      WEIGHER: NOT AVAILABLE  
-----

## O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
COLON (CO) : -DARK FOCUS(I)/AREA(S); WITHIN MUCOSA: SINGLE DARK BROWN AREA, 0.3 X 0.2 CM; COLLECTED ON ROUTINE SECTION  LN, TRACHEOBRON (TB) : -LARGE; UP TO 1.0 X 0.9 X 0.5 CM (CAP 29)	JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT COLON (CO) : >UNREMARKABLE  CAUSE OF DEATH (CD) : -NECROSIS, PULMONARY, -PRESENT LN, TRACHEOBRON (TB) : -INFLAMMATION, ACUTE, -MODERATE

-----

## Individual Anatomic Pathology Data

## Unscheduled Deaths

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPGS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: 105509      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: UNSCHEDULED (D)  
DATE OF DEATH: 01/27/99      STUDY DAY OF DEATH: 155      STUDY WEEK OF DEATH: 23      TERMINAL BODY WEIGHT: NOT ENTERED  
DATE AND TIME OF NECROPSY: 01/27/99 10:21      PROSECTOR: NANCY DIEDRICH      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: NOT AVAILABLE  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES),  
THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM),  
URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT),  
GENERAL COMMENT (GC), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, STERNUM (SB), BONE, STERNUM (SE), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB), SPLEEN (SP),  
LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA),  
AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB),  
PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

-----



## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05508      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3285.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 10:24      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2650	.0081 %	.0042	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2010	.0061 %	.0032	WEIGHT TAKEN
BRAIN (BR)	62.3670	1.8985 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.8310	.0253 %	.0133	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0370	.0316 %	.0166	WEIGHT TAKEN
LP KIDNEY (KD0)	5.8660	.1786 %	.0941	WEIGHT TAKEN
RT KIDNEY (KD1)	5.4930	.1672 %	.0861	WEIGHT TAKEN
LIVER (LI)	59.3880	1.8073 %	.9522	WEIGHT TAKEN
LP TESTIS (TE0)	5.5360	.1685 %	.0888	WEIGHT TAKEN
RT TESTIS (TE1)	5.1190	.1558 %	.0821	WEIGHT TAKEN
PANCREAS (PA)	4.3000	.1309 %	.0689	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1520	.0046 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1390	.0042 %	.0022	WEIGHT TAKEN

NECROPSY	O B S E R V A T I O N S	HISTOPATHOLOGY
LUNG (LU) : -RED FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI	BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -GLOMERULOSCLEROSIS,-MINIMAL	LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL SPLEEN (SP) : >UNREMARKABLE
SPLEEN (SP) : -LARGE; 7.0 X 4.0 X 3.0 CM		

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

-----  
ANIMAL NUMBER: I05508      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3285.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 10:24      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

NECROPSY      O B S E R V A T I O N S (CONTINUED)      HISTOPATHOLOGY

-----  
LN, MESENTERIC (MS) :  
-HEMORRHAGE,-SLIGHT  
TRACHEA (TR) :  
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT  
SALIV GL, MANDIB (SG) :  
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT  
COLON (CO) :  
-INFILTRATE, EOSINOPHILIC,-SLIGHT  
MAMMARY, MALE (MM) :  
>SECTION EXAMINED; TISSUE NOT PRESENT  
PROSTATE (PR) :  
-INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL  
-----  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLBLADDER WEIGHT IS 0.4890 GRAMS BILE VOLUME IS  
1.6000 ML  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (FPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: 105508      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3285.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 10:24      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES),  
THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK),  
MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYIMIDES (EP), TESTIS (TE),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB),  
THYMUS (TH), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA),  
AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), URINARY BLADDER (UB),  
SEMINAL VESICLES (SV), EPIDIDYIMIDES (EP), TESTIS (TE)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2840	.0093 %	.0045	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1430	.0047 %	.0023	WEIGHT TAKEN
BRAIN (BR)	62.4920	2.0456 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	1.0930	.0358 %	.0175	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.2250	.0401 %	.0196	WEIGHT TAKEN
LP KIDNEY (KD0)	5.9980	.1963 %	.0960	WEIGHT TAKEN
RT KIDNEY (KD1)	5.7530	.1893 %	.0921	WEIGHT TAKEN
LIVER (LI)	44.2710	1.4491 %	.7084	WEIGHT TAKEN
LP TESTIS (TE0)	8.0310	.2629 %	.1285	WEIGHT TAKEN
RT TESTIS (TE1)	8.1690	.2674 %	.1307	WEIGHT TAKEN
PANCREAS (PA)	5.8790	.1924 %	.0941	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1490	.0049 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1400	.0046 %	.0022	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MODERATE MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR, -MINIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL LN, MESENTERIC (MS) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE	

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

-----  
ANIMAL NUMBER: I05517      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3055.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 8:11      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

NECROPSY      O B S E R V A T I O N S (CONTINUED)      HISTOPATHOLOGY

-----  
TRACHEA (TR) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
ADRENAL, CORTEX (AC) :  
-HYPERTROPHY, CORTICAL CELL, -MINIMAL  
SALIV GL, MANDIB (SG) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
PANCREAS (PA) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
COLON (CO) :  
-PARASITISM, INTRAMUSCULAR, -PRESENT  
-----  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
-NO MACROSCOPIC LESIONS  
GENERAL INFORMATION (XI) :  
>NOTE:>GALLEBLADDER WEIGHT IS 0.6330 GRAMS BILE VOLUME IS  
1.6600 ML  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05517      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3055.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 8:11      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYIMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, STERNUM (SB), BONE, STERNUM (SE), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB),  
SPLEEN (SP), THYMUS (TH), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU),  
JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB),  
PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYIMIDES (EP), TESTIS (TE)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2820	.0090 %	.0045	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2330	.0074 %	.0037	WEIGHT TAKEN
BRAIN (BR)	62.8980	2.0031 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.7730	.0246 %	.0123	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.8270	.0263 %	.0131	WEIGHT TAKEN
LP KIDNEY (KD0)	5.5490	.1767 %	.0882	WEIGHT TAKEN
RT KIDNEY (KD1)	5.3860	.1715 %	.0856	WEIGHT TAKEN
LIVER (LI)	53.1740	1.6934 %	.8454	WEIGHT TAKEN
LP TESTIS (TE0)	2.7780	.0885 %	.0442	WEIGHT TAKEN
RT TESTIS (TE1)	2.9990	.0955 %	.0477	WEIGHT TAKEN
PANCREAS (PA)	5.5570	.1770 %	.0883	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1310	.0042 %	.0021	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1220	.0039 %	.0019	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MODERATELY SEVERE MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MINIMAL KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR, -SLIGHT	

Individual Anatomic Pathology Data  
Terminal Sacrifice26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

-----  
ANIMAL NUMBER: I05519      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3140.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 6:57      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

## NECROPSY

## O B S E R V A T I O N S (CONTINUED)

## HISTOPATHOLOGY

-----  
LIVER (LI) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL  
GALLBLADDER (GB) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
TRACHEA (TR) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
PARATHYROID (PT) :  
- CYST, -PRESENT  
ADRENAL, CORTEX (AC) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
SALIV GL, MANDIB (SG) :  
- INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
JEJUNUM (JE) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
ILEUM (IL) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
CECUM (CE) :  
- INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
MAMMARY, MALE (MM) :  
>SECTION EXAMINED; TISSUE NOT PRESENT  
PROSTATE (PR) :  
- INFLAMMATION, LYMPHOHISTIOCYTIC, -MINIMAL  
EPIDIDYMIDES (EP) :  
- HYOSPERMIA, -MODERATE  
TESTIS (TE) :  
- IMMATURE, -PRESENT  
-----

GENERAL COMMENT (GC) :  
- BONE MARROW SMEAR TAKEN  
- EYES - DAVIDSONS



## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05519      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3140.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 6:57      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER

NECROPSY      O B S E R V A T I O N S (CONTINUED)      HISTOPATHOLOGY

GENERAL COMMENT (GC) :  
 -NO MACROSCOPIC LESIONS  
 GENERAL INFORMATION (XX) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.7260 GRAMS BILE VOLUME IS  
 1.2000 ML

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:  
 BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
 LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
 ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
 PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
 STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
 SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
 TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:  
 MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS),  
 ESOPHAGUS (ES), THYROID (TY), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM),  
 SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), COLON (CO), RECTUM (RE),  
 SKIN (SK), URINARY BLADDER (UB), SEMINAL VESICLES (SV)

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 10

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3120	.0057 %	.0048	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2600	.0056 %	.0040	WEIGHT TAKEN
BRAIN (BR)	64.8130	1.3849 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	1.8660	.0399 %	.0288	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.7750	.0379 %	.0274	WEIGHT TAKEN
LP KIDNEY (KD0)	7.5090	.1604 %	.1159	WEIGHT TAKEN
RT KIDNEY (KD1)	7.3890	.1579 %	.1140	WEIGHT TAKEN
LIVER (LI)	62.8470	1.3429 %	.9637	WEIGHT TAKEN
LP TESTIS (TE0)	11.5730	.2473 %	.1786	WEIGHT TAKEN
RT TESTIS (TE1)	10.6940	.2285 %	.1650	WEIGHT TAKEN
PANCREAS (PA)	6.0920	.1302 %	.0940	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2380	.0051 %	.0037	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2750	.0059 %	.0042	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
	BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-SLIGHT MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -GRANULOMA,-MINIMAL, FOCAL	

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 11

-----  
 ANIMAL NUMBER: I05527      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 4680.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 11:00      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
 -----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
SKIN (SK) : -ABRASION(S)/ULCERATION(S); 2.0 CM FROM TIP OF TAIL: SINGLE RED, MOIST ABRADED AREA, 0.8 CM IN DIAMETER; COLLECTED		THYMUS (TH) : -ATROPHY,-SEVERE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOCYTOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -INFILTRATE, LYMPHOCYTOCYTIC,-MINIMAL DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE SKIN (SK) : -HYPERPLASIA, EPIDERMAL (ACANTHOSIS),-MODERATE -INFLAMMATION, CHRONIC-ACTIVE,-SLIGHT -ULCERATION,-MODERATELY SEVERE URINARY BLADDER (UB) : -INFILTRATE, LYMPHOCYTOCYTIC,-MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.6430 GRAMS BILE VOLUME IS 2.4000 ML		

-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 12

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (FPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05527      SEX: MALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 4680.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 11:00      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, STERNUM (SB), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP),  
LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC),  
ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
PANCREAS (PA), JEJUNUM (JE), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, MALE (MM), PROSTATE (PR),  
SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 13

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05514 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3495.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3620	.0104 %	.0058	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2420	.0069 %	.0039	WEIGHT TAKEN
BRAIN (BR)	62.4280	1.7862 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	1.1580	.0331 %	.0185	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0010	.0286 %	.0160	WEIGHT TAKEN
LP KIDNEY (KD0)	6.0230	.1723 %	.0965	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1700	.1765 %	.0988	WEIGHT TAKEN
LIVER (LI)	64.2170	1.8374 %	1.0287	WEIGHT TAKEN
LP TESTIS (TE0)	6.7090	.1920 %	.1075	WEIGHT TAKEN
RT TESTIS (TE1)	5.1600	.1476 %	.0827	WEIGHT TAKEN
PANCREAS (PA)	4.7970	.1373 %	.0768	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.3130	.0090 %	.0050	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3200	.0092 %	.0051	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	
	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL	
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS	THYMUS (TH) : -ATROPHY, -MODERATE	

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 14

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05514      SEX: MALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3495.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:21      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.7220 GRAMS BILE VOLUME IS  
1.4000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 15

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05515 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 6:45 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2770	.0080 %	.0043	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1900	.0055 %	.0030	WEIGHT TAKEN
BRAIN (BR)	63.7670	1.8350 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.7590	.0218 %	.0119	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.8690	.0250 %	.0136	WEIGHT TAKEN
LP KIDNEY (KD0)	6.4220	.1848 %	.1007	WEIGHT TAKEN
RT KIDNEY (KD1)	6.2010	.1794 %	.0972	WEIGHT TAKEN
LIVER (LI)	55.8260	1.5965 %	.8755	WEIGHT TAKEN
LP TESTIS (TE0)	2.7190	.0782 %	.0426	WEIGHT TAKEN
RT TESTIS (TE1)	3.3300	.0958 %	.0522	WEIGHT TAKEN
PANCREAS (PA)	5.0260	.1446 %	.0788	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1340	.0039 %	.0021	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1240	.0036 %	.0019	WEIGHT TAKEN

NECROPSY OBSERVATIONS HISTOPATHOLOGY

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS  
 GENERAL INFORMATION (XI) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.4620 GRAMS BILE VOLUME IS 1.2000 ML

LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL

## Individual Anatomic Pathology Data

## Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 16

-----

ANIMAL NUMBER: I05515	SEX: MALE	DOSE GROUP: 2	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99	STUDY DAY OF DEATH: 185	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 3475.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 6:45	PROSECTOR: STEVE VAN ADESTINE	RECORDER: JOHN S. HALFORD	
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE	WEIGHER: JOHN S. HALFORD	

-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

THYMUS (TH)

-----



APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 17

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05516      SEX: MALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3170.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 7:15      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2940	.0093 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2410	.0076 %	.0036	WEIGHT TAKEN
BRAIN (BR)	67.0240	2.1143 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.8820	.0278 %	.0132	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.7570	.0239 %	.0113	WEIGHT TAKEN
LP KIDNEY (KD0)	6.8380	.2157 %	.1020	WEIGHT TAKEN
RT KIDNEY (KD1)	7.0240	.2216 %	.1048	WEIGHT TAKEN
LIVER (LI)	68.1040	2.1494 %	1.0161	WEIGHT TAKEN
LP TESTIS (TE0)	3.3570	.1059 %	.0501	WEIGHT TAKEN
RT TESTIS (TE1)	5.1290	.1618 %	.0765	WEIGHT TAKEN
PANCREAS (PA)	3.0500	.0962 %	.0455	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2040	.0064 %	.0030	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1430	.0045 %	.0021	WEIGHT TAKEN

NECROPSY	O B S E R V A T I O N S	HISTOPATHOLOGY
SPLEEN (SP) : -LARGE; 7.0 X 5.0 X 3.0 CM		SPLEEN (SP) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL
TESTIS (TE) : -LARGE; RIGHT: 2.5 X 1.5 X 1.4 CM (FOR COMPARISON, LEFT IS 2.0 X 1.5 X 1.0 CM)		THYMUS (TH) : -CYST, -PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS		TESTIS (TE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 18

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: 105516	SEX: MALE	DOSE GROUP: 2	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99	STUDY DAY OF DEATH: 185	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 3170.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15	PROSECTOR: KEVIN BILLINGS	RECORDER: MICHELE ZIMA	WEIGHER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE		

-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.6300 GRAMS BILE VOLUME IS  
1.4000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

LIVER (LI)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 19

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05521      SEX: MALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 4385.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 10:48      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3090	.0070 %	.0057	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2230	.0051 %	.0041	WEIGHT TAKEN
BRAIN (BR)	53.9580	1.2305 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	2.8840	.0658 %	.0534	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	2.7980	.0638 %	.0519	WEIGHT TAKEN
LP KIDNEY (KD0)	7.1230	.1624 %	.1320	WEIGHT TAKEN
RT KIDNEY (KD1)	7.6030	.1734 %	.1409	WEIGHT TAKEN
LIVER (LI)	60.2000	1.3723 %	1.1157	WEIGHT TAKEN
LP TESTIS (TE0)	18.7540	.4277 %	.3476	WEIGHT TAKEN
RT TESTIS (TE1)	18.8730	.4304 %	.3498	WEIGHT TAKEN
PANCREAS (PA)	6.3800	.1455 %	.1182	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.4490	.0102 %	.0083	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.4660	.0106 %	.0086	WEIGHT TAKEN

NECROPSY

OBSERVATIONS

HISTOPATHOLOGY

LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL  
 -VACUOLATION, HEPATOCELLULAR, -MINIMAL, MULTI-FOCAL  
 -STASIS, BILE, -MODERATE, MULTI-FOCAL  
 THYMUS (TH) :  
 -ATROPHY, -MODERATELY SEVERE

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 20

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: I05521	SEX: MALE	DOSE GROUP: 2	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99	STUDY DAY OF DEATH: 185	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 4385.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:48	PROSECTOR: KEVIN BILLINGS	RECORDER: MICHELE ZIMA	WEIGHER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE		

-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.4810 GRAMS BILE VOLUME IS  
1.4000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 21

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05510 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3180.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 9:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2490	.0078 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1600	.0050 %	.0028	WEIGHT TAKEN
BRAIN (BR)	56.7600	1.7849 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	1.0910	.0343 %	.0192	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0750	.0338 %	.0189	WEIGHT TAKEN
LP KIDNEY (KD0)	6.4950	.2042 %	.1144	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1190	.1924 %	.1078	WEIGHT TAKEN
LIVER (LI)	54.2060	1.7046 %	.9550	WEIGHT TAKEN
LP TESTIS (TE0)	6.0950	.1917 %	.1074	WEIGHT TAKEN
RT TESTIS (TE1)	5.8860	.1851 %	.1037	WEIGHT TAKEN
PANCREAS (PA)	3.8800	.1220 %	.0684	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1660	.0052 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1960	.0062 %	.0035	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); BILATERAL CAUDAL LOBES TO PLEURA AND DIAPHRAGM; MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT ADIPOSE TISSUE (AT) : -RAISED FOCUS(I)/AREA(S); DIFFUSE, THROUGHOUT MESENTERY AND THORACIC CAVITY; MULTIPLE, TAN, FIRM NODULES, UP TO 0.6 CM IN DIAMETER WITHIN MESENTERY (CAP 29), UP TO 0.3 CM IN DIAMETER WITHIN THORACIC CAVITY (CAP 30) AND COLLECTED INTACT WITH LUNG ADHESIONS GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL ADIPOSE TISSUE (AT) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 22

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05510      SEX: MALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3180.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 9:48      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.6690 GRAMS BILE VOLUME IS  
2.4000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

LIVER (LI), THYMUS (TH)

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 23

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05518 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3070.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2790	.0091 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2460	.0080 %	.0039	WEIGHT TAKEN
BRAIN (BR)	62.8420	2.0470 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.8790	.0286 %	.0140	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0970	.0357 %	.0175	WEIGHT TAKEN
LP KIDNEY (KD0)	5.6790	.1850 %	.0904	WEIGHT TAKEN
RT KIDNEY (KD1)	5.6110	.1828 %	.0893	WEIGHT TAKEN
LIVER (LI)	57.5330	1.8760 %	.9165	WEIGHT TAKEN
LP TESTIS (TE0)	4.5720	.1489 %	.0728	WEIGHT TAKEN
RT TESTIS (TE1)	4.6220	.1506 %	.0735	WEIGHT TAKEN
PANCREAS (PA)	3.1580	.1029 %	.0503	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2450	.0080 %	.0039	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3110	.0101 %	.0049	WEIGHT TAKEN

NECROPSY OBSERVATIONS HISTOPATHOLOGY

THYMUS (TH) :  
 -ATROPHY, -MINIMAL

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS  
 GENERAL INFORMATION (XI) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.5320 GRAMS BILE VOLUME IS 1.3300 ML

## Individual Anatomic Pathology Data

## Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 24

-----  
ANIMAL NUMBER: I05518           SEX: MALE           DOSE GROUP: 3           SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99       STUDY DAY OF DEATH: 185   STUDY WEEK OF DEATH: 27   TERMINAL BODY WEIGHT: 3070.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 9:20   PROSECTOR: KEVIN BILLINGS   RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE   PATHOLOGIST: ROBERT LEEDLE   WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

LIVER (LI)  
-----



APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 25

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
 ANIMAL NUMBER: I05524      SEX: MALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3035.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 7:42      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
 -----

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2420	.0080 %	.0038	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1860	.0061 %	.0029	WEIGHT TAKEN
BRAIN (BR)	63.9330	2.1065 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.9350	.0308 %	.0146	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.9840	.0324 %	.0154	WEIGHT TAKEN
LP KIDNEY (KD0)	5.0370	.1660 %	.0788	WEIGHT TAKEN
RT KIDNEY (KD1)	4.8440	.1596 %	.0758	WEIGHT TAKEN
LIVER (LI)	52.5550	1.7316 %	.8220	WEIGHT TAKEN
LP TESTIS (TE0)	4.6940	.1547 %	.0734	WEIGHT TAKEN
RT TESTIS (TE1)	4.2750	.1409 %	.0669	WEIGHT TAKEN
PANCREAS (PA)	4.6550	.1534 %	.0728	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1210	.0040 %	.0019	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1330	.0044 %	.0021	WEIGHT TAKEN

-----  
 NECROPSY      O B S E R V A T I O N S      HISTOPATHOLOGY  
 -----  
 THYMUS (TH) :  
 -ATROPHY, -MINIMAL  
 -----  
 GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS  
 GENERAL INFORMATION (XI) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.9610 GRAMS BILE VOLUME IS  
 0.8000 ML  
 -----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 26

-----

ANIMAL NUMBER: I05524	SEX: MALE	DOSE GROUP: 3	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99	STUDY DAY OF DEATH: 185	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 3035.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:42	PROSECTOR: STEVE VAN ADESTINE	RECORDER: JOHN S. HALFORD	
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE	WEIGHER: JOHN S. HALFORD	

-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

LIVER (LI)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05528 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 10:19 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3070	.0088 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2620	.0075 %	.0037	WEIGHT TAKEN
BRAIN (BR)	69.8730	2.0107 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.9990	.0287 %	.0143	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.9290	.0267 %	.0133	WEIGHT TAKEN
LP KIDNEY (KD0)	6.3390	.1824 %	.0907	WEIGHT TAKEN
RT KIDNEY (KD1)	6.3690	.1833 %	.0912	WEIGHT TAKEN
LIVER (LI)	64.9760	1.8698 %	.9299	WEIGHT TAKEN
LP TESTIS (TE0)	5.0300	.1447 %	.0720	WEIGHT TAKEN
RT TESTIS (TE1)	5.2350	.1506 %	.0749	WEIGHT TAKEN
PANCREAS (PA)	5.8230	.1676 %	.0833	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2980	.0086 %	.0043	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3900	.0112 %	.0056	WEIGHT TAKEN

NECROPSY OBSERVATIONS HISTOPATHOLOGY

LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL  
 -HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE  
 THYMUS (TH) :  
 -ATROPHY,-SLIGHT

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS  
 GENERAL INFORMATION (XX) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.5220 GRAMS BILE VOLUME IS 1.8000 ML

## Individual Anatomic Pathology Data

## Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 28

-----  
ANIMAL NUMBER: I05528      SEX: MALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3475.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 10:19      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP),  
TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)  
-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 29

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.4540	.0117 %	.0063	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3210	.0083 %	.0045	WEIGHT TAKEN
BRAIN (BR)	71.7900	1.8550 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	2.0740	.0536 %	.0289	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	2.3260	.0601 %	.0324	WEIGHT TAKEN
LP KIDNEY (KD0)	6.5150	.1683 %	.0908	WEIGHT TAKEN
RT KIDNEY (KD1)	6.2950	.1627 %	.0877	WEIGHT TAKEN
LIVER (LI)	112.4190	2.9049 %	1.5659	WEIGHT TAKEN
LP TESTIS (TE0)	12.6370	.3265 %	.1760	WEIGHT TAKEN
RT TESTIS (TE1)	12.5000	.3230 %	.1741	WEIGHT TAKEN
PANCREAS (PA)	5.2280	.1351 %	.0728	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2850	.0074 %	.0040	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3460	.0089 %	.0048	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LIVER (LI) : -MOTTLED; ALL LOBES: BROWN AND TAN	BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-SLIGHT MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR,-MINIMAL -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL -MINERALIZATION, CORTEX,-MINIMAL LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR,-MODERATE, DIFFUSE	

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 30

-----  
ANIMAL NUMBER: I05507      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3870.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 8:11      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
		LIVER (LI) : -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR, -MODERATELY SEVERE
		THYMUS (TH) : -CYST, -PRESENT -ATROPHY, -MODERATELY SEVERE
LN, MESENTERIC (MS) : -DIFFUSELY RED; DARK RED		LN, MESENTERIC (MS) : >UNREMARKABLE
		TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: DARK BROWN		ADRENAL, CORTEX (AC) : >UNREMARKABLE
		JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE
		ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE
		PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC, -MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS		
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5330 GRAMS BILE VOLUME IS 2.0000 ML		

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 31

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: 105507      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3870.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 8:11      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY),  
PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM),  
SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL),  
CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR),  
SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB),  
LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM),  
URINARY BLADDER (UB), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 32

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05512      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2285.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 9:21      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2790	.0122 %	.0046	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2240	.0098 %	.0037	WEIGHT TAKEN
BRAIN (BR)	60.7370	2.6581 %	1.0000	WEIGHT TAKEN
LP EPIDIDYMIS (EP0)	.5450	.0239 %	.0090	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.4350	.0190 %	.0072	WEIGHT TAKEN
LP KIDNEY (KD0)	4.5470	.1990 %	.0749	WEIGHT TAKEN
RT KIDNEY (KD1)	4.5140	.1975 %	.0743	WEIGHT TAKEN
LIVER (LI)	59.1440	2.5446 %	.9573	WEIGHT TAKEN
LP TESTIS (TE0)	1.4310	.0626 %	.0236	WEIGHT TAKEN
RT TESTIS (TE1)	1.3310	.0582 %	.0219	WEIGHT TAKEN
PANCREAS (PA)	3.0430	.1332 %	.0501	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1190	.0052 %	.0020	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1260	.0055 %	.0021	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LIVER (LI) : -MOTTLED; ALL LOBES: BROWN AND TAN	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MODERATE MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MINIMAL LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR, -SLIGHT GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT THYMUS (TH) : -ATROPHY, -MODERATELY SEVERE	



APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 33

-----  
ANIMAL NUMBER: I05512      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2285.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:21      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN	LN, MESENTERIC (MS) : -HEMORRHAGE,-MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -INFLAMMATION, ACUTE,-MINIMAL ADRENAL, CORTEX (AC) : >UNREMARKABLE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, MALE (MM) : >SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL EPIDIDYMIDES (EP) : -HYOSPERMIA,-SEVERE TESTIS (TE) : -IMMATURE,-PRESENT	
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLEBLADDER WEIGHT IS 0.3100 GRAMS BILE VOLUME IS 1.2000 ML		

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 34

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (FPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05512      SEX: MALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2285.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:21      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK),  
MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, STERNUM (SB), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), LUNG (LU), HEART (HT), SPLEEN (SP),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA),  
ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), URINARY BLADDER (UB), SEMINAL VESICLES (SV)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 35

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2480	.0090 %	.0041	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1640	.0060 %	.0027	WEIGHT TAKEN
BRAIN (BR)	60.5500	2.1978 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.6520	.2052 %	.0933	WEIGHT TAKEN
RT KIDNEY (KD1)	5.4770	.1988 %	.0905	WEIGHT TAKEN
LIVER (LI)	49.1800	1.7851 %	.8122	WEIGHT TAKEN
LP OVARY (OV0)	.1220	.0044 %	.0020	WEIGHT TAKEN
RT OVARY (OV1)	.1280	.0046 %	.0021	WEIGHT TAKEN
PANCREAS (PA)	4.2470	.1542 %	.0701	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2100	.0076 %	.0035	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2150	.0078 %	.0036	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM; MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MINIMAL BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MODERATE KIDNEY (KD) : -GLOMERULOSCLEROSIS, -MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR, -MINIMAL -FIBROSIS, PLEURAL/SUBPLEURAL, -SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL	

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 36

-----  
ANIMAL NUMBER: I05530      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2755.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 11:29      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

NECROPSY

O B S E R V A T I O N S (CONTINUED)

HISTOPATHOLOGY

-----  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLEBLADDER WEIGHT IS 0.5970 GRAMS BILE VOLUME IS  
1.2000 ML  
-----

-----  
THYROID (TY) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
SALIV GL, MANDIB (SG) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
MUSCLE, SKELETAL (SM) :  
-DEGENERATION, -SLIGHT  
-INFLAMMATION, GRANULOMATOUS, -MODERATE  
-REGENERATION, MYOFIBER, -MODERATELY SEVERE  
URINARY BLADDER (UB) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: 105530	SEX: FEMALE	DOSE GROUP: 1	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99	STUDY DAY OF DEATH: 184	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 2755.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:29	PROSECTOR: KEVIN BILLINGS	RECORDER: MICHELE ZIMA	WEIGHER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE		

-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MP), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), GALLBLADDER (GB), SPLEEN (SP),  
THYMUS (TH), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA),  
AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA),  
JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MP), UTERUS (UT),  
OVARY (OV), VAGINA (VA), CERVIX (CV)

-----

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 38

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05531      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2625.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 7:15      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.2360	.0090 %	.0043	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1480	.0056 %	.0027	WEIGHT TAKEN
BRAIN (BR)	54.3050	2.0688 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	4.3520	.1658 %	.0801	WEIGHT TAKEN
RT KIDNEY (KD1)	4.2910	.1635 %	.0790	WEIGHT TAKEN
LIVER (LI)	42.1310	1.6050 %	.7758	WEIGHT TAKEN
LP OVARY (OV0)	.0990	.0038 %	.0018	WEIGHT TAKEN
RT OVARY (OV1)	.0930	.0035 %	.0017	WEIGHT TAKEN
PANCREAS (PA)	3.9080	.1489 %	.0720	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1970	.0075 %	.0036	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1740	.0066 %	.0032	WEIGHT TAKEN

## NECROPSY

## OBSERVATIONS

## HISTOPATHOLOGY

MARROW, FEMUR (FM) :  
 -SECTION EXAMINED; TISSUE NOT PRESENT  
 BRAIN (BR) :  
 -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -SLIGHT  
 KIDNEY (KD) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
 LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL  
 ADRENAL, CORTEX (AC) :  
 -HYPERTROPHY, CORTICAL CELL, -MINIMAL  
 SPINAL CORD (SC) :  
 -PIGMENT, NEURONAL, -SLIGHT  
 JEJUNUM (JE) :  
 -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 39

-----  
ANIMAL NUMBER: I05531      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2625.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 7:15      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
-----

-----  
NECROPSY      O B S E R V A T I O N S (CONTINUED)      HISTOPATHOLOGY  
-----

GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
-NO MACROSCOPIC LESIONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLBLADDER WEIGHT IS 0.7250 GRAMS BILE VOLUME IS  
1.8000 ML  
-----

ILEUM (IL) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -MINIMAL  
UTERUS (UT) :  
-AMYLOID, -SLIGHT  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (FPOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05531      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2625.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 7:15      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB),  
SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT),  
ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM),  
NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), OVARY (OV), VAGINA (VA), CERVIX (CV)

-----



APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 41

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05535      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3270.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 8:13      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3770	.0115 %	.0073	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3150	.0096 %	.0061	WEIGHT TAKEN
BRAIN (BR)	51.9670	1.5892 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	6.6940	.2047 %	.1288	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1830	.1891 %	.1190	WEIGHT TAKEN
LIVER (LI)	64.3990	1.9694 %	1.2392	WEIGHT TAKEN
LP OVARY (OV0)	.2280	.0070 %	.0044	WEIGHT TAKEN
RT OVARY (OV1)	.2100	.0064 %	.0040	WEIGHT TAKEN
PANCREAS (PA)	5.0450	.1543 %	.0971	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.4660	.0143 %	.0090	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.4370	.0134 %	.0084	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, AND PERICARDIAL SAC: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT	MARROW, FEMUR (FM) : >SECTION EXAMINED; TISSUE NOT PRESENT LUNG (LU) : -FIBROSIS, PLEURAL/SUBPLEURAL, -SEVERE -FIBROSIS, INTERSTITIAL, -MODERATELY SEVERE	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL -VACUOLATION, HEPATOCELLULAR, -MINIMAL, MULTI-FOCAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT STOMACH, GL (ST) : >UNREMARKABLE
STOMACH, GL (ST) : -RED FOCUS(1)/AREA(S); MUCCOSA, FUNDIC: SINGLE RED FOCUS, 0.3 MM IN DIAMETER; FOCUS HAS A STELLATE PATTERN		

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 42

-----  
ANIMAL NUMBER: I05535      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3270.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 8:13      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

NECROPSY      O B S E R V A T I O N S (CONTINUED)      HISTOPATHOLOGY

-----  
STOMACH, GL (ST) :  
>NOTE:>FUNDIC MUCOSA, ALONG GREATER CURVATURE: SINGLE  
APARENT HOOK WORM EMBEDDED INTO MUCOSA, 3.0 X 0.1 X  
0.1 CM

DUODENUM (DU) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
JEJUNUM (JE) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
ILEUM (IL) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE  
CECUM (CE) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
MAMMARY, FEMALE (MF) :  
-INFLAMMATION, ACUTE, -MINIMAL  
URINARY BLADDER (UB) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
UTERUS (UT) :  
-AMYLOID, -SLIGHT

GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>ANIMAL APPEARS TO BE IN ESTROUS GALLBLADDER WEIGHT IS  
0.6970 GRAMS BILE VOLUME IS 2.6000 ML  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 43

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05535      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3270.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 8:13      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), DUODENUM (DU),  
PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF),  
URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB),  
LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT),  
GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY),  
PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM),  
SPINAL CORD (SC), NERVE, SCIATIC (SN), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), OVARY (OV), VAGINA (VA),  
CERVIX (CV)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 44

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3120	.0118 %	.0052	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2440	.0093 %	.0041	WEIGHT TAKEN
BRAIN (BR)	59.7410	2.2672 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.3110	.2016 %	.0889	WEIGHT TAKEN
RT KIDNEY (KD1)	5.2470	.1991 %	.0878	WEIGHT TAKEN
LIVER (LI)	48.6600	1.8467 %	.8145	WEIGHT TAKEN
LP OVARY (OVO)	.2260	.0086 %	.0038	WEIGHT TAKEN
RT OVARY (OV1)	.1380	.0052 %	.0023	WEIGHT TAKEN
PANCREAS (PA)	4.5080	.1711 %	.0755	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1540	.0058 %	.0026	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1560	.0059 %	.0026	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LIVER (LI) : -LIGHT FOCUS(1)/AREA(S); TRIM COMMENT: DIAPHRAGMATIC SURFACE OF LEFT LATERAL LOBE; SINGLE TAN AREA, 1.0 CM IN DIAMETER; SUBMITTED ON ROUTINE SECTION	MARROW, STERNUM (SE) : -HYPOCELLULAR, MARROW, -SLIGHT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MODERATE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL	GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL LN, MESENTERIC (MS) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 45

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05544      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2635.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:55      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## NECROPSY

## O B S E R V A T I O N S (CONTINUED)

## HISTOPATHOLOGY

-----  
ESOPHAGUS (ES) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL  
PARATHYROID (PT) :  
>SECTION EXAMINED; TISSUE NOT PRESENT  
MUSCLE, SKELETAL (SM) :  
-PARASITES, CYST, -PRESENT  
>NOTE:>HEAVY BURDEN, SARCOCYST-LIKE.  
DUODENUM (DU) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
JEJUNUM (JE) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
ILEUM (IL) :  
-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT  
MAMMARY, FEMALE (MF) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
URINARY BLADDER (UB) :  
-INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT  
OVARY (OV) :  
-MINERALIZATION, -MODERATE  
-----

GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLEBLADDER WEIGHT IS 0.3810 GRAMS BILE VOLUME IS  
2.2000 ML  
-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 46

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05544      SEX: FEMALE      DOSE GROUP: 1      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2635.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:55      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

BONE, FEMUR (FE), MARROW, FEMUR (FM), BONE, STERNUM (SE), EYE (EY), KIDNEY (KD), LUNG (LU), HEART (HT),  
SPLEEN (SP), THYMUS (TH), THYROID (TY), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), CECUM (CE),  
COLON (CO), RECTUM (RE), SKIN (SK), UTERUS (UT), VAGINA (VA), CERVIX (CV)

-----

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 47

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05537      SEX: FEMALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 4055.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 7:31      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN S T A T U S
LEFT ADRENAL (AD0)	.3730	.0092 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3030	.0075 %	.0049	WEIGHT TAKEN
BRAIN (BR)	61.3750	1.5136 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	7.0240	.1732 %	.1144	WEIGHT TAKEN
RT KIDNEY (KD1)	6.6650	.1644 %	.1086	WEIGHT TAKEN
LIVER (LI)	75.2140	1.8548 %	1.2255	WEIGHT TAKEN
LP OVARY (OV0)	.2790	.0069 %	.0045	WEIGHT TAKEN
RT OVARY (OV1)	.2280	.0056 %	.0037	WEIGHT TAKEN
PANCREAS (PA)	6.1370	.1513 %	.1000	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.3200	.0079 %	.0052	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3400	.0084 %	.0055	WEIGHT TAKEN

NECROPSY      O B S E R V A T I O N S      HISTOPATHOLOGY

LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL  
 THYMUS (TH) :  
 -ATROPHY,-MINIMAL  
 SPINAL CORD (SC) :  
 -PIGMENT, NEURONAL,-SLIGHT

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -ANIMAL CESE

GENERAL INFORMATION (XX) :  
 >NOTE:>GALLBLADDER WEIGHT IS 0.5100 GRAMS BILE VOLUME IS  
 3.0000 ML

## Individual Anatomic Pathology Data

## Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 48

-----  
ANIMAL NUMBER: I05537      SEX: FEMALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 4055.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 7:31      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)  
-----



APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 49

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05541 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2510.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 9:47 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.4170	.0166 %	.0066	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3060	.0122 %	.0048	WEIGHT TAKEN
BRAIN (BR)	63.2760	2.5210 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	4.9450	.1970 %	.0781	WEIGHT TAKEN
RT KIDNEY (KD1)	4.6380	.1868 %	.0741	WEIGHT TAKEN
LIVER (LI)	47.6610	1.8988 %	.7532	WEIGHT TAKEN
LP OVARY (OVO)	.1240	.0049 %	.0020	WEIGHT TAKEN
RT OVARY (OVL)	.1570	.0063 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	5.0750	.2022 %	.0802	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2130	.0085 %	.0034	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2300	.0092 %	.0036	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); RIGHT AND LEFT CAUDAL LOBES AND LEFT INTERMEDIATE LOBE TO DIAPHRAGM; MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT -DARK FOCUS(I)/AREA(S); ALL LOBES; MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.7 X 0.4 CM	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	
LIVER (LI) : -ADHESION(S); DIAPHRAGMATIC SURFACE OF RIGHT LATERAL LOBE TO SURROUNDING MESENTERY, ALONG MARGIN; MULTIPLE TAN, FIBROUS ADHESIONS (CAP 29)	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL	
	THYMUS (TH) : -ATROPHY, -MODERATE	
	SPINAL CORD (SC) : -PIGMENT, NEURONAL, -MODERATE	

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 50

-----  
ANIMAL NUMBER: I05541      SEX: FEMALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2510.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 9:47      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
-----

O B S E R V A T I O N S (CONTINUED)

NECROPSY

HISTOPATHOLOGY

-----  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLEBLADDER WEIGHT IS 0.5260 GRAMS BILE VOLUME IS  
1.0000 ML  
-----

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:  
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), GALLEBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES),  
THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK),  
MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT),  
LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)  
-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 51

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05547 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2570.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3130	.0122 %	.0051	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2300	.0089 %	.0038	WEIGHT TAKEN
BRAIN (BR)	60.8690	2.3684 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.4180	.2108 %	.0890	WEIGHT TAKEN
RT KIDNEY (KD1)	5.5840	.2173 %	.0917	WEIGHT TAKEN
LIVER (LI)	49.9520	1.9437 %	.8206	WEIGHT TAKEN
LP OVARY (OV0)	.1590	.0062 %	.0026	WEIGHT TAKEN
RT OVARY (OV1)	.2030	.0079 %	.0033	WEIGHT TAKEN
PANCREAS (PA)	5.1480	.2003 %	.0846	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1550	.0060 %	.0025	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1410	.0055 %	.0023	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); LEFT CAUDAL LOBE TO DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT -DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.5 X 0.3 CM	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL THYMUS (TH) : -CYST, -PRESENT -ATROPHY, -SLIGHT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS		

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 52

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: I05547	SEX: FEMALE	DOSE GROUP: 2	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99	STUDY DAY OF DEATH: 185	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 2570.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:20	PROSECTOR: STEVE VAN ADESTINE	RECORDER: JOHN S. HALFORD	
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE	WEIGHER: JOHN S. HALFORD	

-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.5380 GRAMS BILE VOLUME IS  
1.2000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

SPINAL CORD (SC)

-----

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 53

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05550      SEX: FEMALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2820.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 6:43      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.4230	.0150 %	.0074	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2680	.0095 %	.0047	WEIGHT TAKEN
BRAIN (BR)	56.9130	2.0182 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	6.0900	.2160 %	.1070	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1500	.2181 %	.1081	WEIGHT TAKEN
LIVER (LI)	54.4840	1.9321 %	.9573	WEIGHT TAKEN
LP OVARY (OVO)	.1270	.0045 %	.0022	WEIGHT TAKEN
RT OVARY (OVL)	.1270	.0045 %	.0022	WEIGHT TAKEN
PANCREAS (PA)	7.2830	.2593 %	.1280	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1670	.0059 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2290	.0081 %	.0040	WEIGHT TAKEN

NECROPSY	O B S E R V A T I O N S	HISTOPATHOLOGY
<p>LUNG (LU) :</p> <p>-ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, CAUDAL LOBES TO DIAPHRAGM; MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT</p> <p>GENERAL COMMENT (GC) :</p> <p>-BONE MARROW SMEAR TAKEN</p> <p>-EYES - DAVIDSONS</p>	<p>LUNG (LU) :</p> <p>&gt;NOT REQUIRED TO BE EXAMINED FOR ANIMAL</p> <p>LIVER (LI) :</p> <p>-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL</p> <p>-VACUOLATION, HEPATOCELLULAR, -SLIGHT, MULTI-FOCAL</p> <p>THYMUS (TH) :</p> <p>-ATROPHY, -MINIMAL</p> <p>SPINAL CORD (SC) :</p> <p>-PIGMENT, NEURONAL, -SLIGHT</p>	

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 54

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05550      SEX: FEMALE      DOSE GROUP: 2      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2820.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 6:43      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.6200 GRAMS BILE VOLUME IS  
1.2000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

PAGE: 55

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05532      SEX: FEMALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2550.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 6:47      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3230	.0127 %	.0054	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2160	.0085 %	.0036	WEIGHT TAKEN
BRAIN (BR)	60.2360	2.3622 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.0310	.1973 %	.0835	WEIGHT TAKEN
RT KIDNEY (KD1)	4.9920	.1958 %	.0829	WEIGHT TAKEN
LIVER (LI)	58.3190	2.2870 %	.9682	WEIGHT TAKEN
LP OVARY (OV0)	.0630	.0025 %	.0010	WEIGHT TAKEN
RT OVARY (OV1)	.0870	.0034 %	.0014	WEIGHT TAKEN
PANCREAS (PA)	4.5080	.1768 %	.0748	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1150	.0045 %	.0019	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1020	.0040 %	.0017	WEIGHT TAKEN

-----

NECROPSY	O B S E R V A T I O N S	HISTOPATHOLOGY
----------	-------------------------	----------------

-----

<p>LUNG (LU) :</p> <p>-RED FOCUS(1)/AREA(S); ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI</p>	<p>LUNG (LU) :</p> <p>&gt;NOT REQUIRED TO BE EXAMINED FOR ANIMAL</p> <p>THYMUS (TH) :</p> <p>-ATROPHY,-SEVERE</p> <p>SPINAL CORD (SC) :</p> <p>-PIGMENT, NEURONAL,-MODERATE</p>	
---	---	--

GENERAL COMMENT (GC) :

-BONE MARROW SMEAR TAKEN

-EYES - DAVIDSONS

GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.4650 GRAMS BILE VOLUME IS  
1.2000 ML

-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 56

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: I05532	SEX: FEMALE	DOSE GROUP: 3	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99	STUDY DAY OF DEATH: 184	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 2550.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:47	PROSECTOR: KEVIN BILLINGS	RECORDER: MICHELE ZIMA	WEIGHER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE		

-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

LIVER (LI)

-----



APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 57

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05538 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3200.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 10:25 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3850	.0120 %	.0069	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2630	.0082 %	.0047	WEIGHT TAKEN
BRAIN (BR)	55.6900	1.7403 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.8390	.1825 %	.1048	WEIGHT TAKEN
RT KIDNEY (KD1)	5.3480	.1671 %	.0960	WEIGHT TAKEN
LIVER (LI)	59.5780	1.8618 %	1.0698	WEIGHT TAKEN
LP OVARY (OV0)	.2420	.0076 %	.0043	WEIGHT TAKEN
RT OVARY (OV1)	.1690	.0053 %	.0030	WEIGHT TAKEN
PANCREAS (PA)	4.8070	.1502 %	.0863	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1350	.0042 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1480	.0046 %	.0027	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -DARK FOCUS(I)/AREA(S); ALL LOBES, DIFFUSE: MULTIPLE BLACK PINPOINT FOCI	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	
SPLEEN (SP) : -LIGHT FOCUS(I)/AREA(S); DIFFUSE: MULTIPLE GRAY AREAS, UP TO 1.2 X 0.7 CM	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL SPLEEN (SP) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	
	THYMUS (TH) : -ATROPHY, -SLIGHT SPINAL CORD (SC) : -PIGMENT, NEURONAL, -MINIMAL CECUM (CE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 58

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----

ANIMAL NUMBER: I05538	SEX: FEMALE	DOSE GROUP: 3	SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99	STUDY DAY OF DEATH: 184	STUDY WEEK OF DEATH: 27	TERMINAL BODY WEIGHT: 3200.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:25	PROSECTOR: STEVE VAN ADESTINE	RECORDER: TODD ACKER	
POST-FIX WEIGHER: NOT AVAILABLE	PATHOLOGIST: ROBERT LEEDLE	WEIGHER: TODD ACKER	

-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

-----

CECUM (CE) :  
-RED FOCUS(1)/AREA(S); SEROSAL SURFACE: MULTIPLE DARK RED  
FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS  
GENERAL INFORMATION (XX) :  
>NOTE:>GALLBLADDER WEIGHT IS 0.5060 GRAMS BILE VOLUME IS  
1.6000 ML

-----

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:  
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES),  
THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI),  
SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST),  
DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF),  
URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB),  
LN, ANT MES/PANC (AP)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 59

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
 ANIMAL NUMBER: I05545      SEX: FEMALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2460.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 7:31      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
 -----

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN S T A T U S
LEFT ADRENAL (AD0)	.2640	.0107 %	.0047	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2060	.0084 %	.0037	WEIGHT TAKEN
BRAIN (BR)	55.6590	2.2626 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.4870	.2230 %	.0986	WEIGHT TAKEN
RT KIDNEY (KD1)	5.2040	.2115 %	.0935	WEIGHT TAKEN
LIVER (LI)	52.4930	2.1339 %	.9431	WEIGHT TAKEN
LP OVARY (OVO)	.2040	.0083 %	.0037	WEIGHT TAKEN
RT OVARY (OVL)	.1400	.0057 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	4.1150	.1673 %	.0739	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.2030	.0083 %	.0036	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1190	.0048 %	.0021	WEIGHT TAKEN

-----  
 NECROPSY      O B S E R V A T I O N S      HISTOPATHOLOGY  
 -----

LIVER (LI) :  
 -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL  
 -DEGENERATION/NECROSIS, HEPATOCYLLULAR, -MINIMAL, MULTI-FOCAL  
 THYMUS (TH) :  
 -CYST, -PRESENT  
 -ATROPHY, -MINIMAL  
 SPINAL CORD (SC) :  
 -PIGMENT, NEURONAL, -MINIMAL

GENERAL COMMENT (GC) :  
 -BONE MARROW SMEAR TAKEN  
 -EYES - DAVIDSONS  
 -NO MACROSCOPIC LESIONS

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 60

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05545      SEX: FEMALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2460.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 7:31      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## O B S E R V A T I O N S (CONTINUED)

## NECROPSY

## HISTOPATHOLOGY

## GENERAL INFORMATION (XX) :

>NOTE:>GALLBLADDER WEIGHT IS 0.7210 GRAMS BILE VOLUME IS  
1.4000 ML

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV),  
ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 61

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05548      SEX: FEMALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2865.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 11:00      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN S T A T U S
LEFT ADRENAL (AD0)	.3880	.0135 %	.0063	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2850	.0099 %	.0046	WEIGHT TAKEN
BRAIN (BR)	61.9790	2.1633 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	6.0250	.2103 %	.0972	WEIGHT TAKEN
RT KIDNEY (KD1)	6.0670	.2118 %	.0979	WEIGHT TAKEN
LIVER (LI)	57.7670	2.0163 %	.9320	WEIGHT TAKEN
LP OVARY (OV0)	.2400	.0084 %	.0039	WEIGHT TAKEN
RT OVARY (OV1)	.1510	.0053 %	.0024	WEIGHT TAKEN
PANCREAS (PA)	5.0690	.1769 %	.0818	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1640	.0057 %	.0026	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1640	.0057 %	.0026	WEIGHT TAKEN

NECROPSY	O B S E R V A T I O N S	HISTOPATHOLOGY
LUNG (LU) : -ADHESION(S); ADHERED TO PLEURA, DIAPHRAGM, PERICARDIUM, AND EACH OTHER; MULTIPLE GRAY, FIBROUS ADHESIONS; COLLECTED INTACT	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MODERATE, FOCAL THYMUS (TH) : -ATROPHY, -MODERATELY SEVERE SPINAL CORD (SC) : -PIGMENT, NEURONAL, -SLIGHT CECUM (CE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL
CECUM (CE) : -RED FOCUS(1)/AREA(S); DIFFUSE; MULTIPLE DARK RED FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION		

APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 62

-----  
ANIMAL NUMBER: I05548      SEX: FEMALE      DOSE GROUP: 3      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2865.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 11:00      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

O B S E R V A T I O N S (CONTINUED)

NECROPSY

HISTOPATHOLOGY

-----  
GENERAL COMMENT (GC) :  
-BONE MARROW SMEAR TAKEN  
-EYES - DAVIDSONS

GENERAL INFORMATION (XX) :  
>NOTE:>GALLEBLADDER WEIGHT IS 0.7810 GRAMS BILE VOLUME IS  
2.6000 ML

-----  
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), COLON (CO), RECTUM (RE), SKIN (SK),  
MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT),  
LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 63

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3290	.0132 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2270	.0091 %	.0042	WEIGHT TAKEN
BRAIN (BR)	54.3510	2.1740 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	4.8280	.1931 %	.0888	WEIGHT TAKEN
RT KIDNEY (KD1)	4.9920	.1997 %	.0918	WEIGHT TAKEN
LIVER (LI)	75.5500	3.0220 %	1.3900	WEIGHT TAKEN
LP OVARY (OV0)	.1500	.0054 %	.0029	WEIGHT TAKEN
RT OVARY (OV1)	.1480	.0053 %	.0027	WEIGHT TAKEN
PANCREAS (PA)	4.4740	.1790 %	.0823	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1370	.0055 %	.0025	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1210	.0048 %	.0022	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN PINPOINT FOCI -LIGHT FOCUS(I)/AREA(S); RIGHT AND LEFT CAUDAL LOBES: MULTIPLE TAN AREAS, UP TO 0.2 X 0.1 CM	BONE, FEMUR (FE) : -GROWTH PLATE OPEN, -MODERATE KIDNEY (KD) : -MINERALIZATION, MEDULLA, -MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR, -MINIMAL -INFILTRATE, MACROPHAGE, ALVEOLAR, -MINIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR, -SLIGHT, DIFFUSE -VACUOLATION, HEPATOCELLULAR, -SLIGHT, DIFFUSE	

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 64

-----  
 ANIMAL NUMBER: I05534      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2500.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 8:14      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
 -----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN		THYMUS (TH) : -ATROPHY, -MODERATE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT ADRENAL, CORTEX (AC) : -UNREMARKABLE
CECUM (CE) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED AREAS, UP TO 0.5 X 0.2 CM; COLLECTED ON ROUTINE SECTION		DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED, -MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT CECUM (CE) : -PARASITISM, -PRESENT
COLON (CO) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED FOCI, UP TO 0.3 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION		COLON (CO) : -PARASITISM, INTRAMUSCULAR, -PRESENT
ADIPOSE TISSUE (AT) : -RAISED FOCUS(I)/AREA(S); MESENTERY, DIFFUSE: MULTIPLE TAN FOCI, UP TO 0.3 CM IN DIAMETER (CAP 29)		URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL OVARY (OV) : -MINERALIZATION, -MINIMAL ADIPOSE TISSUE (AT) : -LYMPHOID TISSUE, -PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN		



## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 65

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05534      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2500.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 8:14      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
-----

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
-----	
GENERAL COMMENT (GC) :	
-EYES - DAVIDSONS	
GENERAL INFORMATION (XX) :	
>NOTE:>GALLBLADDER WEIGHT IS 0.5260 GRAMS BILE VOLUME IS 2.0000 ML	
-----	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:	
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:	
MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKLELTAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), UTERUS (UT), VAGINA (VA), CERVIX (CV)	
-----	

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 66

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3290	.0103 %	.0056	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2360	.0074 %	.0040	WEIGHT TAKEN
BRAIN (BR)	58.3990	1.8336 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	6.9900	.2195 %	.1197	WEIGHT TAKEN
RT KIDNEY (KD1)	7.4110	.2327 %	.1269	WEIGHT TAKEN
LIVER (LI)	93.8600	2.9469 %	1.6072	WEIGHT TAKEN
LP OVARY (OVO)	.1610	.0032 %	.0017	WEIGHT TAKEN
RT OVARY (OVL)	.1360	.0043 %	.0023	WEIGHT TAKEN
PANCREAS (PA)	4.7900	.1504 %	.0820	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1910	.0060 %	.0033	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2400	.0075 %	.0041	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) :		MARROW, FEMUR (FM) :
-DARK FOCUS(I)/AREA(S); ALL LOBES, DIFFUSE; MULTIPLE		>SECTION EXAMINED; TISSUE NOT PRESENT
PINPOINT BLACK FOCI		BRAIN (BR) :
LIVER (LI) :		-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR, -MINIMAL
-MOTTLED; ALL LOBES: BROWN AND TAN		LUNG (LU) :
		>UNREMARKABLE
		LIVER (LI) :
		-HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR, -MODERATE
		-VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR, -MODERATELY SEVERE
		GALLBLADDER (GB) :
		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 67

-----  
 ANIMAL NUMBER: I05536      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3185.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/99 9:56      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
 -----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN	THYMUS (TH) : -CYST, -PRESENT -ATROPHY, MODERATELY SEVERE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT THYROID (TY) : -CYST, ULTIMOBRANCHIAL, -PRESENT ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL, -MINIMAL -PIGMENT, -SLIGHT SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL SPINAL CORD (SC) : -PIGMENT, NEURONAL, -MODERATE DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT UTERUS (UT) : -AMYLOID, -MODERATE OVARY (OV) : -AMYLOID, -MODERATE -ONE EXAMINED, -PRESENT	
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN		

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 68

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05536      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/25/99      STUDY DAY OF DEATH: 184      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 3185.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/99 9:56      PROSECTOR: STEVE VAN ADESTINE      RECORDER: TODD ACKER  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: TODD ACKER  
-----

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL COMMENT (GC) : -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.6650 GRAMS BILE VOLUME IS 2.6000 ML -----	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), VAGINA (VA), CERVIX (CV)	

Individual Anatomic Pathology Data  
Terminal Sacrifice

PAGE: 69

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05540      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2700.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 10:20      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3440	.0127 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2550	.0094 %	.0045	WEIGHT TAKEN
BRAIN (BR)	56.3190	2.0859 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	5.2090	.1929 %	.0925	WEIGHT TAKEN
RT KIDNEY (KD1)	4.8440	.1794 %	.0860	WEIGHT TAKEN
LIVER (LI)	63.0760	2.3361 %	1.1200	WEIGHT TAKEN
LP OVARY (OV0)	.1400	.0052 %	.0025	WEIGHT TAKEN
RT OVARY (OV1)	.1410	.0052 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	4.4510	.1649 %	.0790	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2480	.0092 %	.0044	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2540	.0094 %	.0045	WEIGHT TAKEN

## NECROPSY

## OBSERVATIONS

## HISTOPATHOLOGY

LUNG (LU) :  
 -RED FOCUS(1)/AREA(S); RIGHT CAUDAL AND APICAL LOBES;  
 MULTIPLE DARK RED INDISTINCT AREAS

897

3M\_MN03279730

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 70

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
 ANIMAL NUMBER: I05540      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2700.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 10:20      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
 POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
 -----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
SKIN (SK) :		TRACHEA (TR) :
-ALOPECIA-FOCAL; RIGHT DORSAL THORACIC REGION: 0.3 X 2.5 CM		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL
(CAP 29)		THYROID (TY) :
GENERAL COMMENT (GC) :		-CYST, ULTIMOBRANCHIAL, -PRESENT
-BONE MARROW SMEAR TAKEN		AORTA (AO) :
-EYES - DAVIDSONS		-PROLIFERATION, INTIMAL, -MODERATE
GENERAL INFORMATION (XX) :		MUSCLE, SKELETAL (SM) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5650 GRAMS BILE VOLUME IS		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL
1.6000 ML		DUODENUM (DU) :
		-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT
		SKIN (SK) :
		-HAIR FOLLICLES, DECREASED, -MODERATE

-----

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 71

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: 105540      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2700.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 10:20      PROSECTOR: STEVE VAN ADESTINE      RECORDER: JOHN S. HALFORD  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: JOHN S. HALFORD  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT),  
LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), GALLBLADDER (GB),  
SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA),  
PITUITARY (PI), SALIV GL, MANDIB (SG), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA),  
JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB),  
UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV)

-----

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Terminal Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 72

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
 DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	ORGAN STATUS
LEFT ADRENAL (AD0)	.3850	.0173 %	.0065	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2960	.0133 %	.0050	WEIGHT TAKEN
BRAIN (BR)	59.3140	2.6598 %	1.0000	WEIGHT TAKEN
LP KIDNEY (KD0)	6.0280	.2703 %	.1016	WEIGHT TAKEN
RT KIDNEY (KD1)	5.9040	.2648 %	.0995	WEIGHT TAKEN
LIVER (LI)	68.7130	3.0813 %	1.1585	WEIGHT TAKEN
LP OVARY (OV0)	.2350	.0105 %	.0040	WEIGHT TAKEN
RT OVARY (OV1)	.1740	.0078 %	.0029	WEIGHT TAKEN
PANCREAS (PA)	3.7750	.1693 %	.0636	WEIGHT TAKEN
LP THYROID/PARA (TT0)	.1730	.0078 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1630	.0073 %	.0027	WEIGHT TAKEN

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LUNG (LU) : -RED FOCUS(1)/AREA(S); ALL LOBES: MULTIPLE DARK RED FOCI, PINPOINT AND UP TO 1 MM IN DIAMETER	MARROW, FEMUR (FM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFLAMMATION, LYMPHOHISTIOCYTIC, -MINIMAL KIDNEY (KD) : -MINERALIZATION, MEDULLA, -MINIMAL LUNG (LU) : >UNREMARKABLE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR, -SLIGHT GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL	



APPENDIX 5  
Individual Anatomic Pathology Data  
Terminal Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 73

-----  
ANIMAL NUMBER: I05551      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2230.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 7:43      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

NECROPSY	O B S E R V A T I O N S (CONTINUED)	HISTOPATHOLOGY
SKIN (SK) :		TRACHEA (TR) :
-ALOPECIA-DIFFUSE; ALL FOUR LIMBS: HAIRCOAT THIN; COLLECTED		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL
GENERAL COMMENT (GC) :		THYROID (TY) :
-BONE MARROW SMEAR TAKEN		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL
-EYES - DAVIDSONS		SALIV GL, MANDIB (SG) :
GENERAL INFORMATION (XX) :		-INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL
>NOTE:>ANIMAL APPEARS TO BE IN ESTROUS GALLBLADDER WEIGHT IS		MUSCLE, SKELETAL (SM) :
0.6040 GRAMS BILE VOLUME IS 1.8000 ML		-PARASITES, CYST, -PRESENT
		SPINAL CORD (SC) :
		-PIGMENT, NEURONAL, -MODERATE
		JEJUNUM (JE) :
		-INFILTRATE, MACROPHAGE, PIGMENTED, -SLIGHT
		SKIN (SK) :
		-HAIR FOLLICLES, DECREASED, -SLIGHT

## Individual Anatomic Pathology Data

## Terminal Sacrifice

PAGE: 74

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

-----  
ANIMAL NUMBER: I05551      SEX: FEMALE      DOSE GROUP: 4      SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE  
DATE OF DEATH: 02/26/99      STUDY DAY OF DEATH: 185      STUDY WEEK OF DEATH: 27      TERMINAL BODY WEIGHT: 2230.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/26/99 7:43      PROSECTOR: KEVIN BILLINGS      RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE      PATHOLOGIST: ROBERT LEEDLE      WEIGHER: MICHELE ZIMA  
-----

## THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:

BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD),  
HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR),  
ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN),  
STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE),  
MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT),  
LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

## THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:

BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), SPLEEN (SP), THYMUS (TH),  
LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO),  
PITUITARY (PI), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), ILEUM (IL), CECUM (CE),  
COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA),  
CERVIX (CV)

-----

APPENDIX 5  
Individual Anatomic Pathology Data  
Recovery Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER: I05511 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED FIRST POST-RECOV SAC  
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4240.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/00 7:56 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

\*\*\* ORGAN WEIGHTS WERE NOT RECORDED \*\*\*

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
GENERAL COMMENT (GC) : -NO MACROSCOPIC LESIONS	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), CAVITY, THORACIC (TA)		
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (LIO)		

APPENDIX 5  
 Individual Anatomic Pathology Data  
 Recovery Sacrifice

Covance 6329-223  
 3M T-6295.7

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
 ACID POTASSIUM SALT (PPGS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05523 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED FIRST POST-RECOV SAC  
 DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4350.0 GRAMS  
 DATE AND TIME OF NECROPSY: 02/25/00 8:35 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
 POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

\*\*\* ORGAN WEIGHTS WERE NOT RECORDED \*\*\*

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
		LIVER, BIOPSY (LI0): -PIGMENT, HEPATOCELLULAR, -SLIGHT
		LIVER (LI): -INFILTRATE, LYMPHOHISTIOCYTIC, -MODERATE -PIGMENT, HEPATOCELLULAR, -SLIGHT -HYPERPLASIA, BILE DUCT, -MODERATE -INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT, -MODERATE
LUNG (LU): -ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE TAN FIBROUS ADHESIONS		LUNG (LU): >NOT REQUIRED TO BE EXAMINED FOR ANIMAL
CAVITY THORACIC (TA): -NODULE(S); WITHIN ADHESIONS: MULTIPLE TAN AND FIRM NODULES, UP TO 0.3 CM IN DIAMETER		
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), GENERAL COMMENT (GC)		

APPENDIX 5  
Individual Anatomic Pathology Data  
Recovery Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER: I05533 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED FIRST POST-RECOV SAC  
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 2535.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/00 8:58 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

\*\*\* ORGAN WEIGHTS WERE NOT RECORDED \*\*\*

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
LIVER (LI) : -ADHESION(S) : DIAPHRAGMATIC SURFACE OF RIGHT MEDIAN LOBE TO DIAPHRAGM: SINGLE TAN, FIBROUS LINEAR AREA, 2.0 CM IN LENGTH GALLBLADDER (GB) : >NOTE:>NO BILE AVAILABLE FOR SPECIAL PROCEDURE	LIVER (LI) : -FIBROSIS, CAPSULAR, -SLIGHT GALLBLADDER (GB) : -NOT REQUIRED TO BE EXAMINED FOR ANIMAL	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SB), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), GENERAL COMMENT (GC), CAVITY, THORACIC (TA)		
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (L10)		

APPENDIX 5  
Individual Anatomic Pathology Data  
Recovery Sacrifice

Covance 6329-223  
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PPGS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER: I05542 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED FIRST POST-RECOV SAC  
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 3795.0 GRAMS  
DATE AND TIME OF NECROPSY: 02/25/00 9:23 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA  
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

\*\*\* ORGAN WEIGHTS WERE NOT RECORDED \*\*\*

NECROPSY	OBSERVATIONS	HISTOPATHOLOGY
GENERAL COMMENT (GC) : -NO MACROSCOPIC LESIONS	LIVER (LI) : -INFILTRATE, LYMPHOCYTOCYTIC, -MINIMAL	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), CAVITY, THORACIC (TA)		
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (LIO)		

**APPENDIX 6**

AniLytics Inc. Quality Assurance Statements  
Summary and Individual Blood Hormone Determination


Note: This appendix contains information supplied and audited by  
AniLytics Inc.



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, E1, E2, E3, TSH			
TESTOS, T3, T4	9-6-98	9-8-98	98-681

  
MANAGEMENT 9/18/98






200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS INC

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TEST, E1, E2			
E3, T3, T4, T5H	11-27-98	11-30-98 Rewrite KAW 11/30/98	98-911


  
MANAGEMENT 11/30/98



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
TESTOS, CORT, E1, E2 E3, T3, T4, TSH	12-27-98	12-28-98	98-991


  
MANAGEMENT 12/28/98



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TEST, E1, E2, E3			
T3, T4, T5H	3-21-99	3-22-99	99-229

  
MANAGEMENT 3/22/99



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

*Frank Newman*

Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TESTOS, E1, E2, E3, T3, T4, TSH	4-25-99	4-26-99	99-336

*Frank Newman*  
MANAGEMENT 4/26/99



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

*Frank B. Newman*

Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS INC

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
CORTISOL, TESTOS, E1 E2, E3, T3, T4, T311	7-4-99	7-5-99	99-564


*Frank B. Newman*  
MANAGEMENT 5/12/99



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS INC

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
CORTISOL, TESTOS, E1 E2, E3, J3, T4, TSH, FT3, FT4	11-21-99	11-22-99	99-987


  
MANAGEMENT 11/22/99



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0158 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS INC

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
T3, T4, T3H, E1, E2, E3, CORT, TESTOS	4-2-00	4-3-00	00-229


  
MANAGEMENT 4/1/00



200 Girard Street, Suite 200, Gaithersburg, MD 20877  
301-921-0168 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

  
Franklin B. Newman  
QA Auditor

SPONSOR: COVANCE LABS INC

STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
FT3, FT4	4-16-00	4-17-00	00-299

  
MANAGEMENT 4/17/00



Appendix 6

Summary and Individual Blood Hormone Determination  
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	54.69	14.54	29.48	20.01	0.00	0.44	89.59	4.96
I05517	49.55	3.04	51.76	54.86	0.00	0.98	125.67	3.25
I05519	64.74	6.12	31.21	17.51	0.00	0.92	82.21	5.11
I05520	47.30	10.74	30.92	39.76	0.00	2.11	122.59	3.13
I05526	60.37	0.09	31.69	27.63	0.00	0.86	132.25	3.80
I05527	50.69	6.48	43.40	24.47	0.00	3.34	102.72	3.52
MEAN	54.56	6.84	36.41	30.71	0.00	1.44	109.17	3.96
S.D.	6.785	5.199	9.077	14.158	0.000	1.084	20.673	0.864
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	71.04	1.18	38.90	51.37	0.00	1.44	133.26	6.14
I05515	38.63	9.81	27.91	17.75	0.00	1.04	83.16	3.32
I05516	58.36	0.34	32.30	29.41	0.00	1.13	138.37	8.91
I05521	58.05	14.26	59.78	62.35	0.00	1.45	130.08	4.56
MEAN	56.52	6.40	39.72	40.22	0.00	1.27	121.22	5.73
S.D.	13.374	6.767	14.114	20.296	0.000	0.211	25.600	2.412
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	48.00	3.04	43.24	30.43	0.00	1.20	122.64	5.60
I05510	38.05	0.41	23.74	26.96	0.00	0.60	115.95	3.48
I05518	50.92	3.77	53.56	28.80	0.00	1.67	124.80	4.29
I05523	56.98	4.38	43.26	39.35	0.00	0.00	162.12	6.48
I05524	62.46	1.02	30.26	26.55	0.00	0.62	117.52	4.28
I05528	63.18	0.97	26.50	18.67	0.00	1.04	113.68	4.49
MEAN	53.27	2.27	36.76	28.46	0.00	0.86	126.12	4.77
S.D.	9.606	1.674	11.692	6.698	0.000	0.578	18.122	1.079
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	46.92	3.31	26.45	29.18	0.00	0.08	148.18	4.90
I05507	41.20	21.45	49.83	33.79	0.00	1.45	113.67	4.66
I05509	65.60	2.21	30.80	24.47	0.00	1.81	112.11	5.14
I05511	48.27	18.86	32.75	46.01	0.00	0.42	152.20	4.13
I05512	49.15	0.29	38.12	22.90	0.00	0.60	162.79	4.63
I05522	44.81	12.56	49.93	48.77	0.00	1.66	151.90	3.36
MEAN	49.33	9.78	37.98	34.19	0.00	1.00	140.14	4.47
S.D.	8.464	9.117	9.951	10.950	0.000	0.726	21.669	0.639
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	68.63	0.49	48.75	38.12	0.00	0.75	91.26	5.25
I05530	64.90	0.03	48.53	32.43	0.00	0.74	153.02	8.79
I05531	55.89	0.36	53.05	61.53	0.00	0.30	45.26	16.59
I05535	51.86	0.38	50.13	31.55	0.00	1.14	128.93	3.80
I05544	55.61	0.38	37.23	26.87	0.00	2.67	96.13	4.13
I05549	52.20	0.04	50.33	27.55	0.00	0.69	87.95	4.43
MEAN	58.18	0.28	48.0	36.34	0.00	1.05	100.43	7.17
S.D.	6.956	0.195	5.519	12.984	0.000	0.838	37.095	4.963
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	73.24	0.19	91.05	129.22	0.00	0.00	158.33	6.80
I05541	82.66	0.66	60.26	42.73	0.00	0.65	140.97	6.99
I05547	71.82	0.16	55.87	39.96	0.00	0.79	115.35	4.66
I05550	46.90	0.29	50.49	46.09	0.00	0.88	107.01	4.27
MEAN	68.66	0.33	64.44	64.50	0.00	0.58	130.42	5.68
S.D.	15.280	0.230	18.191	43.219	0.000	0.398	23.561	1.414
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05532	56.59	0.13	51.67	35.53	0.00	4.46	64.50	5.49
I05538	51.32	0.23	52.69	35.81	0.00	0.00	137.04	3.21
I05539	66.59	0.34	129.12	82.62	0.00	1.48	117.92	5.68
I05545	63.69	0.25	176.45	132.50	0.00	0.67	135.57	5.05
I05548	65.26	0.45	53.53	47.80	0.00	0.00	104.23	4.24
I05552	49.09	0.33	23.32	15.96	0.00	1.52	71.94	6.35
MEAN	58.76	0.29	82.80	58.37	0.00	1.36	105.20	5.00
S.D.	7.502	0.110	57.794	42.484	0.000	1.663	31.182	1.123
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	58.99	0.35	96.99	64.39	0.00	2.10	101.63	4.25
I05534	59.49	0.05	42.90	34.98	0.00	0.98	97.38	4.94
I05536	51.68	0.29	47.76	46.31	0.00	0.17	124.27	5.78
I05540	46.17	0.15	54.58	88.38	0.00	1.51	126.16	5.23
I05542	87.39	0.63	39.07	31.81	0.00	0.32	109.29	6.44
I05551	67.04	0.38	86.86	107.99	0.00	0.21	95.16	5.78
MEAN	61.79	0.31	61.36	62.31	0.00	0.88	108.98	5.40
S.D.	14.438	0.201	24.447	30.672	0.000	0.795	13.480	0.766
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	57.43	3.30	23.93	11.61	0.00	0.26	113.08	4.24
I05517	43.65	2.35	42.46	29.34	0.00	0.50	104.32	2.99
I05519	71.52	0.37	32.19	19.63	0.00	0.56	122.61	5.26
I05520	52.42	11.10	46.29	35.48	0.00	0.34	137.32	3.54
I05526	84.79	0.21	26.36	20.87	0.00	1.13	154.19	3.86
I05527	79.36	5.72	33.96	34.93	0.00	0.95	99.03	4.72
MEAN	64.86	3.84	34.20	25.31	0.00	0.62	121.76	4.10
S.D.	16.197	4.098	8.780	9.507	0.000	0.345	20.932	0.819
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	79.55	1.10	35.50	4.64	0.00	1.16	140.65	6.28
I05515	67.38	5.86	21.00	28.82	0.00	0.21	97.32	4.57
I05516	87.16	0.19	23.13	23.58	0.00	0.94	127.13	5.92
I05521	62.83	9.82	63.80	49.29	0.00	1.12	120.13	6.34
MEAN	74.23	4.24	35.86	26.58	0.00	0.86	121.31	5.78
S.D.	11.141	4.473	19.695	18.359	0.000	0.442	19.118	0.826
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	50.93	4.07	45.97	18.34	0.00	0.85	130.66	6.01
I05510	77.83	0.53	31.51	17.29	0.00	0.69	104.25	3.94
I05518	67.52	0.93	45.46	25.93	0.00	1.87	145.93	4.76
I05523	61.48	1.81	34.64	27.49	0.00	0.00	136.56	5.13
I05524	63.60	0.68	31.45	16.37	0.00	0.75	107.44	4.14
I05528	72.30	6.04	28.17	13.10	0.00	0.00	111.71	3.63
MEAN	65.61	2.34	36.20	19.75	0.00	0.69	122.76	4.60
S.D.	9.320	2.235	7.651	5.688	0.000	0.689	17.258	0.881
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05506	49.42	1.27	28.98	21.20	0.00	0.82	157.93	5.12
I05507	44.53	7.01	32.46	30.79	0.00	1.92	88.90	6.69
I05509	32.95	1.03	27.21	14.40	0.00	0.57	116.45	4.44
I05511	75.12	16.78	37.12	42.06	0.00	0.59	188.61	4.90
I05512	81.05	0.14	37.24	21.98	0.00	0.25	169.66	3.80
I05522	58.08	10.11	52.20	49.26	0.00	1.54	158.85	3.42
MEAN	65.19	6.06	35.87	29.95	0.00	0.95	146.73	4.73
S.D.	16.683	6.565	8.991	13.432	0.000	0.643	36.914	1.157
N	6	6	6	6	6	6	6	6
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05529	81.80	0.41	42.94	31.46	0.00	0.00	75.62	4.60
I05530	70.50	0.01	90.55	65.47	0.00	0.00	128.68	5.65
I05531	85.44	0.25	52.80	91.87	0.00	0.11	73.71	4.93
I05535	85.08	0.37	79.48	52.46	0.00	0.73	125.42	4.02
I05544	89.58	0.44	72.70	46.44	0.00	2.16	106.71	3.73
I05549	66.75	0.15	50.29	34.57	0.00	0.69	76.27	4.49
MEAN	79.86	0.27	64.79	53.71	0.00	0.62	97.74	4.57
S.D.	9.123	0.168	18.833	22.407	0.000	0.827	25.813	0.680
N	6	6	6	6	6	6	6	6
Group: Female 2		Dose Level: 0.03		Dosage Unit: mg/kg/day				
I05537	79.24	0.17	59.21	48.11	0.00	0.01	131.29	6.03
I05541	108.45	0.77	116.25	90.73	0.00	0.26	132.70	6.63
I05547	67.50	0.19	40.43	67.42	0.00	1.14	86.87	4.59
I05550	89.13	0.23	62.40	61.31	0.00	0.93	88.98	2.99
MEAN	86.08	0.34	69.57	66.89	0.00	0.59	109.96	5.06
S.D.	17.337	0.288	32.593	17.818	0.000	0.536	25.465	1.624
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05532	63.15	0.06	33.18	28.09	0.00	1.38	95.64	4.36
I05538	70.84	0.08	53.04	40.85	0.00	0.00	114.53	3.19
I05539	68.60	0.35	492.12	272.75	0.00	1.33	114.65	6.09
I05545	64.50	0.13	114.49	81.43	0.00	0.17	106.43	4.61
I05548	67.75	0.66	75.11	55.06	0.00	0.00	116.19	4.02
I05552	53.55	0.40	45.64	48.94	0.00	2.13	82.66	4.69
MEAN	64.73	0.28	135.60	88.02	0.00	0.84	105.02	4.49
S.D.	6.148	0.234	176.980	92.174	0.000	0.901	13.401	0.953
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	69.41	0.73	90.70	76.17	0.00	0.00	108.13	4.03
I05534	60.42	0.28	60.87	66.05	0.00	0.13	81.98	4.39
I05536	66.67	0.15	66.36	59.95	0.00	0.04	114.01	5.41
I05540	65.40	0.08	35.46	33.64	0.00	1.39	119.54	4.36
I05542	92.90	0.32	59.88	43.92	0.00	1.02	151.57	7.00
I05551	64.20	0.42	76.86	82.48	0.00	0.24	108.31	5.21
MEAN	69.83	0.33	65.02	60.37	0.00	0.47	113.92	5.07
S.D.	11.681	0.230	18.541	18.740	0.000	0.587	22.513	1.087
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	59.85	2.60	18.82	27.46	0.00	0.00	101.15	3.82
I05517	50.40	2.25	35.11	41.06	0.00	0.00	112.05	3.11
I05519	74.30	0.40	25.09	31.24	0.00	0.00	112.26	4.39
I05520	55.75	3.11	29.31	51.38	0.00	0.00	115.75	2.89
I05526	72.92	0.48	22.23	21.97	0.00	0.00	127.37	2.83
I05527	67.71	2.43	29.56	26.74	0.00	0.00	92.95	3.90
MEAN	63.49	1.88	26.69	33.31	0.00	0.00	110.26	3.49
S.D.	9.676	1.151	5.838	10.926	0.000	0.000	11.939	0.637
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	81.35	1.41	31.71	43.75	0.00	0.00	120.88	5.30
I05515	77.44	1.40	26.17	32.63	0.00	0.00	126.21	2.51
I05516	50.15	0.31	29.91	35.52	0.00	0.00	97.87	5.85
I05521	61.80	3.03	40.47	57.63	0.00	0.00	105.02	4.16
MEAN	67.69	1.54	32.07	42.38	0.00	0.00	112.50	4.46
S.D.	14.422	1.121	6.060	11.204	0.000	0.000	13.269	1.475
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	58.10	5.40	30.42	27.04	0.00	0.00	117.98	5.76
I05510	68.33	0.38	25.88	22.77	0.00	0.00	114.00	3.90
I05518	54.45	1.06	26.53	39.19	0.00	0.32	149.51	4.50
I05523	66.60	2.36	25.62	37.12	0.00	0.00	140.05	6.33
I05524	91.70	1.11	23.61	32.22	0.00	0.00	86.43	3.74
I05528	69.75	0.74	22.60	21.66	0.00	0.00	100.82	3.55
MEAN	68.16	1.84	25.78	30.00	0.00	0.05	118.13	4.63
S.D.	13.025	1.867	2.718	7.358	0.000	0.131	23.608	1.155
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	47.35	0.85	26.15	31.68	0.00	0.00	149.78	5.35
I05507	48.45	1.81	32.25	32.53	0.00	0.00	117.94	6.72
I05509	71.85	1.13	24.82	22.42	0.00	0.00	130.15	5.49
I05511	71.00	2.40	24.62	48.45	0.00	0.00	137.80	4.61
I05512	65.67	0.17	33.79	36.30	0.00	0.00	128.50	3.49
I05522	61.00	3.96	36.25	41.15	0.00	0.00	133.19	3.60
MEAN	60.89	1.72	29.66	35.42	0.00	0.00	132.89	4.88
S.D.	10.801	1.341	5.047	8.885	0.000	0.000	10.561	1.235
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	72.55	0.28	35.08	49.80	0.00	0.00	82.65	4.40
I05530	76.75	0.07	122.95	102.72	0.00	0.01	184.14	8.76
I05531	48.35	0.50	75.71	92.55	0.00	0.00	90.39	8.31
I05535	68.60	0.35	61.83	59.99	0.00	0.00	109.23	5.76
I05544	52.84	0.42	208.06	101.29	0.00	1.26	145.88	5.54
I05549	55.44	0.07	45.31	59.93	0.00	0.00	99.05	5.97
MEAN	62.42	0.28	91.49	77.71	0.00	0.21	118.56	6.46
S.D.	11.701	0.179	64.841	23.710	0.000	0.514	38.982	1.705
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	80.90	0.16	63.92	82.77	0.00	0.00	167.85	9.01
I05541	66.41	0.17	70.21	78.87	0.00	0.00	119.83	7.95
I05547	83.87	0.46	65.82	70.18	0.00	0.00	284.36	6.35
I05550	47.16	0.31	44.95	119.41	0.00	0.00	110.60	4.93
MEAN	69.59	0.28	61.23	87.81	0.00	0.00	170.66	7.06
S.D.	16.783	0.141	11.165	21.716	0.000	0.000	79.847	1.792
N	4	4	4	4	4	4	4	4



Appendix 6

Summary and Individual Blood Hormone Determination  
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05532	57.80	0.18	73.31	64.68	0.00	1.98	221.66	8.42
I05538	87.05	0.09	34.86	46.45	0.00	0.00	133.62	6.15
I05539	50.45	0.08	45.40	87.24	0.00	0.00	122.82	8.69
I05545	57.66	0.03	97.36	92.73	0.00	0.00	126.61	7.04
I05548	56.95	0.59	80.60	76.53	0.00	0.00	125.43	5.95
I05552	62.72	0.54	35.64	71.52	0.00	0.08	99.82	6.53
MEAN	62.11	0.25	61.20	73.19	0.00	0.34	138.33	7.13
S.D.	12.832	0.248	26.181	16.617	0.000	0.802	42.411	1.168
N	6	6	6	6	6	6	6	6
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05533	80.05	0.55	197.69	243.31	0.00	0.04	298.47	7.38
I05534	71.00	0.19	75.81	98.79	0.00	0.00	161.23	6.76
I05536	48.50	0.16	51.69	75.52	0.00	0.00	130.92	6.89
I05540	68.05	0.05	27.69	27.51	0.00	0.00	94.60	4.96
I05542	82.95	0.37	53.10	54.14	0.00	0.00	124.93	8.88
I05551	63.39	0.18	133.61	259.85	0.00	0.00	119.61	7.73
MEAN	68.99	0.25	89.93	126.52	0.00	0.01	154.96	7.10
S.D.	12.436	0.179	63.894	99.828	0.000	0.016	73.494	1.295
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	59.57	0.56	14.21	21.01	0.00	0.02	252.81	3.21
I05517	58.12	1.38	30.66	42.28	0.00	0.86	298.92	4.67
I05519	56.30	0.36	19.61	34.97	0.00	0.00	279.29	4.28
I05520	51.45	2.11	31.75	65.45	0.00	0.00	241.26	4.63
I05526	54.80	0.89	17.02	32.02	0.00	0.47	316.62	3.30
I05527	56.59	10.76	31.22	47.15	0.00	0.70	250.74	4.37
MEAN	56.14	2.68	24.08	40.48	0.00	0.34	273.27	4.06
S.D.	2.818	4.010	8.004	15.181	0.000	0.387	30.061	0.649
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	72.96	2.64	32.81	84.41	0.00	0.70	306.12	6.21
I05515	56.42	0.94	23.69	39.25	0.00	0.43	283.59	3.96
I05516	53.39	0.22	14.32	48.23	0.00	0.13	272.54	4.83
I05521	60.98	10.10	37.38	98.72	0.00	0.14	229.90	5.43
MEAN	60.94	3.48	27.05	67.65	0.00	0.35	273.04	5.11
S.D.	8.601	4.532	10.218	28.460	0.000	0.272	31.973	0.951
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	61.35	0.76	23.37	36.78	0.00	0.07	265.64	4.21
I05510	66.10	0.60	24.13	29.76	0.00	0.68	255.41	4.29
I05518	52.23	0.83	26.75	38.59	0.00	0.92	272.85	3.46
I05523	61.98	2.11	27.07	44.88	0.00	0.00	284.01	5.45
I05524	64.07	0.68	15.77	33.62	0.00	0.32	221.20	3.41
I05528	73.61	1.04	10.40	23.33	0.00	0.01	228.32	3.17
MEAN	63.22	1.00	21.25	34.49	0.00	0.33	254.57	4.00
S.D.	6.968	0.563	6.703	7.452	0.000	0.387	25.007	0.844
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05506	60.57	1.13	24.16	182.56	0.00	0.00	229.83	3.61
I05507	69.37	14.80	51.78	91.86	0.00	0.36	199.81	3.33
I05509	86.47	1.24	17.49	35.79	0.00	0.66	259.19	4.31
I05511	75.68	1.50	6.35	35.89	0.00	0.14	230.58	4.22
I05512	64.22	0.25	21.10	39.97	0.00	0.04	246.92	2.99
I05522	53.06	37.59	69.66	162.36	0.00	0.03	270.21	3.18
MEAN	68.23	9.42	31.76	91.41	0.00	0.21	239.42	3.61
S.D.	11.785	14.866	23.908	66.580	0.000	0.259	25.037	0.549
N	6	6	6	6	6	6	6	6
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05529	58.61	0.31	42.85	72.21	0.00	0.18	256.85	5.54
I05530	77.09	0.08	39.24	74.66	0.00	0.69	189.21	8.01
I05531	60.99	0.20	88.53	208.96	0.00	0.27	211.24	6.09
I05535	61.72	0.25	40.91	63.01	0.00	0.40	267.83	5.64
I05544	62.18	0.46	75.30	65.02	0.00	2.61	216.47	4.38
I05549	56.68	0.18	65.95	56.58	0.00	0.21	236.08	5.23
MEAN	62.88	0.25	58.80	90.07	0.00	0.73	229.61	5.82
S.D.	7.266	0.130	20.805	58.605	0.000	0.941	29.621	1.217
N	6	6	6	6	6	6	6	6
Group: Female 2		Dose Level: 0.03		Dosage Unit: mg/kg/day				
I05537	76.40	0.23	64.21	177.41	0.00	0.00	279.90	6.02
I05541	81.53	0.31	61.86	127.77	0.00	0.01	240.82	6.09
I05547	63.15	0.39	45.86	76.97	0.00	0.68	223.65	4.37
I05550	64.55	0.27	55.39	143.29	0.00	0.27	232.10	3.75
MEAN	71.41	0.30	56.83	131.36	0.00	0.24	244.12	5.06
S.D.	8.993	0.068	8.209	41.770	0.000	0.319	24.864	1.180
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05532	66.39	0.20	383.80	351.81	0.00	1.56	192.15	4.53
I05538	54.30	0.07	27.95	58.49	0.00	0.00	225.80	3.21
I05539	50.23	0.08	38.80	86.17	0.00	1.21	221.63	3.49
I05545	46.45	0.09	119.09	227.52	0.00	0.00	237.82	4.18
I05548	46.73	0.30	34.02	52.35	0.00	0.00	184.62	2.78
I05552	56.82	0.48	27.36	51.92	0.00	0.91	220.15	3.89
MEAN	53.49	0.20	105.17	138.04	0.00	0.61	213.70	3.68 *
S.D.	7.537	0.162	140.935	124.485	0.000	0.703	20.701	0.646
N	6	6	6	6	6	6	6	6
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05533	63.27	0.29	70.06	150.87	0.00	1.07	190.90	3.51
I05534	53.74	0.15	49.92	123.86	0.00	1.59	203.76	5.03
I05536	55.56	0.19	42.44	63.03	0.00	0.00	204.79	3.62
I05540	54.54	0.07	31.28	47.69	0.00	0.26	191.80	3.16
I05542	54.14	0.09	67.52	67.27	0.00	0.52	196.18	4.84
I05551	68.07	0.12	104.58	271.41	0.00	0.10	190.95	5.21
MEAN	58.22	0.15	60.97	120.69	0.00	0.59	196.40	4.23 *
S.D.	5.998	0.080	25.978	83.839	0.000	0.622	6.414	0.895
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	64.62	0.50	17.70	28.21	0.00	0.25	119.34	2.89
I05517	57.71	1.30	35.89	51.07	0.00	1.72	163.61	2.79
I05519	60.20	0.39	27.43	24.22	0.00	0.00	145.97	2.77
I05520	50.13	2.28	27.41	69.97	0.00	0.00	164.61	3.81
I05526	63.25	0.65	15.13	34.66	0.00	0.00	139.41	1.73
I05527	43.13	1.40	38.03	42.05	0.00	1.42	135.30	2.55
MEAN	56.51	1.09	26.93	41.70	0.00	0.57	144.71	2.76
S.D.	8.318	0.719	9.256	16.877	0.000	0.790	17.407	0.667
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	86.10	2.10	29.19	71.76	0.00	0.54	147.03	4.36
I05515	59.33	0.67	27.02	53.19	0.00	0.11	143.03	3.15
I05516	49.45	0.27	17.22	77.85	0.00	0.47	118.77	4.47
I05521	62.77	3.13	44.97	95.20	0.00	0.57	148.62	3.64
MEAN	64.41	1.54	29.60	74.50 *	0.00	0.42	139.36	3.91 *
S.D.	15.522	1.318	11.494	17.333	0.000	0.213	13.928	0.624
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	70.82	1.07	34.40	36.91	0.00	1.22	131.32	3.22
I05510	58.68	0.51	25.73	26.22	0.00	1.53	117.68	2.56
I05518	60.80	0.77	31.30	30.11	0.00	2.85	167.15	2.73
I05523	76.60	2.83	35.79	62.53	0.00	0.00	166.99	4.44
I05524	62.76	0.94	21.61	31.79	0.00	0.00	135.36	2.60
I05528	63.38	0.77	14.54	33.29	0.00	0.29	131.96	2.90
MEAN	65.51	1.15	27.23	36.81	0.00	0.98	141.74	3.08
S.D.	6.813	0.845	8.199	13.086	0.000	1.118	20.528	0.711
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	70.92	0.61	6.89	84.83	0.00	0.00	110.61	2.24
I05507	69.36	2.05	14.27	50.89	0.00	0.33	96.11	2.24
I05509	80.21	1.10	8.28	33.15	0.00	0.97	120.78	3.61
I05511	83.50	1.52	4.43	43.47	0.00	0.00	133.14	3.42
I05512	69.38	0.19	20.03	35.68	0.00	0.00	121.31	1.84
I05522	65.14	1.87	30.27	56.44	0.00	0.00	142.07	2.79
MEAN	73.09 *	1.22	14.03	50.75	0.00	0.22	120.67	2.59
S.D.	7.137	0.728	9.757	18.886	0.000	0.392	16.237	0.585
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	73.17	0.25	42.49	95.52	0.00	2.88	86.34	2.55
I05530	80.23	0.03	40.60	73.45	0.00	0.32	157.85	5.01
I05531	63.57	0.23	87.01	154.45	0.00	0.00	105.00	3.16
I05535	77.78	0.29	135.19	166.44	0.00	0.00	104.25	3.14
I05544	72.02	0.24	110.97	116.03	0.00	3.86	94.26	3.32
I05549	67.18	0.11	88.68	104.97	0.00	0.10	141.85	3.98
MEAN	72.33	0.19	84.16	118.48	0.00	1.19	114.93	3.53
S.D.	6.264	0.100	37.377	35.602	0.000	1.718	28.369	0.859
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	75.87	0.24	97.35	171.29	0.00	0.00	178.52	4.64
I05541	88.44	0.30	95.89	128.24	0.00	0.09	124.69	5.27
I05547	67.51	0.41	71.56	148.12	0.00	1.74	122.85	3.51
I05550	72.45	0.42	63.70	160.38	0.00	0.00	116.15	2.87
MEAN	76.07	0.34	82.13	152.26	0.00	0.46	135.55	4.07
S.D.	8.934	0.087	17.053	18.393	0.000	0.856	28.879	1.083
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05532	63.46	0.05	196.89	162.41	0.00	3.00	100.87	4.30
I05538	62.14	0.06	40.91	57.31	0.00	0.00	122.69	1.97
I05539	65.91	0.00	50.54	122.72	0.00	1.30	109.98	3.15
I05545	60.86	0.05	142.62	226.73	0.00	0.00	147.17	2.68
I05548	48.14	0.36	50.76	96.83	0.00	0.48	99.01	1.94
I05552	61.25	0.44	60.28	85.06	0.00	0.13	102.13	2.55
MEAN	60.29	0.16	92.00	125.18	0.00	0.82	113.64	2.77
S.D.	6.228	0.189	63.048	61.195	0.000	1.176	18.596	0.880
N	6	6	6	6	6	6	6	6
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05533	68.36	1.04	539.64	637.44	0.00	1.64	92.49	2.41
I05534	67.55	0.05	21.16	92.30	0.00	1.91	104.34	3.70
I05536	73.98	0.12	53.49	103.29	0.00	0.17	101.67	2.53
I05540	73.87	0.09	47.69	87.57	0.00	0.00	102.37	1.65
I05542	66.81	0.40	414.10	248.93	0.00	0.69	84.83	3.75
I05551	113.15	0.10	98.43	208.43	0.00	0.00	85.64	4.45
MEAN	77.29	0.30	195.75	229.66	0.00	0.74	95.22	3.08
S.D.	17.850	0.384	222.733	210.776	0.000	0.849	8.753	1.049
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL	
Group: Male 1		Dose Level: 0		Dosage Unit: mg/kg/day					
I05508	63.12	0.65	3.16	20.61	0.00	0.00	141.51	3.96	
I05517	72.02	1.78	22.72	53.30	0.00	0.00	162.07	4.25	
I05519	68.04	0.44	14.07	30.75	0.00	0.00	144.10	3.67	
I05520	50.11	2.53	19.55	65.61	0.00	0.00	148.94	4.53	
I05526	60.09	0.96	16.52	29.74	0.00	0.00	161.62	2.93	
I05527	48.19	1.57	35.93	51.35	0.00	0.00	162.45	4.02	
MEAN	60.26	1.32	18.66	41.90	0.00	0.00	153.45	3.89	
S.D.	9.547	0.786	10.784	17.359	0.000	0.000	9.720	0.553	
N	6	6	6	6	6	6	6	6	
Group: Male 2		Dose Level: 0.03		Dosage Unit: mg/kg/day					
I05514	70.30	1.86	29.08	82.17	0.00	0.00	166.24	5.41	
I05515	48.85	0.96	29.88	40.06	0.00	0.00	148.07	4.38	
I05516	58.29	0.34	28.37	40.27	0.00	0.00	151.67	5.22	
I05521	64.30	10.76	41.20	107.46	0.00	0.00	146.06	6.17	
MEAN	60.44	3.48	32.13 *	67.49	0.00	0.00	153.01	5.30 *	
S.D.	9.148	4.893	6.076	33.199	0.000	0.000	9.120	0.735	
N	4	4	4	4	4	4	4	4	
Group: Male 3		Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	63.97	1.54	17.57	37.08	0.00	0.00	143.76	4.56	
I05510	58.44	1.05	20.81	34.69	0.00	0.00	141.60	4.37	
I05518	52.27	0.90	20.88	26.72	0.00	0.17	156.52	4.49	
I05523	64.33	2.03	20.84	47.88	0.00	0.00	174.10	6.03	
I05524	73.62	0.82	13.64	34.88	0.00	0.00	119.61	3.93	
I05528	72.47	0.73	21.33	23.84	0.00	0.00	143.77	3.45	
MEAN	64.18	1.18	19.18	34.18	0.00	0.03	146.56	4.47	
S.D.	8.157	0.506	3.040	8.478	0.000	0.069	18.023	0.870	
N	6	6	6	6	6	6	6	6	



Appendix 6

Summary and Individual Blood Hormone Determination  
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	73.97	0.48	2.29	48.87	0.00	0.00	107.40	4.98
I05507	49.60	2.71	22.58	40.22	0.00	0.00	89.57	4.45
I05509	86.62	1.73	4.65	34.03	0.00	0.00	127.61	4.61
I05511	60.08	1.70	3.05	38.67	0.00	0.00	144.57	5.46
I05512	64.66	0.26	13.32	33.13	0.00	0.00	102.29	3.78
I05522	67.73	1.87	19.66	57.55	0.00	0.00	136.40	4.38
MEAN	67.11	1.46	10.93	42.08	0.00	0.00	117.97 *	4.61
S.D.	12.571	0.923	8.875	9.438	0.000	0.000	21.468	0.570
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	74.49	0.55	59.28	96.58	0.00	0.00	95.65	3.94
I05530	69.78	0.05	30.39	37.67	0.00	0.00	200.64	6.12
I05531	50.36	0.30	76.52	104.81	0.00	0.00	117.41	4.52
I05535	62.89	0.29	126.05	94.80	0.00	0.00	144.43	4.54
I05544	70.71	1.05	218.24	115.65	0.00	0.00	160.65	4.46
I05549	65.26	0.32	85.32	88.15	0.00	0.00	139.16	5.01
MEAN	65.58	0.43	99.30	89.61	0.00	0.00	142.99	4.77
S.D.	8.513	0.342	66.222	27.146	0.000	0.000	36.187	0.746
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	75.93	0.30	276.11	579.38	0.00	0.00	161.68	5.86
I05541	89.16	0.37	88.60	143.45	0.00	0.00	144.58	6.55
I05547	68.87	0.38	48.03	87.11	0.00	0.00	121.55	5.03
I05550	61.58	0.28	34.29	106.94	0.00	0.00	160.17	6.54
MEAN	73.89	0.33	111.76	229.22	0.00	0.00	147.00	6.00
S.D.	11.748	0.050	111.968	234.602	0.000	0.000	18.641	0.720
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05532	53.44	0.07	208.42	161.28	0.00	0.09	120.33	4.88
I05538	54.36	0.09	55.31	71.47	0.00	0.00	113.79	3.27
I05539	56.38	0.01	48.35	96.47	0.00	0.00	114.24	3.49
I05545	50.87	0.00	64.59	142.80	0.00	0.00	113.45	4.38
I05548	46.19	0.30	29.92	64.58	0.00	0.00	109.64	3.13
I05552	55.40	0.38	74.01	74.24	0.00	0.00	92.26	3.47
MEAN	52.77	0.14	80.10	101.81	0.00	0.02	110.62 *	3.77
S.D.	3.737	0.159	64.629	40.773	0.000	0.037	9.628	0.697
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	63.67	0.51	162.24	186.20	0.00	0.00	95.87	4.18
I05534	57.80	0.04	34.90	67.09	0.00	0.00	81.56	5.45
I05536	71.04	0.14	29.06	60.95	0.00	0.00	92.51	4.94
I05540	85.09	0.26	42.06	65.39	0.00	0.00	90.84	3.81
I05542	58.02	0.23	95.90	72.08	0.00	0.00	81.86	5.99
I05551	91.43	0.42	394.36	503.53	0.00	0.00	83.67	5.15
MEAN	71.18	0.27	126.42	159.21	0.00	0.00	87.72 *	4.92
S.D.	14.228	0.174	140.697	175.397	0.000	0.000	6.128	0.807
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05508	49.36	0.80	11.03	16.55	0.00	0.01	153.39	4.94
I05517	44.88	0.89	26.64	34.19	0.00	1.43	155.85	4.14
I05519	54.72	0.41	21.40	24.00	0.00	0.48	152.78	4.19
I05520	37.96	3.20	19.07	35.67	0.00	0.35	169.82	4.97
I05526	60.22	0.91	15.79	22.56	0.00	0.30	162.99	3.38
I05527	39.62	2.05	43.81	46.79	0.00	0.02	164.16	4.68
MEAN	47.79	1.38	22.96	29.96	0.00	0.43	159.67	4.38
S.D.	8.681	1.049	11.485	10.990	0.000	0.524	6.579	0.608
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05514	57.72	1.43	29.26	65.16	0.00	0.76	148.24	5.02
I05515	41.90	0.44	9.14	29.60	0.00	0.32	133.97	3.70
I05516	43.62	0.31	16.57	29.96	0.00	0.11	77.19	5.04
I05521	53.31	8.03	41.46	70.45	0.00	0.15	117.72	5.13
MEAN	49.14	2.55	24.11	48.79	0.00	0.34	119.28 *	4.72
S.D.	7.613	3.686	14.242	22.060	0.000	0.298	30.705	0.683
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	42.54	0.25	28.98	21.56	0.00	1.10	134.08	4.41
I05510	39.10	2.63	25.43	19.76	0.00	0.51	110.87	3.40
I05518	46.25	0.70	28.63	25.41	0.00	2.09	136.26	4.42
I05523	57.87	2.06	26.43	39.59	0.00	0.18	144.20	4.67
I05524	51.67	0.73	20.26	20.89	0.00	0.09	114.48	3.94
I05528	52.89	0.42	9.63	13.61	0.00	0.46	107.88	3.12
MEAN	48.39	1.13	23.23	23.47	0.00	0.74	124.63 *	3.99
S.D.	7.014	0.973	7.363	8.774	0.000	0.751	15.365	0.621
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05507	59.90	2.10	0.00	33.59	0.00	1.59	58.09	5.27
I05511	43.70	0.69	1.01	27.68	0.00	0.34	97.68	7.00
I05512	70.20	0.04	0.00	22.69	0.00	0.59	34.06	3.25
I05522	59.49	1.80	2.00	36.89	0.00	1.18	75.57	5.85
MEAN	58.32	1.16	0.75 *	30.21	0.00	0.93	66.35 *	5.34
S.D.	10.935	0.961	0.958	6.298	0.000	0.566	26.941	1.569
N	4	4	4	4	4	4	4	4
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	65.21	0.17	232.49	351.64	0.00	1.33	95.65	4.83
I05530	74.89	0.01	47.22	68.58	0.00	0.00	183.66	7.22
I05531	35.19	0.03	51.65	77.36	0.00	0.00	115.47	5.01
I05535	74.58	0.52	318.47	239.29	0.00	0.06	139.41	5.84
I05544	61.62	0.34	162.44	153.92	0.00	2.75	152.04	5.08
I05549	41.85	0.02	78.63	61.78	0.00	0.22	125.36	5.95
MEAN	58.89	0.18	148.48	158.75	0.00	0.73	135.27	5.66
S.D.	16.743	0.209	110.143	116.512	0.000	1.115	30.659	0.894
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	76.03	0.29	254.69	492.79	0.00	0.00	148.10	5.29
I05541	61.45	0.13	47.66	101.86	0.00	0.08	131.20	5.85
I05547	39.39	0.26	41.73	164.10	0.00	0.85	98.77	3.35
I05550	59.31	0.14	156.72	364.55	0.00	1.77	102.12	2.84
MEAN	59.05	0.21	125.20	280.83	0.00	0.68	120.05	4.33
S.D.	15.063	0.082	101.227	180.363	0.000	0.824	23.703	1.462
N	4	4	4	4	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05532	47.71	0.01	197.86	141.98	0.00	4.33	90.44	4.36
I05538	36.38	0.04	45.10	64.69	0.00	0.25	100.45	2.83
I05539	42.82	0.00	52.30	100.79	0.00	0.89	106.11	3.63
I05545	48.24	0.04	52.62	74.46	0.00	0.62	86.22	4.00
I05548	32.13	0.03	39.61	51.74	0.00	0.98	103.15	4.03
I05552	48.26	0.16	36.02	60.51	0.65	0.57	93.10	4.59
MEAN	42.59	0.05	70.59	82.36	0.11	1.27	96.58 *	3.91 *
S.D.	6.904	0.058	62.705	33.716	0.265	1.520	7.824	0.622
N	6	6	6	6	6	6	6	6
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05533	63.42	0.17	36.11	55.31	0.00	2.31	83.76	5.31
I05534	66.38	0.05	9.45	37.27	0.00	1.10	81.38	6.31
I05536	51.73	0.09	0.00	53.37	0.00	0.62	76.41	5.96
I05540	60.27	0.15	47.41	60.05	0.00	0.21	71.65	3.74
I05542	56.03	0.19	93.61	115.82	0.00	0.55	92.22	5.83
I05551	96.30	0.07	52.80	99.85	0.00	0.22	104.92	6.49
MEAN	65.69	0.12	39.90	70.28	0.00	0.84	85.06 *	5.61
S.D.	15.876	0.058	33.589	30.505	0.000	0.793	11.963	1.002
N	6	6	6	6	6	6	6	6

Appendix 6

Summary and Individual Blood Hormone Determination  
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day				
I05508	126.89	5.18	3.46	1.02
I05519	110.98	3.61	2.73	0.86
I05527	107.16	3.83	3.56	1.15
MEAN	115.01	4.21	3.25	1.01
S.D.	10.464	0.850	0.453	0.145
N	3	3	3	3
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day				
I05514	111.98	5.14	3.97	1.07
I05515	103.61	4.58	3.01	1.10
I05516	120.14	5.44	4.11	1.16
I05521	106.40	5.36	4.31	1.50
MEAN	110.53	5.13	3.85	1.21
S.D.	7.289	0.388	0.577	0.199
N	4	4	4	4
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day				
I05510	95.90	4.19	2.88	1.02
I05518	93.03	4.41	2.49	0.93
I05524	86.79	3.88	2.38	0.79
I05528	100.26	4.85	3.07	1.01
MEAN	94.00 *	4.33	2.71	0.94
S.D.	5.649	0.408	0.324	0.106
N	4	4	4	4

Appendix 6

Summary and Individual Blood Hormone Determination  
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 4      Dose Level: 0.75      Dosage Unit: mg/kg/day				
I05506	59.28	2.74	4.90	1.36
I05507	55.46	3.07	3.16	1.15
I05512	13.96	1.55	1.83	0.86
MEAN	42.90 *	2.45 *	3.30	1.12
S.D.	25.135	0.800	1.540	0.251
N	3	3	3	3
Group: Female 1      Dose Level: 0      Dosage Unit: mg/kg/day				
I05530	131.98	5.33	5.50	1.43
I05531	87.43	3.10	2.62	0.78
I05535	98.87	3.48	4.93	1.17
I05544	104.98	4.28	3.52	0.86
MEAN	105.82	4.05	4.14	1.06
S.D.	18.899	0.986	1.313	0.299
N	4	4	4	4
Group: Female 2      Dose Level: 0.03      Dosage Unit: mg/kg/day				
I05541	109.59	4.13	4.24	1.32
I05547	81.34	3.14	3.41	0.86
I05550	86.09	3.49	2.80	0.85
MEAN	92.34	3.59	3.48	1.01
S.D.	15.127	0.502	0.723	0.269
N	3	3	3	3

Appendix 6

Summary and Individual Blood Hormone Determination  
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 3      Dose Level: 0.15      Dosage Unit: mg/kg/day				
I05532	74.72	3.27	3.03	1.04
I05538	77.02	2.98	1.89	0.59
I05545	72.24	2.96	2.71	0.90
I05548	94.86	3.87	3.88	1.06
MEAN	79.71 *	3.27	2.88	0.90
S.D.	10.287	0.424	0.823	0.217
N	4	4	4	4
Group: Female 4      Dose Level: 0.75      Dosage Unit: mg/kg/day				
I05534	51.14	2.88	4.52	1.49
I05536	59.03	2.43	3.87	1.00
I05540	60.77	3.13	2.04	0.79
I05551	64.05	2.83	3.30	1.03
MEAN	58.75 *	2.82	3.43	1.08
S.D.	5.482	0.290	1.054	0.295
N	4	4	4	4



Appendix 6

Summary and Individual Blood Hormone Determination  
Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05520	38.18	2.66	17.90	64.49	0.00	1.61	159.60	3.75
I05526	44.16	2.51	10.98	25.43	0.00	2.12	183.22	2.87
MEAN	41.17	2.59	14.44	44.96	0.00	1.87	171.41	3.31
S.D.	4.228	0.106	4.893	27.620	0.000	0.361	16.702	0.622
N	2	2	2	2	2	2	2	2
Group: Male 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05505	27.26	0.89	17.56	32.66	0.00	1.21	154.43	3.28
I05523	52.61	3.84	21.73	59.98	0.00	0.97	164.81	4.20
MEAN	39.94	2.42	19.65	46.32	0.00	1.09	159.62	3.74
S.D.	17.925	2.015	2.949	19.318	0.000	0.170	7.340	0.651
N	2	2	2	2	2	2	2	2
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05511	51.54	4.72	0.00	37.83	0.00	1.67	165.18	4.74
I05522	44.31	5.36	27.09	70.81	0.00	1.05	129.72	2.51
MEAN	47.93	5.04	13.55	54.32	0.00	1.36	147.45	3.625
S.D.	5.112	0.453	19.156	23.320	0.000	0.438	25.074	1.577
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	54.69	0.86	53.08	83.74	0.00	1.78	116.20	4.89
I05549	40.39	0.12	43.63	64.84	0.00	1.66	133.52	6.58
MEAN	47.54	0.49	48.36	74.29	0.00	1.72	124.86	5.74
S.D.	10.112	0.523	6.682	13.364	0.000	0.85	12.247	1.195
N	2	2	2	2	2	2	2	2
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05539	57.55	0.10	44.84	71.13	0.00	1.88	114.34	3.37
I05552	59.07	0.82	68.85	88.81	0.00	0.59	121.25	3.91
MEAN	58.31	0.46	56.85	79.97	0.00	1.24	117.80	3.64
S.D.	1.075	0.509	16.978	12.502	0.000	0.912	4.886	0.382
N	2	2	2	2	2	2	2	2
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	55.91	0.61	133.46	289.99	0.00	1.76	99.29	3.93
I05542	66.34	0.37	88.23	154.68	0.00	1.56	101.57	3.51
MEAN	61.13	0.49	110.85	222.34	0.00	1.66	100.43	3.72
S.D.	7.375	0.170	31.982	95.679	0.000	0.141	1.612	0.297
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05520	52.17	2.83	40.85	79.85	0.00	0.25	171.00	4.18
I05526	44.90	1.40	16.61	31.48	0.00	0.00	133.39	1.74
MEAN	48.54	2.12	28.73	55.67	0.00	0.13	152.20	2.96
S.D.	5.141	1.011	17.140	34.203	0.000	0.177	26.594	1.725
N	2	2	2	2	2	2	2	2
Group: Male 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05505	46.88	0.50	23.84	43.65	0.00	0.10	154.84	3.79
I05523	54.44	7.18	25.40	59.41	0.00	0.00	151.74	3.37
MEAN	50.66	3.84	24.62	51.53	0.00	0.05	153.29	3.58
S.D.	5.346	4.723	1.103	11.144	0.000	0.071	2.192	0.297
N	2	2	2	2	2	2	2	2
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05511	37.08	1.55	17.87	53.05	0.00	0.67	170.42	4.18
I05522	25.17	2.99	26.57	77.43	0.00	0.33	137.27	2.45
MEAN	31.13	2.27	22.22	65.25	0.00	0.50	153.85	3.32
S.D.	8.422	1.018	6.152	17.232	0.000	0.240	23.441	1.223
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05529	56.47	0.12	38.61	95.66	0.00	0.68	130.32	4.93
I05549	43.54	0.07	112.14	115.58	0.00	0.98	136.09	5.81
MEAN	50.01	0.10	75.38	105.62	0.00	0.83	133.21	5.37
S.D.	9.143	0.035	51.994	14.086	0.000	0.212	4.080	0.622
N	2	2	2	2	2	2	2	2
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05539	63.10	0.07	61.24	137.78	0.00	0.81	127.17	3.56
I05552	60.29	0.28	88.08	94.05	0.00	0.00	142.77	3.76
MEAN	61.70	0.18	74.66	115.92	0.00	0.41	134.97	3.66
S.D.	1.987	0.148	18.979	30.922	0.000	0.573	11.031	0.141
N	2	2	2	2	2	2	2	2
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05533	62.75	0.65	257.61	255.84	0.00	1.04	118.99	3.84
I05542	81.69	0.06	114.63	120.11	0.00	0.82	121.98	3.38
MEAN	72.22	0.36	186.12	187.98	0.00	0.93	120.49	3.61
S.D.	13.393	0.424	101.102	95.976	0.000	0.156	2.114	0.325
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1		Dose Level: 0		Dosage Unit: mg/kg/day				
I05520	34.89	1.76	17.17	62.84	0.00	0.00	134.97	5.56
I05526	45.23	1.40	14.11	34.27	0.00	0.02	167.54	2.40
MEAN	40.06	1.58	15.64	48.56	0.00	0.01	151.26	3.98
S.D.	7.311	0.255	2.164	20.202	0.000	0.014	23.030	2.234
N	2	2	2	2	2	2	2	2
Group: Male 3		Dose Level: 0.15		Dosage Unit: mg/kg/day				
I05505	42.85	3.64	25.06	39.86	0.00	0.25	146.70	2.43
I05523	61.34	2.55	25.26	63.44	0.00	0.00	161.73	3.31
MEAN	52.10	3.10	25.16	51.65	0.00	0.13	154.22	2.87
S.D.	13.074	0.771	0.141	16.674	0.000	0.177	10.628	0.622
N	2	2	2	2	2	2	2	2
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day				
I05511	59.62	2.36	6.94	51.42	0.00	0.24	163.13	4.19
I05522	26.17	4.12	30.46	83.94	0.00	0.09	163.73	2.36
MEAN	42.90	3.24	18.70	67.68	0.00	0.17	163.43	3.28
S.D.	23.653	1.245	16.631	22.995	0.000	0.106	0.424	1.294
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	64.71	0.44	43.91	115.88	0.00	0.00	91.10	4.88
I05549	47.01	0.02	42.07	57.38	0.00	0.68	130.21	4.88
MEAN	55.86	0.23	42.99	86.63	0.00	0.34	110.66	4.88
S.D.	12.516	0.297	1.301	41.366	0.000	0.481	27.655	0.000
N	2	2	2	2	2	2	2	2
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05539	45.77	0.04	48.03	127.24	0.00	0.29	114.25	3.00
I05552	44.48	0.18	114.70	124.21	0.00	0.00	103.46	2.98
MEAN	45.13	0.11	81.37	125.73	0.00	0.15	108.86	2.99
S.D.	0.912	0.099	47.143	2.143	0.000	0.205	7.630	0.014
N	2	2	2	2	2	2	2	2
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	49.13	0.49	109.08	153.99	0.00	0.64	115.88	2.59
I05542	63.28	0.40	108.09	128.04	0.00	0.01	85.17	3.22
MEAN	56.21	0.45	108.59	141.02	0.00	0.33	100.53	2.91
S.D.	10.006	0.064	0.700	18.349	0.000	0.445	21.715	0.445
N	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PROS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1      Dose Level: 0      Dosage Unit: mg/kg/day										
I05520	48.93	1.68	22.29	66.72	0.00	0.00	113.68	4.34	3.20	1.27
I05526	54.85	1.47	12.73	34.79	0.00	0.08	167.98	6.23	3.35	1.26
MEAN	51.89	1.58	17.51	50.76	0.00	0.04	140.83	5.29	3.28	1.27
S.D.	4.186	0.148	6.760	22.578	0.000	0.057	38.396	1.336	0.106	0.007
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3      Dose Level: 0.15      Dosage Unit: mg/kg/day										
I05505	35.82	0.16	21.68	35.93	0.00	0.15	141.49	4.68	3.96	1.44
I05523	56.14	2.50	21.64	55.20	0.00	0.00	150.29	5.39	4.09	1.51
MEAN	45.98	1.33	21.66	45.57	0.00	0.08	145.89	5.04	4.03	1.48
S.D.	14.368	1.655	0.028	13.626	0.000	0.106	6.223	0.502	0.092	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4      Dose Level: 0.75      Dosage Unit: mg/kg/day										
I05511	52.62	1.59	0.00	43.71	0.00	0.01	145.00	4.78	4.61	1.17
I05522	27.46	1.66	14.90	66.78	0.00	0.05	116.61	4.24	2.84	0.95
MEAN	40.04	1.63	7.45	55.25	0.00	0.03	130.81	4.51	3.73	1.06
S.D.	17.791	0.049	10.536	16.313	0.000	0.028	20.075	0.382	1.252	0.156
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	60.74	0.66	93.93	136.07	0.00	0.14	95.57	3.84	3.87	1.16
I05549	55.31	0.04	67.50	78.68	0.00	0.22	102.40	3.31	4.09	1.37
MEAN	58.03	0.35	80.72	107.38	0.00	0.18	98.99	3.58	3.98	1.27
S.D.	3.840	0.438	18.689	40.581	0.000	0.057	4.830	0.375	0.156	0.148
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	54.81	0.00	46.03	127.28	0.00	0.00	102.53	2.30	3.24	0.99
I05552	61.78	0.15	78.67	179.51	0.00	0.33	86.79	2.66	3.34	1.04
MEAN	58.30	0.08	62.35	153.40	0.00	0.17	94.66	2.48	3.29	1.02
S.D.	4.929	0.106	23.080	36.932	0.000	0.233	11.130	0.255	0.071	0.035
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	40.44	0.02	95.89	182.57	0.00	0.85	127.50	4.40	4.41	1.38
I05542	66.14	0.03	95.19	116.98	0.00	0.00	94.51	2.64	4.04	1.08
MEAN	53.29	0.03	95.54	149.78	0.00	0.43	111.01	3.52	4.23	1.23
S.D.	18.173	0.007	0.495	46.379	0.000	0.601	23.327	1.245	0.262	0.212
N	2	2	2	2	2	2	2	2	2	2



Appendix 6

Summary and Individual Blood Hormone Determination  
Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1    Dose Level: 0    Dosage Unit: mg/kg/day										
I05520	56.87	2.87	31.48	71.33	0.00	0.00	142.33	4.92	3.54	1.36
I05526	50.92	2.98	22.18	39.48	0.00	0.01	173.51	5.87	3.31	1.43
MEAN	53.90	2.93	26.83	55.41	0.00	0.01	157.92	5.40	3.43	1.40
S.D.	4.207	0.078	6.576	22.521	0.000	0.007	22.048	0.672	0.163	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3    Dose Level: 0.15    Dosage Unit: mg/kg/day										
I05505	35.11	5.86	27.97	33.61	0.00	0.15	141.33	4.17	3.71	1.35
I05523	69.91	3.19	21.80	59.64	0.00	0.00	136.42	4.73	3.76	1.21
MEAN	52.51	4.53	24.89	46.63	0.00	0.08	138.88	4.45	3.74	1.28
S.D.	24.607	1.888	4.363	18.406	0.000	0.106	3.472	0.396	0.035	0.099
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4    Dose Level: 0.75    Dosage Unit: mg/kg/day										
I05511	53.56	2.07	12.59	50.72	0.00	0.00	189.73	6.84	3.92	1.07
I05522	42.27	1.98	22.13	61.86	0.00	0.00	142.92	6.13	3.06	1.07
MEAN	47.92	2.03	17.36	56.29	0.00	0.00	166.33	6.49	3.49	1.07
S.D.	7.983	0.064	6.746	7.877	0.000	0.000	33.100	0.502	0.608	0.000
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	56.92	0.36	46.66	106.07	0.00	0.38	114.22	3.48	3.48	1.17
I05549	54.02	0.01	72.28	120.53	0.00	0.00	94.96	2.75	3.89	1.40
MEAN	55.47	0.19	59.47	113.30	0.00	0.19	104.59	3.12	3.69	1.29
S.D.	2.051	0.247	18.116	10.225	0.000	0.269	13.619	0.516	0.290	0.163
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	48.00	0.01	53.88	120.92	0.00	0.12	113.58	2.73	3.40	1.10
I05552	74.04	0.13	25.95	71.07	0.00	0.39	89.22	3.99	3.06	1.03
MEAN	61.02	0.07	39.92	96.00	0.00	0.26	101.40	3.36	3.23	1.07
S.D.	18.413	0.085	19.749	35.249	0.000	0.191	17.225	0.891	0.240	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	61.92	0.13	166.75	352.52	0.00	0.28	108.62	3.84	3.20	1.15
I05542	89.59	0.07	164.57	175.61	0.00	0.00	105.87	3.34	3.31	1.07
MEAN	75.76	0.10	165.66	264.07	0.00	0.14	107.25	3.59	3.26	1.11
S.D.	19.566	0.042	1.541	125.094	0.000	0.198	1.945	0.354	0.078	0.057
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PROS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day										
I05520	45.28	3.12	24.62	33.29	0.00	4.00	160.85	7.90	5.07	2.53
I05526	42.55	2.03	20.60	17.89	0.00	3.18	158.81	7.34	3.03	1.83
MEAN	43.92	2.58	22.61	25.59	0.00	3.59	159.83	7.62	4.05	2.18
S.D.	1.930	0.771	2.843	10.889	0.000	0.580	1.442	0.396	1.442	0.495
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day										
I05505	35.05	5.77	33.45	15.52	0.00	3.02	156.75	5.12	4.10	1.85
I05523	58.45	4.15	34.94	31.76	0.00	2.40	189.99	8.58	4.63	2.07
MEAN	46.75	4.96	34.20	23.64	0.00	2.71	173.37	6.85	4.37	1.96
S.D.	16.546	1.146	1.054	11.483	0.000	0.438	23.504	2.447	0.375	0.156
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day										
I05511	34.37	2.19	15.15	34.29	0.00	2.70	200.22	8.55	3.56	1.51
I05522	18.72	5.27	32.89	47.87	0.00	2.67	142.75	6.89	4.05	1.83
MEAN	26.55	3.73	24.02	41.08	0.00	2.69	171.49	7.72	3.81	1.67
S.D.	11.066	2.178	12.544	9.603	0.000	0.021	40.637	1.174	0.346	0.226
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	61.24	0.75	60.82	62.11	0.00	3.41	131.39	6.12	4.81	2.15
I05549	45.43	0.16	58.64	17.39	0.00	2.27	127.08	5.03	4.72	2.27
MEAN	53.34	0.46	59.73	39.75	0.00	2.84	129.24	5.58	4.77	2.21
S.D.	11.179	0.417	1.541	31.622	0.000	0.806	3.048	0.771	0.064	0.085
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	59.18	0.06	111.82	73.29	0.00	5.31	127.44	4.32	3.48	1.46
I05552	40.35	0.15	63.26	56.27	0.00	5.26	104.90	5.02	3.31	1.10
MEAN	49.77	0.11	87.54	64.78	0.00	5.29	116.17	4.67	3.40	1.28
S.D.	13.315	0.064	34.337	12.035	0.000	0.035	15.938	0.495	0.120	0.255
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	52.84	0.73	101.24	86.37	0.00	5.20	140.68	4.86	3.55	1.56
I05542	98.82	0.30	180.10	115.95	0.00	4.19	147.41	4.23	3.15	1.11
MEAN	70.83	0.52	140.67	101.16	0.00	4.70	144.05	4.55	3.35	1.34
S.D.	25.442	0.304	55.762	20.916	0.000	0.714	4.759	0.445	0.283	0.318
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1		Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	41.44	3.51	19.03	35.81	0.00	3.01	141.17	5.57	4.31	1.98
I05526	48.80	2.29	21.13	22.20	0.00	3.34	144.88	5.51	4.10	1.97
MEAN	45.12	2.90	20.08	29.01	0.00	3.18	143.03	5.54	4.21	1.98
S.D.	5.204	0.863	1.485	9.624	0.000	0.233	2.623	0.042	0.148	0.007
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3		Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	43.54	2.03	22.13	11.11	0.00	3.11	127.36	4.68	3.06	1.51
I05523	55.25	4.77	33.60	27.76	0.00	3.17	164.68	7.26	3.91	1.83
MEAN	49.40	3.40	27.87	19.44	0.00	3.14	146.02	5.97	3.49	1.67
S.D.	8.280	1.937	8.111	11.773	0.000	0.042	26.389	1.824	0.601	0.226
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4		Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	31.74	6.17	27.18	34.39	0.00	1.92	211.71	7.91	5.89	1.92
I05522	17.51	6.28	30.18	40.74	0.00	3.36	133.42	6.19	3.90	1.80
MEAN	24.63	6.23	28.68	37.57	0.00	2.64	172.57	7.05	4.90	1.86
S.D.	10.062	0.078	2.121	4.490	0.000	1.018	55.359	1.216	1.407	0.085
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual Blood Hormone Determination  
Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1		Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	61.95	0.32	88.86	60.95	0.00	2.28	113.93	4.61	4.23	1.65
I05549	50.10	0.15	55.18	29.70	0.00	2.66	122.28	4.59	4.96	1.91
MEAN	56.03	0.24	72.02	45.33	0.00	2.57	118.11	4.60	4.60	1.78
S.D.	8.379	0.120	23.815	22.097	0.000	0.410	5.904	0.014	0.516	0.184
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3		Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	58.68	0.22	249.40	112.37	0.00	4.32	133.88	QNS	3.65	1.63
I05552	26.08	0.18	228.31	104.83	0.00	2.22	194.67	7.69	6.48	1.81
MEAN	42.38	0.20	238.86	108.60	0.00	3.27	164.28	7.69	5.07	1.72
S.D.	23.052	0.028	14.913	5.332	0.000	1.485	42.985	-	2.001	0.127
N	2	2	2	2	2	2	2	1	2	2
Group: Female 4		Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	49.05	0.73	89.07	85.47	0.00	3.89	122.53	4.63	3.41	1.41
I05542	82.98	0.40	94.97	46.34	0.00	4.50	131.85	4.36	3.46	1.31
MEAN	66.02	0.57	92.02	65.91	0.00	4.20	127.19	4.50	3.44	1.36
S.D.	23.992	0.233	4.172	27.669	0.000	0.431	6.590	0.191	0.035	0.071
N	2	2	2	2	2	2	2	2	2	2

Appendix 6

Summary and Individual E2, FSH, and LH  
Additional Serum Analysis at Analytics

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
-----			
Group: Male 1    Dose Level: 0    Dosage Unit: mg/kg/day			
I05508	0.00		
I05527	9.89		
MEAN	4.95		
S.D.	6.993		
N	2		
Group: Male 2    Dose Level: 0.03    Dosage Unit: mg/kg/day			
I05514	17.02		
I05515	0.49		
I05516	1.53		
I05521	47.01		
MEAN	16.51		
S.D.	21.691		
N	4		
Group: Male 3    Dose Level: 0.15    Dosage Unit: mg/kg/day			
I05510	6.62		
I05518	3.35		
I05524	0.76		
I05528	3.24		
MEAN	3.49		
S.D.	2.404		
N	4		

Appendix 6

Summary and Individual E2, FSH, and LH  
Additional Serum Analysis at Analytica

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
-----			
Group: Male 4    Dose Level: 0.75    Dosage Unit: mg/kg/day			
I05506	0.00		
I05507	0.00		
I05512	0.00		
I05522a	18.68		
I05511a	12.85		
MEAN	6.31		
S.D.	8.877		
N	5		

a Recovery animal.



Appendix 6

Summary and Individual E2, FSH, and LH  
Additional Serum Analysis at Analytica

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PROS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
-----			
Group: Female 1     Dose Level: 0     Dosage Unit: mg/kg/day			
I05530	27.79	3.46	0.75
I05531	132.76	1.61	0.81
I05535	27.20	1.21	2.93
I05544	85.52	0.36	1.95
MEAN	68.32	1.66	1.61
S.D.	50.931	1.308	1.039
N	4	4	4
Group: Female 2     Dose Level: 0.03     Dosage Unit: mg/kg/day			
I05541	76.34	2.24	2.25
I05547	68.20	2.83	0.83
I05550	33.55	0.51	1.85
MEAN	66.03	1.86	1.64
S.D.	28.747	1.206	0.732
N	3	3	3
Group: Female 3     Dose Level: 0.15     Dosage Unit: mg/kg/day			
I05532	40.88	2.03	2.79
I05538	87.24	1.80	2.19
I05545	42.82	0.38	2.17
I05548	33.03	0.42	1.86
MEAN	50.99	1.16	2.25
S.D.	24.533	0.88	0.389
N	4	4	4

Appendix 6

Summary and Individual E2, FSH, and LH  
Additional Serum Analysis at Analytica

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PROS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
-----			
Group: Female 4      Dose Level: 0.75      Dosage Unit: mg/kg/day			
I05534	0.00	0.38	2.20
I05536	0.00	0.76	2.03
I05540	4.45	0.38	2.06
I05551	19.30	0.32	1.73
I05542a	159.41	1.37	2.55
I05533a	122.77	1.50	1.58
MEAN	50.99	0.87	2.03
S.D.	71.102	0.490	0.344
N	6	6	6

a Recovery animal.

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol  
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 1	Dose Level: 0 Dosage Unit: mg/kg/day				
I05508	160	3	1.4	0.24	<35
I05527	132	3.5	1.5	0.86	<35
Mean	146.0	3.3	1.5	0.6	NA
SD	19.80	0.35	0.07	0.44	NA
N	2	2	2	2	NA
Group: Male 2	Dose Level: 0.03 Dosage Unit: mg/kg/day				
I05514	154	3.6	1.5	0.48	<35
I05515	135	3	1.4	0.49	<35
I05516	166	4	1.8	0.7	<35
I05521	126	4.1	1.4	0.55	<35
Mean	151.7	3.5	1.6	0.6	NA
SD	15.63	0.50	0.21	0.12	NA
N	3	3	3	3	NA
Group: Male 3	Dose Level: 0.15 Dosage Unit: mg/kg/day				
I05510	123	3.2	1.3	1.5	<35
I05524	128	2.9	1.6	0.55	<35
I05528	133	2.8	NS	NS	<35
Mean	128.0	3.0	1.5	1.0	NA
SD	5.00	0.21	0.21	0.67	NA
N	3	3	2	2	NA

NS Test cancelled. Quantity not sufficient.

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol  
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05506	94	5.6	1.6	1.7	<35
I05507	81	3.3	1.5	1.4	<35
I05512	53	2.4	1.4	1.2	<35
Mean	76.0	3.8	1.5	1.4	NA
SD	20.95	1.65	0.10	0.25	NA
N	3	3	3	3	NA
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05530	176	4.7	1.8	0.69	<35
I05531	128	2.9	1.4	0.27	146
I05535	134	4.7	1.7	NS	<35
I05544	154	2.8	1.2	2.1	83
Mean	148.0	3.8	1.5	1.0	114.5
SD	27.73	1.07	0.28	0.96	44.55
N	4	4	4	3	2
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05541	140	4.4	2	0.52	73
I05547	150	4.4	1.6	0.7	48
I05550	124	3.3	1.5	1.1	<35
Mean	138.0	4.0	1.7	0.8	60.5
SD	13.11	0.64	0.26	0.30	17.68
N	3	3	3	3	2

NS Test cancelled. Quantity not sufficient.

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol  
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	100	3.5	1.4	3	<35
I05538	121	2.5	1.1	0.63	78
I05545	105	3.3	1.3	0.68	<35
I05548	137	3.6	1.6	0.99	<35
I05538	121	2.5	1.1	0.63	78
Mean	116.8	3.1	1.3	1.2	78.0
SD	14.70	0.54	0.21	1.03	0.00
N	5	5	5	5	2
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05534	79	4.2	1.9	3.3	<35
I05540	101	2.8	1.3	1.5	<35
I05551	120	4	1.6	0.88	<35
Mean	100.0	3.7	1.6	1.9	NA
SD	20.52	0.76	0.30	1.26	NA
N	3	3	3	3	NA

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol  
Additional Serum Analysis at Mayo Clinic - Week 79

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 4	Dose Level: 0.75 Dosage Unit: mg/kg/day				
I05522	132	3	1.2	0.49	<35
I05511	240	5.3	1.3	0.035	<35
Mean	186.0	4.2	1.3	0.3	NA
SD	76.37	1.63	0.07	0.32	NA
N	2	2	2	2	NA
Group: Female 4	Dose Level: 0.75 Dosage Unit: mg/kg/day				
I05542	134	3.3	1.4	0.79	152
I05533	134	3.5	1.4	1.4	53
Mean	134.0	3.4	1.4	1.1	102.5
SD	0.00	0.14	0.00	0.43	70.00
N	2	2	2	2	2

**APPENDIX 7**

Cell Proliferation Report

Note: This appendix contains information supplied and audited by Pathology Associates International (PAI).



**CELL PROLIFERATION REPORT**

**26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCCTANE SULFONIC  
ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS  
COVANCE STUDY NUMBER 6329-223**

**PREPARED FOR:**

**3M  
TOXICOLOGY SERVICES  
BUILDING 220-2E-02, 3M CENTER  
ST. PAUL, MN 55144-1000**

**PREPARED BY:**

**PATHOLOGY ASSOCIATES - A CHARLES RIVER COMPANY  
15 WORMAN'S MILL COURT, SUITE I  
FREDERICK, MD 21701**

---

15 Worman's Mill Court, Suite I \* Frederick, Maryland 21701 \* (301) 663-1644 \* (301) 663-8994 FAX



**TABLE OF CONTENTS**

Contents	Section
Narrative	I
Table	II
Signature Page	III
Quality Assurance Statement	IV
Appendix	V

## I. CELL PROLIFERATION REPORT

### 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS COVANCE STUDY NUMBER 6329-223

#### PURPOSE

The purpose of the study was to assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks.

This report, submitted by Pathology Associates - A Charles River Company (PAI) to the study Sponsor, 3M, represents the cell proliferation findings and interpretation for Covance Study Number 6329-223 entitled "26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys". All aspects of the tasks associated with PAI's portion of this study were conducted in compliance with the Environmental Protection Agency Good Laboratory Practice (GLP) Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments.

#### MATERIALS AND METHODS

##### Tissue Collection for Cell Proliferation

Four animals per sex in groups 1 - 4 were sacrificed after 26 weeks on study. A representative sample of the liver, testes (males only) and pancreas from each animal was fixed in formalin, processed and embedded to paraffin block by Covance per protocol specifications. Tissue blocks were then shipped to PAI for sectioning and staining. From each block, a slide was prepared for H&E evaluation and immunohistochemical detection of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation.

##### Immunohistochemistry for Cell Proliferation

Sections of paraffin-embedded tissues were cut at 5  $\mu$ m and placed on positively charged slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA) to ensure adhesion during processing for PCNA. Standard immunohistochemical methods were used to stain tissues for PCNA (PAI's Standard Operating Procedure for Immunohistochemical Staining (SOP #707). Briefly, tissue sections were incubated with a monoclonal antibody to PCNA and reagents required for the avidin-biotin peroxidase method for the detection of the antigen-antibody complex. PCNA expression in cells was localized by the chromagen 3,3'-diaminobenzidine (DAB). Tissue sections were counterstained with hematoxylin.

### **Cell Proliferation Measurements**

The percentage of hepatocytes in S-phase (labeling index, LI) was determined by scoring at least 3000 hepatocytes in 10 fields of liver. The LI in the testes (males only) was determined by scoring the number of PCNA-positive Leydig cells among at least 100 Leydig cells. The labeling index in the pancreas was scored subjectively with 4 being both acinar and islets stained heavily and 3 being predominant staining in the acinar region. A negative control slide was included in the staining run and consisted of study tissue that was not incubated with the primary antibody.

For cell proliferation evaluations, slides were first perused at low magnification (100X) to judge quality of staining, processing and sectioning, potential patterns of cellular proliferation, and histomorphologic changes. Cell proliferation was then quantified at higher magnification (200X for liver and pancreas, and 400X for testes) as described above. Histomorphology was further assessed by evaluating the H&E slide prepared from the same tissue block for each animal evaluated for cell proliferation.

### **Statistical Analysis**

The Student's *t*-test (two-sided, unequal variance) was used to test for statistical significance in LI between control and treatment groups using Microsoft Excel version 5.0. A *P* value of 0.05 or less was judged to be statistically significant.

## **RESULTS**

### **Cell Proliferation**

Individual animal cell proliferation data are presented in Section II (Table II-1). Cell proliferation in the liver, testes and pancreas of control and test material-treated animals was similar.

### **Histopathology**

Sections from the same tissue blocks used for preparation of PCNA-stained slides were stained with hematoxylin and eosin (H&E) for histopathologic evaluation to facilitate the interpretation of the immunostained slides. Individual animal findings are presented in Appendix I.

Single sections of liver, pancreas, and testes from 16 adult male monkeys and single sections of liver and pancreas from 16 adult female monkeys representing control, low-dose (0.03 mg/kg/day), mid-dose (0.15 mg/kg/day) and high-dose (0.75 mg/kg/day) treatment groups were evaluated histologically. Each tissue section was stained with hematoxylin and eosin. The purpose of this evaluation was to determine whether or not morphologic changes were occurring in these tissues which may alter or confound the specificity of the PCNA staining observed in these animals.

The results showed that no significant changes were observed in either the liver, pancreas, or testicular tissues from male monkeys or the liver and pancreas tissues from female monkeys, which would alter the interpretation of the PCNA staining in this study.

#### **DISCUSSION**

In the present study, cell proliferation was measured within the liver, testes and pancreas of male monkeys, and the liver and pancreas of female monkeys from control (0 mg/kg/day), low dose (0.03 mg/kg/day), mid-dose (0.15 mg/kg/day) and high dose (0.75 mg/kg/day) groups after 26 weeks on study to assess the effect of the test material on critical enzyme levels, hormones, and other selected biological parameters, including cell proliferation.

There did not appear to be a cell proliferative response to the test material in the liver, testes or pancreas, as determined by labeling indices, which were similar in all animals.

#### **SUMMARY**

In the present study, cell proliferation, as determined by measuring the labeling index, was not increased in the liver, testes or pancreas of monkeys.

## II. TABLE

### Legend

ND, not determined due to suboptimal staining

NP, slide not present

Liver labeling index: Percentage of hepatocytes in S-phase

Pancreas labeling index: Scored subjectively with 4 = islets and acinar staining heavily; 3 = staining more abundant in acinar cells than islets

Testes labeling index: Percentage of PCNA-positive Leydig cells

TABLE II-1. CELL PROLIFERATION IN MONKEYS

Dose Group	Sex/Group	Animal Number	Labeling Index Liver	Labeling Index Pancreas	Labeling Index Testes
0 mg/kg/day (Control)	F/1	IO5530	0.000%	4	NP
0 mg/kg/day (Control)	F/1	IO5531	0.027%	3	NP
0 mg/kg/day (Control)	F/1	IO5535	0.000%	3	NP
0 mg/kg/day (Control)	F/1	IO5544	0.199%	4	NP
		<b>Mean</b>	<b>0.057%</b>	<b>3.5</b>	-
		<b>SEM</b>	<b>0.048%</b>	<b>0.3</b>	-
0.03 mg/kg/day (Low dose)	F/2	IO5537	0.113%	3	NP
0.03 mg/kg/day (Low dose)	F/2	IO5541	0.125%	4	NP
0.03 mg/kg/day (Low dose)	F/2	IO5547	0.000%	3	NP
0.03 mg/kg/day (Low dose)	F/2	IO5550	0.212%	3	NP
		<b>Mean</b>	<b>0.112%</b>	<b>3.3</b>	-
		<b>SEM</b>	<b>0.044%</b>	<b>0.3</b>	-
0.15 mg/kg/day (Mid dose)	F/3	IO5532	0.000%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5538	0.086%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5545	0.029%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5548	0.120%	4	NP
		<b>Mean</b>	<b>0.059%</b>	<b>3.3</b>	-
		<b>SEM</b>	<b>0.027%</b>	<b>0.3</b>	-
0.75 mg/kg/day (High dose)	F/4	IO5534	0.000%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5536	0.313%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5540	0.000%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5551	0.000%	3	NP
		<b>Mean</b>	<b>0.078%</b>	<b>3.0</b>	-
		<b>SEM</b>	<b>0.078%</b>	<b>0.0</b>	-
0 mg/kg/day (Control)	M/1	IO5508	0.100%	4	9.52%
0 mg/kg/day (Control)	M/1	IO5517	0.062%	3	9.00%
0 mg/kg/day (Control)	M/1	IO5519	0.108%	3	20.75%
0 mg/kg/day (Control)	M/1	IO5527	0.464%	4	19.23%
		<b>Mean</b>	<b>0.184%</b>	<b>3.5</b>	<b>14.63%</b>
		<b>SEM</b>	<b>0.094%</b>	<b>0.3</b>	<b>3.12%</b>
0.03 mg/kg/day (Low dose)	M/2	IO5514	0.095%	3	16.36%
0.03 mg/kg/day (Low dose)	M/2	IO5515	0.000%	3	18.52%
0.03 mg/kg/day (Low dose)	M/2	IO5516	0.000%	3	22.95%
0.03 mg/kg/day (Low dose)	M/2	IO5521	0.000%	4	12.38%
		<b>Mean</b>	<b>0.024%</b>	<b>3.3</b>	<b>17.55%</b>
		<b>SEM</b>	<b>0.024%</b>	<b>0.3</b>	<b>2.20%</b>
0.15 mg/kg/day (Mid dose)	M/3	IO5510	0.053%	3	9.17%
0.15 mg/kg/day (Mid dose)	M/3	IO5518	0.029%	4	17.14%
0.15 mg/kg/day (Mid dose)	M/3	IO5524	0.155%	3	14.42%
0.15 mg/kg/day (Mid dose)	M/3	IO5528	0.000%	4	10.71%
		<b>Mean</b>	<b>0.059%</b>	<b>3.5</b>	<b>12.86%</b>
		<b>SEM</b>	<b>0.034%</b>	<b>0.3</b>	<b>1.80%</b>
0.75 mg/kg/day (High dose)	M/4	IO5506	0.030%	3	7.69%
0.75 mg/kg/day (High dose)	M/4	IO5507	0.027%	3	19.61%
0.75 mg/kg/day (High dose)	M/4	IO5509	NP	NP	NP
0.75 mg/kg/day (High dose)	M/4	IO5512	0.000%	3	ND
		<b>Mean</b>	<b>0.019%</b>	<b>3.0</b>	<b>13.65%</b>
		<b>SEM</b>	<b>0.009%</b>	<b>0.0</b>	<b>5.96%</b>
ND, not determined due to suboptimal staining					
NP, slide not present					
Liver: Percentage of hepatocytes in S-phase					
Pancreas: Scored subjectively with 4=islets and acinar stained heavily (>50% labeled); 3=acinar>>islets					
Testes: Percentage of proliferating Leydig cells					

III. SIGNATURE PAGE

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt  
(PFOS; T-6295) in Cynomolgus Monkeys (Covance Study Number 6329-223)

Submitted by:

PAI Project Manager:

  
\_\_\_\_\_  
Sandra R. Eldridge, Ph.D.

1-2-02  
\_\_\_\_\_  
Date

PAI Project Pathologist:

  
\_\_\_\_\_  
Carolyn Moyer, D.V.M., Diplomate, A.C.V.P.

12/31/01  
\_\_\_\_\_  
Date

#### IV. QUALITY ASSURANCE STATEMENT





Cell Proliferation Report


26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid  
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Covance Study No.: 6329-223

QUALITY ASSURANCE STATEMENT

This cell proliferation project has been inspected and audited by the PAI Quality Assurance Unit (QAU) as required by the Good Laboratory Practice (GLP) regulations promulgated by the U.S. Environmental Protection Agency (TSCA). The cell proliferation report is an accurate reflection of the recorded data. The following table is a record of the inspections/audits performed and reported by the QAU.

<u>Date of Inspection</u>	<u>Phase Inspected</u>	<u>Date Findings Reported to Project Manager/PAI Management</u>	<u>Date Findings Reported to Study Director/Study Director Management</u>
12/06/99	Primary Antibody Dilution	12/06/99	12/27/01
02/17/00	Study Data and Supporting Documentation	02/17/00	12/27/01
02/17/00	Draft Cell Proliferation Report	02/17/00	12/27/01
12/27/01	Final Cell Proliferation Report	12/27/01	12/27/01

  
\_\_\_\_\_  
Karen E. Butler  
Quality Assurance Officer

12/27/01  
\_\_\_\_\_  
Date

**APPENDIX I**

Individual Animal Findings

3MP #6329-223

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	SEX	DOSE GROUP	HISTOLOGIC FINDINGS
I05530	F	1	Liver - NSF Pancreas - NSF
I05531	F	1	Liver - NSF Pancreas - NSF
I05535	F	1	Liver - chronic inflammation, minimal Pancreas - NSF
I05544	F	1	Liver - NSF Pancreas - NSF
I05537	F	2	Liver - NSF Pancreas - NSF
I05541	F	2	Liver - chronic inflammation, minimal Pancreas - NSF
I05547	F	2	Liver - NSF Pancreas - NSF
I05550	F	2	Liver - NSF Pancreas - NSF
I05532	F	3	Liver - NSF Pancreas - NSF
I05538	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05545	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05548	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05534	F	4	Liver - NSF Pancreas - NSF
I05536	F	4	Liver - fat infiltration, centrilobular, moderate Pancreas - NSF
I05540	F	4	Liver - NSF Pancreas - NSF
I05551	F	4	Liver - NSF Pancreas - NSF
I05508	M	1	Liver - chronic inflammation, minimal Pancreas - chronic inflammation, minimal Testes - NSF
I05517	M	1	Liver - NSF Pancreas - NSF Testes - crush artifact, focal
I05519	M	1	Liver - NSF Pancreas - NSF Testes - NSF
I05527	M	1	Liver - NSF Pancreas - NSF Testes - NSF
I05514	M	2	Liver - chronic inflammation, minimal Pancreas - chronic inflammation, minimal Testes - NSF
I05515	M	2	Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF
I05516	M	2	Liver - NSF Pancreas - NSF Testes - NSF
I05521	M	2	Liver - NSF Pancreas - NSF Testes - NSF
I05510	M	3	Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF

Legend: NSF = no significant findings

Individual Animal Findings

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID  
POTASSIUM SALT (PFOS; T6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	SEX	DOSE GROUP	HISTOLOGIC FINDINGS
I05518	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05524	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05528	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05507	M	4	Liver - fat infiltration, centrilobular, moderate Pancreas - NSF Testes - NSF
I05512	M	4	Liver - NSF Pancreas - NSF Testes - NSF
I05506	M	4	Liver - NSF Pancreas - NSF Testes - NSF
I05509	M	4	No microscopic slides available. (Inventory shows blocks submitted; STPR does not show blocks sectioned.)

Legend: NSF = no significant findings

## **APPENDIX 8**

### Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys

Note: This appendix contains information supplied and audited by Pathology Associates International (PAI).



**Pathology Associates International**  
*A Company of Science Applications International Corporation*



---

PATHOLOGY REPORT  
(ANCILLARY STUDY)

ELECTRON MICROSCOPIC EVALUATION  
OF LIVER IN CYNOMOLGUS MONKEYS  
(RECOVERY ANIMALS)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROCTANE  
SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS  
MONKEYS

CLIENT STUDY NUMBER 6329-223  
PAI STUDY NUMBER EM 99.76

Prepared by:

James B. Nold, D.V.M., Ph.D., Diplomate, A.C.V.P.

Pathology Associates International  
4915-D Prospectus Drive  
Durham, NC 27713

September 1, 2000

PREPARED FOR 3M CORPORATE TOXICOLOGY,  
3M CENTER, ST. PAUL, MN 55144-1000

	<u>Section</u>
Pathology Narrative	I
Light Microscopy and Transmission Electron Micrograph Interpretation Forms	II
Transmission Electron Micrographs	III
Quality Assurance Statement	IV

I. Pathology Narrative



Electron Microscopy Report  
Covance Study No. 6329 223  
Recovery Sacrifice Animals

**PATHOLOGY REPORT  
(ANCILLARY STUDY)**

**ELECTRON MICROSCOPIC EVALUATION  
OF LIVER IN CYNOMOLGUS MONKEYS  
(RECOVERY ANIMALS)**

**26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCANE  
SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS  
MONKEYS**

**CLIENT STUDY NUMBER 6329-223  
PAI STUDY NUMBER EM 99.76**

**SUMMARY**

Two male and two female cynomolgus monkeys treated for 26 weeks with 0.75 mg/kg PFOS were removed from treatment for up to 53 weeks. Liver samples obtained by biopsy at Week 57 and necropsy at Week 79 were examined for reversibility, persistence, or delayed occurrence of toxic effects. Light and electron microscopic evaluation of livers identified no pathological changes. The treatment-related changes of hepatocellular hypertrophy and vacuolation, noted at 26 weeks and characterized ultrastructurally by increased numbers of lipid droplets within hepatocytes, had completely disappeared during the recovery period.

**PROCEDURES**

The objective of this study was to examine by electron microscopy the livers from selected animals in a 26-week capsule toxicity study with PFOS in cynomolgus monkeys. In addition to a general qualitative evaluation for differences between control and treated animals, the ultrastructural endpoints included quantitation of peroxisomes within hepatocytes and membrane and mitochondrial changes in hepatocytes. Light microscopy of paraffin-embedded liver sections was also performed.

This report details the light and electron microscopy findings in the four high-dose male and female monkeys designated as recovery animals. A previous report (dated 6-24-1999) indicated that treatment of cynomolgus monkeys with 0.75 mg PFOS/kg/day for 26 weeks resulted in hepatocellular vacuolation and hypertrophy by light microscopy. Hepatocellular vacuolation and hypertrophy were primarily centrilobular in distribution and did vary in incidence and severity between individual animals. Ultrastructurally, there were increased lipid droplets within hepatocytes. Increased lipid droplets were

I-1

Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

present in both the high-dose males examined and in two of four high-dose females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group). Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15, or 0.75 mg PFOS/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined. The recovery animals were examined to assess for reversibility or persistence of these hepatocellular changes, or for the delayed occurrence of additional PFOS-induced effects.

For the toxicity study, 22 male and 22 female cynomolgus monkeys were given the test article or the vehicle once daily for at least 26 weeks according to Text Table 1.

Dosage Group	Dose Level (mg/kg/day) <sup>a</sup>	Total Material Dose Level (mg/kg/day) <sup>b</sup>	Number of Males	Number of Females
I	0 <sup>c</sup>	30 <sup>d</sup>	6 <sup>d</sup>	6 <sup>d</sup>
II	0.03	15 <sup>b</sup>	4	4
III	0.15	6 <sup>e</sup>	6 <sup>d</sup>	6 <sup>d</sup>
IV	0.75	30 <sup>e</sup>	6 <sup>d</sup>	6 <sup>d</sup>

<sup>a</sup> Dose levels were provided. The control group (Group 1) received an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

<sup>b</sup> The low-dose group (Group 2) received the test material diluted with lactose (1:499, w/w).

<sup>c</sup> The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w/w).

<sup>d</sup> Two animals in Groups 1, 3, and 4, designated as recovery animals, were treated for at least 26 weeks, then treatment was discontinued and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

During Week 57 (approximately 31 weeks into the recovery period), the 2 high-dose recovery males and 2 high-dose recovery females were anesthetized and liver biopsies were surgically obtained from each animal and chemically preserved and processed as described below.

During Week 79, the 4 high-dose recovery animals were necropsied and liver samples obtained as described below. The two control recovery animals were returned to the Covance stock animal colony, and the two Group III animals were transferred to a subsequent study (Covance 6329-268). Liver samples were not obtained and examined in the control recovery or Group III recovery animals.

Animals to be sacrificed at recovery sacrifice times were anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied. Multiple tissues were collected and preserved in 10% neutral-buffered formalin according to the protocol. Additionally,

Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

pieces of liver from each animal were thin-sliced and placed in 1/2 strength Karnovsky's fixative (2.0% paraformaldehyde/2.5% glutaraldehyde in 0.1M phosphate buffer) for subsequent ultrastructural examination. These livers were processed into Epon blocks and submitted to this laboratory for subsequent electron microscopy processing and evaluation. Hematoxylin and eosin (H&E) stained slide sections of formalin-fixed, paraffin-embedded livers were submitted for light microscopic examination.

The four high-dose recovery animals are listed in Text Table 2. For each animal, there was a 57-Week liver biopsy sample and a 79-Week terminal necropsy liver sample.

Text Table 2. Recovery Animals Examined by Light and Electron Microscopy	
0.75 mg/kg/day PFOS (Group 4 High-Dose)	
Males	Females
I05511	I05533
I05522	I05542

Thin sections (approximately 90 nm) from the Epon-embedded livers were cut, mounted on 200-mesh copper grids, stained with 5% methanolic uranyl acetate and Reynold's lead citrate, and examined on a Zeiss 900 transmission electron microscope. Centrilobular hepatocytes, where clearly identifiable in liver sections, were preferentially examined. Representative electron photomicrographs of liver were taken and significant ultrastructural features were summarized for each photograph and animal on a designated transmission electron micrograph interpretation form. The number of peroxisomes in hepatocytes was manually counted for each center photographed hepatocyte and recorded. For light microscopy, the H&E slides from the same animals selected for electron microscopy were evaluated and significant features were summarized on a light microscopic evaluation form.

## RESULTS AND DISCUSSION

Individual interpretations of light microscopy slides and electron micrographs for each animal are shown in Section II. Representative electron photomicrographs were selected as report figures, labeled, and are shown in Section III. All remaining electron micrographs are separately attached to this report.

### Light Microscopy

A summary of the incidence and severity of light microscopic findings in the control and high-dose livers is shown in Text Table 3. There were no microscopic findings that appeared to be associated with test material administration. Hepatocellular hypertrophy and vacuolation, noted after 26 weeks of treatment in some high-dose animals, were not identified in recovery samples at either the 57-Week biopsy or 79-Week terminal necropsy samples, indicating complete reversal of the light microscopic liver changes.

Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

The liver findings noted in the recovery animals were considered normal background histopathology of cynomolgus monkeys.

Text: Table 3. Incidence and Severity of Light Microscopic Liver Findings -- Recovery Animals		
(number examined)	0.75 mg/kg/day (High-Dose)	
	Males	Females
	(2)	(2)
57-Week Biopsy		
Infiltrate, lymphohistiocytic, minimal	1	2
Terminal Necropsy		
Infiltrate, lymphohistiocytic, minimal	2	2
Hyperplasia, bile duct, slight	1	—
Inflammation, lymphohistiocytic, slight	1	—
Inflammation, eosinophilic, slight	1	—
Clearing, cytoplasmic, centrilobular, minimal	—	1

— Incidence of zero.

**Electron Microscopy**

Electron microscopic evaluation of the 57-week biopsy and 79-week necropsy liver samples identified no abnormal features, and all tissue samples were considered to be ultrastructurally normal (Text: Table 4). The hepatocellular hypertrophy and vacuolation seen after 26 weeks of treatment, and characterized ultrastructurally by increased lipid droplets, were not seen in the recovery animal liver samples, indicating recovery of these test material related effects. The electron microscopic features described in these recovery samples were considered normal ultrastructural findings in hepatocytes. Figures 1-4 are representative electron micrographs from these samples and illustrate normal liver and hepatocellular features.

Text Table 4. Summary of Ultrastructural Findings – Recovery Animals		
Treatment Group (mg/kg/day)/Sex	Animal No.	Comments
(0.75) Male, 57-week biopsy	I05511	Normal
(0.75) Male, 79-week necropsy	I05511	Normal
(0.75) Male, 57-week biopsy	I05522	Normal
(0.75) Male, 79-week necropsy	I05522	Normal
(0.75) Female, 57-week biopsy	I05533	Normal
(0.75) Female, 79-week necropsy	I05533	Normal
(0.75) Female, 57-week biopsy	I05542	Normal
(0.75) Female, 79-week necropsy	I05542	Normal

Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

Peroxisomes were identified and quantitated in representative hepatocytes (Text Table 5). Mean peroxisome numbers per hepatocyte were considered normal.


Text Table 5. Quantitation of Hepatocellular Peroxisomes							
0.75 mg PFOS/kg/day (High-Dose) Recovery Animals							
Male				Female			
57-week biopsy		79-week necropsy		57-week biopsy		79-week necropsy	
Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
105511	18.5	105511	19.2	105533	29.8	105533	20.8
105522	19.4	105522	25.8	105542	23.0	105542	15.2
Mean =	18.95	Mean =	22.5	Mean =	26.4	Mean =	18.0


<sup>1</sup> Average number of peroxisomes per hepatocyte for five hepatocytes counted per animal. For Animal No. 105511 (biopsy), peroxisomes were counted in only four hepatocytes

#### CONCLUSION

Light and electron microscopic evaluation of livers from cynomolgus monkeys treated with 0.75 mg PFOS/kg/day for 26 weeks and allowed to "recover" untreated for 31 and 53 weeks identified no pathological changes. The treatment-related changes of hepatocellular hypertrophy and vacuolation, characterized ultrastructurally by increased numbers of lipid droplets within hepatocytes at 26 weeks, had completely resolved during the recovery period.

#### SIGNATURE OF AUTHOR

  
James B. Nold, D.V.M., Ph.D.,  
Diplomate, A.C.V.P.

  
Date

II. Light Microscopy and Transmission Electron  
Micrograph Interpretation Forms <sup>1</sup>

<sup>1</sup> Forms are exact copies of signed/dated raw data sheets maintained  
in archived study file.

LIGHT MICROSCOPIC EVALUATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkeys

Animal No.: see below Tissue: Liver

Sex: see below

Interpreting Pathologist (signature and date): James B. N. et al April 7, 2000

Dose/Group	Animal Number	Microscopic Findings and Comments
0.75 mg/kg (High-dose) Recovery Males 57 wk biopsy	105511	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	105522	Normal
0.75 mg/kg (High-dose) Recovery Females 57 wk biopsy	105533	1. Infiltrate, lymphohistiocytic, focal, minimal
	105542	1. Infiltrate, lymphohistiocytic, multifocal, minimal
0.75 mg/kg (High-dose) Recovery Males 79 wk necropsy	105511	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	105522	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Hyperplasia, focal, slight, bile duct 3. Inflammation, lymphohistiocytic, multifocal, slight 4. Inflammation, eosinophilic, multifocal, slight
0.75 mg/kg (High-dose) Recovery Females 798 week necropsy	105533	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	105542	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99-76) Species/Strain: Cynomolgus Monkey  
Animal No.: 10551 Tissue: Liver - centrilobular  
57-week biopsy  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99-76-31-1A  
Z18823 -  
Sex: Male Photo/Negative No(s): Z18827  
Significant Lesions (check one):        Yes   X   No  
Interpreting Pathologist (signature and date): James B. N. et al May 26, 2000

**Features:** Z18823. Liver. Hepatocyte. 15,290X. This hepatocyte has a small round central nucleus. The surrounding cytoplasm contains numerous round to oval mitochondria and several small to large lipid droplets. The darker round organelles, mostly slightly smaller than the mitochondria, are peroxisomes. Twenty-four (24) peroxisomes counted. The intervening cytosol contains profiles of endoplasmic reticulum and some fine granules, which may be glycogen.

Z18824. Liver. 10,320X. Portions of three cells are present. The dorsal two hepatocytes exhibit a mixture of normal appearing cytoplasmic elements, including mitochondria, endoplasmic reticulum and scattered peroxisomes. The larger ventral cell's cytoplasm contains irregular clear spaces surrounded by membranous material. Only a couple of mitochondria are evident, and this cell is probably not a hepatocyte. Around the periphery are several large structures containing finely granular and reticular material. This may represent smooth endoplasmic reticulum intermixed with glycogen and/or ribosomes. It appears to be membrane bound, but this may be a pseudomembrane caused by compacting of the surrounding cytoplasm. Or, these structures may represent cytoplasmic invaginations of extracellular material such as plasma. The nuclear profiles in these cells appear normal. Peroxisomes were not counted in this electron micrograph because an individual hepatocyte showing most of its cytoplasm is not present.

Z18825. Liver. Hepatocyte. 10,320X. This hepatocyte is polygonal with a round central nucleus. Its surrounding cytoplasm contains numerous mitochondria and a few small lipid droplets. The intervening cytoplasm contains profiles of endoplasmic reticulum, scattered fine glycogen granules, and some dark round peroxisomes. Twenty-two (22) peroxisomes counted. Three adjacent hepatocytes appear essentially normal. At the bottom right of the photograph is a finely granular structure, which is outside of the centered hepatocyte and appears similar to that described in Z18224.

Z18826. Liver. Hepatocyte. 10,320X. This hepatocyte is bordered by an extracellular space along its right margin. The cell has a small nuclear profile and abundant cytoplasm containing numerous mitochondria and slightly dilated endoplasmic reticulum. Several lipid droplets are present. Seventeen (17) peroxisomes counted.



**105511 Biopsy Continued.**

Z18827 Liver. Hepatocyte. 10.320X. A large round nucleus is present in the centered hepatocyte. The surrounding cytoplasm contains numerous mitochondria and abundant endoplasmic reticulum. A few dark residual bodies are present. Eleven (11) peroxisomes counted. At the right dorsal margin of the photograph are an endothelial cell and a granular structure that appears to be an invagination of plasma.

**Conclusions:** Normal hepatocytes. Peroxisomes average 18.5 per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105511 Tissue: Liver - centrilobular  
79-week necropsy  
Treatment Group: 75 mg/kg (hi-dose) Block No(s): 99.76-32-2A  
Z18828 -  
Sex: Male Photo/Negative No(s): Z18832  
Significant Lesions (check one): Yes  No

Interpreting Pathologist (signature and date): *James R. ...* May 29, 2000

**Features:** Z18828. Liver. Hepatocyte. 10,320X. This hepatocyte is somewhat oval in shape with a small round nucleus. Approximately 8-9 small to medium sized lipid droplets are present in the cytoplasm. The majority of the cytoplasm contains numerous round to rod-shaped mitochondria, intervening areas of smooth endoplasmic reticulum (SER) and "more clear" patches of glycogen. Some profiles of rough endoplasmic reticulum (RER) and round dark peroxisomes are also evident. Twenty-eight (28) peroxisomes counted. Bile canaliculi can be seen between the hepatocytes situated on the right and left with the central hepatocyte.

Z18829. Liver. Hepatocyte. 10,320X. The central vein and surrounding extracellular collagen are present at the top right margin of this electron micrograph. A sinusoid is also present at the lower left margin. The intervening hepatocyte has a round nucleus and surrounding cytoplasm containing numerous profiles of endoplasmic reticulum and dark mitochondria. There is mild dilatation of the endoplasmic reticulum and nuclear envelope, which is a fixation artifact. Several dark residual bodies and occasional small lipid droplets are also identified. Differentiation between peroxisomes and mitochondria is difficult. Eleven (11) peroxisomes counted.

Z18830. Liver. Hepatocyte. 10,320X. The cytoplasm of this hepatocyte contains abundant SER, although some profiles of RER are also evident, especially around some mitochondria. A nuclear profile is not evident in this plane of section of the centered hepatocyte. Approximately 20 lipid droplets are present. Twenty (20) peroxisomes counted. This hepatocyte's microvillous border is evident both dorsally and ventrally along sinusoids. The nucleus of an endothelial cell is present at the lower right. Adjacent hepatocytes are present to the left and right of the centered hepatocyte.

Z18831. Liver. Hepatocyte. 10,320X. The morphology of this hepatocyte is very similar to Z18828. The cytoplasm contains numerous mitochondria, endoplasmic reticulum and "more clear" patches of glycogen. Several lipid droplets are present. Nineteen (19) peroxisomes counted. The surrounding hepatocytes appear ultrastructurally similar.

**I05511 Necropsy Continued.**

Z18832, Liver, Hepatocyte, 10,320X. This hepatocyte appears similar to Z18830. Its cytoplasm contains abundant SER. Other recognizable organelles include some RER, lipid droplets, mitochondria, peroxisomes and residual bodies. Eighteen (18) peroxisomes counted. At the lower right margin of the photograph is a sinusoid containing several erythrocytes. A prominent bile canaliculus is present at the right where three hepatocytes appear to meet. These hepatocytes are considered to be ultrastructurally normal.

**Conclusions:** Normal hepatocytes. Average 19.2 peroxisomes per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99,76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105522 Tissue: Liver - centrilobular  
57-week biopsy  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99,76-33-1A  
Z18833 -  
Sex: Male Photo/Negative No(s): Z18837  
Significant Lesions (check one): Yes  No

Interpreting Pathologist (signature and date): James B. Nedel May 29, 2000

**Features:** Z18833, Liver. Hepatocyte. 10,320X. A sinusoid containing finely granular plasma is along the right microvillous margin of this hepatocyte. The hepatocyte has an oval nucleus. In the surrounding cytoplasm are several very electron-dense residual bodies. There is mild dilatation of the nuclear envelope and endoplasmic reticulum, which is a fixation artifact. Eighteen (18) peroxisomes counted. Mitochondria are numerous and are variably shaped.

Z18834, Liver. Hepatocyte. 10,320X. This hepatocyte appears ultrastructurally similar to Z 18833. There is mild dilatation of the endoplasmic reticulum and nuclear envelope. The hepatocyte lines a sinusoid, which contains two erythrocytes and a granulated eosinophil. Eight (8) peroxisomes counted.

Z18835, Liver. Hepatocyte. 10,320X. Several small lipid droplets are present in the cytoplasm of this hepatocyte. It has a slightly oval nucleus and abundant cytoplasm which contains numerous mitochondria and profiles of endoplasmic reticulum. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A distinct myelin figure is evident associated with a lipid droplet to the left of the nucleus. Twenty-two (22) peroxisomes counted.

Z18836, Liver. Hepatocyte. 10,320X. The hepatocyte has a large polygonal nucleus. The cytoplasm contains abundant SER and RER, which exhibit slight dilatation. Several small to large lipid droplets are present. Numerous round dark peroxisomes are evident. Thirty-five (35) peroxisomes counted. Mitochondria are numerous and variably shaped, but appear ultrastructurally normal.

Z18837, Liver. Hepatocyte. 10,320X. A sinusoid is present along the left and lower margins of this electron micrograph. The lighter-staining endothelial cell is present along the lower margin. The centered hepatocyte has an oval nucleus and numerous mitochondria and endoplasmic reticulum in its surrounding cytoplasm. There is mild dilatation of the endoplasmic reticulum and nuclear envelope. Several lipid droplets and residual bodies are also discernible. Fourteen (14) peroxisomes counted.

**Conclusions:** Normal hepatocytes. Peroxisomes average 19.4 per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05522 Tissue: Liver - centrilobular  
79-week necropsy  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-34-2A  
Z18838 -  
Sex: Male Photo/Negative No(s): Z18842  
Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. et al May 29, 2000

**Features:** Z18838. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round nucleus. At the very top left margin of the electron micrograph is a segment of sinusoid along its microvillous border. A bile canaliculus is evident at the lower left margin of the photograph, where the centered hepatocyte meets an adjacent hepatocyte. The centered hepatocyte has abundant cytoplasm, which contains numerous profiles of RER and SER. There is slight dilatation of the endoplasmic reticulum. Mitochondria are numerous and are round to oval in shape. Approximately twenty-three (23) peroxisomes counted.  
Z18839. Liver. Hepatocyte. 10,320X. Two hepatocytes are clearly evident in this electron micrograph. They appear ultrastructurally similar. They exhibit mild dilatation of their endoplasmic reticulum and nuclear envelopes. They have numerous mitochondria and occasional lipid droplets and residual bodies. Peroxisomes are usually round and more electron-dense than the mitochondria. Seventeen (17) peroxisomes counted in the upper hepatocyte.  
Z18840. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round central nucleus. The surrounding cytoplasm has numerous mitochondria and many slightly dilated profiles of endoplasmic reticulum. Both the SER and RER appear slightly dilated. Approximately 15-16 small to medium sized lipid droplets are present, as are a few very electron dense residual bodies. Twenty-one (21) peroxisomes counted.  
Z18841. Liver. Hepatocyte. 10,320X. This hepatocyte's nucleus is not evident in this plane of section. A sinusoid containing an erythrocyte is present along the very top margin of this electron micrograph. There is slight dilatation of the endoplasmic reticulum throughout the cytoplasm. Also, random small to medium sized lipid droplets are present. Numerous peroxisomes are evident. Forty (40) peroxisomes counted.  
Z18842. Liver. Hepatocyte. 10,320X. This hepatocyte appears similar to Z18838, and is ultrastructurally normal. It has an oval nucleus and abundant surrounding cytoplasm containing numerous mitochondria and slightly dilated profiles of endoplasmic reticulum. Twenty-eight (28) peroxisomes counted. Sinusoids are evident at the upper left and lower right margins of the photograph.

**Conclusions:** Normal hepatocytes. Peroxisomes average 25.8 per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105533 Tissue: Liver - centrilobular  
57-week biopsy  
Treatment Group: 75 mg/kg (hi-dose) Block No(s): 99.76-35-1A  
Z18843 -  
Sex: Female Photo/Negative No(s): Z18847  
Significant Lesions (check one):        Yes   X   No

Interpreting Pathologist (signature and date): *James B. N. M.D.* May 29, 2000

**Features:** Z18843. Liver. Hepatocyte. 10,320X. This hepatocyte has a small nuclear profile. A sinusoid lined by an endothelial cell is present along the upper right margin of the electron micrograph, and an adjacent hepatocyte is present at the lower left margin. A prominent bile canaliculus is present between the two hepatocytes. The cytoplasm of the centered hepatocyte is voluminous and contains numerous mitochondria and endoplasmic reticulum. The endoplasmic reticulum, nuclear envelope, and mitochondria appear to be slightly dilated. This dilatation is a fixation artifact. A few small to medium sized lipid droplets are present. Forty (40) peroxisomes counted.  
Z18844. Liver. Hepatocyte. 10,320X. This somewhat triangular-shaped hepatocyte has a large oval nucleus. Its cytoplasm contains numerous mitochondria and slightly dilated profiles of RER. Some glycogen granules appear to be intermixed with the SER. Eighteen (18) peroxisomes counted.  
Z18845. Liver. Hepatocyte. 10,320X. This electron micrograph appears similar to Z18844, although two nuclear profiles are present, which is probably a function of the plane of section although it may be binucleated. Thirty-four (34) peroxisomes counted.  
Z18846. Liver. Hepatocyte. 10,320X. The centered hepatocyte contains a small round nucleus. The surrounding cytoplasm contains numerous mitochondria and slightly dilated profiles of endoplasmic reticulum, both SER and RER. One myelin figure and several lipid droplets are present. Thirty-three (33) peroxisomes counted. Some extracellular collagen and a sinusoid are present along the lower right margin of the photograph. The hepatocyte at the top right is more lightly staining than the centered hepatocyte, and its cytoplasm contain abundant SER. Some mitochondria and peroxisomes are also evident.  
Z18847. Liver. Hepatocyte. 10,320X. This electron micrograph appears very similar to Z18844. Although there is slight dilatation of the endoplasmic reticulum, this hepatocyte appears ultrastructurally normal. Twenty-four (24) peroxisomes counted.

**Conclusions:** Normal hepatocytes. Peroxisomes average 29.8 per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105533 Tissue: Liver - centrilobular  
79-week necropsy  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-36-2A  
Z18848 -  
Sex: Female Photo/Negative No(s): Z18852  
Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): Juan B. A. S. L. May 29, 2000

**Features:** Z18848. Liver. Hepatocyte. 10,320X. This electron micrograph illustrates a hepatocyte with adjacent hepatocytes along either side. Sinusoids are present along the top right and bottom left margins. Along the sinusoids, the hepatocytes exhibit microvillous borders. Lightly staining endothelial cells line the sinusoids. The centered hepatocyte has a large oval nucleus and abundant surrounding cytoplasm. The cytoplasm contains large amounts of SER and numerous scattered mitochondria. A few lipid droplets and residual bodies are present. RER is evident as clusters, usually around mitochondria. Thirty-five (35) peroxisomes counted.

Z18849. Liver. Hepatocyte. 10,320X. This pentagonally-shaped hepatocyte has a somewhat "trapezoid" appearance and is bounded by hepatocytes on five sides. It has a round central nucleus and abundant surrounding cytoplasm. The cytoplasm contains numerous mitochondria and lots of SER. Some profiles of RER are present around the mitochondria. Twenty-four (24) peroxisomes counted.

Z18850. Liver. Hepatocyte. 10,320X. This hepatocyte is bordered by a sinusoid at its lower left margin. The sinusoid is lined by an endothelial cell and contains two profiles of erythrocytes. The hepatocyte has a small central nucleus. Its cytoplasm contains numerous areas of glycogen. These are lightly stained areas with fine granular material. Mitochondria, SER and RER appear ultrastructurally normal. Eight (8) peroxisomes counted.

Z18851. Liver. Hepatocyte. 10,320X. This electron micrograph appears essentially similar to Z18850. Near the top center there is a sinusoid lined by an endothelial cell and containing an erythrocyte. The hepatocyte's cytoplasm contains multiple patches of glycogen interspersed between SER and mitochondria. Eighteen (18) peroxisomes counted.

Z18852. Liver. Hepatocyte. 10,320X. This hepatocyte is round, with a round nucleus, and contains one medium sized lipid droplet in its cytoplasm. A sinusoid containing an erythrocyte is present along the lower right margin of the electron micrograph. Abundant SER, mitochondria, and some glycogen are present in the cytoplasm of the hepatocyte. Approximately nineteen (19) peroxisomes counted.

**Conclusions:** Normal hepatocytes. Peroxisomes average 20.8 per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105542 Tissue: Liver - periportal  
57-week biopsy  
Treatment Group: .75 mg/kg/ (hi-dose) Block No(s): 99.76-37-1A  
Z18853 -  
Sex: Female Photo/Negative No(s): Z18857  
Significant Lesions (check one):        Yes   X   No  
Interpreting Pathologist (signature and date): James B. A. M. May 29, 2000

**Features:** Z18853. Liver. Hepatocyte. 10,320X. This hepatocyte appears surrounded by adjacent hepatocytes on all sides. It has a large polygonal nucleus and abundant surrounding cytoplasm. Just to the lower left of its nucleus is a small segment of extracellular space containing some microvilli and collagen, probably next to a sinusoid. Several small lipid droplets are present in the cytoplasm of the centered hepatocyte. The endoplasmic reticulum is slightly dilated, and several residual bodies are present. Nineteen (19) peroxisomes counted.  
Z18854. Liver. Hepatocyte. 10,320X. Similar to Z18853, the endoplasmic reticulum of this hepatocyte is slightly dilated, which along with the dilated nuclear envelope, is an artifact of fixation. The mitochondria appear to also exhibit some slight artifactual swelling. Multiple bile canaliculi are evident along the margins of this cell's contact with adjacent hepatocytes. Approximately thirteen (13) peroxisomes counted.  
Z18855. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round nucleus. Its surrounding cytoplasm contains numerous profiles of SER, which are minimally dilated. Approximately 20 small to medium sized lipid droplets are present in the cytoplasm. Fifty-one (51) peroxisomes counted.  
Z18856. Liver. Hepatocyte. 10,320X. Extracellular space containing numerous collagen fibrils is present next to the centered hepatocyte. The hepatocyte has a large oval nucleus and abundant surrounding cytoplasm with numerous mitochondria and endoplasmic reticulum. A few small lipid droplets are present. Thirteen (13) peroxisomes counted.  
Z18837. Liver. Hepatocyte. 10,320X. Smooth endoplasmic reticulum and mitochondria are abundant in the cytoplasm of this hepatocyte. The hepatocyte has a large round nucleus and several small to medium sized lipid droplets are present. Nineteen (19) peroxisomes counted.

**Conclusions:** Normal hepatocytes. Peroxisomes average 23.0 per hepatocyte.



TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION


Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105542 Tissue: Liver - centrilobular  
79-week necropsy  
Treatment Group: 75 mg/kg (hi-dose) Block No(s): 99.76-38.2A  
Z18858 -  
Sex: Female Photo/Negative No(s): Z18862  
Significant Lesions (check one):  Yes  No


Interpreting Pathologist (signature and date): J. B. N. N. May 29, 2000

**Features:** Z18858. Liver. Hepatocyte. 10,320X. This hepatocyte has a round central nucleus. To the left of and beneath the nucleus are several medium sized lipid droplets. The remaining cytoplasm contains abundant SER, patches of glycogen, mitochondria, and some profiles of RER. Six (6) peroxisomes counted.  
Z18859. Liver. Hepatocyte. 10,320X. The cytoplasm of this hepatocyte contains multiple areas of glycogen granule accumulation. These are lightly stained areas with numerous small electron dense granules. A few lipid droplets are also present in the cytoplasm. The darker and irregular cytoplasmic material is SER intermixed with glycogen. Five (5) peroxisomes counted.  
Z18860. Liver. Hepatocyte. 10,320X. Thirty-two (32) peroxisomes are counted in this hepatocyte's cytoplasm. The cell has a large round nucleus. Most of the cytoplasm is occupied by SER, mitochondria, and occasional lipid droplets. Some profiles of RER are evident around mitochondria. A microvillous border and adjacent sinusoid are present along the right margin of this hepatocyte.  
Z18861. Liver. Hepatocyte. 10,320X. For this hepatocyte, its nuclear profile is not present in this plane of section. A moderate number of medium sized lipid droplets are present. Several of these contain some membranous or myelin-like debris. Numerous profiles of SER and RER are present. There is slight dilatation of the endoplasmic reticulum. Numerous variably shaped mitochondria are present, but they appear ultrastructurally normal. Eleven (11) peroxisomes counted.  
Z18862. Liver. Hepatocyte. 10,320X. This hepatocyte appears somewhat triangular shaped in this plane of section. It has a large round nucleus and abundant surrounding cytoplasm. Several small to medium sized lipid droplets are present. Abundant SER, some profiles of RER, mitochondria, and peroxisomes occupy the majority of the cytoplasm. Approximately twenty two (22) peroxisomes counted. A sinusoid with an endothelial cell and erythrocyte is present at the lower left margin of the photograph.

**Conclusions:** Normal hepatocytes. Peroxisomes average 15.2 per hepatocyte.

III. Transmission Electron Micrographs






1000

3M\_MN03279833


1818.1000



1001

3M\_MN03279834

1818.1001



Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

#### Figure Legends

**Magnification.** Print magnification is indicated on the back of each photograph. The measurement bar on each photomicrograph equals one micron (0.001mm).

Figure 1. Liver. Hepatocyte showing normal cytoplasmic organelles. Some peroxisomes and other normal organelles are identified. There is slight artifactual dilatation of the nuclear envelope and endoplasmic reticulum. Animal No. I05522, 0.75 mg/kg/day (high dose male), 57-week biopsy, 10,320X magnification.

Figure 2. Liver. Hepatocyte. Glycogen accumulations are shown. Glycogen are the small granules within the clear areas. Animal No. I05511, 0.75 mg/kg/day (high-dose male), 79-week necropsy, 10,320X magnification.

Figure 3. Liver. Hepatocyte showing normal cytoplasmic organelles. There is slight artifactual dilatation of the endoplasmic reticulum and nuclear envelope. Animal No. I05542, 0.75 mg/kg/day (high-dose female), 57-week biopsy, 10,320X magnification.

Figure 4. Liver. Hepatocyte showing normal cytoplasmic organelles. Animal No. I05533, 0.75 mg/kg/day (high dose female), 79-week necropsy, 10,320X magnification.

Electron Microscopy Report  
Covance Study No. 6329-223  
Recovery Sacrifice Animals

**Index of Labels for Ultrastructural Structures**

<u>Abbreviation</u>	<u>Structure</u>
BC	Bile canaliculus
EV	Nuclear envelope
G	Glycogen
L	Lipid droplet
M	Mitochondria
N	Nucleus
P	Peroxisome
RB	Residual body
RER	Rough endoplasmic reticulum
SER	Smooth endoplasmic reticulum




IV. Quality Assurance Statement

QUALITY ASSURANCE STATEMENT

This electron microscopy study has been inspected and audited by the Quality Assurance Unit as required by the Good Laboratory Practices Regulations promulgated by the U.S. Food and Drug Administration. PAI has a functioning and responsive Quality Assurance Unit which reports directly to management. The following is a record of inspections/audits and their resulting reports:

<u>Date of Inspection</u>	<u>Phase Inspected</u>	<u>Date Findings Reported to Management and Study Pathologist</u>
4/1, 2/99	Data Audit	4/2/99
4/2/99	Draft Report Audit	4/2/99
7/13/99	Audit of Data from Additional Groups	7/13/99
7/13/99	Final Report Audit	7/13/99
5/25, 30/00	Data and Draft Report Audit Recovery Animals	5/30/00
9/1/00	Final Report Audit	9/1/00

  
Jeanne deWard, B.S., RQAP-GLP  
Quality Assurance Specialist

9/1/00  
Date

Sponsor: 3M Corporate Toxicology

Test Article: PFOS

Study Number: 6329-223, PAI Study EM-99.76



**Pathology Associates International**  
*A Company of Science Applications International Corporation*



**PATHOLOGY REPORT  
(ANCILLARY STUDY)**

**ELECTRON MICROSCOPIC EVALUATION  
OF LIVER IN CYNOMOLGUS MONKEYS**

**26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE  
SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS  
MONKEYS**

**CLIENT STUDY NUMBER 6329-223  
PAI STUDY NUMBER EM 99.76**

**Prepared by:**

**James B. Nold, D.V.M., Ph.D., Diplomate, A.C.V.P.**

**Pathology Associates International  
4915-D Prospectus Drive  
Durham, NC 27713**

**July 13, 1999**

**PREPARED FOR 3M CORPORATE TOXICOLOGY,  
3M CENTER, ST. PAUL, MN 55144-1000**

	<u>Section</u>
Pathology Narrative	I
Light Microscopy and Transmission Electron Micrograph Interpretation Forms	II
Transmission Electron Micrographs	III
Quality Assurance Statement	IV

I. Pathology Narrative

1009

3M\_MN03279842

**1818.1009**

Ancillary Pathology Report  
Covance Study No. 6329-223

**PATHOLOGY REPORT  
(ANCILLARY STUDY)**

**ELECTRON MICROSCOPIC EVALUATION  
OF LIVER IN CYNOMOLGUS MONKEYS**

**26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE  
SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS  
MONKEYS**

**CLIENT STUDY NUMBER 6329-223  
PAI STUDY NUMBER EM 99.76**

**SUMMARY**

Treatment of cynomolgus monkeys with 0.75 mg PFOS/kg/day for 26 weeks resulted in hepatocellular vacuolation and hypertrophy by light microscopy. Hepatocellular vacuolation and hypertrophy were primarily centrilobular in distribution and did vary in incidence and severity between individual animals. Ultrastructurally, there were increased lipid droplets within hepatocytes. Increased lipid droplets were present in both the high-dose males examined and in two of four high-dose females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group).

Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15, or 0.75 mg PFOS/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined.

**PROCEDURES**

The objective of this study was to examine by electron microscopy the livers from selected animals in a 26-week capsule toxicity study with PFOS in cynomolgus monkeys. In addition to a general qualitative evaluation for differences between control and treated animals, the ultrastructural endpoints included quantitation of peroxisomes within hepatocytes and membrane and mitochondrial changes in hepatocytes. Light microscopy of paraffin-embedded liver sections was also performed.

For the toxicity study, 22 male and 22 female cynomolgus monkeys were given the test article or the vehicle once daily for at least 26 weeks according to Text Table 1.

I-1

Ancillary Pathology Report  
Covance Study No. 6329-223

Text Table 1. Group Designations and Dosage Levels

Dosage Group	Dose Level (mg/kg/day) <sup>a</sup>	Total Material Dose Level (mg/kg/day) <sup>b</sup>	Number of Males	Number of Females
I	0 <sup>d</sup>	30 <sup>a</sup>	6 <sup>d</sup>	6 <sup>d</sup>
II	0.03	15 <sup>b</sup>	4	4
III	0.15	6 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>
IV	0.75	30 <sup>c</sup>	6 <sup>d</sup>	6 <sup>d</sup>

<sup>a</sup> Dose levels were provided. The control group (Group 1) received an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

<sup>b</sup> The low-dose group (Group 2) received the test material diluted with lactose (1:499, w:w).

<sup>c</sup> The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).

<sup>d</sup> Two animals in Groups 1, 3, and 4, designated as recovery animals, were treated for at least 26 weeks, then treatment was discontinued and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 13 weeks posttreatment.

Animals to be sacrificed at scheduled terminal and recovery sacrifice times were anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied. Multiple tissues were collected and preserved in 10% neutral-buffered formalin according to the protocol. Additionally, pieces of liver from each animal were thin-sliced and placed in ½ strength Karnovsky's fixative (2.0% paraformaldehyde/2.5% glutaraldehyde in 0.1M phosphate buffer) for subsequent ultrastructural examination. These livers were processed into Epon blocks and submitted to this laboratory for subsequent electron microscopy processing and evaluation. Hematoxylin and eosin (H&E)-stained slide sections of formalin-fixed, paraffin-embedded livers were submitted for light microscopic examination.

Per sponsor request, tissue samples from terminal sacrifice control and high-dose males and females were initially processed and evaluated ultrastructurally (Text Table 2). Two high-dose males, Animals Nos. I05506 and I05509, died or were sacrificed in a moribund condition prior to scheduled terminal sacrifice. Ultrastructural examination of livers from these two unscheduled death animals was not performed. Following evaluation of the electron micrographs from the control and high-dose livers, the sponsor requested that electron microscopy be performed on the low- and mid-dose livers to evaluate whether increased lipid droplet accumulation was evident in these dose groups.

Text Table 2. Animals Selected for Electron Microscopy

0 mg/kg/day PFOS (Group 1 Control)		0.03 mg/kg/day PFOS (Group 2 low-dose)		0.15 mg/kg/day PFOS (Group 3 mid-dose)		0.75 mg/kg/day PFOS (Group 4 High-Dose)	
Males	Females	Males	Females	Males	Females	Males	Females
I05508	I05530	I05514	I05537	I05510	I05532	I05507	I05534
I05517	I05531	I05515	I05541	I05518	I05538	I05512	I05536
I05519	I05535	I05516	I05547	I05524	I05545		I05540
I05527	I05544	I05521	I05550	I05528	I05548		I05551

Thin sections (approximately 90 nm) from the Epon-embedded livers were cut, mounted on 200-mesh copper grids, stained with 5% methanolic uranyl acetate and Reynold's lead

Ancillary Pathology Report  
Covance Study No. 6329-223

citrate, and examined on a Zeiss EM10C/CR, a Zeiss EM10, or a JEOL 100S transmission electron microscope. Centrilobular hepatocytes, where clearly identifiable in liver sections, were preferentially examined. Representative electron photomicrographs of liver were taken and significant ultrastructural features were summarized for each photograph and animal on a designated transmission electron micrograph interpretation form. The number of peroxisomes in hepatocytes was manually counted for each center photographed hepatocyte and recorded. For light microscopy, the H&E slides from the same animals selected for electron microscopy were evaluated and significant features were summarized on a light microscopic evaluation form.

**RESULTS AND DISCUSSION**

Individual interpretations of light microscopy slides and electron micrographs for each animal are shown in Section II. Representative electron photomicrographs were selected as report figures, labeled, and are shown in Section III. All remaining electron micrographs are maintained in the archived study file.

Light Microscopy

A summary of the incidence and severity of light microscopic findings in the control and high-dose livers is shown in Text Table 3. There was an increased incidence of vacuolation of the cytoplasm of hepatocytes in high-dose treated animals compared with control animals. The distribution of this vacuolation was predominantly centrilobular, but for one high-dose female, Animal No. I05534, there was diffuse slight hepatocellular vacuolation. Affected animals generally also had enlargement (hypertrophy) of centrilobular hepatocytes. This enlargement appeared to be related to the presence of the small to large vacuoles with the cytoplasm. Some sporadic vacuolation noted in low- and mid-dose animals did not appear to be treatment-related and was not clearly associated with hepatocellular hypertrophy.

Text Table 3. Incidence and Severity of Light Microscopic Liver Findings

Microscopic Finding	0 mg/kg/day (Control)		0.03 mg/kg (Low-Dose)		0.15 mg/kg (Mid-Dose)		0.75 mg/kg/day (High-Dose)	
	Males	Females	Males	Females	Males	Females	Males	Females
(number examined)	(4)	(4)	(4)	(4)	(4)	(4)	(2)	(4)
Vacuolation, hepatocellular, centrilobular								
minimal	-	-	1	-	-	-	-	2
slight	-	-	-	-	-	-	-	-
moderately-severe	-	-	-	-	-	-	1	1
Vacuolation, hepatocellular, diffuse								
slight	-	-	-	-	-	-	-	1
Vacuolation, hepatocellular, multifocal								
minimal	-	-	1	1	-	-	-	-



Ancillary Pathology Report  
Covance Study No. 6329-223

Text Table 3 Continued. Incidence and Severity of Light Microscopic Liver Findings

Microscopic Finding	0 mg/kg/day (Control)		0.03 mg/kg (Low-Dose)		0.15 mg/kg (Mid-Dose)		0.75 mg/kg/day (High-Dose)	
	Males	Females	Males	Females	Males	Females	Males	Females
(number examined)	(4)	(4)	(4)	(4)	(4)	(4)	(2)	(4)
Hypertrophy, hepatocellular, centrilobular								
minimal	-	-	-	-	-	-	1	2
slight	-	-	-	-	-	-	-	-
moderate	-	-	-	-	-	-	1	1
Clearing, cytoplasmic, centrilobular								
minimal	1	2	-	2	1	-	-	-
slight	-	-	3	1	1	2	1	2
Clearing, cytoplasmic, diffuse								
minimal	-	-	-	-	1	-	-	-
slight	-	-	-	-	1	-	-	-
Infiltrate, lymphohistiocytic								
minimal	4	4	4	4	3	3	1	3
slight	-	-	-	-	-	1	-	-
Inflammation, eosinophilic- granulomatous								
minimal	-	-	1	-	-	-	-	-
slight	-	1	-	-	-	-	-	-
Pigment, hepatocellular, centrilobular								
slight	-	-	1	-	-	-	-	-
Ectasia, biliary								
minimal	-	-	-	1	-	-	-	-
Angiectasis								
minimal	1	-	-	-	-	-	-	-

**Electron Microscopy**

**Control (0 mg/kg/day).** Ultrastructural features of control hepatocytes are demonstrated in Figures 1 - 3. Hepatocytes characteristically contain numerous mitochondria and abundant endoplasmic reticulum. Peroxisomes are common organelles composed of a fine granular matrix surrounded by a membrane and normally vary in size from 0.1 - 1.5 microns in diameter. Hepatocytes exhibit a microvillous border which protrudes into the perisinusoidal space. Tight junctions border bile canaliculi between hepatocytes. Glycogen is common in the cytoplasm and may be in the form of small granules or slightly larger rosettes. Residual bodies are secondary lysosomes (phagolysosomes) containing electron dense degenerative cytoplasmic material. Lipid metabolism is a normal liver function, and it's normal to see random lipid droplets within hepatocytes.

There were no discernible differences between control males and females in this study, and all were considered normal. A summary of ultrastructural findings is shown in Text Table 4. One male, Animal No. I05527, appeared to have increased numbers of peroxisomes compared with the other control animals. However, because so few animals and individual hepatocytes were examined, this value may not be significantly increased.



**Pathology Associates International**

A Company of Science Applications International Corporation  
Ancillary Pathology Report  
Covance Study No. 6329-223



Text Table 4. Summary of Ultrastructural Findings

Treatment Group (mg/kg/day)/Sex	Animal No.	Comments
(0) Male	I05508	Normal
(0) Male	I05517	Normal
(0) Male	I05519	Normal
(0) Male	I05527	Normal. Increased peroxisomes
(0.03) Male	I05514	Mild increase in lipid droplets
(0.03) Male	I05515	Slight increase in lipid droplets
(0.03) Male	I05516	Normal
(0.03) Male	I05521	Normal
(0.15) Male	I05510	Normal
(0.15) Male	I05518	Normal
(0.15) Male	I05524	Normal, slight increase in peroxisomes
(0.15) Male	I05528	Normal
(0.75) Male	I05507	Lipid droplet accumulation, hepatocellular, moderately severe. Increased glycogen
(0.75) Male	I05512	Lipid droplet accumulation, moderate, hepatocellular. Increased peroxisomes
(0) Female	I05530	Normal
(0) Female	I05531	Normal
(0) Female	I05535	Normal
(0) Female	I05544	Normal
(0.03) Female	I05537	Normal
(0.03) Female	I05541	Normal
(0.03) Female	I05547	Normal
(0.03) Female	I05550	Normal
(0.15) Female	I05532	Normal
(0.15) Female	I05538	Increased glycogen
(0.15) Female	I05545	Normal
(0.15) Female	I05548	Normal
(0.75) Female	I05534	Increased glycogen
(0.75) Female	I05536	Lipid droplet accumulation, moderately severe
(0.75) Female	I05540	Lipid droplet accumulation, mild to moderate
(0.75) Female	I05551	Increased glycogen

Peroxisomes were identified and quantitated in representative hepatocytes. For the control livers, the average number of peroxisomes counted per hepatocyte photographed was 11.50 for control males and 10.94 peroxisomes per cell for control females. (Text Table 5). Depending upon fixation and staining, peroxisomes may be difficult to differentiate in routine electron photomicrographs from primary lysosomes or marginal cuts through the ends of mitochondria. Cytochemical and immunocytochemical methods are available for specifically identifying peroxisomes by light and electron microscopy, and utilization of these methods would provide a more specific and accurate method of peroxisome quantitation (Beier K, 1992; Reddy UN, 1988).

Text Table 5 Quantitation of Hepatocellular Peroxisomes

0 mg PFOS/kg/day (Control)				0.03 mg PFOS/kg/day (Low-Dose)			
Male		Female		Male		Female	
Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
I05508	7.50	I05530	12.75	I05514	6.00	I05537	8.80
I05517	12.25	I05531	13.75	I05515	15.00	I05541	12.00
I05519	3.50	I05535	7.00	I05516	7.20	I05547	10.00
I05527	22.75	I05544	10.25	I05521	10.80	I05550	17.60
Mean =	11.50	Mean =	10.94	Mean =	9.75	Mean =	12.10

0.15 mg PFOS/kg/day (Mid-Dose)				0.75 mg PFOS/kg/day (High-Dose)			
Male		Female		Male		Female	
Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
I05510	10.60	I05532	4.20	I05507	11.0	I05534	5.50
I05518	18.40	I05538	7.20	I05512	23.25	I05536	3.75
I05524	23.20	I05545	9.00			I05540	12.50
I05528	14.60	I05548	17.00			I05551	9.50
Mean =	16.70	Mean =	9.35	Mean =	17.12	Mean =	7.81

<sup>1</sup> Average number of peroxisomes per hepatocyte for four hepatocytes counted per animal for control and high-dose groups and five hepatocytes counted per animal for low- and mid-dose groups.

**High-Dose (0.75 mg/kg/day).** Lipid droplets were increased in animals given 0.75 mg PFOS/kg/day (Text Table 4). This increase was present in both high-dose males examined (Animal Nos. I05507 and I05512) and in two high-dose females (Animal Nos. I05536 and I05540). These are illustrated in Figures 4 - 7. Lipid droplets were randomly distributed in the cytosol and varied in size from less than .1 micron to greater than several microns in diameter. They generally were clear, but occasionally contained wispy lamellar material or faint smooth electron density. They were not membrane-bound, but appeared to form a defined margin with surrounding cytoplasm. These lipid droplets correlate with hepatocellular vacuolation described in these animals by light microscopy.

Increased cytoplasmic glycogen was evident in two high-dose females (Animal Nos. I05534 and I05551), and often formed distinct "pockets" of glycogen, resembling vacuoles or clear droplets, but containing glycogen particles (Figure 8). The accumulation of glycogen apparently correlates with the hepatocellular vacuolation described by light microscopy in these two animals. Lipid droplets did not appear increased in these two animals.

For high-dose animals, the average number of peroxisomes per hepatocyte was 17.12 for males and 7.81 for females (Text Table 5). One male (Animal No. I05512) averaged 23.25 peroxisomes per hepatocyte, however, this is not remarkably higher than that found in the control male Animal No. I05527. Animal No. I05507 averaged 11.0 peroxisomes per hepatocyte, similar to the average control value for males. Thus, administration of 0.75 mg/kg/day of PFOS to monkeys for 26 weeks did not appear to induce peroxisome proliferation in the liver.

Differences in mitochondria and cellular membranes were not discernible between high-dose and control livers. Mitochondria from control and high-dose livers did not exhibit remarkable differences ultrastructurally (Figures 3, 9, 10).

**Low-Dose (0.03 mg/kg/day).** Electron microscopic examination of the livers from monkeys given 0.03 mg/kg/day of PFOS did not identify any atypical ultrastructural features compared with control sample. Lipid droplets were identified in some hepatocytes, and two low-dose males appeared to have slightly increased lipid droplet accumulation (Animal Nos. I05514 and I05515). However, increased lipid droplet accumulation was not seen in the low-dose females or in the mid-dose males and females, and this observation in the two low-dose males was believed to represent normal biological variance and sampling. As noted earlier, lipid metabolism is a normal liver function, and it's normal to see random lipid droplets within hepatocytes. Figure 11 illustrates a hepatocyte from the low-dose group.

For low-dose animals, the average number of peroxisomes per hepatocyte was 9.75 for males and 12.10 for females (Text Table 5).

**Mid-Dose (0.15 mg/kg/day).** There was no consistent ultrastructural evidence of increased lipid droplet accumulation in the livers of the mid-dose monkeys given 0.15 mg/kg/day of PFOS. This mid-dose level, 0.15 mg/kg/day, is the no-effect level for the PFOS-related effect of increased hepatocellular lipid accumulation (vacuolation) in monkeys given PFOS. One female, Animal No. I05538, had increased glycogen, but a marked increase in glycogen was not seen in any other mid-dose livers examined.

For mid-dose animals, the average number of peroxisomes per hepatocyte was 16.70 for males and 9.35 for females (Text Table 5). Figure 12 illustrates a hepatocyte from the mid-dose group.

## CONCLUSION

Ultrastructural evaluation of livers from cynomolgus monkeys treated with 0.75 mg PFOS /kg/day for 26 weeks identified increased lipid droplets within hepatocytes. Increased lipid droplets were present in both treated males examined and in two of four treated females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group). Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15 or 0.75 mg/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined.

Draft Ancillary Pathology Report  
Covance Study No. 6329-223

**SIGNATURE OF AUTHOR**

James B. Nold  
James B. Nold, D.V.M., Ph.D.,  
Diplomate, A.C.V.P.

July 13, 1999  
Date

**REFERENCES**

Beier K: Light microscopic morphometric analysis of peroxisomes by automatic image analysis: advantages of immunostaining over the alkaline DAB method. *J. Histochem. Cytochem.*, 40(1):115-121, 1992.

Reddy, UN et. al: Tissue specificity and species differences in the distribution of urate oxidase in peroxisomes. *Lab. Invest.*, 58(1)100-111, 1988.

II. Light Microscopy and Transmission Electron  
Micrograph Interpretation Forms <sup>1</sup>

<sup>1</sup>Forms are typographically corrected versions of signed/dated raw data sheets maintained in archived study file.

**LIGHT MICROSCOPIC EVALUATION**

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkeys

Animal No: see below

Tissue: Liver

Sex: see below

Interpreting Pathologist (signature and date): James B. Nold 6-24-99

Dose/Group	Animal Number	Microscopic Findings and Comments
0 mg/kg (Control) Males	I05508	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05517	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05519	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05527	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Angiectasis, focal, minimal
0 mg/kg (Control) Females	I05530	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05531	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05535	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05544	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Inflammation, eosinophilic-granulomatous, focal, slight
0.75 mg/kg (High-dose) Males	I05507	1. Infiltrate, lymphohistiocytic, focal, minimal 2. Vacuolation, hepatocellular, centrilobular, moderately-severe 3. Hypertrophy, hepatocellular, centrilobular, moderate
	I05512	1. Clearing, cytoplasmic, centrilobular, slight 2. Hypertrophy, hepatocellular, centrilobular, minimal
0.75 mg/kg (High-dose) Females	I05534	1. Infiltrate, lymphohistiocytic, focal, minimal 2. Vacuolation, hepatocellular, diffuse, slight 3. Hypertrophy, hepatocellular, centrilobular, minimal
	I05536	1. Vacuolation, hepatocellular, centrilobular, moderately-severe 2. Hypertrophy, hepatocellular, centrilobular, moderate
	I05540	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal 3. Clearing, cytoplasmic, centrilobular, slight 4. Hypertrophy, hepatocellular, centrilobular, minimal
	I05551	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal 3. Clearing, cytoplasmic, centrilobular, slight

Dose/Group	Animal Number	Microscopic Findings and Comments
0.03 mg/kg  (Low-dose)  Males	I05514	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Inflammation, eosinophilic-granulomatous, focal, minimal 3. Pigment, hepatocellular, multifocal, centrilobular, minimal 4. Clearing, cytoplasmic, centrilobular, slight
	I05515	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal
	I05516	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
	I05521	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Pigment, hepatocellular, multifocal, centrilobular, slight 3. Vacuolation, hepatocellular, multifocal, minimal 4. Clearing, cytoplasmic, centrilobular, slight
0.03 mg/kg  (Low-dose)  Females	I05537	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
	I05541	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05547	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Ectasia, biliary, focal, minimal
	I05550	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal 3. Vacuolation, hepatocellular, multifocal, minimal
0.15 mg/kg  (Mid-dose)  Males	I05510	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, diffuse, minimal
	I05518	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05524	1. Clearing, cytoplasmic, centrilobular, slight
	I05528	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, diffuse, slight
0.15 mg/kg  (Mid-dose)  Females	I05532	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05538	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
	I05545	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05548	1. Infiltrate, lymphohistiocytic, multifocal, slight 2. Clearing, cytoplasmic, centrilobular, slight

Interpreting Pathologist (signature and date): James B. N. del 6-14-99



TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105508 Tissue: Liver  
Treatment Group: 0 mg/kg (Control) Block No(s): ~~99076-1~~ 99.76-1 88 4-5-99  
Sex: Male Photo/Negative No(s): 43401 - 43405

Significant Lesions (check one): \_\_\_\_\_ Yes  No

Interpreting Pathologist (signature and date): James B. N. del MAR 31 1999

1 88-4-5-99  
**Features:** 43402: Liver. Hepatocyte exhibiting large central nucleus. The cytoplasm contains many mitochondria and abundant endoplasmic reticulum. Bile canaliculi are evident at the lower right and left margins of this hepatocyte. A number (approximately 20-25) of small to medium-size clear lipid droplets are present, principally in the upper portion of the cell. Mitochondria appear normal; normal matrix granules are evident in most. Several lysosomes and peroxisomes are present. Five (5) peroxisomes counted.  
43402: Liver. Hepatocyte is possibly bi-nucleate, but this may be function of cut through the nucleus. Some small to medium-sized clear lipid droplets present, similar to 43402. Microvillous border in space of Disse evident at top margin of cell. Several lamellar myelin-like bodies present within lysosomes. Five (5) peroxisomes counted. 88-4-5-99  
43403: Liver. Hepatocyte with bile canaliculus at lower right. Only a few small to medium-size clear lipid droplets are evident. Numerous mitochondria and abundant endoplasmic reticulum are evident. Clear structure at the bottom may be dilated Golgi, reticulum or artifact. Nine (9) peroxisomes counted.  
43404: Liver. Hepatocyte with adjacent endothelial cell and sinusoid at the bottom of the photograph. Hepatocyte contains several small to medium-sized clear lipid droplets. One droplet contains some lamellar material. Eleven (11) peroxisomes counted.  
43405: Liver. Hepatocyte with higher magnification of mitochondria. Seven mitochondria present with intervening rough endoplasmic reticulum and cytosol. Outer membrane, cristae, matrix and granules appear normal.

**Conclusions:** Normal hepatocyte. Average 7.5 peroxisomes counted per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05517 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-2  
Sex: Male Photo/Negative No(s): 43406 - 43410

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. et al MAR 31 1999

*John A. J.*

**Features:** 43406: Liver. Hepatocyte surrounded by other hepatocytes with bile canaliculi in the lower right and upper left margins of the cell. There are numerous mitochondria and abundant endoplasmic reticulum. The ER and nuclear envelope appear slightly dilated. Only a couple small clear lipid droplets evident. Several small lysosomes or vacuoles with microvesicles in them are present. Five (5) peroxisomes counted.  
43407: Liver. Hepatocyte with perisinusoidal microvillous border evident in lower right and upper left of photograph. A bile canaliculus is present on the right middle margin of the cell. Several small to medium-sized clear lipid droplets are evident. One larger one contains some lamellar profiles. Four (4) peroxisomes counted.  
43408: Liver. Hepatocyte with sinusoid containing erythrocytes at the top. A lipid-containing perisinusoidal cell (Ito cell) is present at the top left and a bile canaliculus is present at the bottom. Random small clear lipid droplets are present in the hepatocellular cytoplasm and some of the ER appears mildly dilated. Eleven (11) peroxisomes counted.  
43409: Liver. Hepatocyte contains numerous dense lysosomes and/or peroxisomes intermixed with mitochondria and abundant ER. Several small clear lipid droplets are evident. Twenty-nine (29) peroxisomes counted.  
43410: Liver. Enlarged photograph of mitochondria. Ten mitochondria are clustered together in this photograph. Although the image is a little out of focus, these organelles appear essentially normal. There may be mild dilatation of the ER in the cytoplasm.

**Conclusions:** Normal hepatocyte. Average 12.25 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05519 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-3  
43421 - 43425,  
Sex: Male Photo/Negative No(s): 43431

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James S. M. et al MAR 31 1999

**Features:** 43421: Liver. Hepatocyte. At lower left is a prominent perisinusoidal fat-storing cell (Ito cell) containing numerous large clear lipid droplets. The centered hepatocyte contains one large clear lipid droplet and several smaller ones. The nuclear envelope and ER is mildly dilated. Moderate numbers of glycogen granules present. Scattered residual bodies noted. Four (4) peroxisomes counted.  
43422: Liver. Mitochondria and surrounding cytosol and ER. Membranes of ER are not very distinct. Glycogen in cytosol. Mitochondria appear essentially normal. Lamina of membranes and cristae appear parallel. Several normal granules in the matrix of the mitochondria.  
43423: Liver. Mitochondria. Same view as 43422 but slightly less magnification. Some dilatation of ER. Mitochondria appear normal. A peroxisome is present in the lower left of the photograph.  
43224: Liver. Hepatocyte with several medium-sized and one large clear lipid droplets. Small granules within cytosol and around ER appear to be glycogen particles or ribosomes and polyribosomes. Four (4) peroxisomes counted. Slightly out of focus.  
43425: Liver. Hepatocyte surrounded by other hepatocytes and a sinusoid at lower right. Several bile canaliculi evident between hepatocytes. A single medium-sized clear lipid droplet is present in the hepatocyte. Four (4) peroxisomes counted. A couple of larger dense lysosomes also identified.  
43431: Liver. The centered hepatocyte is oblong diagonally in the photograph, and doesn't contain any distinct lipid droplets. A few lipid droplets are present in adjacent hepatocytes. There is mild dilation of the ER and nuclear envelope. Only a few lysosomal structures noted. Two (2) peroxisomes counted.

**Conclusions:** Normal hepatocyte. Average 3.5 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05527 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-4  
Sex: Male Photo/Negative No(s): 43426 -  
43420

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Adl **MAR 31 1999**

**Features:** 43426: Liver. Hepatocyte with several small to medium-sized lipid droplets (approximately 20). The adjacent lower left hepatocyte shows significant dilatation of its ER. At top left and right margin, the extracellular interstitium has some collagen fibers. Some residual bodies noted. Twenty-one (21) peroxisomes counted.  
43427: Liver. Mitochondria. Membrane, cristae and matrix appear normal. Several normal granules present matrix. Some rough ER present adjacent to mitochondria. Lysosome present at left of center mitochondrion.  
43428: Liver. Hepatocyte. There is mild dilation of the ER and nuclear envelope. Scattered small to medium-size clear lipid droplets (approximately 18). Scattered residual bodies noted. Twenty-five (25) peroxisomes counted.  
43429: Liver. Hepatocyte. Bile canaliculi are evident at the lower right and top of the cell. The ER is mildly dilated. Scattered clear lipid droplets are evident. Abundant numbers of dense bodies (peroxisomes)/lysosomes and residual bodies are present. Thirty (30) peroxisomes counted.  
43430: Liver. Hepatocyte appears similar to above described cells. There are some scattered small to medium-size clear lipid droplets. Some residual bodies are present. Fifteen (15) peroxisomes counted.

**Conclusions:** Normal hepatocyte. Appear to be increased numbers of peroxisomes compared with other control samples. Average 22.75 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05507 Tissue: Liver  
Treatment Group: 0.75 mg/kg (hi-dose) Block No(s): 99.76-9  
Sex: Male Photo/Negative No(s): 43411 - 43415

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Noel MAR 31 1999

*1 gm 4-5-99*

**Features:** 43411: Liver. Hepatocyte containing a single very large clear lipid droplet and many small to medium-size clear lipid droplets. There appears to be an increase in the amount of glycogen  $\alpha$ -rosette granules. Several foci of ER appear irregularly dilated. A few scattered lysosomes and peroxisomes noted. Nine (9) peroxisomes counted.  
43412: Liver. Hepatocyte contains a large number of small to medium-sized clear lipid droplets in the cytosol (approximately 125), most being very small. Abundant glycogen as  $\alpha$ -rosettes is present in the cytoplasm. Twenty-six (26) peroxisomes counted.  
43413: Liver. Hepatocyte containing several very large clear lipid droplets and many smaller droplets. Some interstitial tissue containing some collagen fibers is present at the lower left of the photograph. Some residual bodies present. Many glycogen rosettes present in cytoplasm. Three (3) peroxisomes counted.  
43414: Liver. Several mitochondria are shown which appear essentially normal. Some normal dense granules are present in the matrix and the cristae and enveloping membrane appear normal. In the cytoplasm there are multiple small lipid droplets, usually surrounded by fine dense granules (glycogen or ribosomes).  
43415: Liver. Hepatocyte with a bile canaliculus at the bottom margin and an interstitial fibroblastic cell at the upper right. The hepatocyte contains abundant small to medium-sized clear lipid droplets (>170). Random residual bodies are present. Six (6) peroxisomes counted.

**Conclusions:** Lipid accumulation, moderately-severe, hepatocellular. Increased glycogen. Average 11.0 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05512 Tissue: Liver  
Treatment Group: 0.75 mg/kg (hi-dose) Block No(s): 99.76-10  
Sex: Male Photo/Negative No(s): 43416 -  
43420

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. Y. MAR 31 1999

**Features:** 43416: Liver. Photographed hepatocyte is binucleated and contains many small clear lipid droplets. Most appear around 100 nm in diameter, although a few are larger and one is about 1.75 microns in diameter. They are too numerous to count. The droplets appear to be free within the cytosol and are not membrane-bound. Nine (9) peroxisomes counted.  
43417: Liver. Hepatocyte contains multiple medium-sized clear lipid droplets (approximately 90). There are abundant numbers of dense primary lysosomes or peroxisomes. Forty-five (45) peroxisomes counted.  
43418: Liver. Hepatocyte containing numerous small to medium-sized clear lipid droplets within the cytosol. They are too numerous to count. Twelve (12) peroxisomes counted.  
43419: Liver. Hepatocyte adjacent to a central vein. Microvillous border in the perisinusoidal space and endothelium and erythrocytes are evident. Cell contains small lipid droplets too numerous to count. A moderate number of primary lysosomes and/or peroxisomes are evident. Twenty-five (25) peroxisomes counted.  
43420: Liver. Mitochondria. Mitochondria appear essentially normal. Numerous small lipid droplets are present in the surrounding cytosol.

**Conclusions:** Lipid accumulation, moderate, hepatocellular. Numbers of peroxisomes and lysosomes appear increased, average ~~23.25~~ 22.75 per hepatocyte.

9.5.99

22.75

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05530 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-5  
L4756 -  
Sex: Female Photo/Negative No(s): L4760

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. H. **MAR 31 1993**

**Features:** L4756: Liver. Hepatocyte contains three small lipid droplets. There are bile canaliculi at the top right at top left, and a perisinusoidal microvillous border at the bottom. The nuclear envelope and ER shows some mild artifactual (fixation) dilation. Numerous mitochondria are present. Five (5) peroxisomes counted.  
L4757: Liver. Mitochondria. Higher magnification of five mitochondria. Matrix and dense granules appear normal. ER between mitochondria is slightly dilated.  
L4758: Liver. Hepatocyte. A sinusoid is present at the top of the photograph, lined by an endothelial cell. Four (4) medium-sized lipid droplets are present in this cell. The nuclear envelope and ER shows some mild artifactual (fixation) dilation. Numerous mitochondria are present. Four (4) peroxisomes counted.  
L4759: Liver: Hepatocyte containing scattered small to medium-sized lipid droplets (approximately 14). Scattered primary lysosomes and/or peroxisomes present. There is a perisinusoidal microvillous border at the top beneath an endothelial cell and sinusoid. Twenty-five (25) peroxisomes counted.  
L4760: Liver. Hepatocyte containing approximately nine (9) small to medium-sized lipid droplets. Seventeen (17) peroxisomes counted.

**Conclusions:** Normal hepatocyte. Average 12.75 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105531 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-6 99.76-5 Jan 15  
Sex: Female Photo/Negative No(s): L4761 - L4765

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Smith MAR 31 1999

**Features:** L4761: Liver. Hepatocyte with large central nucleus. Two margins are straight-edged by the grid bar. A few small to medium-sized clear to slightly shaded lipid droplets are present (approximately 32). ER profiles and glycogen granules are scattered throughout the cytosol. A moderate number of primary lysosomes and/or peroxisomes noted. Nine (9) peroxisomes counted.

L4762: Liver. Mitochondria. One oval and one club-shaped mitochondria present. Both appear normal with cristae, membranes, and matrix. The club-shaped one contains several normal dense granules and some slightly dilated cristae, probably fixation artifact. Some RER and smooth ER (SER) are evident in the cytosol.

L4763: Liver. Hepatocyte surrounded by interstitium containing some collagen fibers. Cell has slightly dilated ER and nuclear envelope. A single small lipid droplet is present in this cell. Four (4) peroxisomes counted.

L4764: Liver. This hepatocyte shows some dilation of ER and several lamellar residual bodies in the cytoplasm. Four (4) small lipid droplets are evident. Numerous scattered glycogen granules are present. Eight (8) peroxisomes counted.

L4765: Liver. Hepatocyte containing 5 small to medium-sized clear lipid droplets. Bile canaliculi are evident at the lower left and top right of the cell margins. A cluster of RER is present in the lower left side of the nucleus. Some larger dark lysosomes/peri-oxisomes are present among some of the mitochondria. Thirty-four (34) peroxisomes counted.

*Jan 15*

**Conclusions:** Normal hepatocyte. Average 13.75 peroxisomes per hepatocyte.



**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05535 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-7  
Sex: Female Photo/Negative No(s): L4766 -  
L4770

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *James B. N. et al* MAR 31 1999

**Features:** L4766: Liver. Hepatocyte contains some mild dilatation of the nuclear envelope and ER (fixation artifact). On the left and right sides are bile canaliculi, and ventrally is the sinusoidal margin showing the perisinusoidal microvillous border. Several dense residual bodies are present in the cytoplasm. Three small lipid droplets, one containing a lamellar body, are evident. One (1) peroxisome counted.

L4767: Liver. Mitochondria. Higher magnification of four mitochondria show normal morphology. Membranes, cristae and matrix appear normal. Scattered dense granules are present. The ER in the cytosol is mildly dilated.

L4768: Liver. Hepatocyte. There is moderate dilatation of the ER and nuclear envelope. Several scattered small to medium-sized clear lipid droplets are evident, as are some scattered residual bodies. Sinusoids are present at the bottom right and upper left of the photograph, and a bile canaliculus is present on the right margin of this centered hepatocyte with its neighbor hepatocyte. Two (2) peroxisomes counted.

L4769: Liver. Hepatocyte with sinusoid in upper right corner and canaliculi prominent along ~~to~~ <sup>the</sup> bottom border. The cell exhibits dilated ER and nuclear envelope like the previously described cells for this animal – indicating suboptimal fixation. Multiple residual bodies are present. Nineteen (19) peroxisomes counted.

L4770: Liver. Hepatocyte with similar overall morphology as L4769. Six (6) peroxisomes counted.

*John*  
*9-5-99*

**Conclusions:** Normal hepatocyte. Suboptimal fixation. Average 7.0 peroxisomes per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05544 Tissue: Liver  
Treatment Group: 0 mg/kg (control) Block No(s): 99.76-8  
L4771 -  
Sex: Female Photo/Negative No(s): L4775

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James R. V. et al MAR 31 1999

*see pgs 4-5-99*  
**Features:** L4771: Liver. Along left margin of hepatocyte ~~is~~ some interstitium and collagen fibers. Hepatocyte contains approximately 17 small to medium-sized clear lipid droplets. A few residual bodies are evident. There is some minimal to mild dilatation of ER. Eight (8) peroxisomes counted.  
L4772: Liver. Enlarged photograph of three mitochondria. No abnormalities noted.  
L4773: Liver. Hepatocyte with one large and several small to medium-sized lipid droplets in the cytoplasm. Eight (8) peroxisomes counted.  
L4774: Liver. Hepatocyte with prominent microvillous border along bottom sinusoid. An endothelial cell nucleus is evident along this border. In the hepatocyte are several medium-sized clear lipid droplets. The ER does show some mild dilatation and there are abundant glycogen granules in the cytoplasm. Several dark residual bodies are present. Eight (8) peroxisomes counted.  
L4775: Liver. Hepatocyte with sinusoid on the right and prominent canaliculus on top and left margins. No lipid droplets present in centered hepatocyte, although one medium-sized lipid droplet is present in top adjacent hepatocyte. Cytoplasm contains some RER but not much SER, possibly a periportal hepatocyte. Random peroxisomes and/or primary lysosomes noted. Seventeen (17) peroxisomes counted.

**Conclusions:** Normal hepatocyte. Average 10.25 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05534 Tissue: Liver  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-11  
L4798 -  
Sex: Female Photo/Negative No(s): L4802

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): Jimmie B. N. L. **MAR 31 1999**

**Features:** L4798: Liver. Hepatocyte surrounded by adjacent hepatocytes. It contains abundant numbers of mitochondria and ER. There is mild dilatation of the nuclear envelope and of some ER. Scattered residual bodies are present. Just one distinct lipid droplet is evident. Four (4) peroxisomes counted.  
L4799: Liver. Enlarged view of five mitochondria. Mitochondria appear essentially normal. Several dense granules are present in the matrix. The cristae and limiting membranes appear normal. At the ~~side~~ <sup>right</sup> side is the mildly dilated nuclear envelope and the nucleus.  
L4800: Liver. Hepatocyte. A few small clear lipid droplets are present in the cytoplasm. There are also abundant glycogen granules in the cytoplasm. A number of "clear areas" in the cytoplasm appear to contain glycogen granules without a distinct lipid droplet margin. Two (2) peroxisomes counted.  
L4801: Liver. Hepatocyte. There are numerous small to medium-sized rarefied "pockets" in the cytoplasm (approximately 57). Some contain some wispy lamellar material, and some glycogen granules appear to be in these spaces. The margins of these droplets are not as sharply defined as clear round lipid droplets usually are. Four (4) peroxisomes counted.  
L4802: Liver. Hepatocyte appears similar to L4801 with some small to medium-sized lipid droplets and other rarefied areas with glycogen in the cytoplasm (approximately 29). Some contain some wispy lamellar material. There are also abundant glycogen granules throughout the cytoplasm. Twelve (12) peroxisomes counted.

**Conclusions:** Increased glycogen in this animal. Increased number of glycogen granules. Average 4.75 peroxisomes per hepatocyte.  
5.5

JBN 1-5-99

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105536 Tissue: Liver  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-12  
Sex: Female Photo/Negative No(s): L4804 -  
L4808

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *John B. M. del* MAR 31 1999

**Features:** L4804: Liver. Hepatocyte. Only a small segment of the nucleus is evident. There are multiple large clear lipid droplets in the cytoplasm. Numerous smaller droplets appear as less distinct dilatations in the cytosol. There are abundant glycogen granules in the cytoplasm. Three (3) peroxisomes counted.  
L4805: Liver. Hepatocyte. Multiple small to large clear lipid droplets in cytoplasm. Four (4) peroxisomes counted.  
L4806: Liver. Enlarged magnification of a cluster of mitochondria. Cristae are not well defined in this photograph, but matrix, granules and outer limiting membrane appear normal.  
L4507: Liver. Hepatocyte. Multiple small to large clear lipid droplets in cytoplasm (approximately 123). There are abundant glycogen granules in the cytoplasm. Three (3) peroxisomes counted.  
L4808: Liver. Hepatocyte contains multiple small to large lipid droplets. Droplets are too numerous to count. Several dense residual bodies present. Five (5) peroxisomes counted.

**Conclusions:** Moderately-severe lipid accumulation in hepatocytes. Membranes and mitochondria appear essentially similar to controls. Average 3.75 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05540 Tissue: Liver  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-13  
L4809 -  
Sex: Female Photo/Negative No(s): L4813

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Ndy MAR 31 1999

**Features:** L4809: Liver. Hepatocyte. Only a small segment of nucleus is present in this photograph. Abundant ER and glycogen granules are present. There are scattered small to large lipid droplets, but not too many in this hepatocyte (approximately 15). A few dark residual bodies are evident. Fifteen (15) peroxisomes counted.  
L4810: Liver. Enlarged photograph of several mitochondria. No abnormalities noted. Cytoplasm contains some ER and scattered glycogen granules.  
L4811: Liver. Hepatocyte contains multiple medium to large clear lipid droplets (approximately 41). There is abundant glycogen in the cytoplasm. Five (5) peroxisomes counted.  
L4812: Liver. Hepatocyte. Similar to L4811. Hepatocyte contains multiple small to large clear lipid droplets, too numerous to count. There is abundant glycogen in the cytoplasm. Twenty-eight (28) peroxisomes counted.  
L4813: Liver. Hepatocyte contains abundant mitochondria and ER. Only a few clear lipid droplets are present. An endothelial cell is present at the top of the photograph. There is minimal to mild dilatation of the ER and nuclear envelope. Scattered residual bodies are present. Two (2) peroxisomes clearly identified.

**Conclusions:** Mild to moderate increase in cytoplasmic lipid droplets. Increased glycogen in most hepatocytes. Average 12.5 peroxisomes per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05551 Tissue: Liver  
Treatment Group: .75 mg/kg (hi-dose) Block No(s): 99.76-14  
L4814 -  
Sex: Female Photo/Negative No(s): L4818

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. A. B. A. MAR 31 1999

**Features:** L4814. Liver. Hepatocyte. There is a dilated canaliculus at the top right of the hepatocyte. In the cytoplasm there are multiple rarefied areas that mostly appear to contain glycogen granules. However, a few have some lamellar material in them. There is slight dilatation of the nuclear envelope and ER. Some residual bodies are present. No distinct lipid droplets are present in this hepatocyte, however, there are several lipid droplets in the perisinusoidal fat-storing cell (Ito cell) at the top left. Nine (9) peroxisomes counted.  
L4815: Liver. Enlargement of a cluster of mitochondria. These organelles appear essentially normal.  
L4816: Liver. Hepatocyte contains a single medium-sized clear lipid droplet. The cytoplasm contains abundant glycogen granules. Several residual bodies present. Four (4) peroxisomes clearly identified. Several small dark bodies appear to be tips of mitochondria.  
L4817: Liver. Hepatocyte appears similar to L4814. There is abundant glycogen in the cytoplasm, often making clear areas containing just glycogen granules. Several clusters of RER present. One small lipid droplet present. Fourteen (14) peroxisomes counted.  
L4818: Liver. Hepatocyte contains multiple rarefied "pockets" of glycogen granules. No lipid droplets present. Eleven (11) peroxisomes counted.

**Conclusions:** Increased glycogen. Average 9.5 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05514 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 99.76-15  
Sex: Male Photo/Negative No(s): Z16232 -  
Z16236

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. et al MAY 20 1999

**Features:** Z16232. Liver. Hepatocyte. Hepatocyte contains multiple small to medium-sized lipid droplets scattered throughout its cytoplasm. At the top margin is a microvillous border and some collagen fibers in the space of Disse. Smooth endoplasmic reticulum (SER) and rough endoplasmic reticulum (RER) are present throughout the cytoplasm with many mitochondria also throughout. Mitochondria are well-preserved and cristae, granules and matrix are clearly evident. Several irregular dark staining residual bodies are present. One (1) peroxisome counted.  
Z16233. Liver. Hepatocyte. A moderate number of small to medium-sized lipid droplets are present in the cytoplasm, as well as several prominent residual bodies. The upper left and lower left borders show microvilli and collagen fibers adjacent to a sinusoid or central vein. The RER forms a distinct palisade at the bottom of the cell. Nine (9) peroxisomes counted.  
Z16234. Liver. Hepatocyte. Centered hepatocyte shows minimal fixation artifact with some slight dilatation of SER and the nuclear envelope. There are a few small to medium-sized lipid droplets present. Four (4) peroxisomes counted.  
Z16235. Liver. Hepatocyte. Cell appears similar to those described above. There are random lipid droplets and multiple residual bodies. Five (5) peroxisomes counted.  
Z16236. Liver. Hepatocyte. Multiple small to medium-sized lipid droplets present in the cytoplasm. Only a small nuclear profile is evident in this cell. Eleven (11) probable peroxisomes counted.

**Conclusions:** Tissue appears well-fixed for ultrastructural examination. There appears to be a mild increase in numbers of lipid droplets. Average 6.0 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05515 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 99.76-16  
Sex: Male Photo/Negative No(s): Z16237 -  
Z16241

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *James B. N. H.* MAY 20 1999

**Features:** Z16237. Liver. Hepatocyte. A central vein is present at the top margin and contains a large amount of collagen extracellularly. A bile canaliculus is present on the left between three hepatocytes. The endoplasmic reticulum and nuclear envelope are slightly dilated – this is a fixation artifact. Several lipid droplets are present. Prominent glycogen granules are present throughout the cytoplasm. Twenty-two (22) peroxisomes.  
Z16238. Liver. Hepatocyte. A bile canaliculus is present at the top border with another hepatocyte. One large and several smaller lipid droplets are present. Mitochondria appear normal and have fine cristae, matrix, and granules. Twenty-one (21) peroxisomes.  
Z16239. Liver. Hepatocyte. Large central nucleus is adjacent to a large lipid droplet. A few smaller lipid droplets are present. There is artifactual dilatation of the RER and the nuclear envelope. Several residual bodies are present. Fourteen (14) peroxisomes counted.  
Z16240. Liver. Hepatocyte. The centered hepatocyte contains several medium-sized lipid droplets. There is marked dilatation of the RER and the nuclear envelope. A bile canaliculus is present on the left margin of this cell and extracellular collagen is evident in the upper right. Ten (10) peroxisomes counted.  
Z16241. Liver. Hepatocyte. Hepatocyte contains two larger lipid droplets and several smaller ones. The RER and nuclear envelope are dilated. The ventral margin shows a microvillous border next to an endothelial cell at the bottom. A prominent bile canaliculus is present on the left, surrounded by dark desmosomes. Eight (8) peroxisomes counted.

**Conclusions:** Slight (equivocal) increase in lipid droplets. Average 15.0 peroxisomes per hepatocyte.



**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05516 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 97.76-17  
Sex: Male Photo/Negative No(s): Z16242 -  
Z16246

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. ed MAY 20 1999

**Features:** Z16242. Liver. Hepatocyte. Hepatocyte is adjacent to a cell containing a large lipid droplet, probably a perisinusoidal fat-storing cell (Ito cell). The hepatocyte contains numerous normal-appearing mitochondria and scattered dark irregular residual bodies. Smooth and RER are present throughout the cytoplasm. One (1) probable peroxisome counted.  
Z16243. Liver. Hepatocyte. Hepatocyte has a bile canaliculus present along its right margin with an adjacent hepatocyte. The cytosol contains abundant smooth and RER and numerous mitochondria. A few residual bodies are present. Two (2) peroxisomes seen.  
Z16244. Liver. Hepatocyte. Hepatocyte exhibits very slight dilatation of the endoplasmic reticulum and nuclear envelope. Glycogen granules are present throughout the cytoplasm, and scattered residual bodies are present. Two (2) probable peroxisomes identified.  
Z16245. Liver. Hepatocyte. A clear vacuole with a central round density is present to the left of the nucleus of the hepatocyte. This appears to be a cytoplasmic invagination from the plasma membrane. Normal-appearing mitochondria are present throughout the cytoplasm. A few residual bodies are present. Fifteen (15) peroxisomes counted.  
Z16246. Liver. Hepatocyte. The centered hepatocyte appears essentially similar to above-described cells. There are glycogen granules throughout the cytoplasm. Sixteen (16) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Average 7.2 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05521 Tissue: Liver  
Treatment Group: 0.03 mg/kg (low-dose) Block No(s): 99.76-18  
Sex: Male Photo/Negative No(s): Z16247 -  
Z16251

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Noy MAY 20 1999

**Features:** Z16247. Liver. Hepatocyte. Several large irregular electron-dense residual bodies are present in the centered hepatocyte and the subjacent hepatocyte. The SER and nuclear envelope are slightly dilated. Also, the mitochondria appears slightly swollen, although this appears to be artifactual along with the dilated SER. A few small lipid droplets are present. Fourteen (14) peroxisomes counted.  
Z16248. Liver. Hepatocyte. Clusters of fine granules, probably glycogen, are present in the cytoplasm. The mitochondria appears slightly dilated, as does the SER in an adjacent hepatocyte to the top left. The smooth ER is poorly defined. Several small lipid droplets are present. Two erythrocytes are present at the lower right of the photograph. Eleven (11) peroxisomes counted.  
Z16249. Liver. Hepatocyte. The RER, nuclear envelope, and SER in the hepatocyte are slightly dilated, consistent with some fixation artifact. Several small lipid droplets and residual bodies are present. A small segment of a perisinusoidal fat-storing cell is present at the lower right, adjacent to an endothelial cell. Sixteen (16) peroxisomes identified.  
Z16250. Liver. Hepatocyte. Several small lipid droplets are present in the hepatocyte. Multiple dark and irregular residual bodies are also present. The ER is slightly dilated throughout. Three (3) probable peroxisomes counted.  
Z16251. Liver. Hepatocyte. There is mild dilatation of the nuclear envelope and the endoplasmic reticulum throughout. Mitochondria have a paler matrix and may be slightly enlarged. On the left is the hepatocyte's microvillous border, with an adjacent endothelial cell and erythrocyte in the sinusoid. A bile canaliculus is present in the lower right. Ten (10) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Some minimal to slight fixation artifacts. Average 10.8 peroxisomes per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05537 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 99.76-19  
Sex: Female Photo/Negative No(s): Z16252 -  
Z16256

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James R. N. S. J MAY 20 1999

**Features:** Z16252. Liver. Hepatocyte. Fixation appears good. Dorsal to the hepatocyte is a central vein or sinusoid area. Several medium-sized lipid droplets are present in the cytoplasm. Fine glycogen granules are scattered throughout the cytoplasm. A desmosome is present at the lower left margin with an adjacent hepatocyte. Ten (10) peroxisomes counted.

Z16253. Liver. Hepatocyte. Hepatocyte shows very slight dilatation of endoplasmic reticulum. There is one large lipid droplet and several small droplets within the cytoplasm. A bile canaliculus is present at the top right margin of the cell. Five (5) peroxisomes counted.

Z16254. Liver. Hepatocyte. This cell appears essentially similar to Z16253, although there are lesser numbers of lipid droplets. Two irregular dark-staining residual bodies are present on the left and right side of the nucleus. The one on the right is somewhat vacuolated. Eleven (11) peroxisomes counted.

Z16255. Liver. Hepatocyte. A medium-sized lipid droplet containing some lamellar material is present to the right of the nucleus. Just a few smaller lipid droplets are present elsewhere in the cytoplasm. The endoplasmic reticulum is slightly dilated. At the bottom is the microvillous border extending into the space of Disse. A few small residual bodies are present. Six (6) probable peroxisomes counted.

Z16256. Liver. Hepatocyte. In this hepatocyte two mitochondria appear paler and somewhat swollen. The rest appear normal. Twelve (12) probable peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Quantity of lipid appears within normal expectations. Average 8.8 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05541 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 99.76-20  
Z16257 -  
Sex: Female Photo/Negative No(s): Z16261

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Nash MAY 20 1999

**Features:** Z16257. Liver. Hepatocyte. Microvillar borders are present along the lower left and upper right margins of this hepatocyte. A bile canaliculus is present at the lower right. Lamellar material within a lipid droplet is present to the lower right of the central nucleus. There is abundant SER throughout the cell, and the RER appears slightly dilated. Seven (7) probable peroxisomes counted.  
Z16258. Liver. Hepatocyte. Several medium-size lipid droplets are present, as well as approximately eight residual bodies, in the cytoplasm. The lower left margin is a microvillous border, and a bile canaliculus is present in the mid and upper right margins of this hepatocyte. Eight (8) peroxisomes counted.  
Z16259. Liver. Hepatocyte. This cell is surrounded by several other hepatocytes, and contains approximately ten medium-sized lipid droplets in its cytoplasm. Several very dark round to oval residual bodies are present at the top of the cell. Several dark mitochondria noted; these are often difficult to differentiate from lysosomes or peroxisomes. Fourteen (14) peroxisomes counted.  
Z16260. Liver. Hepatocyte. Hepatocyte appears essentially similar to those described above. Two lipid droplets noted. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Twenty-three (23) peroxisomes counted.  
Z16261. Liver. Hepatocyte. Cell contains approximately 5 small to medium-sized lipid droplets. At the bottom is a sinusoid containing a platelet or segment of a granulocyte in the circulation. Another sinusoidal margin and microvillous border is present at the top. There is slight dilatation of the endoplasmic reticulum. Eight (8) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Some lipid droplets noted, but within normal expectations for hepatocytes. Average 12.0 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05547 Tissue: Liver  
Treatment Group: 0.3 mg/kg (low-dose) Block No(s): 99.76-21  
Z16262 -  
Sex: Females Photo/Negative No(s): Z16266

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Nelson MAY 20 1999

**Features:** Z16262. Liver. Hepatocyte. Photograph shows a hepatocyte with just a small nuclear profile. A microvillous border is present at the top right. Some artifactual knife marks are present. Several dark residual bodies are present, and only about six small lipid droplets are evident in the cytoplasm. Abundant SER and RER are throughout the cytoplasm intermixed with numerous mitochondria. Four (4) peroxisomes identified.  
Z16263. Liver. Hepatocyte. Numerous collagen fibers are present along the dorsal extracellular margin. At the lower left this hepatocyte's microvillous border extends in the space of Disse. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Several residual bodies and lipid droplets are present. Fine glycogen granules are randomly scattered throughout the cytoplasm. Six (6) peroxisomes clearly identified.  
Z16264. Liver. Hepatocyte. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A bile canaliculus is present at the dorsal right margin of the cell, and another hepatocyte is present along the ventral margin. The general morphology is similar to the above described cells. Only one lipid droplet is evident in this cell. Several residual bodies are evident. Fourteen (14) probable peroxisomes identified.  
Z16265. Liver. Hepatocyte. A central vein and sinusoid surround this hepatocyte on the lower and upper left margins. Erythrocytes are present in the vascular lumens. Within the hepatocyte there is slight dilatation of the endoplasmic reticulum and nuclear envelope. Two small lipid droplets are present. Nine (9) peroxisomes counted.  
Z16266. Liver. Hepatocyte. Hepatocyte appears essentially similar to cells described above. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A large irregularly-shaped residual body is present to the lower left of the nucleus. Seventeen (17) probable peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Average 10.0 peroxisomes per hepatocyte.

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105550 Tissue: Liver  
Treatment Group: .03 mg/kg (low-dose) Block No(s): 99.76-22  
Z16267 -  
Sex: Female Photo/Negative No(s): Z16272

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. May MAY 20 1999

**Features:** Z16267. Liver. Hepatocyte. Abundant numbers of glycogen granules are present throughout the cytoplasm of this hepatocyte. Bile canaliculi are evident on the right, left and lower left margins. A large dark residual body is present in an adjacent hepatocyte at the top left. Several smaller residual bodies are present in the cytoplasm of the centered hepatocyte. Mitochondria appear normal, having cristae, sporadic granules and a fine grainy matrix. Five (5) probable peroxisomes counted.

Z16268. Liver. Hepatocyte. Cytoplasm has a somewhat light appearance due to slight dilatation of the endoplasmic reticulum. The nuclear envelope is also slightly dilated. These are artifactual fixation-related changes. Prominent bile canaliculi are present on the left and lower right cellular margins. No lipid droplets evident. Fifteen (15) peroxisomes counted.

Z16269. Liver. Hepatocyte. Cell appears similar to Z16267 described above. There appears to be abundant glycogen granules in the cytosol. A microvillous border is present at the upper right extending in to the space of Disse, while bile canaliculi are evident along the lower left and upper left margins. There are many dark mitochondria which are difficult to differentiate from peroxisomes. Twenty-seven (27) probable peroxisomes counted.

Z16270. Liver. Hepatocyte. This hepatocyte appears to be binucleate. An endothelial cell is present lining the sinusoid ventrally and two erythrocytes are present dorsal to this cell. The endoplasmic reticulum and nuclear envelope is slightly dilated. Twenty (20) peroxisomes seen.

Z16272. Liver. Hepatocyte. Two large and multiple smaller lipid droplets are present in this hepatocyte. Dorsally, the microvillous border extends into the space of Disse and is adjacent to an endothelial cell. Ventrally are a small segment of a lipid-containing cell, probably a perisinusoidal fat-storing cell and an adjacent hepatocyte. Twenty-one (21) probable peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Although one cell (Z16272) had a lot of lipid droplets, the overall impression is that lipid content in this liver was within expected normal limits. Average 17.5 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05510 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-23  
Sex: Male Photo/Negative No(s): Z16273 -  
Z16277

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. [Signature] MAY 20 1999

**Features:** Z16273. Liver. Hepatocyte. Numerous glycogen granules are present randomly throughout the SER and cytosol. Fixation appears good. One swollen "barbell-shaped" mitochondria is present, but all other mitochondria appear normal. Scattered dark residual bodies are present. Thirteen (13) peroxisomes counted.  
Z16274. Liver. Hepatocyte. Several small to medium-sized lipid droplets are present in the cytoplasm of the hepatocyte. Along its right margin its microvillous border faces another hepatocyte. A poorly-defined bile canaliculus is present at the lower left. The cytoplasm is filled with SER, RER, mitochondria and glycogen granules throughout. Some peroxisomes are noted. Scattered dark residual bodies are present. Ten (10) peroxisomes counted.  
Z16275. Liver. Hepatocyte. Centered hepatocyte has only a small nuclear profile. At the bottom is a central vein surrounded by an endothelial cell and a moderate number of extracellular collagen fibers. An endothelial cell is the lighter shaded cell at the top right. Three lipid droplets present in the cytoplasm. Thirteen (13) peroxisomes counted.  
Z16276. Liver. Hepatocyte. This cell appears similar to Z16273. Approximately 10 small to medium-sized lipid droplets are present in the cytoplasm. Numerous glycogen granules are evident in the cytosol. A lamellar body is present at the bottom margin of the cell. Fourteen (14) peroxisomes counted.  
Z16277. Liver. Hepatocyte. Approximately a dozen small to medium-sized lipid droplets are present in the cytoplasm. The cluster of 5 droplets at the far right are in another cell. The cytoplasm contains abundant fine glycogen granules. Several residual bodies are noted. Three (3) probable peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Moderate amount of glycogen in several cells. Number of lipid droplets appears normal. Average ~~8.6~~ peroxisomes per hepatocyte. 10.6

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05518 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-24  
Sex: Male Photo/Negative No(s): Z16278 -  
Z16282

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Noel MAY 20 1999

**Features:** Z16278. Liver. Hepatocyte. At the top right this hepatocyte is bordered by a perisinusoidal fat-storing cell containing several prominent lipid droplets. Four small lipid droplets are present in the hepatocyte. A bile canaliculus, adjacent to a large residual body, is present on the left margin of the cell. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Multiple irregular residual bodies are evident. Thirteen (13) peroxisomes clearly identified.  
Z16279. Liver. Hepatocyte. The centered hepatocyte is bordered by a darker hepatocyte on the right. On its left is a band of interstitial collagen. The nuclear envelope and endoplasmic reticulum are slightly dilated. Several endocytotic vesicles are present along the right cellular membrane. Sixteen (16) probable peroxisomes counted.  
Z16280. Liver. Hepatocyte. Hepatocyte has prominent bile canaliculi along its right and left margins with the adjacent hepatocytes. One small lipid droplet noted. Mitochondria stain somewhat more pale in this cell and contrast with darker peroxisomes. Multiple clusters of RER evident. Twelve (12) peroxisomes counted.  
Z16281. Liver. Hepatocyte. This hepatocyte appears to be binucleate. At the top left is an erythrocyte within the central vein or sinusoid. Several small lipid droplets are present in the cytoplasm. There is slight to moderate dilatation of the endoplasmic reticulum and nuclear envelope. Some shrunken mitochondria are difficult to differentiate from lysosomes or peroxisomes. Thirty-two (32) probable peroxisomes counted.  
Z16282. Liver. Hepatocyte. General cellular morphology is similar to cell described above. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Nineteen (19) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Only small numbers of lipid droplets seen. Average 18.4 peroxisomes per hepatocyte.



**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05524 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-25  
Sex: Male Photo/Negative No(s): Z16283 -  
Z16287

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *James Brown* MAY 20 1999

**Features:** Z16283. Liver. Hepatocyte. Hepatocyte contains two medium-sized lipid droplets. The nuclear envelope and endoplasmic reticulum are slightly dilated. At the top right is a bile canaliculus between this cell and an adjacent hepatocyte. Desmosomes are present around the canaliculus. Thirty-one (31) peroxisomes counted.  
Z16284. Liver. Hepatocyte. This centered hepatocyte is surrounded by other hepatocytes on all margins in this photograph. Bile canaliculi are evident at the top left and bottom left margins. No lipid droplets are evident in this cell. Mitochondria, RER and SER appear normal. Twenty-nine (29) probable peroxisomes counted.  
Z16285. Liver. Hepatocyte. Two erythrocytes are present in the sinusoid adjacent to the left of this hepatocyte. Collagen fibers are present in the space of Disse. Along the right margin of this cell is a prominent bile canaliculus. A single medium-sized lipid droplet is present in this cell. Twenty-seven (27) peroxisomes counted.  
Z16286. Liver. Hepatocyte. Cell appears essentially similar to cells described above. At top left and bottom right are erythrocytes within sinusoids. No distinct lipid droplets are present in this cell. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Several dark residual bodies are present. Twenty-one (21) peroxisomes counted.  
Z16287. Liver. Hepatocyte. Cell has two large and several smaller lipid droplets present in its cytoplasm. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Several dark residual bodies are present. Glycogen granules are present throughout the cytoplasm. Eight (8) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Slight increase in average number of peroxisomes. No increase in lipid noted. Average 23.2 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05528 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-26  
Z16288 -  
Sex: Male Photo/Negative No(s): Z16292

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. N. et al MAY 20 1999

**Features:** Z16288. Liver. Hepatocyte. This hepatocyte contains about five medium-sized and approximately fifteen small lipid droplets in its cytoplasm. Microvillous border beneath endothelial cells are evident at the upper right and lower left margins. A bile canaliculus surrounded by desmosomes is present at the lower right margin. Scattered dark-staining residual bodies are present in the cytoplasm. There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Five (5) peroxisomes clearly identified.

Z16289. Liver. Hepatocyte. This hepatocyte's microvillous border extends into the space of Disse at the upper left margin of the photograph. At the lower left is a perisinusoidal fat-storing cell (Ito cell). There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Two small lipid droplets are evident. Sixteen (16) peroxisomes counted.

Z16290. Liver. Hepatocyte. This cell is a little darker staining than previous cells. At lower left a granulocyte is present in the sinusoid or central vein. At the top right a perisinusoidal fat-storing cell (Ito cell) is present. Several small lipid droplets are present in the hepatocyte and a few residual bodies are evident. There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Nineteen (19) peroxisomes counted.

Z16291. Liver. Hepatocyte. Much of the cytoplasm has a dense granular appearance, composed of SER, glycogen granules, and probable cytoskeletal components. Approximately eighteen small to medium-sized lipid droplets are present. Nineteen (19) probable peroxisomes counted.

Z16292. Liver. Hepatocyte. Hepatocyte appears similar to Z16291. There are several lipid droplets present in the cytoplasm. Fourteen probable (14) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Lipid droplet numbers within normal expectations. Average 14.6 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: 105532 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-27  
Sex: Female Photo/Negative No(s): Z16293 -  
Z16297

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *James B. Noh* MAY 20 1999

**Features:** Z16293. Liver. Hepatocyte. This photograph has a centered hepatocyte. At the top are multiple lipid droplets which are in an adjacent perisinusoidal fat-storing cell (Ito cell), not in this hepatocyte. There are numerous glycogen granules in the cytosol intermixed with the endoplasmic reticulum. Two very small lipid droplets are present. Mitochondria appear normal. They show fine cristae, some granules and finely grainy matrix. Four (4) peroxisomes clearly identified.  
Z16294. Liver. Hepatocyte. A single large lipid droplet is present in the cytoplasm beneath the nucleus. Similar to Z16293, there are many fine granules in the cytoplasm which appear to be glycogen granules. Three (3) peroxisomes identified in this hepatocyte.  
Z16295. Liver. Hepatocyte. Several medium-sized lipid droplets are present in this hepatocyte. At the upper right is a "P"-shaped extracellular area containing collagen fibers. Moderate amounts of glycogen are present in the cytoplasm of the hepatocyte. Several residual bodies are also present. Five (5) probable peroxisomes counted.  
Z16296. Liver. Hepatocyte. Centered hepatocyte appears similar to those described above. Three lipid droplets are evident in its cytoplasm. At the bottom is a longitudinal profile of a bile canaliculus and a cross-section of a canaliculus at the top margin. Fine glycogen granules are present throughout. Six (6) peroxisomes counted.  
Z16297. Liver. Hepatocyte. Centered hepatocyte appears similar to those described above. Two medium-sized and several small lipid droplets present. To the right is an area of interstitium containing some collagen fibers. The nucleus probably belongs to an endothelial cell. Three (3) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. Moderate amounts of glycogen present in most cells. Lipid droplet numbers appear normal. Average 4.2 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05538 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-28  
Sex: Female Photo/Negative No(s): Z16298 -  
Z16302

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. A. et al MAY 20 1999

**Features:** Z16298. Liver. Hepatocyte. Section has a prominent single knife mark transecting the cell beneath the nucleus. Numerous glycogen granules are present in the cytoplasm. A single small lipid droplet is present. Mitochondria and other organelles appear normal. Five (5) peroxisomes counted.  
Z16299. Liver. Hepatocyte. Hepatocyte has a single large and several small lipid droplets. A sinusoid is present at the upper left margin where the microvillous border extends into the space of Disse. There are abundant glycogen granules in the cytoplasm. Some mitochondria are lighter staining than the majority of darker one. These light mitochondria are somewhat difficult to differentiate from lysosomes or peroxisomes. Eighteen (18) probable peroxisomes counted.  
Z16300. Liver. Hepatocyte. Cell contains abundant glycogen often in irregular clear spaces or pockets in the cytosol. A single lipid droplet is present. Three (3) peroxisomes identified.  
Z16301. Liver. Hepatocyte. This centered hepatocyte has adjacent hepatocyte dorsally and ventrally and a microvillous-sinusoidal border at the top right. Its cytoplasm contains multiple irregular pockets of glycogen granules. Other organelles appear somewhat clumped between the glycogen pockets. Nine (9) peroxisomes counted.  
Z16302. Liver. Hepatocyte. This cell appears similar to Z16301, although it has more pockets of glycogen granules and has an overall light appearance. Other organelles appear clumped between the glycogen granules. One (1) peroxisome clearly identified.

**Conclusions:** Essentially normal hepatocytes. There is increased glycogen in some of these hepatocytes. Average 7.2 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05545 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-29  
Sex: Female Photo/Negative No(s): Z16303 -  
Z16307

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): James B. Noel MAY 20 1999

**Features:** Z16303. Liver. Hepatocyte. This cell is bordered by hepatocytes on the top right and bottom right and by an interstitial margin on the left. Prominent bile canaliculi are evident between adjacent hepatocytes. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. No lipid droplets are evident. Several dark irregular residual bodies are present. Six (6) probable peroxisomes counted.  
Z16304. Liver. Hepatocyte. Centered hepatocyte is surrounded by hepatocytes on all margins. Bile canaliculi are evident at the right and bottom margins. Its endoplasmic reticulum and nuclear envelope are slightly dilated. Several residual bodies are present. No lipid droplets are present. Fourteen (14) probable peroxisomes counted.  
Z16305. Liver. Hepatocyte. Hepatocyte appears similar to Z16303 above. At top left is a central vein, lined by an endothelial cell and containing a segment of an erythrocyte. No lipid droplets are evident in this hepatocyte. Seven (7) peroxisomes clearly identified.  
Z16306. Liver. Hepatocyte. This cell is somewhat lighter staining than previous hepatocytes, although the mitochondria still are staining fairly darkly. Cell on the far right may be an endothelial cell. Twelve (12) probable peroxisomes counted.  
Z16307. Liver. Hepatocyte. All mitochondria in this cell are darkly staining. There is slight dilatation of the endoplasmic reticulum. Six (6) peroxisomes identified.

**Conclusions:** Essentially normal hepatocytes. No evidence of increased lipid droplets. Average 9.0 peroxisomes per hepatocyte.

**TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION**

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkey  
Animal No.: I05548 Tissue: Liver  
Treatment Group: .15 mg/kg (mid-dose) Block No(s): 99.76-30  
Z16308 - Z16309  
Sex: Female Photo/Negative No(s): Z16311-  
Z16313

Significant Lesions (check one):  Yes  No

Interpreting Pathologist (signature and date): *James B. N. Ed* MAY 20 1999

**Features:** Z16308. Liver. Hepatocyte. The centered hepatocyte is bordered by adjacent hepatocytes on its left and right margins. On the right is a prominent bile canaliculus. A microvillous border is evident at the top right. Fixation appears good and cytoplasmic organelles appear normal. No lipid droplets are present in the cytoplasm. Abundant SER is present in the cytoplasm. There are a number of shrunken dark, variably-sized mitochondria, which are difficult to clearly differentiate from possible lysosomes or peroxisomes. One large lysosome is present at about "4:40 o'clock" from the nucleus, and contains some linear debris. Twenty-nine (29) peroxisomes identified.

Z16309. Liver. Hepatocyte. This hepatocyte exhibits slight dilatation of the endoplasmic reticulum and nuclear envelope. Three small to medium-sized lipid droplets are present. An erythrocyte is evident in a sinusoid at the bottom left of the photograph. Random dark and irregular residual bodies are present. Seventeen (17) peroxisomes clearly identified.

Z16310. Liver. Hepatocyte. Crystalloid inclusions in some mitochondria, an occasional finding in mitochondria. Peroxisomes not counted in this hepatocyte.

Z16311. Liver. Hepatocyte. One large and several smaller lipid droplets are present in the cytoplasm. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Prominent bile canaliculi are present on the left and right margins with adjacent hepatocytes. Sixteen (16) probable peroxisome counted.

Z16312. Liver. Hepatocyte. This hepatocyte is bordered by adjacent hepatocyte on all margins. Several small lipid droplets are present in the cytoplasm. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Nine (9) probable peroxisomes counted.

Z16313. Liver. Hepatocyte. Two medium-sized and several smaller lipid droplets are evident in the cytoplasm. At the bottom left of the photograph are some interstitial collagen fibers. A bile canaliculus is present at the top right margin of the cell. There is slight dilatation of the endoplasmic reticulum, especially the RER, and the nuclear envelope. A large lysosome is present in close proximity to the noted bile canaliculus; it contains some electron-dense material. Fourteen (14) peroxisomes counted.

**Conclusions:** Essentially normal hepatocytes. No substantial increase in lipid droplets noted. Average 17.0 peroxisomes per hepatocyte.

III. Transmission Electron Micrographs

### Figure Legends

**Magnification.** Print magnification is indicated on the back of each photograph. The measurement bar on each photomicrograph equals one micron (0.001 mm).

Figure 1. Liver. Hepatocyte showing normal cytoplasmic organelles. Some peroxisomes are identified and other normal organelles. Ventrally the microvillous border extends into the perisinusoidal space. Animal No. I05517, 0 mg/kg/day (control male), 10,920X magnification.

Figure 2. Liver. Hepatocyte. Several lipid droplets are present. There is slight artifactual dilatation of some rough endoplasmic reticulum. Some extracellular collagen is present in the interstitium in the upper right corner. An endothelial cell nucleus is present lining the sinusoid in the lower right corner of the photograph. Animal No. I05544, 0 mg/kg/day (control female), 11,200X magnification.

Figure 3. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae, matrix and granules. These granules within the mitochondrial matrix are normal and are sites of calcium accumulation. Animal No. I05519, 0 mg/kg/day (control male), 112,000X magnification.

Figure 4. Liver. Hepatocyte showing increased lipid droplet accumulation. Lipid droplets vary from small to very large. Several residual bodies are present. Peroxisomes are scarce. Animal No. I05507, 0.75 mg/kg/day (high-dose male), 10,920X magnification.

Figure 5. Liver. Hepatocyte showing numerous lipid droplets and peroxisomes. Several peroxisomes are labeled. Animal No. I05512, 0.75 mg/kg/day (high-dose male), 10,920X magnification.

Figure 6. Liver. Hepatocyte with many small to large lipid droplets. Representative peroxisomes are labeled. Desmosomes and a bile canaliculus is evident at the right. Animal No. I05536, 0.75 mg/kg/day (high-dose female), 11,200X magnification.

Figure 7. Liver. Hepatocyte with multiple lipid droplets and abundant glycogen granules in the cytoplasm. Animal No. I05540, 0.75 mg/kg/day (high-dose female), 11,200X magnification.

Figure 8. Liver. Hepatocyte containing numerous "pockets" of glycogen. Animal No. I05551, 0.75 mg/kg/day (high-dose female), 11,200X magnification.



Draft Ancillary Pathology Report  
Covance Study No. 6329-223

Figure 9. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae and matrix. Small lipid droplets are present in the surrounding cytosol. Animal No. I05512, 0.75 mg/kg/day (high-dose male), 112,000X magnification.


Figure 10. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae, matrix, and granules. The nucleus is present on the right. Animal No. I05534, 0.75 mg/kg/day (high-dose female), 95,200X magnification.

Figure 11. Liver. Hepatocyte. There is moderate accumulation of small to medium-sized lipid droplets in this hepatocyte. Only a small nuclear profile is evident in this cell. The endoplasmic reticulum is slightly dilated. Animal No. I05514, 0.03 mg/kg/day (low-dose male), 11,200X magnification.

Figure 12. Liver. Hepatocyte. Mitochondria, endoplasmic reticulum and some residual bodies make up the majority of this hepatocyte's cytoplasm. A few small dark mitochondria are present, but no clearly identifiable peroxisomes are present. No lipid droplets are present in this cell, although a single lipid droplet is present in the subjacent cell at the bottom of the photograph. Animal No. I05545, 0.15 mg/kg/day (mid-dose female), 11,200X magnification

**Index of Labels for Ultrastructural Structures**


<u>Abbreviation</u>	<u>Structure</u>
BC	Bile canaliculus
CO	Collagen
CR	Cristae
D	Desmosome
EC	Endothelial cell
G	Glycogen
GR	Granules
LD	Lipid droplet
M	Mitochondria
MV	Microvilli
MX	Matrix
N	Nucleus
OM	Outer membrane
P	Peroxisome
RB	Residual body
RER	Rough endoplasmic reticulum
SER	Smooth endoplasmic reticulum



1055

3M\_MN03279888


1818.1055



1056

3M\_MN03279889


1818.1056




1057

3M\_MN03279890

1818.1057






1059

3M\_MN03279892

1818.1059




1060

3M\_MN03279893

1818.1060






1061

3M\_MN03279894

1818.1061



1062

3M\_MN03279895


1818.1062



1063

3M\_MN03279896


1818.1063



1064

3M\_MN03279897


1818.1064



1065

3M\_MN03279898

1818.1065



1066

3M\_MN03279899

1818.1066

IV. Quality Assurance Statement




**Pathology Associates International**  
A Company of Science Applications International Corporation



QUALITY ASSURANCE STATEMENT

This electron microscopy study has been inspected and audited by the Quality Assurance Unit as required by the Good Laboratory Practices Regulations promulgated by the U.S. Food and Drug Administration. PAI has a functioning and responsive Quality Assurance Unit which reports directly to management. The following is a record of inspections/audits and their resulting reports:

<u>Date of Inspection</u>	<u>Phase Inspected</u>	<u>Date Findings Reported to Management and Study Director</u>
4/1, 2/99	Data Audit	4/2/99
4/2/99	Draft Report Audit	4/2/99
7/13/99	Audit of Data from Additional Groups	7/13/99
7/13/99	Final Report Audit	7/13/99

  
Jeanne deWard, B.S., RQAP-GLP  
Quality Assurance Specialist

7/13/99  
Date

Sponsor: 3M Corporate Toxicology

Test Article: PFOS

Study Number: 6329-223, PAI Study EM-99.76



## **APPENDIX 9**

### Urobilinogen Analysis Report

Note: The report in this appendix was supplied by the Sponsor, based on data supplied by the Mayo Clinic. The analysis at the Mayo Clinic was not done in compliance with Good Laboratory Practice Regulations and was not audited by a Quality Assurance Unit.

Urobilinogen Analysis Report for Study title: 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys Covance 6329-223, (3M Medical Dept number: T- 6295.7).

Author: Andrew M. Seacat

Final Report Date: 3/1/01

#### Introduction

In an effort to understand the lowering of bilirubin in the blood of the PFOS high dose (0.75 mg/kg/day) Cynomolgus monkeys, the potential excretion of urobilinogen was evaluated. The hypothesis being tested is that increased fecal urobilinogen excretion is responsible for the observed lowering of bilirubin in the blood in the high dose animals. The null hypothesis would state that there is no significant difference between the control and high dose fecal urobilinogen values.

#### Method summary

Six-hour fecal samples were collected from the cages of the control and high dose male and female monkeys and were sent to Dr. Joe McConnell at Mayo Clinic for fecal urobilinogen analysis (1).

#### Results

The urobilinogen values obtained from the six hour fecal samples collected were not significantly different between the control and high dose groups of male and female Cynomolgus monkeys (Table 1). Therefore the null hypothesis cannot be rejected. The urobilinogen values were within the assay detection limits, but were very low compared to the typical human range of urobilinogen values. This could be due to a true physiological species difference or possibly due to analytical difficulties encountered with a new matrix.

#### Reference:

1. Urobilinogen (UB) Analysis Results from Dr Joseph P. McConnell., Porphyrins and nutritional Biochemistry lab, Dept of Laboratory Medicine and Pathology. Mayo Clinic, Rochester MN.

Covance: 6329-223  
3M T-6295.7

Urobilinogen Report

Table I Urobilinogen results:

Animal#	Dose level	Sex	mg UB/g feces	mg UB/24 hours	Diuretic Test	Diuretic Test
					Female control Vs female high dose PFOS, mg UB/g Feces	Female control Vs female high dose PFOS, mg UB/24 hour Feces
105530	0 mg/kg/d	F	0.142	5.68		0.63
105530	0 mg/kg/d	F	0.245	7.84		
105531	0 mg/kg/d	F	0.155	5.67		
105535	0 mg/kg/d	F	0.277	5.42		
105534	0 mg/kg/d	F	0.133	4.25		
105549	0 mg/kg/d	F	0.227	5.44		
	Avg		0.197	5.542		
	SD		0.061	1.434		
105533	0.75 mg/kg/d	F	0.288	14.995		
105534	0.75 mg/kg/d	F	0.175	6.308		
105526	0.75 mg/kg/d	F	0.435	20.86		
105546	0.75 mg/kg/d	F	0.188	7.52		
105542	0.75 mg/kg/d	F	0.123	2.94		
105521	0.75 mg/kg/d	F	0.135	2.70		
	Avg		0.224	9.221		
	SD		0.128	7.452		
					Male Control Vs male high dose PFOS, mg UB/g Feces	Male Control Vs male high dose PFOS, mg UB/24 hour Feces
105508	0 mg/kg/d	M	0.413	9.92		0.17
105517	0 mg/kg/d	M	0.150	5.02		
105519	0 mg/kg/d	M	0.216	6.91		
105520	0 mg/kg/d	M	0.214	8.55		
105525	0 mg/kg/d	M	0.165	4.62		
105527	0 mg/kg/d	M	0.151	4.82		
	Avg		0.218	6.805		
	SD		0.032	1.621		
105506	0.75 mg/kg/d	M	0.212	6.77		
105507	0.75 mg/kg/d	M	0.156	1.87		
105511	0.75 mg/kg/d	M	0.133	7.32		
105512	0.75 mg/kg/d	M	0.168	3.56		
105522	0.75 mg/kg/d	M	0.175	4.90		
	Avg		0.172	4.844		
	SD		0.021	2.285		

UB = urobilinogen  
Normal values, human adults 50-300 mg UB/24 hours

**APPENDIX 10**

Dose Confirmation Analysis Report  
Compound Stability Report  
Analytical Laboratory Report  
Certificate of Analysis  
Quality Assurance Statement

Note: This appendix contains information supplied and audited by the Sponsor.

Dose Confirmation Analysis Report for Study title: 26-Week Capsule Toxicity Study  
with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys  
Covance 6329-223, (3M Medical Dept number: T- 6295.7).

Author: Andrew M. Seacat

Final Report Date: 3/1/01

Introduction

Dose confirmation analysis were performed on samples of perfluorooctanesulfonic acid potassium salt (KPFOS) triturated in lactose at dilutions of 1:499 and 1:39 w:w. The low dose group (0.03 mg/kg/day of PFOS) received 15 mg/kg/d of the 1:499 w:w dilution in gelatin capsules. The mid-dose (0.25 mg/kg/day PFOS) and the high-dose (0.75 mg/kg/day) groups received 6 and 30 mg/kg/day respectively of the 1:39 w:w dilution in gelatin capsule. Samples from the top, middle and bottom of each mixture were collected on day -15 prior to the in-life phase of the study for homogeneity analysis and sent to 3M Environmental lab. Samples collected from the middle of the preparations were collected prestudy and at the end of the treatment phase for material content analysis to assess compound stability in the dosing vehicle.

Method summary

The dose confirmation data were collected according to a method described fully in the Analytical Laboratory Report (1). Briefly, dose confirmation was performed by diluting the lactose dose samples 1000-fold with Milli-Q water, which were then extracted using the ion-pair reagent tetrabutylammonium hydrogen sulfate according to the procedure (1). The extracts from the 1:499 and the 1:39 dilutions were then diluted 1:5 and 1:50, respectively, to bring the PFOS levels in the linear range of the instrument. For each sample, (top, middle and bottom), the average PFOS spiked matrix extract value was used as correction factor for calculating the percent recovery. In all cases, samples were analyzed versus an unextracted curve using HPLC-ESMS/MS.

Results

The results indicated that the 1:499 dilution used for the 0.03 mg/kg/day dose group was  $86 \pm 4$  % of the target concentration, and that the 1:39 dilution used for the 0.75 and 0.15 mg/kg/day dose groups were  $113 \pm 31$  % of the target concentration (Table 1)

The stability samples were obtained from the middle of each mixture and were received on 5-07-99. The stability sample for the 1:499 was  $100 \pm 4$  % of the target concentration, and the stability sample for the 1:39 was  $69 \pm 0$  % of the target concentration (Table 2).

Covance: 6329-223  
3M T-6295.7

Dose Analysis Report

Reference:

1. Hansen K. J. Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples. Project Identification: Covance 6329-222, 6329-223, 3M Medical Dept number: T- 6295.7, Analytical study: FACT TOX030, 3M Laboratory request No. U2279. 214 pp, 2000.

Covance: 6329-223  
3M T-6295.7

Dose Analysis Report

Appendix

Table 1. Dose sample analysis

6329-223 Lactose Dose Verification								
8/21/95 Analysis								
1:39 Dose (25000 ppm PFOS)								
	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g	MS Average Recovery Corrected Conc. ug/g	Corrected % Recovery for ug/g
Top	580	479	83	25000	20947	83	236.8	94
Middle	500	556	130	25000	32537	130	37210	149
Bottom	500	422	84	25000	21108	84	2445	97
Avg							28328	113
SD							7705	31
1:499 Dose (2000 ppm PFOS)								
	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g	MS Average Recovery Corrected Conc. ug/g	Corrected % Recovery for ug/g
Top	410	305	74	2000	1480	74	1795	90
Middle	404	287	71	2000	1425	71	1716	85
Bottom	400	272	68	2000	1361	68	1859	92
Avg							1717	86
SD							78	4
Actual Matrix Spike (MS) Conc. - Actual Background Conc. divided by Expected times 100 Spiked too low which accounts for the wide differences in recovery								
1:39 Dose (25000 ppm PFOS) Matrix Spike (MS)								
	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Conc. ug/g	% Recovery for ug/g		
Top	604	507	84	21658	10.8	12.1		112
Middle	524	465	92	24252	12.5	-82.8		-864*
Bottom	524	438	83	21889	12.5	7.82		65
Avg								87
*an outlier, not used in any calculations								
Actual Matrix Spike Conc. - Actual Background Conc. divided by Expected times 100								
1:499 Dose (2000 ppm PFOS) MS								
	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g		
Top	506	475	95	2320	9.77	5.30		85
Middle	500	447	90	2217	9.92	7.92		80
Bottom	586	440	75	2202	10.0	8.41		54
Avg								83
PFOS = Perfluorooctanesulfonate								

3

Covance: 6329-223  
3M T-6295.7

Dose Analysis Report

Table 2. Stability Sample analysis

Group Dose	Sample #	Expected Conc. PFOS ng/mL	PFOS-Bckgrnd Conc. ng/mL	PFOS % Recovery Accuracy
Method Blk	Lact091800-WBlk-1	0.00	NA	NA
	Lact091800-WBlk-2	0.00	NA	NA
QC	Lact091800-(1:39)-MS1	25	6.21	25%
	Lact091800-(1:39)-MSD1	25	-17.89	-71%
	Lact091800-(1:499)-MS1	200	236.6	118%
	Lact091800-(1:499)-MSD1	200	177.4	89%
Dose	Lact091800-(1:39)-1	515	NA	69%
	Lact091800-(1:39)-2	515	NA	69%
	Avg			69%
	Lact091800-(1:499)-1	414	NA	103%
	Lact091800-(1:499)-2	414	NA	98%
	Avg			100%

4

1076

3M\_MN03279909



Covance: 6329-223  
3M T-6295.7

Dose Analysis Report

Example calculations

$$\text{Calculating conc. (Top 1:39) ug/g: } \frac{(479.02 \text{ ng/mL} \times 100 \text{ mL} \times 1 \text{ mL})}{(0.02 \text{ mL} \times 0.116 \text{ g} \times 1000 \text{ ng/ug})} = 20647 \text{ ug/g}$$

$$\text{Expected concentration (Top 1:39) ug/g: } \frac{(50 \text{ ug/mL} \times 0.025 \text{ mL})}{0.1160 \text{ g}} = 10.8 \text{ ug/g}$$

Actual Calculated Conc. (Top 1:39) ug/g:

$$\frac{(507 \text{ ng/mL} \times 100 \text{ mL} \times 1 \text{ mL}) - (479.02 \text{ ng/mL} \times 100 \text{ mL} \times 1 \text{ mL})}{(0.02 \text{ mL} \times 0.116 \text{ g} \times 1000 \text{ ng/ug}) - (0.02 \text{ mL} \times 0.116 \text{ g} \times 1000 \text{ ng/ug})} = 12.1 \text{ ug/g}$$

100

The number is divided by 100 since the sample was diluted 1:100, 1.0 mL of diluted sample removed, then spiked with standard.

5

1077

3M\_MN03279910

1818.1077

Corporate Health Physics  
Corporate Occupational Medicine  
Corporate Product Responsibility  
Corporate Toxicology  
3M Medical Department

3M Center, 220-2E-02  
PO Box 33220  
St. Paul, MN 55133-3220  
651 733 1110

September 6, 2000



Peter J. Thomford, Ph.D.  
Study Director, Toxicology  
Covance Laboratories Inc.  
3301 Kinsman Blvd.  
Madison WI 53704

Re. Covance 6329-222 (T-6295.6), 6329-223 (T-6295.7). Perfluorooctanesulfonate  
Compound Stability Report

Peter:

The perfluorooctanesulfonic acid potassium salt (PFOS, FC-95 Lot 217) used in Covance 6329-222, 6329-223, has remained stable for the entire duration of the study. A Certificate of Analysis (C of A) dated March 9, 2000 (1), identified the compound as being 90.49% C<sub>8</sub>F<sub>17</sub>SO<sub>3</sub>-K<sup>+</sup> by a combination of LC/MS, <sup>1</sup>H-NMR, <sup>19</sup>F-NMR, and elemental analysis techniques. Previously, on December 1<sup>st</sup> 1997, <sup>19</sup>F-NMR was used to characterize FC-95 lot 217 and showed that the isomer distribution was identical to the C of A sent to you earlier this year (2). Additionally, <sup>19</sup>F-NMR and <sup>1</sup>H NMR conducted on August 24<sup>th</sup> 2000 (3) were compared to the <sup>19</sup>F-NMR completed on December 1<sup>st</sup> 1997 and indicated that there was no significant differences in the composition of this lot of PFOS over intervening 3 and a half year time period. Thus, PFOS, FC-95 Lot 217 used was stable for greater the time period during which these studies were conducted.

Sincerely,

A handwritten signature in cursive script that reads "Andrew M. Seacat".

Andrew M. Seacat Ph.D.  
Toxicology Specialist

Peter Thomford, Ph.D.  
Page 2  
September 6, 2000

References:

1. Payfer R.M. Certificate Of Analysis FC-95, Lot 217. 3M Specialty Chemicals Division. March 9, 2000
2. Kestner T. Fluorochemical Isomer Distribution by  $^{19}\text{F}$ -NMR Spectroscopy. FC-95, lot 217 Analytical Request 53030 . SA&C Analytical Lab. December 1, 1997
3. Kestner T. Chemical Characterization of PFOS (FC-95, lot 217) by  $^1\text{H}$ -NMR &  $^{19}\text{F}$ -NMR Spectroscopy. Comparison to FC-95/217 analysis from Req.#53030-Request No. 61886. 3M SA&C Analytical Lab - 236-2B-11. August 24, 2000.

---

**ANALYTICAL LABORATORY REPORT**

FROM THE

**26-Week Capsule Toxicity Study with  
Perfluorooctanesulfonic Acid Potassium Salt  
(T-6295) in Cynomolgus Monkeys**

ON THE

**Determination of the Presence and Concentration  
of Perfluorooctanesulfonate (PFOS) in  
Liver and Serum Samples**

***Project Identification***

3M Medical Department Study: T-6295.7  
Covance In-Life Study: #6329-223

Analytical Study: FACT TOX-030  
3M Laboratory Request No. U2279

***Study Completion Date***

At signing

***Total Number of Pages***

233

3m Medical Department Study: T-6295.7

Report No. FACT TOX-030  
Laboratory Request Number-U2279

3M Medical Department Study: T-6295.7

Report No. FACT TOX-030  
Laboratory Request Number-U2279

---

### GLP COMPLIANCE STATEMENT

Study Title: Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (T-6295) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples

Study Identification Number: FACT TOX-030, T-6295.7, Covance #6329-223

This study was conducted in compliance with United States Environmental Protection Agency Good Laboratory Practice (GLP) Standards 40 CFR Part 792, with the exceptions in the bulleted list below. All raw data and samples for this study are retained in archives at the 3M Lab and will be retained for a period of at least ten years. The analytical phase completed at the 3M Lab was performed in accordance with 3M ET&SS Standard Operating Procedures.

Exceptions to GLP compliance:

- There were two study directors in this study. This study was designed as two separate studies. The in-life phase study was considered to end at the generation and shipment of specimens. The analytical study was considered to start at the receipt of these specimens for analysis. This resulted in having two separate study directors, one for each phase of the same study. However, since the technical performance of each phase was entirely separate, no effect is expected from this exception.
- On a few occasions, data were not recorded or corrected exactly as required by the GLPs.
- The 3M TOX 030 protocol states in the Regulatory Compliance section that "This study will be conducted in accordance with the United States Environmental Protection Agency Good Laboratory Practices Standards, 40 CFR 792, with the exception that analysis of the test material mixture for concentration, solubility, homogeneity, and stability will not be conducted, and is the responsibility of the Sponsor." Analyses were, however, completed on the concentration and homogeneity of the test material mixture, according to non-GLP validated methods, and are included in this report. As per the protocol, solubility and stability determinations were not conducted.

Andrew M. Seawat                      9/19/00  
Study Director                                      Date

John L. Butenheff                      19 SEPT 2000  
Study Sponsor                                      Date

3m Medical Department Study: T-6295.7

Report No. FACT TOX-030  
Laboratory Request Number-U2279

3M Medical Department Study: T-6295.7

Report No. FACT TOX-030  
Laboratory Request Number-U2279


**GLP STUDY—QUALITY ASSURANCE STATEMENT**

Study Title: Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (T-6295) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples

Study Identification Number: FACT TOX-030, T-6295.7, Covance #6329-223

The analytical phase of this study has been inspected by the 3M Lab Quality Assurance Unit (QAU) as indicated in the following table. The findings were reported to the study director and management.

Inspection Dates	Phase	Date Reported to Management	Study Director
December 01/98	Sample receipt	1/17/00	1/17/00
March 19,22,23/99	Analysis	3/25/99	3/25/99
October 14/99	Extraction	10/20/99	10/20/99
May 3,8-12,15-19,22-26,29-31/00, June 1,2,5,7,8/00	Data	6/14/00	6/14/00
June 1,5,7,12-16/00	Draft report	6/16/00	6/16/00
September 14/00	Draft report	9/14/00	9/14/00

  
\_\_\_\_\_  
QAU Representative Date 9/22/00

**INTERIM CERTIFICATE OF ANALYSIS**

Revision 1(9/7/00)

Centre Analytical Laboratories COA Reference #: 023-018A

3M Product: PFOS, Lot 217

Reference #: SD-018

Purity: 86.9%

Test Name	Specifications	Result
<b>Purity<sup>1</sup></b>		<b>86.9%</b>
Appearance	White Crystalline Powder	Conforms
Identification NMR		Positive
Metals (ICP/MS)		
1. Calcium		1. 0.005 wt./wt.%
2. Magnesium		2. 0.001 wt./wt.%
3. Sodium		3. 1.439 wt./wt.%
4. Potassium <sup>2</sup>		4. 6.849 wt./wt.%
5. Nickel		5. <0.001 wt./wt.%
6. Iron		6. 0.005 wt./wt.%
7. Manganese		7. <0.001 wt./wt.%
Total % Impurity (NMR)		1.93 wt./wt.%
Total % Impurity (LC/MS)		8.41 wt./wt.%
Total % Impurity (GC/MS)		None Detected
Related Compounds – POAA		0.33 wt./wt.%
Residual Solvents (TGA)		None Detected
Purity by DSC		Not Applicable <sup>3</sup>
Inorganic Anions (IC)		
1. Chloride		1. <0.015 wt./wt.%
2. Fluoride		2. 0.59 wt./wt.%
3. Bromide		3. <0.040 wt./wt.%
4. Nitrate		4. <0.009 wt./wt.%
5. Nitrite		5. <0.006 wt./wt.%
6. Phosphate		6. <0.007 wt./wt.%
7. Sulfate <sup>4</sup>		7. 8.76 wt./wt.%
Organic Acids <sup>5</sup> (IC)		
1. TFA		1. <0.1 wt./wt.%
2. PFPA		2. <0.1 wt./wt.%
3. HFBA		3. 0.10 wt./wt.%
4. NFPA		4. 0.28 wt./wt.%
Elemental Analysis <sup>6</sup> :		
1. Carbon	1. Theoretical Value = 17.8%	1. 12.48 wt./wt.%
2. Hydrogen	2. Theoretical Value = 0%	2. 0.244 wt./wt.%
3. Nitrogen	3. Theoretical Value = 0%	3. 1.74 wt./wt.%
4. Sulfur	4. Theoretical Value = 5.95%	4. 8.84 wt./wt.%
5. Fluorine	5. Theoretical Value = 60%	5. 54.1 wt./wt.%

***INTERIM CERTIFICATE OF ANALYSIS***  
**Centre Analytical Laboratories COA Reference #: 023-018A**

Date of Last Analysis: 08/31/00

Expiration Date: 08/31/01

Storage Conditions: Frozen  $\leq$ -10°C

Re-assessment Date: 08/31/01

<sup>1</sup>Purity = 100% - (sum of metal impurities, 1.45% +LC/MS impurities, 8.41%+Inorganic Fluoride, 0.59%+NMR impurities, 1.93%+organic acid impurities, 0.38%+POAA, 0.33%)

Total impurity from all tests = 13.09%

Purity = 100% - 13.09% = 86.9%

<sup>2</sup>Potassium is expected in this salt form and is therefore not considered an impurity.

<sup>3</sup>Purity by DSC is generally not applicable to materials of low purity. No endotherm was observed for this sample.

<sup>4</sup>Sulfur in the sample appears to be converted to SO<sub>4</sub> and hence detected using the inorganic anion method conditions. The anion result agrees well with the sulfur determination in the elemental analysis, lending confidence to this interpretation. Based on the results, the SO<sub>4</sub> is not considered an impurity.

<sup>5</sup>TFA            Trifluoroacetic acid  
HFBA         Heptafluorobutyric acid  
NFPA         Nonofluoropentanoic acid  
PFPA         Pentafluoropropanoic acid

<sup>6</sup>Theoretical value calculations based on the empirical formula, C<sub>8</sub>F<sub>17</sub>SO<sub>3</sub><sup>-</sup>K<sup>+</sup> (MW=538)

This work was conducted under EPA Good Laboratory Practice Standards (40 CFR 160).



**INTERIM CERTIFICATE OF ANALYSIS**  
Centre Analytical Laboratories COA Reference #: 023-018A

LC/MS Purity Profile:

<b>Impurity</b>	<b>wt./wt. %</b>
C4	1.22
C5	1.33
C6	4.72
C7	1.14
<b>Total</b>	<b>8.41</b>

Note: The C4 and C6 values were calculated using the C4 and C6 standard calibration curves, respectively. The C5 value was calculated using the average response factors from the C4 and C6 standard curves. Likewise, the C7 value was calculated using the average response factors from the C6 and C8 standard curves.

Prepared By: \_\_\_\_\_  
David S. Bell  
Scientist, Centre Analytical Laboratories  
Date \_\_\_\_\_


Reviewed By: \_\_\_\_\_  
John Flaherty  
Laboratory Manager, Centre Analytical Laboratories  
Date \_\_\_\_\_

Sponsor Protocol No.: FACT-TCR001  
Centre Study No.: 023-018

**QUALITY ASSURANCE STATEMENT**

Centre Study Number 023-018, entitled, "Characterization Study of PFOS, Lot 217 and Lot 171" was reviewed by Centre Analytical Laboratories' Quality Assurance Unit. All reviewed phases were reviewed for conduct according to Centre Analytical Laboratories' Standard Operating Procedures, the Study Protocol, and all applicable Good Laboratory Practice Standards. All findings were reported to the Study Director and to management.

<u>Phase</u>	<u>Date Inspected</u>	<u>Date Reported to Study Director and Centre Management</u>	<u>Date Reported to Sponsor Management</u>
1. Protocol Review	5/19/00	5/19/00	7/14/00
2. Label Checks (solubility)	7/14/00	7/17/00	Pending
3. Standard Solution Preparation and analysis by instrumentation	6/20,21/00 6/22/00	6/22/00 6/22/00	7/14/00 7/14/00
4. Raw Data Review (NMR)	7/11-13/00	7/15/00	Pending
5. Standard Solution Preparation (Solubility)	7/14/00	7/20/00	Pending
6. Standard Solution Preparation	6/29, 30/00 7/26/00	6/30/00 7/27/00	7/14/00 Pending
7. Report Review (DSC/TGA)	8/8/00	8/8/00	Pending
8. Data Review and Interim Report Review	8/8,9/00	8/9/00	Pending

  
\_\_\_\_\_  
Lisa Manning  
Quality Assurance Officer

8-9-00  
\_\_\_\_\_  
Date

"THIS IS AN EXACT COPY OF  
THE ORIGINAL DOCUMENT"